{"meta":{"query_hash":"a8073ea30bc6","filters":{"venue":"Molecular Cancer Therapeutics"},"cohort_total":759,"direct_labels_cover":2,"predictions_cover":759,"exported":759,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a8073ea30bc6","api":"https://metacan.xera.ac/api/v1/cohort?venue=Molecular+Cancer+Therapeutics"},"results":[{"id":"W1638855221","doi":"10.1158/1535-7163.mct-06-0562","title":"Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Leukemia and Lymphoma Society; V Foundation for Cancer Research; U.S. Department of Defense","keywords":"XIAP; Vorinostat; Clonogenic assay; Cancer research; Chemistry; Apoptosis; Biology; Cell biology; Histone deacetylase; Histone; Programmed cell death; Caspase; Biochemistry","score_opus":0.012058875052699262,"score_gpt":0.263187212290849,"score_spread":0.25112833723814976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1638855221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895878,0.006238225,0.0026992795,0.00010953349,0.000017052316,0.000026267064,0.00018562343,0.0000693634,0.0010667556],"genre_scores_gemma":[0.9972959,0.0010666067,0.00063321437,0.000031615124,0.0000074200448,0.000023685296,0.00019272332,0.0000031233312,0.0007457534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999169,0.000016460774,0.0000069852413,0.000018766335,0.00001944322,0.000021411848],"domain_scores_gemma":[0.9999558,0.000008484922,0.000015937885,0.0000056135796,0.0000054951524,0.000008629412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119819226,0.0002968566,0.00019216794,0.00020544503,0.00012264604,0.00025231467,0.0001954938,0.00021475747,0.000969122],"category_scores_gemma":[0.00008010228,0.00011960405,0.00021576541,0.00010623369,0.00018921358,0.00025942377,0.00014120882,0.0002985801,0.00020706096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001348046,0.0000123484715,0.00024346003,0.000028866398,0.000005039877,0.00009285533,0.000011179409,0.00006740567,0.9977908,0.00015354174,0.00001850124,0.0014412829],"study_design_scores_gemma":[0.000032786847,0.00033610009,0.0096872235,0.0000060408797,0.000021731068,0.00044738338,0.000033049735,0.0010570282,0.98623705,0.00014574551,0.001991187,0.0000046232517],"about_ca_topic_score_codex":0.00019724615,"about_ca_topic_score_gemma":0.00022855941,"teacher_disagreement_score":0.000969122,"about_ca_system_score_codex":0.00031824945,"about_ca_system_score_gemma":0.000091418384,"threshold_uncertainty_score":0.0032420158},"labels":[],"label_agreement":null},{"id":"W1864382350","doi":"10.1158/1535-7163.641.3.5","title":"Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Pancreatic cancer; Identification (biology); Cancer; Polo-like kinase; Kinase; Biology; Cancer research; Computational biology; Genetics; Cell cycle","score_opus":0.010385604758839588,"score_gpt":0.2819086709854192,"score_spread":0.2715230662265796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1864382350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96061534,0.032116015,0.0032931836,0.00089895236,0.00008195619,0.00004148283,0.00020897931,0.00006883064,0.002675111],"genre_scores_gemma":[0.9866218,0.009884911,0.0018779216,0.00012086381,0.00003530747,0.00001911497,0.00030934732,0.000005769841,0.0011249294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995923,0.000008605231,0.0000037502737,0.000009549372,0.000009091406,0.000009877263],"domain_scores_gemma":[0.999941,0.000019373017,0.000016593773,0.0000045422344,0.000006834886,0.000011761788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013551148,0.00019648048,0.000217527,0.00021623744,0.00010665278,0.00032286748,0.00011223967,0.00024893117,0.0007753855],"category_scores_gemma":[0.00014738328,0.00010159853,0.0001079992,0.00016116822,0.00019921218,0.00021524864,0.00010735162,0.00040049021,0.00018047332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045974643,0.00005828988,0.0028281498,0.00017906429,0.000011363704,0.00025718432,0.000027231477,0.00033338397,0.9732755,0.00033412752,0.00023272478,0.022003235],"study_design_scores_gemma":[0.00008189044,0.0013619614,0.013827325,0.000024286172,0.00007014969,0.002351666,0.000056860335,0.001527234,0.9650949,0.00035635178,0.015238195,0.000009059013],"about_ca_topic_score_codex":0.0001506803,"about_ca_topic_score_gemma":0.00039513328,"teacher_disagreement_score":0.0007753855,"about_ca_system_score_codex":0.00026324886,"about_ca_system_score_gemma":0.00017825243,"threshold_uncertainty_score":0.0025939345},"labels":[],"label_agreement":null},{"id":"W1924355940","doi":"10.1158/1535-7163.149.3.2","title":"Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy <i>in vitro</i>","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Government of Ontario","keywords":"Cancer research; Cancer cell; Biology; Cisplatin; Immunology; Chemistry; Cancer; Chemotherapy","score_opus":0.011094331950695117,"score_gpt":0.25953332959864456,"score_spread":0.24843899764794944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924355940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882608,0.0016748008,0.0068844124,0.00015611337,0.00007821871,0.00009193076,0.00033099414,0.00018085321,0.002341878],"genre_scores_gemma":[0.9889599,0.0011941988,0.0065134666,0.000080558275,0.000014689539,0.000060171707,0.00048099965,0.000030070636,0.0026659714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990094,0.000013084573,0.000009047407,0.000024131023,0.000029234565,0.00002353997],"domain_scores_gemma":[0.99990773,0.00002691348,0.000021549724,0.000015137505,0.000011387856,0.000017179906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010336496,0.00027824787,0.00026803833,0.00015494159,0.00013466556,0.00021247365,0.0001588354,0.00021163965,0.0010445621],"category_scores_gemma":[0.0000745489,0.00014961112,0.00020376903,0.00010376255,0.00014528913,0.00012187509,0.00011238961,0.00042648238,0.0002558288],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014749766,0.000016954113,0.000051760726,0.000015565298,0.000002248913,0.0000135039445,0.0000072259627,0.00004845874,0.99941516,0.000028605144,0.000032562464,0.00035320545],"study_design_scores_gemma":[0.0000036906038,0.00014456581,0.0013586163,0.0000011135356,0.0000038011672,0.00006402344,0.0000050692593,0.00046932866,0.9972128,0.0000064741357,0.00072942465,0.0000011413304],"about_ca_topic_score_codex":0.0015954616,"about_ca_topic_score_gemma":0.0030899842,"teacher_disagreement_score":0.0015954616,"about_ca_system_score_codex":0.00031055365,"about_ca_system_score_gemma":0.00016265248,"threshold_uncertainty_score":0.0034944415},"labels":[],"label_agreement":null},{"id":"W1964263225","doi":"10.1158/1535-7163.targ-13-a299","title":"Abstract A299: Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biological Stains and Phytochemicals","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Vinca; Cytotoxic T cell; Microtubule polymerization; Tubulin; Microtubule; Cancer research; Epothilone; Mitosis; Cell culture; Biology; Haematopoiesis; Chemistry; In vitro; Pharmacology; Cell biology; Stem cell; Biochemistry; Genetics","score_opus":0.01379377703811732,"score_gpt":0.267030862395834,"score_spread":0.2532370853577167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964263225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991087,0.0019142992,0.0010775026,0.000121935525,0.000056036097,0.00007496471,0.0020654122,0.0001456788,0.0034572277],"genre_scores_gemma":[0.9897259,0.0011095471,0.0013258634,0.000084279374,0.000009687604,0.000054622407,0.0027816943,0.000018785731,0.0048896438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999534,0.000006688346,0.0000058025125,0.000010107291,0.000012272069,0.000011751832],"domain_scores_gemma":[0.99996626,0.0000068813847,0.0000054234924,0.0000037874645,0.0000049477435,0.00001270393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057663477,0.0002699343,0.00020043824,0.00019692366,0.00010966449,0.00014370863,0.00011788783,0.0001642755,0.0024502934],"category_scores_gemma":[0.000044230215,0.000076159035,0.00017454816,0.0002002604,0.000069571906,0.000081001854,0.00010453431,0.00033891562,0.0006037246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003142452,0.00013585883,0.00014373603,0.000043714106,0.0000061546116,0.00004928972,0.0000075725397,0.000103991784,0.9966072,0.00004699676,0.00021640022,0.0023248193],"study_design_scores_gemma":[0.000060161856,0.0010868636,0.002958401,0.000004641764,0.000010815815,0.00010731199,0.0000149257385,0.0006564661,0.9925573,0.000028143859,0.0025121314,0.0000030305753],"about_ca_topic_score_codex":0.00091576995,"about_ca_topic_score_gemma":0.0013721929,"teacher_disagreement_score":0.0024502934,"about_ca_system_score_codex":0.00012265352,"about_ca_system_score_gemma":0.00016141123,"threshold_uncertainty_score":0.00819701},"labels":[],"label_agreement":null},{"id":"W1965097080","doi":"10.1158/1535-7163.mct-04-0297","title":"Raf kinase as a target for anticancer therapeutics","year":2005,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"MAPK/ERK pathway; Receptor tyrosine kinase; Kinase; Tyrosine kinase; Cancer research; Signal transduction; Biology; Medicine; Cell biology","score_opus":0.055910670510332154,"score_gpt":0.36204434229330806,"score_spread":0.3061336717829759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965097080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003678441,0.99304765,0.00043412394,0.0005790961,0.0003264497,0.000012512174,0.000020745883,0.00002085433,0.005190707],"genre_scores_gemma":[0.0025842339,0.9908551,0.0006722364,0.00057366106,0.00026118252,0.000024246538,0.000043812375,0.000004314791,0.00498122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984896,0.000023264467,0.000013114961,0.000028604052,0.000069389454,0.000016613081],"domain_scores_gemma":[0.999913,0.00003211134,0.000012033165,0.0000048863767,0.00002675534,0.000011263908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040862212,0.0007972847,0.0012011616,0.0018327003,0.00031401077,0.0007984849,0.0006603867,0.0012596041,0.0046002767],"category_scores_gemma":[0.00024167066,0.000309167,0.00040832974,0.0010389611,0.00045186337,0.0011572167,0.0005106917,0.002204577,0.0045649847],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010556317,0.00015580498,0.00015269019,0.0067802505,0.00006514633,0.00074951403,0.0000807338,0.0008187987,0.014444341,0.011973619,0.04159804,0.92307544],"study_design_scores_gemma":[0.00003225938,0.00010347248,0.00031731592,0.0007546347,0.000034033794,0.0016710596,0.000023977891,0.00014095467,0.0018600082,0.0023736928,0.99267596,0.000012691172],"about_ca_topic_score_codex":0.0005228252,"about_ca_topic_score_gemma":0.0013583713,"teacher_disagreement_score":0.0046002767,"about_ca_system_score_codex":0.00081028073,"about_ca_system_score_gemma":0.0005276783,"threshold_uncertainty_score":0.015389502},"labels":[],"label_agreement":null},{"id":"W1966863570","doi":"10.1158/1535-7163.targ-09-b242","title":"Abstract B242: A phase I/II study of oncolytic reovirus plus chemotherapy (carboplatin/paclitaxel) in patients with advanced solid tumors (with emphasis on patients with squamous cell carcinoma of the head and neck (SCCHN)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Oncolytic virus; Carboplatin; Neutropenia; Internal medicine; Chemotherapy; Paclitaxel; Oncology; Head and neck cancer; Cancer; Gastroenterology; Leukopenia; Cisplatin","score_opus":0.012069501451377059,"score_gpt":0.29479091423690734,"score_spread":0.28272141278553026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966863570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920266,0.0014844685,0.0004932292,0.0003064923,0.00012187062,0.0035222974,0.0008363912,0.00007177966,0.0011368694],"genre_scores_gemma":[0.9835413,0.0025951052,0.002210971,0.00060511194,0.0002447059,0.0048069153,0.0024881265,0.000042827978,0.0034648327],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958104,0.00019350032,0.000020711648,0.00007614163,0.000044558878,0.00008408112],"domain_scores_gemma":[0.99947745,0.000053745258,0.00007140162,0.000043098345,0.00003670684,0.00031771985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013310906,0.0021172927,0.002236049,0.0006388394,0.00068277447,0.0011289363,0.0011592988,0.0011093941,0.003706742],"category_scores_gemma":[0.0005821843,0.00094605115,0.0011949468,0.0006992422,0.0010685842,0.00067613786,0.00036941032,0.003433844,0.0011018456],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5088125,0.24858734,0.009237007,0.001410912,0.0015287142,0.0007035989,0.0006584173,0.0032882774,0.1376579,0.00032596817,0.0046052453,0.083184175],"study_design_scores_gemma":[0.40044734,0.5801878,0.009112451,0.000030971387,0.00037800928,0.0003711125,0.00007356746,0.0007544171,0.0058034514,0.00010409293,0.0027067557,0.000030049147],"about_ca_topic_score_codex":0.0014294187,"about_ca_topic_score_gemma":0.0024215507,"teacher_disagreement_score":0.003706742,"about_ca_system_score_codex":0.0009194341,"about_ca_system_score_gemma":0.0019512604,"threshold_uncertainty_score":0.012400329},"labels":[],"label_agreement":null},{"id":"W1968812521","doi":"10.1158/1535-7163.targ-09-c155","title":"Abstract C155: External Qi of Yan Xin Qigong induces apoptosis and inhibits migration and invasion of estrogen-independent breast cancer cells by down-regulating Akt/NF-κB signaling","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biofield Effects and Biophysics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Clonogenic assay; Apoptosis; Protein kinase B; Viability assay; Cancer research; Flow cytometry; Cancer cell; Trypan blue; Matrigel; Medicine; Biology; Molecular biology; Cancer; Chemistry; Angiogenesis; Internal medicine; Biochemistry","score_opus":0.014483333280025,"score_gpt":0.26233191273311546,"score_spread":0.24784857945309047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968812521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820486,0.0062010954,0.0025078908,0.00051191275,0.0004363047,0.00020793434,0.0013928508,0.0001074315,0.0065860064],"genre_scores_gemma":[0.98134387,0.0037197552,0.0016080824,0.00035208045,0.0000843996,0.00018128198,0.002472501,0.00001657098,0.010221424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999083,0.000012492445,0.000010320289,0.000015167094,0.000030101442,0.000023531302],"domain_scores_gemma":[0.99996495,0.0000049471473,0.000007667094,0.00000393119,0.000008730264,0.0000098242035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012422014,0.00054253155,0.0003806157,0.0002849471,0.00019535852,0.0001647131,0.00019756026,0.00032311442,0.008857078],"category_scores_gemma":[0.00009456266,0.00011563936,0.00042677933,0.0003099015,0.00023697867,0.00013317229,0.00021011876,0.0005570363,0.0007650878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014908694,0.00033928143,0.00058868725,0.00085365947,0.00004509306,0.00033566562,0.00004491486,0.00019811791,0.98326576,0.00027777493,0.0009332381,0.011626943],"study_design_scores_gemma":[0.0008862703,0.0044236835,0.017209101,0.00007129791,0.00012445716,0.0008889452,0.00012965364,0.00118237,0.954747,0.0002870556,0.020030063,0.000020084395],"about_ca_topic_score_codex":0.0006837372,"about_ca_topic_score_gemma":0.00059080473,"teacher_disagreement_score":0.008857078,"about_ca_system_score_codex":0.00019639338,"about_ca_system_score_gemma":0.0004560448,"threshold_uncertainty_score":0.029629827},"labels":[],"label_agreement":null},{"id":"W1970298367","doi":"10.1158/1535-7163.pms-ia7","title":"Abstract IA7: Chromosome instability and synthetic lethality in yeast and cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fungal and yeast genetics research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Synthetic lethality; Biology; Cohesin; Gene; Mutant; Genetics; DNA replication; DNA repair; Mutation; Molecular biology; Chromosome","score_opus":0.02327029834187335,"score_gpt":0.30067677469375226,"score_spread":0.27740647635187893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970298367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094118,0.026395706,0.015905164,0.0017933114,0.00059215777,0.00010882727,0.0075555793,0.002309962,0.035927467],"genre_scores_gemma":[0.98204535,0.002907371,0.0018507739,0.00024383113,0.000031743686,0.000043543594,0.0041956455,0.0000973604,0.008584449],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.0000193496,0.000010545829,0.00001953425,0.00004491719,0.000023248702],"domain_scores_gemma":[0.99986875,0.000015565623,0.00003474652,0.000014034394,0.000023586581,0.00004317307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013720644,0.00056090666,0.00030501143,0.00063167315,0.0003403607,0.0004982748,0.00040741908,0.00044845775,0.0042419415],"category_scores_gemma":[0.00013783299,0.00012283694,0.0002924892,0.00042086598,0.00023951552,0.00011756487,0.0006234394,0.00057464186,0.0018348431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006024288,0.000102496284,0.0032527528,0.00026759194,0.000072642084,0.0016131735,0.000037136495,0.000957549,0.9649025,0.0037298594,0.0046629934,0.019798888],"study_design_scores_gemma":[0.00013496494,0.0008442118,0.04408213,0.000121321704,0.0001724765,0.009802166,0.0002306754,0.0101316385,0.82264376,0.0035143972,0.10826216,0.00006007688],"about_ca_topic_score_codex":0.0015276202,"about_ca_topic_score_gemma":0.0010589926,"teacher_disagreement_score":0.0042419415,"about_ca_system_score_codex":0.00058990816,"about_ca_system_score_gemma":0.00030546015,"threshold_uncertainty_score":0.014190733},"labels":[],"label_agreement":null},{"id":"W1970969296","doi":"10.1158/1535-7163.mct-07-2444","title":"Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Bortezomib; Head and neck squamous-cell carcinoma; Cisplatin; Proteasome inhibitor; Cancer research; Apoptosis; Programmed cell death; Cancer cell; Small interfering RNA; Cancer; Chemistry; Chemotherapy; Head and neck cancer; Medicine; Biology; Cell culture; Internal medicine; Transfection; Multiple myeloma","score_opus":0.014035730986765017,"score_gpt":0.23229907220717882,"score_spread":0.2182633412204138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970969296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871414,0.00694336,0.0011965546,0.00019213014,0.000113374415,0.00013526736,0.00046671045,0.00017639347,0.0036348572],"genre_scores_gemma":[0.9916015,0.002694063,0.0015561422,0.00010278074,0.00002125601,0.00019987332,0.00080760865,0.000013853332,0.0030027928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998123,0.000034777113,0.00002733647,0.000023922647,0.00005916831,0.000042567088],"domain_scores_gemma":[0.9999608,0.0000047288586,0.000006014033,0.0000058258997,0.0000055317287,0.00001727903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014249489,0.000497346,0.00058724824,0.0003799501,0.00023175933,0.00022946185,0.00018720208,0.00018118489,0.001242025],"category_scores_gemma":[0.00008841734,0.00023610271,0.00032507893,0.00030129982,0.00015466481,0.00020478205,0.0003247258,0.0005623485,0.00043153073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075328175,0.0002069047,0.00035126635,0.00015464764,0.000025103212,0.00011680009,0.00003010134,0.00022943909,0.99030966,0.0001348534,0.0003277536,0.007360138],"study_design_scores_gemma":[0.00027434356,0.0023152707,0.01106661,0.000015634389,0.00004631296,0.000679067,0.00003954186,0.0014987179,0.9758672,0.00009448015,0.008087144,0.000015639012],"about_ca_topic_score_codex":0.00048515768,"about_ca_topic_score_gemma":0.0012367895,"teacher_disagreement_score":0.001242025,"about_ca_system_score_codex":0.0002856568,"about_ca_system_score_gemma":0.00039824913,"threshold_uncertainty_score":0.0041549206},"labels":[],"label_agreement":null},{"id":"W1971180088","doi":"10.1158/1535-7163.pms-a10","title":"Abstract A10: MLL2 interactions in follicular and diffuse large B-cell lymphoma","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Biology; Epigenetics; Gene; Genetics; Diffuse large B-cell lymphoma; Cancer research; Follicular lymphoma; Lymphoma","score_opus":0.011402309642660745,"score_gpt":0.260975255464491,"score_spread":0.24957294582183026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971180088","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924583,0.0026638827,0.0011280122,0.00013387603,0.000012194777,0.000012421761,0.0022750623,0.00012434901,0.0011917995],"genre_scores_gemma":[0.9952814,0.0004543527,0.00064081146,0.000114387716,0.000011582557,0.00001290736,0.0022607564,0.000017911687,0.0012057809],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998357,0.000014386863,0.00000882624,0.000057886464,0.000057465026,0.00002571716],"domain_scores_gemma":[0.99983954,0.000022759383,0.00006684675,0.000008029825,0.000026978174,0.000035865105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013591017,0.00023016654,0.00018172455,0.0005045995,0.00022305221,0.0004466529,0.00017657349,0.00026985453,0.0026079563],"category_scores_gemma":[0.00018860889,0.00010750404,0.00016195173,0.0005017531,0.00013752094,0.00017274244,0.00027174366,0.00025399434,0.00064216356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053981645,0.00006072095,0.12106537,0.00022959817,0.00010788938,0.0004948999,0.000085738466,0.00033274354,0.859638,0.00015451391,0.0012738107,0.016016938],"study_design_scores_gemma":[0.00005579042,0.00031623675,0.8444124,0.00004252962,0.00018609138,0.003882861,0.0003748533,0.002405307,0.13307846,0.00041534303,0.014811582,0.000018616973],"about_ca_topic_score_codex":0.001758829,"about_ca_topic_score_gemma":0.0031019875,"teacher_disagreement_score":0.0026079563,"about_ca_system_score_codex":0.00044529905,"about_ca_system_score_gemma":0.000182828,"threshold_uncertainty_score":0.008724451},"labels":[],"label_agreement":null},{"id":"W1972475443","doi":"10.1158/1535-7163.targ-11-c17","title":"Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Pharmacodynamics; Pharmacology; Pharmacokinetics; Notch signaling pathway; Internal medicine; Gastroenterology; Toxicity; Response Evaluation Criteria in Solid Tumors; Maximum tolerated dose; Adverse effect; Oncology; Phases of clinical research; Receptor","score_opus":0.018376902107883335,"score_gpt":0.27997071752476477,"score_spread":0.2615938154168814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972475443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490775,0.0033503913,0.00086729083,0.0005741492,0.00017779434,0.0040025865,0.0020556534,0.00018664771,0.0038777734],"genre_scores_gemma":[0.9796736,0.002482155,0.0029791885,0.0013033357,0.00019643281,0.0036073443,0.004715368,0.00007612979,0.004966427],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99963653,0.0001313412,0.000023403576,0.00007255564,0.00004922877,0.00008698651],"domain_scores_gemma":[0.9992674,0.00008403286,0.000090219466,0.000054801712,0.00004056679,0.00046295626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011256144,0.0016860146,0.002069687,0.00063254515,0.000519194,0.0011341949,0.0012476976,0.001434081,0.0056702117],"category_scores_gemma":[0.00064865075,0.0006302737,0.0012781,0.00051764137,0.0008673288,0.000744634,0.00038149426,0.0034110618,0.0019945863],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53271604,0.13353978,0.011603157,0.0020306518,0.0025067385,0.0013945091,0.00054755935,0.004950132,0.11198295,0.0010042562,0.014851075,0.18287323],"study_design_scores_gemma":[0.44245657,0.52969664,0.013161691,0.00006125186,0.00042945435,0.0009325291,0.00007290764,0.0013429828,0.0054106107,0.00019627373,0.0061929957,0.00004612655],"about_ca_topic_score_codex":0.0017065681,"about_ca_topic_score_gemma":0.0032776962,"teacher_disagreement_score":0.0056702117,"about_ca_system_score_codex":0.0011238225,"about_ca_system_score_gemma":0.0020444968,"threshold_uncertainty_score":0.018968761},"labels":[],"label_agreement":null},{"id":"W1973760749","doi":"10.1158/1535-7163.targ-13-b129","title":"Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Prostate; Genetic heterogeneity; Genome instability; Biology; SNP; Single-nucleotide polymorphism; Biochemical recurrence; Oncology; Medicine; Internal medicine; Cancer; Gene; Genetics; Prostatectomy; Genotype; DNA; Phenotype","score_opus":0.0746681729146952,"score_gpt":0.4133804645949236,"score_spread":0.33871229168022843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973760749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709356,0.0009633036,0.00029275028,0.00020168422,0.00000692596,0.0000075402027,0.00033063896,0.000017159515,0.0010863718],"genre_scores_gemma":[0.99957055,0.00006088891,0.000055839537,0.00002734725,0.000015359858,0.0000017809956,0.0001240675,0.000004738134,0.0001394306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999824,0.00003464706,0.000011364239,0.000046891375,0.000053507832,0.000029647215],"domain_scores_gemma":[0.999218,0.00017703934,0.0003144309,0.00004677102,0.000041315652,0.0002024243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023543171,0.00012443698,0.00019196063,0.0005997019,0.0002856143,0.0004729106,0.00021856878,0.00027103443,0.004517823],"category_scores_gemma":[0.00097123324,0.00011205134,0.000117153824,0.0005459743,0.00044153398,0.00022662077,0.00030502336,0.00037530996,0.00037721387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012213059,0.000059982896,0.9512191,0.00007174276,0.00011327925,0.0019753003,0.00011991804,0.00027549927,0.024949428,0.00043487202,0.0008952713,0.01866431],"study_design_scores_gemma":[0.000012294645,0.0001246556,0.99155605,0.000008492974,0.000037443897,0.0051688575,0.000095081654,0.0003658117,0.0015325563,0.00045925594,0.0006338001,0.000005810626],"about_ca_topic_score_codex":0.0009958337,"about_ca_topic_score_gemma":0.00085971283,"teacher_disagreement_score":0.004517823,"about_ca_system_score_codex":0.00015926035,"about_ca_system_score_gemma":0.00013574492,"threshold_uncertainty_score":0.015113652},"labels":[],"label_agreement":null},{"id":"W1975292630","doi":"10.1158/1535-7163.mct-13-1066","title":"Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of Manitoba; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Estrogen receptor; Cancer research; Selective estrogen receptor modulator; Estrogen receptor alpha; Autophagy; Cyclin D1; Chemistry; Estrogen receptor beta; Estrogen; Agonist; Biology; Breast cancer; Endocrinology; Internal medicine; Receptor; Cancer; Apoptosis; Cell cycle; Medicine; Biochemistry","score_opus":0.007841281655722841,"score_gpt":0.25968884507432854,"score_spread":0.2518475634186057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975292630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919161,0.002813244,0.0013723967,0.00017837825,0.00007489024,0.00006674159,0.0006905673,0.00013446424,0.0027532207],"genre_scores_gemma":[0.985642,0.0025303662,0.0033984964,0.00022006163,0.000021178737,0.00011879986,0.0014251288,0.000041736053,0.0066022365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998716,0.00002583507,0.000017415008,0.000023207069,0.000032557058,0.000029395016],"domain_scores_gemma":[0.99992776,0.000016375197,0.000014086862,0.000012342742,0.00000939452,0.000020075558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001286559,0.000240422,0.00047367095,0.0001795047,0.00014029765,0.00028321022,0.00019015749,0.00021301913,0.0015991909],"category_scores_gemma":[0.00006969875,0.0001523812,0.00028495502,0.00024679082,0.00013551058,0.00013915492,0.00015783503,0.00052865094,0.00068335386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021992558,0.000086864995,0.00011060082,0.000037501566,0.000006073417,0.000039148494,0.000019163555,0.000044830234,0.99790883,0.00005800562,0.000096257856,0.0013728201],"study_design_scores_gemma":[0.000045881665,0.0006498821,0.0019918089,0.000004304303,0.000010817838,0.00018963522,0.000024110355,0.0003909012,0.99320894,0.000019523393,0.0034607744,0.000003396749],"about_ca_topic_score_codex":0.00038624767,"about_ca_topic_score_gemma":0.0008290364,"teacher_disagreement_score":0.0015991909,"about_ca_system_score_codex":0.00021852503,"about_ca_system_score_gemma":0.00021597743,"threshold_uncertainty_score":0.005349815},"labels":[],"label_agreement":null},{"id":"W1975783060","doi":"10.1158/1535-7163.targ-13-b282","title":"Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemcitabine; Pancreatic cancer; Medicine; Internal medicine; Cancer research; Metastasis; Oncology; Cancer; Biology","score_opus":0.009383804395736776,"score_gpt":0.23557580562191097,"score_spread":0.2261920012261742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975783060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921989,0.0021194173,0.000950751,0.00023831386,0.00009018972,0.0000821356,0.0016308457,0.0001860133,0.0025034372],"genre_scores_gemma":[0.9900176,0.0010133829,0.001645825,0.00008503838,0.000016703327,0.000098920194,0.003217718,0.00002916589,0.0038756628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999866,0.000028078255,0.000009764314,0.000024752047,0.000033729786,0.00003761197],"domain_scores_gemma":[0.99990845,0.000023536555,0.000014346093,0.000010806241,0.000008052818,0.000034779336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018544965,0.000519486,0.00038933632,0.00030361649,0.00015329334,0.00023890634,0.00028102915,0.00042898982,0.0037664818],"category_scores_gemma":[0.00010971784,0.00014387768,0.00027696608,0.00023922682,0.00017067364,0.00018841134,0.00014619117,0.0010159749,0.000533421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025478154,0.0010456897,0.000528948,0.00011740053,0.000037576283,0.00010680584,0.000022960154,0.00034638145,0.9874085,0.000100479396,0.0010515759,0.006685821],"study_design_scores_gemma":[0.00045498562,0.007431635,0.007754805,0.000010745323,0.00005813705,0.0007265922,0.000032873475,0.0017994277,0.977275,0.000047239355,0.004400246,0.000008345043],"about_ca_topic_score_codex":0.0011606263,"about_ca_topic_score_gemma":0.0012441362,"teacher_disagreement_score":0.0037664818,"about_ca_system_score_codex":0.00033982785,"about_ca_system_score_gemma":0.00033563352,"threshold_uncertainty_score":0.012600124},"labels":[],"label_agreement":null},{"id":"W1976746884","doi":"10.1158/1535-7163.targ-09-a146","title":"Abstract A146: The role of cystine transport in darinaparsin-induced cell death","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Glutathione; Intracellular; Cystine; Extracellular; Propidium iodide; Buthionine sulfoximine; Cysteine; Chemistry; Apoptosis; Oxidative stress; Flow cytometry; Biochemistry; Programmed cell death; Molecular biology; Biology; Enzyme","score_opus":0.013043837165822353,"score_gpt":0.26035562462680084,"score_spread":0.24731178746097848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976746884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566145,0.006854862,0.0032364018,0.00026699645,0.00005666712,0.000055756394,0.00048519278,0.00012388454,0.0032588441],"genre_scores_gemma":[0.9935644,0.0010904195,0.0011069516,0.0000610128,0.000013858732,0.000019779056,0.0005129091,0.000010759122,0.0036199673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998914,0.00001988611,0.0000119007045,0.000021759995,0.000038378996,0.000016659053],"domain_scores_gemma":[0.9998909,0.00002248586,0.00002481492,0.000010541727,0.000027146261,0.00002406806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015589685,0.0002561925,0.00024024717,0.0001743991,0.00016217101,0.00029710546,0.00023854173,0.00043419193,0.002466815],"category_scores_gemma":[0.00013523859,0.00006932443,0.00017382517,0.00014856468,0.00014727763,0.00022242843,0.00013682066,0.00038228117,0.0005702293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023530456,0.000030086685,0.00023459583,0.000068790665,0.00000774064,0.00016121629,0.0000142780345,0.000040658942,0.99708194,0.00011459825,0.00005517405,0.0019555294],"study_design_scores_gemma":[0.000027732933,0.0006187733,0.0077372524,0.000010604454,0.000016828575,0.00080655236,0.000030299643,0.0009428442,0.9859853,0.00011845347,0.0037017488,0.0000036969204],"about_ca_topic_score_codex":0.0003368314,"about_ca_topic_score_gemma":0.00021203917,"teacher_disagreement_score":0.002466815,"about_ca_system_score_codex":0.00020759668,"about_ca_system_score_gemma":0.00013621728,"threshold_uncertainty_score":0.008252382},"labels":[],"label_agreement":null},{"id":"W1977237795","doi":"10.1158/1535-7163.targ-09-a55","title":"Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Dosing; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; Adverse effect","score_opus":0.03588005930201919,"score_gpt":0.34989656382648365,"score_spread":0.31401650452446445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977237795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930153,0.0014520508,0.000630133,0.00024563275,0.0000922782,0.0018370816,0.0011419919,0.00012640546,0.0014591193],"genre_scores_gemma":[0.9904357,0.0012026282,0.0014862408,0.0006662365,0.00014239574,0.0011443894,0.001822629,0.000030990985,0.00306875],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996327,0.00013053927,0.000028365357,0.00008228644,0.00004461727,0.000081479535],"domain_scores_gemma":[0.99950373,0.00006020392,0.00007539433,0.000042861862,0.000039149556,0.00027861385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011149617,0.001654191,0.0015634961,0.00040694358,0.00051978446,0.00095587166,0.00075593055,0.0009149183,0.005098708],"category_scores_gemma":[0.0005424173,0.00062442536,0.0012501492,0.00030149377,0.0007964867,0.0006604081,0.000280934,0.0027044476,0.0013977888],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4915066,0.12735164,0.014918496,0.0014839707,0.0030222083,0.0008513745,0.00057577883,0.0022327753,0.22585014,0.00038829117,0.009640192,0.1221786],"study_design_scores_gemma":[0.3394175,0.6180347,0.02659784,0.000036651156,0.00083675794,0.00047381633,0.00007666891,0.0010366866,0.010215642,0.0001308831,0.0031069575,0.000035910878],"about_ca_topic_score_codex":0.0016878487,"about_ca_topic_score_gemma":0.0037842402,"teacher_disagreement_score":0.005098708,"about_ca_system_score_codex":0.0007485632,"about_ca_system_score_gemma":0.0014513618,"threshold_uncertainty_score":0.017056823},"labels":[],"label_agreement":null},{"id":"W1978648859","doi":"10.1158/1535-7163.targ-11-b147","title":"Abstract B147: P-Rex1 is required for efficient melanoma metastasis.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Metastasis; Melanoma; Cancer research; Biology; Cancer; Medicine; Internal medicine","score_opus":0.07008065111251921,"score_gpt":0.3093644996851106,"score_spread":0.23928384857259138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978648859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98079705,0.0026608538,0.005651079,0.000449682,0.00017650219,0.00010683838,0.004452187,0.00059024245,0.005115445],"genre_scores_gemma":[0.9824225,0.0005647202,0.0027658734,0.00012882035,0.000026832508,0.000089088746,0.0036092475,0.00029696504,0.010096089],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969745,0.000030157984,0.00003254716,0.00008421667,0.00010565928,0.000049932998],"domain_scores_gemma":[0.99964464,0.000044777782,0.00013258845,0.000034523073,0.000023232136,0.00012023186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017457496,0.00054904126,0.00031049564,0.00035613615,0.00028113605,0.0004980353,0.0004350508,0.00076350867,0.008407462],"category_scores_gemma":[0.00016990544,0.00023456327,0.00035328363,0.00014192589,0.00036222988,0.00019891116,0.00038918905,0.0012423197,0.004352787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009944681,0.000027736132,0.00010383294,0.000028765116,0.000002370842,0.00013713258,0.0000043791742,0.000026568727,0.99882907,0.00008070501,0.00011503677,0.000544915],"study_design_scores_gemma":[0.000059749047,0.0002695301,0.011769044,0.000023184955,0.000011729142,0.0018519297,0.000040359268,0.0011959283,0.9786754,0.00008912401,0.0060061687,0.00000777445],"about_ca_topic_score_codex":0.0005330518,"about_ca_topic_score_gemma":0.00063882297,"teacher_disagreement_score":0.008407462,"about_ca_system_score_codex":0.0003434103,"about_ca_system_score_gemma":0.0002563452,"threshold_uncertainty_score":0.028125823},"labels":[],"label_agreement":null},{"id":"W1979154472","doi":"10.1158/1535-7163.targ-09-c92","title":"Abstract C92: DNA methylating combi-molecule ZRS1 induces p53 and blocks the epidermal growth factor (EGFR)-activated pathways in EGFR-expressing human tumor cells: Relationship to O6-methylguanine DNA methyltransferase (MGMT) status","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Methyltransferase; Cancer research; Biology; DNA methyltransferase; DNA damage; Molecular biology; Chemistry; Biochemistry; DNA; Methylation","score_opus":0.03847306299729982,"score_gpt":0.30269716673723207,"score_spread":0.26422410373993227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979154472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972799,0.00062044425,0.00054890785,0.00008136346,0.000019496581,0.000029961418,0.0003909275,0.00005528182,0.00097381824],"genre_scores_gemma":[0.99627966,0.00035294506,0.00066907745,0.000029274335,0.0000075318276,0.000025188303,0.00076456525,0.00001097054,0.0018608496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991524,0.000011436886,0.000007754363,0.000015106886,0.000026274487,0.000024270654],"domain_scores_gemma":[0.9999349,0.000012126073,0.000014609925,0.000011061973,0.000010124141,0.000017083814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009576969,0.00028208407,0.00024193233,0.00019770877,0.00010507818,0.000143431,0.00019033691,0.00024532175,0.0028681785],"category_scores_gemma":[0.000105131105,0.000094661715,0.00019670824,0.00015425948,0.00017064353,0.00009761128,0.000086554515,0.00040566988,0.0003847213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026364857,0.00007675962,0.00015175523,0.000029452585,0.00000917447,0.000024933754,0.000009089055,0.000092532675,0.99766904,0.000076436816,0.00011239525,0.0014847753],"study_design_scores_gemma":[0.000049746763,0.0013143653,0.0018704642,0.0000022099332,0.00001576708,0.00010276135,0.0000113395245,0.00047307604,0.995046,0.000011248887,0.001100979,0.0000020963391],"about_ca_topic_score_codex":0.0009977348,"about_ca_topic_score_gemma":0.0012374022,"teacher_disagreement_score":0.0028681785,"about_ca_system_score_codex":0.00022439925,"about_ca_system_score_gemma":0.00017318015,"threshold_uncertainty_score":0.009594977},"labels":[],"label_agreement":null},{"id":"W1979880713","doi":"10.1158/1535-7163.targ-11-a125","title":"Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Survivin; Cancer research; Cancer; Angiogenesis; Biology; Medicine; Signal transduction; Cell biology; Internal medicine","score_opus":0.0905372937456725,"score_gpt":0.31531432319890795,"score_spread":0.22477702945323547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979880713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8252195,0.062577225,0.024960175,0.0017377101,0.0018382571,0.0018958045,0.0126581555,0.0016538389,0.06745937],"genre_scores_gemma":[0.90870565,0.021592109,0.013228013,0.0007229347,0.00016833545,0.00051032635,0.0075666225,0.000111696165,0.04739437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999565,0.000005178597,0.000003381818,0.0000072545545,0.000014757263,0.0000129086],"domain_scores_gemma":[0.99998,0.0000030055646,0.0000036580493,0.000001463667,0.0000030948827,0.000008804309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008151699,0.0005497314,0.00022716158,0.00035490972,0.000104442945,0.00022551522,0.00024246181,0.00024256493,0.004488815],"category_scores_gemma":[0.000048293805,0.00011498621,0.0003134066,0.00018968286,0.00010049757,0.00010756454,0.00011806851,0.0004918604,0.0013271758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006930509,0.0002869525,0.0001214249,0.00023771191,0.000028404747,0.0001110104,0.00001670552,0.00059522555,0.9618428,0.0007602857,0.00438628,0.030920178],"study_design_scores_gemma":[0.00075241947,0.004032892,0.0030107545,0.00004171876,0.00009400858,0.00049190153,0.000010692379,0.0018342511,0.9527635,0.0002580769,0.03668701,0.000022694365],"about_ca_topic_score_codex":0.0008848791,"about_ca_topic_score_gemma":0.00163443,"teacher_disagreement_score":0.004488815,"about_ca_system_score_codex":0.0002726452,"about_ca_system_score_gemma":0.0002961098,"threshold_uncertainty_score":0.015016615},"labels":[],"label_agreement":null},{"id":"W1980976141","doi":"10.1158/1535-7163.mct-08-0762","title":"Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Saffron Plant Research Studies","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Crocetin; In vivo; Pancreatic cancer; Cell growth; In vitro; Apoptosis; Cancer research; Cancer; Proliferating cell nuclear antigen; Nude mouse; Cell cycle; Chemistry; Molecular biology; Biology; Pharmacology; Biochemistry; Internal medicine; Medicine; Carotenoid","score_opus":0.029456163390863842,"score_gpt":0.34228013323689965,"score_spread":0.31282396984603583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980976141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786187,0.00883999,0.005281791,0.00042238657,0.000265907,0.00038957133,0.0012194917,0.00045257076,0.0045096395],"genre_scores_gemma":[0.9713038,0.0098690055,0.0056973174,0.00028437257,0.00006242602,0.00050888886,0.0022176027,0.00007157806,0.00998503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977857,0.0000346752,0.000018160392,0.00004749139,0.00006571474,0.00005547416],"domain_scores_gemma":[0.99980146,0.000022102615,0.000058886653,0.000028188751,0.000025012007,0.00006439725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030341017,0.00079126045,0.00081645214,0.0008592059,0.00021684881,0.00037611296,0.00043917718,0.0007526647,0.0014034308],"category_scores_gemma":[0.00013699074,0.00034829215,0.0005560894,0.00050117617,0.00024741326,0.00042252883,0.00023995827,0.0021373162,0.00037552253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093585445,0.000668075,0.00034292042,0.000117070085,0.000024300492,0.00011235898,0.000025123285,0.00018900508,0.99384636,0.00009031527,0.00021828021,0.0034303588],"study_design_scores_gemma":[0.0002689107,0.00668064,0.005784563,0.000027722637,0.00010576962,0.00057699595,0.000064610984,0.003215208,0.9773505,0.000089275556,0.0058214227,0.0000143297],"about_ca_topic_score_codex":0.0013429264,"about_ca_topic_score_gemma":0.00220798,"teacher_disagreement_score":0.0014034308,"about_ca_system_score_codex":0.00049562287,"about_ca_system_score_gemma":0.0004284959,"threshold_uncertainty_score":0.0046949387},"labels":[],"label_agreement":null},{"id":"W1982868690","doi":"10.1158/1535-7163.targ-11-b55","title":"Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Gemcitabine; Tolerability; Medicine; Internal medicine; Pancreatic cancer; Oncology; Chemotherapy; Cancer; Gastroenterology; Pharmacology; Adverse effect","score_opus":0.020648776372777462,"score_gpt":0.27699074372922605,"score_spread":0.2563419673564486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982868690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951925,0.0020305233,0.00025467834,0.00014935645,0.00006867636,0.0009695643,0.00024757785,0.000031049323,0.0010560183],"genre_scores_gemma":[0.9960537,0.0011060208,0.0005799571,0.00020483976,0.0001013748,0.0005216932,0.00039580523,0.000008738116,0.0010278333],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99937963,0.00029482483,0.000055755765,0.00012182117,0.00005683566,0.00009114939],"domain_scores_gemma":[0.9994733,0.00008473573,0.00008494625,0.00004628554,0.00002816523,0.00028261222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010159134,0.0009170521,0.0022262523,0.0006136962,0.0004907732,0.00077510695,0.0006131217,0.0009018312,0.002598512],"category_scores_gemma":[0.00072067045,0.0004994879,0.0012510213,0.0005899849,0.00058137666,0.0006933751,0.00039966832,0.0018556011,0.0006382375],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73328936,0.07569813,0.017383873,0.0010585746,0.0020217139,0.00076131255,0.00038550617,0.0017294745,0.051717695,0.00018058337,0.0009746468,0.11479911],"study_design_scores_gemma":[0.09431354,0.8747675,0.021763075,0.00003822421,0.0006986805,0.00035148885,0.000069160065,0.00062012987,0.004796496,0.000042595322,0.0025106317,0.000028544016],"about_ca_topic_score_codex":0.0008728818,"about_ca_topic_score_gemma":0.0016873425,"teacher_disagreement_score":0.002598512,"about_ca_system_score_codex":0.0007349363,"about_ca_system_score_gemma":0.0011150765,"threshold_uncertainty_score":0.00869292},"labels":[],"label_agreement":null},{"id":"W1983005412","doi":"10.1158/1535-7163.mct-07-0179","title":"Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; Cancer research; ABL; Imatinib mesylate; breakpoint cluster region; Apoptosis; Tyrosine kinase; Leukemia; Tyrosine-kinase inhibitor; Chemistry; Pharmacology; Biology; Immunology; Cancer; Cell biology; Signal transduction; Receptor; Biochemistry","score_opus":0.05143331692213097,"score_gpt":0.3044808825892281,"score_spread":0.25304756566709713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983005412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630673,0.003220863,0.02689535,0.0003781951,0.00008808033,0.00029389386,0.00038546036,0.00020295556,0.0054678875],"genre_scores_gemma":[0.9783417,0.0014190158,0.016127432,0.00010061336,0.000017212638,0.00018527772,0.00021493084,0.000016102696,0.0035776433],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99995923,0.0000048253396,0.0000015003333,0.000010007904,0.000014831856,0.000009558193],"domain_scores_gemma":[0.99998534,0.0000014923953,0.0000058006403,0.0000010525537,0.0000024535984,0.0000037418404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070901995,0.00028210453,0.00017304151,0.00011800177,0.000071057,0.00019662798,0.00026513322,0.00029963805,0.0006340774],"category_scores_gemma":[0.000037054204,0.00008889687,0.00012661322,0.00007626907,0.00009715598,0.00019419649,0.00010221132,0.00030203868,0.00020117902],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010712504,0.00012838354,0.000065673776,0.00005802405,0.0000067905557,0.00005953934,0.0000103176335,0.0007281779,0.9924044,0.0011788374,0.00023583909,0.005016867],"study_design_scores_gemma":[0.00015461321,0.0019292005,0.0008468135,0.0000049288974,0.000026464171,0.0003686775,0.0000059775693,0.011820406,0.97239584,0.00016343045,0.01226805,0.000015619265],"about_ca_topic_score_codex":0.00036545793,"about_ca_topic_score_gemma":0.00041183946,"teacher_disagreement_score":0.0006340774,"about_ca_system_score_codex":0.00029340698,"about_ca_system_score_gemma":0.00015473872,"threshold_uncertainty_score":0.00212878},"labels":[],"label_agreement":null},{"id":"W1985530449","doi":"10.1158/1535-7163.mct-15-0039","title":"Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ovarian cancer; Serous fluid; Serous carcinoma; Ovarian carcinoma; Cancer research; Cancer; Oncology; PI3K/AKT/mTOR pathway; Biology; Comparative genomic hybridization; Internal medicine; Medicine; Gene; Genetics; Signal transduction; Genome","score_opus":0.02712509881237877,"score_gpt":0.2853249266071337,"score_spread":0.2581998277947549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985530449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99945706,0.00015694434,0.00006980234,0.000019042052,9.526157e-7,0.00000207398,0.000091351656,0.000005499828,0.00019714332],"genre_scores_gemma":[0.99956983,0.00006274977,0.00009246147,0.000011503982,0.0000017338297,0.0000017498546,0.00017978634,0.0000016868019,0.00007839855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999262,0.000017705848,0.000008343455,0.000012678151,0.000017830293,0.00001716054],"domain_scores_gemma":[0.99976784,0.00003695565,0.000115530864,0.00002265282,0.000017329869,0.000039807623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020939278,0.00009661569,0.00016859488,0.00042003454,0.00010926815,0.00033965762,0.00008897744,0.00012275673,0.00069194037],"category_scores_gemma":[0.00039835396,0.0000945549,0.0001852261,0.000368616,0.00021269622,0.00008306133,0.00019649733,0.00018711,0.00006889349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013312416,0.000031598476,0.9143952,0.000030446668,0.00010616711,0.0002559612,0.000046407655,0.00040237643,0.07539982,0.00007505049,0.00016424818,0.00776141],"study_design_scores_gemma":[0.000011265917,0.00011871642,0.9936267,0.0000023042592,0.00003942698,0.0004340984,0.000037039248,0.00044344357,0.004923835,0.00004748537,0.00031371773,0.0000019230783],"about_ca_topic_score_codex":0.0015925985,"about_ca_topic_score_gemma":0.0025683164,"teacher_disagreement_score":0.0015925985,"about_ca_system_score_codex":0.00018322011,"about_ca_system_score_gemma":0.00013539937,"threshold_uncertainty_score":0.003166616},"labels":[],"label_agreement":null},{"id":"W1986700293","doi":"10.1158/1535-7163.targ-11-c69","title":"Abstract C69: Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: An NCIC-CTG phase II clinical trial.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Medicine; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Progressive disease; Phases of clinical research; Oncology; Adenosquamous carcinoma; Cancer; Chemotherapy; Cervix; Adenocarcinoma; Surgery; Clinical trial; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.09987743406618643,"score_gpt":0.3790143645730128,"score_spread":0.27913693050682636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986700293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740214,0.0034555702,0.0003191284,0.0005216618,0.000101873185,0.0019918059,0.0019649768,0.00017116642,0.004071744],"genre_scores_gemma":[0.98747927,0.0018638298,0.0009254739,0.00085894734,0.00016041243,0.0011333311,0.0032741055,0.000030217045,0.004274433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99988997,0.00003975444,0.00000693496,0.000018264427,0.000014260302,0.000030763236],"domain_scores_gemma":[0.9998086,0.000024894509,0.000029188797,0.000009620672,0.000011765358,0.00011595547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039415155,0.0009354192,0.0009783118,0.00026482195,0.00030030982,0.00043261558,0.00046646953,0.00096115016,0.0074869203],"category_scores_gemma":[0.00029983782,0.00022379585,0.0005232408,0.0003267241,0.00033554743,0.00026224207,0.0001988063,0.0018299235,0.0011203821],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6381706,0.03848379,0.008100257,0.0020576098,0.00093464943,0.0012231146,0.00026370503,0.0031733077,0.13195951,0.00040988237,0.017553104,0.15767051],"study_design_scores_gemma":[0.52387357,0.43223155,0.023253653,0.00011004294,0.00045087578,0.00090803794,0.000044078482,0.0014969215,0.0105095105,0.00011996352,0.006964529,0.00003729522],"about_ca_topic_score_codex":0.001868864,"about_ca_topic_score_gemma":0.004786796,"teacher_disagreement_score":0.0074869203,"about_ca_system_score_codex":0.0005574657,"about_ca_system_score_gemma":0.0011861287,"threshold_uncertainty_score":0.02504623},"labels":[],"label_agreement":null},{"id":"W1986763134","doi":"10.1158/1535-7163.targ-09-a185","title":"Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Pharmacodynamics; Adverse effect; Gastroenterology; Internal medicine; Peripheral blood mononuclear cell; Pharmacology; Colorectal cancer; Cmax; Cancer; Biology; In vitro","score_opus":0.023379375978761066,"score_gpt":0.4074113515472472,"score_spread":0.3840319755684862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986763134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990721,0.0020855402,0.0008878342,0.00028476503,0.00007200969,0.0011413032,0.0021877764,0.00014958724,0.0024701229],"genre_scores_gemma":[0.988751,0.00124359,0.0013966113,0.00043559857,0.00006151507,0.00092308514,0.0033068396,0.000031042477,0.0038507709],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998672,0.000036977763,0.000009325595,0.000029493278,0.000024395213,0.000032591335],"domain_scores_gemma":[0.9998419,0.000014019491,0.000031058305,0.000012700049,0.000014336194,0.0000859087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037918496,0.0008274375,0.0008631324,0.0002603579,0.00032746533,0.0006098677,0.00033140625,0.00045104788,0.0040183384],"category_scores_gemma":[0.00024703023,0.00032731582,0.000638819,0.0003255013,0.0003670258,0.0003099337,0.00023297388,0.0017588792,0.0012884205],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2903179,0.061744776,0.027833967,0.0012078615,0.0014167599,0.00086281146,0.00042267828,0.0050307433,0.34463227,0.0005959733,0.0164307,0.24950351],"study_design_scores_gemma":[0.12473763,0.75458306,0.061407756,0.0000740783,0.00069038727,0.001132256,0.000116037576,0.0028994463,0.034961466,0.00030315714,0.0190511,0.00004371187],"about_ca_topic_score_codex":0.0009842901,"about_ca_topic_score_gemma":0.0019147643,"teacher_disagreement_score":0.0040183384,"about_ca_system_score_codex":0.00065045623,"about_ca_system_score_gemma":0.00101752,"threshold_uncertainty_score":0.013442695},"labels":[],"label_agreement":null},{"id":"W1989623500","doi":"10.1158/1535-7163.pms-b16","title":"Abstract B16: Cells containing mutations in the cohesin component, STAG2, are sensitive to PARP inhibition","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cohesin; Synthetic lethality; Olaparib; Establishment of sister chromatid cohesion; Biology; Cancer cell; Chromosome instability; Cancer research; Molecular biology; PARP1; Genome instability; Genetics; Cancer; DNA repair; DNA damage; Poly ADP ribose polymerase; Chromosome; DNA; Polymerase; Gene","score_opus":0.016924990088164046,"score_gpt":0.2661388540910567,"score_spread":0.24921386400289264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989623500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166274,0.0018751019,0.0013699065,0.000114659626,0.00008062505,0.000036446174,0.0029224893,0.00020206968,0.0017360498],"genre_scores_gemma":[0.9876628,0.000647035,0.0011822352,0.00008223845,0.000010140736,0.00007724372,0.0035596262,0.00004529583,0.0067335046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984074,0.000019422558,0.000022233547,0.000029745077,0.000055818582,0.00003197621],"domain_scores_gemma":[0.9998379,0.000018886432,0.0000457082,0.000027254491,0.000015763075,0.000054629698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008694174,0.00055341626,0.0002978105,0.00036157455,0.00014637614,0.0003418146,0.00021895175,0.0003778329,0.003457392],"category_scores_gemma":[0.00009066041,0.00018338022,0.00029743652,0.00028423572,0.00016553845,0.00015068834,0.00022070526,0.00068212865,0.0011229974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006616964,0.00002001779,0.00015446148,0.0000145806625,0.000005920752,0.00004698,0.0000045533075,0.000032008018,0.99932826,0.000025830908,0.00006436671,0.00023688802],"study_design_scores_gemma":[0.000024157609,0.00045533772,0.008580314,0.000006405355,0.0000123752325,0.00045191517,0.000029113751,0.00055455253,0.98771065,0.000027603937,0.0021430582,0.0000044907615],"about_ca_topic_score_codex":0.0012415905,"about_ca_topic_score_gemma":0.0014280268,"teacher_disagreement_score":0.003457392,"about_ca_system_score_codex":0.00020473811,"about_ca_system_score_gemma":0.00013112342,"threshold_uncertainty_score":0.011566162},"labels":[],"label_agreement":null},{"id":"W1989966460","doi":"10.1158/1535-7163.mct-07-0515","title":"UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cleveland Clinic Foundation; National Institutes of Health; Cleveland Clinic; National Cancer Institute; Samuel Waxman Cancer Research Foundation","keywords":"Promyelocytic leukemia protein; Acute promyelocytic leukemia; Ubiquitin; Biology; Retinoic acid; Cancer research; ISG15; Psychological repression; HEK 293 cells; Tretinoin; Cell biology; Gene expression; Receptor; Gene; Biochemistry","score_opus":0.016154917774387618,"score_gpt":0.27062417790616555,"score_spread":0.25446926013177795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989966460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439585,0.0017038431,0.0019904592,0.00011246668,0.00002051883,0.000026529648,0.00027624183,0.00009567451,0.0013783432],"genre_scores_gemma":[0.99405307,0.0007067748,0.0015311447,0.000059035705,0.000007771024,0.000022531389,0.000652516,0.000019698517,0.0029474928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984276,0.000029006478,0.000022555654,0.000033126944,0.000029831528,0.000042793556],"domain_scores_gemma":[0.99992764,0.000007358388,0.00002453477,0.00001330271,0.0000075643316,0.00001960325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016267358,0.00033864047,0.0002565249,0.00017774226,0.00015390101,0.00037014374,0.00017024894,0.0001818072,0.000672757],"category_scores_gemma":[0.00008111362,0.00013483723,0.00027532215,0.00013625885,0.00024727508,0.00014733577,0.00020889085,0.00039387774,0.00047617764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092642586,0.000022279452,0.00011712539,0.00002475876,0.0000033297033,0.000027375461,0.0000116239125,0.00005550321,0.9988084,0.0000749749,0.000023094544,0.00073893665],"study_design_scores_gemma":[0.000009866386,0.00006874883,0.0011453836,0.0000027844922,0.0000045111506,0.00007915659,0.000008906824,0.00047658817,0.9964623,0.000015209071,0.0017251788,0.000001444435],"about_ca_topic_score_codex":0.00042391024,"about_ca_topic_score_gemma":0.0006916806,"teacher_disagreement_score":0.000672757,"about_ca_system_score_codex":0.00039821572,"about_ca_system_score_gemma":0.00024878193,"threshold_uncertainty_score":0.0028892756},"labels":[],"label_agreement":null},{"id":"W1990418094","doi":"10.1158/1535-7163.mct-08-0198","title":"Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Hypoxia (environmental); Senescence; Biology; Population; Small interfering RNA; Apoptosis; Etoposide; Pharmacology; Daunorubicin; Mitoxantrone; Clonogenic assay; Drug resistance; Hypoxia-inducible factors; Cancer research; Immunology; Cell biology; Chemistry; Cell culture; Medicine; Transfection; Biochemistry; Chemotherapy; Leukemia; Oxygen","score_opus":0.02930541796033482,"score_gpt":0.2765230141652082,"score_spread":0.24721759620487338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990418094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908283,0.0061735855,0.001849562,0.00008582102,0.000012318942,0.000018704237,0.0002612833,0.00003556329,0.0007348698],"genre_scores_gemma":[0.9955205,0.0022903397,0.0007707078,0.00003346423,0.000012156463,0.000016065671,0.00037945644,0.0000056234157,0.0009717355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999193,0.0000151877275,0.000009260222,0.000015700682,0.000023825794,0.000016678578],"domain_scores_gemma":[0.9998803,0.000017838793,0.00005789368,0.000010610523,0.000016380134,0.000016906462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008411402,0.00012594841,0.00019650164,0.00013501504,0.000094703966,0.00017608055,0.00006401835,0.000117820404,0.0007730445],"category_scores_gemma":[0.000109233355,0.00008850499,0.00015024414,0.0001185022,0.00008525784,0.00010889317,0.000087123255,0.00020529896,0.00019860415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004474878,0.00000815788,0.0005232391,0.000024182622,0.0000042624374,0.00002941149,0.000011927131,0.000015159373,0.9981401,0.00002292348,0.000015566107,0.0011603261],"study_design_scores_gemma":[0.000008901519,0.00054021116,0.07978137,0.000010544315,0.000019891915,0.0012244896,0.000041449217,0.0006285874,0.91422844,0.00006141702,0.0034494733,0.0000051294096],"about_ca_topic_score_codex":0.0004457637,"about_ca_topic_score_gemma":0.00048872165,"teacher_disagreement_score":0.0007730445,"about_ca_system_score_codex":0.00016743659,"about_ca_system_score_gemma":0.00009807284,"threshold_uncertainty_score":0.0025860667},"labels":[],"label_agreement":null},{"id":"W1991500129","doi":"10.1158/1535-7163.targ-13-b133","title":"Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Kinase; Cancer research; Androgen; Cancer; LNCaP; Kinome; Biology; Medicine; Internal medicine; Endocrinology; Cell biology; Hormone","score_opus":0.022211170552774218,"score_gpt":0.29957309379486463,"score_spread":0.2773619232420904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991500129","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58782005,0.27046764,0.009482948,0.021206966,0.007136607,0.00035197826,0.028416459,0.002365802,0.07275164],"genre_scores_gemma":[0.81628424,0.07069185,0.006344672,0.0022384494,0.00139962,0.00017972616,0.01826073,0.00018410286,0.084416665],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999317,0.0000085163665,0.000003959889,0.000015427297,0.000029425168,0.0000109412385],"domain_scores_gemma":[0.9999398,0.0000060820007,0.00001842463,0.000002790274,0.0000118313565,0.00002102233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104826984,0.00047154052,0.0002754156,0.0004684388,0.00038450662,0.00066183176,0.000245475,0.00044846733,0.010604155],"category_scores_gemma":[0.0001186036,0.00016332604,0.00030624864,0.0005403146,0.0001670072,0.00028205127,0.00026125484,0.0007245709,0.0030027411],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016003216,0.00019730724,0.0035278918,0.002099072,0.00006303017,0.0011716647,0.00007396192,0.0004756812,0.82163906,0.0043949434,0.049074635,0.11568229],"study_design_scores_gemma":[0.00027696678,0.0015840055,0.17700866,0.00027894304,0.00019326946,0.006548755,0.00018002705,0.0027867425,0.43522063,0.0031157846,0.3727069,0.00009935588],"about_ca_topic_score_codex":0.0022520036,"about_ca_topic_score_gemma":0.0029932843,"teacher_disagreement_score":0.010604155,"about_ca_system_score_codex":0.00093120727,"about_ca_system_score_gemma":0.00070353213,"threshold_uncertainty_score":0.03547442},"labels":[],"label_agreement":null},{"id":"W1992078544","doi":"10.1158/1535-7163.targ-13-c246","title":"Abstract C246: SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Annexin; STAT3; Viability assay; Angiogenesis; Cancer research; Molecular biology; Cell culture; Annexin A5; Multiple myeloma; Cancer cell; Chemistry; Apoptosis; Flow cytometry; Biology; Medicine; Cancer; Immunology; Biochemistry; Internal medicine","score_opus":0.04529557599727723,"score_gpt":0.3077879985497879,"score_spread":0.26249242255251065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992078544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98054814,0.0068836347,0.0038996548,0.0003782982,0.00017395776,0.0001481401,0.0018067264,0.0004140622,0.0057473606],"genre_scores_gemma":[0.9845009,0.002246381,0.0028018507,0.00016085524,0.00003060639,0.000089105066,0.002554062,0.000025567426,0.0075906813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993503,0.0000068125505,0.0000044493518,0.000012605744,0.000020813548,0.000020236672],"domain_scores_gemma":[0.999966,0.0000046342266,0.000008804546,0.0000032512887,0.0000049951773,0.000012279624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009052202,0.00049064524,0.00022634394,0.00024551223,0.00010485558,0.00014240415,0.0003330628,0.00033446378,0.003997317],"category_scores_gemma":[0.000068363646,0.000090593436,0.00026021744,0.00015863305,0.00013340855,0.000093320006,0.000109184206,0.00046155305,0.0009161378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003979374,0.0001678018,0.00017018525,0.00008988175,0.00002140818,0.00007391385,0.0000048405814,0.00030855913,0.9924292,0.00009291799,0.0005861494,0.005657123],"study_design_scores_gemma":[0.00018865045,0.001619597,0.002172271,0.0000073375977,0.000042089392,0.00031788214,0.0000044316475,0.0012859384,0.9888355,0.000034673896,0.005484552,0.0000071678346],"about_ca_topic_score_codex":0.0007386774,"about_ca_topic_score_gemma":0.00079094,"teacher_disagreement_score":0.003997317,"about_ca_system_score_codex":0.00026692057,"about_ca_system_score_gemma":0.00018090196,"threshold_uncertainty_score":0.013372362},"labels":[],"label_agreement":null},{"id":"W1995058453","doi":"10.1158/1535-7163.targ-09-a189","title":"Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; DNA damage; DNA repair; Vorinostat; Cancer research; Cell biology; Fusion protein; Histone; Gene silencing; Myeloid leukemia; Histone deacetylase; Molecular biology; Genetics; Gene; DNA","score_opus":0.010349741509557865,"score_gpt":0.27076716155885505,"score_spread":0.2604174200492972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995058453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460715,0.0012492441,0.0013462224,0.00016936059,0.00007807072,0.00004202604,0.0012023438,0.000105834275,0.0011997232],"genre_scores_gemma":[0.9924705,0.00072264025,0.0015987434,0.00007522544,0.000023755087,0.00007202693,0.0022257327,0.000018210809,0.0027931656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998374,0.000019447347,0.000023395532,0.00002992908,0.00004965945,0.00004011402],"domain_scores_gemma":[0.9999181,0.000013981436,0.000023434784,0.000009553242,0.000009851419,0.0000249344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000789365,0.0003112861,0.00031691967,0.00022703038,0.00013840155,0.00022361841,0.00019936058,0.00029342095,0.002519046],"category_scores_gemma":[0.00008831774,0.00010729492,0.0002982111,0.0002913617,0.00015620695,0.00013215787,0.00013353545,0.0006359839,0.00071932183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012533665,0.00006472054,0.00017817227,0.000019404868,0.0000041731496,0.000037688165,0.0000068046197,0.00002963215,0.9988005,0.000042999673,0.000088472094,0.00060193386],"study_design_scores_gemma":[0.000022766411,0.0005942761,0.0031114642,0.000004017828,0.00001055617,0.00019261084,0.000018459303,0.00048202538,0.993471,0.000028499406,0.002061811,0.0000025543886],"about_ca_topic_score_codex":0.00048755747,"about_ca_topic_score_gemma":0.0004050624,"teacher_disagreement_score":0.002519046,"about_ca_system_score_codex":0.00026397244,"about_ca_system_score_gemma":0.00015476145,"threshold_uncertainty_score":0.008427024},"labels":[],"label_agreement":null},{"id":"W1997050616","doi":"10.1158/1535-7163.targ-11-a201","title":"Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Cancer research; Macroglobulinemia; Waldenstrom macroglobulinemia; Biology; Cell growth; Transcription factor; Carcinogenesis; STAT5; Lymphoma; Signal transduction; Gene; Immunology; Multiple myeloma; Cell biology; Genetics","score_opus":0.05389147754549747,"score_gpt":0.3120570654793618,"score_spread":0.25816558793386435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997050616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787365,0.0069647366,0.002841211,0.0004364004,0.00017526744,0.0001958792,0.0015485253,0.0003805648,0.008720808],"genre_scores_gemma":[0.9864288,0.002410924,0.0025707362,0.00016284332,0.000032180327,0.000077458455,0.0029600721,0.000020449736,0.005336493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999429,0.000008165432,0.0000043175096,0.0000068380223,0.00002070903,0.000017042812],"domain_scores_gemma":[0.99996305,0.000007673553,0.0000052142573,0.0000036088081,0.00000477488,0.000015687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013148237,0.00043909682,0.00021095625,0.00020377115,0.000108487824,0.00016405995,0.00022096865,0.00025726878,0.0032819565],"category_scores_gemma":[0.00007401749,0.000091911556,0.00015702398,0.00014161768,0.00011628601,0.00010149764,0.00007265349,0.0006747417,0.0008961692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006823748,0.00072696566,0.0003692116,0.00011812049,0.000018645796,0.00010918663,0.000014445584,0.00031395155,0.980719,0.0001174658,0.0009871973,0.01582347],"study_design_scores_gemma":[0.00071456016,0.009022482,0.008767352,0.000016602648,0.00005314661,0.0009354643,0.000010432484,0.0017057532,0.97043633,0.00005763297,0.008271623,0.000008660462],"about_ca_topic_score_codex":0.000771445,"about_ca_topic_score_gemma":0.0010872714,"teacher_disagreement_score":0.0032819565,"about_ca_system_score_codex":0.00015876,"about_ca_system_score_gemma":0.00022278652,"threshold_uncertainty_score":0.010979235},"labels":[],"label_agreement":null},{"id":"W1997663619","doi":"10.1158/1535-7163.targ-13-a236","title":"Abstract A236: The orphan G-protein coupled receptor GPR161 is an oncogene in triple negative breast cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Cancer; Biology; Breast cancer; mTORC1; Carcinogenesis; Gene knockdown; PI3K/AKT/mTOR pathway; Cell growth; Oncogene; Signal transduction; Cell biology; Cell culture; Genetics; Cell cycle","score_opus":0.019466022167806518,"score_gpt":0.27534674363905204,"score_spread":0.2558807214712455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997663619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686525,0.014174826,0.0018139858,0.0016765527,0.0005799143,0.00009680797,0.0049885227,0.00024775774,0.007769161],"genre_scores_gemma":[0.9747218,0.00599784,0.001304612,0.00044411668,0.00010264759,0.00006995113,0.0056739664,0.000026800371,0.011658301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993515,0.00000816378,0.0000052409086,0.000019308958,0.000017352151,0.000014717006],"domain_scores_gemma":[0.9999635,0.0000024365092,0.000013063383,0.0000023569105,0.0000042335632,0.000014298502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008787686,0.00039774622,0.00022913239,0.0002462042,0.00022387845,0.00022032509,0.00024915815,0.00041094882,0.004982631],"category_scores_gemma":[0.000090473186,0.000101728736,0.00035488943,0.0002889696,0.00017719298,0.00013858815,0.00030910686,0.0004270646,0.0019061709],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010958456,0.0000946001,0.009602145,0.00029394095,0.000050439237,0.00289675,0.000038087484,0.00019547775,0.95407206,0.00050384743,0.0050063524,0.02615056],"study_design_scores_gemma":[0.0004144774,0.0031716318,0.21268608,0.00018114189,0.00047506654,0.053253762,0.00040460503,0.001998102,0.5744309,0.0014718242,0.15146543,0.000046981022],"about_ca_topic_score_codex":0.00090118573,"about_ca_topic_score_gemma":0.0006707512,"teacher_disagreement_score":0.004982631,"about_ca_system_score_codex":0.0003657849,"about_ca_system_score_gemma":0.0002217039,"threshold_uncertainty_score":0.016668499},"labels":[],"label_agreement":null},{"id":"W2000068551","doi":"10.1158/1535-7163.targ-09-b154","title":"Abstract B154: Thymoquinone causes mitochondrial membrane disruption and potentiates chemotherapeutic drug- and radiation-induced cytotoxicity in breast cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nigella sativa pharmacological applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Thymoquinone; Propidium iodide; Pharmacology; Apoptosis; Cytotoxicity; Cancer cell; Cancer research; Chemistry; Programmed cell death; Medicine; Cancer; Biochemistry; Internal medicine; In vitro; Antioxidant","score_opus":0.01958534159994146,"score_gpt":0.3112050312178061,"score_spread":0.29161968961786466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000068551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872186,0.0064783604,0.0015172202,0.00019461659,0.00012770975,0.000060894585,0.00092133775,0.00014917375,0.0033320624],"genre_scores_gemma":[0.9942926,0.001569155,0.00078103924,0.00006481947,0.000028073482,0.00004093071,0.0011047536,0.000012491498,0.0021060987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998884,0.000022580574,0.000012669948,0.000018939136,0.000026451733,0.000030973144],"domain_scores_gemma":[0.9999144,0.00001960374,0.00001787728,0.000012503082,0.000015928428,0.000019645213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011027564,0.0004483363,0.00036326525,0.00027862642,0.00015145325,0.00015584855,0.00026089314,0.00035109,0.0037283693],"category_scores_gemma":[0.00012242065,0.000116300434,0.00021382209,0.00025180975,0.00012188159,0.00013724728,0.00014506765,0.00040927046,0.0008433601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047044686,0.00008168135,0.00010942427,0.00008389881,0.000009354891,0.000100794154,0.000012129889,0.000043060947,0.99755645,0.000034274028,0.00011517268,0.0013832458],"study_design_scores_gemma":[0.00005671495,0.0012756813,0.0023914592,0.000010213867,0.000019051107,0.00037614538,0.000015507328,0.0002633018,0.9933294,0.000017461949,0.0022418336,0.0000032002704],"about_ca_topic_score_codex":0.0006897072,"about_ca_topic_score_gemma":0.000535275,"teacher_disagreement_score":0.0037283693,"about_ca_system_score_codex":0.0001788009,"about_ca_system_score_gemma":0.00015007706,"threshold_uncertainty_score":0.01247263},"labels":[],"label_agreement":null},{"id":"W2000610923","doi":"10.1158/1535-7163.targ-09-a106","title":"Abstract A106: A phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Adverse effect; Refractory (planetary science); Internal medicine; Gastroenterology; Dosing; Surgery","score_opus":0.025273758897927222,"score_gpt":0.3350625837744868,"score_spread":0.30978882487655957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000610923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479115,0.0010699151,0.00040093748,0.00021892926,0.00007665187,0.0011554209,0.0007475419,0.00007095707,0.0014685311],"genre_scores_gemma":[0.9902265,0.0012267901,0.0018449561,0.000570106,0.00009429505,0.0010394702,0.0026146888,0.000019315374,0.0023638634],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997563,0.00012518314,0.0000157107,0.000038061204,0.000028083234,0.00003661068],"domain_scores_gemma":[0.9997373,0.00005219625,0.000032226133,0.000021119664,0.000020168982,0.00013701298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084817613,0.0008749899,0.0012594128,0.00029459404,0.0003073446,0.0005378387,0.0005769649,0.0005898637,0.0021865873],"category_scores_gemma":[0.00041524807,0.00031107577,0.0005878334,0.00026995668,0.00040545184,0.0003031141,0.00025057135,0.0016457464,0.0007234239],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39275944,0.11345017,0.025201848,0.0014055707,0.0013912191,0.002014183,0.00051709363,0.0068677384,0.2256287,0.0006957924,0.012207327,0.21786086],"study_design_scores_gemma":[0.2799624,0.6658275,0.030079301,0.00005725232,0.0003160527,0.0013922071,0.00008921182,0.0027984555,0.012521194,0.00018852454,0.006724865,0.00004300196],"about_ca_topic_score_codex":0.00076953607,"about_ca_topic_score_gemma":0.0017909664,"teacher_disagreement_score":0.0021865873,"about_ca_system_score_codex":0.00042260173,"about_ca_system_score_gemma":0.00092264597,"threshold_uncertainty_score":0.0073149204},"labels":[],"label_agreement":null},{"id":"W2001379228","doi":"10.1158/1535-7163.targ-13-a247","title":"Abstract A247: BT2111, a new anticancer agent composed of trastuzumab and transcend a vector for brain delivery for the treatment of metastatic Her2+ breast cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institute for Biological Sciences","funders":"","keywords":"Trastuzumab; Medicine; Parenchyma; Monoclonal antibody; Breast cancer; Antibody; Confocal microscopy; Blood–brain barrier; Intracardiac injection; Pathology; Metastatic breast cancer; Cancer research; Pharmacology; Cancer; Internal medicine; Immunology; Central nervous system; Biology; Cell biology","score_opus":0.05868971413243731,"score_gpt":0.3592567249271313,"score_spread":0.300567010794694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001379228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709138,0.0074370294,0.014734563,0.00033927275,0.00016559847,0.00016843357,0.0008000815,0.0002733251,0.0051678508],"genre_scores_gemma":[0.9722468,0.0033717316,0.009661265,0.000141646,0.000034877627,0.00009496675,0.0016868727,0.000043491345,0.01271842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992967,0.0000074884074,0.0000046081404,0.000018998006,0.000027592894,0.00001167529],"domain_scores_gemma":[0.99996734,0.000002335462,0.000011438299,0.0000017360151,0.0000062652866,0.00001081857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098732016,0.00043864688,0.00018695004,0.00023696285,0.00012581026,0.00024637117,0.00020457398,0.0003803991,0.00087254995],"category_scores_gemma":[0.000059256556,0.000097904085,0.00021049514,0.0001757429,0.00017286702,0.0002031126,0.00015269683,0.00035258697,0.0004948232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069481,0.000036263,0.00007753228,0.000051131716,0.000005903497,0.000069602225,0.000007750769,0.00008772111,0.9957404,0.00017645734,0.00017898333,0.003498859],"study_design_scores_gemma":[0.00003872589,0.0005556372,0.001322876,0.0000069246803,0.000037651796,0.00065949076,0.000006121479,0.00080800685,0.9883386,0.000042254564,0.008176274,0.0000073597225],"about_ca_topic_score_codex":0.00086478534,"about_ca_topic_score_gemma":0.000535452,"teacher_disagreement_score":0.00087254995,"about_ca_system_score_codex":0.000440672,"about_ca_system_score_gemma":0.00023008294,"threshold_uncertainty_score":0.0031973124},"labels":[],"label_agreement":null},{"id":"W2002734325","doi":"10.1158/1535-7163.targ-13-c205","title":"Abstract C205: Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Carfilzomib; Tolerability; Proteasome inhibitor; Cancer research; Proteasome; Cytotoxicity; Apoptosis; Pharmacology; Cell cycle; Cell culture; Chemistry; Medicine; In vitro; Biology; Adverse effect; Biochemistry","score_opus":0.01292518297111887,"score_gpt":0.25261422608241035,"score_spread":0.2396890431112915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002734325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657999,0.024455728,0.0019603812,0.00049118855,0.00008271659,0.00016156895,0.0026686303,0.0002327674,0.0041471915],"genre_scores_gemma":[0.98367876,0.008515567,0.0019827855,0.00011502605,0.0000558265,0.00008233236,0.0036418976,0.000013335451,0.0019144735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989223,0.000019728568,0.000008732461,0.000019740934,0.000030190135,0.000029440062],"domain_scores_gemma":[0.9999393,0.000014546689,0.000016429727,0.000004394105,0.000010051091,0.000015222339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017666814,0.00041205308,0.00029686934,0.00026045847,0.00014947436,0.00022095558,0.00018160345,0.00028764035,0.0010044216],"category_scores_gemma":[0.00010175813,0.00008662528,0.00013397803,0.00030165218,0.00016576069,0.000101432706,0.000080331,0.00041336575,0.00038125864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014553807,0.0003421949,0.0035121501,0.0006223313,0.000026884569,0.0007151031,0.0000373413,0.00086015364,0.9636013,0.00018453923,0.0019265721,0.026715973],"study_design_scores_gemma":[0.00021415231,0.004810803,0.020006618,0.00003477257,0.00006349944,0.00422204,0.000036761317,0.001444118,0.95436233,0.000063786174,0.01472942,0.0000118074495],"about_ca_topic_score_codex":0.0017183243,"about_ca_topic_score_gemma":0.0027356227,"teacher_disagreement_score":0.0017183243,"about_ca_system_score_codex":0.0005079984,"about_ca_system_score_gemma":0.00045566322,"threshold_uncertainty_score":0.0036857724},"labels":[],"label_agreement":null},{"id":"W2003518997","doi":"10.1158/1535-7163.targ-09-a170","title":"Abstract A170: High-content screening for inhibitors of oncogenic transcription by c-Myc","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Förster resonance energy transfer; Fluorescence; Bimolecular fluorescence complementation; Protein-fragment complementation assay; Protein–protein interaction; Computational biology; Transcription factor; Fluorescence microscope; Small molecule; Biology; Chemistry; Biochemistry; Cancer research; Cell biology; Gene; Complementation","score_opus":0.03336528089470042,"score_gpt":0.3012368638498766,"score_spread":0.26787158295517616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003518997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641404,0.0046343682,0.015182773,0.00045058233,0.00018820829,0.0007534088,0.005192488,0.00078811485,0.008669632],"genre_scores_gemma":[0.9434086,0.0035534478,0.024861963,0.00035993432,0.000077511235,0.0006854304,0.012330355,0.00021904006,0.0145037975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998259,0.00002298369,0.000017093766,0.000021216156,0.00008474768,0.000028171702],"domain_scores_gemma":[0.9998833,0.00002860858,0.000014889059,0.000010976305,0.000026645486,0.00003553726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019789378,0.0007121592,0.0003525542,0.00071940373,0.00021892421,0.00025117028,0.00038548987,0.00046834347,0.0037522716],"category_scores_gemma":[0.00015966114,0.0001605798,0.00030794146,0.00041711592,0.000121490324,0.00011204408,0.00017898358,0.00048701427,0.00094942196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014492148,0.0001201604,0.00010185236,0.000047094098,0.000009318049,0.000045185807,0.0000050825697,0.000102951104,0.9962685,0.00005298867,0.00028327797,0.002818686],"study_design_scores_gemma":[0.000074481104,0.0012362286,0.0010174061,0.000005581748,0.000021263562,0.0002444574,0.000005897109,0.00067138334,0.99182796,0.000029001574,0.0048593543,0.0000069623297],"about_ca_topic_score_codex":0.00044573628,"about_ca_topic_score_gemma":0.0006658143,"teacher_disagreement_score":0.0037522716,"about_ca_system_score_codex":0.00022633508,"about_ca_system_score_gemma":0.0002386443,"threshold_uncertainty_score":0.012552559},"labels":[],"label_agreement":null},{"id":"W2004062881","doi":"10.1158/1535-7163.targ-11-a121","title":"Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Synthesis and biological activity","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"SH2 domain; STAT3; Cancer research; STAT protein; Cancer cell; Cancer; Biology; Chemistry; Signal transduction; Cell biology; Tyrosine phosphorylation","score_opus":0.02840876955575181,"score_gpt":0.25265526855958653,"score_spread":0.22424649900383473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004062881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8442071,0.06186885,0.019113831,0.002352336,0.0017802246,0.00086529145,0.005009948,0.0014176696,0.063384704],"genre_scores_gemma":[0.9363758,0.016500223,0.005984129,0.00082816154,0.00017059864,0.00024720564,0.0027818063,0.00005805882,0.037054088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994195,0.00000893002,0.000004292044,0.000011498436,0.00001767249,0.000015733445],"domain_scores_gemma":[0.9999695,0.0000031149232,0.0000060947577,0.0000023677997,0.0000047541994,0.000014224802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009716107,0.00047456083,0.0002176963,0.000356335,0.00017138744,0.00024000839,0.0003064998,0.00041636985,0.0056021656],"category_scores_gemma":[0.000051884886,0.00010623765,0.00030173446,0.00024469526,0.00012011563,0.00021855005,0.00021240744,0.00068111985,0.0016314167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001664017,0.0008672713,0.00029818562,0.00037697397,0.00006127414,0.0003587241,0.000023942082,0.00094756595,0.92519706,0.0021419404,0.00780175,0.060261298],"study_design_scores_gemma":[0.0012722794,0.0077957935,0.0037286452,0.000051117426,0.000125903,0.0011462565,0.000026781483,0.004546435,0.8963488,0.0006271155,0.08428601,0.00004496948],"about_ca_topic_score_codex":0.0002502371,"about_ca_topic_score_gemma":0.00045710415,"teacher_disagreement_score":0.0056021656,"about_ca_system_score_codex":0.00017609297,"about_ca_system_score_gemma":0.00019610334,"threshold_uncertainty_score":0.018741071},"labels":[],"label_agreement":null},{"id":"W2005166484","doi":"10.1158/1535-7163.mct-04-0214","title":"Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Oncosuisse; Terry Fox Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Cancer Institute; National Science Foundation","keywords":"Cancer research; Biology; MSH2; DNA repair; DNA mismatch repair; Cancer; Cancer cell; DNA; Genetics","score_opus":0.03412404557386352,"score_gpt":0.32579379448660695,"score_spread":0.29166974891274344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005166484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208474,0.0016721721,0.004676048,0.00011839526,0.000031175674,0.000028918646,0.00038053232,0.000089358866,0.00091874006],"genre_scores_gemma":[0.9942854,0.0006059958,0.0028914758,0.000039633946,0.0000054039147,0.000030886178,0.0004747481,0.000018275909,0.0016481323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999219,0.000014723212,0.000009898979,0.00002009613,0.000020855417,0.00001249836],"domain_scores_gemma":[0.9998908,0.000024007377,0.000027831122,0.00002232045,0.000014392171,0.000020603606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009717923,0.00018282903,0.00017572865,0.0001365743,0.000112587615,0.0001583749,0.000081061735,0.00016419061,0.0007664071],"category_scores_gemma":[0.0000791068,0.00008559819,0.00015613712,0.000084841544,0.000118057804,0.00012295964,0.00010108298,0.00030192785,0.0002101849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001759135,0.000006245368,0.000095130235,0.000007360639,0.0000016210665,0.000013802304,0.000008417602,0.000016605592,0.99955267,0.00002452931,0.000011056626,0.0002448718],"study_design_scores_gemma":[0.0000025666636,0.00009243823,0.0035108828,0.0000010917843,0.0000050252356,0.00013854289,0.00001283371,0.0003411291,0.9952603,0.000018328212,0.00061573327,0.0000011556488],"about_ca_topic_score_codex":0.0005842497,"about_ca_topic_score_gemma":0.00080976327,"teacher_disagreement_score":0.0007664071,"about_ca_system_score_codex":0.00016626946,"about_ca_system_score_gemma":0.00010449256,"threshold_uncertainty_score":0.0025638342},"labels":[],"label_agreement":null},{"id":"W2005910933","doi":"10.1158/1535-7163.targ-11-b63","title":"Abstract B63: Targeting cancer cells with a glucose-conjugated DNA repair inhibitor.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Temozolomide; Cancer research; O-6-methylguanine-DNA methyltransferase; Methyltransferase; DNA repair; Guanine; DNA damage; Cancer cell; DNA; Lomustine; DNA methyltransferase; Cancer; Cisplatin; Chemistry; Pharmacology; Chemotherapy; Biology; Biochemistry; Vincristine; Methylation; Glioma; Nucleotide; Genetics","score_opus":0.02793375412653739,"score_gpt":0.26911507958806247,"score_spread":0.24118132546152507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005910933","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93171877,0.03162763,0.014211497,0.0013157689,0.0011389432,0.00033443968,0.0024724253,0.0013326432,0.015847798],"genre_scores_gemma":[0.9649173,0.008912926,0.009265219,0.000380823,0.000059401762,0.00013747551,0.0030713838,0.00013115903,0.013124237],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999033,0.000011358357,0.000008240536,0.0000302219,0.000024918863,0.000021972624],"domain_scores_gemma":[0.999969,0.0000027035203,0.00000835492,0.0000031725858,0.0000039761426,0.000012844329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008841878,0.0005114636,0.00038580367,0.00031741738,0.00017568191,0.000279384,0.0002633287,0.0006080325,0.0014100093],"category_scores_gemma":[0.00006955141,0.0001360606,0.00027934246,0.00041294532,0.00014734647,0.00014568368,0.00014659432,0.0006985891,0.0009949247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042340107,0.0002102635,0.00008225349,0.00016494567,0.00001427119,0.0001245997,0.000019618714,0.00027865486,0.98776627,0.00023616159,0.0008015443,0.009877986],"study_design_scores_gemma":[0.00008844455,0.00096709514,0.0013338825,0.000015099538,0.000028036635,0.00028579726,0.00001059148,0.0013708742,0.98358893,0.000068905654,0.012233257,0.0000091282855],"about_ca_topic_score_codex":0.001691721,"about_ca_topic_score_gemma":0.0009784712,"teacher_disagreement_score":0.001691721,"about_ca_system_score_codex":0.00023569966,"about_ca_system_score_gemma":0.0001930953,"threshold_uncertainty_score":0.004716933},"labels":[],"label_agreement":null},{"id":"W2006293080","doi":"10.1158/1535-7163.targ-13-a110","title":"Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Temozolomide; Medicine; Oncology; Internal medicine; Progression-free survival; Univariate analysis; Glioblastoma; Radiation therapy; Epidermal growth factor receptor; Multivariate analysis; Hazard ratio; Population; Dacarbazine; Cancer; Overall survival; Cancer research; Confidence interval; Chemotherapy","score_opus":0.01286034333198139,"score_gpt":0.2714484211420608,"score_spread":0.2585880778100794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006293080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977502,0.0015426236,0.00005390903,0.0000742161,0.000024345278,0.000028359149,0.00026394374,0.000007494538,0.00025493387],"genre_scores_gemma":[0.998865,0.00021278998,0.00007210338,0.00007668999,0.000035488243,0.000017494473,0.0005770529,0.000002362914,0.00014099825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994684,0.00024660616,0.00004681912,0.00010149152,0.00009226158,0.000044538476],"domain_scores_gemma":[0.99919516,0.00020276784,0.00032268712,0.00005228095,0.000055723256,0.00017136396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001561492,0.0003835173,0.0006823461,0.00023166258,0.00017745436,0.0007329188,0.00037148123,0.00048924674,0.0014717256],"category_scores_gemma":[0.0011606623,0.00017127325,0.00090454967,0.000494681,0.00034849843,0.00028031654,0.00018745073,0.0006421972,0.00016180062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3437751,0.0022202022,0.57101333,0.0007408872,0.010845713,0.0003852243,0.00013486481,0.0012216476,0.020970264,0.00013190636,0.003712505,0.044848405],"study_design_scores_gemma":[0.0196761,0.028705038,0.93935573,0.000060119444,0.005418198,0.0006417653,0.000071957664,0.0014644589,0.0027001568,0.00012544983,0.001749694,0.000031341977],"about_ca_topic_score_codex":0.0009538716,"about_ca_topic_score_gemma":0.0012997976,"teacher_disagreement_score":0.001561492,"about_ca_system_score_codex":0.00039557423,"about_ca_system_score_gemma":0.00041304238,"threshold_uncertainty_score":0.008258045},"labels":[],"label_agreement":null},{"id":"W2006884048","doi":"10.1158/1535-7163.targ-11-a194","title":"Abstract A194: A QT/QTc and multi-dose pharmacokinetic (PK) study of abiraterone acetate (AA) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; QT interval; Docetaxel; Pharmacokinetics; Internal medicine; Prednisone; Pharmacology; Cancer; Androgen deprivation therapy; Urology","score_opus":0.07343865574434846,"score_gpt":0.3474244786887221,"score_spread":0.2739858229443737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006884048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559915,0.00093966356,0.00057048665,0.00016098483,0.00005949309,0.0010594705,0.0007125964,0.00006408299,0.00083414634],"genre_scores_gemma":[0.9955996,0.0006152628,0.0009375371,0.0001986443,0.00012936686,0.00068834896,0.00073313265,0.000017585813,0.0010804049],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99952793,0.00022574078,0.000033560413,0.000092415634,0.00007196686,0.000048356545],"domain_scores_gemma":[0.9992061,0.00012713131,0.00018339779,0.000076078024,0.000043798605,0.00036343737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008714902,0.0010296436,0.0016637485,0.00033747102,0.00043476166,0.0006741417,0.000592101,0.00074320793,0.003877641],"category_scores_gemma":[0.0013519782,0.00055774767,0.0010925824,0.00047148732,0.0008177929,0.0009038015,0.00034841237,0.0027174733,0.0008157141],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8081913,0.04673549,0.008589542,0.0005899664,0.0011354983,0.0003869378,0.0003284901,0.0018376391,0.07646264,0.00014359021,0.0014396089,0.054159272],"study_design_scores_gemma":[0.29869327,0.6579803,0.031996295,0.000020838848,0.00068417843,0.00056479964,0.000067228095,0.0015576166,0.005748737,0.00017107707,0.002465001,0.000050633407],"about_ca_topic_score_codex":0.0009835135,"about_ca_topic_score_gemma":0.0017539724,"teacher_disagreement_score":0.003877641,"about_ca_system_score_codex":0.0007094442,"about_ca_system_score_gemma":0.0010898717,"threshold_uncertainty_score":0.012971997},"labels":[],"label_agreement":null},{"id":"W2007517393","doi":"10.1158/1535-7163.mct-09-0148","title":"Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Hsp27; Bladder cancer; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Cytotoxicity; In vivo; Medicine; Heat shock protein; Cancer; Pharmacology; Apoptosis; Chemistry; Internal medicine; Biology; In vitro; Hsp70; Biochemistry","score_opus":0.02672840169013674,"score_gpt":0.3180621902871511,"score_spread":0.29133378859701436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007517393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990952,0.0042500533,0.0034092118,0.000099729245,0.00007049736,0.000081507096,0.00010595368,0.000093694645,0.00093727757],"genre_scores_gemma":[0.99396074,0.0020986602,0.0024614006,0.000043644206,0.00001906263,0.0000433601,0.00015966943,0.00000991892,0.0012035281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999143,0.000013041891,0.0000068612576,0.000021126743,0.000024963047,0.000019730865],"domain_scores_gemma":[0.99995923,0.000006095387,0.000010295755,0.0000059029803,0.0000052120704,0.000013221122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012235683,0.00027022036,0.00042209824,0.0002326407,0.000141973,0.00021556493,0.00019781587,0.0002208728,0.00078667165],"category_scores_gemma":[0.000055794986,0.00013387113,0.00029771708,0.00016051032,0.00016957593,0.0001352564,0.00017559298,0.0004975027,0.0001266265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027159008,0.00013480286,0.00028227354,0.00009751514,0.00002155322,0.00005088763,0.000020835341,0.0002336787,0.9913481,0.000050464565,0.000083793166,0.0074046007],"study_design_scores_gemma":[0.00006804465,0.0031687305,0.0036610877,0.0000078892335,0.000086402324,0.00036893552,0.00003351893,0.0012051739,0.98868525,0.000022288554,0.0026824547,0.000010237487],"about_ca_topic_score_codex":0.00047685602,"about_ca_topic_score_gemma":0.001450287,"teacher_disagreement_score":0.00078667165,"about_ca_system_score_codex":0.00016763565,"about_ca_system_score_gemma":0.00020657429,"threshold_uncertainty_score":0.0026316643},"labels":[],"label_agreement":null},{"id":"W2008744352","doi":"10.1158/1535-7163.targ-11-c22","title":"Abstract C22: A phase II study of intravenous wild-type reovirus (Reolysin®) in combination with paclitaxel plus carboplatin in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Carboplatin; Regimen; Tolerability; Chemotherapy; Phases of clinical research; Oncology; Population; Surgery; Adverse effect; Cisplatin","score_opus":0.03269678786943771,"score_gpt":0.2977749498705359,"score_spread":0.2650781620010982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008744352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380106,0.0010744991,0.00036059375,0.000205466,0.000100550395,0.0026286836,0.0005163213,0.00007030402,0.0012424815],"genre_scores_gemma":[0.9910493,0.0012891561,0.0010896723,0.0005106188,0.00017107111,0.0019596005,0.0013053876,0.000029185903,0.0025959979],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965584,0.00014480946,0.000017604496,0.00006775306,0.000036199774,0.00007770505],"domain_scores_gemma":[0.99944943,0.000075599964,0.00008221292,0.000051415453,0.00003838344,0.00030299745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001062451,0.001521894,0.0018911003,0.00050299696,0.00046995791,0.0008901351,0.0010488039,0.0013713189,0.003066188],"category_scores_gemma":[0.00065768533,0.0006100682,0.001051383,0.00042729996,0.0008461141,0.0006520787,0.0002648904,0.002932543,0.0008363899],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5889704,0.17915426,0.0058640344,0.0014383247,0.0017556763,0.00077631505,0.00055059924,0.0038593544,0.11757945,0.0003583773,0.0039501153,0.09574304],"study_design_scores_gemma":[0.41038927,0.5728136,0.007766514,0.00002677091,0.00026534207,0.00032351774,0.000055666795,0.0009013821,0.0056179506,0.00006332139,0.0017486743,0.00002807786],"about_ca_topic_score_codex":0.0020754712,"about_ca_topic_score_gemma":0.0040894677,"teacher_disagreement_score":0.003066188,"about_ca_system_score_codex":0.0009842489,"about_ca_system_score_gemma":0.0017915,"threshold_uncertainty_score":0.010257423},"labels":[],"label_agreement":null},{"id":"W2008775683","doi":"10.1158/1535-7163.targ-13-a203","title":"Abstract A203: An in vitro tumor model to characterize tumor cell metabolism in heterogeneous complex microenvironments.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tumor microenvironment; In vivo; Cell culture; Biology; Context (archaeology); Cancer cell; Cell biology; Cell; Cell type; In vitro; Cancer research; Chemistry; Cancer; Tumor cells; Biochemistry; Genetics","score_opus":0.0242807989622685,"score_gpt":0.25734573396754634,"score_spread":0.23306493500527783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008775683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8990891,0.0021967231,0.08117187,0.00034575688,0.00020941418,0.0004514729,0.009514788,0.00081922254,0.006201762],"genre_scores_gemma":[0.91942906,0.0014469,0.06383696,0.0001715087,0.000025583484,0.0005764538,0.007556135,0.00015720613,0.006800171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983037,0.000030183117,0.000016670003,0.000041934847,0.000053621832,0.000027138587],"domain_scores_gemma":[0.9998287,0.000041023955,0.0000348508,0.000028424922,0.000015600295,0.000051453215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027638944,0.000630166,0.00029208235,0.0006665727,0.0002667102,0.0003679475,0.0004155423,0.0005420429,0.0015359487],"category_scores_gemma":[0.000101626145,0.00023278182,0.00042400436,0.00055604515,0.0001938073,0.00023580753,0.0002885759,0.0006602502,0.00075283006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012786822,0.00009272055,0.00037467884,0.000040201732,0.0000070716524,0.00015364395,0.000012962775,0.0005860323,0.99712664,0.00018638316,0.00019648529,0.0010953464],"study_design_scores_gemma":[0.00003717815,0.0008741505,0.0052006305,0.000011713985,0.000043147076,0.00068050245,0.000030591942,0.008267379,0.97753376,0.0001685652,0.0071377964,0.000014657124],"about_ca_topic_score_codex":0.0025210658,"about_ca_topic_score_gemma":0.004248069,"teacher_disagreement_score":0.0025210658,"about_ca_system_score_codex":0.00042247487,"about_ca_system_score_gemma":0.0003952885,"threshold_uncertainty_score":0.005138278},"labels":[],"label_agreement":null},{"id":"W2014051778","doi":"10.1158/1535-7163.targ-11-b126","title":"Abstract B126: Optimization of culture conditions for the establishment of de novo renal cell carcinoma cell lines.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Clear cell renal cell carcinoma; Cancer research; Cell culture; Cancer; Biology; Gene knockdown; Malignancy; Cancer cell; Fetal bovine serum; Cell growth; Renal cell carcinoma; Medicine; Pathology; Genetics","score_opus":0.01720443224136935,"score_gpt":0.2534081869839953,"score_spread":0.23620375474262595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014051778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7046227,0.013643594,0.17078146,0.0012006735,0.0017335681,0.007104626,0.05719966,0.0027057545,0.04100798],"genre_scores_gemma":[0.5337652,0.009292092,0.2740624,0.0007092929,0.00015121029,0.006044032,0.12942542,0.00090106117,0.045649376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987569,0.00018217502,0.00024232609,0.00027371506,0.00040025244,0.00014468985],"domain_scores_gemma":[0.999361,0.000117820426,0.000061074905,0.00015027355,0.0002302179,0.0000797019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001235089,0.00081637426,0.00077706564,0.00069052965,0.00072904426,0.0006132284,0.0012124244,0.00089716713,0.0034256736],"category_scores_gemma":[0.00061485864,0.00036443007,0.00074493204,0.0011358204,0.00025203696,0.00031890368,0.00053433067,0.0013005801,0.004486474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011788038,0.00012573684,0.00029415326,0.00017727881,0.000011153534,0.000120237586,0.00010401141,0.00023709207,0.99388206,0.0002787557,0.0009676516,0.0036839414],"study_design_scores_gemma":[0.000031577103,0.00044120286,0.003492606,0.00004657554,0.00005170307,0.00036890223,0.00005198613,0.0013979061,0.95650893,0.000078405144,0.037499785,0.00003051721],"about_ca_topic_score_codex":0.004589555,"about_ca_topic_score_gemma":0.0072937263,"teacher_disagreement_score":0.004589555,"about_ca_system_score_codex":0.0004888111,"about_ca_system_score_gemma":0.00062807155,"threshold_uncertainty_score":0.011460066},"labels":[],"label_agreement":null},{"id":"W2014093910","doi":"10.1158/1535-7163.targ-13-b267","title":"Abstract B267: Inhibition of PLK4 as a therapeutic strategy for genomically unstable cancers deficient for PTEN.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"PTEN; Cancer; Cancer research; Biology; Centrosome; Kinase; Mitosis; Cancer cell; Cell cycle; Apoptosis; PI3K/AKT/mTOR pathway; Cell biology; Genetics","score_opus":0.049749592852205884,"score_gpt":0.34668496005035554,"score_spread":0.29693536719814967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014093910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815285,0.003306354,0.0046711825,0.0005381495,0.00013619362,0.00033618227,0.0014140431,0.00043902584,0.007630348],"genre_scores_gemma":[0.98725605,0.002030494,0.0027838717,0.000114066315,0.000015278607,0.00015029754,0.0011599886,0.00003169081,0.0064582336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992037,0.000011015744,0.000005301177,0.000012432267,0.00002420012,0.000026731717],"domain_scores_gemma":[0.9999678,0.0000031581162,0.000007646553,0.0000028547915,0.000004303825,0.000014289771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017091025,0.0005955396,0.00027329192,0.0004556014,0.00017544939,0.00027768392,0.0003319938,0.00030585998,0.001847346],"category_scores_gemma":[0.000060687566,0.0001611581,0.00029713154,0.00021566916,0.00021471654,0.0001473608,0.00018837597,0.0007256959,0.0005887033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007044596,0.00025153134,0.00012305616,0.000086630636,0.000020766243,0.00015682667,0.000012329175,0.00037481365,0.99135065,0.00044381243,0.00047838787,0.0059966957],"study_design_scores_gemma":[0.00029821778,0.0030245595,0.0018229558,0.000011814116,0.000045118588,0.00041484227,0.000020684865,0.0011965764,0.98710424,0.00011652722,0.005935417,0.000009141813],"about_ca_topic_score_codex":0.00079914375,"about_ca_topic_score_gemma":0.0011324892,"teacher_disagreement_score":0.001847346,"about_ca_system_score_codex":0.00032898894,"about_ca_system_score_gemma":0.00040572905,"threshold_uncertainty_score":0.006180048},"labels":[],"label_agreement":null},{"id":"W2016041796","doi":"10.1158/1535-7163.targ-09-c29","title":"Abstract C29: Bladder cancer-associated single nucleotide polymorphisms of vascular endothelial growth factor in 12 human cell lines","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Single-nucleotide polymorphism; dbSNP; Genotype; Bladder cancer; SNP; Vascular endothelial growth factor; Angiogenesis; Biology; Cancer; Cancer research; Cell culture; Metastasis; SNP genotyping; Oncology; Molecular biology; Immunology; Genetics; Gene; Medicine; VEGF receptors","score_opus":0.019033190470462008,"score_gpt":0.2629453667457473,"score_spread":0.2439121762752853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016041796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607268,0.0034213648,0.005896189,0.00022638448,0.00009539659,0.0004283886,0.025793279,0.00018105112,0.0032312009],"genre_scores_gemma":[0.9331278,0.001943762,0.010715326,0.00038732708,0.000051213945,0.0013172713,0.04575423,0.000091911825,0.006611224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999151,0.0001620174,0.00013974235,0.00023125226,0.00021476494,0.00010126402],"domain_scores_gemma":[0.9993543,0.00017682336,0.000061403116,0.00013962263,0.00019701612,0.0000708186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053206575,0.00044394174,0.0007240094,0.00071686984,0.0006231905,0.00055550376,0.00049251463,0.00057517004,0.00733317],"category_scores_gemma":[0.0008508494,0.0001992669,0.0005158699,0.0021308325,0.00020856665,0.00009102693,0.00035191016,0.00046697666,0.0025739132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040441207,0.0009002439,0.10507167,0.0008945425,0.000459141,0.0030083722,0.0008180446,0.0011548408,0.84084326,0.00037303986,0.008259457,0.034173287],"study_design_scores_gemma":[0.00082860544,0.004580286,0.528456,0.0002215999,0.0010340898,0.019706875,0.00068843854,0.0041993847,0.37140313,0.00039145027,0.06831199,0.00017825693],"about_ca_topic_score_codex":0.006693092,"about_ca_topic_score_gemma":0.0051968717,"teacher_disagreement_score":0.00733317,"about_ca_system_score_codex":0.00030494892,"about_ca_system_score_gemma":0.0004684274,"threshold_uncertainty_score":0.024531841},"labels":[],"label_agreement":null},{"id":"W2018891796","doi":"10.1158/1535-7163.targ-09-c161","title":"Abstract C161: Modulation of thymidine phosphorylase (TP) expression in breast cancer cell lines exposed to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Thymidine phosphorylase; SKBR3; Pharmacology; Cytidine deaminase; Cell growth; Cancer research; Capecitabine; Epidermal growth factor receptor; Cancer; Growth inhibition; Chemistry; Biology; Cancer cell; Internal medicine; Biochemistry; Medicine; Colorectal cancer; Enzyme","score_opus":0.025792739691510157,"score_gpt":0.3074214845298739,"score_spread":0.28162874483836375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018891796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618393,0.00070883014,0.0006368821,0.000063267864,0.00003336556,0.0000407492,0.0012254864,0.000033051896,0.0010743138],"genre_scores_gemma":[0.9918262,0.0006842346,0.0012264118,0.000051364994,0.000010620863,0.00010088169,0.0026487124,0.0000141270975,0.0034374746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998234,0.000023647133,0.000024570703,0.000034613582,0.00005267201,0.00004111347],"domain_scores_gemma":[0.9998871,0.000020523812,0.00002267385,0.000014450224,0.00003073963,0.000024549407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011843678,0.00027827334,0.00036358056,0.00028378106,0.00022192957,0.00028070272,0.00018929207,0.00026438857,0.0018593372],"category_scores_gemma":[0.000110063644,0.00012123758,0.00028522222,0.00048495078,0.0001489099,0.00013889586,0.00013572213,0.00042968008,0.0005207592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020962996,0.00006954368,0.00042717878,0.000021787748,0.000004770166,0.00003764578,0.0000286897,0.00004106483,0.9985273,0.000023482782,0.00006164579,0.0005471868],"study_design_scores_gemma":[0.000025969775,0.0009158421,0.01674227,0.0000044121994,0.000019518973,0.00019109533,0.000115735194,0.0007281609,0.97950715,0.000015759473,0.001728513,0.000005595726],"about_ca_topic_score_codex":0.0028828103,"about_ca_topic_score_gemma":0.002424009,"teacher_disagreement_score":0.0028828103,"about_ca_system_score_codex":0.00031583745,"about_ca_system_score_gemma":0.00019372712,"threshold_uncertainty_score":0.0062201023},"labels":[],"label_agreement":null},{"id":"W2020280952","doi":"10.1158/1535-7163.mct-08-0864","title":"ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Heart, Lung, and Blood Institute","keywords":"Ovarian cancer; Cancer research; Vascular endothelial growth factor; Apoptosis; Angiogenesis; Ovarian tumor; Cell growth; Cancer; Biology; Thrombospondin 1; Medicine; Internal medicine; VEGF receptors","score_opus":0.021197709795987216,"score_gpt":0.2728384742654683,"score_spread":0.2516407644694811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020280952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952166,0.0005723436,0.0013794164,0.00016502423,0.000081978804,0.000083499275,0.00058867305,0.000113091366,0.0017994534],"genre_scores_gemma":[0.9928832,0.0008050567,0.0013307489,0.000092044276,0.00002217882,0.00012031553,0.0012503727,0.000026137648,0.0034700015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976367,0.00003516965,0.000025228943,0.00004505496,0.00006882784,0.00006192996],"domain_scores_gemma":[0.999833,0.000029399936,0.00004394855,0.000026020705,0.000015684482,0.000051855706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023316631,0.00046363132,0.00034814194,0.000491108,0.00018413592,0.00022870176,0.000215463,0.0003698115,0.0013136519],"category_scores_gemma":[0.0001281198,0.00023362607,0.0003917612,0.0002748498,0.00027978173,0.0002045857,0.00015466807,0.0010374513,0.0003337681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005639949,0.00047302947,0.00025258906,0.000048659338,0.000008867408,0.00006896155,0.00002994866,0.00026858368,0.99673635,0.00013354656,0.00015872844,0.0012565943],"study_design_scores_gemma":[0.0002605962,0.006128238,0.0053895945,0.000011878832,0.000028575605,0.00036467126,0.00006232016,0.0036440499,0.9816803,0.00008569424,0.0023354825,0.00000858976],"about_ca_topic_score_codex":0.0010768413,"about_ca_topic_score_gemma":0.0014670659,"teacher_disagreement_score":0.0013136519,"about_ca_system_score_codex":0.00036968247,"about_ca_system_score_gemma":0.00037068827,"threshold_uncertainty_score":0.004394591},"labels":[],"label_agreement":null},{"id":"W2021144570","doi":"10.1158/1535-7163.targ-13-c77","title":"Abstract C77: A novel BRCA2 targeting antisense oligonucleotide sensitizes human tumor cells to chemotherapy and radiotherapy - the induction of ‘complementary lethality’ by targeting DNA repair.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Cisplatin; RAD51; Carboplatin; Cancer research; Synthetic lethality; DNA repair; Cancer; Biology; Cancer cell; Homologous recombination; DNA damage; Population; Molecular biology; Medicine; Chemotherapy; DNA; Genetics","score_opus":0.013807759295505187,"score_gpt":0.26765255118332104,"score_spread":0.25384479188781583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021144570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843441,0.0030762246,0.005919964,0.00024734274,0.00021048158,0.00023769327,0.0007641152,0.00026962397,0.0049304483],"genre_scores_gemma":[0.98380166,0.001627772,0.0066627897,0.00024575822,0.0000430444,0.00018909959,0.0018474183,0.00004859268,0.005533923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999859,0.0000162108,0.000014985907,0.00003810242,0.00004646167,0.000025234598],"domain_scores_gemma":[0.9999231,0.000015063141,0.000015030868,0.000007979599,0.000015857604,0.00002299055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012284068,0.00047763935,0.00029017607,0.00029098697,0.00013046154,0.00015240649,0.00023896262,0.00040209448,0.002196396],"category_scores_gemma":[0.00010801938,0.00011850897,0.00021612574,0.00011526934,0.00018457572,0.00010177209,0.00011484955,0.00039337826,0.00050559896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007956577,0.0000599086,0.000052873187,0.000042514024,0.000005820254,0.00003855009,0.0000086496375,0.00006602352,0.997343,0.000087574284,0.00014561547,0.0020699734],"study_design_scores_gemma":[0.00005539212,0.0011474072,0.0009796028,0.0000066481925,0.000022709652,0.00022037889,0.000008108419,0.00061507866,0.99323094,0.00001867226,0.0036896823,0.0000053831623],"about_ca_topic_score_codex":0.0010291331,"about_ca_topic_score_gemma":0.0013694123,"teacher_disagreement_score":0.002196396,"about_ca_system_score_codex":0.00033312154,"about_ca_system_score_gemma":0.0003289701,"threshold_uncertainty_score":0.007347703},"labels":[],"label_agreement":null},{"id":"W2021253518","doi":"10.1158/1535-7163.targ-09-a115","title":"Abstract A115: Contextual synthetic lethality: Repair-deficient hypoxic tumor cells are sensitized to poly(ADP-ribose) polymerase (PARP) inhibition","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"PARP1; Poly ADP ribose polymerase; Synthetic lethality; PARP inhibitor; RAD51; Cancer research; Cancer cell; Hypoxia (environmental); Biology; DNA repair; Clonogenic assay; Homologous recombination; Molecular biology; Programmed cell death; DNA damage; Polymerase; Cell culture; Chemistry; Cancer; Apoptosis; DNA; Genetics","score_opus":0.031868384040929426,"score_gpt":0.30876111917182025,"score_spread":0.27689273513089085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021253518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885012,0.0007523667,0.004996132,0.00017105161,0.00008609484,0.0000510704,0.002853952,0.00029095943,0.002297112],"genre_scores_gemma":[0.99245465,0.0003436954,0.0013231211,0.00010492249,0.000013310412,0.00005194139,0.0020499479,0.000083827195,0.0035746542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998604,0.000018614324,0.000018010182,0.00003324634,0.000038535363,0.000031246465],"domain_scores_gemma":[0.99981266,0.00002755572,0.000050293773,0.000030306664,0.00001175317,0.000067431945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009900808,0.00043075395,0.00034333646,0.00021028974,0.00017578363,0.00027644503,0.0002316544,0.0003622254,0.0043866765],"category_scores_gemma":[0.00010077942,0.00013595412,0.00031359433,0.00014722806,0.00023787466,0.00014945399,0.0002349572,0.0006901576,0.0008101021],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088096574,0.00002936974,0.00014114627,0.000022564114,0.0000061061396,0.00009978994,0.000009046038,0.000065782995,0.9987985,0.00010720182,0.00010761688,0.0005248473],"study_design_scores_gemma":[0.000018716717,0.00066324516,0.007311581,0.000008771663,0.000017652505,0.00076692336,0.00004022386,0.0008863837,0.9871192,0.000079984406,0.0030799906,0.000007300384],"about_ca_topic_score_codex":0.00085700804,"about_ca_topic_score_gemma":0.00055805314,"teacher_disagreement_score":0.0043866765,"about_ca_system_score_codex":0.00017896805,"about_ca_system_score_gemma":0.00013285963,"threshold_uncertainty_score":0.014674842},"labels":[],"label_agreement":null},{"id":"W2022249592","doi":"10.1158/1535-7163.targ-09-b32","title":"Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c-MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Immunohistochemistry; Cancer; Univariate analysis; Head and neck squamous-cell carcinoma; Head and neck cancer; Epidermal growth factor receptor; Multivariate analysis","score_opus":0.018213220886722625,"score_gpt":0.31584793952418144,"score_spread":0.29763471863745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022249592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924386,0.00019896757,0.000049555103,0.000009508293,0.0000032679711,0.00001976293,0.00030263886,0.0000021182996,0.00017037972],"genre_scores_gemma":[0.9992731,0.000060992646,0.000049079266,0.0000293879,0.000010198329,0.000025462474,0.0004221247,0.0000013455036,0.00012818736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997055,0.000053862772,0.00003963661,0.000110511435,0.000045029232,0.000045346795],"domain_scores_gemma":[0.9993755,0.0001455728,0.00020895997,0.00006204552,0.00006272465,0.00014519844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043606575,0.0002611109,0.00044598957,0.00041276467,0.00040968967,0.00043963143,0.00021362444,0.00043003532,0.0019195727],"category_scores_gemma":[0.0008734622,0.0003200413,0.0003311053,0.00052017457,0.00031069256,0.00036163296,0.00021173975,0.00048800875,0.0005244951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016622095,0.00011007131,0.9949201,0.000018040559,0.00006615615,0.00031874346,0.000045797202,0.000036653102,0.0012881575,0.0000048673865,0.000112161695,0.0014169457],"study_design_scores_gemma":[0.00014297663,0.0017094536,0.9951781,0.0000059422487,0.00010453482,0.0016718276,0.00007980404,0.00013444213,0.00054897,0.000011794941,0.0004073977,0.000004703199],"about_ca_topic_score_codex":0.0019617912,"about_ca_topic_score_gemma":0.0015578817,"teacher_disagreement_score":0.0019617912,"about_ca_system_score_codex":0.00041712588,"about_ca_system_score_gemma":0.00028972907,"threshold_uncertainty_score":0.006421566},"labels":[],"label_agreement":null},{"id":"W2022590973","doi":"10.1158/1535-7163.targ-13-c184","title":"Abstract C184: Thyroid hormone receptors: Future targets for breast cancer therapy?.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Thyroid Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Lymphovascular invasion; Internal medicine; Lymph node; Oncology; Cancer; Hormone receptor; Immunohistochemistry; Pathological; Thyroid; Tissue microarray; Thyroid cancer; Pathology; Metastasis","score_opus":0.015472260958944847,"score_gpt":0.2815190106673419,"score_spread":0.2660467497083971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022590973","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26097268,0.59291303,0.0055865096,0.06848632,0.0063266032,0.00026615805,0.0050818617,0.0004946768,0.059872136],"genre_scores_gemma":[0.57020044,0.26384175,0.007650905,0.012723649,0.012923903,0.00021917355,0.0065645496,0.00013215771,0.12574352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998704,0.000030761756,0.000008799315,0.000017738796,0.000051465082,0.000020729027],"domain_scores_gemma":[0.99972194,0.00007371359,0.00005650804,0.000009510484,0.000089292946,0.00004908361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056061323,0.00039882644,0.0004559122,0.00042061252,0.00017200528,0.00070801977,0.00042573662,0.0007400298,0.018728964],"category_scores_gemma":[0.0005447538,0.00011012999,0.00022022912,0.0006679383,0.00025507645,0.00042733704,0.00017413821,0.0005355273,0.0047607925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005325315,0.0005323588,0.04058343,0.004103443,0.00016955714,0.0019496996,0.0001340237,0.0008601301,0.051350202,0.003065561,0.16915405,0.7227722],"study_design_scores_gemma":[0.0010201784,0.008382669,0.14463396,0.0016454594,0.0005192448,0.012103556,0.00051048485,0.0048065023,0.033801015,0.00836845,0.78411907,0.00008937573],"about_ca_topic_score_codex":0.0012744901,"about_ca_topic_score_gemma":0.0017744167,"teacher_disagreement_score":0.018728964,"about_ca_system_score_codex":0.0006591769,"about_ca_system_score_gemma":0.00069963746,"threshold_uncertainty_score":0.062654674},"labels":[],"label_agreement":null},{"id":"W2022649408","doi":"10.1158/1535-7163.targ-13-b256","title":"Abstract B256: Ring-DIMs induce mitochondrial dysfunction and ER stress in human prostate cancer cells.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Redox biology and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"","keywords":"LNCaP; Unfolded protein response; Programmed cell death; Apoptosis; Mitochondrion; Chemistry; Cancer research; Endoplasmic reticulum; Prostate cancer; Biology; Endocrinology; Cell biology; Internal medicine; Medicine; Cancer; Biochemistry","score_opus":0.013490378062112498,"score_gpt":0.2759282278425214,"score_spread":0.2624378497804089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022649408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992393,0.0031277426,0.0007948115,0.00015402997,0.0000720771,0.000044981625,0.0011700697,0.000071318536,0.0021718643],"genre_scores_gemma":[0.9907733,0.0011584366,0.00075952534,0.00009227511,0.000020795143,0.000041108153,0.0018540237,0.000011415344,0.0052891425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999218,0.000014108613,0.000005913273,0.000013676427,0.000024378776,0.0000199675],"domain_scores_gemma":[0.99995065,0.000007035278,0.000009706332,0.000009310235,0.0000074173745,0.000015977095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098110526,0.00021497259,0.00019273403,0.00014739986,0.00015342761,0.00012178935,0.00020777153,0.00018228906,0.0042126887],"category_scores_gemma":[0.00007408691,0.00010464602,0.0002016553,0.0001912392,0.00012932082,0.000083754494,0.00012908908,0.00042348084,0.00083486474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036649933,0.000055768996,0.000163101,0.0000574199,0.0000073463902,0.00007247917,0.000012987452,0.000041061638,0.9979717,0.000038826394,0.00013595911,0.0010768004],"study_design_scores_gemma":[0.000045286593,0.0012184539,0.006247625,0.0000055504106,0.0000146067705,0.0003985295,0.00003066136,0.0002748127,0.98863643,0.00003131456,0.0030924582,0.000004267747],"about_ca_topic_score_codex":0.00079242274,"about_ca_topic_score_gemma":0.0010003372,"teacher_disagreement_score":0.0042126887,"about_ca_system_score_codex":0.0001755396,"about_ca_system_score_gemma":0.00017410502,"threshold_uncertainty_score":0.014092803},"labels":[],"label_agreement":null},{"id":"W2022706281","doi":"10.1158/1535-7163.targ-11-a143","title":"Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Kingston General Hospital","funders":"","keywords":"Pharmacokinetics; Pharmacology; Kinase; Drug; Potency; Metastatic breast cancer; Tyrosine-kinase inhibitor; Medicine; Cancer; Chemistry; Breast cancer; Cancer research; Internal medicine; In vitro; Biochemistry","score_opus":0.23610018967859558,"score_gpt":0.45589901344279576,"score_spread":0.21979882376420018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022706281","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3343767,0.481229,0.016010588,0.021356331,0.0073584393,0.0032936388,0.0060094674,0.0020737327,0.12829207],"genre_scores_gemma":[0.65124714,0.19143684,0.016560296,0.014085354,0.0038122889,0.0009572844,0.006985922,0.000244576,0.11467025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998198,0.000030263558,0.000016206053,0.000027300668,0.00007633419,0.000030114164],"domain_scores_gemma":[0.99985754,0.000013654984,0.000025203464,0.0000060217676,0.00003868847,0.000058899055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077403814,0.00088148436,0.00057901954,0.0004022447,0.0002098725,0.00069240044,0.00067315006,0.00078935653,0.010116569],"category_scores_gemma":[0.00031703842,0.0002146852,0.00030663368,0.0003015274,0.00029878767,0.00054846436,0.00032750124,0.0014563287,0.003646498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011829155,0.0022114282,0.0012693915,0.002601049,0.00014748423,0.001868326,0.00011821128,0.001043304,0.16150597,0.005398604,0.07968744,0.73231965],"study_design_scores_gemma":[0.020597374,0.06957703,0.014113915,0.0010891621,0.00056312076,0.011377837,0.00009026289,0.0045487136,0.18354967,0.0039901664,0.6903493,0.00015338445],"about_ca_topic_score_codex":0.0008722305,"about_ca_topic_score_gemma":0.0016609281,"teacher_disagreement_score":0.010116569,"about_ca_system_score_codex":0.00060064456,"about_ca_system_score_gemma":0.0010398424,"threshold_uncertainty_score":0.03384334},"labels":[],"label_agreement":null},{"id":"W2023431277","doi":"10.1158/1535-7163.mct-15-0067","title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Antibody-drug conjugate; Pharmacology; Medicine; Drug; Conjugate; Antibody; Immunology; Monoclonal antibody","score_opus":0.05551429481243274,"score_gpt":0.3826702077750343,"score_spread":0.32715591296260155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023431277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96022654,0.02365246,0.008139794,0.0005953451,0.00012479957,0.00014755764,0.00019384641,0.00016373333,0.0067560077],"genre_scores_gemma":[0.98545146,0.007118938,0.003549034,0.0002108673,0.000031280844,0.000031943404,0.00027167227,0.000015187051,0.0033195876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993753,0.000011074351,0.00000419332,0.000010991651,0.000018945015,0.000017231217],"domain_scores_gemma":[0.99998033,0.0000023168757,0.0000034716268,0.0000024722638,0.000003855382,0.0000075595235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009783885,0.00023221808,0.00017377132,0.00024179257,0.000084999934,0.00024025954,0.00012841432,0.00026630238,0.0007626263],"category_scores_gemma":[0.000059955528,0.00011166459,0.00015881253,0.00012432881,0.00012578027,0.00021489554,0.00017368418,0.00033672465,0.00025622325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022734539,0.000111112924,0.0004194812,0.00013063192,0.000015462285,0.00022179825,0.000028608014,0.00043485838,0.9614942,0.0009975085,0.00053378777,0.035385307],"study_design_scores_gemma":[0.00015829528,0.0019096497,0.0026914112,0.000013883598,0.00004182053,0.0014391558,0.0000151755285,0.0023447229,0.9605694,0.00017658019,0.03062873,0.000011221931],"about_ca_topic_score_codex":0.0003364708,"about_ca_topic_score_gemma":0.0005847488,"teacher_disagreement_score":0.0007626263,"about_ca_system_score_codex":0.00027353724,"about_ca_system_score_gemma":0.00019028937,"threshold_uncertainty_score":0.002551198},"labels":[],"label_agreement":null},{"id":"W2023617697","doi":"10.1158/1535-7163.targ-11-b25","title":"Abstract B25: Emerging role of heterogeneous ribonucleoproteins (hnRNPs) as early predictive marker and prognosticator for head and neck oral squamous cell carcinoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Biomarker; Immunohistochemistry; Heterogeneous ribonucleoprotein particle; Ribonucleoprotein; Malignancy; Biology; Pathology; Cancer research; Head and neck squamous-cell carcinoma; Tissue microarray; Cancer; Medicine; RNA; Head and neck cancer; Biochemistry","score_opus":0.017955821812976655,"score_gpt":0.258876544099643,"score_spread":0.24092072228666633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023617697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758523,0.018938951,0.0024496764,0.00033743866,0.000044049873,0.00003800416,0.0008664923,0.00008844139,0.0013846388],"genre_scores_gemma":[0.9910523,0.003353204,0.0030417303,0.000082031605,0.000058256283,0.000023381415,0.0011028148,0.000009673132,0.0012764912],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989223,0.000022249753,0.000010029964,0.000032627788,0.000032073025,0.000010781453],"domain_scores_gemma":[0.99978715,0.000059404,0.000055764885,0.000014907248,0.000050137904,0.000032580956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006851971,0.0003158109,0.00022634004,0.00052632455,0.00012238763,0.00038731933,0.00021738498,0.00024566092,0.0013623962],"category_scores_gemma":[0.0003750837,0.00010992519,0.0001365601,0.00029123286,0.00026868616,0.00014784424,0.00012694726,0.00024302563,0.00046694084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029105057,0.00025520005,0.2873907,0.0005384764,0.00017224296,0.0010257742,0.000078273246,0.0004732358,0.5996739,0.00020714401,0.0011055011,0.10616906],"study_design_scores_gemma":[0.000052333166,0.001531948,0.84554106,0.00006949143,0.00026630762,0.0034383107,0.00013751263,0.0026492493,0.1407392,0.00040188667,0.0051518427,0.000020908636],"about_ca_topic_score_codex":0.0011474163,"about_ca_topic_score_gemma":0.00091673195,"teacher_disagreement_score":0.0013623962,"about_ca_system_score_codex":0.00026280349,"about_ca_system_score_gemma":0.00021890666,"threshold_uncertainty_score":0.0045576096},"labels":[],"label_agreement":null},{"id":"W2024119342","doi":"10.1158/1535-7163.targ-11-c225","title":"Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by rapamycin.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Epitope; Immunogenicity; Vaccinia; Biology; CD8; T cell; Cytotoxic T cell; Immune system; Cancer; Adjuvant; Virus; Antigen; Immunology; Cancer research; Virology; In vitro; Recombinant DNA; Genetics; Gene","score_opus":0.03717051993193556,"score_gpt":0.30991346684701493,"score_spread":0.2727429469150794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024119342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992634,0.0012759934,0.0017097549,0.00012426618,0.00011737314,0.000054951804,0.00052825373,0.00023107504,0.0060318774],"genre_scores_gemma":[0.98958206,0.000539704,0.002041666,0.00009727803,0.00005434907,0.0000462092,0.00083089905,0.000060354894,0.006747426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999052,0.000012324961,0.000007689672,0.000022445603,0.000018784489,0.000033426124],"domain_scores_gemma":[0.99992144,0.000010519651,0.000012663856,0.000010217878,0.000007889817,0.000037322232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071477676,0.00032342476,0.00022027134,0.00026592382,0.0001414904,0.00018622399,0.00015718202,0.00025352617,0.0032158496],"category_scores_gemma":[0.000059750222,0.000073850395,0.00014682444,0.00011958923,0.00016630325,0.00010243954,0.00010533441,0.00042581253,0.0007952729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045426787,0.000057510526,0.00011787269,0.000029695977,0.0000032536036,0.00006817421,0.0000056496388,0.0000604632,0.99602795,0.00007777895,0.00024089315,0.0028565673],"study_design_scores_gemma":[0.000043777007,0.0011980941,0.0048943507,0.0000055619926,0.000020079384,0.00039473473,0.00001622667,0.0005289661,0.98958707,0.000045539426,0.0032600577,0.0000056091985],"about_ca_topic_score_codex":0.00038972477,"about_ca_topic_score_gemma":0.0005536389,"teacher_disagreement_score":0.0032158496,"about_ca_system_score_codex":0.00022007881,"about_ca_system_score_gemma":0.00016860999,"threshold_uncertainty_score":0.010758102},"labels":[],"label_agreement":null},{"id":"W2025569005","doi":"10.1158/1535-7163.targ-11-a22","title":"Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Anoikis; Small hairpin RNA; Gene knockdown; Biology; Population; Molecular biology; Programmed cell death; Cell culture; Cell biology; Cancer research; Genetics; Apoptosis; Medicine","score_opus":0.03650405908379534,"score_gpt":0.30219000174368676,"score_spread":0.2656859426598914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025569005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98152024,0.0013252354,0.008005049,0.00017875395,0.00007109175,0.00021966573,0.0059745004,0.0003944464,0.002311021],"genre_scores_gemma":[0.97079134,0.0012318284,0.009676457,0.00021667198,0.00002389385,0.00013084119,0.009688088,0.000088179535,0.008152793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998938,0.000012244849,0.000009809069,0.00002315245,0.000043851367,0.000017222712],"domain_scores_gemma":[0.9999021,0.000023242108,0.000024929841,0.000008493558,0.000015493084,0.000025740608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014106443,0.00045789455,0.0003238981,0.00029753748,0.00021950631,0.00024040988,0.00027571514,0.000302045,0.0014218186],"category_scores_gemma":[0.00010631344,0.00014803342,0.00024844342,0.0002288586,0.00017138613,0.00008690991,0.00014980469,0.0003845662,0.00049774646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003380352,0.000018086079,0.00029647595,0.00001816828,0.0000070172196,0.000062277446,0.000002892873,0.00009292012,0.99858886,0.000026140626,0.00010989987,0.0007434708],"study_design_scores_gemma":[0.000038108377,0.00038034873,0.011539033,0.000005954965,0.00006830088,0.00065614725,0.000020174823,0.002655523,0.9797881,0.000045535526,0.0047928235,0.0000099489425],"about_ca_topic_score_codex":0.0012065426,"about_ca_topic_score_gemma":0.002101669,"teacher_disagreement_score":0.0014218186,"about_ca_system_score_codex":0.00027872314,"about_ca_system_score_gemma":0.0002826947,"threshold_uncertainty_score":0.0047564507},"labels":[],"label_agreement":null},{"id":"W2026071766","doi":"10.1158/1535-7163.pms-pr12","title":"Abstract PR12: A genome-wide shRNA screen reveals that inhibiting kinases potentiates the anti-breast cancer activity of fluvastatin","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Fluvastatin; Small hairpin RNA; Kinase; Cancer research; RNA interference; Gene knockdown; Pharmacology; Small interfering RNA; Biology; Medicine; Simvastatin; Transfection; Cell culture; Cell biology; Gene; Genetics; RNA","score_opus":0.0189061889641678,"score_gpt":0.2651292238012099,"score_spread":0.2462230348370421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026071766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173976,0.0013595558,0.0070092115,0.00027078277,0.00003780369,0.00019393228,0.00610428,0.000621455,0.0026632384],"genre_scores_gemma":[0.9747712,0.0013325529,0.007778541,0.0002723825,0.000017959012,0.0001746914,0.009619856,0.00012246416,0.0059102867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997546,0.00002358344,0.000032046784,0.00004720236,0.00010709108,0.00003543773],"domain_scores_gemma":[0.99986315,0.000034578534,0.00003495075,0.000014594743,0.000027007436,0.000025691219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021183465,0.00045524733,0.0005694762,0.00038212232,0.00023437345,0.00027031958,0.0003098888,0.00031388836,0.0017567797],"category_scores_gemma":[0.00016702025,0.00019266992,0.00033320094,0.00034706612,0.00017870938,0.00009995462,0.00015614946,0.00042623203,0.000592125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008582115,0.000034235367,0.00038371386,0.00003184742,0.0000115943785,0.00004336237,0.0000057683715,0.00014556256,0.99715555,0.000019791532,0.00019389183,0.0018887816],"study_design_scores_gemma":[0.000044197113,0.00066540425,0.010892297,0.000007661155,0.00010595595,0.00043697015,0.000026785032,0.0022403053,0.9824206,0.000021522788,0.0031285963,0.000009691315],"about_ca_topic_score_codex":0.0015938416,"about_ca_topic_score_gemma":0.0043439553,"teacher_disagreement_score":0.0017567797,"about_ca_system_score_codex":0.000314399,"about_ca_system_score_gemma":0.0003215947,"threshold_uncertainty_score":0.005877018},"labels":[],"label_agreement":null},{"id":"W2026797869","doi":"10.1158/1535-7163.targ-13-a248","title":"Abstract A248: Integrated therapeutic antibody development at the National Research Council of Canada.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Antibody; Monoclonal antibody; Computational biology; Immunization; Panning (audio); clone (Java method); Biology; Immunology; Gene; Genetics","score_opus":0.15013527047675648,"score_gpt":0.38545341106528863,"score_spread":0.23531814058853215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026797869","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025510542,0.0297917,0.06411594,0.026179194,0.0064525576,0.004098041,0.06035941,0.01784662,0.765646],"genre_scores_gemma":[0.053988922,0.011386712,0.054605603,0.0036468261,0.00026008845,0.00077778957,0.036943946,0.0014397625,0.8369503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972113,0.00014578005,0.000050599905,0.00029106546,0.00185817,0.00044312692],"domain_scores_gemma":[0.9926725,0.00023660307,0.00016736567,0.00022943775,0.004063617,0.0026304305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041399384,0.0015754896,0.00094361877,0.0020850531,0.0025816727,0.0029516278,0.002902054,0.0015766533,0.1288527],"category_scores_gemma":[0.0019116765,0.00080278475,0.00059467176,0.0015147503,0.0010385574,0.000781569,0.001507526,0.0018856344,0.047562554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084016554,0.00037594474,0.0029737295,0.0005463455,0.00004456002,0.00052240223,0.00026134276,0.0013029589,0.056381263,0.01389273,0.7014798,0.2213789],"study_design_scores_gemma":[0.00015898091,0.0002529638,0.0034473557,0.000111506626,0.000021121197,0.00017443729,0.000100526515,0.00213107,0.007373675,0.00082193175,0.98537064,0.000035835903],"about_ca_topic_score_codex":0.5697708,"about_ca_topic_score_gemma":0.63311046,"teacher_disagreement_score":0.5697708,"about_ca_system_score_codex":0.016802978,"about_ca_system_score_gemma":0.058406938,"threshold_uncertainty_score":0.8655258},"labels":[],"label_agreement":null},{"id":"W2027281639","doi":"10.1158/1535-7163.mct-06-0073","title":"Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Lawson Health Research Institute","funders":"","keywords":"Mesothelioma; Cancer research; Pemetrexed; Thymidylate synthase; HeLa; Apoptosis; Antisense therapy; Cell culture; Cancer; Growth inhibition; Medicine; Biology; Chemotherapy; Pathology; Internal medicine; Cisplatin; Oligonucleotide; Gene; Fluorouracil","score_opus":0.010329654757341293,"score_gpt":0.2676101548514891,"score_spread":0.2572805000941478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027281639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889444,0.0041796854,0.004669747,0.00011264795,0.00008345649,0.00008811955,0.00018787959,0.000072180264,0.0016619561],"genre_scores_gemma":[0.993321,0.0023083952,0.0032466482,0.0000470258,0.000017880004,0.00004285277,0.00015289517,0.000006854449,0.00085653126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999491,0.000010700262,0.0000061566916,0.000010729814,0.000014258806,0.000008976979],"domain_scores_gemma":[0.9999527,0.000015728723,0.000010614104,0.000005234017,0.0000072589487,0.000008507121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011878605,0.00028034966,0.00017380348,0.00015288405,0.00009231719,0.00014558661,0.00009460378,0.00018201431,0.00039674513],"category_scores_gemma":[0.00010292404,0.00008323346,0.00017398603,0.000072712675,0.00012708241,0.00007221811,0.00007451578,0.0003211734,0.00008768885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003151264,0.000016097001,0.00006577828,0.000022056025,0.0000023805997,0.00001521794,0.000005352009,0.0000892896,0.9985726,0.000036147136,0.000012638815,0.0011308732],"study_design_scores_gemma":[0.000023306513,0.0008912706,0.0016514332,0.0000048621914,0.000021008625,0.00014568836,0.0000121667235,0.0007967567,0.9942384,0.000031273637,0.0021805144,0.0000033059198],"about_ca_topic_score_codex":0.00054823986,"about_ca_topic_score_gemma":0.0010487904,"teacher_disagreement_score":0.00054823986,"about_ca_system_score_codex":0.00015504725,"about_ca_system_score_gemma":0.00018280062,"threshold_uncertainty_score":0.0013272762},"labels":[],"label_agreement":null},{"id":"W2027782825","doi":"10.1158/1535-7163.targ-11-b48","title":"Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Exome sequencing; Sanger sequencing; Exome; Medicine; COLD-PCR; Germline mutation; DNA sequencing; Oncology; Ion semiconductor sequencing; Liquid biopsy; Mutation; Targeted therapy; Internal medicine; Computational biology; Cancer; Genetics; Gene; Biology; Point mutation","score_opus":0.02792714412372515,"score_gpt":0.2875685918545766,"score_spread":0.25964144773085146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027782825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706453,0.00013407157,0.00090246863,0.000097052834,0.000008387637,0.00023502237,0.000580298,0.000039616327,0.0009385616],"genre_scores_gemma":[0.9952742,0.000070224494,0.0025865089,0.00011425061,0.000020354684,0.0002579541,0.0012876849,0.000019288029,0.00036948806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992331,0.000326793,0.000047651305,0.0001965938,0.000118885895,0.00007697211],"domain_scores_gemma":[0.9977495,0.00091904047,0.00034798266,0.0001587777,0.00037364732,0.00045108012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020674034,0.00036504027,0.00035798812,0.00042007456,0.0003397817,0.0006780664,0.0003032332,0.00049717416,0.0029727437],"category_scores_gemma":[0.003631017,0.00021168766,0.0003917162,0.00031057498,0.00024612583,0.00040344655,0.00056877185,0.0005106053,0.0011816933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021519016,0.0024317333,0.86690223,0.00020216235,0.00019184407,0.0015604721,0.00048267737,0.0014138089,0.052056085,0.00009575893,0.0019239715,0.051220253],"study_design_scores_gemma":[0.0014709233,0.048075493,0.91325325,0.000028872319,0.00025835395,0.004230046,0.00042431752,0.0039976067,0.024050267,0.00015154583,0.00402299,0.000036245892],"about_ca_topic_score_codex":0.0008100877,"about_ca_topic_score_gemma":0.000600756,"teacher_disagreement_score":0.0029727437,"about_ca_system_score_codex":0.00036025196,"about_ca_system_score_gemma":0.00045513234,"threshold_uncertainty_score":0.010933578},"labels":[],"label_agreement":null},{"id":"W2029933153","doi":"10.1158/1535-7163.targ-11-c1","title":"Abstract C1: BRCA1 protein levels and PI3KA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Chemotherapy; Logistic regression; Exact test; Cancer; Neoadjuvant therapy; Immunohistochemistry; Pathology","score_opus":0.024380037405454764,"score_gpt":0.3019271508783546,"score_spread":0.27754711347289984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029933153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99928266,0.000072694005,0.00012405282,0.000024790605,0.0000018331704,0.00004639731,0.00029290962,0.0000033603783,0.00015146354],"genre_scores_gemma":[0.9991374,0.00001535484,0.0002131822,0.000020151803,0.00000569336,0.00005292156,0.0003721637,0.000001960225,0.00018120304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938524,0.0002379002,0.000048987597,0.00012448762,0.00011507657,0.00008833152],"domain_scores_gemma":[0.99822944,0.00075735984,0.00040923065,0.000110759975,0.00014797115,0.00034529265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013378749,0.0004992266,0.00048043983,0.00076344074,0.0003974186,0.00043046882,0.00037853612,0.00041062303,0.0029727223],"category_scores_gemma":[0.0024056952,0.00022852629,0.000694364,0.00056781503,0.0003623449,0.00033303865,0.00048781504,0.00051677175,0.00047892184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005094399,0.0004195577,0.98654306,0.000049852628,0.00024231497,0.0006012477,0.00017463167,0.00019562742,0.0032388645,0.000029292485,0.0002755221,0.003135648],"study_design_scores_gemma":[0.00013997123,0.003029694,0.99164987,0.000011055684,0.00018728811,0.0019555513,0.00027545218,0.0008336722,0.0012929259,0.000054570468,0.00055504363,0.000014951267],"about_ca_topic_score_codex":0.0009113394,"about_ca_topic_score_gemma":0.0011677097,"teacher_disagreement_score":0.0029727223,"about_ca_system_score_codex":0.00043341142,"about_ca_system_score_gemma":0.00048020273,"threshold_uncertainty_score":0.009944737},"labels":[],"label_agreement":null},{"id":"W2030324514","doi":"10.1158/1535-7163.mct-08-0499","title":"A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Cell growth; Cell cycle; Cancer cell; Cancer research; Protein subunit; Cell cycle checkpoint; Retinoblastoma protein; Cancer; Kinase; PI3K/AKT/mTOR pathway; Biology; Cell; Chemistry; Molecular biology; Cell biology; Signal transduction; Biochemistry","score_opus":0.03244883850122982,"score_gpt":0.27934309793475687,"score_spread":0.24689425943352705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030324514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95670223,0.019880343,0.012558335,0.0005322622,0.0002615564,0.00051881897,0.0007472211,0.00035886336,0.008440419],"genre_scores_gemma":[0.9790806,0.008101,0.006610766,0.00019019596,0.0000535565,0.00030094822,0.0011068358,0.000018995694,0.0045371116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999962,0.0000036878023,0.0000028758482,0.000007825109,0.000009414178,0.000014202736],"domain_scores_gemma":[0.9999857,0.0000017074801,0.0000037734703,0.0000013578209,0.0000018779702,0.0000054887328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007849828,0.00042779167,0.00029390672,0.00023973988,0.00014988084,0.00022428525,0.00032885815,0.00031829742,0.0007841823],"category_scores_gemma":[0.000048846367,0.00008367291,0.00024999195,0.00017467585,0.00013372608,0.00016901465,0.00013362257,0.00055145245,0.0003361755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055936555,0.00036683897,0.0002092946,0.00017604533,0.000024522547,0.00027918522,0.000019777824,0.00045389458,0.96175456,0.00050065323,0.00079655176,0.034859233],"study_design_scores_gemma":[0.0009899834,0.004225906,0.0039721075,0.000018262075,0.00012662595,0.002324489,0.000017415992,0.0026266386,0.9493693,0.00016725612,0.036136817,0.00002525067],"about_ca_topic_score_codex":0.0005931819,"about_ca_topic_score_gemma":0.0007406606,"teacher_disagreement_score":0.0007841823,"about_ca_system_score_codex":0.00032390244,"about_ca_system_score_gemma":0.0002441206,"threshold_uncertainty_score":0.0026233792},"labels":[],"label_agreement":null},{"id":"W2031077597","doi":"10.1158/1535-7163.targ-13-c265","title":"Abstract C265: Significant <i>in vivo</i> activity of ENMD-2076, a novel multi-targeted kinase inhibitor, towards xenograft models of human hepatocellular carcinomas .","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Doxorubicin; Tolerability; In vivo; Cancer; Liver cancer; Pharmacology; Cancer research; Chemotherapy; Oncology; Internal medicine; Adverse effect; Biology","score_opus":0.029832691583120387,"score_gpt":0.2663489538847015,"score_spread":0.2365162623015811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031077597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844564,0.0025945823,0.0023958564,0.00021780554,0.00013832697,0.00017546724,0.0014563882,0.00023079013,0.004345029],"genre_scores_gemma":[0.987576,0.0015139616,0.003282676,0.0001023266,0.000026710244,0.0001292772,0.003069757,0.00003384215,0.004265398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990344,0.000020745612,0.000008741491,0.000016977512,0.0000248114,0.000025349693],"domain_scores_gemma":[0.9998987,0.000027385697,0.000016336598,0.000008231324,0.000013672747,0.000035672918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022391621,0.00059463293,0.00031090082,0.00027194165,0.00014286018,0.00017803317,0.00025202808,0.00026001732,0.0023847169],"category_scores_gemma":[0.0000824554,0.00011977571,0.0002307552,0.00017201956,0.0001998461,0.00017893853,0.00007993053,0.00070499966,0.00040403235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019305564,0.00041568073,0.00016737904,0.00016527684,0.000017458504,0.00010445595,0.00001576712,0.00041552258,0.99324715,0.000117537995,0.0005386608,0.002864623],"study_design_scores_gemma":[0.00021334644,0.0047276253,0.0015226708,0.00001012897,0.00003587509,0.00033030385,0.000015388363,0.0010380006,0.98970383,0.000019409184,0.002376408,0.000006993379],"about_ca_topic_score_codex":0.0018723917,"about_ca_topic_score_gemma":0.001849173,"teacher_disagreement_score":0.0023847169,"about_ca_system_score_codex":0.00034606006,"about_ca_system_score_gemma":0.00046669436,"threshold_uncertainty_score":0.0079776645},"labels":[],"label_agreement":null},{"id":"W2032186020","doi":"10.1158/1535-7163.targ-13-c51","title":"Abstract C51: eIF2alpha phosphorylation determines cell susceptibility to oxidative stress via Akt activation.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Protein kinase B; Oxidative stress; Biology; Reactive oxygen species; Phosphorylation; Cell biology; PI3K/AKT/mTOR pathway; Kinase; Molecular biology; Cancer research; Chemistry; Signal transduction; Biochemistry","score_opus":0.014399531608537927,"score_gpt":0.2682460381234599,"score_spread":0.25384650651492197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032186020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791542,0.003701327,0.0025839736,0.0002926748,0.00015520099,0.000057679197,0.004503735,0.0001696999,0.009381537],"genre_scores_gemma":[0.9850921,0.0014259822,0.0009947079,0.0000622787,0.000026287924,0.00002762109,0.003271487,0.000025303883,0.009074231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999095,0.000010381276,0.0000072710995,0.000025213958,0.000025257039,0.000022282116],"domain_scores_gemma":[0.99992526,0.000009509452,0.00002498871,0.000008276899,0.0000116361125,0.000020179892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120624565,0.00025975145,0.00011548706,0.000336694,0.00023270879,0.00037264213,0.00014994344,0.0002854205,0.010898868],"category_scores_gemma":[0.00014498287,0.00014722554,0.00015168333,0.0003180881,0.00016016357,0.00020946546,0.00018196712,0.00033633484,0.0022905958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059777073,0.0000481871,0.0017714428,0.00006631131,0.0000069628823,0.000098597055,0.000012245905,0.0000706942,0.9911843,0.00027898332,0.0007353786,0.005129096],"study_design_scores_gemma":[0.00007259911,0.0004828786,0.11452754,0.000027408172,0.000035577144,0.0015422582,0.00005839002,0.0010258581,0.8674158,0.00039639662,0.014396631,0.000018666058],"about_ca_topic_score_codex":0.0005791006,"about_ca_topic_score_gemma":0.0005689689,"teacher_disagreement_score":0.010898868,"about_ca_system_score_codex":0.00044798688,"about_ca_system_score_gemma":0.00023487881,"threshold_uncertainty_score":0.03646034},"labels":[],"label_agreement":null},{"id":"W2032990424","doi":"10.1158/1535-7163.targ-13-a186","title":"Abstract A186: Novel target to control lung tumor growth: Disruption of cell membrane remodeling by modulating myoferlin expression.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cell biology; Biology; Cancer; Cancer cell; Gene silencing; Cancer research; Cell growth; Cell; Endocytosis; Genetics","score_opus":0.009870320619063575,"score_gpt":0.25294147505257303,"score_spread":0.24307115443350946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032990424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9287351,0.03865096,0.015278024,0.0026551983,0.0010320551,0.0004973756,0.0027292517,0.0009199883,0.009502127],"genre_scores_gemma":[0.9525404,0.016025612,0.010724196,0.0008558975,0.0002073005,0.00044835405,0.0033519026,0.000068365596,0.01577792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994326,0.000009011716,0.0000061629235,0.000012221747,0.000017059665,0.00001222641],"domain_scores_gemma":[0.99995935,0.000004051693,0.000012813105,0.0000026005475,0.0000057249563,0.000015474432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014670871,0.0005180054,0.00030601514,0.00027616395,0.00026128173,0.0003479326,0.00035650778,0.00059996423,0.0029608014],"category_scores_gemma":[0.000074146774,0.00013858036,0.0003044237,0.00019080607,0.00018912916,0.00021911945,0.00017937551,0.0008733951,0.000983729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043142049,0.00020988182,0.00022229906,0.00026731353,0.000020933341,0.00018368545,0.000011583499,0.00018484067,0.9883343,0.0004702204,0.00087626337,0.008787266],"study_design_scores_gemma":[0.0007051775,0.00482548,0.0046697753,0.00004839674,0.00014912052,0.0013669329,0.000040658488,0.0014772179,0.9437548,0.00033378453,0.04260769,0.00002099817],"about_ca_topic_score_codex":0.00025529275,"about_ca_topic_score_gemma":0.0004407415,"teacher_disagreement_score":0.0029608014,"about_ca_system_score_codex":0.0003228136,"about_ca_system_score_gemma":0.00034411394,"threshold_uncertainty_score":0.009904861},"labels":[],"label_agreement":null},{"id":"W2034458673","doi":"10.1158/1535-7163.targ-11-b50","title":"Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Nausea; Vomiting; Dosing; Hypophosphatemia; Pharmacology; Cancer; Adverse effect; Internal medicine; Oncology; Gastroenterology","score_opus":0.02431198423476477,"score_gpt":0.32397939890351174,"score_spread":0.29966741466874697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034458673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971295,0.0021236774,0.001176574,0.00036231132,0.00009088552,0.0025424256,0.0015126787,0.0001957836,0.0022827776],"genre_scores_gemma":[0.98565996,0.0021140762,0.002575155,0.000735233,0.000089785404,0.0023834924,0.0024897507,0.00006591545,0.0038865982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997038,0.00011336599,0.000015333964,0.000072223826,0.00003093242,0.00006420156],"domain_scores_gemma":[0.9995654,0.00006272078,0.00007792925,0.00005669631,0.00002210661,0.00021501204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009921328,0.0014495254,0.0013957715,0.0005795711,0.00037125588,0.00082459726,0.0008650829,0.0011823885,0.00508511],"category_scores_gemma":[0.0006381576,0.000642488,0.0009665079,0.00044122266,0.00093689683,0.00079688296,0.00033039047,0.003020671,0.0018810208],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41465932,0.17027505,0.006582004,0.0015230912,0.0014443247,0.00063376524,0.0006692867,0.006040358,0.2274469,0.0006953709,0.009547335,0.16048327],"study_design_scores_gemma":[0.14443691,0.83303726,0.010007649,0.00004174915,0.00025897715,0.0005327889,0.00007145336,0.001350346,0.0067127906,0.00021812599,0.003284174,0.000047784222],"about_ca_topic_score_codex":0.00088158227,"about_ca_topic_score_gemma":0.0018993529,"teacher_disagreement_score":0.00508511,"about_ca_system_score_codex":0.00065021886,"about_ca_system_score_gemma":0.0010165549,"threshold_uncertainty_score":0.017011404},"labels":[],"label_agreement":null},{"id":"W2034981234","doi":"10.1158/1535-7163.targ-09-a135","title":"Abstract A135: Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Cytarabine; Daunorubicin; Leukemia; Pharmacology; Bone marrow; Immunology","score_opus":0.03370912947750481,"score_gpt":0.3120673052806275,"score_spread":0.27835817580312266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034981234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119407,0.0009644374,0.003675124,0.00008371729,0.00005736032,0.0005511526,0.0013969998,0.00021184323,0.0018653489],"genre_scores_gemma":[0.9882653,0.0010623311,0.005209453,0.00003644052,0.000013800891,0.00032783055,0.0016984147,0.000044089757,0.0033423603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997888,0.00004526204,0.000018912524,0.000041245763,0.000066075125,0.00003971366],"domain_scores_gemma":[0.9998567,0.00002798443,0.0000291268,0.000015230579,0.000028723183,0.000042187945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043129365,0.0006001293,0.00037270004,0.00045556185,0.0001861157,0.00037305552,0.00027180664,0.00039452562,0.0019740711],"category_scores_gemma":[0.000115053335,0.00016269002,0.00032408838,0.0003158609,0.0002149609,0.0002970412,0.00016054368,0.00088052865,0.00042240237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010539863,0.0010678621,0.0002035872,0.00007881885,0.00001557881,0.00003884637,0.000042897063,0.00036513532,0.9931687,0.00015071598,0.00017844704,0.0036353497],"study_design_scores_gemma":[0.00010982712,0.010134831,0.0016419217,0.0000041947533,0.000030905332,0.0000891786,0.000021736074,0.00097476743,0.9852223,0.000019035047,0.001745036,0.0000063706057],"about_ca_topic_score_codex":0.001768276,"about_ca_topic_score_gemma":0.0013519266,"teacher_disagreement_score":0.0019740711,"about_ca_system_score_codex":0.0003982013,"about_ca_system_score_gemma":0.00035302914,"threshold_uncertainty_score":0.006603956},"labels":[],"label_agreement":null},{"id":"W2035386385","doi":"10.1158/1535-7163.mct-05-0128","title":"Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Temozolomide; Poly ADP ribose polymerase; Glioma; DNA repair; Pharmacology; O-6-methylguanine-DNA methyltransferase; Cancer research; PARP inhibitor; Growth inhibition; Medicine; Chemistry; Polymerase; DNA; Methyltransferase; Cell growth; Biochemistry; Methylation","score_opus":0.024224175741875877,"score_gpt":0.3031121217187833,"score_spread":0.27888794597690747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035386385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707913,0.0005003871,0.0012557437,0.0000635562,0.000041701453,0.00003659816,0.0003255755,0.00011781132,0.00057940534],"genre_scores_gemma":[0.992694,0.0007414566,0.0024501926,0.000044077333,0.000014630774,0.000065694454,0.0011539564,0.000040972525,0.0027950474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999856,0.000020544556,0.000014994326,0.000028614184,0.000038867627,0.00004091911],"domain_scores_gemma":[0.9998504,0.000020195515,0.00003920417,0.000023470679,0.000015771317,0.000050991333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019365322,0.0005000088,0.00050383166,0.00030626325,0.00012088398,0.0003316692,0.00035965434,0.00024718337,0.0008380097],"category_scores_gemma":[0.000104441846,0.00020326955,0.0002553261,0.00015102494,0.00017484784,0.00021792184,0.00011537282,0.0011580487,0.00037485975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018279125,0.00015688839,0.00013700854,0.000019081228,0.0000074607246,0.000024835732,0.000012827622,0.0001030955,0.99797136,0.000052163414,0.00009566098,0.0012367915],"study_design_scores_gemma":[0.00010017552,0.003626856,0.0030578307,0.000005991068,0.000026405409,0.00018033039,0.000024762048,0.0030701528,0.98799443,0.000026607484,0.0018804768,0.0000059418376],"about_ca_topic_score_codex":0.0013279079,"about_ca_topic_score_gemma":0.0022388902,"teacher_disagreement_score":0.0013279079,"about_ca_system_score_codex":0.00031923156,"about_ca_system_score_gemma":0.0002543273,"threshold_uncertainty_score":0.0028034449},"labels":[],"label_agreement":null},{"id":"W2036143910","doi":"10.1158/1535-7163.targ-13-pr09","title":"Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer research; Bevacizumab; Camptothecin; Angiogenesis; Metastasis; Cancer; Ovarian cancer; Tumor hypoxia; Gemcitabine; Oncology; Pharmacology; Internal medicine; Chemotherapy; Biology; Radiation therapy","score_opus":0.1639044074039281,"score_gpt":0.47201744317284133,"score_spread":0.30811303576891325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036143910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663689,0.010258796,0.0050144256,0.002576724,0.00040441967,0.0060634296,0.002327337,0.0005213499,0.0064645344],"genre_scores_gemma":[0.9714225,0.005110904,0.008803413,0.0014686775,0.00020580784,0.002361277,0.004160376,0.000067103,0.0064000674],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995976,0.00015663265,0.000031968346,0.00006813347,0.00007318974,0.00007259103],"domain_scores_gemma":[0.99953616,0.00007424606,0.000099049,0.000035275738,0.000053353946,0.00020191894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015884556,0.0009313559,0.0007752414,0.00049959694,0.00030119155,0.00086892606,0.0010569214,0.0013206186,0.004691409],"category_scores_gemma":[0.0005500981,0.00029665462,0.0007450837,0.00037133854,0.0005695104,0.0006827413,0.00037181602,0.0022424199,0.0009320253],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118029535,0.06583082,0.003727607,0.0019063742,0.0009894711,0.0007410266,0.00026658873,0.0030232165,0.5365533,0.0013971223,0.0103968885,0.25713792],"study_design_scores_gemma":[0.15690409,0.64122057,0.013829712,0.00011716607,0.00078557566,0.0015898966,0.00010697393,0.00327854,0.16459708,0.00029256832,0.017213888,0.00006395105],"about_ca_topic_score_codex":0.0007623484,"about_ca_topic_score_gemma":0.0018177096,"teacher_disagreement_score":0.004691409,"about_ca_system_score_codex":0.00070635346,"about_ca_system_score_gemma":0.0013380547,"threshold_uncertainty_score":0.01569438},"labels":[],"label_agreement":null},{"id":"W2036366645","doi":"10.1158/1535-7163.mct-08-0743","title":"Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Agencia Estatal de Investigación","keywords":"Cytidine; Biology; Methyltransferase; DNA demethylation; Biochemistry; Molecular biology; Nucleoside; Uridine; DNA; Methylation; DNA methylation; RNA; Enzyme; Gene","score_opus":0.019738416773341136,"score_gpt":0.29972183852093753,"score_spread":0.2799834217475964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036366645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939469,0.0020826468,0.0022031786,0.000083874016,0.00002059526,0.000019717934,0.00019533084,0.00008338798,0.0013642554],"genre_scores_gemma":[0.99394614,0.00082756113,0.002405931,0.000032693813,0.000010772006,0.0000106186835,0.00051890896,0.000021367927,0.0022260468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998846,0.000016554146,0.000006919253,0.00003635071,0.000032809046,0.000022751881],"domain_scores_gemma":[0.9999399,0.000016154145,0.00001283536,0.000008620065,0.0000099562285,0.000012457126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015411469,0.00021166648,0.0003646149,0.00011439432,0.00011568888,0.00033288662,0.00018302003,0.00024297093,0.001185984],"category_scores_gemma":[0.00011549356,0.00012807889,0.00020374844,0.00011556661,0.00017197199,0.00021043955,0.00014275695,0.00035272498,0.00035910992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026345915,0.000006196535,0.00005619486,0.000011359682,0.0000020665452,0.000012540215,0.000008831931,0.000012958795,0.99943346,0.00004085581,0.000010776475,0.00037848583],"study_design_scores_gemma":[0.0000038091284,0.00009704504,0.0017184266,0.0000014628076,0.0000064451624,0.000103440936,0.0000068310487,0.0005671073,0.99626404,0.000011667064,0.0012179689,0.0000018122396],"about_ca_topic_score_codex":0.0014596594,"about_ca_topic_score_gemma":0.0016936235,"teacher_disagreement_score":0.0014596594,"about_ca_system_score_codex":0.0004779393,"about_ca_system_score_gemma":0.00017422209,"threshold_uncertainty_score":0.0039675236},"labels":[],"label_agreement":null},{"id":"W2036796362","doi":"10.1158/1535-7163.targ-09-c88","title":"Abstract C88: Imiquimod induces reactive oxygen species- and caspase-independent cell cycle arrest and apoptosis in MDA-MB-468 breast cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Imiquimod; Propidium iodide; Apoptosis; Cancer research; Reactive oxygen species; Annexin; Biology; Molecular biology; Chemistry; Programmed cell death; Immunology; Cell biology; Biochemistry","score_opus":0.019305760937364216,"score_gpt":0.277632966839723,"score_spread":0.2583272059023588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036796362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127144,0.0020355238,0.0015285868,0.00017026089,0.00008094687,0.00012032304,0.0014684631,0.00012329701,0.0032012423],"genre_scores_gemma":[0.9898432,0.0010787279,0.0023183655,0.00013773415,0.0000406352,0.00014964168,0.002421835,0.000021966081,0.003988048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988544,0.000016589243,0.00001134432,0.000021661972,0.000027172997,0.00003781974],"domain_scores_gemma":[0.99995613,0.0000066311973,0.000008985839,0.000007497996,0.00001126909,0.000009441529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008078301,0.00039098813,0.00030172814,0.00023500965,0.00011961123,0.00012701954,0.00016446138,0.00027374437,0.0022239476],"category_scores_gemma":[0.00006697188,0.00008977662,0.00017950298,0.00019877958,0.00010477502,0.00009959061,0.000092445196,0.00040986194,0.0008546257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028286155,0.00008261478,0.000119783006,0.000058655936,0.0000043499504,0.000047934707,0.000011960282,0.0000494985,0.9975829,0.000036555524,0.00023918056,0.0014835672],"study_design_scores_gemma":[0.000075909156,0.00089019403,0.0032786753,0.00000681,0.000010514774,0.00027508277,0.000017249153,0.0007022847,0.9912544,0.000020377587,0.0034655216,0.0000029763341],"about_ca_topic_score_codex":0.00076934864,"about_ca_topic_score_gemma":0.00062937185,"teacher_disagreement_score":0.0022239476,"about_ca_system_score_codex":0.00027084947,"about_ca_system_score_gemma":0.00017898683,"threshold_uncertainty_score":0.007439792},"labels":[],"label_agreement":null},{"id":"W2039457659","doi":"10.1158/1535-7163.targ-11-a221","title":"Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Lymph node; Prostate; Clinical trial","score_opus":0.08893729981605718,"score_gpt":0.3766998605302653,"score_spread":0.2877625607142081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039457659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908103,0.002341571,0.0005496205,0.0004503268,0.000113734604,0.0025161721,0.001464967,0.00012683148,0.0016265897],"genre_scores_gemma":[0.9850154,0.0023858794,0.0014830659,0.001111156,0.0002378776,0.0024202133,0.0037385945,0.000054345284,0.0035534466],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961865,0.00019927506,0.000019237035,0.00006120751,0.000037170394,0.000064506436],"domain_scores_gemma":[0.99945265,0.000060962717,0.00008509011,0.00003854085,0.000035965706,0.0003267635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012790229,0.0020899891,0.002074621,0.00048528926,0.0005081657,0.0008066672,0.00096290355,0.0010925704,0.0045610038],"category_scores_gemma":[0.0005637936,0.00062610285,0.0012064897,0.00050859386,0.000768085,0.00052731275,0.0003330942,0.0024804308,0.0015547222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55450565,0.15160851,0.012931114,0.0016013919,0.0026101202,0.0010232788,0.00050548697,0.0033966077,0.13042979,0.0003233656,0.009266002,0.13179867],"study_design_scores_gemma":[0.38795543,0.58765745,0.016426455,0.000036378053,0.0005616738,0.00049156504,0.000068251924,0.0009065733,0.0034224116,0.00008677735,0.0023562908,0.00003071155],"about_ca_topic_score_codex":0.0023191068,"about_ca_topic_score_gemma":0.004888492,"teacher_disagreement_score":0.0045610038,"about_ca_system_score_codex":0.0007890332,"about_ca_system_score_gemma":0.0015953501,"threshold_uncertainty_score":0.015258074},"labels":[],"label_agreement":null},{"id":"W2040706169","doi":"10.1158/1535-7163.targ-11-c170","title":"Abstract C170: The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Statin; Medicine; Cancer; Pharmacology; Atorvastatin; Cancer research; Combination therapy; Apoptosis; Breast cancer; Cancer cell; Internal medicine; Chemistry; Biochemistry","score_opus":0.017725676646052145,"score_gpt":0.2920528456197336,"score_spread":0.2743271689736815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040706169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709753,0.0076487917,0.0016129654,0.0006029212,0.00017113225,0.0006387988,0.004908495,0.00033726924,0.01310447],"genre_scores_gemma":[0.97290325,0.0060164006,0.0033993896,0.00034640852,0.00004415516,0.00023125019,0.0064925337,0.00004743396,0.010519059],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998599,0.000015072794,0.000011494423,0.000018638973,0.000050156763,0.00004471709],"domain_scores_gemma":[0.99990356,0.000011190266,0.000012670249,0.000008063153,0.000016794751,0.000047725996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016469898,0.0005684919,0.00064581697,0.000920229,0.00022499313,0.0003159555,0.00037391233,0.00033018642,0.005086181],"category_scores_gemma":[0.00015508644,0.00017526747,0.00036497298,0.0006246361,0.00018486775,0.00017655834,0.00022512038,0.00080672145,0.0009445182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002119168,0.0016063829,0.0008093678,0.00029501936,0.00007062229,0.00024914488,0.000027686221,0.00042543927,0.9651783,0.0002776715,0.0015368304,0.027404381],"study_design_scores_gemma":[0.00102919,0.028723573,0.011399393,0.000059880735,0.00025425624,0.0009247379,0.000057678528,0.0010040783,0.932663,0.00013379949,0.02372172,0.000028697956],"about_ca_topic_score_codex":0.0021675383,"about_ca_topic_score_gemma":0.0051522683,"teacher_disagreement_score":0.005086181,"about_ca_system_score_codex":0.00030178393,"about_ca_system_score_gemma":0.0006848785,"threshold_uncertainty_score":0.01701498},"labels":[],"label_agreement":null},{"id":"W2041065385","doi":"10.1158/1535-7163.targ-13-c2","title":"Abstract C2: Cross-talk between the O(6)-Methylguanine-DNA methyltransferase (MGMT) and p53 in glioblastoma multiforme.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Temozolomide; Sunitinib; Methyltransferase; Cancer research; Angiogenesis; DNA repair; Biology; Glioma; Medicine; Cancer; Internal medicine; DNA; Methylation","score_opus":0.022498644374585212,"score_gpt":0.31439804526733445,"score_spread":0.29189940089274924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041065385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98589325,0.008057064,0.0016364463,0.00037760357,0.00011367077,0.00006144675,0.0013066175,0.00008320869,0.0024708235],"genre_scores_gemma":[0.99274045,0.0015010022,0.0009364455,0.00013659569,0.000038267124,0.000044414057,0.002055778,0.000010869849,0.0025362542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998567,0.00001839171,0.000009681421,0.000041311163,0.000041592626,0.000032366985],"domain_scores_gemma":[0.99991286,0.0000115874645,0.00002218148,0.0000053929793,0.000020677897,0.000027382977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015646171,0.0003430015,0.00022110816,0.00035077432,0.0002296098,0.00024691861,0.00020742475,0.00035425328,0.0020571777],"category_scores_gemma":[0.00012762622,0.00008075666,0.00029846653,0.00029198127,0.00017341065,0.00014468195,0.00014416415,0.00032193706,0.00042213147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003866121,0.00004972477,0.0018501619,0.000116213036,0.00001538157,0.00018784142,0.0000107500555,0.000041742358,0.9945616,0.00010264708,0.00031836223,0.002358954],"study_design_scores_gemma":[0.000071160524,0.00077560433,0.063127205,0.000015205057,0.00007511313,0.0018537663,0.000042962238,0.0008565992,0.9268639,0.000106579464,0.006202625,0.000009218578],"about_ca_topic_score_codex":0.0025489624,"about_ca_topic_score_gemma":0.0020185884,"teacher_disagreement_score":0.0025489624,"about_ca_system_score_codex":0.00062424026,"about_ca_system_score_gemma":0.000266713,"threshold_uncertainty_score":0.0068818927},"labels":[],"label_agreement":null},{"id":"W2041687360","doi":"10.1158/1535-7163.targ-13-a192","title":"Abstract A192: Role of O(6)-Methylguanine-DNA Methyltransferase in the Proliferation/Invasion Dichotomy and Differential Effect of FAK inhibitor Y11 based on expression of MGMT in Glioblastoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer research; U87; Cell growth; Focal adhesion; Gene knockdown; Methyltransferase; Regulator; DNA methyltransferase; Blot; Biology; Small hairpin RNA; Western blot; Glioblastoma; Cell culture; Phosphorylation; Molecular biology; Cell biology; DNA; Biochemistry; Methylation; Genetics","score_opus":0.009265723989132292,"score_gpt":0.26543543821942756,"score_spread":0.2561697142302953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041687360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946333,0.0023135752,0.00070175796,0.00012684408,0.00008444297,0.000057957095,0.0006511462,0.00006201514,0.001368998],"genre_scores_gemma":[0.9932166,0.0014556912,0.0011950032,0.00006652793,0.00001875154,0.00008730465,0.0014741325,0.00001616197,0.0024699792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998846,0.000016934922,0.00001371654,0.000021518073,0.000024735073,0.000038377897],"domain_scores_gemma":[0.9999567,0.0000066227512,0.000009146076,0.0000038037028,0.0000066267694,0.000016970902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010537821,0.00036145755,0.00033568472,0.00023606265,0.00015971475,0.00017022133,0.00019909805,0.00029291896,0.0016232923],"category_scores_gemma":[0.00006806345,0.00012086912,0.00039305235,0.00019944557,0.00017330602,0.00015320115,0.00010833669,0.00043386803,0.0003337904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009409132,0.00018473339,0.0003032129,0.00007316419,0.000010998418,0.00006877139,0.000014362313,0.00005101433,0.99592835,0.00006300648,0.00015896153,0.0022024997],"study_design_scores_gemma":[0.000102717015,0.0027084083,0.007148272,0.000006995616,0.00004336262,0.00019788614,0.000027659491,0.0006036136,0.9872089,0.000028428707,0.0019185884,0.0000052442233],"about_ca_topic_score_codex":0.0014774476,"about_ca_topic_score_gemma":0.0013199496,"teacher_disagreement_score":0.0016232923,"about_ca_system_score_codex":0.00019932845,"about_ca_system_score_gemma":0.0002311194,"threshold_uncertainty_score":0.00543046},"labels":[],"label_agreement":null},{"id":"W2042130205","doi":"10.1158/1535-7163.targ-13-c175","title":"Abstract C175: Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Apoptosis; Caspase; Caspase 3; Kinase; Growth inhibition; Pharmacology; Cancer research; Caspase 8; Chemistry; Cell growth; Biology; Cell biology; Programmed cell death; Biochemistry","score_opus":0.01573195703276472,"score_gpt":0.27608041828657137,"score_spread":0.2603484612538067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042130205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925364,0.001837875,0.0008130344,0.00012873743,0.00005993033,0.0001585781,0.0014284891,0.00014499636,0.0028918257],"genre_scores_gemma":[0.9942516,0.0010734905,0.0013567708,0.00008425381,0.000014679648,0.00007343774,0.0019339533,0.00002203046,0.0011898592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993944,0.000008125801,0.0000053697304,0.000011294325,0.000017172848,0.000018553408],"domain_scores_gemma":[0.9999684,0.0000042784222,0.00000602401,0.0000040893415,0.0000040538434,0.000013036093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010362393,0.0004171014,0.0003509774,0.00029128342,0.000109123524,0.0001869399,0.00028418124,0.0002508814,0.0014782245],"category_scores_gemma":[0.00009156356,0.000080466016,0.00016687492,0.00028847164,0.00015947505,0.00012339669,0.000160398,0.0004791248,0.00040048716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014674126,0.0006179151,0.00083163846,0.00023054377,0.00003995818,0.00034560237,0.000035383437,0.0009785079,0.9707345,0.00036854565,0.0015978501,0.022752136],"study_design_scores_gemma":[0.0006247366,0.0098390505,0.008146084,0.00002672522,0.000086422646,0.0014349242,0.000025713209,0.0012844417,0.96714336,0.000055039927,0.011318939,0.000014482853],"about_ca_topic_score_codex":0.0012977095,"about_ca_topic_score_gemma":0.001863087,"teacher_disagreement_score":0.0014782245,"about_ca_system_score_codex":0.00036234336,"about_ca_system_score_gemma":0.0004158276,"threshold_uncertainty_score":0.004945159},"labels":[],"label_agreement":null},{"id":"W2044602856","doi":"10.1158/1535-7163.targ-13-c232","title":"Abstract C232: B-raf/Mek/Erk Pathway inhibition induces GPNMB expression and sensitizes melanoma cells to the antibody-drug conjugate glembatumumab vedotin.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vemurafenib; Trametinib; Dabrafenib; Melanoma; Medicine; Cancer research; Selumetinib; Antibody-drug conjugate; MAPK/ERK pathway; Targeted therapy; MEK inhibitor; Cancer; Kinase; Antibody; Immunology; Internal medicine; Monoclonal antibody; Biology; KRAS; Metastatic melanoma","score_opus":0.014183342169906209,"score_gpt":0.27512767143708655,"score_spread":0.26094432926718036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044602856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236804,0.0011751741,0.0008759223,0.00019096458,0.00008722008,0.00007702235,0.001904269,0.00009102416,0.003230429],"genre_scores_gemma":[0.9876084,0.00079067564,0.0012471488,0.000091168775,0.00001731513,0.00009389921,0.0041976054,0.000020174883,0.00593364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999913,0.000009742041,0.0000061772353,0.000016498883,0.00002638622,0.000028176546],"domain_scores_gemma":[0.999969,0.000005377597,0.0000051220395,0.000004620833,0.000005057492,0.000010878129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067287925,0.00036756572,0.00019028828,0.00015195897,0.00016521961,0.00018623198,0.00018303747,0.0002550186,0.0040415847],"category_scores_gemma":[0.000051065083,0.000108112945,0.00029983296,0.00017846894,0.00011354025,0.00010462287,0.00009104465,0.00059331785,0.0010221043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019816586,0.00010173521,0.00009377061,0.00004076938,0.000007732896,0.00005710051,0.000007238292,0.000042153137,0.9985012,0.000044944885,0.00027649698,0.00062868185],"study_design_scores_gemma":[0.00008113165,0.0006629321,0.0059646964,0.0000067021188,0.000013826957,0.00031744945,0.000023740438,0.0006644923,0.98921543,0.000025645753,0.0030199932,0.000003978057],"about_ca_topic_score_codex":0.0017106688,"about_ca_topic_score_gemma":0.0016284528,"teacher_disagreement_score":0.0040415847,"about_ca_system_score_codex":0.00032594972,"about_ca_system_score_gemma":0.00023816127,"threshold_uncertainty_score":0.01352042},"labels":[],"label_agreement":null},{"id":"W2046235081","doi":"10.1158/1535-7163.targ-09-a104","title":"Abstract A104: Safety and effectiveness of phase I solid tumor trial designs of molecularly targeted combination therapies","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical trial; Cancer; Pharmacology; Oncology; Population; Internal medicine; Pharmacokinetics","score_opus":0.034705481045193866,"score_gpt":0.3695591450582382,"score_spread":0.33485366401304434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046235081","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77358997,0.1401737,0.019195175,0.002893477,0.0012840271,0.02293268,0.017993623,0.0010054223,0.020931832],"genre_scores_gemma":[0.9634539,0.010387671,0.0070685255,0.0012760615,0.0008454695,0.009559743,0.005154024,0.000116360316,0.0021383055],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.971752,0.022889672,0.002495664,0.0010246214,0.0015469227,0.00029115312],"domain_scores_gemma":[0.96890926,0.017886223,0.009517455,0.0014058368,0.0014373556,0.0008438746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020390363,0.0011307515,0.0024246858,0.0015448278,0.00035890372,0.0019517925,0.000672557,0.0011128893,0.006974253],"category_scores_gemma":[0.035150103,0.0004888668,0.003869514,0.0014770419,0.000523149,0.0013020192,0.0005431996,0.0017925629,0.00097380026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68921626,0.003582836,0.014121434,0.005818579,0.017945442,0.00013426751,0.0001132853,0.004421019,0.0053211534,0.00059086387,0.008092959,0.25064197],"study_design_scores_gemma":[0.49298725,0.3813261,0.0597428,0.0025960654,0.024897309,0.0009163983,0.000113225986,0.008772244,0.008480797,0.0022328969,0.017810961,0.0001239015],"about_ca_topic_score_codex":0.00023137823,"about_ca_topic_score_gemma":0.00036379969,"teacher_disagreement_score":0.020390363,"about_ca_system_score_codex":0.0014695409,"about_ca_system_score_gemma":0.0016430933,"threshold_uncertainty_score":0.10783583},"labels":[],"label_agreement":null},{"id":"W2049741091","doi":"10.1158/1535-7163.targ-13-b20","title":"Abstract B20: Defining the minimal ING1b-derived peptide that is pro-apoptotic.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Apoptosis; Biology; Cancer research; Cancer cell; Carcinogenesis; Cancer; Cell biology; Molecular biology; Genetics","score_opus":0.02411590153455583,"score_gpt":0.27174845487526633,"score_spread":0.2476325533407105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049741091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704874,0.0065710307,0.016455142,0.00038519816,0.00016118343,0.0003077503,0.0012527177,0.000084935346,0.0042945254],"genre_scores_gemma":[0.96204114,0.0035852466,0.025217375,0.00039952341,0.000072587645,0.00018577349,0.003969218,0.00008164214,0.0044475584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990416,0.000019928208,0.000011137849,0.00001921237,0.000022233258,0.000023277604],"domain_scores_gemma":[0.99983823,0.000017703715,0.00004528293,0.000007847994,0.000025515314,0.00006534244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021609092,0.00052211207,0.00021900248,0.00020116752,0.00016249654,0.00030642882,0.0003029194,0.00038224744,0.0014780514],"category_scores_gemma":[0.00017338023,0.00014617153,0.00023425998,0.00015137788,0.00022781445,0.00022588925,0.00023445101,0.00057696796,0.0010359002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001573743,0.000035941917,0.00007154165,0.000048694383,0.0000032903724,0.00006777757,0.0000062019767,0.00018585022,0.9976949,0.00016240921,0.000072525916,0.0014934903],"study_design_scores_gemma":[0.000099659235,0.0010240235,0.0013259227,0.00002655683,0.000026611313,0.00072131696,0.000019199975,0.0012346271,0.9801608,0.00017111153,0.015179374,0.000010753747],"about_ca_topic_score_codex":0.00023131404,"about_ca_topic_score_gemma":0.00026881992,"teacher_disagreement_score":0.0014780514,"about_ca_system_score_codex":0.00034821132,"about_ca_system_score_gemma":0.00020955077,"threshold_uncertainty_score":0.004944563},"labels":[],"label_agreement":null},{"id":"W2049880080","doi":"10.1158/1535-7163.targ-13-b81","title":"Abstract B81: Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Medicine; Vorinostat; Etoposide; Pharmacology; Internal medicine; Oncology; Regimen; Toxicity; Chemotherapy; Histone deacetylase; Biology; Histone","score_opus":0.016198980365157555,"score_gpt":0.30262396926699425,"score_spread":0.2864249889018367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049880080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874816,0.0033494912,0.0006807289,0.0005736009,0.00011342128,0.0029289473,0.0017252556,0.00012742657,0.0030194777],"genre_scores_gemma":[0.98327315,0.002958722,0.0027541958,0.0007727339,0.00015069901,0.0034998963,0.0035276406,0.000034950044,0.0030279993],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997589,0.00010937581,0.000022032857,0.00004475378,0.00002373358,0.0000412299],"domain_scores_gemma":[0.99968123,0.000039002512,0.00007785033,0.000023196102,0.000024397375,0.00015435196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067711517,0.001069297,0.0011604676,0.0002989122,0.0003374506,0.0005976075,0.00051546266,0.0007025844,0.0030067936],"category_scores_gemma":[0.00036268376,0.0003806157,0.00048343046,0.00038854528,0.0004955858,0.00048841594,0.0002734293,0.0020900925,0.0008142592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6320563,0.050242335,0.010955657,0.0023452975,0.0012827965,0.0013456406,0.00041073037,0.0048678787,0.118044704,0.0010630128,0.010752915,0.16663277],"study_design_scores_gemma":[0.49401593,0.4681307,0.013668163,0.000116324634,0.0004094182,0.0011047304,0.00005793156,0.0016845899,0.013015,0.00021049452,0.0075593432,0.000027336655],"about_ca_topic_score_codex":0.0007167506,"about_ca_topic_score_gemma":0.0015598617,"teacher_disagreement_score":0.0030067936,"about_ca_system_score_codex":0.0007268549,"about_ca_system_score_gemma":0.0014994321,"threshold_uncertainty_score":0.010058701},"labels":[],"label_agreement":null},{"id":"W2051367856","doi":"10.1158/1535-7163.targ-13-b59","title":"Abstract B59: Zhangfei/CREBZF arrests the growth of osteosarcoma cells by displacing Mdm2 and stabilizing p53.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Osteosarcoma; Leucine zipper; Cancer research; Transcription factor; Suppressor; Cell growth; Biology; Mdm2; Cell culture; Cell; Cancer cell; Cancer; Cell biology; Gene; Genetics","score_opus":0.013964043401972806,"score_gpt":0.2555600314737198,"score_spread":0.241595988071747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051367856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885007,0.0029585892,0.0025477516,0.00031268646,0.00014242147,0.00007903956,0.0014810598,0.00030495995,0.003672823],"genre_scores_gemma":[0.99093574,0.0007631807,0.0018434159,0.000092145485,0.000029467394,0.000052964122,0.0018216303,0.000031219734,0.004430354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998964,0.000008747568,0.000009191708,0.000024039311,0.000026720421,0.000034903453],"domain_scores_gemma":[0.9999404,0.000008963881,0.000016781602,0.000007781747,0.0000063536277,0.000019674297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010878991,0.00048462453,0.00031393144,0.00022330563,0.00016324867,0.00016277116,0.00033626475,0.00034474357,0.0037825347],"category_scores_gemma":[0.00008161328,0.00012164265,0.0003027072,0.00016476086,0.00027894648,0.00016829741,0.00013204098,0.0006006924,0.0009224789],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002679791,0.00009271025,0.0000914777,0.000056073208,0.000005388793,0.000044195833,0.000005923604,0.0000562344,0.9975752,0.00007584014,0.00017977117,0.0015492227],"study_design_scores_gemma":[0.000062164385,0.00051430915,0.0019798386,0.0000041407106,0.000008081752,0.00014808959,0.000008993809,0.00041434087,0.9946232,0.000019175526,0.0022137752,0.0000039042434],"about_ca_topic_score_codex":0.0009891085,"about_ca_topic_score_gemma":0.0008293414,"teacher_disagreement_score":0.0037825347,"about_ca_system_score_codex":0.00031061584,"about_ca_system_score_gemma":0.00019741095,"threshold_uncertainty_score":0.012653887},"labels":[],"label_agreement":null},{"id":"W2051884443","doi":"10.1158/1535-7163.targ-09-b91","title":"Abstract B91: RNAi knockdown of Mek2, but not Mek1, increases proliferation of malignant and non-malignant human breast cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Gene knockdown; Kinase; Cell growth; Cancer research; MAPK/ERK pathway; Phosphorylation; Small hairpin RNA; Cell culture; Biology; Cell biology; Downregulation and upregulation; Biochemistry; Gene","score_opus":0.014301344045576989,"score_gpt":0.2705639052180859,"score_spread":0.2562625611725089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051884443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851985,0.0023831448,0.0022776665,0.00015073139,0.000058247562,0.000042939762,0.0022680964,0.00023334716,0.0040660896],"genre_scores_gemma":[0.9837467,0.0011288109,0.0030221224,0.00008530757,0.000013863242,0.000054489894,0.0028628206,0.00006145511,0.009024469],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988544,0.000010869516,0.000013226603,0.000024063198,0.00004102601,0.00002537352],"domain_scores_gemma":[0.99993443,0.000012501186,0.000010240605,0.000010408558,0.000011333511,0.000021108965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008265417,0.00029149954,0.00019563682,0.00023410078,0.00013696829,0.00019583428,0.00013545928,0.00017325199,0.0033135784],"category_scores_gemma":[0.00007010517,0.00015563323,0.00021228535,0.000113743656,0.00012108542,0.0001010879,0.00013926641,0.00042027442,0.00093062903],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004931713,0.000016974633,0.00009654682,0.000018670245,0.0000030932276,0.00001688506,0.000005342763,0.00001779943,0.9989392,0.000030506331,0.0001059854,0.00069963606],"study_design_scores_gemma":[0.000009057019,0.00015557634,0.003895528,0.000003011626,0.000008480714,0.00016720474,0.0000112093285,0.00029089834,0.9932153,0.000010712829,0.0022310375,0.000002044634],"about_ca_topic_score_codex":0.001330948,"about_ca_topic_score_gemma":0.0015118639,"teacher_disagreement_score":0.0033135784,"about_ca_system_score_codex":0.00020802348,"about_ca_system_score_gemma":0.00013275744,"threshold_uncertainty_score":0.011084974},"labels":[],"label_agreement":null},{"id":"W2052027458","doi":"10.1158/1535-7163.targ-11-b220","title":"Abstract B220: Artificially inducing protein-membrane anchorage: Introducing a new therapeutic modality.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cell biology; Cancer cell; STAT3; Prenylation; STAT protein; Membrane protein; Gene knockdown; Target protein; Chemistry; Biology; Biochemistry; Cancer; Membrane; Signal transduction; Gene; Enzyme","score_opus":0.055904775003702833,"score_gpt":0.2895475400700889,"score_spread":0.2336427650663861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052027458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94508934,0.00705478,0.039393097,0.0007958202,0.00026011738,0.00026131282,0.0008190215,0.000400254,0.0059261722],"genre_scores_gemma":[0.9793585,0.0020812633,0.01473255,0.00015741649,0.000022703878,0.00008176893,0.00037547704,0.000026117503,0.0031643151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999317,0.000016491751,0.0000048441752,0.000015531074,0.000018895267,0.000012477426],"domain_scores_gemma":[0.9999552,0.000008480759,0.000016445023,0.0000044620783,0.000004247322,0.000011129348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012396598,0.00030616834,0.0001273057,0.00018316421,0.00009656153,0.00021751891,0.00017493038,0.00038365807,0.00094325066],"category_scores_gemma":[0.000083701154,0.00011210895,0.00019706906,0.00012242205,0.00019363662,0.0002488571,0.00019059387,0.0005991651,0.00037542678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000545508,0.000025729129,0.00004148554,0.000038055696,0.000002643688,0.000030980103,0.000005761809,0.00006181864,0.9978352,0.00027747976,0.0000577022,0.0015686034],"study_design_scores_gemma":[0.000016149823,0.0002655187,0.00028866206,0.000003888657,0.000008790124,0.00018538683,0.000004925883,0.0003748712,0.99370885,0.000060392133,0.005078844,0.0000037035363],"about_ca_topic_score_codex":0.00019563832,"about_ca_topic_score_gemma":0.00019550312,"teacher_disagreement_score":0.00094325066,"about_ca_system_score_codex":0.0002254202,"about_ca_system_score_gemma":0.0001507973,"threshold_uncertainty_score":0.00315547},"labels":[],"label_agreement":null},{"id":"W2053354626","doi":"10.1158/1535-7163.mct-08-0885","title":"WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of California, Irvine","keywords":"Wnt signaling pathway; Cancer research; Biology; Ectopic expression; Gene silencing; Cell biology; Signal transduction; Cell culture; Gene","score_opus":0.01596058149435428,"score_gpt":0.2749779907451785,"score_spread":0.25901740925082417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053354626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926992,0.003179263,0.001649379,0.00008570897,0.000024257542,0.000045310673,0.00071995903,0.00013282856,0.0014641096],"genre_scores_gemma":[0.9901508,0.0019880936,0.0013772686,0.000057666308,0.000007458452,0.00008485295,0.0019376348,0.000021773385,0.0043744673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999263,0.000007733962,0.0000063982175,0.000015413449,0.00001820702,0.000025897441],"domain_scores_gemma":[0.9999633,0.000005054744,0.000010617425,0.000003660082,0.000004670801,0.000012731206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000729212,0.00043003104,0.00022483186,0.00030794146,0.00015507432,0.00020361968,0.00016363422,0.0001933866,0.0010172001],"category_scores_gemma":[0.000059065587,0.0001705848,0.00026710515,0.00020147099,0.00012405241,0.000096743,0.00011938847,0.00035061603,0.00037149043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007950727,0.00003537736,0.00019159103,0.000032755583,0.0000055352484,0.000038345952,0.000008846271,0.00004758824,0.9983876,0.0000453135,0.00007570086,0.001051867],"study_design_scores_gemma":[0.000017608294,0.00014174423,0.005422903,0.0000050248086,0.000017033908,0.00018488271,0.00001213766,0.0010204524,0.9905872,0.000016144275,0.002572626,0.0000023658135],"about_ca_topic_score_codex":0.0017165713,"about_ca_topic_score_gemma":0.0033361474,"teacher_disagreement_score":0.0017165713,"about_ca_system_score_codex":0.00035164016,"about_ca_system_score_gemma":0.00027001667,"threshold_uncertainty_score":0.0034131408},"labels":[],"label_agreement":null},{"id":"W2053411198","doi":"10.1158/1535-7163.targ-11-c165","title":"Abstract C165: Breast cancer, statins, and 3-D cell culture.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Fluvastatin; Cell culture; Cancer; Breast cancer; Cancer research; Cell growth; Cell cycle; Apoptosis; Cell; Statin; Cancer cell; Medicine; Pharmacology; Chemistry; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.017975087999392958,"score_gpt":0.26066453214097673,"score_spread":0.24268944414158378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053411198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.592925,0.11732645,0.03367692,0.006592586,0.003733122,0.0018576845,0.13281469,0.0025172383,0.10855635],"genre_scores_gemma":[0.6777626,0.04733437,0.058348548,0.002510265,0.00053080387,0.0021221226,0.13336477,0.00033710198,0.07768932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994597,0.000093592025,0.00008203716,0.00009088811,0.00018466599,0.000089041394],"domain_scores_gemma":[0.9998338,0.000030084477,0.000021818316,0.000029847255,0.000052398453,0.000032004056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005092781,0.0007105478,0.0005794209,0.0012370945,0.00064016716,0.00048028165,0.0007035583,0.0005919174,0.006833625],"category_scores_gemma":[0.0001833435,0.000245468,0.0006918487,0.0017055747,0.00023163541,0.00022713863,0.00044655177,0.00096586085,0.005911467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012595268,0.0006937831,0.0017519657,0.00086239626,0.00005689932,0.00077365764,0.00020627516,0.0008232638,0.9547201,0.0013182235,0.013388275,0.02414561],"study_design_scores_gemma":[0.00018282158,0.0014194396,0.027022578,0.0001313864,0.00013930142,0.0019443466,0.0001846657,0.0028391618,0.74819195,0.00052572764,0.21733011,0.000088419554],"about_ca_topic_score_codex":0.011223798,"about_ca_topic_score_gemma":0.014276496,"teacher_disagreement_score":0.011223798,"about_ca_system_score_codex":0.00072223286,"about_ca_system_score_gemma":0.00063026417,"threshold_uncertainty_score":0.022860706},"labels":[],"label_agreement":null},{"id":"W2053902344","doi":"10.1158/1535-7163.targ-13-c70","title":"Abstract C70: A phase 2 study of intravenous administration of REOLYSIN® (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Carboplatin; Oncolytic virus; Internal medicine; Chemotherapy; Regimen; Clinical endpoint; Oncology; Gastroenterology; Phases of clinical research; Rash; Paclitaxel; Clinical trial; Cancer; Cisplatin","score_opus":0.010920829223191287,"score_gpt":0.2704467142879798,"score_spread":0.2595258850647885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053902344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321175,0.0010906678,0.00048221266,0.00024320126,0.00009242471,0.0028198392,0.0005704508,0.00010547303,0.001383901],"genre_scores_gemma":[0.991863,0.0010890787,0.0010725101,0.0005385343,0.00014174674,0.0018393984,0.0009829679,0.000028719709,0.0024439835],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996112,0.00016040356,0.000016352506,0.00006698666,0.000043331333,0.000101756275],"domain_scores_gemma":[0.9994517,0.00008344329,0.0000892883,0.000039336923,0.00004294072,0.00029342223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011988705,0.0017381526,0.0016511187,0.0006437745,0.00045940594,0.0010524181,0.00088945177,0.0016937185,0.0036028598],"category_scores_gemma":[0.0005835921,0.00061491336,0.0011810333,0.00045921002,0.0009073932,0.0006974629,0.0002926493,0.0030352063,0.00079972384],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62537587,0.18517508,0.0027367165,0.0011941801,0.001268379,0.00038638356,0.00034523802,0.0026228067,0.09950012,0.0003773801,0.0030086348,0.078009196],"study_design_scores_gemma":[0.34020317,0.6466863,0.0044582407,0.00002519773,0.0003038237,0.000185518,0.00004617525,0.000908145,0.005740597,0.00008567151,0.0013270543,0.000030170739],"about_ca_topic_score_codex":0.002088667,"about_ca_topic_score_gemma":0.0037616289,"teacher_disagreement_score":0.0036028598,"about_ca_system_score_codex":0.0010779328,"about_ca_system_score_gemma":0.002153659,"threshold_uncertainty_score":0.012052774},"labels":[],"label_agreement":null},{"id":"W2053960137","doi":"10.1158/1535-7163.targ-11-a50","title":"Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Pfizer (Canada); London Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Ontario Clinical Oncology Group; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"PTEN; Neuroblastoma RAS viral oncogene homolog; Medicine; Biomarker; Cancer; Genotyping; Exact test; Mutation; Internal medicine; Oncology; Genotype; Cancer research; KRAS; Gene; Biology; Genetics; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.06901843089128866,"score_gpt":0.3468851743945893,"score_spread":0.27786674350330065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053960137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101174,0.0023520007,0.000629251,0.0003531874,0.000113168,0.001421596,0.001990462,0.00008408697,0.002044528],"genre_scores_gemma":[0.98945427,0.0009352203,0.0015159141,0.0006260183,0.00010750393,0.000997291,0.003790705,0.000028854874,0.0025441824],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965644,0.00014442048,0.000027429765,0.00007012811,0.000048710524,0.000052863634],"domain_scores_gemma":[0.9994636,0.0000990165,0.00006570363,0.00003824798,0.000054384156,0.00027917183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013726531,0.0009508038,0.0012273706,0.0003438683,0.00026789424,0.0006690823,0.0004635288,0.0007709276,0.0042116805],"category_scores_gemma":[0.0008713885,0.00037727863,0.0007826605,0.0003628399,0.00041140252,0.00042652473,0.00021434648,0.0015723723,0.0009245767],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65461284,0.030512476,0.029405368,0.0010489366,0.0029890817,0.0006961365,0.0001940497,0.0024111583,0.17387396,0.00019737733,0.00861937,0.09543924],"study_design_scores_gemma":[0.34071112,0.54434025,0.07708984,0.00005996319,0.0022449035,0.0010418232,0.00005879392,0.003112507,0.02623515,0.00023678839,0.0048100017,0.000058846315],"about_ca_topic_score_codex":0.00061277737,"about_ca_topic_score_gemma":0.0013916541,"teacher_disagreement_score":0.0042116805,"about_ca_system_score_codex":0.00048361186,"about_ca_system_score_gemma":0.0007737387,"threshold_uncertainty_score":0.014089525},"labels":[],"label_agreement":null},{"id":"W2054755055","doi":"10.1158/1535-7163.targ-11-ed01-01","title":"Abstract ED01-01: Preventing multiple types of cancer through HPV vaccination.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical cancer; Genital warts; HPV vaccines; Medicine; Vaccination; Recurrent Respiratory Papillomatosis; Virology; Cancer; Antibody; Cervix; Penile cancer; Immunology; Human papillomavirus; HPV infection; Internal medicine","score_opus":0.09091567059140804,"score_gpt":0.378963751330603,"score_spread":0.28804808073919497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054755055","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33428472,0.08975903,0.012641048,0.04216022,0.019846056,0.005017534,0.022593727,0.0037556482,0.4699419],"genre_scores_gemma":[0.52968514,0.02997861,0.009456341,0.020194605,0.003918834,0.0011422626,0.015706725,0.00014331192,0.3897742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997954,0.00004203933,0.00001029401,0.000029592864,0.000060509275,0.00006218173],"domain_scores_gemma":[0.9998031,0.000027544998,0.000021960535,0.000012628349,0.00003935815,0.000095503354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060679705,0.00046343644,0.0003125884,0.00047670395,0.0001853853,0.00045011775,0.0006998562,0.0015156918,0.03868811],"category_scores_gemma":[0.0003594233,0.0001763973,0.00051140727,0.00017361795,0.0001433379,0.00034268183,0.0004467359,0.001270072,0.008079876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007019846,0.007459421,0.005746354,0.0013827181,0.00011351384,0.00048682166,0.00005398166,0.00040327583,0.034310516,0.0024877677,0.17278193,0.7677539],"study_design_scores_gemma":[0.0059191366,0.040372107,0.048299804,0.0010161202,0.00037481534,0.0026383277,0.00012154856,0.0011525939,0.043960366,0.0013685988,0.8547363,0.000040252235],"about_ca_topic_score_codex":0.0008033759,"about_ca_topic_score_gemma":0.0011522307,"teacher_disagreement_score":0.03868811,"about_ca_system_score_codex":0.0004121124,"about_ca_system_score_gemma":0.0006223174,"threshold_uncertainty_score":0.12942457},"labels":[],"label_agreement":null},{"id":"W2057360831","doi":"10.1158/1535-7163.targ-11-c25","title":"Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"ATP Synthase and ATPases Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Mucositis; Febrile neutropenia; Epirubicin; Cancer; Pharmacology; Doxorubicin; Cardiotoxicity; Pharmacokinetics; Anthracycline; Toxicity; Internal medicine; Chemotherapy; Gastroenterology; Breast cancer","score_opus":0.0660289416052039,"score_gpt":0.39767779684636717,"score_spread":0.3316488552411633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057360831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99024594,0.0016892499,0.00074717775,0.000504871,0.000100849466,0.003408562,0.0011345333,0.000117346,0.002051516],"genre_scores_gemma":[0.9879799,0.0014789714,0.0018987826,0.0008307623,0.00010604237,0.0023077633,0.0020428402,0.000029550512,0.003325446],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997757,0.00007022,0.00001347576,0.00005635823,0.000025194482,0.000059131733],"domain_scores_gemma":[0.9995628,0.000043534637,0.000060310405,0.000022864717,0.000026188067,0.0002842746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007203223,0.0013757233,0.0013342472,0.0004838998,0.00047339784,0.0009132818,0.0007703093,0.0012873177,0.0047751404],"category_scores_gemma":[0.0005077493,0.00044942598,0.0008935252,0.0004756389,0.00071183726,0.000620516,0.00028826905,0.0023845525,0.00106356],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47003534,0.12496449,0.008768469,0.002431798,0.0018780077,0.0012607367,0.00058309047,0.0052030743,0.19074383,0.00069305085,0.011324795,0.1821133],"study_design_scores_gemma":[0.2893266,0.68460786,0.0109262485,0.00005722087,0.00049474393,0.0004794262,0.00006353065,0.0014050743,0.008359114,0.00012636422,0.004121708,0.000032284683],"about_ca_topic_score_codex":0.0024551793,"about_ca_topic_score_gemma":0.0057019806,"teacher_disagreement_score":0.0047751404,"about_ca_system_score_codex":0.001011672,"about_ca_system_score_gemma":0.0020018085,"threshold_uncertainty_score":0.015974402},"labels":[],"label_agreement":null},{"id":"W2057494314","doi":"10.1158/1535-7163.targ-11-a19","title":"Abstract A19: Establishment of patient primary tumor-derived xenograft models for testing anticancer agents.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Irinotecan; Gemcitabine; Docetaxel; In vivo; Paclitaxel; Cancer; Cisplatin; Doxorubicin; Erlotinib; Cancer research; Primary tumor; Pharmacology; Colorectal cancer; Chemotherapy; Internal medicine; Metastasis; Biology","score_opus":0.06952482561264713,"score_gpt":0.3080648751406081,"score_spread":0.23854004952796098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057494314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696562,0.009294414,0.04108942,0.0007102486,0.0007136183,0.0040882844,0.049211767,0.0014061428,0.023829961],"genre_scores_gemma":[0.8295777,0.0074335695,0.04774356,0.00039579987,0.00014976821,0.002712406,0.08612075,0.00028190023,0.025584616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991954,0.00014833671,0.00012132698,0.00019128178,0.00021635434,0.00012732626],"domain_scores_gemma":[0.99941814,0.00012168351,0.00006951359,0.0001561491,0.000114288945,0.00012031346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014219425,0.0010750465,0.00071942946,0.00080497866,0.00042112186,0.0005232507,0.0006494196,0.0005372321,0.009990217],"category_scores_gemma":[0.00031428662,0.0003323504,0.00084508554,0.00088145916,0.0003216266,0.00040881772,0.00038497485,0.0013348375,0.0042465325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019445276,0.0016258995,0.0033258952,0.0005167528,0.00010162675,0.0006780198,0.00010595514,0.00043230003,0.9728808,0.00065121497,0.005478367,0.012258691],"study_design_scores_gemma":[0.00031116357,0.0071925777,0.019764813,0.000050298193,0.00022334412,0.005043487,0.00007167697,0.0016140352,0.926692,0.00014616775,0.038857114,0.00003324121],"about_ca_topic_score_codex":0.0010840812,"about_ca_topic_score_gemma":0.0017087262,"teacher_disagreement_score":0.009990217,"about_ca_system_score_codex":0.00047321472,"about_ca_system_score_gemma":0.0007168972,"threshold_uncertainty_score":0.033420622},"labels":[],"label_agreement":null},{"id":"W2058563691","doi":"10.1158/1535-7163.targ-13-b235","title":"Abstract B235: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to vemurafenib in melanoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal General Hospital; McGill University","funders":"","keywords":"Vemurafenib; Melanoma; Cancer research; Cell growth; Gene silencing; Cell culture; EIF4E; Biology; Autophagy; Carcinogenesis; Cancer; Apoptosis; Translation (biology); Messenger RNA; Genetics; Gene","score_opus":0.011321510108316304,"score_gpt":0.2647805564617168,"score_spread":0.2534590463534005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058563691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717971,0.014685175,0.0041599697,0.00062084035,0.00039608023,0.00007838826,0.0022932824,0.00025949578,0.0057096644],"genre_scores_gemma":[0.98338276,0.0029245918,0.0026453733,0.000115618,0.000049855556,0.00004782857,0.0020513816,0.000026764563,0.008755846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994814,0.000008134664,0.0000053560348,0.000011319418,0.000013862931,0.000013211636],"domain_scores_gemma":[0.9999628,0.0000045602155,0.0000088850475,0.000003109622,0.000005997767,0.000014589169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088895766,0.00031739802,0.00022254087,0.00021795467,0.00019634994,0.00019005382,0.0001357431,0.0002528165,0.0032534346],"category_scores_gemma":[0.00007478965,0.00009458303,0.00025875974,0.0001103276,0.000111285946,0.00012151443,0.00014181537,0.0004071927,0.0006912938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032321084,0.00003347131,0.00021886003,0.00012244289,0.000007810898,0.00007798264,0.000004563118,0.00005916295,0.9956552,0.000087878645,0.00019723107,0.003212186],"study_design_scores_gemma":[0.00006896356,0.0008740746,0.012838892,0.000023056298,0.000041048945,0.0006454076,0.000029282355,0.0006901396,0.9705493,0.00014110043,0.014089995,0.000008673548],"about_ca_topic_score_codex":0.00030295664,"about_ca_topic_score_gemma":0.0003819473,"teacher_disagreement_score":0.0032534346,"about_ca_system_score_codex":0.00018504639,"about_ca_system_score_gemma":0.00016983095,"threshold_uncertainty_score":0.010883808},"labels":[],"label_agreement":null},{"id":"W2060486960","doi":"10.1158/1535-7163.targ-09-b223","title":"Abstract B223: Protein kinase C iota as a target for glioblastoma therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lamellipodium; Motility; Cancer research; MARCKS; Mitosis; Protein kinase C; Biology; Cell growth; Cell biology; Small hairpin RNA; Cell; Cancer; Cancer cell; Filopodia; Pseudopodia; Kinase; Cell migration; Actin; Cell culture; Genetics","score_opus":0.020119616501461834,"score_gpt":0.29111817036076626,"score_spread":0.27099855385930444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060486960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45236996,0.2859071,0.0076700505,0.032125175,0.014262286,0.0015719067,0.007362827,0.001784463,0.19694628],"genre_scores_gemma":[0.74736327,0.12116195,0.007519196,0.0052928803,0.0023526056,0.00070138235,0.009866507,0.0001518248,0.10559039],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994314,0.000009543719,0.000004408128,0.0000062358963,0.000021771622,0.000014810218],"domain_scores_gemma":[0.99995553,0.000003439017,0.000007807139,0.000002745759,0.000009365618,0.000021066253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011281395,0.00046258504,0.00039425338,0.0005579702,0.00022143054,0.0005368103,0.00026281728,0.0006417649,0.014352011],"category_scores_gemma":[0.000099399906,0.000105773564,0.00025834906,0.00042834377,0.00014166387,0.00019819138,0.00025269386,0.00092140026,0.0044923984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00572052,0.0018350638,0.0018155987,0.0022092178,0.000113783106,0.0016845579,0.000041628125,0.00093412236,0.4451513,0.00622454,0.18457435,0.34969535],"study_design_scores_gemma":[0.002974691,0.007685394,0.030448606,0.0006225383,0.0003158813,0.0059644273,0.000086324944,0.0033359355,0.29309002,0.003225094,0.65218014,0.0000711199],"about_ca_topic_score_codex":0.0008914881,"about_ca_topic_score_gemma":0.0012693687,"teacher_disagreement_score":0.014352011,"about_ca_system_score_codex":0.0007851584,"about_ca_system_score_gemma":0.00061897765,"threshold_uncertainty_score":0.048012316},"labels":[],"label_agreement":null},{"id":"W2060631498","doi":"10.1158/1535-7163.mct-05-0167","title":"Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Lactalbumin; Cancer research; Breast cancer; Biology; Promoter; Molecular biology; Genetic enhancement; Gene; Cell culture; Cancer; Gene expression; Genetics; Biochemistry","score_opus":0.027214311535851344,"score_gpt":0.3120649585151987,"score_spread":0.28485064697934737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060631498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078473,0.029196132,0.057580914,0.0002796118,0.00014019021,0.00024982003,0.00032266296,0.00035751096,0.004025916],"genre_scores_gemma":[0.9488405,0.010066682,0.036275357,0.00009069625,0.000029850637,0.00019134209,0.0004660518,0.000036112484,0.0040034167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980146,0.00003854515,0.000018257777,0.0000491411,0.00005550628,0.00003706504],"domain_scores_gemma":[0.9999237,0.000020617414,0.000022348491,0.000011506914,0.000010480861,0.00001138566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034930086,0.0004309359,0.00027077793,0.00026774078,0.00012518188,0.00043983728,0.00023133808,0.00034710398,0.0004972189],"category_scores_gemma":[0.00016205941,0.00020766536,0.00035777094,0.0002135161,0.00028167828,0.00038383147,0.00022674397,0.0007072412,0.0003103796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009558094,0.000048710164,0.00013221023,0.000089030924,0.0000064555443,0.000039878996,0.000028243783,0.00017723229,0.99371123,0.00039147725,0.000034691846,0.0052453484],"study_design_scores_gemma":[0.000032767442,0.0003782667,0.0006499126,0.00001372322,0.000032040818,0.00038072298,0.000017653392,0.0010358929,0.98910916,0.00010956962,0.00823193,0.000008332743],"about_ca_topic_score_codex":0.00045068876,"about_ca_topic_score_gemma":0.00031807568,"teacher_disagreement_score":0.0004972189,"about_ca_system_score_codex":0.0003849763,"about_ca_system_score_gemma":0.00019181884,"threshold_uncertainty_score":0.0027931929},"labels":[],"label_agreement":null},{"id":"W2061181299","doi":"10.1158/1535-7163.mct-07-2166","title":"Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Cell biology; Biology; Endoplasmic reticulum; Gene knockdown; Unfolded protein response; Apoptosis; Molecular biology; Protein kinase A; Cathepsin; Kinase; Cancer research; Biochemistry","score_opus":0.01816623585862282,"score_gpt":0.25395953258808807,"score_spread":0.23579329672946525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061181299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934823,0.0025407395,0.002159482,0.000082109946,0.000041691652,0.000050339633,0.00053669396,0.00009909716,0.0010074752],"genre_scores_gemma":[0.9958687,0.000824526,0.0011564451,0.000026065314,0.00000588424,0.00006389911,0.0005516483,0.000009004781,0.0014938391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988294,0.000016456212,0.000014608691,0.000019749901,0.000027813127,0.000038463495],"domain_scores_gemma":[0.9999502,0.000004482392,0.0000143402485,0.000007452113,0.00000999023,0.000013571636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000942944,0.00037170865,0.00023706185,0.00016164982,0.00012307201,0.00022868409,0.00012844053,0.00015168608,0.0009545375],"category_scores_gemma":[0.00005365824,0.000103635095,0.00035688916,0.00012312084,0.00015376224,0.00014491448,0.00013790569,0.0004540475,0.0003950444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015419672,0.00003709757,0.000105006424,0.00003868692,0.0000056679546,0.000038919166,0.000017560404,0.000047951813,0.9985844,0.000090279194,0.00004434196,0.0008359285],"study_design_scores_gemma":[0.000020407033,0.00018496721,0.0021803363,0.0000024673645,0.0000101330525,0.00015539378,0.000015192767,0.00059845706,0.99571604,0.000030129886,0.0010840172,0.000002492607],"about_ca_topic_score_codex":0.00039778228,"about_ca_topic_score_gemma":0.00061974267,"teacher_disagreement_score":0.0009545375,"about_ca_system_score_codex":0.00029119066,"about_ca_system_score_gemma":0.00022114045,"threshold_uncertainty_score":0.0031932592},"labels":[],"label_agreement":null},{"id":"W2063170049","doi":"10.1158/1535-7163.mct-06-0043","title":"Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an<i>in vitro</i>bladder cancer carcinogenesis model","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Erlotinib; Epidermal growth factor receptor; Cancer research; Tyrosine-kinase inhibitor; Epidermal growth factor; MAPK/ERK pathway; Tyrosine kinase; Biology; Chemistry; Kinase; Cell biology; Molecular biology; Signal transduction; Receptor; Cancer; Biochemistry","score_opus":0.024786608915299935,"score_gpt":0.31071206138325674,"score_spread":0.2859254524679568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063170049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552876,0.0008283162,0.0014312961,0.0000739266,0.000059833852,0.000056068162,0.00039359595,0.000074806296,0.0015534298],"genre_scores_gemma":[0.99312556,0.0013377466,0.002451759,0.00006292234,0.000013966957,0.00006823477,0.0008153123,0.000021931155,0.0021024484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997614,0.000070831986,0.00002449198,0.00003800801,0.000039913957,0.00006527943],"domain_scores_gemma":[0.9998041,0.000038444912,0.000057595815,0.000030269779,0.000022650054,0.00004706117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025520296,0.0005661451,0.00043937736,0.00022614417,0.00014292232,0.00024010474,0.00027422214,0.00026865082,0.00084317086],"category_scores_gemma":[0.00009253233,0.00021068752,0.00057117385,0.00024060869,0.00015109681,0.00013417478,0.00012936263,0.00062154507,0.00022057713],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036331077,0.00021930649,0.00015776286,0.000037044407,0.000012177879,0.000036307472,0.00001006753,0.00018216847,0.9980059,0.000035476896,0.00006966685,0.0008708049],"study_design_scores_gemma":[0.000017837852,0.0016434191,0.0013167806,0.0000025878378,0.000031455504,0.000057599747,0.000008810164,0.0006499805,0.995771,0.000005264634,0.0004921297,0.000003089734],"about_ca_topic_score_codex":0.002077731,"about_ca_topic_score_gemma":0.0023310925,"teacher_disagreement_score":0.002077731,"about_ca_system_score_codex":0.00031311216,"about_ca_system_score_gemma":0.0003112383,"threshold_uncertainty_score":0.004131317},"labels":[],"label_agreement":null},{"id":"W2063990365","doi":"10.1158/1535-7163.mct-08-0309","title":"A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of General Medical Sciences; University of Alberta","keywords":"STAT3; stat; Signal transduction; Cancer research; Tyrosine phosphorylation; Cancer cell; Cell signaling; JAK-STAT signaling pathway; Phosphorylation; Biology; PIM1; Cell culture; Cancer; Tyrosine kinase; Cell biology; Genetics","score_opus":0.08874461016305578,"score_gpt":0.3205069088335087,"score_spread":0.2317622986704529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063990365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776732,0.008108101,0.0069330046,0.0002320646,0.000098941266,0.00042396612,0.0019727016,0.00035822415,0.004199762],"genre_scores_gemma":[0.98092365,0.006021626,0.0058178795,0.00010561868,0.000015457035,0.00016364455,0.0023318427,0.0000137150855,0.004606614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999243,0.000009471764,0.000006806425,0.00001799538,0.000025621513,0.000015803846],"domain_scores_gemma":[0.99997306,0.000005522556,0.000006555665,0.0000029660332,0.000004486566,0.000007359045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112545866,0.0005374016,0.0003509697,0.0003907791,0.00014758071,0.00016160173,0.00025287532,0.00024517375,0.0014168716],"category_scores_gemma":[0.000060420607,0.00012559138,0.00032006414,0.0002873868,0.00011240621,0.000100723795,0.00014632702,0.00040627146,0.00043330344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013312776,0.00014673144,0.00027779408,0.00010774734,0.000015666868,0.00010802308,0.00001190507,0.00024355589,0.9931966,0.0000659169,0.00016133072,0.0055317525],"study_design_scores_gemma":[0.00013697185,0.0019394817,0.0028315412,0.000010252247,0.000053624986,0.00046820455,0.000014619919,0.0010888765,0.98982376,0.000022841774,0.0036006786,0.000009152996],"about_ca_topic_score_codex":0.00061926944,"about_ca_topic_score_gemma":0.0019284355,"teacher_disagreement_score":0.0014168716,"about_ca_system_score_codex":0.00018892298,"about_ca_system_score_gemma":0.00023480672,"threshold_uncertainty_score":0.0047398806},"labels":[],"label_agreement":null},{"id":"W2065683374","doi":"10.1158/1535-7163.mct-06-0389","title":"C35 (<i>C17orf37</i>) is a novel tumor biomarker abundantly expressed in breast cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cancer Institute, University of Pittsburgh; Tufts University School of Medicine; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Biology; Biomarker; Breast cancer; Gene; Immunohistochemistry; Cancer; Oncogene; Cancer research; Complementary DNA; Open reading frame; Pathology; Gene expression; Medicine; Immunology; Genetics; Cell cycle; Peptide sequence","score_opus":0.04298584457033967,"score_gpt":0.3514532504766201,"score_spread":0.30846740590628047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065683374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883394,0.0036181335,0.002709681,0.00022058497,0.000080227364,0.00004300134,0.0036802627,0.0001550648,0.0011535335],"genre_scores_gemma":[0.9894456,0.0007643061,0.0042890836,0.00019226814,0.00004823998,0.00003476266,0.004264132,0.000037270034,0.0009242399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998227,0.000015450158,0.000014724728,0.00007161461,0.00004118702,0.00003430838],"domain_scores_gemma":[0.9997719,0.000036565438,0.00011706107,0.000012208657,0.000021537202,0.00004069269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020935526,0.0006023027,0.0003663649,0.0007455635,0.00030614762,0.00039727878,0.0002479737,0.00068576745,0.0020454193],"category_scores_gemma":[0.00034341522,0.00009939051,0.00043243504,0.000710775,0.00045887876,0.00014215587,0.00020783019,0.00029296614,0.0006523979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071473815,0.000028389812,0.01701533,0.00018981393,0.0000596977,0.002396509,0.00007030353,0.00034823272,0.96428263,0.0004036143,0.0011598695,0.013330806],"study_design_scores_gemma":[0.0001245874,0.0010376067,0.24474277,0.000102628714,0.0002580637,0.028625071,0.00016926507,0.004257144,0.68087196,0.0008671773,0.03884412,0.00009966792],"about_ca_topic_score_codex":0.0016387376,"about_ca_topic_score_gemma":0.0017648604,"teacher_disagreement_score":0.0020454193,"about_ca_system_score_codex":0.0005804235,"about_ca_system_score_gemma":0.00031302022,"threshold_uncertainty_score":0.006842613},"labels":[],"label_agreement":null},{"id":"W2065864502","doi":"10.1158/1535-7163.mct-08-0930","title":"<i>Connexin43</i> pseudogene in breast cancer cells offers a novel therapeutic target","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pseudogene; Gene knockdown; Cancer; Cancer research; Biology; Cancer cell; Breast cancer; Cytotoxic T cell; Gene; Carcinogenesis; In vitro; Molecular biology; Genetics","score_opus":0.014954157037738666,"score_gpt":0.2660059375885211,"score_spread":0.2510517805507824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065864502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691159,0.007247506,0.014526038,0.0011223627,0.00026133182,0.000057570087,0.00048747144,0.00030699902,0.0068747867],"genre_scores_gemma":[0.98133093,0.0028406784,0.008674774,0.00022919779,0.000056480058,0.000045895635,0.0006603254,0.00005321875,0.006108535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999194,0.000025285583,0.000006418304,0.000017028668,0.000019382542,0.000012416544],"domain_scores_gemma":[0.99993646,0.000016143647,0.00001925839,0.000010466133,0.000006293604,0.000011264248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012840318,0.00017856204,0.00016308048,0.00011376676,0.00020250562,0.00023244756,0.00010424364,0.0002544852,0.0018214033],"category_scores_gemma":[0.000096852295,0.000097968434,0.00016850841,0.00010787043,0.00021808918,0.00018643097,0.00014568798,0.0004301639,0.0004578511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039295526,0.000009088396,0.00010958804,0.00003075808,0.0000022234085,0.000081230035,0.000007813839,0.00003919541,0.9974692,0.0005098126,0.00012914513,0.0015727449],"study_design_scores_gemma":[0.000007925774,0.00017598535,0.0020337608,0.0000050227877,0.000010817608,0.0010950719,0.000016712493,0.0005062569,0.9847456,0.00018799154,0.011211044,0.0000037552775],"about_ca_topic_score_codex":0.00025309218,"about_ca_topic_score_gemma":0.00041029663,"teacher_disagreement_score":0.0018214033,"about_ca_system_score_codex":0.00023129045,"about_ca_system_score_gemma":0.00015185062,"threshold_uncertainty_score":0.006093204},"labels":[],"label_agreement":null},{"id":"W2066040725","doi":"10.1158/1535-7163.mct-05-0495","title":"β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Azoxymethane; Aberrant crypt foci; Apoptosis; Grape seed extract; Colorectal cancer; Medicine; Flow cytometry; Cell; Cell growth; Cancer; Pharmacology; Internal medicine; Cancer research; Pathology; Chemistry; Immunology; Biochemistry","score_opus":0.007171750770668461,"score_gpt":0.22606718763604047,"score_spread":0.21889543686537202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066040725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969013,0.0014467483,0.00056739745,0.00008278041,0.000022655566,0.000022810555,0.00020901175,0.000090351736,0.0006569221],"genre_scores_gemma":[0.9929508,0.001873839,0.0008907983,0.00005785194,0.000015390571,0.00004869021,0.00053751376,0.000017681677,0.0036073686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999325,0.000011300432,0.0000066974426,0.000009399422,0.0000134078255,0.000026787187],"domain_scores_gemma":[0.9998864,0.000010233416,0.000037453952,0.000011174633,0.000012345833,0.000042387375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009721519,0.00058493164,0.00033572325,0.0005742462,0.00013362932,0.00011638875,0.00014645851,0.00021294723,0.001234695],"category_scores_gemma":[0.00008311529,0.0001589795,0.0002501753,0.000195412,0.00022115666,0.00018039109,0.00013567155,0.00064360927,0.00023423406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075955124,0.0002612974,0.0003621871,0.00005463136,0.000011519517,0.000047936646,0.00001354738,0.00006804249,0.99597305,0.000029657946,0.000053447522,0.002365096],"study_design_scores_gemma":[0.000109188666,0.00456735,0.01576475,0.000015639218,0.000037821635,0.00014328373,0.00005438188,0.0007290294,0.97703576,0.000048853664,0.0014878894,0.000006074549],"about_ca_topic_score_codex":0.000980436,"about_ca_topic_score_gemma":0.0016810482,"teacher_disagreement_score":0.001234695,"about_ca_system_score_codex":0.0001738048,"about_ca_system_score_gemma":0.00022381122,"threshold_uncertainty_score":0.004130423},"labels":[],"label_agreement":null},{"id":"W2066244997","doi":"10.1158/1535-7163.pms-b17","title":"Abstract B17: Dexamethasone synthetic lethal screens uncover two potential combination therapies for the treatment of multiple myeloma","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"","keywords":"Dexamethasone; Cancer research; Multiple myeloma; Programmed cell death; Apoptosis; Glucocorticoid receptor; Medicine; Pharmacology; Biology; Glucocorticoid; Immunology; Internal medicine","score_opus":0.041579972672195674,"score_gpt":0.33072438364142387,"score_spread":0.2891444109692282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066244997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94962573,0.013432107,0.0072920495,0.0015426216,0.0003997558,0.00092104916,0.009996193,0.0007735746,0.01601701],"genre_scores_gemma":[0.9602831,0.0060701217,0.01090828,0.000603053,0.00004145017,0.00037501036,0.0069699096,0.00011417157,0.014634847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997775,0.000023012184,0.00001596906,0.000033497356,0.000105777544,0.000044188095],"domain_scores_gemma":[0.99987626,0.00001778355,0.000022256698,0.000008806233,0.000029735642,0.00004519509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017803129,0.0007547019,0.00075036334,0.0009449454,0.00027914252,0.00062198774,0.00046711246,0.0006615395,0.0069323657],"category_scores_gemma":[0.00016955312,0.00022998732,0.00060024654,0.00046878945,0.00019714855,0.00018633535,0.00030402606,0.00095103483,0.0012966859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087783363,0.00044474524,0.0008402926,0.0002678968,0.000081272054,0.00037838347,0.000020691738,0.0009390037,0.9761479,0.00041572438,0.0014558122,0.018130472],"study_design_scores_gemma":[0.00043961196,0.005702796,0.00457079,0.000047222547,0.0003109919,0.0012564112,0.000085214946,0.002883722,0.9506833,0.00028257756,0.033696994,0.000040364823],"about_ca_topic_score_codex":0.00097378355,"about_ca_topic_score_gemma":0.0021642705,"teacher_disagreement_score":0.0069323657,"about_ca_system_score_codex":0.00047560784,"about_ca_system_score_gemma":0.00044132254,"threshold_uncertainty_score":0.023191094},"labels":[],"label_agreement":null},{"id":"W2068506100","doi":"10.1158/1535-7163.targ-11-a10","title":"Abstract A10: Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aflibercept; Angiogenesis; Tumor hypoxia; Colorectal cancer; Cancer research; Medicine; HIF1A; Pharmacology; Oxaliplatin; Bevacizumab; Combination therapy; Cancer; Blockade; Tumor progression; CD31; Internal medicine; Chemotherapy; Receptor; Radiation therapy","score_opus":0.015542342030486595,"score_gpt":0.24402229729944142,"score_spread":0.22847995526895482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068506100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914015,0.0015309978,0.0019104758,0.00019891557,0.00013010106,0.00010848322,0.0011153696,0.00023799043,0.0033661],"genre_scores_gemma":[0.990245,0.00063729123,0.0031021414,0.00010709263,0.00003061013,0.00009741099,0.0015836445,0.000036832484,0.004160017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980956,0.000030838717,0.000017321734,0.00003951418,0.00005378609,0.000049031398],"domain_scores_gemma":[0.99985373,0.000022315917,0.000035645608,0.00001261084,0.000009857665,0.000065748136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018427572,0.0006069194,0.00034594955,0.00023462209,0.00011578821,0.0002771325,0.00026597633,0.0003173478,0.0017755985],"category_scores_gemma":[0.00009614063,0.0001812141,0.00028568378,0.00017842486,0.00018707487,0.00018559647,0.00014882401,0.00088570826,0.00059549185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000676663,0.00040396993,0.00014677695,0.00006558352,0.000022907963,0.00006109105,0.000010185162,0.00013142929,0.9956748,0.00004325341,0.00039578526,0.0023675172],"study_design_scores_gemma":[0.00024050596,0.005781388,0.0038019205,0.000006631178,0.000037757687,0.0005797175,0.000014632101,0.001728908,0.98487586,0.000022803668,0.0029039069,0.0000060627285],"about_ca_topic_score_codex":0.0013319631,"about_ca_topic_score_gemma":0.0022449957,"teacher_disagreement_score":0.0017755985,"about_ca_system_score_codex":0.0004486279,"about_ca_system_score_gemma":0.00040800092,"threshold_uncertainty_score":0.0059399605},"labels":[],"label_agreement":null},{"id":"W2068863254","doi":"10.1158/1535-7163.targ-09-c182","title":"Abstract C182: Use of an oncolytic adenovirus (ONYX-015) <i>in vitro</i> to enhance chemotherapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncolytic virus; Oncolytic adenovirus; Cancer research; Cell culture; Cisplatin; Virus; Carboplatin; Cytotoxicity; In vitro; Genetic enhancement; Melphalan; Biology; Viability assay; Virology; Chemotherapy; Gene","score_opus":0.028011019677393806,"score_gpt":0.34984623422599664,"score_spread":0.32183521454860287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068863254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837647,0.0029365625,0.005716146,0.00015555644,0.00011885515,0.0002411098,0.0012070606,0.00012207273,0.005737843],"genre_scores_gemma":[0.98559004,0.0013149359,0.006992002,0.00007910514,0.000013827723,0.00009888247,0.0018649206,0.0000414966,0.0040047155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983716,0.00003355249,0.000015354242,0.000034791647,0.00003734187,0.000041734216],"domain_scores_gemma":[0.9999031,0.000021030863,0.00002047796,0.000013963637,0.000019849394,0.000021538137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017431233,0.00043098436,0.00020789835,0.00025562692,0.0001742834,0.00040311785,0.00023755692,0.00030210003,0.0019213384],"category_scores_gemma":[0.00013759623,0.00011025745,0.00022904109,0.0002000749,0.00013780725,0.00018762596,0.00013156502,0.0003659373,0.0004172772],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002465395,0.00010169386,0.00020103574,0.000057420883,0.0000061021788,0.000041013653,0.000014399193,0.00021275645,0.995843,0.00018106015,0.0002280568,0.0028669115],"study_design_scores_gemma":[0.000015743088,0.0003891689,0.0005808942,0.0000041957014,0.000008313329,0.00008126636,0.000007217451,0.0005959326,0.9956813,0.000010071782,0.0026240495,0.0000018886923],"about_ca_topic_score_codex":0.004861794,"about_ca_topic_score_gemma":0.0020535686,"teacher_disagreement_score":0.004861794,"about_ca_system_score_codex":0.0007093354,"about_ca_system_score_gemma":0.00031236972,"threshold_uncertainty_score":0.009666979},"labels":[],"label_agreement":null},{"id":"W2070026312","doi":"10.1158/1535-7163.targ-13-b181","title":"Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Missense mutation; Exon; Nonsense mutation; Mutation; Medicine; Cancer; Population; Genetics; Olaparib; Gene mutation; Cancer research; Molecular biology; Oncology; Biology; Internal medicine; Gene","score_opus":0.020973451297443265,"score_gpt":0.2818688197757348,"score_spread":0.26089536847829153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070026312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998487,0.00065442914,0.000055336805,0.00007401529,0.000008661682,0.000032479435,0.00024284724,0.000012443035,0.00043283985],"genre_scores_gemma":[0.99912244,0.00017712677,0.00015683002,0.000055084918,0.0000178592,0.000018220999,0.0002819502,0.0000033488416,0.00016710669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999713,0.000051582367,0.000040722203,0.00006682572,0.00007908002,0.00004866309],"domain_scores_gemma":[0.9994748,0.00011650969,0.00019338659,0.000018189325,0.00004757586,0.0001495445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004467764,0.00037236727,0.0004990489,0.00074013806,0.00034646757,0.00032188641,0.0003300347,0.00040615976,0.001521423],"category_scores_gemma":[0.00171351,0.000203064,0.00021584175,0.00050134247,0.00018063617,0.00023687791,0.00022144488,0.00034244245,0.00054167357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019205889,0.00014681714,0.9788062,0.000070778435,0.00002750993,0.002957179,0.00009982788,0.000088965986,0.0030888112,0.000011812775,0.0006157265,0.012165683],"study_design_scores_gemma":[0.00018944581,0.0031344162,0.97795814,0.000022955244,0.00008384005,0.014759968,0.00013311052,0.00063278974,0.0019359515,0.000033401942,0.0011053054,0.000010705113],"about_ca_topic_score_codex":0.0014977454,"about_ca_topic_score_gemma":0.0016692064,"teacher_disagreement_score":0.001521423,"about_ca_system_score_codex":0.0004645884,"about_ca_system_score_gemma":0.00030456015,"threshold_uncertainty_score":0.0050896406},"labels":[],"label_agreement":null},{"id":"W2072454789","doi":"10.1158/1535-7163.mct-08-0192","title":"Anticancer drugs affect the alternative splicing of <i>Bcl-x</i> and other human apoptotic genes","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Alternative splicing; RNA splicing; Biology; HeLa; Cell culture; Gene; Cancer cell; Apoptosis; Cell biology; Cancer research; Cancer; Gene isoform; Genetics","score_opus":0.022857436595253623,"score_gpt":0.2884122166424213,"score_spread":0.26555478004716765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072454789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905212,0.005690897,0.0011810208,0.00011746506,0.000039794213,0.000027809205,0.00021696168,0.00003961995,0.002165336],"genre_scores_gemma":[0.99195427,0.004878894,0.0018067618,0.0000900885,0.000015474787,0.000018653487,0.0003325142,0.000015898699,0.0008874532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997558,0.00006224263,0.000033045246,0.00004149192,0.000069495574,0.000037994098],"domain_scores_gemma":[0.9997892,0.00008994647,0.000059954484,0.000021535192,0.000016750811,0.000022589682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021059412,0.00025023948,0.00033639834,0.00022652333,0.00016685201,0.00030828133,0.00013434223,0.00020503212,0.0014399772],"category_scores_gemma":[0.0002013623,0.000100041296,0.00031356176,0.00021281125,0.00021422106,0.00017658174,0.00011405069,0.00041327198,0.0002387433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019443574,0.00012583754,0.0012222499,0.00007571143,0.000031120042,0.00008502357,0.000017963708,0.00016622439,0.98934877,0.00017445935,0.00007509596,0.008483085],"study_design_scores_gemma":[0.000021851469,0.0011248522,0.0053155497,0.0000062836634,0.00003385048,0.00033733403,0.00001983073,0.00021752574,0.9905019,0.000038678707,0.0023787494,0.0000036691142],"about_ca_topic_score_codex":0.00024677458,"about_ca_topic_score_gemma":0.0005115492,"teacher_disagreement_score":0.0014399772,"about_ca_system_score_codex":0.0001879771,"about_ca_system_score_gemma":0.00011093991,"threshold_uncertainty_score":0.0048172474},"labels":[],"label_agreement":null},{"id":"W2072767047","doi":"10.1158/1535-7163.targ-11-b49","title":"Abstract B49: GRN1005 phase I studies: Final results.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Tolerability; Pharmacokinetics; Immunogenicity; Medicine; Glioma; Brain tumor; Pharmacology; Transcytosis; Paclitaxel; Cancer; Internal medicine; Cancer research; Oncology; Receptor; Antibody; Immunology; Adverse effect; Pathology; Endocytosis","score_opus":0.09631823802331448,"score_gpt":0.35380369026139524,"score_spread":0.2574854522380808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072767047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9155819,0.014769598,0.009495291,0.003033277,0.0008509141,0.016813848,0.017399386,0.0012133265,0.020842513],"genre_scores_gemma":[0.92165065,0.0071239737,0.01036539,0.004017226,0.00037231884,0.007705622,0.024358988,0.0002542216,0.02415154],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995072,0.00020978345,0.000029147623,0.00006208104,0.00008745009,0.00010430842],"domain_scores_gemma":[0.9992269,0.00012263349,0.00014357653,0.000091344904,0.00009320881,0.00032245865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023564962,0.0015063859,0.0012387524,0.00042003812,0.00031207953,0.00089639844,0.0011935425,0.0015027463,0.007943072],"category_scores_gemma":[0.0009419063,0.00039271303,0.0011154971,0.00034988092,0.0004952904,0.0004958785,0.0003338219,0.0029709646,0.0029080608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32811,0.063133515,0.0057117506,0.0032871617,0.002867619,0.0009523835,0.00032669038,0.005472107,0.27102023,0.0008960165,0.05538783,0.26283467],"study_design_scores_gemma":[0.28901234,0.5835008,0.02369295,0.0002598113,0.0015056821,0.0015413325,0.0000719008,0.0023668385,0.05600707,0.00078707945,0.041188944,0.00006522613],"about_ca_topic_score_codex":0.0013464995,"about_ca_topic_score_gemma":0.001980463,"teacher_disagreement_score":0.007943072,"about_ca_system_score_codex":0.0008748002,"about_ca_system_score_gemma":0.0017568733,"threshold_uncertainty_score":0.026572168},"labels":[],"label_agreement":null},{"id":"W2072861311","doi":"10.1158/1535-7163.targ-09-a122","title":"Abstract A122: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"RAD51; Clonogenic assay; Molecular biology; Cell cycle; Flow cytometry; DNA repair; Biology; Cancer research; Cell; DNA; Biochemistry","score_opus":0.008518994146340443,"score_gpt":0.23325091246906274,"score_spread":0.2247319183227223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072861311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98760813,0.0035455034,0.0020615833,0.00028403004,0.00009358057,0.000086122534,0.001312308,0.00049754925,0.0045112725],"genre_scores_gemma":[0.990747,0.0015668949,0.0014195637,0.00010625269,0.000039055165,0.00007170949,0.0016514627,0.000043005122,0.0043550953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990475,0.000014570831,0.0000102075,0.00001516166,0.000028361768,0.000026914606],"domain_scores_gemma":[0.9999149,0.000015650354,0.0000213055,0.000009874395,0.000010048297,0.000028243912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010234776,0.00042011283,0.00034548517,0.00031342218,0.00013098208,0.00029730552,0.00022541442,0.00034593075,0.00503727],"category_scores_gemma":[0.00011203586,0.00012887703,0.00024041653,0.0002322515,0.00015735702,0.00013450439,0.0001245095,0.0008120083,0.0011091897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043017179,0.00020915172,0.00015513427,0.00007213106,0.000014831382,0.00005542392,0.000008364058,0.00016671435,0.9922328,0.00008501694,0.0006977338,0.0058724964],"study_design_scores_gemma":[0.00010867546,0.0026626415,0.0025580514,0.000008773306,0.000030306512,0.00021810827,0.0000118704875,0.0009703876,0.9905145,0.000022838889,0.0028890988,0.0000047726994],"about_ca_topic_score_codex":0.00057294016,"about_ca_topic_score_gemma":0.00065618864,"teacher_disagreement_score":0.00503727,"about_ca_system_score_codex":0.00018340189,"about_ca_system_score_gemma":0.00024039269,"threshold_uncertainty_score":0.016851366},"labels":[],"label_agreement":null},{"id":"W2073326558","doi":"10.1158/1535-7163.targ-11-b224","title":"Abstract B224: Structure-based drug design of signal transducers and activator of transcription 5 inhibitors.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Toronto","funders":"","keywords":"STAT5; STAT protein; Biology; SH2 domain; STAT3; Cancer research; Transcription factor; Chemistry; Cell biology; Signal transduction; Tyrosine kinase; Biochemistry; Gene","score_opus":0.048708493380333104,"score_gpt":0.2768567224036029,"score_spread":0.22814822902326976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073326558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7396082,0.08716309,0.0603614,0.002790548,0.0017932595,0.003670055,0.011724911,0.0020667156,0.09082178],"genre_scores_gemma":[0.9014766,0.029178439,0.028280322,0.0010598286,0.00008676246,0.0008969768,0.006740771,0.00009116905,0.032188985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999176,0.00001491925,0.0000055391865,0.00001552631,0.000024497114,0.00002193222],"domain_scores_gemma":[0.9999726,0.000002823446,0.000006477519,0.0000019342292,0.0000055006612,0.000010789921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015828945,0.00062240876,0.0003924821,0.00051985186,0.0001890154,0.0002802342,0.0004989309,0.0003840253,0.005353489],"category_scores_gemma":[0.00010425976,0.00020225416,0.00037601654,0.00032875818,0.00013331522,0.00022500663,0.00025034163,0.00058269757,0.0018505624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015284762,0.0009019412,0.00035662006,0.0013977254,0.0001236287,0.000543054,0.000056934783,0.008721837,0.88130295,0.00627429,0.008881214,0.089911334],"study_design_scores_gemma":[0.003012005,0.014624371,0.0026508502,0.00022470253,0.0002725136,0.001200347,0.000056500845,0.015394501,0.8069975,0.001533055,0.15392777,0.00010591636],"about_ca_topic_score_codex":0.00087094103,"about_ca_topic_score_gemma":0.0016822097,"teacher_disagreement_score":0.005353489,"about_ca_system_score_codex":0.00040840736,"about_ca_system_score_gemma":0.0003797712,"threshold_uncertainty_score":0.01790917},"labels":[],"label_agreement":null},{"id":"W2075821315","doi":"10.1158/1535-7163.targ-13-c284","title":"Abstract C284: IRE1 and PERK as targets of cellular adaptation and survival to hypoxia.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Unfolded protein response; ATF6; Hypoxia (environmental); Integrated stress response; XBP1; Gene knockdown; Endoplasmic reticulum; Cancer research; Biology; Cell biology; Signal transduction; Chemistry; Apoptosis; Translation (biology); Biochemistry; Gene; RNA splicing; Messenger RNA","score_opus":0.0179218119996761,"score_gpt":0.2571078537452758,"score_spread":0.23918604174559968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075821315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96962947,0.0136160245,0.006475981,0.0010089051,0.00024699737,0.00016266009,0.0019796307,0.00036153375,0.006518878],"genre_scores_gemma":[0.9786357,0.0038783345,0.006303515,0.00030951074,0.00004549845,0.00017528531,0.0023743748,0.00004516893,0.008232525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999051,0.0000103325565,0.000009845939,0.000024947822,0.000030227025,0.000019436335],"domain_scores_gemma":[0.9999391,0.000007809646,0.000024045656,0.0000052733017,0.0000096822005,0.000014059817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016667535,0.0003421618,0.00030129953,0.00021547801,0.00015389998,0.00025908067,0.0002717035,0.00027905047,0.0018950097],"category_scores_gemma":[0.00009068947,0.00013296698,0.00022357512,0.00014519303,0.00022144488,0.000232802,0.00015749918,0.0005756453,0.00045936895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003073574,0.000035562887,0.00013665188,0.000106105166,0.00000797845,0.00004053384,0.0000057805983,0.00021756464,0.9953734,0.00017426696,0.0002366453,0.003358187],"study_design_scores_gemma":[0.00004690603,0.00031295285,0.0018682225,0.00000622815,0.000015638585,0.00014717743,0.0000059498043,0.00073900766,0.99368954,0.000057909612,0.0031055028,0.0000048732263],"about_ca_topic_score_codex":0.00042146156,"about_ca_topic_score_gemma":0.00058217265,"teacher_disagreement_score":0.0018950097,"about_ca_system_score_codex":0.0004711681,"about_ca_system_score_gemma":0.0002659038,"threshold_uncertainty_score":0.006339431},"labels":[],"label_agreement":null},{"id":"W2077011774","doi":"10.1158/1535-7163.targ-11-a186","title":"Abstract A186: KIF14 is a novel therapeutic target for ovarian cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Serous fluid; Carcinogenesis; Ovarian cancer; Cancer; Retinoblastoma; Oncogene; Tumor progression; Oncology; Biology; Cancer research; Internal medicine; Medicine; Cell cycle; Gene; Genetics","score_opus":0.05762617491862869,"score_gpt":0.2977113244404225,"score_spread":0.24008514952179377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077011774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7848169,0.1612829,0.0075040236,0.007487588,0.0021035029,0.00080062414,0.0054888907,0.0008716109,0.029643932],"genre_scores_gemma":[0.9226996,0.036293235,0.00490444,0.001626648,0.0005247458,0.00034825067,0.0053659193,0.00007254087,0.028164653],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990463,0.000011702968,0.0000098947685,0.000013953196,0.000036295663,0.000023628789],"domain_scores_gemma":[0.9998832,0.000018909222,0.000033032502,0.000006782003,0.00003151797,0.000026628566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025146117,0.00036160505,0.0003734649,0.00042240316,0.00023493434,0.00045540967,0.00028178116,0.0005328699,0.008973548],"category_scores_gemma":[0.0002620871,0.00011996705,0.00035757126,0.0003336695,0.00014912785,0.0002709962,0.0002203566,0.00061879004,0.0019685426],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047314176,0.001003664,0.025671043,0.002641958,0.00029268317,0.0011355217,0.000102210215,0.0009938288,0.4303714,0.0018515073,0.028357409,0.5028472],"study_design_scores_gemma":[0.0022867268,0.010261021,0.17429496,0.0006475658,0.0007571808,0.01057253,0.00029147355,0.006060561,0.39060095,0.0027251984,0.4014221,0.00007968937],"about_ca_topic_score_codex":0.0005604794,"about_ca_topic_score_gemma":0.0012003434,"teacher_disagreement_score":0.008973548,"about_ca_system_score_codex":0.00050175865,"about_ca_system_score_gemma":0.00057190325,"threshold_uncertainty_score":0.030019462},"labels":[],"label_agreement":null},{"id":"W2078578614","doi":"10.1158/1535-7163.targ-09-b168","title":"Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Cancer; Internal medicine; Adverse effect; Mucositis; Oncology; Brain metastasis; Metastatic breast cancer; Taxane; Breast cancer; Metastasis; Chemotherapy","score_opus":0.02621273335514649,"score_gpt":0.38129536866898156,"score_spread":0.35508263531383505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078578614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925211,0.0025945539,0.0006433606,0.00045114866,0.00010164939,0.0009771497,0.0012102525,0.00009054552,0.0014102476],"genre_scores_gemma":[0.98830545,0.00254082,0.0015884375,0.0009145609,0.00015870557,0.00085507653,0.0031419871,0.000034727334,0.0024603796],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99969685,0.0001284444,0.000017423856,0.000053442687,0.000047055542,0.000056801568],"domain_scores_gemma":[0.99939525,0.00009179242,0.00008779266,0.000041059044,0.000055310444,0.0003288235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012830006,0.0010083839,0.0015308479,0.00030985303,0.000315854,0.0005658727,0.0005093813,0.0007492826,0.0022081241],"category_scores_gemma":[0.0006958462,0.00035269908,0.0010141766,0.00029846767,0.0004947336,0.0004896956,0.00023471742,0.0025492713,0.00076900783],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43569726,0.1468838,0.029901829,0.001262705,0.0029900826,0.0012714008,0.0004921313,0.004447982,0.12914857,0.00031722971,0.013841028,0.23374604],"study_design_scores_gemma":[0.20184468,0.72721374,0.054253794,0.000060733968,0.00088049774,0.0009493934,0.000102461854,0.0024301978,0.0068658656,0.00023934634,0.005112046,0.00004726783],"about_ca_topic_score_codex":0.0014023387,"about_ca_topic_score_gemma":0.00275824,"teacher_disagreement_score":0.0022081241,"about_ca_system_score_codex":0.0006746224,"about_ca_system_score_gemma":0.001045349,"threshold_uncertainty_score":0.007386863},"labels":[],"label_agreement":null},{"id":"W2079176280","doi":"10.1158/1535-7163.targ-11-a2","title":"Abstract A2: Development of a phenotypic profiling platform with high predictive value for the identification of novel antiangiogenic drugs.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Angiogenesis; High-content screening; Phenotypic screening; Drug discovery; In vivo; Drug development; Receptor tyrosine kinase; Pharmacology; Drug; Cancer research; Small molecule; Medicine; Computational biology; Chemistry; Biology; Receptor; Phenotype; Bioinformatics; Biochemistry; Cell; Genetics","score_opus":0.03656891870939759,"score_gpt":0.27520221290191177,"score_spread":0.23863329419251417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079176280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8014063,0.0025277305,0.16875915,0.0008234284,0.00022633011,0.000983452,0.013296509,0.0048747403,0.0071023107],"genre_scores_gemma":[0.87804615,0.0011458363,0.10374853,0.00031357745,0.000076637574,0.0007087587,0.009976316,0.00014641296,0.00583783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99958867,0.00006581583,0.00002125024,0.000098502365,0.00018095928,0.00004481026],"domain_scores_gemma":[0.9995765,0.00008291672,0.00008881695,0.000038227867,0.00013497466,0.00007859738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063873467,0.0007684994,0.0006239637,0.0009954248,0.0002509242,0.00085650524,0.00042961945,0.00056508364,0.0020746032],"category_scores_gemma":[0.0007822489,0.0003011634,0.0003592736,0.0006418316,0.00021010255,0.0004528726,0.00048051222,0.000665356,0.0010266257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027577995,0.00016530495,0.0017437486,0.000070089845,0.000023359838,0.000065801505,0.000009118387,0.0018925458,0.970448,0.00019781885,0.0009685095,0.024139864],"study_design_scores_gemma":[0.00008051316,0.0011572514,0.009810869,0.000009295734,0.000056845613,0.00027966706,0.000014733574,0.04131555,0.94286484,0.00018878246,0.0041852794,0.000036408124],"about_ca_topic_score_codex":0.0010594175,"about_ca_topic_score_gemma":0.0012993996,"teacher_disagreement_score":0.0020746032,"about_ca_system_score_codex":0.0004579284,"about_ca_system_score_gemma":0.0005814964,"threshold_uncertainty_score":0.0069402456},"labels":[],"label_agreement":null},{"id":"W2079525831","doi":"10.1158/1535-7163.targ-13-a260","title":"Abstract A260: BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gene knockdown; STAT3; Cancer research; Small hairpin RNA; In vivo; Apoptosis; Cell culture; Biology; Molecular biology; Biochemistry; Genetics","score_opus":0.09090890726976292,"score_gpt":0.3443109252553725,"score_spread":0.2534020179856096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079525831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863116,0.002864563,0.004110456,0.000266235,0.0000907101,0.00012209626,0.0014205492,0.00045865902,0.0043551605],"genre_scores_gemma":[0.98548764,0.0015830969,0.0033903285,0.000099311816,0.000018428938,0.00009289708,0.0019459252,0.000028499833,0.007353899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999391,0.000008198688,0.0000044159906,0.000011760363,0.000021889267,0.000014609331],"domain_scores_gemma":[0.9999615,0.0000043099913,0.000011378632,0.0000031381883,0.000005316823,0.000014357914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011005683,0.00045325723,0.0001923232,0.00024191546,0.000105208324,0.00016404071,0.00023639014,0.0002721606,0.002881318],"category_scores_gemma":[0.00004576181,0.000111903784,0.00019828134,0.00016428286,0.00014808297,0.00012812285,0.00008704286,0.0006877607,0.0006770119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034301265,0.00018075583,0.000090692934,0.00006145363,0.000008230879,0.000031956428,0.0000051940524,0.00017623957,0.99583167,0.000091640606,0.00022892887,0.002950381],"study_design_scores_gemma":[0.00011693815,0.0020328462,0.0014378144,0.000004455845,0.00002075775,0.00016957655,0.000004931856,0.0008337995,0.99269885,0.000031472064,0.0026446213,0.0000040770065],"about_ca_topic_score_codex":0.0006953643,"about_ca_topic_score_gemma":0.0008205015,"teacher_disagreement_score":0.002881318,"about_ca_system_score_codex":0.00022511865,"about_ca_system_score_gemma":0.00024944934,"threshold_uncertainty_score":0.009638965},"labels":[],"label_agreement":null},{"id":"W2080020172","doi":"10.1158/1535-7163.targ-09-b236","title":"Abstract B236: A small molecule disrupts the BCL6 transcriptional repressor complex and kills lymphoma cells <i>in vitro</i> and <i>in vivo</i>","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"BCL6; Corepressor; Repressor; Chemistry; Small molecule; Cancer research; Psychological repression; Lymphoma; Biology; Cell biology; Germinal center; Stereochemistry; Biochemistry; Transcription factor; Genetics; B cell; Gene; Immunology; Antibody; Gene expression","score_opus":0.022255415707319235,"score_gpt":0.25882615254623875,"score_spread":0.23657073683891952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080020172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619765,0.0054347734,0.0019267551,0.00020749375,0.00008807163,0.00014913805,0.0015890494,0.00035983857,0.0040472345],"genre_scores_gemma":[0.9885521,0.0025922363,0.0022869369,0.0001174762,0.000015676704,0.00007394759,0.002122956,0.000047585283,0.004191197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999355,0.000009102045,0.000003945835,0.0000109053835,0.000021900318,0.00001865009],"domain_scores_gemma":[0.99995697,0.000006207295,0.00000652346,0.000003208653,0.000004904622,0.000022203098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075740914,0.0004928441,0.00038937628,0.00027936805,0.00020957095,0.00029406676,0.00034109128,0.00025769934,0.0044909506],"category_scores_gemma":[0.000090209134,0.00011809092,0.00027654917,0.00025217302,0.00017325497,0.0000976272,0.00014047234,0.0005519247,0.00076237053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077690714,0.00030996252,0.00022788951,0.00014831274,0.000048315276,0.00015127531,0.000011249156,0.0011382313,0.9900558,0.00014337231,0.0005895146,0.0063992394],"study_design_scores_gemma":[0.00051586493,0.0046923696,0.0022434194,0.000013962365,0.00006947595,0.0004183919,0.00002028705,0.002519164,0.9826382,0.000073270254,0.006773287,0.000022337535],"about_ca_topic_score_codex":0.0017839684,"about_ca_topic_score_gemma":0.0026837029,"teacher_disagreement_score":0.0044909506,"about_ca_system_score_codex":0.0002937756,"about_ca_system_score_gemma":0.00023589886,"threshold_uncertainty_score":0.015023708},"labels":[],"label_agreement":null},{"id":"W2080417833","doi":"10.1158/1535-7163.targ-11-c210","title":"Abstract C210: Microregional distribution and activity of camptothecins in tumor xenografts.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Spinal Cord Injury BC","funders":"","keywords":"Topotecan; Irinotecan; Camptothecin; Distribution (mathematics); Pharmacology; Topoisomerase; Medicine; Cancer research; Cancer; Chemistry; Pathology; Chemotherapy; Internal medicine; Enzyme; Biochemistry; Colorectal cancer","score_opus":0.04322675754856139,"score_gpt":0.32258226187078576,"score_spread":0.2793555043222244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080417833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894916,0.0016035526,0.0034992187,0.00009387992,0.00003242677,0.000049322287,0.0014137132,0.00014476663,0.0036715239],"genre_scores_gemma":[0.98343974,0.00081096176,0.0048868456,0.00003721753,0.00001330928,0.00007616867,0.0018330183,0.000049665723,0.008852957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999274,0.000004326424,0.0000033432937,0.000023829398,0.000022039976,0.000018993234],"domain_scores_gemma":[0.99991584,0.000022121803,0.000022232776,0.000007950714,0.000013003201,0.000018756778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091778515,0.00022944568,0.0001288317,0.00024856994,0.0001275413,0.00016593766,0.00013267442,0.00022577448,0.00244941],"category_scores_gemma":[0.00007147345,0.000120722034,0.00013354614,0.00017977755,0.00016884423,0.00015980295,0.00010296741,0.00049612153,0.00044766563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004799291,0.000009452393,0.00009464601,0.00001016654,9.3266317e-7,0.000021517597,0.0000073255405,0.000027708462,0.9992925,0.000017580098,0.000031741743,0.00043840235],"study_design_scores_gemma":[0.0000066596253,0.00037706256,0.0124374535,0.000003929475,0.0000067439514,0.00023534808,0.000029813313,0.00071049586,0.9848567,0.000015312442,0.00131705,0.0000034691122],"about_ca_topic_score_codex":0.0033438508,"about_ca_topic_score_gemma":0.002812237,"teacher_disagreement_score":0.0033438508,"about_ca_system_score_codex":0.00042797523,"about_ca_system_score_gemma":0.00020309945,"threshold_uncertainty_score":0.008194149},"labels":[],"label_agreement":null},{"id":"W2080430705","doi":"10.1158/1535-7163.targ-11-b24","title":"Abstract B24: Detection of O6- and N7-methylguanine adducts by LC/MS in brain tumor tissues obtained from patients treated with temozolomide.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemical Reactions and Isotopes","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Université de Montréal; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Temozolomide; O-6-methylguanine-DNA methyltransferase; Cancer; Medicine; Guanine; Cancer research; Regimen; Adduct; Radiation therapy; Methylation; DNA; Glioblastoma; Oncology; Chemistry; Internal medicine; Methyltransferase; Biochemistry; Gene","score_opus":0.051507694884336624,"score_gpt":0.35029806211871256,"score_spread":0.2987903672343759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080430705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96970797,0.0063363644,0.0082126325,0.00040839228,0.0002632914,0.00019801743,0.010034634,0.000694757,0.004143904],"genre_scores_gemma":[0.95844084,0.0030347377,0.016364876,0.0005453252,0.00011405539,0.00020879199,0.013952414,0.00016497081,0.007174064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998399,0.000018151271,0.000013016493,0.000048876205,0.00005222615,0.000027896267],"domain_scores_gemma":[0.999841,0.000037479942,0.000031248514,0.00000995458,0.000041190997,0.000039097125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001960452,0.0006297607,0.00030438282,0.001511327,0.0003635187,0.00024599678,0.00028206123,0.0005747158,0.0029649483],"category_scores_gemma":[0.0003461262,0.00014275547,0.00018548591,0.00051148725,0.00020744077,0.00012748939,0.00017022052,0.00036493922,0.0015096011],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060697016,0.000060915223,0.0039354097,0.00007165046,0.00003539193,0.0003724493,0.000042185446,0.00003747885,0.9871106,0.000015096943,0.00047748588,0.007234348],"study_design_scores_gemma":[0.00005582769,0.0013383914,0.100614175,0.000019420244,0.00010790891,0.0035490165,0.000072901414,0.0007895809,0.8880073,0.00009146816,0.0053287596,0.000025357002],"about_ca_topic_score_codex":0.002135582,"about_ca_topic_score_gemma":0.0025722294,"teacher_disagreement_score":0.0029649483,"about_ca_system_score_codex":0.00019369827,"about_ca_system_score_gemma":0.00023604621,"threshold_uncertainty_score":0.009918749},"labels":[],"label_agreement":null},{"id":"W2082176717","doi":"10.1158/1535-7163.pms-pr01","title":"Abstract PR01: Functional characterization of breast cancer using pooled lentivirus shRNA screens","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Small hairpin RNA; Synthetic lethality; Breast cancer; Cancer; Oncogene; Biology; Cancer research; Gene; Genetics; Computational biology; Cell cycle; Gene knockdown; DNA repair","score_opus":0.02258048701726297,"score_gpt":0.2837138328554489,"score_spread":0.2611333458381859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082176717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488213,0.0012348689,0.034083158,0.00018131334,0.000052553518,0.0006211407,0.009989707,0.0008363704,0.0041794623],"genre_scores_gemma":[0.94187826,0.0012482554,0.030609898,0.00023207317,0.000018215309,0.0005316663,0.018686766,0.00030706814,0.0064878403],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99956995,0.000044074048,0.000067633366,0.00006582903,0.00019681617,0.00005562982],"domain_scores_gemma":[0.99975795,0.000057091194,0.000045905967,0.000037615406,0.00006467349,0.000036740963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004583651,0.0005099961,0.00048341893,0.000572725,0.00024233425,0.00043029676,0.0003985186,0.00025886143,0.0015347229],"category_scores_gemma":[0.0003592274,0.00018415855,0.00037801702,0.0003404675,0.00020488886,0.00016176993,0.00028305905,0.0005590053,0.00073010556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003448395,0.000038821185,0.00041888334,0.000033520126,0.000014395834,0.000044648194,0.000011435874,0.00025350903,0.9964818,0.00007087777,0.000164701,0.002432986],"study_design_scores_gemma":[0.000019183906,0.00041215902,0.0066441367,0.000007108512,0.00006241978,0.0003411531,0.00002527653,0.0041765445,0.98326164,0.000050027676,0.004990869,0.000009406145],"about_ca_topic_score_codex":0.0020968146,"about_ca_topic_score_gemma":0.0032913713,"teacher_disagreement_score":0.0020968146,"about_ca_system_score_codex":0.0005198432,"about_ca_system_score_gemma":0.0003741707,"threshold_uncertainty_score":0.0051341653},"labels":[],"label_agreement":null},{"id":"W2083169847","doi":"10.1158/1535-7163.targ-09-b98","title":"Abstract B98: Induction of metabolic and oxidative stresses by the novel inhibitor of NAD+ biosynthesis, GMX 1778, for specific killing of human glioblastomas","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"NAD+ kinase; Nicotinamide adenine dinucleotide; Biosynthesis; Cancer; Biochemistry; Nicotinamide; In vivo; Enzyme; Nicotinamide phosphoribosyltransferase; Cancer cell; Oxidative phosphorylation; In vitro; Biology; Cancer research; Chemistry; Genetics","score_opus":0.02997847592673606,"score_gpt":0.3086536899765374,"score_spread":0.27867521404980133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083169847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725176,0.00532703,0.004897065,0.0007551673,0.0002223123,0.00038107,0.0019634163,0.00042611887,0.013510137],"genre_scores_gemma":[0.975895,0.0028915869,0.0070192227,0.00014487444,0.000035159494,0.00016216845,0.0022456758,0.000044938854,0.011561413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999633,0.0000051263646,0.000002515775,0.000004466044,0.000015081455,0.000009448982],"domain_scores_gemma":[0.99998534,0.0000017928566,0.0000024697124,0.000001887295,0.000002810115,0.0000056577587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000693393,0.00037793018,0.00017975167,0.0002630968,0.00018786869,0.000144238,0.00024982847,0.00023696397,0.0027905023],"category_scores_gemma":[0.000050029423,0.00010102604,0.00013306833,0.0001495746,0.00011589138,0.00010444673,0.00012675636,0.00032705194,0.00068376824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006333924,0.00017016268,0.0001171414,0.00008085266,0.00000781929,0.00012113797,0.000010973349,0.00025801445,0.9860874,0.00056884426,0.0013216193,0.010622633],"study_design_scores_gemma":[0.00010476322,0.00080225343,0.0009878901,0.000006582267,0.000012635524,0.0002724762,0.0000054012226,0.0006271081,0.9882442,0.000070817485,0.008862382,0.0000035797098],"about_ca_topic_score_codex":0.0010496426,"about_ca_topic_score_gemma":0.0013599324,"teacher_disagreement_score":0.0027905023,"about_ca_system_score_codex":0.00027164523,"about_ca_system_score_gemma":0.00034322392,"threshold_uncertainty_score":0.00933516},"labels":[],"label_agreement":null},{"id":"W2086921761","doi":"10.1158/1535-7163.targ-11-a229","title":"Abstract A229: BRAF inhibitors upregulate EGFR ligands: A molecular link to RAF inhibitor-induced cutaneous squamous cell carcinomas.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Workplace Health, Safety and Compensation Commission","funders":"","keywords":"Vemurafenib; Cancer research; HRAS; Melanoma; Cancer; Downregulation and upregulation; Neuroblastoma RAS viral oncogene homolog; EGFR inhibitors; MAPK/ERK pathway; Skin cancer; Kinase; Cell growth; Medicine; Biology; KRAS; Epidermal growth factor receptor; Internal medicine; Colorectal cancer; Cell biology","score_opus":0.022563827664879663,"score_gpt":0.2431232919268744,"score_spread":0.22055946426199474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086921761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89732903,0.011444605,0.0088210255,0.002682778,0.0026497305,0.0004203322,0.0041710036,0.0015021799,0.07097931],"genre_scores_gemma":[0.91646737,0.0025480972,0.0023020061,0.00045130317,0.0003160366,0.000092030336,0.0014413928,0.00010834282,0.07627346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999008,0.000014882449,0.000009479964,0.00002347558,0.000034451037,0.000016835631],"domain_scores_gemma":[0.9999013,0.000018908087,0.000021013664,0.000011362561,0.000018068273,0.000029327284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016777588,0.00037512966,0.00024118059,0.00041014043,0.0001882072,0.00046655646,0.00044047838,0.00051911286,0.020211212],"category_scores_gemma":[0.00016041208,0.00017610202,0.00022724218,0.00016589415,0.00014350883,0.0003485082,0.00016814518,0.0005188217,0.0031183863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016015149,0.0003862121,0.001328247,0.00036151477,0.00003266439,0.0017111546,0.00003237602,0.00019528445,0.94801563,0.0017319361,0.007983708,0.036619887],"study_design_scores_gemma":[0.0002363973,0.0029279916,0.021451913,0.000026207988,0.00006105953,0.0053509236,0.000055065353,0.0013576418,0.92059845,0.00078356516,0.04713218,0.000018639716],"about_ca_topic_score_codex":0.00075079245,"about_ca_topic_score_gemma":0.0007251066,"teacher_disagreement_score":0.020211212,"about_ca_system_score_codex":0.00034944495,"about_ca_system_score_gemma":0.0002657748,"threshold_uncertainty_score":0.067613244},"labels":[],"label_agreement":null},{"id":"W2086966942","doi":"10.1158/1535-7163.mct-05-0339","title":"Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Prostate cancer; Angiostatin; Cancer research; Prostate; Adenoviridae; Genetic enhancement; Biology; Cancer; Medicine; Angiogenesis; Internal medicine; Gene","score_opus":0.03225362112432835,"score_gpt":0.3360878543704452,"score_spread":0.30383423324611686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086966942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958755,0.0034945905,0.004781363,0.00006026573,0.00009993062,0.00014812007,0.00013782654,0.00011972157,0.0015706084],"genre_scores_gemma":[0.9909095,0.001460212,0.005315813,0.00002188228,0.000027446895,0.000087793465,0.00023026591,0.000013472311,0.0019335537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997634,0.00004107679,0.000018144397,0.000057450456,0.00007612103,0.000043715758],"domain_scores_gemma":[0.9998882,0.00002250013,0.000024606765,0.000022470922,0.000007973061,0.000034350047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002724267,0.0006792649,0.0005165095,0.00047699534,0.00011540461,0.00029416545,0.0003115658,0.00019685946,0.00079117704],"category_scores_gemma":[0.00011136206,0.00022653284,0.00046468966,0.00030360723,0.00022175761,0.00023277759,0.00025297565,0.0005134453,0.0001742304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066930376,0.00051291834,0.00087836845,0.00012412126,0.000074488635,0.00012565781,0.000046925572,0.000628479,0.9813214,0.0003398464,0.00014627528,0.015132239],"study_design_scores_gemma":[0.00025402365,0.010514262,0.0053251404,0.0000138020905,0.0002493747,0.0010981448,0.000035172347,0.0036570963,0.9709806,0.00007332686,0.0077757216,0.000023377428],"about_ca_topic_score_codex":0.00079798634,"about_ca_topic_score_gemma":0.0016936774,"teacher_disagreement_score":0.00079798634,"about_ca_system_score_codex":0.00030142596,"about_ca_system_score_gemma":0.000405035,"threshold_uncertainty_score":0.0026466846},"labels":[],"label_agreement":null},{"id":"W2087964934","doi":"10.1158/1535-7163.pms-b13","title":"Abstract B13: ATR and PARP inhibition enhances topoisomerase I-dependent DNA damage in colon cancer cell lines","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cytotoxicity; RAD51; DNA damage; PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer cell; Topoisomerase; Cancer research; IC50; Chemistry; Cell culture; Synthetic lethality; Molecular biology; Cancer; DNA; Biology; Polymerase; Biochemistry; In vitro; Genetics","score_opus":0.022851423000106435,"score_gpt":0.3095930713613835,"score_spread":0.286741648361277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087964934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846821,0.0029276938,0.0020641156,0.00026190406,0.000107463275,0.00011612926,0.003765548,0.00028169926,0.0057933102],"genre_scores_gemma":[0.97363394,0.0023616315,0.002718318,0.00012179386,0.00002669907,0.00015029397,0.007372624,0.000038560935,0.013576182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997917,0.000029511364,0.000031311494,0.000037759324,0.00006818622,0.000041539024],"domain_scores_gemma":[0.99986196,0.000027481492,0.000027453698,0.000023499933,0.000025115854,0.00003448924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001405794,0.0004722481,0.00035193766,0.0003025958,0.00016586583,0.00023231884,0.00021065859,0.00028936798,0.0070341844],"category_scores_gemma":[0.00010565652,0.00017502131,0.00030997774,0.00039018554,0.0001355239,0.00015215848,0.00015290343,0.00079427194,0.0017988536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030792062,0.00017028653,0.0001890259,0.00012264038,0.000011654764,0.00007286701,0.000017982746,0.00009015157,0.9967173,0.000034776283,0.00034856607,0.0019167634],"study_design_scores_gemma":[0.000051631592,0.001509028,0.0041573057,0.0000121750945,0.000018422474,0.00023493203,0.000024473615,0.00037446455,0.9907498,0.000014966957,0.0028484254,0.000004421377],"about_ca_topic_score_codex":0.0015873022,"about_ca_topic_score_gemma":0.0017165551,"teacher_disagreement_score":0.0070341844,"about_ca_system_score_codex":0.0002440012,"about_ca_system_score_gemma":0.00029815425,"threshold_uncertainty_score":0.023531675},"labels":[],"label_agreement":null},{"id":"W2088569000","doi":"10.1158/1535-7163.targ-11-b155","title":"Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tolerability; Pharmacodynamics; Medicine; Pharmacokinetics; Dosing; Pharmacology; PI3K/AKT/mTOR pathway; Toxicity; Kinase; Adverse effect; Internal medicine; Oncology; Chemistry; Signal transduction","score_opus":0.012014701293701965,"score_gpt":0.25670900492023707,"score_spread":0.2446943036265351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088569000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880553,0.0024435027,0.00077860017,0.00042473272,0.00012193964,0.0025040072,0.0013001909,0.00018399855,0.0034375212],"genre_scores_gemma":[0.98518455,0.0025260688,0.002441928,0.0008404557,0.0001291983,0.0019094045,0.0030282298,0.000040955794,0.003899262],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997253,0.000105136016,0.000022550012,0.000059785532,0.000034401684,0.00005284852],"domain_scores_gemma":[0.9996076,0.00004164997,0.000061595885,0.000028548915,0.000021836506,0.00023876828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009830872,0.0015824769,0.001526034,0.0005149544,0.00038363083,0.00094003027,0.0009364942,0.001041254,0.0052643167],"category_scores_gemma":[0.00049330445,0.00059620745,0.001169805,0.0004340275,0.00068532216,0.00074469787,0.00031611306,0.0024807185,0.0016754509],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4980728,0.13890015,0.010572338,0.0025512464,0.0019914731,0.0011585315,0.0005987647,0.0045827082,0.15192549,0.000772621,0.009703125,0.17917077],"study_design_scores_gemma":[0.40489158,0.56666005,0.012153777,0.0000804445,0.0005538414,0.0007432124,0.000073972384,0.0011817442,0.008716921,0.0001538757,0.0047464324,0.000044147517],"about_ca_topic_score_codex":0.0013324947,"about_ca_topic_score_gemma":0.0028690663,"teacher_disagreement_score":0.0052643167,"about_ca_system_score_codex":0.0008306669,"about_ca_system_score_gemma":0.001528906,"threshold_uncertainty_score":0.017610908},"labels":[],"label_agreement":null},{"id":"W2088621502","doi":"10.1158/1535-7163.targ-09-b204","title":"Abstract B204: Development of ALN-VSP: An RNAi therapeutic for liver malignancies","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Cancer; Biology; Medicine; Cancer research; Virology; Genetics","score_opus":0.03685174826064542,"score_gpt":0.3027337702390711,"score_spread":0.2658820219784257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088621502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8816056,0.018561771,0.04533998,0.0031939778,0.001134667,0.001343107,0.0034923065,0.0016132692,0.043715358],"genre_scores_gemma":[0.91260207,0.008361669,0.0316125,0.0005034762,0.00016619025,0.0005415675,0.0043308567,0.00009916049,0.041782502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999149,0.00001692439,0.0000062696913,0.000015598946,0.0000340583,0.00001219481],"domain_scores_gemma":[0.9999641,0.0000038135997,0.0000074670006,0.0000023307286,0.000008073229,0.00001416227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017704554,0.00039376324,0.00021544822,0.00045187783,0.00017916271,0.00023755463,0.00030837837,0.00043216735,0.0042300043],"category_scores_gemma":[0.00008035706,0.00011566275,0.00019739137,0.00017033677,0.00017015204,0.0001874593,0.00014253157,0.0005808215,0.0010936898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005039166,0.00026900062,0.00014220712,0.00014386709,0.000013907068,0.00011539017,0.000013203792,0.00041728292,0.9668033,0.00082220597,0.003159468,0.02759628],"study_design_scores_gemma":[0.0002632496,0.0023613288,0.0020821898,0.000018430252,0.00003336562,0.0004944486,0.000007679217,0.0020397727,0.95994127,0.00015773773,0.032589577,0.000010991361],"about_ca_topic_score_codex":0.00088963826,"about_ca_topic_score_gemma":0.0011485849,"teacher_disagreement_score":0.0042300043,"about_ca_system_score_codex":0.0005295393,"about_ca_system_score_gemma":0.00051179866,"threshold_uncertainty_score":0.014150739},"labels":[],"label_agreement":null},{"id":"W2088704835","doi":"10.1158/1535-7163.targ-13-a204","title":"Abstract A204: Flow cytometric assay of proteasome inhibition in whole blood.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Proteasome; Whole blood; Proteasome inhibitor; Chemistry; Pharmacology; Molecular biology; Carfilzomib; Flow cytometry; Multiple myeloma; Biochemistry; Medicine; Biology; Immunology","score_opus":0.01841877815427692,"score_gpt":0.2624383344964026,"score_spread":0.24401955634212566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088704835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5109397,0.019041905,0.3853829,0.0023263576,0.002728194,0.0026214411,0.028381333,0.010997086,0.03758109],"genre_scores_gemma":[0.6256464,0.009785131,0.27291083,0.0016950732,0.001245485,0.0051055048,0.035038777,0.00045937844,0.0481134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874616,0.00020804579,0.00009836426,0.0003319892,0.00046888783,0.00014652935],"domain_scores_gemma":[0.9996278,0.0000785716,0.00009878977,0.000034890047,0.00011060912,0.00004934279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008589804,0.0013540483,0.00045136787,0.0017197103,0.000523755,0.0006964798,0.0008222277,0.0008968671,0.010721569],"category_scores_gemma":[0.00043276369,0.0002466967,0.00041741825,0.001175308,0.00039557612,0.0005346979,0.0003213149,0.0014169794,0.0037330023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067376805,0.00034095588,0.0012399293,0.00026430783,0.00001912249,0.00005894592,0.000055969518,0.00016272913,0.9789386,0.0005584508,0.002638335,0.015048766],"study_design_scores_gemma":[0.00008669598,0.0008036782,0.008907691,0.00006413029,0.000045798428,0.0005060311,0.000039832317,0.00441355,0.97275835,0.0006838484,0.011658568,0.000031736472],"about_ca_topic_score_codex":0.00033968856,"about_ca_topic_score_gemma":0.0004944802,"teacher_disagreement_score":0.010721569,"about_ca_system_score_codex":0.0005762788,"about_ca_system_score_gemma":0.00047735035,"threshold_uncertainty_score":0.035867214},"labels":[],"label_agreement":null},{"id":"W2089316300","doi":"10.1158/1535-7163.mct-07-0568","title":"Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; Howard Hughes Medical Institute","keywords":"Neuroblastoma; Cancer research; Erlotinib; Epidermal growth factor receptor; Tyrosine kinase; Vascular endothelial growth factor; Tumor progression; Vascular endothelial growth inhibitor; Receptor tyrosine kinase; Medicine; Biology; Receptor; Cancer; Vascular endothelial growth factor A; Internal medicine; Cell culture","score_opus":0.013555014707577764,"score_gpt":0.2639087834060725,"score_spread":0.25035376869849474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089316300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954709,0.0024542678,0.0008779742,0.000057331647,0.00003381522,0.00003997237,0.00012318381,0.000038023536,0.00090446294],"genre_scores_gemma":[0.9946308,0.0022380888,0.0014654722,0.000038705828,0.00001124371,0.00002991602,0.00031019712,0.000006978889,0.0012685399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993014,0.000015151666,0.000005518323,0.000009322563,0.000017135326,0.000022685685],"domain_scores_gemma":[0.9999727,0.0000049326845,0.0000061848136,0.0000028291604,0.0000037966095,0.000009522845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011145024,0.00035360846,0.0005028615,0.00023574641,0.0001303003,0.00018207506,0.00017800226,0.00018161039,0.0005592728],"category_scores_gemma":[0.00006896665,0.00011500244,0.00021837653,0.00016533355,0.00013443065,0.00014288566,0.00014265899,0.0004498321,0.00011824528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010494883,0.00037762613,0.0005142139,0.000099214274,0.000037013928,0.00015727895,0.000020538911,0.0005284867,0.9836797,0.00014609277,0.0001704205,0.013219799],"study_design_scores_gemma":[0.0006854425,0.0075427443,0.011577327,0.00001306372,0.00016159684,0.0008459074,0.0000415026,0.0022496225,0.97064644,0.00008661624,0.0061329626,0.000016723532],"about_ca_topic_score_codex":0.001052384,"about_ca_topic_score_gemma":0.003663491,"teacher_disagreement_score":0.001052384,"about_ca_system_score_codex":0.00025352158,"about_ca_system_score_gemma":0.0003577764,"threshold_uncertainty_score":0.0020924807},"labels":[],"label_agreement":null},{"id":"W2089842133","doi":"10.1158/1535-7163.targ-09-c49","title":"Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Medicine; Metastatic breast cancer; Panitumumab; Cetuximab; Triple-negative breast cancer; Cyclophosphamide; Breast cancer; Cancer; Bevacizumab; Docetaxel; Trastuzumab; Oncology; Combination therapy; Cancer research; Targeted therapy; Pharmacology; Monoclonal antibody; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Immunology; Antibody; Colorectal cancer","score_opus":0.03126555443784302,"score_gpt":0.3740643119938047,"score_spread":0.3427987575559617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089842133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955382,0.00078995107,0.00078134076,0.00013505308,0.00010661085,0.00018928095,0.00058041397,0.00008810973,0.0017910535],"genre_scores_gemma":[0.99293786,0.0006712183,0.0017219894,0.00006919339,0.000039622264,0.000191967,0.0009869884,0.000024072442,0.0033571657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982774,0.00002439618,0.000010943337,0.000028455433,0.000052761825,0.000055631484],"domain_scores_gemma":[0.99989676,0.000010978966,0.000019816662,0.000010480339,0.000013368404,0.00004858753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016506812,0.0004597258,0.0006375888,0.00035093172,0.00017643717,0.00025535582,0.0003313892,0.0003958968,0.0016082994],"category_scores_gemma":[0.00011352347,0.00012578662,0.00026590913,0.00017953002,0.00019289416,0.0001675698,0.00011382644,0.0007611042,0.00034871843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033450273,0.0028727762,0.00026830885,0.00006638564,0.00003596234,0.000096948614,0.000021960623,0.00046416261,0.98549575,0.00013284317,0.00065998215,0.006539877],"study_design_scores_gemma":[0.0009950541,0.038418654,0.0049357833,0.000012516992,0.00009182416,0.00041174283,0.000023398274,0.002666214,0.9475146,0.000047921716,0.004866667,0.000015679057],"about_ca_topic_score_codex":0.0017671603,"about_ca_topic_score_gemma":0.0035417008,"teacher_disagreement_score":0.0017671603,"about_ca_system_score_codex":0.000426023,"about_ca_system_score_gemma":0.00057264674,"threshold_uncertainty_score":0.0053803325},"labels":[],"label_agreement":null},{"id":"W2090002637","doi":"10.1158/1535-7163.targ-09-b99","title":"Abstract B99: Dysregulation of HMGCR and the mevalonate pathway in human cancers","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Allergan (Canada); University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Carcinogenesis; Biology; Mevalonate pathway; Cancer research; Ectopic expression; Cancer; Lovastatin; Statin; Cell biology; Genetics; Reductase; Gene; Enzyme; Endocrinology; Cholesterol; Biochemistry","score_opus":0.013108791716325365,"score_gpt":0.2746868128224779,"score_spread":0.2615780211061526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090002637","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8433936,0.13135487,0.0039871586,0.0023391866,0.0002717299,0.000062758576,0.015308513,0.00023094956,0.0030512032],"genre_scores_gemma":[0.98612994,0.0073603205,0.0011217648,0.0003933002,0.00011091543,0.0000339457,0.0038546752,0.000026758162,0.000968262],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99941385,0.00016609947,0.00006615543,0.00015750837,0.00013779536,0.00005859068],"domain_scores_gemma":[0.99931276,0.00014304202,0.00029110833,0.00007921605,0.000088906556,0.00008495659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083723315,0.00028312573,0.00059415336,0.0012282412,0.0002934755,0.00093676866,0.0002884095,0.0003792139,0.0021457472],"category_scores_gemma":[0.0010547829,0.00019106022,0.0007767973,0.002387426,0.00025428293,0.00025726753,0.00044810603,0.00054766407,0.00039812486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005642359,0.000100349345,0.8079564,0.0022465275,0.006937699,0.0004096646,0.00014746533,0.00075641164,0.10069314,0.0007707459,0.0050827283,0.069256626],"study_design_scores_gemma":[0.00005992344,0.0002374837,0.9764307,0.00019699062,0.0020134742,0.00085852697,0.0001457349,0.0009328452,0.010043698,0.00077903416,0.008283181,0.000018379596],"about_ca_topic_score_codex":0.0029756408,"about_ca_topic_score_gemma":0.002091133,"teacher_disagreement_score":0.0029756408,"about_ca_system_score_codex":0.00033074184,"about_ca_system_score_gemma":0.0004751776,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2091036980","doi":"10.1158/1535-7163.targ-11-b72","title":"Abstract B72: Assessing specific biological mechanisms of drug resistance in adult and pediatric AML.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clofarabine; Gemtuzumab ozogamicin; Azacitidine; Daunorubicin; Decitabine; DNA damage; Cancer research; Flow cytometry; Apoptosis; Cytarabine; Pharmacology; Myeloid leukemia; Medicine; Biology; Leukemia; Immunology; Stem cell; CD34; CD33; DNA; DNA methylation; Biochemistry; Cell biology","score_opus":0.05734255629292785,"score_gpt":0.3173960237299353,"score_spread":0.26005346743700747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091036980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005777,0.002160177,0.0038826088,0.00006905971,0.0000091575785,0.000099296994,0.0023335766,0.0001216828,0.0012666043],"genre_scores_gemma":[0.9891139,0.0011439519,0.004924174,0.000049522303,0.00001042045,0.00013195723,0.0033764965,0.000018780365,0.0012308987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997694,0.000023200004,0.000015482683,0.00007373846,0.00008691772,0.00003131632],"domain_scores_gemma":[0.9998547,0.000018169914,0.000057262823,0.000009648193,0.000026921345,0.000033281805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024037412,0.00033188274,0.00031728696,0.0007871849,0.00016082359,0.00034619632,0.00022171784,0.00032951438,0.0016610887],"category_scores_gemma":[0.00023569315,0.0001508485,0.00013468726,0.0006368913,0.0001616025,0.00023572394,0.00021850983,0.00039933034,0.0003845642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013021608,0.00009147906,0.046041653,0.00017076446,0.000033483593,0.00015465892,0.00007540674,0.0004876076,0.92777103,0.0000922948,0.00036659787,0.02341286],"study_design_scores_gemma":[0.00005434656,0.0016643987,0.38715273,0.000017790779,0.000118881326,0.0031069599,0.00012964927,0.0034543427,0.5981294,0.00020652912,0.005953195,0.00001190527],"about_ca_topic_score_codex":0.0005175373,"about_ca_topic_score_gemma":0.0006745424,"teacher_disagreement_score":0.0016610887,"about_ca_system_score_codex":0.00032230926,"about_ca_system_score_gemma":0.00021494205,"threshold_uncertainty_score":0.0055568814},"labels":[],"label_agreement":null},{"id":"W2091977946","doi":"10.1158/1535-7163.pms-a02","title":"Abstract A02: PARP inhibition selectively kills RNF20-depleted cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Homologous recombination; Biology; DNA repair; Genome instability; Cancer cell; Molecular biology; DNA damage; Chromosome instability; Cancer research; Chromosome; Cancer; Gene; Genetics; Cell biology; DNA","score_opus":0.02606190089490515,"score_gpt":0.2985627160633738,"score_spread":0.2725008151684687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091977946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785861,0.004219105,0.0058018016,0.00027500925,0.00028127676,0.0001502326,0.0033927306,0.00050283986,0.0067909057],"genre_scores_gemma":[0.9856514,0.0011612165,0.002535823,0.00016009106,0.000027426904,0.00013228293,0.0036545815,0.00003847245,0.006638689],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998342,0.000019945255,0.000021307313,0.000042749216,0.000047426278,0.00003437398],"domain_scores_gemma":[0.9999083,0.000019682431,0.00001652063,0.000013151161,0.000015388143,0.000026920685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012779866,0.00036954065,0.00041380338,0.00019811769,0.000116665535,0.00027239084,0.000378711,0.00040641206,0.0029014247],"category_scores_gemma":[0.00011868799,0.0000933048,0.0002344365,0.00020038398,0.00012427477,0.00013491954,0.00014045788,0.0005997139,0.00097234664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006216571,0.0002196676,0.00017746355,0.00008120698,0.000019285902,0.00009385838,0.000016813987,0.00018442523,0.993252,0.000117933465,0.00059315487,0.0046226527],"study_design_scores_gemma":[0.00006395374,0.0013463389,0.0024122559,0.0000060829357,0.000016750384,0.00027104744,0.000015400597,0.0012443361,0.99069387,0.000039245802,0.0038850848,0.0000055377577],"about_ca_topic_score_codex":0.0006481039,"about_ca_topic_score_gemma":0.0005056927,"teacher_disagreement_score":0.0029014247,"about_ca_system_score_codex":0.00017818311,"about_ca_system_score_gemma":0.00019097934,"threshold_uncertainty_score":0.009706259},"labels":[],"label_agreement":null},{"id":"W2094097070","doi":"10.1158/1535-7163.targ-13-b69","title":"Abstract B69: Dynamic reprogramming of signaling following Met inhibition reveals pathways for cell proliferation and negative feedback in gastric cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University","funders":"","keywords":"PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Receptor tyrosine kinase; Cancer; Protein kinase B; Cell growth; Reprogramming; Cancer research; Biology; Signal transduction; Cancer cell; Kinase; Cell biology; Cell; Genetics","score_opus":0.02710289600573308,"score_gpt":0.2968725744253503,"score_spread":0.26976967841961724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094097070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97153735,0.0083442535,0.003450961,0.0007422962,0.00024608374,0.00007148652,0.0049069384,0.00049175305,0.010208851],"genre_scores_gemma":[0.9780096,0.0031593163,0.0024216587,0.00025010787,0.000032106906,0.000065226806,0.0029661446,0.00007263902,0.01302328],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989927,0.000007762453,0.0000039367246,0.00001699137,0.00004399818,0.000027992],"domain_scores_gemma":[0.9999702,0.0000030258282,0.000007286125,0.0000026197254,0.0000045455386,0.000012306194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000767255,0.0001877403,0.00018660027,0.00028963268,0.00020116886,0.0002941848,0.00016051321,0.00030671994,0.00449591],"category_scores_gemma":[0.000063031795,0.00012946986,0.00024208598,0.0003135387,0.00012744757,0.0001525609,0.00017066192,0.0005000448,0.0010876459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023035992,0.00002044504,0.00018134968,0.00005280391,0.0000037369894,0.00008064614,0.000014402685,0.00003755286,0.994545,0.00012955535,0.0004680037,0.0042360243],"study_design_scores_gemma":[0.00008096147,0.0010080137,0.06706579,0.000029287981,0.000038397124,0.001235002,0.00012382836,0.0016726675,0.90503067,0.0003800464,0.023312386,0.000022979808],"about_ca_topic_score_codex":0.0012004039,"about_ca_topic_score_gemma":0.0015574219,"teacher_disagreement_score":0.00449591,"about_ca_system_score_codex":0.00036934114,"about_ca_system_score_gemma":0.00021296895,"threshold_uncertainty_score":0.015040338},"labels":[],"label_agreement":null},{"id":"W2095005464","doi":"10.1158/1535-7163.targ-11-b83","title":"Abstract B83: Combination therapy with the histone deacetylase inhibitor panobinostat and the CD20-targeting antibody rituximab in diffuse large B-cell lymphoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Panobinostat; Cancer research; Diffuse large B-cell lymphoma; CD20; Rituximab; Lymphoma; Propidium iodide; Histone deacetylase inhibitor; Histone deacetylase; Medicine; Immunology; Chemistry; Programmed cell death; Histone; Apoptosis; Biochemistry","score_opus":0.012282811002304076,"score_gpt":0.25611898960161394,"score_spread":0.24383617859930987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095005464","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390067,0.009870785,0.0009936616,0.00026820585,0.00013623612,0.0003362035,0.00038469277,0.00011819964,0.003991318],"genre_scores_gemma":[0.992246,0.0030191466,0.0018253665,0.0001596721,0.000054504526,0.00014168765,0.00058712164,0.000014731955,0.0019517482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986947,0.00003353694,0.000009429696,0.000024818413,0.000025519032,0.00003727149],"domain_scores_gemma":[0.9999373,0.000010190539,0.000009264789,0.00000806604,0.0000055802493,0.000029504123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000297771,0.00040800014,0.00094796676,0.00044599618,0.0002270661,0.00033110846,0.00045086362,0.00044260497,0.0015816197],"category_scores_gemma":[0.0001338049,0.0002033364,0.00033110403,0.00035195443,0.00021040044,0.00020765806,0.00025638015,0.00078503054,0.00049788645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028573172,0.00985117,0.0050662616,0.00071666256,0.00047962854,0.0022269548,0.00026550185,0.002198197,0.7386681,0.00040409845,0.003442322,0.20810798],"study_design_scores_gemma":[0.018741898,0.24714428,0.06056019,0.00012661035,0.0015358274,0.00824708,0.0002599288,0.009417311,0.60906684,0.0002761072,0.04454331,0.00008056766],"about_ca_topic_score_codex":0.0013560343,"about_ca_topic_score_gemma":0.004077112,"teacher_disagreement_score":0.0015816197,"about_ca_system_score_codex":0.00038676424,"about_ca_system_score_gemma":0.0003805386,"threshold_uncertainty_score":0.005290985},"labels":[],"label_agreement":null},{"id":"W2095303664","doi":"10.1158/1535-7163.targ-11-cn08-01","title":"Abstract CN08-01: Targeting the androgen receptor in castration-resistant prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Castration; Medicine; Androgen; Enzalutamide; Cancer; Internal medicine; Oncology; Biology; Hormone","score_opus":0.05933011130010995,"score_gpt":0.3317127302610393,"score_spread":0.27238261896092936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095303664","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5887759,0.23570125,0.008529757,0.012434689,0.013838575,0.00419135,0.0121379895,0.0024094942,0.12198106],"genre_scores_gemma":[0.75558525,0.0776229,0.008455101,0.007739704,0.0015630316,0.001550034,0.014884658,0.00024533054,0.13235405],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998387,0.000021111213,0.000007065452,0.000021027503,0.00006648943,0.000045613397],"domain_scores_gemma":[0.9998821,0.000004793651,0.000016040229,0.000006699909,0.000025491285,0.00006482912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048445596,0.0007711374,0.00054058165,0.00072444667,0.00026833033,0.0006578279,0.0011695465,0.00082142773,0.009543426],"category_scores_gemma":[0.00015387901,0.00023366483,0.0005438775,0.00042015323,0.00027168356,0.000296772,0.0003033827,0.0015727931,0.0026717898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00827048,0.0059498516,0.001650999,0.0028734624,0.0002431501,0.0015214705,0.00009855345,0.0014672894,0.4629185,0.0040873876,0.12567368,0.38524517],"study_design_scores_gemma":[0.013394547,0.07253962,0.024626791,0.00070874195,0.0006510009,0.008640792,0.00012006343,0.007467831,0.21618554,0.0014943711,0.65399504,0.00017560595],"about_ca_topic_score_codex":0.0033866887,"about_ca_topic_score_gemma":0.010086677,"teacher_disagreement_score":0.009543426,"about_ca_system_score_codex":0.000873356,"about_ca_system_score_gemma":0.0012605553,"threshold_uncertainty_score":0.031925917},"labels":[],"label_agreement":null},{"id":"W2095681827","doi":"10.1158/1535-7163.mct-06-0745","title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Apoptosis; Multiple myeloma; Cancer research; Medicine; Pharmacology; Cancer; Biology; Immunology; Internal medicine; Genetics; Cholesterol","score_opus":0.024275630030600362,"score_gpt":0.3001197825491058,"score_spread":0.27584415251850547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095681827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990363,0.00029158898,0.000264378,0.000019105635,0.0000019049552,0.0000067384954,0.00012244182,0.000009494585,0.00024807823],"genre_scores_gemma":[0.9993395,0.00014537972,0.00014130815,0.000011422237,0.0000011667614,0.000005773292,0.0001569693,0.00000289912,0.00019549085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997434,0.00005228694,0.0000339153,0.000039440823,0.00008063173,0.00005025318],"domain_scores_gemma":[0.9997373,0.00006557537,0.00007536529,0.000037033937,0.00003626669,0.000048486152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016445699,0.00013155912,0.00031317753,0.00048037825,0.00019799608,0.0003348773,0.0000982238,0.00025126056,0.00072652317],"category_scores_gemma":[0.00039379083,0.00014176089,0.00020656917,0.00028977272,0.00017443403,0.00012979818,0.00022281538,0.00029364566,0.00024325468],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035194238,0.000032658798,0.01411826,0.000012895394,0.000013637838,0.00011920315,0.000055702025,0.00009766272,0.9831192,0.00005507366,0.00002791551,0.0019958592],"study_design_scores_gemma":[0.000028493625,0.0013380428,0.27846855,0.000009496684,0.00006168191,0.0030731622,0.00025854874,0.0014729374,0.7130868,0.000147428,0.0020377503,0.0000171037],"about_ca_topic_score_codex":0.001047028,"about_ca_topic_score_gemma":0.0011552452,"teacher_disagreement_score":0.001047028,"about_ca_system_score_codex":0.00035756413,"about_ca_system_score_gemma":0.00013346889,"threshold_uncertainty_score":0.0025943518},"labels":[],"label_agreement":null},{"id":"W2096108152","doi":"10.1158/1535-7163.mct-06-0412","title":"Chemosensitization of carcinoma cells using epithelial cell adhesion molecule–targeted liposomal antisense against bcl-2/bcl-xL","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Epithelial cell adhesion molecule; Liposome; Endocytosis; Cancer cell; Cancer research; Targeted drug delivery; Drug delivery; Apoptosis; Molecular biology; Targeted therapy; Chemistry; Cancer; Biology; Cell adhesion molecule; Cell; Cell biology; Biochemistry","score_opus":0.012632925320697617,"score_gpt":0.23953368345086448,"score_spread":0.22690075813016686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096108152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130285,0.0012362866,0.0056980476,0.000091345726,0.000044679593,0.00006469134,0.00012778542,0.00013437468,0.0013000048],"genre_scores_gemma":[0.9937831,0.0008666081,0.0029871748,0.000067723326,0.0000107615115,0.0000646982,0.00020045429,0.000023181663,0.0019962394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998658,0.000018850269,0.000014646763,0.000033022196,0.000031965606,0.000035677695],"domain_scores_gemma":[0.99993134,0.000024359253,0.000012514961,0.000012535483,0.000009078028,0.000010232939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014194443,0.00043202259,0.00031724374,0.00020165148,0.0001366905,0.00028433275,0.00017054919,0.00023928202,0.00096804416],"category_scores_gemma":[0.00010023218,0.00015178736,0.0002809308,0.00014605324,0.00017762266,0.00022456599,0.00022685055,0.00043659404,0.00027235577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033260876,0.000029813264,0.0000407728,0.00002578679,0.0000038111154,0.000014727016,0.0000125527085,0.00008488223,0.9988391,0.000049787985,0.000017432067,0.00084816164],"study_design_scores_gemma":[0.000008901083,0.00011284966,0.00031832609,0.0000013079421,0.0000055361293,0.000021569165,0.000005494807,0.0006452287,0.99845886,0.000007917029,0.00041248038,0.00000151503],"about_ca_topic_score_codex":0.00069576566,"about_ca_topic_score_gemma":0.00093241024,"teacher_disagreement_score":0.00096804416,"about_ca_system_score_codex":0.00030387306,"about_ca_system_score_gemma":0.0002058945,"threshold_uncertainty_score":0.0032384396},"labels":[],"label_agreement":null},{"id":"W2096687091","doi":"10.1158/1535-7163.mct-10-0550","title":"Inhibition of Constitutive Activation of STAT3 by Curcurbitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"University of Manitoba; McGill University","keywords":"XIAP; Apoptosis; Gene knockdown; STAT3; Leukemia; Cancer research; Phosphorylation; Chronic lymphocytic leukemia; Cell cycle; Inhibitor of apoptosis; Molecular biology; Chemistry; Programmed cell death; Biology; Cell biology; Immunology; Caspase; Biochemistry","score_opus":0.009510150858963132,"score_gpt":0.26234797743980504,"score_spread":0.2528378265808419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096687091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955622,0.0016058503,0.0010997154,0.00006878519,0.00002366237,0.00003549677,0.00038774175,0.000083729974,0.0011328924],"genre_scores_gemma":[0.9962417,0.0008747621,0.00067355,0.0000302714,0.000005397739,0.000026052783,0.0006737819,0.0000102622735,0.0014642879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999553,0.000007003947,0.000004574992,0.000007331119,0.000011812485,0.000014051948],"domain_scores_gemma":[0.9999715,0.0000049401597,0.000007639496,0.0000042218644,0.0000034386455,0.000008186649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005293875,0.0003643116,0.00014828487,0.00017384026,0.000084887106,0.00013247455,0.00011370993,0.00014812392,0.0012918777],"category_scores_gemma":[0.000043374057,0.00007340008,0.00019988212,0.0001244186,0.000111370035,0.000097376076,0.000080652004,0.0004179771,0.00029131395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011553108,0.000035356337,0.000083605206,0.000026210679,0.000004676693,0.000020850035,0.000008639936,0.000058260674,0.9987872,0.000031616113,0.00003348151,0.00079468766],"study_design_scores_gemma":[0.000021842441,0.00055608054,0.0014886165,0.0000031525294,0.000011672321,0.00010706892,0.000008273096,0.0004259986,0.9961086,0.000014732193,0.0012518133,0.000002216817],"about_ca_topic_score_codex":0.000642586,"about_ca_topic_score_gemma":0.0009770734,"teacher_disagreement_score":0.0012918777,"about_ca_system_score_codex":0.0001853162,"about_ca_system_score_gemma":0.00014428311,"threshold_uncertainty_score":0.004321754},"labels":[],"label_agreement":null},{"id":"W2096717481","doi":"10.1158/1535-7163.targ-09-b174","title":"Abstract B174: The effect of histone deacetylase inhibition on BRCA1 expression: A potential novel mechanism for enhancing platinum sensitivity in breast and ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ovarian cancer; Cisplatin; Cancer research; Breast cancer; Histone deacetylase inhibitor; Histone deacetylase; MTT assay; Flow cytometry; Biology; Western blot; Viability assay; Molecular biology; Cell culture; Cancer; Histone; Chemotherapy; DNA; Biochemistry; Gene","score_opus":0.010002712533497824,"score_gpt":0.2929313654018364,"score_spread":0.28292865286833857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096717481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98137546,0.0094004795,0.0025952423,0.0005311045,0.00018605513,0.00007880895,0.0013071534,0.00020609319,0.004319639],"genre_scores_gemma":[0.9852201,0.0036055066,0.0023179103,0.0001653201,0.000048945534,0.000048192862,0.0013569705,0.000025850108,0.0072111273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995315,0.000005491879,0.0000050478952,0.000011349828,0.000013617898,0.000011427681],"domain_scores_gemma":[0.99996066,0.000006798777,0.000011472384,0.000004505239,0.0000057868165,0.000010772888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008832532,0.0003051656,0.00024805762,0.00015019416,0.00010992949,0.00018409747,0.00019981465,0.00021971714,0.0047184387],"category_scores_gemma":[0.000074216165,0.000095260824,0.00018358315,0.00016811346,0.00013303204,0.00010429535,0.00010642572,0.00041948134,0.00068839383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022161356,0.00003485618,0.00025030551,0.00009753912,0.000008023292,0.000033147906,0.0000056151252,0.00004190935,0.9954255,0.00006685003,0.00022221799,0.0035923389],"study_design_scores_gemma":[0.000053526346,0.0005952087,0.0046791127,0.000008718599,0.000020704907,0.00020670902,0.0000108915265,0.00030105314,0.9894146,0.000040225183,0.004666016,0.0000031007119],"about_ca_topic_score_codex":0.0005542067,"about_ca_topic_score_gemma":0.0007635691,"teacher_disagreement_score":0.0047184387,"about_ca_system_score_codex":0.00026175147,"about_ca_system_score_gemma":0.00021464303,"threshold_uncertainty_score":0.0157848},"labels":[],"label_agreement":null},{"id":"W2097382536","doi":"10.1158/1535-7163.mct-10-0850","title":"Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Deutsche Forschungsgemeinschaft","keywords":"Gene knockdown; LNCaP; Transactivation; Cancer research; Androgen receptor; Prostate cancer; STAT5; Androgen deprivation therapy; DU145; STAT protein; Biology; Transcription factor; Medicine; Apoptosis; Internal medicine; Cancer; Signal transduction; STAT3; Cell biology","score_opus":0.052477183403012474,"score_gpt":0.33209017566095417,"score_spread":0.2796129922579417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097382536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858601,0.0034050043,0.0038587064,0.0002809177,0.000152024,0.00006401704,0.0019425009,0.0004307443,0.004005916],"genre_scores_gemma":[0.9896483,0.0014085018,0.0020131825,0.00010101127,0.000017276443,0.00005189434,0.0015060004,0.000030228535,0.0052236556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998659,0.000013312828,0.000017083057,0.000028868446,0.00003641644,0.000038341615],"domain_scores_gemma":[0.9999496,0.0000050515905,0.000015909463,0.0000045964557,0.000005530918,0.000019475143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098926255,0.00036341927,0.00023271257,0.00022731716,0.00013823326,0.00026032887,0.000175214,0.00019221375,0.0018546997],"category_scores_gemma":[0.000047630885,0.00011732151,0.0003117857,0.00014588302,0.00018100548,0.00015745457,0.00009107807,0.0005569118,0.00038315094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000267237,0.000079312755,0.00015763615,0.0000746247,0.000009200857,0.000023444269,0.000013343944,0.000119812605,0.9967062,0.00014993254,0.0002975711,0.0021018756],"study_design_scores_gemma":[0.000027825607,0.000837083,0.0032345294,0.0000068142385,0.000026246676,0.00010874444,0.000022873119,0.0013394355,0.99078417,0.000027798606,0.0035792717,0.000005125217],"about_ca_topic_score_codex":0.0013302369,"about_ca_topic_score_gemma":0.0028969573,"teacher_disagreement_score":0.0018546997,"about_ca_system_score_codex":0.0003308415,"about_ca_system_score_gemma":0.00025477167,"threshold_uncertainty_score":0.0062045455},"labels":[],"label_agreement":null},{"id":"W2098247131","doi":"10.1158/1535-7163.mct-06-0452","title":"The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression <i>in vitro</i> and <i>in vivo</i>","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Tamoxifen; Cancer research; Estrogen receptor; Pharmacology; Cell growth; Farnesyltransferase inhibitor; Farnesyltransferase; Cell cycle; Cell cycle checkpoint; Cancer; Biology; Breast cancer; Medicine; Internal medicine; Prenylation; Biochemistry","score_opus":0.0036046031280118794,"score_gpt":0.23732967330418847,"score_spread":0.23372507017617658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098247131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980169,0.009930818,0.0018178403,0.00033579077,0.00013990814,0.00017432153,0.00078802207,0.00027176508,0.0063724713],"genre_scores_gemma":[0.9851083,0.0061110226,0.0037300827,0.00015202924,0.00006790886,0.00012450771,0.0017689324,0.00003821692,0.0028991087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981076,0.00003327508,0.000015944255,0.000023432758,0.000053342505,0.00006316633],"domain_scores_gemma":[0.99992,0.000018620975,0.00001865441,0.0000067915344,0.000007728657,0.00002819403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018812505,0.00059442443,0.0008036202,0.0006235716,0.00016668519,0.00034377145,0.0003106502,0.00040910445,0.0017495587],"category_scores_gemma":[0.0001145973,0.00018824812,0.0005153396,0.00044413726,0.00017598369,0.0001820511,0.00024849435,0.0006448283,0.0005784092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009639439,0.0004339256,0.0005601786,0.00019394503,0.000084309744,0.000121030076,0.000023729928,0.00043257515,0.97569615,0.00012095622,0.00052810303,0.020841101],"study_design_scores_gemma":[0.00022011134,0.007996179,0.0051823026,0.000014766974,0.00014043746,0.00070336007,0.000032997166,0.0010947167,0.97780085,0.00003985958,0.006759851,0.00001463054],"about_ca_topic_score_codex":0.0010502838,"about_ca_topic_score_gemma":0.0039260276,"teacher_disagreement_score":0.0017495587,"about_ca_system_score_codex":0.00038736864,"about_ca_system_score_gemma":0.00035480876,"threshold_uncertainty_score":0.0058528185},"labels":[],"label_agreement":null},{"id":"W2098409094","doi":"10.1158/1535-7163.mct-14-0771","title":"Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Public Health Service","keywords":"Integrin-linked kinase; Cancer research; Vimentin; Metastasis; Epithelial–mesenchymal transition; Gene knockdown; Cell migration; Tumor progression; Biology; Downregulation and upregulation; MMP2; Cancer; Kinase; Cell; Cell culture; Protein kinase A; Cell biology; Immunology; Immunohistochemistry; Cyclin-dependent kinase 2","score_opus":0.04722484246943109,"score_gpt":0.29763041294676496,"score_spread":0.25040557047733386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098409094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886464,0.004730417,0.0029530812,0.00026201853,0.000114725975,0.000093277165,0.00048777077,0.00027668788,0.0024356893],"genre_scores_gemma":[0.993558,0.002279989,0.001494033,0.00009700969,0.000012538677,0.00007987726,0.0005771173,0.000019305977,0.0018821313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998661,0.000019197736,0.000016629425,0.000016628426,0.000040831892,0.000040398],"domain_scores_gemma":[0.9999651,0.0000044013645,0.000009134488,0.000004245348,0.0000057743277,0.000011338043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013901314,0.00032294443,0.0005178815,0.00022168065,0.00019557994,0.00026164093,0.00023434285,0.00021618696,0.00088010845],"category_scores_gemma":[0.000091959504,0.00012809048,0.00036850778,0.0002242072,0.00020026001,0.00017191903,0.00013906165,0.0008566191,0.00024075004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026836904,0.00023251113,0.000261814,0.00015959756,0.000024128005,0.000062122795,0.000034934175,0.00020230241,0.9947344,0.00017943866,0.00032893967,0.0035115501],"study_design_scores_gemma":[0.0001596813,0.0012184855,0.0060609425,0.000012222406,0.00009335087,0.00032828527,0.00005999761,0.0029423248,0.98299813,0.00008283247,0.0060308767,0.000012807468],"about_ca_topic_score_codex":0.0011557279,"about_ca_topic_score_gemma":0.002277375,"teacher_disagreement_score":0.0011557279,"about_ca_system_score_codex":0.0002859023,"about_ca_system_score_gemma":0.00044382855,"threshold_uncertainty_score":0.0029442906},"labels":[],"label_agreement":null},{"id":"W2098853281","doi":"10.1158/1535-7163.mct-05-0200","title":"Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells <i>in vitro</i>","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Cidofovir; In vitro; Cervical cancer; Cancer; Cancer research; Pharmacology; Chemistry; Medicine; Biology; Virology; Genetics; Virus","score_opus":0.008883492898231387,"score_gpt":0.2705525696305286,"score_spread":0.2616690767322972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098853281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989805,0.006734647,0.0007639036,0.000041258096,0.000042608746,0.000043417564,0.0004913234,0.000023586346,0.002054303],"genre_scores_gemma":[0.9917567,0.003487657,0.002744915,0.000041682357,0.000020017711,0.000035569836,0.0006878422,0.0000103445445,0.0012153463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999853,0.000037110774,0.00002185122,0.000021005015,0.00003131222,0.000035693578],"domain_scores_gemma":[0.9998785,0.000048931586,0.000016951137,0.000012939739,0.000021753138,0.00002080856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021098001,0.0003639934,0.00030773663,0.00029420387,0.00012592283,0.00025298432,0.00015065013,0.00022084922,0.0006855796],"category_scores_gemma":[0.00017603386,0.00008887432,0.00027880154,0.00022723003,0.000119499855,0.00014870854,0.00010593274,0.0002232805,0.00014446965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028749407,0.00003338205,0.00021638593,0.000080922546,0.000006725213,0.00004280017,0.000028458684,0.00014928046,0.996243,0.000041817235,0.00002478291,0.0028449688],"study_design_scores_gemma":[0.000011421544,0.00047967574,0.0012205308,0.0000058855285,0.000016119437,0.00007051829,0.000014242621,0.00020024426,0.9968299,0.000008917174,0.0011394032,0.000003177643],"about_ca_topic_score_codex":0.001600933,"about_ca_topic_score_gemma":0.001540889,"teacher_disagreement_score":0.001600933,"about_ca_system_score_codex":0.00024545885,"about_ca_system_score_gemma":0.00023269615,"threshold_uncertainty_score":0.003183186},"labels":[],"label_agreement":null},{"id":"W2098999466","doi":"10.1158/1535-7163.mct-05-0178","title":"Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both<i>in vitro</i>and<i>in vivo</i>","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Clusterin; Gene knockdown; Paclitaxel; Cancer research; In vivo; Biology; Apoptosis; SKBR3; Small interfering RNA; Breast cancer; Cell culture; Cancer; Transfection; Biochemistry","score_opus":0.013911167559450929,"score_gpt":0.2822270790386065,"score_spread":0.26831591147915557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098999466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280655,0.0016694422,0.0029132655,0.00018375453,0.000036178717,0.000040490235,0.00059968233,0.000117523174,0.0016331335],"genre_scores_gemma":[0.9891879,0.0014502491,0.0035219602,0.00008840508,0.000010478992,0.000068587804,0.0014772655,0.000035863675,0.0041592694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999069,0.000011677764,0.000008741871,0.000025051628,0.00002566719,0.000022008144],"domain_scores_gemma":[0.99995434,0.000007803511,0.000013661673,0.0000059798344,0.000008865471,0.000009372487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008872478,0.00024381239,0.00021295252,0.00012038441,0.00015812306,0.00023537292,0.00010542143,0.0001507658,0.0007385422],"category_scores_gemma":[0.00006216854,0.000110668894,0.00015893948,0.00015361102,0.00015643054,0.00008736076,0.000086553606,0.00029329595,0.00024203706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004133075,0.000009415271,0.00006661834,0.000018750003,0.0000027719152,0.000008403989,0.000006196554,0.000027897751,0.9993278,0.00002268097,0.000058309386,0.00040982178],"study_design_scores_gemma":[0.000004806912,0.00009429449,0.0017941206,0.0000015853327,0.000008543486,0.000059776532,0.000010673554,0.00031922178,0.9958365,0.0000057423654,0.001863558,0.0000012739795],"about_ca_topic_score_codex":0.0017850761,"about_ca_topic_score_gemma":0.0028863335,"teacher_disagreement_score":0.0017850761,"about_ca_system_score_codex":0.00045544005,"about_ca_system_score_gemma":0.00027491062,"threshold_uncertainty_score":0.003549397},"labels":[],"label_agreement":null},{"id":"W2099228074","doi":"10.1158/1535-7163.mct-06-0154","title":"Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Immunovaccine (Canada); McMaster University Medical Centre","funders":"","keywords":"Thrombomodulin; Protein C; Endothelial protein C receptor; Doxorubicin; Endothelial stem cell; Pharmacology; Endothelium; Umbilical vein; Cancer research; Chemistry; Biology; Immunology; Medicine; Thrombin; Chemotherapy; Biochemistry; Endocrinology; Internal medicine; In vitro; Platelet","score_opus":0.02114866477243443,"score_gpt":0.26014676708645423,"score_spread":0.2389981023140198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099228074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815362,0.012939988,0.0012448651,0.00027883126,0.000067717105,0.00004655283,0.00012261771,0.000026155014,0.0037370482],"genre_scores_gemma":[0.9922035,0.0055116545,0.0005677198,0.00008829721,0.000014850164,0.00002002394,0.000078625264,0.0000035069102,0.0015116811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992406,0.000028573862,0.0000059331246,0.000009859919,0.000016060401,0.000015421207],"domain_scores_gemma":[0.9999317,0.00002562801,0.000018188097,0.0000065624745,0.000008443269,0.000009397729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007831211,0.00014550681,0.00012360867,0.000109554334,0.000078763864,0.00015598489,0.000061029277,0.00012448955,0.0011116554],"category_scores_gemma":[0.00012350758,0.000041350773,0.000076796576,0.000064387044,0.00009841909,0.00011009797,0.000075547025,0.00020263752,0.000086698754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061847334,0.000113617985,0.001043947,0.00012068025,0.000017462458,0.00017575391,0.000025624715,0.00017626018,0.97991,0.00040659076,0.00025633845,0.017135285],"study_design_scores_gemma":[0.00008315539,0.0027797895,0.026979337,0.00003030676,0.00008188695,0.0005936512,0.000055325432,0.0019270353,0.95611304,0.00019808965,0.011148905,0.000009417436],"about_ca_topic_score_codex":0.00047982362,"about_ca_topic_score_gemma":0.0008498341,"teacher_disagreement_score":0.0011116554,"about_ca_system_score_codex":0.00020126306,"about_ca_system_score_gemma":0.00013023184,"threshold_uncertainty_score":0.003718853},"labels":[],"label_agreement":null},{"id":"W2099259281","doi":"10.1158/1535-7163.mct-11-0705","title":"Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Research Resources; National Institute of Dental and Craniofacial Research; National Institutes of Health; National Cancer Institute; Rally Foundation","keywords":"Cyclopamine; Ceramide; Biology; Programmed cell death; Gene knockdown; Apoptosis; Cell biology; GLI1; Hedgehog signaling pathway; Smoothened; Cancer research; Signal transduction; Biochemistry","score_opus":0.017670717036158263,"score_gpt":0.256220465018098,"score_spread":0.2385497479819397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099259281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954417,0.0014452826,0.0010326983,0.000060764116,0.000020461872,0.000030279358,0.0002403868,0.000045198325,0.0016832786],"genre_scores_gemma":[0.9971896,0.0007563324,0.0008091215,0.000029202905,0.000004261218,0.000024411205,0.00024655712,0.000003865874,0.0009365722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993503,0.0000094898405,0.000007385397,0.000010360059,0.0000186714,0.0000190226],"domain_scores_gemma":[0.9999651,0.0000063546086,0.000008614478,0.0000053405283,0.000005503558,0.000009186923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008386086,0.00023233544,0.00018603854,0.0001268704,0.000090169146,0.00018913312,0.0001474343,0.0001711619,0.0005264703],"category_scores_gemma":[0.000068213936,0.00007975564,0.0002443912,0.000089639754,0.00011812943,0.00013264216,0.00012822553,0.00027396475,0.00013759427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013420917,0.000025406047,0.000121555866,0.000025344047,0.0000042921793,0.000036526868,0.000005471764,0.00003990811,0.9982736,0.000059953694,0.000026730077,0.0012469355],"study_design_scores_gemma":[0.000015071506,0.00025548227,0.0022663786,0.000002610925,0.000012087554,0.00010763927,0.000009545778,0.0005565235,0.9956916,0.000015829108,0.0010653713,0.0000018974245],"about_ca_topic_score_codex":0.0007058151,"about_ca_topic_score_gemma":0.0015374332,"teacher_disagreement_score":0.0007058151,"about_ca_system_score_codex":0.00021583065,"about_ca_system_score_gemma":0.00022886251,"threshold_uncertainty_score":0.001761198},"labels":[],"label_agreement":null},{"id":"W2099385922","doi":"10.1158/1535-7163.mct-06-0033","title":"Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Telomerase; Telomere; Cancer research; Cancer; Cancer cell; Telomerase reverse transcriptase; Breast cancer; Biology; DNA; Genetics","score_opus":0.014879848485194812,"score_gpt":0.30000692387022365,"score_spread":0.28512707538502885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099385922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97107905,0.018611588,0.0031693927,0.0002635654,0.00021674592,0.00011107491,0.0011620559,0.00019993866,0.0051866397],"genre_scores_gemma":[0.97749853,0.009018484,0.0035743369,0.00016240208,0.00009292479,0.00013703591,0.0027467874,0.000042816493,0.006726746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972814,0.000077247685,0.000035999026,0.000036162746,0.000075999895,0.000046363526],"domain_scores_gemma":[0.9998104,0.00007471654,0.000027187549,0.00003155047,0.0000304586,0.000025639003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030724882,0.00033013447,0.00063235447,0.0003826505,0.00015985247,0.00035759652,0.00015530278,0.00025480715,0.0024649152],"category_scores_gemma":[0.00023548986,0.00015123072,0.0002804403,0.00039801194,0.00011920043,0.00014672926,0.00016393283,0.0006583325,0.0007436565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035718593,0.00018219068,0.00022614439,0.00007834444,0.000015561178,0.000044256973,0.00003122878,0.00007671228,0.99496955,0.000079834586,0.00017284164,0.0037662347],"study_design_scores_gemma":[0.000053572745,0.0015428287,0.0037984925,0.000009518807,0.000024985997,0.00021681696,0.000017616447,0.00073925446,0.9876286,0.000033969485,0.00592951,0.0000049115724],"about_ca_topic_score_codex":0.00053890527,"about_ca_topic_score_gemma":0.0006481984,"teacher_disagreement_score":0.0024649152,"about_ca_system_score_codex":0.00021576296,"about_ca_system_score_gemma":0.0001893529,"threshold_uncertainty_score":0.008246005},"labels":[],"label_agreement":null},{"id":"W2099591397","doi":"10.1158/1535-7163.mct-08-0929","title":"Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Environmental Health Sciences","keywords":"Oxaliplatin; Cisplatin; Reactive oxygen species; DNA damage; DNA glycosylase; DNA repair; Cytotoxicity; Chemistry; Base excision repair; Pharmacology; Cancer research; Biochemistry; Molecular biology; Biology; Cancer; DNA; Chemotherapy; In vitro; Colorectal cancer","score_opus":0.023975527633122645,"score_gpt":0.2807184961561233,"score_spread":0.25674296852300066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099591397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98875755,0.0048867986,0.004859328,0.00008316648,0.00004136935,0.000038615013,0.00006700412,0.00013477309,0.0011314428],"genre_scores_gemma":[0.9941419,0.0019598722,0.0021563652,0.000041157225,0.00001323972,0.000025262147,0.00019945877,0.000009832303,0.0014528035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998841,0.000027884736,0.000012130292,0.000022499224,0.000022056685,0.00003121915],"domain_scores_gemma":[0.9999244,0.000012124292,0.000023403754,0.000012302451,0.000012314413,0.000015549278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017913332,0.00033217584,0.00041905625,0.00018138852,0.00007027169,0.00019494153,0.00020004685,0.00023199036,0.0006939582],"category_scores_gemma":[0.00015647514,0.00012485012,0.0002230371,0.00012410423,0.000118115015,0.0001589495,0.00012954211,0.00035016728,0.00020955734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059435544,0.00004032559,0.00011082238,0.000032335938,0.000004356846,0.000013485655,0.000005618109,0.00008304425,0.9975001,0.00005287451,0.000021501546,0.002076053],"study_design_scores_gemma":[0.000021557567,0.00069655845,0.0024284623,0.0000061923884,0.000009956523,0.00012618573,0.0000062150243,0.00083746633,0.99412537,0.000029608855,0.0017104128,0.0000020053535],"about_ca_topic_score_codex":0.00033791302,"about_ca_topic_score_gemma":0.00049115525,"teacher_disagreement_score":0.0006939582,"about_ca_system_score_codex":0.00017971653,"about_ca_system_score_gemma":0.00018587397,"threshold_uncertainty_score":0.0023214817},"labels":[],"label_agreement":null},{"id":"W2100604791","doi":"10.1158/1535-7163.mct-07-0449","title":"Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Antifolate; Biology; Intracellular; Cancer cell; Antimetabolite; Cancer research; Methotrexate; Pharmacology; Cancer; Biochemistry; Immunology","score_opus":0.014923779629011456,"score_gpt":0.30925372379734284,"score_spread":0.29432994416833136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100604791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951598,0.002574934,0.00048369923,0.00009907506,0.00004755614,0.00002714465,0.00024601046,0.000043131462,0.0013186313],"genre_scores_gemma":[0.99630886,0.0011223223,0.00063505105,0.00006956974,0.000008938398,0.00003828396,0.00034467498,0.000008844664,0.0014635212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983346,0.000032991888,0.000022852637,0.00003883789,0.000035280074,0.00003648767],"domain_scores_gemma":[0.99991655,0.000023878547,0.000015349153,0.000014387313,0.000014911339,0.000014888049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112900256,0.00024670025,0.00034707173,0.00010775498,0.000105989326,0.00024175338,0.0001524328,0.00025529688,0.00092037197],"category_scores_gemma":[0.00012618366,0.000114291404,0.00022031649,0.00018925146,0.00010466807,0.00014565159,0.00011701604,0.00042013303,0.00022173602],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025068078,0.000054394568,0.00013277304,0.000048619957,0.000009823519,0.000036051635,0.00003013313,0.000090971094,0.9976036,0.000046431414,0.00006293553,0.0016335741],"study_design_scores_gemma":[0.000023317876,0.00055414374,0.002122535,0.0000036018143,0.000026611748,0.00006192718,0.000024588313,0.0005950236,0.9943721,0.000012988791,0.0021983788,0.0000048143625],"about_ca_topic_score_codex":0.0015331308,"about_ca_topic_score_gemma":0.0015472994,"teacher_disagreement_score":0.0015331308,"about_ca_system_score_codex":0.00025570736,"about_ca_system_score_gemma":0.0001635765,"threshold_uncertainty_score":0.0030789971},"labels":[],"label_agreement":null},{"id":"W2101599998","doi":"10.1158/1535-7163.mct-09-0243","title":"Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Irinotecan; Cisplatin; In vivo; Pharmacology; Drug; In vitro; Cytotoxicity; Chemistry; Medicine; Liposome; Chemotherapy; Cancer; Biology; Internal medicine; Biochemistry","score_opus":0.01875205029635636,"score_gpt":0.32668222912345213,"score_spread":0.3079301788270958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101599998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382234,0.001933085,0.0022113293,0.00005222202,0.000015816984,0.000051866897,0.0001721122,0.000073005926,0.0016680484],"genre_scores_gemma":[0.99444157,0.0010229615,0.0032078545,0.00003108335,0.0000080981035,0.00006129895,0.00027187384,0.000019374556,0.00093589124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972004,0.000090534304,0.000029361536,0.00004771842,0.00007693739,0.00003534076],"domain_scores_gemma":[0.99985087,0.00004505382,0.000038539954,0.000013562009,0.000028103603,0.000023852104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028031785,0.00036526742,0.00038973577,0.0002786206,0.00008786145,0.00024363579,0.00019974589,0.00016879417,0.00069479994],"category_scores_gemma":[0.00022673553,0.00019663773,0.00020034099,0.00022968664,0.00016697838,0.00026232735,0.00013618858,0.00044295893,0.00021015543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023801687,0.00005654313,0.00016849843,0.00002846097,0.0000102587765,0.000016456965,0.000010900382,0.00026697028,0.99742967,0.000029516425,0.00003440252,0.001710345],"study_design_scores_gemma":[0.000012579245,0.0006478286,0.00086010323,0.0000015827302,0.000016583319,0.00005858186,0.0000048738457,0.000811538,0.9971624,0.0000081009,0.00041263562,0.0000030907129],"about_ca_topic_score_codex":0.00039391362,"about_ca_topic_score_gemma":0.0006460872,"teacher_disagreement_score":0.00069479994,"about_ca_system_score_codex":0.00028170945,"about_ca_system_score_gemma":0.00025139187,"threshold_uncertainty_score":0.0023244023},"labels":[],"label_agreement":null},{"id":"W2101657719","doi":"10.1158/1535-7163.mct-13-0401","title":"Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research; Alberta Innovates; National Institutes of Health; University of Calgary","keywords":"Microtubule; Cell biology; Nocodazole; Motility; Lamellipodium; Biology; Cytoskeleton; Microtubule polymerization; Paclitaxel; Angiogenesis; Colchicine; Cell migration; Biophysics; Cell; Chemistry; Tubulin; Biochemistry; Genetics","score_opus":0.006482326832698986,"score_gpt":0.2305935236054468,"score_spread":0.22411119677274782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101657719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327624,0.0027442724,0.0019871488,0.00006791873,0.00001313905,0.0000128437705,0.00018104995,0.00003893852,0.0016785249],"genre_scores_gemma":[0.99675035,0.0010475937,0.0008932907,0.000025908932,0.000005217479,0.000014746143,0.00012909033,0.000008068445,0.0011257145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994206,0.000011461694,0.0000049333003,0.000012228004,0.00001535269,0.000014025815],"domain_scores_gemma":[0.9999232,0.0000134698075,0.000029073428,0.0000050326275,0.000015040792,0.000014123065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064857675,0.00014672955,0.00013325067,0.00016875088,0.00013385467,0.00023157048,0.00012031899,0.00017056009,0.0003948486],"category_scores_gemma":[0.00013634775,0.00012091062,0.00007989121,0.0001281666,0.00009020415,0.00012575532,0.000071224975,0.00025612043,0.00018163791],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008243868,0.000009793548,0.00028667707,0.000014720993,0.0000016091697,0.000025471763,0.0000096164595,0.00013304669,0.99821067,0.000075526645,0.000022606022,0.001127746],"study_design_scores_gemma":[0.000019455434,0.00013548518,0.010022688,0.0000055946325,0.000007324476,0.00010091975,0.000018406532,0.0028399818,0.98520225,0.00005823473,0.0015847447,0.0000049681216],"about_ca_topic_score_codex":0.0016466822,"about_ca_topic_score_gemma":0.002373272,"teacher_disagreement_score":0.0016466822,"about_ca_system_score_codex":0.00038510477,"about_ca_system_score_gemma":0.00015370287,"threshold_uncertainty_score":0.0032742023},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2101891042","doi":"10.1158/1535-7163.mct-13-0748","title":"Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Monoclonal antibody; Antibody; Cancer research; Radioimmunotherapy; Cetuximab; Chemistry; Molecular biology; Receptor; Biology; Immunology; Biochemistry","score_opus":0.017743263608985843,"score_gpt":0.31687297863078867,"score_spread":0.29912971502180286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101891042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992335,0.0012515442,0.005241335,0.000051768337,0.000010290577,0.000026697531,0.000056748,0.000054066448,0.0009724733],"genre_scores_gemma":[0.99461937,0.00054518384,0.0039038244,0.000044154564,0.000005968244,0.000020743832,0.000096585565,0.000007600173,0.0007565978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999118,0.0000148188665,0.0000071806503,0.000016110984,0.00002518244,0.000024967483],"domain_scores_gemma":[0.9999559,0.000007993479,0.000012314165,0.0000036242097,0.00000779326,0.000012457515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115657116,0.00025865197,0.00019708784,0.000120754616,0.00005008723,0.00017532129,0.00015394739,0.00025836384,0.00045926758],"category_scores_gemma":[0.00008565069,0.00007758973,0.00016464324,0.00007374505,0.00008136556,0.00014445395,0.00015668028,0.00030493436,0.00014089854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020513175,0.000017760987,0.000083285006,0.000016348462,0.0000032805463,0.00003126627,0.0000037096042,0.00017244273,0.9979479,0.000044177235,0.000017272507,0.0016420927],"study_design_scores_gemma":[0.000018672014,0.0004442678,0.0018170582,0.0000033384588,0.000021472675,0.0003836587,0.000006146904,0.0029808346,0.991698,0.000030263713,0.0025917224,0.0000045309866],"about_ca_topic_score_codex":0.00024178426,"about_ca_topic_score_gemma":0.00021892169,"teacher_disagreement_score":0.00045926758,"about_ca_system_score_codex":0.00019827852,"about_ca_system_score_gemma":0.000107314154,"threshold_uncertainty_score":0.0015363693},"labels":[],"label_agreement":null},{"id":"W2102442341","doi":"10.1158/1535-7163.mct-04-0048","title":"<i>In vitro</i> and <i>in vivo</i> irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Biology; Cell cycle; Myeloid leukemia; Flow cytometry; Molecular biology; Apoptosis; In vivo; Gene expression; Cancer research; Myeloid; Leukemia; Gene; Immunology; Genetics","score_opus":0.010233188221277525,"score_gpt":0.2466762618659913,"score_spread":0.23644307364471376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102442341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607915,0.0010150106,0.00083499355,0.000082535094,0.00002264917,0.0000326978,0.00066017214,0.00004827401,0.0012244195],"genre_scores_gemma":[0.99278355,0.001024818,0.0013396768,0.00011124447,0.000022509377,0.00009163174,0.0021057138,0.000017858916,0.0025030356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998048,0.00003921434,0.000013994765,0.000048956965,0.000045075467,0.000048045775],"domain_scores_gemma":[0.9998828,0.000024360997,0.000036411395,0.000015425454,0.000019354791,0.000021662203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013163705,0.00032056955,0.00028493354,0.00022144764,0.00014262987,0.0002707906,0.00011851812,0.00022292676,0.0017646236],"category_scores_gemma":[0.00012987631,0.00010514895,0.00020252433,0.00019325112,0.00026148607,0.00017633053,0.00008722882,0.0005313402,0.0004132162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002888323,0.00005655118,0.0003139281,0.00003274024,0.0000064287137,0.000027408609,0.000011137872,0.00009681047,0.9982703,0.000026099311,0.00005512592,0.0008146322],"study_design_scores_gemma":[0.000023384322,0.0013187282,0.008338042,0.0000041292433,0.000018878472,0.00016009343,0.000024061135,0.0004570508,0.98858994,0.00002067191,0.001041422,0.0000035995643],"about_ca_topic_score_codex":0.0008297251,"about_ca_topic_score_gemma":0.0009884505,"teacher_disagreement_score":0.0017646236,"about_ca_system_score_codex":0.00046968518,"about_ca_system_score_gemma":0.00021644312,"threshold_uncertainty_score":0.005903244},"labels":[],"label_agreement":null},{"id":"W2102474050","doi":"10.1158/1535-7163.mct-10-0909","title":"Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Mitosis; Cell biology; Mitotic exit; Cyclin B1; Biology; Cyclin B; Cell cycle; Chemistry; Spindle apparatus; Cyclin-dependent kinase 1; Cell division; Cell; Cyclin; Genetics","score_opus":0.024925979636441938,"score_gpt":0.24567223632081003,"score_spread":0.2207462566843681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102474050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960957,0.0015768405,0.0009573768,0.000060530554,0.000027213642,0.00003500074,0.0001584589,0.000049327144,0.0010395561],"genre_scores_gemma":[0.9955379,0.00115727,0.0013642912,0.00003108149,0.00000901275,0.00003957227,0.00045772857,0.000009316776,0.0013938296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998964,0.000015875079,0.000015671181,0.000016508053,0.000027491404,0.000028049722],"domain_scores_gemma":[0.9999161,0.000011181659,0.00003526822,0.000013309637,0.0000058419014,0.000018337561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010833266,0.00044147592,0.00022223809,0.00023888516,0.000103057,0.00021711114,0.00014605881,0.0002234072,0.0009700052],"category_scores_gemma":[0.00008400669,0.00014677335,0.00031036718,0.00015756302,0.00017843099,0.00016203483,0.00015819634,0.00047125478,0.00021766683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014823434,0.00004858347,0.00010428453,0.0000291001,0.00000605173,0.000038947404,0.0000066198118,0.000050068153,0.9983925,0.00009922963,0.000019314539,0.0010571103],"study_design_scores_gemma":[0.00003701336,0.0003684184,0.0012855049,0.0000027835204,0.000007117824,0.00013446741,0.000005725598,0.00042341597,0.9968681,0.000020409749,0.0008449048,0.0000022820054],"about_ca_topic_score_codex":0.00024066376,"about_ca_topic_score_gemma":0.000511046,"teacher_disagreement_score":0.0009700052,"about_ca_system_score_codex":0.00025652026,"about_ca_system_score_gemma":0.00019740229,"threshold_uncertainty_score":0.003244996},"labels":[],"label_agreement":null},{"id":"W2102672521","doi":"10.1158/1535-7163.mct-12-0753","title":"New Directions for Biologic Targets in Urothelial Carcinoma – Response","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pazopanib; Sunitinib; Medicine; Cancer; Angiogenesis; Oncology; Kidney cancer; Bladder cancer; Renal cell carcinoma; Internal medicine; Cabozantinib; Disease; Urothelial cancer; Clinical trial; Metastatic Urothelial Carcinoma; Cancer research; Urothelial carcinoma","score_opus":0.042735871982933736,"score_gpt":0.33199900550733463,"score_spread":0.2892631335244009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102672521","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022045395,0.37836787,0.0052905693,0.5844929,0.02126061,0.00016096309,0.000264631,0.00039437745,0.007563448],"genre_scores_gemma":[0.049825568,0.39531493,0.018085092,0.36842725,0.1544698,0.00079848454,0.0008404652,0.0002894648,0.011948974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361646,0.00310599,0.0007086858,0.00065791036,0.0013799082,0.00053098216],"domain_scores_gemma":[0.98092276,0.010762617,0.0017675854,0.0010428998,0.0035145162,0.0019896408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020442313,0.0010822971,0.0026382192,0.0015133244,0.0009161365,0.004388035,0.002310706,0.0067872703,0.013263349],"category_scores_gemma":[0.0136406,0.00046777818,0.002151331,0.0011775896,0.0032195633,0.0124966595,0.0022703575,0.017071374,0.0056943838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001813223,0.0010786462,0.0024063194,0.0035608977,0.00038698636,0.0006520218,0.0002823118,0.00086935365,0.0036527722,0.032672647,0.37503564,0.57758915],"study_design_scores_gemma":[0.00079925294,0.0020597354,0.0037383416,0.0023781694,0.0003207693,0.001076727,0.00046317957,0.0019707137,0.0010114533,0.041896638,0.94417524,0.00010975667],"about_ca_topic_score_codex":0.00062992726,"about_ca_topic_score_gemma":0.0017394869,"teacher_disagreement_score":0.020442313,"about_ca_system_score_codex":0.0038549604,"about_ca_system_score_gemma":0.0033511356,"threshold_uncertainty_score":0.10811055},"labels":[],"label_agreement":null},{"id":"W2103272465","doi":"10.1158/1535-7163.mct-09-0872","title":"ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Synthetic lethality; Olaparib; Poly ADP ribose polymerase; Cancer research; Mantle cell lymphoma; Biology; DNA damage; Cell culture; DNA repair; Cancer cell; Polymerase; Molecular biology; Cancer; Lymphoma; Gene; DNA; Genetics; Immunology","score_opus":0.014287442575405696,"score_gpt":0.2850526350548136,"score_spread":0.2707651924794079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103272465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939884,0.0016492162,0.001323168,0.00010553678,0.000034950415,0.000046795234,0.00051271904,0.00023864192,0.0021005317],"genre_scores_gemma":[0.99574333,0.0010778222,0.0009038309,0.00006448828,0.000010575271,0.00005271252,0.00083274336,0.000013333585,0.0013010455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981755,0.000028751849,0.000023832983,0.000029467243,0.000055947537,0.000044522094],"domain_scores_gemma":[0.9999056,0.000019894473,0.000024473935,0.000020130845,0.000006148655,0.00002370702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011267718,0.00038656942,0.00037545076,0.00024103577,0.00012090289,0.00031650267,0.00028549018,0.00024850242,0.0014982119],"category_scores_gemma":[0.000102702455,0.00016623967,0.00028541966,0.00021886492,0.00018663178,0.00017263937,0.00021417427,0.00075484725,0.0002889627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018375811,0.00012880177,0.00045585894,0.000048588907,0.000017907654,0.000057574438,0.000015564035,0.00017600431,0.99578923,0.000094465264,0.00013089899,0.0029013613],"study_design_scores_gemma":[0.00008988026,0.0018984539,0.009010573,0.0000078972635,0.000030392692,0.00048910856,0.000028615623,0.0010646117,0.98324263,0.000060711318,0.0040695197,0.000007672217],"about_ca_topic_score_codex":0.0005836811,"about_ca_topic_score_gemma":0.0012204923,"teacher_disagreement_score":0.0014982119,"about_ca_system_score_codex":0.00026143374,"about_ca_system_score_gemma":0.00018571348,"threshold_uncertainty_score":0.0050120354},"labels":[],"label_agreement":null},{"id":"W2103596673","doi":"10.1158/1535-7163.mct-12-0967","title":"Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Doxorubicin; Distribution (mathematics); Docetaxel; Pharmacology; Melphalan; Monoclonal antibody; Drug; Cancer; Cancer research; Chemistry; Medicine; Antibody; Chemotherapy; Internal medicine; Immunology","score_opus":0.011499604327096668,"score_gpt":0.2684066430607366,"score_spread":0.2569070387336399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103596673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7697809,0.041818112,0.18091775,0.0005613313,0.00020576328,0.00035937707,0.001058334,0.0009178954,0.0043804767],"genre_scores_gemma":[0.9014307,0.0122453105,0.08176472,0.00026550342,0.000059329457,0.00038633318,0.0006641615,0.000080056765,0.0031039782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994454,0.0001291703,0.000039058294,0.00011641719,0.00022011345,0.00004985038],"domain_scores_gemma":[0.9987268,0.000296269,0.0005666488,0.000075262404,0.00025848387,0.00007657517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075726805,0.0006593083,0.00052811456,0.0019914564,0.0002789704,0.00081915624,0.00033760618,0.0008017256,0.0008164163],"category_scores_gemma":[0.0008365226,0.00039610593,0.0002998129,0.0008920085,0.00033118358,0.0011192615,0.0003028221,0.0008228367,0.00037075666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011132709,0.000055288943,0.005086515,0.00030550334,0.00005985679,0.00006469045,0.00004368925,0.000539435,0.9809426,0.00017455747,0.000108688386,0.012507845],"study_design_scores_gemma":[0.000013520465,0.00051701406,0.027637504,0.000052207455,0.00011633288,0.00043822083,0.00014251622,0.004501963,0.9619929,0.0002796075,0.004280768,0.000027526983],"about_ca_topic_score_codex":0.0005416248,"about_ca_topic_score_gemma":0.0011348525,"teacher_disagreement_score":0.0019914564,"about_ca_system_score_codex":0.00056802423,"about_ca_system_score_gemma":0.00025715324,"threshold_uncertainty_score":0.004121244},"labels":[],"label_agreement":null},{"id":"W2104386241","doi":"10.1158/1535-7163.mct-06-0434","title":"Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University","funders":"","keywords":"Angiostatin; Proinflammatory cytokine; Immune system; Immunology; Cancer research; Cancer; Biology; Angiogenesis; Population; Vasculogenic mimicry; Inflammation; Metastasis; Medicine","score_opus":0.013736588472239084,"score_gpt":0.2711282613187341,"score_spread":0.257391672846495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104386241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462587,0.0024456382,0.0011324332,0.00011591449,0.000027087868,0.00003598491,0.00020650122,0.00008391345,0.0013267348],"genre_scores_gemma":[0.996298,0.00123077,0.0009036594,0.000048197115,0.000016026475,0.00003621245,0.00031802696,0.00000853294,0.0011406146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998523,0.000032333493,0.000015592319,0.000015898453,0.000025016881,0.00005877143],"domain_scores_gemma":[0.99990356,0.000014729711,0.000035469824,0.0000098169985,0.0000064885094,0.000029895373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013676051,0.00036415292,0.00019027483,0.0002596638,0.00009928689,0.00020261163,0.00021040827,0.00019676375,0.0011738775],"category_scores_gemma":[0.000093216215,0.00009438609,0.00024339711,0.000114644616,0.00018521657,0.00017076186,0.000112801245,0.0005079427,0.00019682043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001274821,0.00043255422,0.00025865732,0.00010024887,0.000014594953,0.000080192745,0.000018350605,0.00016936424,0.9921929,0.00018299844,0.00010805861,0.0051672445],"study_design_scores_gemma":[0.00020268993,0.005390211,0.0050416333,0.000014707613,0.000040214152,0.00029887998,0.000030183935,0.0012006375,0.9843187,0.00008094575,0.0033733943,0.000007838063],"about_ca_topic_score_codex":0.000491529,"about_ca_topic_score_gemma":0.0010904081,"teacher_disagreement_score":0.0011738775,"about_ca_system_score_codex":0.00017826009,"about_ca_system_score_gemma":0.00032726186,"threshold_uncertainty_score":0.003927052},"labels":[],"label_agreement":null},{"id":"W2105020329","doi":"10.1158/1535-7163.mct-12-1150","title":"Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Cancer research; Fibroblast growth factor receptor; Cancer; Urothelial Cell; Medicine; Fibroblast growth factor receptor 2; Targeted therapy; Monoclonal antibody; Fibroblast growth factor receptor 4; Fibroblast growth factor; Receptor; Antibody; Internal medicine; Immunology","score_opus":0.02118418005377775,"score_gpt":0.29294327350275723,"score_spread":0.27175909344897947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105020329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87278455,0.08997469,0.015860606,0.00851588,0.00023489857,0.00023228835,0.000718327,0.00026366717,0.01141508],"genre_scores_gemma":[0.96578383,0.024591703,0.0060451664,0.00064102793,0.00007997211,0.00007795553,0.0003506542,0.000020757187,0.0024088759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999863,0.00004659982,0.000007809604,0.000017613485,0.000031594707,0.000033301007],"domain_scores_gemma":[0.99995744,0.000011162156,0.000009862214,0.0000038717603,0.000007910248,0.00000972135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041129725,0.00024864628,0.00046631988,0.00032142553,0.0002000953,0.00036503683,0.00022365658,0.00033954592,0.0010139022],"category_scores_gemma":[0.0002213307,0.000111744266,0.00021710637,0.00027522113,0.00023133853,0.00020567945,0.00018771489,0.0005665551,0.0003444164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014860742,0.0006895959,0.00754048,0.00048786617,0.00006956188,0.0010293681,0.00016685389,0.005052224,0.8017459,0.005279548,0.0045339568,0.17191845],"study_design_scores_gemma":[0.0011538098,0.010855436,0.03153212,0.00030761643,0.0003496138,0.008821162,0.000290831,0.011799922,0.75207084,0.005473169,0.17725353,0.00009186134],"about_ca_topic_score_codex":0.0013838909,"about_ca_topic_score_gemma":0.0035667398,"teacher_disagreement_score":0.0013838909,"about_ca_system_score_codex":0.00061931723,"about_ca_system_score_gemma":0.0005431957,"threshold_uncertainty_score":0.0044935346},"labels":[],"label_agreement":null},{"id":"W2106131552","doi":"10.1158/1535-7163.mct-08-0335","title":"Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network","funders":"University Health Network","keywords":"Fas ligand; Mitoxantrone; Apoptosis; Docetaxel; Prostate cancer; Cancer research; Fas receptor; Survivin; Cancer cell; Cytotoxic T cell; Biology; Cancer; Medicine; Chemistry; Programmed cell death; Internal medicine; In vitro; Chemotherapy; Biochemistry","score_opus":0.010026724583103308,"score_gpt":0.22776108589238314,"score_spread":0.21773436130927984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106131552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754555,0.008121623,0.0014826473,0.000099787874,0.000067363886,0.00007507921,0.0004331249,0.000109755776,0.0020651207],"genre_scores_gemma":[0.9908279,0.003101917,0.0012403976,0.000041232255,0.000017177494,0.00007974382,0.00078569935,0.000013517324,0.0038925055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969304,0.00006404138,0.000031121275,0.000033916116,0.0000969345,0.00008105253],"domain_scores_gemma":[0.99983335,0.000040170708,0.00002567162,0.000019275734,0.00003385882,0.000047740214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016744538,0.0003605256,0.0005112891,0.00029698142,0.00019922605,0.00035483428,0.00015945682,0.00018568675,0.0016645812],"category_scores_gemma":[0.00022339528,0.00018489383,0.0002946682,0.000334793,0.0001545631,0.00020522182,0.00015714754,0.0005090478,0.0003676537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032212245,0.00009483415,0.00031677203,0.00007727614,0.000011526861,0.000088122266,0.00005146179,0.00009868021,0.9967353,0.000060319588,0.000092143906,0.0020514478],"study_design_scores_gemma":[0.000050320716,0.001534854,0.012668569,0.000007939132,0.00002991155,0.0005200876,0.000042979613,0.0006558419,0.9813292,0.000024939465,0.0031283516,0.000006919115],"about_ca_topic_score_codex":0.0019211255,"about_ca_topic_score_gemma":0.0038026534,"teacher_disagreement_score":0.0019211255,"about_ca_system_score_codex":0.0006179994,"about_ca_system_score_gemma":0.00044191675,"threshold_uncertainty_score":0.005568564},"labels":[],"label_agreement":null},{"id":"W2106198555","doi":"10.1158/1535-7163.mct-05-0146","title":"Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cancer research; Lymphoma; Biology; Diffuse large B-cell lymphoma; Immune system; Tumor microenvironment; Immunology","score_opus":0.015815451971037616,"score_gpt":0.2625357891127456,"score_spread":0.246720337141708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820113,0.00034294382,0.00064997707,0.000018141873,0.0000030021415,0.000011049978,0.00036758988,0.000010562541,0.00039560779],"genre_scores_gemma":[0.99757904,0.0001733619,0.0007739339,0.000029899835,0.0000040126315,0.00002800335,0.00094611367,0.000005598715,0.0004599597],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998505,0.000025132626,0.000011608309,0.000039092163,0.000038935566,0.00003466642],"domain_scores_gemma":[0.9998739,0.00003469412,0.00003612727,0.000010590084,0.000023353921,0.000021335163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013106366,0.00010557736,0.00013378909,0.00045799583,0.00014496685,0.0002441704,0.00006970147,0.00015235113,0.0006960827],"category_scores_gemma":[0.00029774575,0.00006591931,0.00011086091,0.0003763149,0.00017102029,0.00007875372,0.00014088671,0.00013077242,0.0001597819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092089456,0.000034256616,0.07616861,0.00007818941,0.000023695713,0.0004605836,0.00027081426,0.00013044855,0.91160667,0.00011388606,0.00008991945,0.01010208],"study_design_scores_gemma":[0.00006965185,0.0010592539,0.8123078,0.000019721443,0.00013086015,0.0045717764,0.00086701155,0.0020045897,0.17521478,0.00027207355,0.0034678113,0.000014639598],"about_ca_topic_score_codex":0.0004617579,"about_ca_topic_score_gemma":0.0012395893,"teacher_disagreement_score":0.0006960827,"about_ca_system_score_codex":0.0001678887,"about_ca_system_score_gemma":0.00011033634,"threshold_uncertainty_score":0.0023286343},"labels":[],"label_agreement":null},{"id":"W2106336697","doi":"10.1158/1535-7163.mct-05-0223","title":"Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant <i>Commiphora mukul</i>, in PC-3 human prostate cancer cells is mediated by Bax and Bak","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pharmacological Effects of Medicinal Plants","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Apoptosis; Programmed cell death; Biology; Caspase; Caspase 3; Cell growth; Cancer research; Biochemistry","score_opus":0.022257129652861387,"score_gpt":0.3115336007673237,"score_spread":0.28927647111446236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106336697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531794,0.0027469248,0.0010060305,0.000057318735,0.000013874813,0.000020777097,0.00018384446,0.000043494572,0.00060989853],"genre_scores_gemma":[0.9962612,0.0016850542,0.00091787224,0.000037236183,0.000005503536,0.000022051336,0.00040905658,0.0000045741504,0.0006574166],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993694,0.000011895891,0.000007977191,0.000013626121,0.0000142421195,0.000015376423],"domain_scores_gemma":[0.99994206,0.000010242002,0.000020243764,0.000007653776,0.000007507235,0.000012235622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057756755,0.00031402215,0.00026769176,0.00018592911,0.00013311997,0.00014792434,0.00013338248,0.00021562557,0.0006816734],"category_scores_gemma":[0.000056480098,0.00010366316,0.00030119356,0.00016251295,0.00015113472,0.00019159583,0.00015830454,0.0004593939,0.00018559735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018579008,0.000019635052,0.00016560197,0.00005606799,0.0000057318202,0.00007184622,0.000012780429,0.000020957652,0.9985989,0.000021102012,0.000010340307,0.00083131646],"study_design_scores_gemma":[0.000023592906,0.0007896701,0.0064296112,0.000005513687,0.000022671165,0.00048078928,0.000036010824,0.0002723906,0.99114686,0.000031116568,0.0007573094,0.0000043401587],"about_ca_topic_score_codex":0.00031350256,"about_ca_topic_score_gemma":0.00059422443,"teacher_disagreement_score":0.0006816734,"about_ca_system_score_codex":0.00013439362,"about_ca_system_score_gemma":0.00015845148,"threshold_uncertainty_score":0.002280414},"labels":[],"label_agreement":null},{"id":"W2106888030","doi":"10.1158/1535-7163.mct-11-0510","title":"A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Public Health Agency; National Institute for Health and Care Research; Cancer Research UK; Shijiazhuang Tiedao University","keywords":"Gene silencing; Irinotecan; Colorectal cancer; Cancer research; Biology; Drug resistance; Cancer; Gene; Genetics","score_opus":0.030433607074460474,"score_gpt":0.28134143341862733,"score_spread":0.25090782634416686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106888030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94690084,0.002645536,0.0441072,0.0009158677,0.00007049355,0.00011839724,0.0013904999,0.0007871542,0.0030638298],"genre_scores_gemma":[0.9773731,0.0013430545,0.018349633,0.00014254202,0.0000143251,0.000085173706,0.0014014335,0.000025571053,0.0012650709],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998473,0.000028052036,0.000009212284,0.00004668026,0.000046138528,0.000022588129],"domain_scores_gemma":[0.99993134,0.000024474472,0.000017652157,0.000007585468,0.000009180046,0.000009763165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031787105,0.00045334687,0.00046781407,0.00042592335,0.00036180383,0.0006658143,0.0003040023,0.0004061429,0.0013074004],"category_scores_gemma":[0.00020375561,0.0002841498,0.0005095393,0.00024110425,0.00029106464,0.0002320722,0.00025397667,0.00065752864,0.00027889965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010037676,0.000036143665,0.0011996164,0.00011308007,0.00002416336,0.000052001134,0.000019850402,0.0020260816,0.99231017,0.00047719263,0.0001567143,0.0034845201],"study_design_scores_gemma":[0.00004865883,0.000897451,0.02681197,0.000031598833,0.00014009686,0.000571677,0.00013179697,0.11107364,0.85122466,0.00095045805,0.0080666095,0.00005126317],"about_ca_topic_score_codex":0.0014962659,"about_ca_topic_score_gemma":0.0027311747,"teacher_disagreement_score":0.0014962659,"about_ca_system_score_codex":0.0011655537,"about_ca_system_score_gemma":0.00044480077,"threshold_uncertainty_score":0.008456707},"labels":[],"label_agreement":null},{"id":"W2107790510","doi":"10.1158/1535-7163.mct-09-0193","title":"Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"U.S. National Library of Medicine; National Cancer Institute","keywords":"Imatinib mesylate; GiST; Imatinib; Stromal tumor; Medicine; Cancer research; PDGFRA; Oncology; Internal medicine; Stromal cell","score_opus":0.022835729548239446,"score_gpt":0.32724604666114254,"score_spread":0.3044103171129031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107790510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993315,0.00023126403,0.0000933756,0.000020327192,0.0000022589797,0.0000037705265,0.0001981346,0.0000039589922,0.00011540943],"genre_scores_gemma":[0.9987269,0.00014917103,0.00023181463,0.00003084748,0.0000041859635,0.000015636322,0.0006412707,0.000002345597,0.00019786334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998832,0.00002247994,0.00000912472,0.000032825585,0.000027397655,0.000024875648],"domain_scores_gemma":[0.99985945,0.000044304048,0.000044416578,0.000009109793,0.000016555436,0.000026106829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012606087,0.000107562395,0.00023855126,0.00031216608,0.00010045589,0.00019203716,0.000057176578,0.00020772815,0.0004667524],"category_scores_gemma":[0.0003862318,0.00007946428,0.00011146321,0.0003112876,0.00014730194,0.0001022741,0.00009262758,0.00016865757,0.00012360407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031003323,0.00013282092,0.22456123,0.00007864398,0.000077611745,0.00038954025,0.00014434606,0.0006253923,0.7574726,0.00006522713,0.00026943476,0.013082822],"study_design_scores_gemma":[0.000026361788,0.0007775857,0.9571737,0.0000043420255,0.000045934885,0.00067342457,0.00013929768,0.0014598779,0.038999535,0.00007567426,0.00061650225,0.000007729986],"about_ca_topic_score_codex":0.00029189637,"about_ca_topic_score_gemma":0.00045039348,"teacher_disagreement_score":0.0004667524,"about_ca_system_score_codex":0.00015265476,"about_ca_system_score_gemma":0.000090992224,"threshold_uncertainty_score":0.0015614629},"labels":[],"label_agreement":null},{"id":"W2107867323","doi":"10.1158/1535-7163.mct-04-0077","title":"Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Jurkat cells; Apoptosis; Biology; Cancer cell; Programmed cell death; Cytotoxic T cell; Cell biology; Cell culture; Cytochrome c; Annexin; Caspase; Molecular biology; Biochemistry; In vitro; Immunology; T cell; Cancer; Immune system","score_opus":0.018128054094807257,"score_gpt":0.25673612980095234,"score_spread":0.2386080757061451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107867323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864747,0.006296625,0.0037265553,0.00016963507,0.000046528967,0.0001257572,0.0006312476,0.0001532905,0.0023755622],"genre_scores_gemma":[0.9927027,0.0020214778,0.0021206597,0.00008555697,0.000013275069,0.00008725175,0.0011011078,0.00001697352,0.0018509699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969435,0.00006239493,0.000035041867,0.00005435668,0.00008612964,0.00006776149],"domain_scores_gemma":[0.9998573,0.000036480156,0.000027825306,0.00002812711,0.000024968718,0.000025432013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024681576,0.00035258345,0.00039902097,0.0003251635,0.00018447613,0.00032022866,0.0001447384,0.0003209365,0.0011662768],"category_scores_gemma":[0.00023049924,0.00014129693,0.00027451356,0.00038912764,0.00016632782,0.00018714588,0.00020210556,0.0006151669,0.00042317013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003659947,0.0000806831,0.00033352908,0.000060581006,0.00001081198,0.000106399864,0.000051034665,0.00007349699,0.99702966,0.0000748693,0.00009344028,0.0017195102],"study_design_scores_gemma":[0.00008078929,0.00097091025,0.0043608225,0.000010695898,0.00002529594,0.0008959513,0.00004403628,0.000888511,0.9893322,0.000038267957,0.0033469945,0.0000056959657],"about_ca_topic_score_codex":0.0014811666,"about_ca_topic_score_gemma":0.0012651321,"teacher_disagreement_score":0.0014811666,"about_ca_system_score_codex":0.0004331754,"about_ca_system_score_gemma":0.0002938669,"threshold_uncertainty_score":0.0039016008},"labels":[],"label_agreement":null},{"id":"W2108052323","doi":"10.1158/1535-7163.mct-11-0058","title":"Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ovarian Cancer Canada; Government of Ontario","keywords":"Docetaxel; Dosing; Chemotherapy; Pharmacology; Ovarian cancer; Drug resistance; Medicine; Cancer; Downregulation and upregulation; Efflux; Internal medicine; Oncology; Biology; Gene","score_opus":0.04093129730218682,"score_gpt":0.3039166700605155,"score_spread":0.2629853727583287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108052323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812526,0.0008727207,0.0004200224,0.000034670393,0.000017663479,0.000027573378,0.000109036315,0.000019281952,0.00037390253],"genre_scores_gemma":[0.9983909,0.0003788221,0.00044609915,0.000041648575,0.000010086572,0.000030961368,0.00013814354,0.000012318672,0.0005510302],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998264,0.000040196104,0.000017638506,0.00004486599,0.000053912096,0.00001707997],"domain_scores_gemma":[0.99971515,0.000083686384,0.000110976354,0.000030646304,0.000025496049,0.000034072287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012031544,0.00012785094,0.00023179557,0.00018473734,0.000063168445,0.00021822228,0.000114037415,0.00014297724,0.0009128733],"category_scores_gemma":[0.000516257,0.0001136812,0.00013576524,0.00019640743,0.000094944764,0.00018197855,0.00008353251,0.00030885058,0.000100882404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013775597,0.00025831032,0.008918185,0.00004866958,0.000021426085,0.00006964465,0.00003604331,0.00024878277,0.977354,0.000031786483,0.00008742314,0.011548123],"study_design_scores_gemma":[0.00014906046,0.009962306,0.29155236,0.000019731877,0.00016564794,0.00070195325,0.0001266907,0.0040902463,0.68757826,0.000114714065,0.0055050356,0.000034003257],"about_ca_topic_score_codex":0.00036070985,"about_ca_topic_score_gemma":0.0005725032,"teacher_disagreement_score":0.0009128733,"about_ca_system_score_codex":0.00023263691,"about_ca_system_score_gemma":0.00011643081,"threshold_uncertainty_score":0.003053844},"labels":[],"label_agreement":null},{"id":"W2108585358","doi":"10.1158/1535-7163.mct-12-1012","title":"Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Antibody; Antigen; Bispecific antibody; Fragment crystallizable region; Fc receptor; Monoclonal antibody; Cytotoxic T cell; Chemistry; Antibody-dependent cell-mediated cytotoxicity; Carcinoembryonic antigen; Receptor; Cytotoxicity; Peripheral blood mononuclear cell; Molecular biology; Cancer research; Biology; Immunology; In vitro; Biochemistry; Cancer","score_opus":0.0477747923252392,"score_gpt":0.32061872969535077,"score_spread":0.2728439373701116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108585358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778235,0.0022510365,0.017456781,0.00006107425,0.000031470216,0.00005993868,0.00013196832,0.00011517992,0.0020690265],"genre_scores_gemma":[0.98865986,0.0007722696,0.0077565648,0.00008129631,0.000011044025,0.00006132794,0.0003305551,0.000016371023,0.0023106528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.000016879674,0.000009383125,0.00003494096,0.00003507932,0.000028028579],"domain_scores_gemma":[0.9999238,0.000008620863,0.00003364236,0.000008047545,0.000010532627,0.00001541979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015449694,0.00036385795,0.00016544551,0.00019673526,0.000059262653,0.00020453558,0.00031869428,0.00034663623,0.00072653394],"category_scores_gemma":[0.00009727705,0.00012695318,0.00019899369,0.000114887785,0.00013181403,0.0002640107,0.00017234463,0.00041394777,0.00030407912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055558045,0.000037761944,0.00007732406,0.00003788404,0.000005740658,0.000018083061,0.000007714939,0.00017660503,0.9967753,0.00013090484,0.000030864052,0.0026462793],"study_design_scores_gemma":[0.000025268288,0.0005068514,0.0008068147,0.0000034436798,0.000012741391,0.00012962623,0.0000056833946,0.0008574327,0.99518234,0.000023492626,0.0024421131,0.0000041630637],"about_ca_topic_score_codex":0.00012615672,"about_ca_topic_score_gemma":0.00022403283,"teacher_disagreement_score":0.00072653394,"about_ca_system_score_codex":0.00020893171,"about_ca_system_score_gemma":0.00008837908,"threshold_uncertainty_score":0.002430439},"labels":[],"label_agreement":null},{"id":"W2110033484","doi":"10.1158/1535-7163.mct-07-0302","title":"Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Gene silencing; Cyclin D1; Biology; Small interfering RNA; Cancer research; Apoptosis; Molecular biology; Cell culture; Cell cycle; Biochemistry; Genetics; Transfection; Gene","score_opus":0.043564459720718846,"score_gpt":0.26053918392861986,"score_spread":0.216974724207901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110033484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930016,0.0016098516,0.0031513534,0.00018049603,0.000042232226,0.00012311836,0.0003588555,0.00020737277,0.0013251666],"genre_scores_gemma":[0.9937763,0.00095265906,0.002049768,0.00005156154,0.00001293352,0.00018456834,0.000535781,0.000028048498,0.0024084132],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997825,0.00003978551,0.000018646151,0.00004057532,0.00007230904,0.000046173307],"domain_scores_gemma":[0.9998568,0.000019517476,0.000049108967,0.000024169154,0.000011187674,0.000039196268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022479007,0.000569346,0.0003948426,0.000556303,0.00023157487,0.0003895268,0.00037297816,0.00042339426,0.0014607788],"category_scores_gemma":[0.00013075683,0.00020409471,0.00032851505,0.00032259146,0.00040009717,0.00037635883,0.00024071996,0.0011407601,0.00031520965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039813513,0.00024113941,0.00025430394,0.00004253016,0.000009840011,0.000090121146,0.000025559879,0.000071116556,0.99702054,0.00014753186,0.00006074389,0.0016382935],"study_design_scores_gemma":[0.00017848882,0.0032295948,0.0027199208,0.00000730115,0.000043273212,0.00064377696,0.000052314823,0.0009202716,0.989317,0.0001037162,0.0027779317,0.0000063912717],"about_ca_topic_score_codex":0.0005363497,"about_ca_topic_score_gemma":0.0010228514,"teacher_disagreement_score":0.0014607788,"about_ca_system_score_codex":0.00049660436,"about_ca_system_score_gemma":0.00026098223,"threshold_uncertainty_score":0.004886806},"labels":[],"label_agreement":null},{"id":"W2110468894","doi":"10.1158/1535-7163.mct-05-0244","title":"Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Paclitaxel; Lung cancer; Internal medicine; Oncology; Chemotherapy; Tubulin; Survival analysis; Medicine; Cancer; Prognostic variable; Cancer research; Immunology; Biology; Microtubule","score_opus":0.00737668742288458,"score_gpt":0.24447623848799582,"score_spread":0.23709955106511124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110468894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99950457,0.0001876859,0.000043758075,0.00003352083,0.0000038301214,0.0000035463227,0.00002729201,0.0000020262744,0.00019382293],"genre_scores_gemma":[0.9997447,0.00005710242,0.000023563041,0.000015544705,0.0000072021357,0.000002860951,0.00007476459,6.513382e-7,0.0000736045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988294,0.000034501023,0.000012843127,0.000019301526,0.000023463073,0.000026908758],"domain_scores_gemma":[0.99940574,0.00019904139,0.00017277288,0.000024560835,0.000057808124,0.00014011403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001961013,0.00017062499,0.0002760597,0.00026602627,0.0001937988,0.00028047344,0.00013166881,0.0002986003,0.0005992719],"category_scores_gemma":[0.0011808077,0.00011201448,0.00018557507,0.00026302607,0.00018163343,0.00018868606,0.00012113231,0.00045534692,0.00015291043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073937204,0.000056699002,0.99189997,0.000007875116,0.000027584332,0.00014530511,0.000041473846,0.00021060188,0.0033227666,0.000008427505,0.000085707776,0.0034541555],"study_design_scores_gemma":[0.000023147693,0.00052825676,0.99724305,0.000003690645,0.00003422678,0.00046519464,0.00006904828,0.0008284592,0.00060374953,0.000027100232,0.00017139492,0.0000026652272],"about_ca_topic_score_codex":0.00099164,"about_ca_topic_score_gemma":0.0014439607,"teacher_disagreement_score":0.00099164,"about_ca_system_score_codex":0.0002065934,"about_ca_system_score_gemma":0.00015439089,"threshold_uncertainty_score":0.0020047426},"labels":[],"label_agreement":null},{"id":"W2110804935","doi":"10.1158/1535-7163.mct-12-1039","title":"Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Vorinostat; DNA damage; DNA repair; Biology; Cancer research; Histone deacetylase inhibitor; Apoptosis; Downregulation and upregulation; Histone deacetylase; Myeloid leukemia; Cell cycle; Molecular biology; Cell cycle checkpoint; Histone; DNA; Biochemistry; Gene","score_opus":0.016967447127626288,"score_gpt":0.2886146272937587,"score_spread":0.27164718016613243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110804935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997698,0.00089042814,0.00072329945,0.000037427657,0.00001027702,0.000014084393,0.00011506902,0.000037457616,0.00047390212],"genre_scores_gemma":[0.9978517,0.00047751245,0.0006851965,0.00002034467,0.000005194512,0.000016306825,0.0003211145,0.000006028297,0.00061652187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998499,0.000019733154,0.000018579403,0.00002944134,0.00004910544,0.000033177294],"domain_scores_gemma":[0.9999044,0.000026834197,0.000029331712,0.0000113534425,0.000008831562,0.000019264678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013002909,0.00016891604,0.00028097554,0.00017930524,0.0000922059,0.00024265515,0.00009653225,0.00018200354,0.0009500979],"category_scores_gemma":[0.00011292384,0.00008796582,0.00021163942,0.000169727,0.00014994988,0.00016902594,0.00011400024,0.0004044011,0.00015163937],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085257016,0.000035847588,0.00029329036,0.00001309911,0.0000050202743,0.000018955245,0.000009639629,0.000041718267,0.9986186,0.000029671204,0.000016969965,0.00083200383],"study_design_scores_gemma":[0.000019109377,0.00091979874,0.007849679,0.0000032064243,0.000017815517,0.00022437198,0.000027349537,0.0009161555,0.98861957,0.000024791236,0.0013753341,0.0000028166903],"about_ca_topic_score_codex":0.00025382804,"about_ca_topic_score_gemma":0.00031936035,"teacher_disagreement_score":0.0009500979,"about_ca_system_score_codex":0.00023943561,"about_ca_system_score_gemma":0.00010087913,"threshold_uncertainty_score":0.0031784177},"labels":[],"label_agreement":null},{"id":"W2111521405","doi":"10.1158/1535-7163.mct-11-1014","title":"CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Mesothelioma Applied Research Foundation","keywords":"Blockade; Mesothelioma; Chemotherapy; Cancer research; Repopulation; Medicine; Cancer; Biology; Oncology; Immunology; Internal medicine; Pathology; Cell biology; Receptor; Stem cell","score_opus":0.018637470073894474,"score_gpt":0.2933234176663179,"score_spread":0.27468594759242343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111521405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996309,0.0008495173,0.0015932566,0.000062169405,0.000033199794,0.00004341167,0.00019813627,0.0001173144,0.0007939771],"genre_scores_gemma":[0.99440646,0.00063030253,0.002011675,0.000040904724,0.000020459334,0.00010036,0.00035065878,0.000024850604,0.002414387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981576,0.00003075632,0.000017411576,0.000033753124,0.00003817384,0.00006423189],"domain_scores_gemma":[0.99986124,0.000021598902,0.000037600425,0.00002414141,0.000010522549,0.000044969638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015150163,0.00047656812,0.00036462222,0.00044963998,0.00013169606,0.00019335415,0.00021733317,0.00025363208,0.0007873361],"category_scores_gemma":[0.00009869399,0.00021420735,0.0003594319,0.00018898079,0.00019887873,0.00017744202,0.00016164781,0.00097503635,0.00030604636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019136145,0.000120262404,0.000095975774,0.000018335351,0.0000028392076,0.00003367072,0.0000096828335,0.00011201022,0.99853873,0.000026099706,0.000021547965,0.00082943594],"study_design_scores_gemma":[0.000048112688,0.0018229857,0.0022009055,0.0000040056816,0.000019374505,0.00013447367,0.000014142447,0.0013131319,0.99353653,0.000030313227,0.0008729843,0.0000029643077],"about_ca_topic_score_codex":0.0003403875,"about_ca_topic_score_gemma":0.00057089684,"teacher_disagreement_score":0.0007873361,"about_ca_system_score_codex":0.0002329792,"about_ca_system_score_gemma":0.00021557255,"threshold_uncertainty_score":0.0026339293},"labels":[],"label_agreement":null},{"id":"W2111592390","doi":"10.1158/1535-7163.mct-09-0868","title":"Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Sorafenib; Erlotinib; Medicine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Dosing; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Hepatocellular carcinoma","score_opus":0.023696432221420247,"score_gpt":0.4094501007553262,"score_spread":0.3857536685339059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111592390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997621,0.0005752494,0.00044686644,0.000046169633,0.000012507092,0.00032782523,0.00030742923,0.000034535726,0.0006283829],"genre_scores_gemma":[0.9938625,0.0004399821,0.0009847592,0.00022102706,0.00007619226,0.0005528136,0.002824271,0.000030099336,0.0010083992],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990839,0.00037865597,0.000047317215,0.00016708064,0.00016442803,0.00015861641],"domain_scores_gemma":[0.9987625,0.00020127892,0.0001832931,0.00025952954,0.00011626289,0.0004772496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146275,0.00088580826,0.0018453898,0.00032713488,0.00050326745,0.0008135914,0.00056163396,0.00049447315,0.0015442204],"category_scores_gemma":[0.0013432442,0.00028344497,0.00071568793,0.00031758298,0.0005843315,0.0005727998,0.00047314318,0.0016016932,0.0006220061],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26358086,0.0462382,0.21373591,0.00047517507,0.0020514333,0.0035100237,0.001365227,0.0052593374,0.1836792,0.0004319973,0.006397725,0.27327496],"study_design_scores_gemma":[0.036492538,0.5521132,0.35733652,0.000052195202,0.0016737442,0.0075879367,0.00047268643,0.0050506517,0.025890153,0.00031409907,0.012929459,0.00008690034],"about_ca_topic_score_codex":0.00042616623,"about_ca_topic_score_gemma":0.00048749172,"teacher_disagreement_score":0.002146275,"about_ca_system_score_codex":0.0005905793,"about_ca_system_score_gemma":0.00089654326,"threshold_uncertainty_score":0.011350691},"labels":[],"label_agreement":null},{"id":"W2111954625","doi":"10.1158/1535-7163.mct-10-0590","title":"Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Oncolytic virus; Antigen; Cancer research; Tumor microenvironment; Virotherapy; Immunology; Biology; Immunotherapy; Dendritic cell; Antigen presentation; Tumor antigen; T cell","score_opus":0.03400446285726151,"score_gpt":0.3567167288196482,"score_spread":0.3227122659623867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111954625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266195,0.0019461589,0.0026472863,0.00012012846,0.00008059092,0.000054771495,0.00008509127,0.00023589624,0.0021681304],"genre_scores_gemma":[0.99738437,0.00068800483,0.0007755326,0.000033108958,0.000026172667,0.000020120398,0.00009604894,0.000020483378,0.0009560772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984753,0.000024868854,0.000010273852,0.00002414191,0.000035205416,0.000058006455],"domain_scores_gemma":[0.99990964,0.00002195144,0.000022748436,0.000016833901,0.000006394859,0.000022374961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010694201,0.0004789006,0.0003515304,0.00029739228,0.000091409405,0.00032076673,0.00013602687,0.0002574658,0.0008390869],"category_scores_gemma":[0.00011050355,0.00009113993,0.00020240832,0.000083172454,0.00019911383,0.00023570641,0.0001416062,0.0007793827,0.0002171368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027302006,0.00017269613,0.00013122,0.00004876054,0.000006380979,0.000067500485,0.000016325197,0.00020495719,0.992761,0.00018629966,0.00005981033,0.0060720206],"study_design_scores_gemma":[0.000063514184,0.0018013183,0.0015211428,0.000009406418,0.000024869547,0.00039285785,0.000017965556,0.0010499964,0.9920035,0.00009631069,0.0030137275,0.0000054286297],"about_ca_topic_score_codex":0.00014163037,"about_ca_topic_score_gemma":0.00026136992,"teacher_disagreement_score":0.0008390869,"about_ca_system_score_codex":0.00016944387,"about_ca_system_score_gemma":0.00020934068,"threshold_uncertainty_score":0.0028070211},"labels":[],"label_agreement":null},{"id":"W2112099873","doi":"10.1158/1535-7163.mct-06-0100","title":"A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis <i>in vivo</i>","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"Metastasis; Breast cancer; In vivo; Cancer; Cancer research; Medicine; Metastatic breast cancer; Pathology; Biology; Internal medicine","score_opus":0.019052252458583222,"score_gpt":0.2994801537536257,"score_spread":0.28042790129504247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112099873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947838,0.002319545,0.0008523682,0.000109132416,0.000043449803,0.00006857055,0.0002725602,0.00004787329,0.0015027032],"genre_scores_gemma":[0.99264985,0.0019076021,0.0024743362,0.000111171175,0.000029602461,0.00010621289,0.0008523119,0.0000135524515,0.0018552904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986887,0.000027108925,0.000014241544,0.000023050752,0.000037737223,0.000028974004],"domain_scores_gemma":[0.9999057,0.000018192657,0.000026503552,0.000008076823,0.000011450364,0.000030143045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015643382,0.00039921596,0.00034752965,0.00016412942,0.00012895411,0.00015990446,0.00026670969,0.00034076752,0.0011274209],"category_scores_gemma":[0.000099570476,0.00011792549,0.00021640596,0.000119917306,0.00022645746,0.00017390559,0.00008921448,0.00054527976,0.00041276054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029083184,0.00018370648,0.00013423292,0.00008675206,0.000006963411,0.000045156332,0.000007793996,0.00012472262,0.9972664,0.000029594003,0.00007737987,0.0017464593],"study_design_scores_gemma":[0.000105587256,0.005169688,0.0027077228,0.000008834282,0.000026171769,0.0003571995,0.000011754148,0.000538486,0.98952734,0.000015677511,0.0015249365,0.000006602421],"about_ca_topic_score_codex":0.00055305293,"about_ca_topic_score_gemma":0.00095723924,"teacher_disagreement_score":0.0011274209,"about_ca_system_score_codex":0.0002387326,"about_ca_system_score_gemma":0.00031088424,"threshold_uncertainty_score":0.003771603},"labels":[],"label_agreement":null},{"id":"W2112317932","doi":"10.1158/1535-7163.mct-08-0326","title":"Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"XIAP; Troglitazone; Inhibitor of apoptosis; Apoptosis; Cancer research; Angiogenesis; Chemistry; Cancer cell; Peroxisome proliferator-activated receptor; Receptor; Biology; Cancer; Programmed cell death; Caspase; Biochemistry","score_opus":0.01924725001374443,"score_gpt":0.26673867782384786,"score_spread":0.24749142781010341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112317932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156684,0.004360252,0.0015624054,0.00013988424,0.00008493257,0.000055494787,0.00037984885,0.00012103861,0.0017292991],"genre_scores_gemma":[0.99348927,0.0024324832,0.0014421012,0.00006893225,0.000014621215,0.00005014469,0.0006079695,0.000010439799,0.0018841238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999884,0.000020638648,0.000012453864,0.000022068129,0.000030484265,0.000030348974],"domain_scores_gemma":[0.9999472,0.0000078906305,0.000015067096,0.000008538733,0.000006578875,0.000014828466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001136825,0.0003538278,0.00036718955,0.0002851534,0.00010947372,0.0002912309,0.00013361748,0.0001759285,0.0008748652],"category_scores_gemma":[0.00008750183,0.00011306326,0.00023772365,0.00031950898,0.00014735489,0.00016031499,0.00017957695,0.0005178516,0.00026626227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033812615,0.000086370885,0.0002397995,0.0000739331,0.000014791599,0.00008620532,0.000017703276,0.00014240952,0.99591076,0.00006489562,0.000115531606,0.0029094587],"study_design_scores_gemma":[0.00008584348,0.0016489713,0.0044225054,0.000010143751,0.000043395372,0.00038504126,0.000030948744,0.001189909,0.9880337,0.000031303705,0.004112414,0.0000058598],"about_ca_topic_score_codex":0.00061592105,"about_ca_topic_score_gemma":0.0012709814,"teacher_disagreement_score":0.0008748652,"about_ca_system_score_codex":0.0002722875,"about_ca_system_score_gemma":0.00028274377,"threshold_uncertainty_score":0.0029267669},"labels":[],"label_agreement":null},{"id":"W2112332697","doi":"10.1158/1535-7163.mct-07-0172","title":"Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Survivin; Chromatin immunoprecipitation; Promoter; Cancer research; Molecular biology; Biology; Small interfering RNA; Cancer cell; Sp1 transcription factor; Transcription factor; Gene expression; Transcription (linguistics); LNCaP; Chemistry; Cancer; Gene; Biochemistry; Transfection; Genetics","score_opus":0.0330193369078273,"score_gpt":0.30994565275181263,"score_spread":0.2769263158439853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112332697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791627,0.008954492,0.0086928215,0.00022613506,0.00007973634,0.000035693913,0.000113069305,0.00008546689,0.0026499168],"genre_scores_gemma":[0.98836553,0.005086951,0.0025403362,0.00007459691,0.000016944436,0.00003142341,0.0002833693,0.000016870119,0.003583926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998827,0.000026423393,0.0000112230355,0.000023241435,0.000028908356,0.000027470714],"domain_scores_gemma":[0.9999244,0.000021246617,0.000018087087,0.000008296271,0.000016662987,0.000011190607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014176995,0.00033905555,0.00029530827,0.00019004583,0.0001357017,0.0001885057,0.00025997616,0.00025071853,0.0012221634],"category_scores_gemma":[0.00015735206,0.00012147434,0.00025036812,0.00012517114,0.00024266257,0.00015351453,0.00023033623,0.00052594667,0.00023510825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007775728,0.000026866124,0.00014824119,0.000071193135,0.000006345889,0.000043361648,0.0000136550225,0.0000357986,0.99706656,0.00012967092,0.00003894594,0.0023416942],"study_design_scores_gemma":[0.000016909502,0.0004606593,0.001966345,0.000009136141,0.000015327378,0.00013633058,0.000026803333,0.0005016668,0.9940089,0.000081541824,0.0027733792,0.0000029261575],"about_ca_topic_score_codex":0.000579791,"about_ca_topic_score_gemma":0.0010436017,"teacher_disagreement_score":0.0012221634,"about_ca_system_score_codex":0.00018313157,"about_ca_system_score_gemma":0.00025556696,"threshold_uncertainty_score":0.004088521},"labels":[],"label_agreement":null},{"id":"W2113026440","doi":"10.1158/1535-7163.mct-08-0400","title":"Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Mitochondrial Function and Pathology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Geldanamycin; MAPK/ERK pathway; Protein kinase B; Cancer research; Protein kinase A; Chemistry; p38 mitogen-activated protein kinases; Caspase 8; Kinase; Cell biology; Biology; Molecular biology; Programmed cell death; Apoptosis; Hsp90; Signal transduction; Caspase; Biochemistry; Heat shock protein","score_opus":0.02153823245135176,"score_gpt":0.2646778597574336,"score_spread":0.24313962730608182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113026440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882095,0.004593959,0.0018802845,0.00016920794,0.00009216624,0.00011458367,0.0004987214,0.00019293657,0.0042485613],"genre_scores_gemma":[0.9902227,0.0026153447,0.0029106713,0.00009231085,0.000030466508,0.00017040888,0.0008493016,0.000025031062,0.0030838868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998419,0.000030150693,0.000014496057,0.000020883761,0.000039378974,0.000053156575],"domain_scores_gemma":[0.999912,0.000017916627,0.000021306776,0.000013468937,0.000009076512,0.000026165155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001341268,0.00065516756,0.00044355742,0.0003050885,0.00012396243,0.00022515815,0.00019758703,0.00023220945,0.0013671694],"category_scores_gemma":[0.000108730994,0.00017114166,0.0004832609,0.00017124711,0.0001798988,0.00015740235,0.00017591643,0.00056938094,0.00040904578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005770729,0.00018968177,0.0002373882,0.000113591705,0.000035760502,0.00011229573,0.000032170043,0.0002637195,0.9935446,0.00012832369,0.00021471285,0.004550735],"study_design_scores_gemma":[0.000095941126,0.0019519534,0.002807005,0.0000061803307,0.000032306518,0.00046738487,0.000020975851,0.0005329745,0.9900175,0.000041166128,0.004020728,0.000005990947],"about_ca_topic_score_codex":0.0005645509,"about_ca_topic_score_gemma":0.0012314463,"teacher_disagreement_score":0.0013671694,"about_ca_system_score_codex":0.00032488775,"about_ca_system_score_gemma":0.00030679977,"threshold_uncertainty_score":0.004573703},"labels":[],"label_agreement":null},{"id":"W2114383393","doi":"10.1158/1535-7163.mct-10-0735","title":"Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Windsor","funders":"National Research Council Canada","keywords":"Apoptosis; Programmed cell death; Cancer cell; Biology; Cancer research; Mitochondrion; Cell culture; Molecular biology; Terminal deoxynucleotidyl transferase; Cancer; Cell biology; TUNEL assay; Biochemistry; Genetics","score_opus":0.022704713456772243,"score_gpt":0.2597427636189568,"score_spread":0.23703805016218457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114383393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937251,0.0023500954,0.0011615683,0.00012407484,0.000029197465,0.000033392826,0.00057914393,0.00012964066,0.0018679438],"genre_scores_gemma":[0.9940654,0.001525692,0.0011433511,0.000049987404,0.000008545983,0.000025957768,0.00076582364,0.000025253268,0.0023899043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999925,0.000009886425,0.000006013709,0.000016228021,0.000024161607,0.000018666888],"domain_scores_gemma":[0.9999019,0.000012167142,0.000029106457,0.000011510602,0.00001641522,0.000028846092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006693197,0.0002953125,0.0002809027,0.00016312808,0.000086642875,0.00014229814,0.00012653912,0.00020785673,0.0008443531],"category_scores_gemma":[0.000074040865,0.00009095605,0.00012355823,0.00013471128,0.00009353418,0.0001292535,0.00010098163,0.0004737064,0.00029633037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008779767,0.000024288585,0.000111834204,0.000021958944,0.0000030313936,0.000019298437,0.000006593836,0.000028932229,0.99888057,0.0000127237545,0.00004249478,0.0007606223],"study_design_scores_gemma":[0.000019695384,0.0012152429,0.005072381,0.000004433209,0.000015260195,0.00030542462,0.000019729203,0.00059758103,0.9907851,0.0000136499075,0.0019491711,0.0000023241705],"about_ca_topic_score_codex":0.0010169791,"about_ca_topic_score_gemma":0.0021224965,"teacher_disagreement_score":0.0010169791,"about_ca_system_score_codex":0.00020309305,"about_ca_system_score_gemma":0.00017435553,"threshold_uncertainty_score":0.002824664},"labels":[],"label_agreement":null},{"id":"W2114788766","doi":"10.1158/1535-7163.mct-06-0417","title":"Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; University of British Columbia Hospital","funders":"","keywords":"Hsp27; Gene knockdown; Paclitaxel; Cancer research; Bladder cancer; Heat shock protein; Apoptosis; Cell growth; Cancer cell; In vivo; Biology; Cancer; Medicine; Hsp70; Internal medicine; Biochemistry","score_opus":0.020248630632105562,"score_gpt":0.32835803411700953,"score_spread":0.30810940348490395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114788766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993353,0.0026047435,0.001646294,0.00011984659,0.000021721778,0.000042092342,0.00016515265,0.00009743133,0.0019497056],"genre_scores_gemma":[0.9929859,0.0018246437,0.0015893197,0.000046291087,0.0000071132067,0.000046627556,0.0003565061,0.000020645693,0.0031228852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994767,0.0000102349795,0.000004376321,0.000009351872,0.000014510593,0.000013833037],"domain_scores_gemma":[0.99996674,0.000006677372,0.000008520336,0.0000058041505,0.0000039667557,0.000008373519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070342765,0.0002241044,0.0002607907,0.00013981594,0.00013456134,0.00018012055,0.00011550139,0.000137063,0.0012090286],"category_scores_gemma":[0.00008147293,0.00011463959,0.0001318789,0.00012717345,0.00013726352,0.00009816547,0.00013522904,0.00027810942,0.0003272746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001204833,0.00007322283,0.00013331644,0.00004895844,0.000008522903,0.000036446618,0.000018877428,0.0003325696,0.99486995,0.00012043976,0.00018787279,0.0040493333],"study_design_scores_gemma":[0.000028299844,0.00047090003,0.0016251955,0.00000480732,0.000017634964,0.00012389211,0.000015415762,0.0010919754,0.9929981,0.000029464698,0.003591441,0.000002893118],"about_ca_topic_score_codex":0.0012177918,"about_ca_topic_score_gemma":0.002814863,"teacher_disagreement_score":0.0012177918,"about_ca_system_score_codex":0.00022603337,"about_ca_system_score_gemma":0.0002777983,"threshold_uncertainty_score":0.0040445924},"labels":[],"label_agreement":null},{"id":"W2114905010","doi":"10.1158/1535-7163.1127.3.9","title":"Brain tumor cell lines resistant to <i>O</i>6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have <i>O</i>6-alkylguanine-DNA alkyltransferase mutations","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Carmustine; Nitrosourea; Cell culture; Cancer research; Biology; Molecular biology; Chemotherapy; Etoposide; Genetics","score_opus":0.01190603776951182,"score_gpt":0.2658752838930298,"score_spread":0.25396924612351796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114905010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933749,0.0004962139,0.0025406817,0.000050956085,0.000012629824,0.0001125685,0.0015083858,0.00007804072,0.0018255108],"genre_scores_gemma":[0.98055536,0.00069226394,0.010566687,0.000045390403,0.000006329898,0.00012272682,0.0047266637,0.000037600545,0.0032470399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999811,0.000021716536,0.00002996576,0.000037886337,0.00006412082,0.00003534178],"domain_scores_gemma":[0.9998956,0.000018434148,0.000025545532,0.000026863203,0.000013133822,0.000020470308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013896755,0.00042714964,0.0003325846,0.00027858766,0.00016108635,0.00023209081,0.00029566805,0.00020652878,0.00090345193],"category_scores_gemma":[0.00012453171,0.00015892084,0.00028322186,0.0002620284,0.00021463935,0.0000973563,0.0001681731,0.0004803778,0.00056995405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007457175,0.000053458898,0.00088489155,0.0000255809,0.000008817317,0.000100475954,0.000030948464,0.000105043735,0.99743515,0.0001519754,0.00007373579,0.0010553778],"study_design_scores_gemma":[0.000040755036,0.0006587561,0.011341031,0.000004717504,0.000031610827,0.0008978611,0.000056129265,0.0010335648,0.9803423,0.000055270553,0.0055298842,0.000008065647],"about_ca_topic_score_codex":0.0034172793,"about_ca_topic_score_gemma":0.0061832983,"teacher_disagreement_score":0.0034172793,"about_ca_system_score_codex":0.00032426455,"about_ca_system_score_gemma":0.0002858543,"threshold_uncertainty_score":0.0067948103},"labels":[],"label_agreement":null},{"id":"W2115427861","doi":"10.1158/1535-7163.mct-05-0302","title":"Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"STAT3; STAT protein; Paclitaxel; Cancer research; Head and neck squamous-cell carcinoma; Apoptosis; Activator (genetics); Chemistry; Cancer; Medicine; Biology; Head and neck cancer; Internal medicine; Receptor","score_opus":0.02353293548528013,"score_gpt":0.2876131956695739,"score_spread":0.26408026018429376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115427861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593598,0.027060397,0.008827304,0.0007330088,0.00015145502,0.00021581208,0.0002947861,0.00020650652,0.0031509844],"genre_scores_gemma":[0.9708055,0.018947206,0.0065093986,0.0003411678,0.00003583303,0.00012664008,0.00031970209,0.000010070753,0.002904479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99997807,0.0000028980635,0.0000010536146,0.0000048561446,0.0000057369566,0.0000074348723],"domain_scores_gemma":[0.9999932,7.671212e-7,0.0000022289155,5.332848e-7,9.65734e-7,0.000002244213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006520607,0.00022270855,0.00017226939,0.0001752693,0.000059507074,0.00010520411,0.000174739,0.0002258466,0.0005910804],"category_scores_gemma":[0.000023213897,0.000058792193,0.00019045762,0.00012501309,0.00015132938,0.00012596956,0.00011736749,0.0003121917,0.00009854663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023543338,0.00014490071,0.00024623115,0.00017707968,0.000012040717,0.00009706859,0.000022867163,0.0004826428,0.96927446,0.00046309142,0.0002907644,0.02855342],"study_design_scores_gemma":[0.00056707603,0.006809781,0.0083495155,0.000051786443,0.00014564687,0.0010977947,0.00006860609,0.004867871,0.93506414,0.00064593414,0.042293873,0.000038020287],"about_ca_topic_score_codex":0.0006669139,"about_ca_topic_score_gemma":0.0017687719,"teacher_disagreement_score":0.0006669139,"about_ca_system_score_codex":0.00024109987,"about_ca_system_score_gemma":0.00019581804,"threshold_uncertainty_score":0.0019773245},"labels":[],"label_agreement":null},{"id":"W2117096084","doi":"10.1158/1535-7163.mct-08-0753","title":"UBE1L causes lung cancer growth suppression by targeting cyclin D1","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cyclin D1; Cancer research; Cyclin B; Cyclin D; Cyclin; Biology; Cyclin A; Cyclin A2; Cyclin E; Cell cycle; Gene knockdown; Molecular biology; Cancer; Biochemistry; Apoptosis; Genetics","score_opus":0.01612231471546178,"score_gpt":0.2856829874855768,"score_spread":0.26956067277011503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117096084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922948,0.0023919374,0.0017280198,0.00029292353,0.00011847648,0.00007834618,0.00065440376,0.00024254194,0.002198534],"genre_scores_gemma":[0.9927965,0.0010092825,0.0009180293,0.00010463263,0.000015339752,0.000060030136,0.00068985194,0.000023490904,0.0043827086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998104,0.00002661642,0.000021262395,0.00004360339,0.000043926604,0.00005418545],"domain_scores_gemma":[0.9998988,0.000017206612,0.000025570916,0.000016642678,0.000009544698,0.000032174798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021803885,0.00034629274,0.00040533414,0.00029033463,0.00021584917,0.00033754858,0.00026698853,0.00039808685,0.0018708613],"category_scores_gemma":[0.00011008747,0.00016262736,0.0003237169,0.00019153829,0.00032909308,0.00014765278,0.0001499712,0.000934593,0.00041361587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059077423,0.0003031163,0.00020381244,0.000069646376,0.000012140492,0.00007667292,0.0000144694495,0.00011272405,0.9948632,0.0001482254,0.0001807065,0.003424674],"study_design_scores_gemma":[0.000090162015,0.001370462,0.0019271121,0.0000043781147,0.00002428963,0.000228344,0.000015098296,0.00069138524,0.992265,0.00003384709,0.0033465822,0.0000034800676],"about_ca_topic_score_codex":0.000655473,"about_ca_topic_score_gemma":0.0008399956,"teacher_disagreement_score":0.0018708613,"about_ca_system_score_codex":0.0004807658,"about_ca_system_score_gemma":0.00032745724,"threshold_uncertainty_score":0.0062586665},"labels":[],"label_agreement":null},{"id":"W2117428432","doi":"10.1158/1535-7163.mct-13-0842","title":"The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; IRS1; Cancer research; Insulin-like growth factor 1 receptor; Downregulation and upregulation; Protein kinase B; PI3K/AKT/mTOR pathway; Androgen receptor; MAPK/ERK pathway; Endocrinology; Insulin receptor; Cancer; Signal transduction; Internal medicine; Biology; Growth factor; Receptor; Medicine; Insulin; Insulin resistance; Cell biology; Biochemistry","score_opus":0.014327079659651961,"score_gpt":0.2817261972726698,"score_spread":0.2673991176130178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117428432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672407,0.000950405,0.00055576605,0.00005791946,0.000030574054,0.000035839752,0.00013884301,0.00005932737,0.0014473833],"genre_scores_gemma":[0.99671197,0.00070781086,0.00051473326,0.000034552828,0.000008894004,0.000022746382,0.00032771367,0.000009644219,0.0016619263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994326,0.000007443396,0.000004431754,0.000007084652,0.000025712861,0.000011997285],"domain_scores_gemma":[0.999954,0.00000565702,0.000013108936,0.000004051296,0.0000065805075,0.000016610582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007455381,0.00031135348,0.00031161422,0.0001862311,0.000084206644,0.00017532229,0.00019624065,0.00016236983,0.0011830161],"category_scores_gemma":[0.000070974245,0.000087150416,0.00018796223,0.00010592213,0.000116584575,0.00011253889,0.000087448025,0.000538443,0.00020577302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044946442,0.00041316627,0.00026655215,0.000052446103,0.000012631101,0.00006026754,0.000012848831,0.00029550507,0.9911747,0.00008254771,0.0001482066,0.007031584],"study_design_scores_gemma":[0.00014531282,0.0067291334,0.0076388344,0.000010708785,0.000038103597,0.00045973394,0.00002961783,0.0021910488,0.97864175,0.00003553306,0.0040716073,0.000008567518],"about_ca_topic_score_codex":0.00070464396,"about_ca_topic_score_gemma":0.0016560473,"teacher_disagreement_score":0.0011830161,"about_ca_system_score_codex":0.00023099779,"about_ca_system_score_gemma":0.00027320647,"threshold_uncertainty_score":0.0039575696},"labels":[],"label_agreement":null},{"id":"W2117514750","doi":"10.1158/1535-7163.mct-07-2376","title":"Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death<i>in vitro</i>and<i>in vivo</i>","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"In vivo; In vitro; Programmed cell death; Cancer research; Chemistry; Transient (computer programming); Cell culture; Cell biology; Biology; Apoptosis; Pharmacology; Biochemistry; Genetics","score_opus":0.014835812172876427,"score_gpt":0.22654438564568544,"score_spread":0.211708573472809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117514750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316025,0.0014947053,0.0020326674,0.000102800834,0.00007057512,0.000054415177,0.0005882245,0.00010615475,0.002390223],"genre_scores_gemma":[0.9891726,0.0014939562,0.0028786147,0.000067890425,0.000011787082,0.00014009692,0.0019508755,0.000023723185,0.004260458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979526,0.000033479868,0.000017255998,0.00004135817,0.000048352507,0.00006430333],"domain_scores_gemma":[0.9999248,0.000015198199,0.00001587146,0.000015784512,0.000007327317,0.000021142952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001214228,0.00042681326,0.00036839378,0.00015626998,0.0002102318,0.0002804419,0.00023526185,0.0002387631,0.0016604419],"category_scores_gemma":[0.000062009385,0.00015981331,0.0004225981,0.00021818465,0.00022246534,0.0001701011,0.0001538017,0.0009015893,0.00045792444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032916863,0.00011923039,0.00017902153,0.000030373652,0.00001194934,0.000043912256,0.000018822002,0.000098642435,0.9980551,0.000097861164,0.00008163261,0.00093433855],"study_design_scores_gemma":[0.000008537771,0.00047333256,0.001122111,0.000001843948,0.000009494307,0.00007085223,0.000015433652,0.0003005222,0.99720424,0.0000082541565,0.0007834463,0.0000017732433],"about_ca_topic_score_codex":0.0016511242,"about_ca_topic_score_gemma":0.0031368956,"teacher_disagreement_score":0.0016604419,"about_ca_system_score_codex":0.0004540438,"about_ca_system_score_gemma":0.0003632057,"threshold_uncertainty_score":0.0055547357},"labels":[],"label_agreement":null},{"id":"W2118283685","doi":"10.1158/1535-7163.mct-09-0478","title":"Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i> 6-methylguanine-DNA methyltransferase","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; McGill University; University of British Columbia; Montreal Children's Hospital; BC Cancer Agency","funders":"C17 Council; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Temozolomide; Methyltransferase; Cancer research; Medicine; Glioblastoma; O-6-methylguanine-DNA methyltransferase; Cancer; Brain tumor; Internal medicine; Oncology; Gene; Biology; Pathology; Methylation; Biochemistry","score_opus":0.013756989929822161,"score_gpt":0.27043612883997775,"score_spread":0.2566791389101556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118283685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401605,0.0033345793,0.0013479902,0.00013479234,0.00004658343,0.00002743939,0.00020953981,0.00011356651,0.0007694885],"genre_scores_gemma":[0.9932933,0.0030982299,0.0013119193,0.00006840019,0.000010111337,0.00003837529,0.00047438638,0.000013390581,0.0016919018],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995494,0.0000054790303,0.0000037713467,0.000007884531,0.000010527591,0.000017437398],"domain_scores_gemma":[0.99997056,0.0000031135364,0.000009048339,0.0000024985825,0.0000041324824,0.00001057966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009851666,0.00031039468,0.00027453946,0.0001458897,0.00007478023,0.00014833847,0.00017984254,0.00012063296,0.00057618105],"category_scores_gemma":[0.00006058527,0.00008346826,0.00015117075,0.00009286426,0.0001141226,0.000114548675,0.00009211924,0.00054306915,0.00014785031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002630118,0.00011320943,0.00039716554,0.00006430009,0.000015849606,0.000030479061,0.000016364427,0.00012278506,0.9939458,0.00008197725,0.00022469212,0.0047244304],"study_design_scores_gemma":[0.000058579113,0.0020116658,0.012742293,0.000011025937,0.000042315416,0.00021077754,0.000026081632,0.0017223436,0.9779025,0.0000403114,0.00522493,0.0000070503434],"about_ca_topic_score_codex":0.0012148687,"about_ca_topic_score_gemma":0.002650197,"teacher_disagreement_score":0.0012148687,"about_ca_system_score_codex":0.00022806635,"about_ca_system_score_gemma":0.00023929091,"threshold_uncertainty_score":0.0024155974},"labels":[],"label_agreement":null},{"id":"W2118566193","doi":"10.1158/1535-7163.mct-05-0030","title":"The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sesquiterpenes and Asteraceae Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Parthenolide; Docetaxel; In vivo; Medicine; Pharmacology; Cancer research; Sesquiterpene lactone; Metastasis; Apoptosis; In vitro; Cancer; Internal medicine; Chemistry; Biology; Sesquiterpene; Biochemistry; Stereochemistry","score_opus":0.017568944458584736,"score_gpt":0.2848227319139941,"score_spread":0.26725378745540934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118566193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499136,0.0029888833,0.00080099714,0.00010534849,0.000043611195,0.00005121536,0.00022901947,0.00007519546,0.0007143282],"genre_scores_gemma":[0.99150777,0.0036620768,0.0012494416,0.00006360674,0.00002290286,0.000065124885,0.00058184395,0.000020507214,0.002826713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999007,0.00001854901,0.0000069483076,0.000013577632,0.00003352705,0.000026749372],"domain_scores_gemma":[0.99992216,0.000009015722,0.000024540344,0.000008464448,0.0000063006423,0.000029461306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098672346,0.00052504684,0.00068631856,0.00035303042,0.00010823332,0.00023733797,0.00028057588,0.0002454818,0.0008197141],"category_scores_gemma":[0.00007401953,0.00014648365,0.00022715553,0.00029157737,0.00018690103,0.0002370625,0.00009344993,0.00066881423,0.00022124377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093264255,0.0005590153,0.0002194478,0.00007641302,0.000030380106,0.000045192814,0.000014217511,0.00031201215,0.9921228,0.000037110694,0.00014717341,0.0055035567],"study_design_scores_gemma":[0.00035423788,0.01700723,0.009588063,0.000012892806,0.00014027432,0.00032213825,0.000049524664,0.0016198059,0.9665763,0.000048107504,0.004265234,0.000016329024],"about_ca_topic_score_codex":0.001245995,"about_ca_topic_score_gemma":0.004436955,"teacher_disagreement_score":0.001245995,"about_ca_system_score_codex":0.0003469945,"about_ca_system_score_gemma":0.0002651663,"threshold_uncertainty_score":0.002742231},"labels":[],"label_agreement":null},{"id":"W2119142674","doi":"10.1158/1535-7163.mct-04-0107","title":"Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2–related protein Bad","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Trichostatin A; Histone deacetylase; Histone deacetylase inhibitor; Apoptosis; Cancer research; Cell cycle checkpoint; Biology; Cell cycle; Viability assay; Cell biology; Molecular biology; Chemistry; Histone; Genetics; Gene","score_opus":0.011151770276515777,"score_gpt":0.27048365189860496,"score_spread":0.2593318816220892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119142674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979183,0.00034377107,0.00045739138,0.000044531527,0.00001752095,0.000038360697,0.00027587582,0.000039263574,0.000864987],"genre_scores_gemma":[0.99596006,0.0004855747,0.0008030492,0.000040124265,0.000008073066,0.00007059975,0.00078736135,0.000014491951,0.0018308175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998988,0.0000134971,0.0000139332205,0.000014015528,0.000030525884,0.000029194185],"domain_scores_gemma":[0.99991,0.000018073137,0.000016923179,0.000017199847,0.000011004479,0.000026816491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009212961,0.00023214988,0.0002804887,0.00028673213,0.00011991615,0.00017476415,0.0001689858,0.00016839003,0.0010050806],"category_scores_gemma":[0.00011183156,0.00015198185,0.00026744686,0.00026222382,0.00013059011,0.000120947974,0.00012801819,0.00047201544,0.00029208543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018600165,0.00008157762,0.00030601048,0.000020387655,0.000010031945,0.00005657953,0.000020458865,0.000089403955,0.9982222,0.000059045426,0.00007320232,0.0008751383],"study_design_scores_gemma":[0.00006789833,0.0011094235,0.0091480715,0.0000028975685,0.000016157594,0.00021606812,0.000029723209,0.0011980482,0.9867936,0.00003112943,0.001383665,0.0000034024652],"about_ca_topic_score_codex":0.0010415085,"about_ca_topic_score_gemma":0.0016138824,"teacher_disagreement_score":0.0010415085,"about_ca_system_score_codex":0.00027349472,"about_ca_system_score_gemma":0.0002191861,"threshold_uncertainty_score":0.0033623576},"labels":[],"label_agreement":null},{"id":"W2119501278","doi":"10.1158/1535-7163.mct-07-0299","title":"TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gemcitabine; Pancreatic cancer; Cytotoxicity; Combination therapy; Apoptosis; Cancer research; Medicine; Monoclonal antibody; Pancreatic tumor; Pharmacology; Growth inhibition; Cancer; Internal medicine; Oncology; In vitro; Antibody; Immunology; Chemistry; Biochemistry","score_opus":0.013922291159863435,"score_gpt":0.2705841328905045,"score_spread":0.25666184173064105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119501278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994886,0.0016207497,0.0017629324,0.000054799897,0.000023828577,0.000049174665,0.00012627216,0.000058668098,0.0014176797],"genre_scores_gemma":[0.9935905,0.0009616093,0.002714688,0.000032069926,0.000007905143,0.00005905924,0.00039395833,0.000009050948,0.0022313043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998085,0.00003675396,0.000015384467,0.000040206425,0.00005701247,0.000042185104],"domain_scores_gemma":[0.9999163,0.000010717629,0.000027628203,0.000012626937,0.0000084865615,0.000024223644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019264751,0.00049976126,0.00034676678,0.00033321363,0.000117671974,0.00024314475,0.00023305585,0.0003055787,0.0013694637],"category_scores_gemma":[0.000092009686,0.00016271732,0.00029982437,0.00020072474,0.00017264958,0.00022223301,0.0001506303,0.0006234504,0.0002860266],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061295746,0.00044359104,0.0006314602,0.00008207527,0.000022229868,0.00006261669,0.000021661632,0.00030182535,0.9935393,0.00006303303,0.00010306766,0.00411613],"study_design_scores_gemma":[0.0001195239,0.0052752565,0.0061233947,0.000008734433,0.00006335009,0.000642231,0.000040267696,0.0014943382,0.9842672,0.00002023775,0.0019409184,0.0000044879616],"about_ca_topic_score_codex":0.0008765796,"about_ca_topic_score_gemma":0.0018437086,"teacher_disagreement_score":0.0013694637,"about_ca_system_score_codex":0.00037619346,"about_ca_system_score_gemma":0.0003108724,"threshold_uncertainty_score":0.004581332},"labels":[],"label_agreement":null},{"id":"W2119528020","doi":"10.1158/1535-7163.mct-12-0072","title":"Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Hsp27; Autophagy; Unfolded protein response; Gene silencing; Endoplasmic reticulum; Cell biology; Cancer research; Cancer cell; Programmed cell death; Biology; Heat shock protein; Apoptosis; Cancer; Hsp70; Biochemistry","score_opus":0.020288330371814704,"score_gpt":0.3277551220036669,"score_spread":0.3074667916318522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119528020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938526,0.0017381884,0.0030205245,0.00009089634,0.00003190016,0.00007123725,0.00013638545,0.00013595264,0.00092229753],"genre_scores_gemma":[0.99507767,0.0009939749,0.0025175784,0.000039347236,0.000010387938,0.00004276984,0.00014720098,0.00002256948,0.0011485029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989617,0.00001660446,0.0000089163705,0.000020904343,0.00003093341,0.0000263607],"domain_scores_gemma":[0.99994004,0.0000075786143,0.000014530381,0.0000095595215,0.00000633806,0.00002201954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011484254,0.0003367778,0.00043256363,0.00029859404,0.00017241153,0.00033058514,0.0002393055,0.00020389905,0.00067066104],"category_scores_gemma":[0.00007086874,0.00020586289,0.0002847158,0.00024455483,0.00025016672,0.00017166318,0.0002632328,0.00056453154,0.00019263409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013728008,0.00008410927,0.000109488676,0.00004097939,0.000015339745,0.000043996977,0.000011396204,0.00041521835,0.99623114,0.00015166562,0.000055095697,0.0027042697],"study_design_scores_gemma":[0.000046677575,0.001144054,0.0017248172,0.0000035917622,0.000044019635,0.00028813098,0.000015381214,0.0012530709,0.99298805,0.00005029699,0.0024331268,0.000008759139],"about_ca_topic_score_codex":0.0007649897,"about_ca_topic_score_gemma":0.0025980498,"teacher_disagreement_score":0.0007649897,"about_ca_system_score_codex":0.0003965788,"about_ca_system_score_gemma":0.00036383644,"threshold_uncertainty_score":0.0028774142},"labels":[],"label_agreement":null},{"id":"W2119722464","doi":"10.1158/1535-7163.mct-04-0315","title":"Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Irinotecan; Chemistry; Camptothecin; Pharmacokinetics; Apoptosis; Pharmacology; Cancer research; Biochemistry; Cancer; Biology; Medicine; Internal medicine","score_opus":0.022519276494559825,"score_gpt":0.321063407416807,"score_spread":0.2985441309222472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119722464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874,0.00038607809,0.0002404961,0.000021151256,0.000005862848,0.00001548965,0.00034229143,0.000017690174,0.00023092756],"genre_scores_gemma":[0.9982718,0.00022066853,0.00038739582,0.000018979554,0.000002129792,0.000027310545,0.00043349876,0.0000043354626,0.0006337771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990165,0.000016429485,0.000006017183,0.00002021717,0.00003107533,0.000024671906],"domain_scores_gemma":[0.99995804,0.0000076975775,0.000009415201,0.000005651155,0.000007645581,0.000011605241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012068174,0.00021268244,0.00026241466,0.00027583475,0.00012408163,0.00018189184,0.00007940724,0.00017157383,0.0006797891],"category_scores_gemma":[0.00010534225,0.00014541583,0.00020935005,0.00027469944,0.0001662571,0.000102342194,0.00005796881,0.0002873024,0.0001159806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075206347,0.00006152005,0.0012612102,0.000012613087,0.000015436864,0.000049755545,0.000015473197,0.00017651365,0.99641067,0.00002217892,0.00004221128,0.001180405],"study_design_scores_gemma":[0.00005276756,0.0026442446,0.063193604,0.0000021337016,0.000061009796,0.0004026216,0.00007814084,0.0018760958,0.9307641,0.00003111891,0.0008853386,0.000008817199],"about_ca_topic_score_codex":0.0037686455,"about_ca_topic_score_gemma":0.005002408,"teacher_disagreement_score":0.0037686455,"about_ca_system_score_codex":0.0004803565,"about_ca_system_score_gemma":0.0003210629,"threshold_uncertainty_score":0.0074934363},"labels":[],"label_agreement":null},{"id":"W2119871165","doi":"10.1158/1535-7163.mct-06-0159","title":"Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Antibody; Liposome; Internalization; Trastuzumab; Cancer research; In vivo; Chemistry; Monoclonal antibody; Viability assay; Cancer; Cell; Biology; Immunology; Biochemistry; Breast cancer","score_opus":0.06995553550740947,"score_gpt":0.3823563580540386,"score_spread":0.31240082254662915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119871165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646226,0.0050749253,0.027803298,0.0002866782,0.00005038693,0.00015213998,0.00016500581,0.00015689623,0.0016880712],"genre_scores_gemma":[0.9855232,0.0021545796,0.010455915,0.00008138063,0.00001512955,0.0000897495,0.00019862731,0.00002297185,0.0014583669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998777,0.000025254716,0.000012290348,0.00003062347,0.000028660415,0.000025590234],"domain_scores_gemma":[0.9999219,0.000021319143,0.000023982037,0.000008724928,0.000011995222,0.00001205935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020409316,0.00037662406,0.00025360184,0.00024145875,0.00012018266,0.00043820575,0.00020520129,0.00028672421,0.0007611713],"category_scores_gemma":[0.0001428471,0.00011098837,0.00017703086,0.00015777544,0.00026574032,0.0003103213,0.00031962688,0.0005172954,0.00024092043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007690637,0.000031790903,0.000062243445,0.000051855048,0.0000066823623,0.000026215603,0.00001750668,0.00021790001,0.9959157,0.00039075926,0.000032594686,0.0031698234],"study_design_scores_gemma":[0.000018705146,0.0001668108,0.00015586529,0.000003975087,0.000015914717,0.00006210023,0.0000093691715,0.0007958064,0.99654716,0.000045278906,0.002176174,0.0000029581668],"about_ca_topic_score_codex":0.00039383865,"about_ca_topic_score_gemma":0.00043984232,"teacher_disagreement_score":0.0007611713,"about_ca_system_score_codex":0.00051987835,"about_ca_system_score_gemma":0.00019112325,"threshold_uncertainty_score":0.0037719607},"labels":[],"label_agreement":null},{"id":"W2119900319","doi":"10.1158/1535-7163.mct-07-0181","title":"Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Pharmacology; Pharmacokinetics; CYP3A4; Pharmacodynamics; Cyclophosphamide; Aldehyde dehydrogenase; Dosing; Chemotherapy; Drug; Doxorubicin; Medicine; Chemistry; Cytochrome P450; Enzyme; Internal medicine; Metabolism; Biochemistry","score_opus":0.018920540200897777,"score_gpt":0.3265055325236362,"score_spread":0.3075849923227384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119900319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928242,0.0014261886,0.004016484,0.000106274194,0.00002410104,0.000042002866,0.00076037925,0.0001397393,0.0006605282],"genre_scores_gemma":[0.9940864,0.0007958034,0.0022819673,0.00009615846,0.000021602431,0.00010525066,0.0008461756,0.00005509334,0.0017115262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988616,0.000015353355,0.000004213428,0.000031988522,0.00003339232,0.000029000048],"domain_scores_gemma":[0.99980253,0.000023923734,0.00007116207,0.000022800383,0.00002327386,0.00005633916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014039293,0.0002742407,0.00037462416,0.00023660119,0.000094687086,0.0002716056,0.00017737453,0.00028643705,0.00046932843],"category_scores_gemma":[0.0001654818,0.0001338132,0.0002101334,0.000221709,0.00021139864,0.000218891,0.000075052856,0.0007042905,0.00020831327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010356931,0.000103201215,0.00089093944,0.000019032861,0.000012834335,0.000015802618,0.000011233813,0.00024005782,0.9940528,0.00003163939,0.00009791622,0.0034888326],"study_design_scores_gemma":[0.00012210387,0.0049808947,0.018098151,0.0000051338225,0.00007252278,0.00019901086,0.000020555059,0.003671433,0.969737,0.0000652449,0.0030124946,0.000015583973],"about_ca_topic_score_codex":0.0007397608,"about_ca_topic_score_gemma":0.0009695621,"teacher_disagreement_score":0.0007397608,"about_ca_system_score_codex":0.000321837,"about_ca_system_score_gemma":0.00028323912,"threshold_uncertainty_score":0.0023350716},"labels":[],"label_agreement":null},{"id":"W2120070286","doi":"10.1158/1535-7163.mct-13-0598","title":"Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Università di Catania","keywords":"Pharmacology; In vitro; Signal transduction; Cancer; In vivo; Receptor; Monoclonal antibody; Cancer cell; Growth inhibition; Antibody; Cancer research; Biology; Medicine; Immunology; Cell biology; Internal medicine; Biochemistry","score_opus":0.021321436416336523,"score_gpt":0.3013254112828246,"score_spread":0.28000397486648804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120070286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96407896,0.016813336,0.009803821,0.0007088447,0.00012042448,0.0005351702,0.0005610375,0.00028162944,0.0070968447],"genre_scores_gemma":[0.9842584,0.0061074947,0.007133949,0.00022877335,0.000046745594,0.0001799501,0.00043130293,0.000021015367,0.0015924711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998109,0.00004947128,0.000020115485,0.00002668745,0.00004188615,0.00005103427],"domain_scores_gemma":[0.99993,0.0000079236515,0.000021401696,0.000005689075,0.0000117219515,0.000023212719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030232908,0.00065116055,0.0005257946,0.000446145,0.00016078894,0.00041830612,0.00043596228,0.00033860817,0.00077282905],"category_scores_gemma":[0.00016819059,0.00021315728,0.00031186803,0.00023081593,0.00023141134,0.00030723534,0.00015099268,0.000819811,0.0002738621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022313842,0.0013972496,0.0007359678,0.00024690363,0.00006028539,0.00023194186,0.000037408212,0.0021788036,0.9403977,0.000901596,0.00059419137,0.05098653],"study_design_scores_gemma":[0.0009827428,0.03389262,0.010179744,0.000049743907,0.00029301128,0.0025616374,0.00004910149,0.0075210165,0.918128,0.00036768342,0.025900079,0.0000745995],"about_ca_topic_score_codex":0.0004856905,"about_ca_topic_score_gemma":0.0010393878,"teacher_disagreement_score":0.00077282905,"about_ca_system_score_codex":0.00035946874,"about_ca_system_score_gemma":0.00038098506,"threshold_uncertainty_score":0.00260818},"labels":[],"label_agreement":null},{"id":"W2121030224","doi":"10.1158/1535-7163.mct-10-0413","title":"Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"PI3K/AKT/mTOR pathway; EIF4E; Cancer research; Protein kinase B; Biology; Kinase; Cell biology; Apoptosis; EIF4G; Signal transduction; Translation (biology); Biochemistry; Messenger RNA; Gene","score_opus":0.02080046411245612,"score_gpt":0.31405611619262674,"score_spread":0.2932556520801706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121030224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274194,0.0030502419,0.001977558,0.000098409786,0.00003634952,0.000044139782,0.00045632268,0.00009081147,0.0015042704],"genre_scores_gemma":[0.99389267,0.0016472293,0.0014951195,0.0000456944,0.0000071551585,0.00006035338,0.00069678,0.000016772656,0.0021382913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987483,0.000021217922,0.00001312013,0.000031083746,0.000030255816,0.000029498678],"domain_scores_gemma":[0.99994946,0.000007506818,0.000016942804,0.000005391233,0.000007156937,0.0000135598675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001647244,0.00041044713,0.00025252238,0.00020998398,0.00017669189,0.000268228,0.00020625938,0.0002523777,0.0015578371],"category_scores_gemma":[0.00008836205,0.00014255849,0.00021805654,0.00017426479,0.00021179044,0.0002061935,0.00012146427,0.0006197619,0.00027886537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024797907,0.000046013425,0.00020379515,0.00004211105,0.000005646402,0.000026200463,0.000006331461,0.000081289,0.9979563,0.00008144692,0.000030873194,0.0012721355],"study_design_scores_gemma":[0.000033864773,0.00040647108,0.006193734,0.000004739019,0.00001610155,0.00013975249,0.000013079387,0.00065510854,0.99062145,0.00003455048,0.0018779675,0.000003236338],"about_ca_topic_score_codex":0.00045515748,"about_ca_topic_score_gemma":0.0010377315,"teacher_disagreement_score":0.0015578371,"about_ca_system_score_codex":0.00036275084,"about_ca_system_score_gemma":0.00024648325,"threshold_uncertainty_score":0.0052114725},"labels":[],"label_agreement":null},{"id":"W2121447040","doi":"10.1158/1535-7163.mct-06-0316","title":"Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute","keywords":"Programmed cell death; Apoptosis; Radiation sensitivity; Cancer research; Reactive oxygen species; Autophagy; Biology; Mitotic catastrophe; DNA damage; Radioresistance; Cell biology; Chemistry; Cell culture; Biochemistry; Irradiation; Genetics; DNA","score_opus":0.010005527643853632,"score_gpt":0.24187143673724246,"score_spread":0.23186590909338883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121447040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886841,0.006588926,0.0015625025,0.00010822467,0.00004267495,0.000062987136,0.00046289014,0.000094407034,0.0023932497],"genre_scores_gemma":[0.99183226,0.0028676123,0.002195786,0.00007676104,0.0000110294295,0.00006581117,0.00050800765,0.00001510941,0.0024275973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998995,0.000021947742,0.000018061231,0.00001909255,0.00002298468,0.0000182623],"domain_scores_gemma":[0.9999348,0.000018658722,0.000016635295,0.00001334144,0.0000075679504,0.000008955892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011522582,0.0002753702,0.00039774983,0.00020680405,0.00011604685,0.00023255064,0.00015505982,0.0002796961,0.0011897582],"category_scores_gemma":[0.0000939365,0.00011806727,0.00029052678,0.00013836077,0.00015552671,0.00012085829,0.00012734796,0.00040557652,0.0003815797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002453552,0.000037702768,0.000108173066,0.000060345803,0.0000070669266,0.00003741921,0.000016524424,0.000047959413,0.9974899,0.00004108289,0.000027159858,0.0018813497],"study_design_scores_gemma":[0.000024634426,0.00061039324,0.0026634845,0.000007417873,0.000018361055,0.00028374296,0.000020254682,0.0001622627,0.9930782,0.0000249708,0.0031023717,0.000003842093],"about_ca_topic_score_codex":0.00028375429,"about_ca_topic_score_gemma":0.0005711526,"teacher_disagreement_score":0.0011897582,"about_ca_system_score_codex":0.00017697077,"about_ca_system_score_gemma":0.00013698293,"threshold_uncertainty_score":0.0039801598},"labels":[],"label_agreement":null},{"id":"W2123027432","doi":"10.1158/1535-7163.mct-07-0138","title":"Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of Pittsburgh; AstraZeneca","keywords":"Gefitinib; Erlotinib; Head and neck squamous-cell carcinoma; Cancer research; Epithelial–mesenchymal transition; Epidermal growth factor receptor; Biology; Vimentin; Squamous carcinoma; Medicine; Pathology; Oncology; Carcinoma; Internal medicine; Cancer; Head and neck cancer; Immunohistochemistry; Metastasis","score_opus":0.014017879677184339,"score_gpt":0.2841128916032479,"score_spread":0.27009501192606356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123027432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990491,0.00016606927,0.00017457803,0.000012567915,0.0000027140056,0.000015279531,0.00032169305,0.000013280024,0.00024456411],"genre_scores_gemma":[0.99868625,0.00009279766,0.00021219833,0.0000132791,0.0000026037937,0.00002234362,0.00079457706,0.000002485484,0.00017339482],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981624,0.000027272778,0.000026165293,0.000039086874,0.00005533369,0.000035957968],"domain_scores_gemma":[0.99968517,0.00010685442,0.000076400305,0.000026269794,0.000053757863,0.00005155142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021510669,0.00019132528,0.00036592528,0.0008179013,0.00019401604,0.000417847,0.00012216993,0.00034187487,0.001225132],"category_scores_gemma":[0.00055689726,0.00016777829,0.00021393101,0.0004664457,0.00016410141,0.00013963183,0.0001580097,0.00024717467,0.00027420308],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013887252,0.00022759612,0.606431,0.00007774364,0.00010659283,0.0003566758,0.0001521195,0.00055734126,0.3835047,0.000056662015,0.0003440375,0.006796784],"study_design_scores_gemma":[0.000010475824,0.0002543417,0.97457933,0.000003321619,0.0000414865,0.0007539332,0.00012444294,0.0015415914,0.022337606,0.000026699776,0.00032050532,0.0000063027665],"about_ca_topic_score_codex":0.0019160531,"about_ca_topic_score_gemma":0.0030507399,"teacher_disagreement_score":0.0019160531,"about_ca_system_score_codex":0.00023017026,"about_ca_system_score_gemma":0.00014854726,"threshold_uncertainty_score":0.0040985346},"labels":[],"label_agreement":null},{"id":"W2124328035","doi":"10.1158/1535-7163.mct-05-0157","title":"Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"XIAP; Histone deacetylase inhibitor; Apoptosis; Biology; Inhibitor of apoptosis; Free radical scavenger; Histone deacetylase; Cyclin-dependent kinase; Molecular biology; Chemistry; Cancer research; Programmed cell death; Biochemistry; Cell cycle; Caspase; Histone; Oxidative stress","score_opus":0.01260473809142781,"score_gpt":0.29945841185625754,"score_spread":0.28685367376482973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124328035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583983,0.0016197683,0.0009032378,0.000042878837,0.000014427876,0.000025360232,0.0002400785,0.00005985015,0.0012546128],"genre_scores_gemma":[0.99693537,0.0008279924,0.0005973855,0.000020058742,0.0000073072365,0.000031770564,0.0004936058,0.000010839078,0.0010757868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991953,0.000020078802,0.000009366281,0.000012448203,0.00001838918,0.000020142725],"domain_scores_gemma":[0.9999404,0.000011001508,0.00001558819,0.000011930789,0.000009572891,0.000011570777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011776919,0.00035686637,0.00027010165,0.00015285081,0.00012204232,0.0002336227,0.00018696465,0.00016548512,0.00085476536],"category_scores_gemma":[0.0001047088,0.00010627826,0.00021206887,0.00017724773,0.00012507223,0.00014330687,0.00015490732,0.00032883245,0.00031787768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042877867,0.00008348842,0.00032505093,0.00003393222,0.000015459706,0.00006066525,0.00002875594,0.00020524219,0.9962998,0.00011953577,0.000064755804,0.0023345863],"study_design_scores_gemma":[0.000048881026,0.00076415186,0.0031675133,0.0000029356456,0.000019271842,0.000118475946,0.000016528282,0.0006527198,0.9933442,0.00001887492,0.001843386,0.0000029758357],"about_ca_topic_score_codex":0.0013547235,"about_ca_topic_score_gemma":0.0017796372,"teacher_disagreement_score":0.0013547235,"about_ca_system_score_codex":0.00035007964,"about_ca_system_score_gemma":0.00021983344,"threshold_uncertainty_score":0.0028594732},"labels":[],"label_agreement":null},{"id":"W2124337012","doi":"10.1158/1535-7163.mct-07-2050","title":"Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1α controls sensitivity to econazole","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Discovery Centre; University Health Network","funders":"University of Pennsylvania","keywords":"Econazole; Biology; Mitochondrion; Apoptosis; Cell biology; HL60; Molecular biology; Biochemistry","score_opus":0.015362245277534943,"score_gpt":0.25906216322243636,"score_spread":0.24369991794490142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124337012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963588,0.0013607586,0.0009523178,0.00006045901,0.000016568993,0.000013615978,0.00035406204,0.00003925714,0.0008441386],"genre_scores_gemma":[0.9974353,0.0005144595,0.0003807469,0.000031213305,0.0000041728345,0.000016821446,0.0003796653,0.000010589342,0.00122703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982774,0.00001876468,0.000015528067,0.000043523673,0.00003788936,0.00005652275],"domain_scores_gemma":[0.9998276,0.000022257524,0.00006488553,0.000016609212,0.000027385448,0.00004116908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009196706,0.00017944205,0.00019750508,0.00019007067,0.00013537756,0.00036855767,0.00017277455,0.00022390386,0.0008687112],"category_scores_gemma":[0.00014895957,0.00014164293,0.00016363032,0.0001794246,0.0002310242,0.00015724722,0.00018720583,0.00029311646,0.0002742786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009337293,0.000013177951,0.0004200296,0.000009822747,0.0000014637756,0.000026044114,0.000008068821,0.000025357938,0.9988808,0.000031968673,0.000028097122,0.00046187374],"study_design_scores_gemma":[0.00001646965,0.00016472125,0.039759327,0.0000069505827,0.0000097969305,0.00035243502,0.00006724762,0.0016063757,0.9558126,0.000042439082,0.0021535384,0.000008078172],"about_ca_topic_score_codex":0.0011684323,"about_ca_topic_score_gemma":0.0012900794,"teacher_disagreement_score":0.0011684323,"about_ca_system_score_codex":0.00050978444,"about_ca_system_score_gemma":0.00012733362,"threshold_uncertainty_score":0.0036987662},"labels":[],"label_agreement":null},{"id":"W2125755807","doi":"10.1158/1535-7163.mct-14-0399","title":"ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Angiochem (Canada)","funders":"","keywords":"Transcytosis; Monoclonal antibody; Cancer research; Conjugate; LRP1; In vivo; Blood–brain barrier; In vitro; Biology; Antibody; Receptor; Pharmacology; Immunology; Central nervous system; Biochemistry; Endocrinology; Endocytosis","score_opus":0.019523839949170698,"score_gpt":0.3064393769036586,"score_spread":0.2869155369544879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125755807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302095,0.0014107898,0.002796109,0.00010392278,0.000035625915,0.00005271108,0.00021516223,0.0002153174,0.0021493745],"genre_scores_gemma":[0.99263555,0.0013962896,0.002837173,0.00006542499,0.00002868074,0.00004526333,0.00046100304,0.00002692945,0.002503782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998926,0.000018669823,0.0000053310073,0.00001905302,0.000035802277,0.00002850416],"domain_scores_gemma":[0.99993,0.000008659314,0.000026894631,0.0000051460806,0.000006973379,0.000022158585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011751901,0.0005505261,0.00029261946,0.000332747,0.000115101066,0.00024837285,0.00023975818,0.00038170486,0.0006126629],"category_scores_gemma":[0.00006606689,0.00018228298,0.00019962555,0.00018729368,0.00018828851,0.00022836162,0.00009184234,0.0005435772,0.00025433264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015100888,0.00006899964,0.00007412796,0.000022487226,0.0000065677577,0.000043923377,0.0000064583905,0.00009863186,0.9977387,0.00006780647,0.00006197824,0.001659266],"study_design_scores_gemma":[0.00008771967,0.0027989165,0.003328222,0.0000042123875,0.000038147846,0.00057159126,0.000009230405,0.0011772724,0.98849726,0.00007117604,0.0034081852,0.0000080920545],"about_ca_topic_score_codex":0.00071585097,"about_ca_topic_score_gemma":0.00093867973,"teacher_disagreement_score":0.00071585097,"about_ca_system_score_codex":0.00031788193,"about_ca_system_score_gemma":0.00024227466,"threshold_uncertainty_score":0.0023064613},"labels":[],"label_agreement":null},{"id":"W2126092906","doi":"10.1158/1535-7163.mct-09-0583","title":"Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Cyclophosphamide; Medicine; Angiogenesis; Cancer research; Chemotherapy; Pharmacology; Apoptosis; Cancer; Internal medicine; Biology","score_opus":0.036662051581358324,"score_gpt":0.32175363718286976,"score_spread":0.28509158560151143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126092906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994505,0.0010797934,0.0022278614,0.00008560414,0.000045985234,0.000074627744,0.00045586165,0.0001605122,0.0013647928],"genre_scores_gemma":[0.9945662,0.00076802704,0.001858699,0.00002693203,0.0000138602745,0.00009078022,0.0007509329,0.000024987736,0.0018995714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988747,0.000025333024,0.000009544171,0.000019511783,0.000027223634,0.000031005504],"domain_scores_gemma":[0.99991786,0.0000150653605,0.000019224746,0.0000132997,0.00000886065,0.000025728004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016577382,0.00051757356,0.0004521934,0.00028958352,0.00011589668,0.00023295832,0.0001982097,0.00020984748,0.0013090763],"category_scores_gemma":[0.0000765569,0.00016150267,0.00021435834,0.00021124147,0.000160361,0.00014430801,0.00009558649,0.0008309971,0.00022451952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047212015,0.0003584161,0.0001569798,0.00003425654,0.000010551672,0.000018598672,0.000013865362,0.0001511866,0.9968393,0.000063067906,0.00011837779,0.0017632287],"study_design_scores_gemma":[0.000073850315,0.0039359196,0.002094404,0.0000036535605,0.000023328117,0.000112588954,0.000009208292,0.0009784809,0.99178606,0.000017011396,0.0009623005,0.0000030802614],"about_ca_topic_score_codex":0.001189272,"about_ca_topic_score_gemma":0.0027328364,"teacher_disagreement_score":0.0013090763,"about_ca_system_score_codex":0.0002982148,"about_ca_system_score_gemma":0.00028342064,"threshold_uncertainty_score":0.0043792725},"labels":[],"label_agreement":null},{"id":"W2126163147","doi":"10.1158/1535-7163.mct-08-1186","title":"Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"University of Southern California","keywords":"Breast cancer; Cancer research; Cancer; Doxorubicin; Carcinogen; Paclitaxel; Oxidative stress; Cancer cell; Biology; Cytotoxicity; Molecular biology; Chemistry; Chemotherapy; Endocrinology; Biochemistry; In vitro; Genetics","score_opus":0.009806876768941873,"score_gpt":0.2616770354476037,"score_spread":0.2518701586786618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126163147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891016,0.0057601356,0.0019991281,0.0002621814,0.000033382694,0.000030849285,0.0010065049,0.00017363807,0.0016325684],"genre_scores_gemma":[0.99281824,0.0016306301,0.0011343653,0.00013669682,0.000008738926,0.000030537976,0.0015535441,0.00004193701,0.0026453456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986875,0.000015872869,0.000013791325,0.000028866933,0.000042656782,0.000029987963],"domain_scores_gemma":[0.9997938,0.000030621806,0.000058898444,0.000031045616,0.000031250587,0.00005439559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014620206,0.0002234592,0.0003339422,0.0003410358,0.00019784739,0.00026928112,0.00016276853,0.0002676596,0.0017019422],"category_scores_gemma":[0.00017487434,0.00018180392,0.00030766855,0.00032611072,0.00018949306,0.00012267177,0.00017020901,0.00036605226,0.0005308965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017849302,0.000022083732,0.0011738519,0.000036441495,0.000017329208,0.000193087,0.000010134224,0.000028257,0.996443,0.000037256083,0.00014779723,0.0017121846],"study_design_scores_gemma":[0.000024211402,0.00024319158,0.039679963,0.000007120936,0.00005440904,0.0032095597,0.00004632946,0.0006062377,0.9507496,0.000058567042,0.0053141336,0.0000067403275],"about_ca_topic_score_codex":0.0013430723,"about_ca_topic_score_gemma":0.001535831,"teacher_disagreement_score":0.0017019422,"about_ca_system_score_codex":0.0005254105,"about_ca_system_score_gemma":0.00021736156,"threshold_uncertainty_score":0.0056936145},"labels":[],"label_agreement":null},{"id":"W2126724373","doi":"10.1158/1535-7163.mct-05-0064","title":"A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Antisense therapy; Bcl-xL; Apoptosis; XIAP; Oligonucleotide; Biology; Cancer research; Inhibitor of apoptosis; LNCaP; Prostate cancer; Molecular biology; Caspase; Programmed cell death; Cancer; Biochemistry; Gene; Genetics; Locked nucleic acid","score_opus":0.015963691219313653,"score_gpt":0.26792920004160753,"score_spread":0.25196550882229385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126724373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926475,0.0018831883,0.0039213025,0.00007251594,0.000045940425,0.00005648355,0.00018587553,0.0000824901,0.001104641],"genre_scores_gemma":[0.990914,0.0016212858,0.0046648053,0.000091032176,0.000023010745,0.00007915163,0.00060112163,0.000013650056,0.0019919933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988806,0.00000967806,0.000009866261,0.000028886903,0.000044529057,0.000018863368],"domain_scores_gemma":[0.99993753,0.000011733716,0.000015924756,0.0000055587393,0.000015293293,0.000013991672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010174192,0.00034844095,0.0002495088,0.00016339862,0.00012835018,0.00015285182,0.00015268955,0.00019514852,0.000658748],"category_scores_gemma":[0.0000869133,0.00011289756,0.00015686205,0.00013199665,0.0001066712,0.000102146616,0.00009954646,0.00043221103,0.00011196771],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029944265,0.000021546559,0.00005263307,0.000019100231,0.0000030490646,0.000011379075,0.000006375119,0.0000260164,0.99905473,0.000022514718,0.000015421294,0.00073729863],"study_design_scores_gemma":[0.000043777032,0.0011340441,0.002767277,0.0000046861946,0.000039120452,0.00025675315,0.00001617688,0.00054215355,0.9928992,0.000018562987,0.0022734252,0.0000047747176],"about_ca_topic_score_codex":0.00072951475,"about_ca_topic_score_gemma":0.001947682,"teacher_disagreement_score":0.00072951475,"about_ca_system_score_codex":0.00019792323,"about_ca_system_score_gemma":0.00021980789,"threshold_uncertainty_score":0.0022037625},"labels":[],"label_agreement":null},{"id":"W2127372364","doi":"10.1158/1535-7163.mct-07-0329","title":"Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; QLT (Canada); University of British Columbia","funders":"","keywords":"Integrin-linked kinase; Protein kinase B; Angiogenesis; Apoptosis; Cell growth; Cancer research; CD31; DAPI; In vivo; Chemistry; Cell cycle; Flow cytometry; Biology; Molecular biology; Biochemistry","score_opus":0.022975262270749388,"score_gpt":0.28694280679909334,"score_spread":0.263967544528344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127372364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979023,0.00065248023,0.000553436,0.000050697057,0.000011333671,0.00002751752,0.00019774692,0.00004757282,0.00055696024],"genre_scores_gemma":[0.99761415,0.00042902445,0.0005896308,0.000024193472,0.0000042256597,0.00004391664,0.0003106887,0.0000052766727,0.0009788728],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990964,0.0000143519665,0.00000905383,0.000010561536,0.000022308399,0.000034139222],"domain_scores_gemma":[0.9999701,0.000003636212,0.000010801219,0.0000023603495,0.0000032246069,0.000009877851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001240025,0.00030403415,0.00019265761,0.00017041231,0.0000812642,0.00016396814,0.000111278416,0.00014208906,0.0007043643],"category_scores_gemma":[0.000057131234,0.00010685139,0.00015907125,0.0001411539,0.00012793716,0.000097358985,0.000092453134,0.00034835574,0.00013173826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023636021,0.00009036541,0.00024799223,0.000027138723,0.000003810826,0.000031442345,0.0000105606205,0.00006598708,0.9979036,0.00004929015,0.000049878494,0.0012835666],"study_design_scores_gemma":[0.00011674543,0.0031578706,0.008044783,0.0000042394054,0.00001942383,0.0002691897,0.00002775188,0.0010889823,0.9858499,0.000032763943,0.0013849076,0.0000035902312],"about_ca_topic_score_codex":0.00092358707,"about_ca_topic_score_gemma":0.0021883724,"teacher_disagreement_score":0.00092358707,"about_ca_system_score_codex":0.00029294103,"about_ca_system_score_gemma":0.00023070857,"threshold_uncertainty_score":0.0023563504},"labels":[],"label_agreement":null},{"id":"W2127580939","doi":"10.1158/1535-7163.mct-08-0200","title":"Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Toyota Research Institute, North America","keywords":"Metastasis; Medicine; Cancer research; Cancer; Trastuzumab; Antibody; Oncology; Internal medicine; Breast cancer; Immunology","score_opus":0.0419588195616885,"score_gpt":0.3378455719101534,"score_spread":0.2958867523484649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127580939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877407,0.0029431044,0.0054280185,0.000095170515,0.00006216129,0.00006935758,0.0015119326,0.00024512084,0.0019044826],"genre_scores_gemma":[0.9861725,0.0016818454,0.0042899307,0.0000990731,0.000017884087,0.00016226486,0.0017988819,0.00005571746,0.0057219425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974495,0.000042120035,0.000026332444,0.00006707797,0.00006276525,0.00005671012],"domain_scores_gemma":[0.99962854,0.000059891307,0.00009803555,0.000056417255,0.00006917174,0.00008799985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033025944,0.0003877819,0.0004744294,0.00046320213,0.00018568747,0.000410435,0.00021551561,0.00035477104,0.0007697282],"category_scores_gemma":[0.00021030978,0.00014827173,0.00032927605,0.0003488671,0.00021450962,0.00030247093,0.00018319077,0.00092006684,0.00030584304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020098047,0.00018745789,0.0008520773,0.000032197626,0.000010049876,0.00004306107,0.000043991942,0.00015790551,0.9962379,0.000055992485,0.00008593849,0.002092408],"study_design_scores_gemma":[0.000018711075,0.001801019,0.0076842015,0.0000058908126,0.000032123768,0.0001430118,0.000057560566,0.0019988548,0.98695344,0.000053495598,0.0012405114,0.000011131925],"about_ca_topic_score_codex":0.0010397547,"about_ca_topic_score_gemma":0.0012411701,"teacher_disagreement_score":0.0010397547,"about_ca_system_score_codex":0.00029834817,"about_ca_system_score_gemma":0.00020242568,"threshold_uncertainty_score":0.0025750399},"labels":[],"label_agreement":null},{"id":"W2128317422","doi":"10.1158/1535-7163.mct-06-0532","title":"17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Protein kinase B; MAPK/ERK pathway; Protein kinase A; Chemistry; Kinase; p38 mitogen-activated protein kinases; Geldanamycin; Deoxycholic acid; Heat shock protein; Molecular biology; Apoptosis; Biochemistry; Biology; Hsp90; Bile acid","score_opus":0.02460500927441307,"score_gpt":0.3220273320435263,"score_spread":0.29742232276911323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128317422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357986,0.0018319397,0.0026732925,0.00005741274,0.000036267684,0.000030209498,0.00032859863,0.00010590064,0.0013565894],"genre_scores_gemma":[0.9914141,0.0016505092,0.0029993665,0.000047948044,0.0000144106525,0.000060470957,0.00064462906,0.000033583765,0.0031348297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983704,0.000035676672,0.000020106538,0.000028839628,0.00004053123,0.00003774606],"domain_scores_gemma":[0.9998311,0.000027583095,0.000045979523,0.000026827061,0.000019971765,0.00004849565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017302466,0.00055166095,0.00036298315,0.00027657475,0.00009233595,0.00017043116,0.00014355866,0.00019131086,0.0010346886],"category_scores_gemma":[0.00009762925,0.00014791418,0.00036479955,0.00014978427,0.00020351078,0.00016389546,0.00016410704,0.0004643843,0.00032130143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070373455,0.000018486335,0.000060569346,0.000016275546,0.0000034288075,0.000024116083,0.000007955568,0.000033796383,0.999403,0.00001974174,0.000010083825,0.00033211918],"study_design_scores_gemma":[0.0000041941844,0.00034686725,0.0010447567,0.0000012144976,0.000005168681,0.000057292702,0.0000067347023,0.00014082348,0.99792564,0.0000067298292,0.00045948935,0.0000012457293],"about_ca_topic_score_codex":0.0005947585,"about_ca_topic_score_gemma":0.0010898692,"teacher_disagreement_score":0.0010346886,"about_ca_system_score_codex":0.00023870051,"about_ca_system_score_gemma":0.00018498147,"threshold_uncertainty_score":0.003461361},"labels":[],"label_agreement":null},{"id":"W2128591359","doi":"10.1158/1535-7163.mct-13-0731","title":"Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Smoothened; Hedgehog; Hedgehog signaling pathway; Cancer research; Biology; Cell growth; Chondrosarcoma; Vismodegib; Medicine; Cell biology; Signal transduction; Genetics; Pathology","score_opus":0.020560192702489367,"score_gpt":0.260187499756258,"score_spread":0.2396273070537686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128591359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956363,0.0017563181,0.0009865449,0.000047040117,0.00001431906,0.00004057746,0.00030192608,0.00009131312,0.0011255915],"genre_scores_gemma":[0.9937782,0.0020890203,0.0016136895,0.00003120662,0.0000071968852,0.0000473232,0.000792281,0.00001237609,0.0016287424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998945,0.00001383766,0.000013559226,0.000015951431,0.000035595935,0.000026423806],"domain_scores_gemma":[0.9999541,0.0000067540127,0.0000138896785,0.0000055124065,0.0000062820154,0.000013335783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008298857,0.00034876,0.00033855747,0.00022533275,0.000105244246,0.00019090378,0.00016091041,0.00013648212,0.0006364623],"category_scores_gemma":[0.000053309886,0.00013061041,0.0002656038,0.0001749107,0.00015891554,0.00009831067,0.000094665236,0.0004649637,0.0002137367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001492619,0.00008035643,0.00017766566,0.00004543704,0.000008069498,0.00003013217,0.00000976903,0.00009040328,0.99683857,0.000028246823,0.000045497265,0.002496636],"study_design_scores_gemma":[0.00004638831,0.0015801814,0.005079953,0.000004723695,0.000028733828,0.00023025226,0.000020679076,0.0007610462,0.9911703,0.000015601334,0.0010590762,0.0000030016583],"about_ca_topic_score_codex":0.00067920756,"about_ca_topic_score_gemma":0.0016529212,"teacher_disagreement_score":0.00067920756,"about_ca_system_score_codex":0.00017113466,"about_ca_system_score_gemma":0.00024411548,"threshold_uncertainty_score":0.0021291375},"labels":[],"label_agreement":null},{"id":"W2128701004","doi":"10.1158/1535-7163.mct-08-0126","title":"SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Bosutinib; Proto-oncogene tyrosine-protein kinase Src; Focal adhesion; Cancer research; Src family kinase; Tyrosine kinase; Cancer cell; Kinase; Cancer; Cell biology; Biology; Chemistry; Signal transduction; Dasatinib","score_opus":0.023687532859094515,"score_gpt":0.27067359435683075,"score_spread":0.24698606149773622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128701004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97249675,0.02044941,0.0015717812,0.00025716043,0.00008242765,0.000052576048,0.00064272794,0.0002111726,0.00423603],"genre_scores_gemma":[0.98407215,0.010040287,0.0013713618,0.00008634754,0.00003470988,0.000038715392,0.001209328,0.000021242184,0.003125809],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999232,0.000014476567,0.0000065400773,0.00000838367,0.000022120534,0.000025173242],"domain_scores_gemma":[0.9999721,0.0000040570685,0.0000090502945,0.0000021256737,0.0000032112239,0.000009408484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012266148,0.00045447925,0.00034517175,0.0003094064,0.000098215474,0.00018517788,0.00014781365,0.0001547672,0.00089202425],"category_scores_gemma":[0.00006732431,0.00010032962,0.00015794419,0.00023106651,0.00014364986,0.000093941875,0.000096003765,0.00037617175,0.00047480292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023709575,0.00012273638,0.00025633842,0.00009422486,0.000010466264,0.00006079728,0.000008308445,0.00013712408,0.99085486,0.000064958724,0.00025216624,0.00790098],"study_design_scores_gemma":[0.0001539675,0.0023568822,0.006814973,0.000008555711,0.00004064013,0.00090151565,0.000020429568,0.0008446524,0.98280185,0.00004361239,0.0060076513,0.000005263888],"about_ca_topic_score_codex":0.00065247226,"about_ca_topic_score_gemma":0.0013620517,"teacher_disagreement_score":0.00089202425,"about_ca_system_score_codex":0.00020353291,"about_ca_system_score_gemma":0.00018379754,"threshold_uncertainty_score":0.0029841065},"labels":[],"label_agreement":null},{"id":"W2129000610","doi":"10.1158/1535-7163.mct-12-0978","title":"Spongian Diterpenoids Inhibit Androgen Receptor Activity","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Androgen receptor; Antiandrogens; Androgen; Antiandrogen; Chemistry; Prostate cancer; Flutamide; In vivo; Biology; LNCaP; Internal medicine; Endocrinology; Biochemistry; Medicine; Cancer; Hormone; Genetics","score_opus":0.009160678739824301,"score_gpt":0.2520462786868974,"score_spread":0.2428855999470731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129000610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785735,0.008200428,0.0036915953,0.000115529205,0.000039075367,0.000071327966,0.00066026364,0.0001604056,0.008487989],"genre_scores_gemma":[0.9841942,0.0067062713,0.0019099981,0.00007522187,0.000013170077,0.000027577053,0.0005048296,0.00001610027,0.00655268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999647,0.00000641485,0.0000024159192,0.000005441098,0.00001164694,0.000009368009],"domain_scores_gemma":[0.99996626,0.0000073932874,0.000008524251,0.00000372512,0.000004494673,0.000009458152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060649087,0.0003140997,0.0001365036,0.00018050068,0.00006362701,0.00011497469,0.00011175205,0.000101208556,0.0018790145],"category_scores_gemma":[0.00006649625,0.00006763841,0.00012808584,0.00017338933,0.00013221258,0.000078220226,0.00010918993,0.00020626566,0.00041697678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007729287,0.000028956892,0.00017354032,0.00006777407,0.0000072207235,0.00003170245,0.000008710777,0.0002046789,0.99237317,0.00019879747,0.000079113284,0.00674914],"study_design_scores_gemma":[0.000023382494,0.0006513682,0.0021357874,0.0000051594675,0.000015718966,0.00010000797,0.000014536198,0.00035138172,0.98950386,0.00008942311,0.007106529,0.0000028872078],"about_ca_topic_score_codex":0.00069267565,"about_ca_topic_score_gemma":0.0019779322,"teacher_disagreement_score":0.0018790145,"about_ca_system_score_codex":0.0001804148,"about_ca_system_score_gemma":0.0002288263,"threshold_uncertainty_score":0.006285906},"labels":[],"label_agreement":null},{"id":"W2129867347","doi":"10.1158/1535-7163.mct-12-1093","title":"Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research UK; AstraZeneca","keywords":"PTEN; Tensin; Phosphatase; Biology; DNA repair; Cancer research; Synthetic lethality; DNA damage; Kinase; Molecular biology; DNA; Cell biology; Genetics; Phosphorylation; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.017382240815631517,"score_gpt":0.2850966624290463,"score_spread":0.2677144216134148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129867347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95463896,0.0025979276,0.036081553,0.00028487697,0.000117102514,0.00032830643,0.0012395721,0.0005663996,0.00414534],"genre_scores_gemma":[0.9692472,0.0021290681,0.020422384,0.000081072176,0.000011592555,0.00022897715,0.0016852003,0.000054674423,0.006139902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998271,0.0000247687,0.000017081482,0.00004059516,0.00006465077,0.00002588692],"domain_scores_gemma":[0.99990535,0.000023619048,0.000026729249,0.000013604759,0.000008020832,0.000022721368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023103369,0.000749204,0.00030790333,0.0003109222,0.00021093857,0.0002951239,0.00022200301,0.0002597715,0.0011958332],"category_scores_gemma":[0.00011858595,0.00017920678,0.0002782309,0.00020659478,0.00028851756,0.0001616173,0.00029624393,0.0006810815,0.0003623943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034434852,0.000019542496,0.000061580904,0.000028821185,0.000004875961,0.00003488082,0.000008946516,0.00011436751,0.99841654,0.00017735461,0.000035556674,0.0010631477],"study_design_scores_gemma":[0.000008498239,0.00013326688,0.00032334184,0.000001354244,0.0000076222705,0.000119741155,0.00000383141,0.0005702076,0.9974655,0.000028491677,0.0013359168,0.000002328824],"about_ca_topic_score_codex":0.0006688709,"about_ca_topic_score_gemma":0.0013207757,"teacher_disagreement_score":0.0011958332,"about_ca_system_score_codex":0.00032558976,"about_ca_system_score_gemma":0.00035775505,"threshold_uncertainty_score":0.004000485},"labels":[],"label_agreement":null},{"id":"W2129944198","doi":"10.1158/1535-7163.mct-14-1078","title":"AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Cancer research; Antibody-drug conjugate; Epidermal growth factor receptor; Antibody; Conjugate; Chemistry; Monoclonal antibody; Molecular biology; Medicine; Receptor; Biology; Immunology; Biochemistry","score_opus":0.040843058974255664,"score_gpt":0.33336690187824247,"score_spread":0.2925238429039868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129944198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924509,0.0020834743,0.0030075165,0.000077413555,0.000034218756,0.00008343686,0.00013523045,0.00011384918,0.0020139732],"genre_scores_gemma":[0.9966037,0.0008733179,0.0014318117,0.000043656546,0.000012603434,0.000025883266,0.0002493331,0.000006955778,0.0007526558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999181,0.000015483156,0.000005773341,0.000014406461,0.00002574797,0.000020589221],"domain_scores_gemma":[0.9999654,0.00000496219,0.000009957167,0.0000024842852,0.0000031864984,0.0000139087115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011945963,0.000361634,0.00029202137,0.0004688607,0.000114082555,0.00018946649,0.00021192901,0.0002977895,0.00061966974],"category_scores_gemma":[0.0000715692,0.00013917162,0.00019758233,0.00022510791,0.00015826152,0.00014089089,0.00019065749,0.00035693523,0.00021437407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002518493,0.00023807096,0.00040164692,0.000057322104,0.000019732044,0.00008210089,0.000014219589,0.00028682547,0.98515445,0.000220502,0.00016303934,0.013110204],"study_design_scores_gemma":[0.00020949024,0.005131751,0.006782813,0.000008402513,0.00004461807,0.00056446594,0.000010821004,0.0011748997,0.98185194,0.00005678513,0.004155995,0.00000802217],"about_ca_topic_score_codex":0.00044262735,"about_ca_topic_score_gemma":0.00075044093,"teacher_disagreement_score":0.00061966974,"about_ca_system_score_codex":0.00031710707,"about_ca_system_score_gemma":0.00017352444,"threshold_uncertainty_score":0.002300799},"labels":[],"label_agreement":null},{"id":"W2130441903","doi":"10.1158/1535-7163.mct-08-0891","title":"The phytochemical piceatannol induces the loss of CBL and CBL-associated proteins","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation","funders":"University of Calgary","keywords":"Piceatannol; Phytochemical; Chemistry; Biology; Biochemistry; Resveratrol","score_opus":0.0184652020286719,"score_gpt":0.3016650934681308,"score_spread":0.2831998914394589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130441903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946919,0.0018557714,0.0017090365,0.0000688736,0.000020244168,0.000022285178,0.00026603544,0.000073951785,0.001291741],"genre_scores_gemma":[0.99567115,0.00086255703,0.0011839598,0.00007611015,0.000007924788,0.000018324257,0.00041579647,0.000012606588,0.001751559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999238,0.000015849571,0.0000064930978,0.0000157214,0.000023025475,0.000015204447],"domain_scores_gemma":[0.9999286,0.000015981028,0.000020185831,0.000012452448,0.000008007903,0.000014881359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008172286,0.0003395984,0.00021366029,0.00032437523,0.00011300224,0.00015373132,0.0001108977,0.00016108819,0.001060152],"category_scores_gemma":[0.000092156144,0.0001061794,0.00022591058,0.00016546571,0.0002341642,0.00012825096,0.00014205194,0.00036224854,0.00018503227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005368291,0.000017153983,0.000077827484,0.000018595327,0.0000035147389,0.000021402007,0.000004718344,0.000014680627,0.99917907,0.000016456112,0.000010585581,0.0005821992],"study_design_scores_gemma":[0.000007993923,0.00029725666,0.0027515811,0.0000021192898,0.000010914597,0.00008064726,0.000007488762,0.00016568019,0.9960699,0.000018290595,0.00058664277,0.0000014827119],"about_ca_topic_score_codex":0.0005040911,"about_ca_topic_score_gemma":0.0010436276,"teacher_disagreement_score":0.001060152,"about_ca_system_score_codex":0.00024750482,"about_ca_system_score_gemma":0.00013945246,"threshold_uncertainty_score":0.0035465956},"labels":[],"label_agreement":null},{"id":"W2131496779","doi":"10.1158/1535-7163.mct-07-0615","title":"Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Doxorubicin; Biodistribution; Epithelial cell adhesion molecule; Liposome; Drug delivery; Pharmacology; Pharmacokinetics; Chemistry; Cancer research; Antibody; Internalization; Targeted drug delivery; In vitro; Cell; Medicine; Drug; Immunology; Chemotherapy; Biochemistry; Internal medicine","score_opus":0.020605470227439554,"score_gpt":0.3030636069733631,"score_spread":0.28245813674592357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131496779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876528,0.0022316023,0.008560183,0.000107027554,0.000035317342,0.000045323803,0.00009883215,0.000110273,0.0011586423],"genre_scores_gemma":[0.9939839,0.00093278894,0.0034879819,0.000055261196,0.000012483928,0.000032760167,0.00020886786,0.0000132027935,0.0012728969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999324,0.000011489095,0.0000052809005,0.000018040944,0.000016317841,0.000016433516],"domain_scores_gemma":[0.999951,0.00000960891,0.000014169988,0.0000051452907,0.000010118165,0.000009893888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009754931,0.0001959172,0.00020357812,0.00017237372,0.00007352996,0.0002138335,0.00012900736,0.0002232654,0.0005076586],"category_scores_gemma":[0.00010278329,0.000077159864,0.00013128143,0.00008269415,0.000098375094,0.00016234956,0.00014142213,0.00023358373,0.00020863966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035083824,0.000040242372,0.00006983829,0.000029493938,0.000004826343,0.000019438554,0.0000070009623,0.00016320574,0.9964474,0.000068925445,0.000029781728,0.003084716],"study_design_scores_gemma":[0.00001385208,0.00036219545,0.00052082137,0.0000025642446,0.000013442,0.00004945873,0.0000033276995,0.0013825541,0.9959347,0.0000104439,0.001703766,0.0000028702818],"about_ca_topic_score_codex":0.00030726782,"about_ca_topic_score_gemma":0.00029606407,"teacher_disagreement_score":0.0005076586,"about_ca_system_score_codex":0.00024251292,"about_ca_system_score_gemma":0.00014229285,"threshold_uncertainty_score":0.0017595887},"labels":[],"label_agreement":null},{"id":"W2132090254","doi":"10.1158/1535-7163.mct-07-0560","title":"Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Romidepsin; Cancer research; Histone deacetylase; Histone deacetylase inhibitor; Biology; Cell growth; Cell cycle; Propidium iodide; Cell cycle checkpoint; Vorinostat; Apoptosis; Molecular biology; Programmed cell death; Histone; Biochemistry","score_opus":0.022626705361165556,"score_gpt":0.27782189018545866,"score_spread":0.2551951848242931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132090254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051476,0.0018399251,0.004055463,0.00009383469,0.000040231636,0.00016849476,0.0010191661,0.0001387394,0.0021293256],"genre_scores_gemma":[0.9852189,0.0025028114,0.005591583,0.00006911547,0.000015361682,0.00022194328,0.0023004627,0.000034302167,0.004045528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997589,0.000038903898,0.00003122128,0.00003872755,0.00009290256,0.000039319493],"domain_scores_gemma":[0.99982053,0.00003527568,0.000048360234,0.000021048227,0.000032561944,0.00004222063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020296489,0.0005024806,0.00039752602,0.00045972446,0.00014166792,0.00021195266,0.00028595925,0.00025832173,0.0013303307],"category_scores_gemma":[0.00014831798,0.00021117099,0.00035399568,0.00022582593,0.00018624814,0.00020315697,0.00017615057,0.0007254325,0.00037509532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024078839,0.00017323947,0.00028048726,0.00005415768,0.000012725526,0.00006258863,0.000024367284,0.00016292199,0.99736905,0.000080029786,0.00014768254,0.0013919639],"study_design_scores_gemma":[0.00006352976,0.0016987062,0.003569125,0.0000050066856,0.000022515664,0.0003072144,0.000029804578,0.0011761871,0.9913122,0.00003547894,0.0017753924,0.000004741433],"about_ca_topic_score_codex":0.0012528105,"about_ca_topic_score_gemma":0.0043273806,"teacher_disagreement_score":0.0013303307,"about_ca_system_score_codex":0.00034857885,"about_ca_system_score_gemma":0.00029242897,"threshold_uncertainty_score":0.004450321},"labels":[],"label_agreement":null},{"id":"W2132678065","doi":"10.1158/1535-7163.mct-07-0134","title":"The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Integrin-linked kinase; Gene knockdown; Melanoma; Cancer research; Cell migration; Cell growth; Metastasis; Focal adhesion; Biology; Angiogenesis; Extracellular matrix; Small hairpin RNA; Cell; Small interfering RNA; Kinase; Chemistry; Protein kinase A; Cancer; Cell biology; Medicine; Signal transduction; Internal medicine; Cell culture; Transfection; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.017484134794276626,"score_gpt":0.2895511336196776,"score_spread":0.272066998825401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132678065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8258292,0.15418465,0.0065124114,0.001646802,0.000115208735,0.00003342648,0.00016157927,0.00010589909,0.011410884],"genre_scores_gemma":[0.97592974,0.02065112,0.0012961699,0.000095677955,0.00002765094,0.000013134113,0.00006208718,0.0000066920124,0.0019176477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993277,0.000017179911,0.0000036038668,0.000010171734,0.000017951481,0.00001831326],"domain_scores_gemma":[0.999959,0.0000071005375,0.000015017825,0.0000021729725,0.0000055553605,0.000011052475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010088134,0.0003430767,0.00013348059,0.00017259576,0.0002022557,0.00036055292,0.000091321584,0.00032005348,0.0005175274],"category_scores_gemma":[0.000106836815,0.000082690436,0.0001236181,0.0000842705,0.00020518916,0.0002076426,0.0001286305,0.0004403321,0.00023034941],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029966407,0.000090150774,0.0019088314,0.00022938187,0.000015560303,0.00032251922,0.00004264127,0.00042422075,0.96200514,0.0020358858,0.00055937393,0.032066602],"study_design_scores_gemma":[0.00010992423,0.0013112761,0.07181184,0.000116607,0.00010846323,0.0037317944,0.00025580922,0.006375215,0.8700319,0.0031311482,0.04297539,0.00004068085],"about_ca_topic_score_codex":0.00048821792,"about_ca_topic_score_gemma":0.0005940786,"teacher_disagreement_score":0.0005175274,"about_ca_system_score_codex":0.00029487195,"about_ca_system_score_gemma":0.00018519626,"threshold_uncertainty_score":0.0021395087},"labels":[],"label_agreement":null},{"id":"W2133519168","doi":"10.1158/1535-7163.mct-08-0769","title":"Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institutes of Health","keywords":"Carcinoembryonic antigen; Antigen; Biology; Immunity; Transgene; Genetically modified mouse; Immunology; Cancer research; Cancer; Immune system; Gene; Genetics","score_opus":0.017078938938005637,"score_gpt":0.2640789944945212,"score_spread":0.24700005555651558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133519168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845607,0.0013712187,0.009557438,0.00014672316,0.00009222103,0.0002516454,0.00087346474,0.0005695746,0.0025770012],"genre_scores_gemma":[0.9859352,0.00085629337,0.005863532,0.00010318389,0.000034179164,0.00020256444,0.001091237,0.00007418298,0.0058396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996798,0.000036392965,0.00003004968,0.00007137189,0.000089165624,0.00009330061],"domain_scores_gemma":[0.99978346,0.00003732377,0.00006097045,0.000036491656,0.000022258453,0.00005942259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032256966,0.00052842597,0.00036000836,0.0005690294,0.0001226313,0.00043578196,0.00026038423,0.00048014204,0.0013093587],"category_scores_gemma":[0.00014758902,0.00024269265,0.00039403263,0.00018560071,0.00033665498,0.00026914765,0.00022245367,0.0014725926,0.00057412393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051976756,0.00005501338,0.000052659503,0.000013424632,0.0000030244378,0.000014791916,0.000009697501,0.000032796495,0.9991333,0.00007471388,0.00002905176,0.0005296951],"study_design_scores_gemma":[0.000045432098,0.0007533396,0.001633424,0.0000058990895,0.000015180552,0.00013580384,0.000011021224,0.00088118843,0.995017,0.000052114596,0.0014452379,0.0000044040953],"about_ca_topic_score_codex":0.0006292222,"about_ca_topic_score_gemma":0.0008509341,"teacher_disagreement_score":0.0013093587,"about_ca_system_score_codex":0.00033200046,"about_ca_system_score_gemma":0.0002855057,"threshold_uncertainty_score":0.0043802857},"labels":[],"label_agreement":null},{"id":"W2133803355","doi":"10.1158/1535-7163.mct-08-1152","title":"Silibinin inhibits translation initiation: implications for anticancer therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Silymarin and Mushroom Poisoning","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Faculty of Medicine, McGill University; McGill University","keywords":"Silibinin; Translation (biology); Medicine; Pharmacology; Cancer research; Oncology; Bioinformatics; Biology; Genetics; Messenger RNA","score_opus":0.08830345045470665,"score_gpt":0.3750177748265545,"score_spread":0.28671432437184785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133803355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8431975,0.12729864,0.0068970197,0.003979755,0.00020112091,0.00011636355,0.0007304036,0.00027090503,0.017308218],"genre_scores_gemma":[0.9677498,0.026067372,0.0022246111,0.00029281338,0.00009290732,0.0000377949,0.00023698325,0.000013534505,0.0032842807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999677,0.0000069459174,0.0000034565712,0.000005909389,0.000007118105,0.000008876858],"domain_scores_gemma":[0.99995875,0.000007519018,0.000015966185,0.000002503937,0.000005738099,0.000009530699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014316864,0.000459193,0.0002244536,0.00023472725,0.00019296701,0.00029527617,0.00018842088,0.00036441805,0.0018155668],"category_scores_gemma":[0.00007715361,0.00007659034,0.00015911052,0.00016257,0.00028106262,0.00029099418,0.00010399027,0.00042029767,0.00029393163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006618733,0.00011972061,0.00072434987,0.00021203457,0.000011975253,0.00022670478,0.000024641977,0.00027890404,0.97763103,0.0007923187,0.00025915104,0.019057387],"study_design_scores_gemma":[0.00013195138,0.0021554187,0.01235438,0.000036124005,0.000044317625,0.0009641878,0.000077717355,0.0015075027,0.9634301,0.0007389227,0.018543804,0.00001558405],"about_ca_topic_score_codex":0.00047817806,"about_ca_topic_score_gemma":0.0011331312,"teacher_disagreement_score":0.0018155668,"about_ca_system_score_codex":0.0006732919,"about_ca_system_score_gemma":0.0002087049,"threshold_uncertainty_score":0.0060736537},"labels":[],"label_agreement":null},{"id":"W2135108162","doi":"10.1158/1535-7163.mct-14-0475","title":"Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Irinotecan; Camptothecin; Topotecan; Topoisomerase; Active metabolite; Pharmacology; Cancer research; Pharmacokinetics; Distribution (mathematics); Chemistry; Metabolite; Cancer; Medicine; Colorectal cancer; Chemotherapy; Internal medicine; Biochemistry; Enzyme","score_opus":0.01367049090223115,"score_gpt":0.290800525270385,"score_spread":0.27713003436815387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135108162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287087,0.0016154844,0.002489113,0.000050230898,0.00002061505,0.00010264707,0.0006149396,0.00008597186,0.002150133],"genre_scores_gemma":[0.98999816,0.0013795608,0.002918043,0.000026518072,0.000008081626,0.000107731794,0.0007216976,0.000026083306,0.004814153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998894,0.0000164109,0.00000586603,0.000023276014,0.0000354904,0.000029533225],"domain_scores_gemma":[0.99988735,0.0000338915,0.000021619355,0.000013802713,0.00002593746,0.000017416243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001729008,0.00038586877,0.00033318507,0.00020397663,0.00012597699,0.00022773347,0.00018738514,0.00021683205,0.0011671453],"category_scores_gemma":[0.00013682379,0.00013270693,0.00018338721,0.00020030125,0.00015503011,0.00022461051,0.000096010444,0.0006145856,0.00020456755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013820094,0.000051986528,0.00012784837,0.000028807051,0.0000039686324,0.000026930342,0.000025307472,0.00025431384,0.9979079,0.00003711131,0.000037687856,0.0013600133],"study_design_scores_gemma":[0.000014224353,0.0016531672,0.0033660056,0.000004527248,0.00001639505,0.000104692794,0.000041920168,0.0020885926,0.99176663,0.000020725842,0.0009183811,0.0000047846743],"about_ca_topic_score_codex":0.005420824,"about_ca_topic_score_gemma":0.005235329,"teacher_disagreement_score":0.005420824,"about_ca_system_score_codex":0.00047145694,"about_ca_system_score_gemma":0.00036904076,"threshold_uncertainty_score":0.010778546},"labels":[],"label_agreement":null},{"id":"W2135227533","doi":"10.1158/1535-7163.mct-08-0385","title":"Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"DNA damage; Fludarabine; Chemistry; SOD2; Molecular biology; Reactive oxygen species; Cancer research; Superoxide dismutase; Biology; Biochemistry; DNA; Oxidative stress; Genetics","score_opus":0.02381161412216235,"score_gpt":0.31750936273773106,"score_spread":0.2936977486155687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135227533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98885626,0.0069310707,0.0022058354,0.000091172435,0.000030480805,0.000049485756,0.0002043121,0.0000710582,0.0015603278],"genre_scores_gemma":[0.99677247,0.0012480674,0.00067355443,0.000042695767,0.00001000238,0.000029826922,0.00020717202,0.000004965506,0.0010112254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989986,0.00002244848,0.000008424332,0.000019267662,0.000021855265,0.000028157026],"domain_scores_gemma":[0.9999435,0.0000058205123,0.000024092153,0.0000052896694,0.000008746978,0.000012562298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013865225,0.00031828342,0.00034606105,0.00013301885,0.00012842681,0.00030319765,0.00015253457,0.0002838,0.0009372512],"category_scores_gemma":[0.00009390175,0.00013244803,0.00017862896,0.00009062515,0.00012201346,0.00015954775,0.00016025155,0.00024527943,0.00021791064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003371965,0.000037429065,0.00077352335,0.000055905737,0.00001658904,0.0001139581,0.000021413298,0.000095242176,0.99479216,0.00011715255,0.0000460913,0.0035933193],"study_design_scores_gemma":[0.000084077474,0.0012984073,0.035004705,0.000013734266,0.00006580488,0.00072268257,0.00007442816,0.0015843724,0.9556375,0.00013602502,0.005367528,0.000010702032],"about_ca_topic_score_codex":0.00025000816,"about_ca_topic_score_gemma":0.00043244532,"teacher_disagreement_score":0.0009372512,"about_ca_system_score_codex":0.00030663455,"about_ca_system_score_gemma":0.000121198966,"threshold_uncertainty_score":0.0031354427},"labels":[],"label_agreement":null},{"id":"W2135658143","doi":"10.1158/1535-7163.mct-07-0442","title":"Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Fondation de France","keywords":"DU145; Radiosensitizer; Clonogenic assay; Cancer research; LNCaP; Apoptosis; Chemistry; Cell culture; Cancer cell; Cancer; Biology; Radiation therapy; Internal medicine; Medicine; Biochemistry; Genetics","score_opus":0.024323404240407236,"score_gpt":0.2706454463307952,"score_spread":0.24632204209038794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135658143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931577,0.0032638083,0.0013817211,0.00006485406,0.000030265683,0.000040438208,0.00048058326,0.00019213681,0.0013883956],"genre_scores_gemma":[0.99417984,0.0021065257,0.0011370386,0.000077325174,0.000010801958,0.000031311964,0.00073100434,0.00003154855,0.0016947004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999162,0.000011576324,0.000007376698,0.000016820099,0.000029357663,0.000018729079],"domain_scores_gemma":[0.9999275,0.000012443079,0.000024107578,0.000009361981,0.000009374355,0.00001717199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060948783,0.00042433417,0.00033796977,0.00023845985,0.00015126722,0.00025142063,0.0002461885,0.00019540025,0.0010684575],"category_scores_gemma":[0.00009420668,0.00018207419,0.00028714575,0.00019646305,0.00018600129,0.00016205307,0.00020157131,0.00042269338,0.00027100573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112441536,0.00001967229,0.0001829236,0.00004410986,0.0000119112365,0.00002477288,0.000013000954,0.00008555374,0.9984549,0.00004157315,0.00007180388,0.0009373533],"study_design_scores_gemma":[0.000028889213,0.0006398491,0.0055279247,0.0000049313353,0.000033105196,0.00043919813,0.000018441673,0.00052006444,0.99009633,0.000033111508,0.0026540023,0.000004136865],"about_ca_topic_score_codex":0.001195573,"about_ca_topic_score_gemma":0.002885151,"teacher_disagreement_score":0.001195573,"about_ca_system_score_codex":0.00031615497,"about_ca_system_score_gemma":0.00019947962,"threshold_uncertainty_score":0.0035743117},"labels":[],"label_agreement":null},{"id":"W2136405771","doi":"10.1158/1535-7163.mct-05-0229","title":"Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"AP site; Molecular biology; Melanoma; DNA-(apurinic or apyrimidinic site) lyase; Apoptosis; Transcription factor; Biology; DNA damage; Cancer research; Chemistry; Resveratrol; Base excision repair; DNA; Biochemistry; Gene","score_opus":0.012584265504455867,"score_gpt":0.30510517275107873,"score_spread":0.2925209072466229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136405771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958817,0.0023165264,0.0012927855,0.00003629562,0.000015277028,0.000015601683,0.00012387846,0.000026867256,0.00029108347],"genre_scores_gemma":[0.9967962,0.00094260735,0.0010630407,0.000016131087,0.0000047829417,0.000017421915,0.00021389822,0.000004759408,0.00094127026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999094,0.000017750861,0.000009104194,0.000027956135,0.00001786146,0.000017997343],"domain_scores_gemma":[0.9999485,0.000007946819,0.000015539305,0.0000065626477,0.0000098808305,0.000011585158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013828547,0.0002987817,0.00015783173,0.00020781076,0.0001018153,0.00014166265,0.00010034541,0.00028120575,0.00075000804],"category_scores_gemma":[0.0001005571,0.00014273559,0.00026875304,0.00010541469,0.0001426685,0.000153786,0.00007587046,0.00037302368,0.00020439559],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004911739,0.000014735695,0.00016812466,0.00001559646,0.0000027901938,0.0000284905,0.000011214196,0.0000107624255,0.99932957,0.000020331281,0.000005240532,0.00034414366],"study_design_scores_gemma":[0.000014632203,0.000555454,0.00921743,0.0000038250296,0.000026790463,0.00053962355,0.000033013417,0.00042586974,0.98818886,0.00004595938,0.0009444388,0.0000041719436],"about_ca_topic_score_codex":0.0004178225,"about_ca_topic_score_gemma":0.00037922835,"teacher_disagreement_score":0.00075000804,"about_ca_system_score_codex":0.00015707624,"about_ca_system_score_gemma":0.0000964088,"threshold_uncertainty_score":0.002508998},"labels":[],"label_agreement":null},{"id":"W2136509222","doi":"10.1158/1535-7163.mct-06-0050","title":"Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Apoptosis; Leukemia; Tumor necrosis factor alpha; Biology; Cancer cell; Programmed cell death; Receptor; Ligand (biochemistry); HL60; Recombinant DNA; Cancer research; Cell biology; Molecular biology; Cancer; Gene; Immunology; Genetics","score_opus":0.011518527909936972,"score_gpt":0.23907698181875311,"score_spread":0.22755845390881616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136509222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258363,0.0013943118,0.004459732,0.00011094695,0.000011025854,0.00005317093,0.00021713907,0.00012208367,0.0010479972],"genre_scores_gemma":[0.99689305,0.00071357156,0.0011049282,0.000044793487,0.000009787451,0.000029900539,0.00023675492,0.00001137651,0.00095582183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975306,0.000035058834,0.000035604,0.00004341931,0.000078226716,0.000054617667],"domain_scores_gemma":[0.99979085,0.000030079682,0.00007766338,0.000046089575,0.000031486637,0.000023850467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018301183,0.00036984726,0.00042463458,0.00033988082,0.00014829774,0.0005848338,0.00027948339,0.00044195633,0.0010452409],"category_scores_gemma":[0.00023323145,0.00017138792,0.00031771165,0.00021074718,0.00030387598,0.0003295232,0.00030331762,0.0005249382,0.00068739476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020348921,0.0000321504,0.0023745522,0.0000304659,0.000013250574,0.00020574381,0.000041371593,0.0002043556,0.99334323,0.00027607864,0.000056637695,0.0032186785],"study_design_scores_gemma":[0.00008304667,0.000501148,0.028083632,0.000007790073,0.00004468357,0.0037134252,0.00008720148,0.00281926,0.9613613,0.00052151736,0.00276096,0.000016073267],"about_ca_topic_score_codex":0.00024946764,"about_ca_topic_score_gemma":0.00019836436,"teacher_disagreement_score":0.0010452409,"about_ca_system_score_codex":0.00043301622,"about_ca_system_score_gemma":0.00014787033,"threshold_uncertainty_score":0.0034966469},"labels":[],"label_agreement":null},{"id":"W2136671570","doi":"10.1158/1535-7163.mct-11-0756","title":"New Directions for Biologic Targets in Urothelial Carcinoma","year":2012,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Metastatic Urothelial Carcinoma; Clinical trial; Urothelial carcinoma; Disease; Oncology; Cancer; Stage (stratigraphy); Urothelial cancer; Internal medicine; Bladder cancer; Intensive care medicine; Biology","score_opus":0.09693421337094198,"score_gpt":0.37602540015036656,"score_spread":0.27909118677942457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136671570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039262264,0.99876475,0.0000787512,0.0004893575,0.00017379869,0.0000031903305,0.000007105963,0.000004658809,0.0004391087],"genre_scores_gemma":[0.0003696507,0.99836785,0.00020869137,0.00046874935,0.00020483455,0.0000073588585,0.000014357551,0.0000014804375,0.00035707667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996233,0.00010284806,0.000055479297,0.000052886033,0.00013344045,0.000031915944],"domain_scores_gemma":[0.9993661,0.0003720824,0.00006768512,0.000023610633,0.00013483562,0.00003565028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016526853,0.0010758425,0.0020690863,0.0026297085,0.00039731667,0.001447548,0.0010771208,0.0018351575,0.004763258],"category_scores_gemma":[0.0011162513,0.00038815435,0.0008646168,0.0024133676,0.0009847624,0.003520716,0.0009908043,0.0042290287,0.0024447495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121555546,0.0001640885,0.00016235818,0.019508239,0.00011663224,0.0003068891,0.00009955071,0.00048193603,0.0017022158,0.012430206,0.044659447,0.92024696],"study_design_scores_gemma":[0.00004928724,0.00012873128,0.00043166053,0.004224809,0.00009836257,0.00085561967,0.000084260835,0.00009727124,0.00026855915,0.0054964703,0.9882483,0.000016748088],"about_ca_topic_score_codex":0.00095882744,"about_ca_topic_score_gemma":0.0022768453,"teacher_disagreement_score":0.004763258,"about_ca_system_score_codex":0.00090611493,"about_ca_system_score_gemma":0.0015517671,"threshold_uncertainty_score":0.015934646},"labels":[],"label_agreement":null},{"id":"W2136923586","doi":"10.1158/1535-7163.mct-06-0118","title":"Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Celator Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Pharmacology; In vivo; Daunorubicin; Irinotecan; Pharmacokinetics; Medicine; Therapeutic index; Drug interaction; Floxuridine; In vitro; Dosing; Chemotherapy; Chemistry; Cancer; Internal medicine; Fluorouracil; Biology; Colorectal cancer","score_opus":0.012454386906906128,"score_gpt":0.2571616014258772,"score_spread":0.24470721451897107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136923586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667753,0.0035898923,0.025134888,0.00026524157,0.000116495954,0.00064194034,0.0004913676,0.0005812811,0.002403615],"genre_scores_gemma":[0.9644211,0.0021601715,0.029914644,0.00014986657,0.00007855281,0.00071669504,0.00046799344,0.00014204787,0.0019490351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918646,0.00016008255,0.00007526898,0.0002122477,0.00021195563,0.00015398175],"domain_scores_gemma":[0.9995529,0.00007457338,0.000175344,0.00008165584,0.000045554545,0.00006997408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006662485,0.0009512822,0.00076387846,0.0010574764,0.00019502947,0.00056992803,0.00063517276,0.0006172909,0.00082467945],"category_scores_gemma":[0.0005070321,0.00045540443,0.00037386405,0.0005406165,0.00045015357,0.0007382811,0.00037582195,0.0016004948,0.00035836097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025381419,0.00016656419,0.00011171164,0.000027560929,0.00001011508,0.000011943987,0.000014912595,0.00024157393,0.99538994,0.000092309325,0.00005532691,0.0036243366],"study_design_scores_gemma":[0.00005031165,0.0015900297,0.00046733793,0.0000039930705,0.000027265183,0.00005707443,0.0000058411333,0.0013858365,0.9950021,0.00004645228,0.0013544917,0.000009177071],"about_ca_topic_score_codex":0.0002340954,"about_ca_topic_score_gemma":0.00041855525,"teacher_disagreement_score":0.0010574764,"about_ca_system_score_codex":0.0004567563,"about_ca_system_score_gemma":0.0003435739,"threshold_uncertainty_score":0.003523469},"labels":[],"label_agreement":null},{"id":"W2137268781","doi":"10.1158/1535-7163.mct-09-0960","title":"Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canada Research Chairs; GlaxoSmithKline","keywords":"Topotecan; Medicine; Pazopanib; Ovarian cancer; Pharmacology; Paclitaxel; Irinotecan; Chemotherapy; Cyclophosphamide; Ovarian carcinoma; Cancer; Oncology; Internal medicine; Sunitinib; Colorectal cancer","score_opus":0.030211782874553963,"score_gpt":0.3444115221306979,"score_spread":0.314199739256144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137268781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592113,0.0011015103,0.00085750327,0.00015160759,0.000048816488,0.00024608904,0.00046544473,0.000074088304,0.0011337636],"genre_scores_gemma":[0.99540734,0.00092359894,0.0013959919,0.000055091,0.000021780239,0.00020021533,0.00077797787,0.000017631852,0.0012003079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977356,0.000055329958,0.000015078192,0.000029340323,0.00005555504,0.00007105387],"domain_scores_gemma":[0.9998584,0.000022919865,0.000025311663,0.000015266596,0.000014593489,0.000063571395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032261363,0.0006461433,0.000739091,0.00044285547,0.0002317613,0.00049929135,0.00039562007,0.00042408297,0.0013042855],"category_scores_gemma":[0.00022783769,0.00023756595,0.00030437583,0.00036723685,0.00031601696,0.00035884095,0.00019254284,0.0013957323,0.00019628556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004771585,0.0060364036,0.000700695,0.00015082152,0.00006132445,0.000111994064,0.00006282927,0.0015489354,0.9712804,0.00027824394,0.00053891324,0.014457748],"study_design_scores_gemma":[0.0023254757,0.07252346,0.007325383,0.000017338418,0.00017141005,0.00041526734,0.00004813679,0.0028672267,0.9108428,0.0001057117,0.003334254,0.000023413597],"about_ca_topic_score_codex":0.0016004933,"about_ca_topic_score_gemma":0.0044123936,"teacher_disagreement_score":0.0016004933,"about_ca_system_score_codex":0.0005264979,"about_ca_system_score_gemma":0.00094003836,"threshold_uncertainty_score":0.0043632984},"labels":[],"label_agreement":null},{"id":"W2137667786","doi":"10.1158/1535-7163.mct-05-0504","title":"Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; MAPK/ERK pathway; Ribosomal protein s6; Pharmacology; Epidermal growth factor receptor; Cancer research; Kinase; Epidermal growth factor; Phosphorylation; EGFR inhibitors; Medicine; Vascular endothelial growth factor; Erlotinib Hydrochloride; Chemistry; Biology; Protein kinase A; Internal medicine; Receptor; Biochemistry; Protein phosphorylation; VEGF receptors","score_opus":0.015827044223813883,"score_gpt":0.2724241610232969,"score_spread":0.25659711679948305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137667786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531245,0.0016288925,0.00041746435,0.00014577886,0.00007123053,0.000051452764,0.000399754,0.000089201254,0.0018836954],"genre_scores_gemma":[0.99651873,0.0008612006,0.0008248939,0.000038135284,0.000014628643,0.000056285528,0.00051537436,0.000012819607,0.0011579811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999826,0.00003820508,0.000012645607,0.000027494241,0.000041906478,0.00005375067],"domain_scores_gemma":[0.99990594,0.000019824178,0.000017194348,0.000011637307,0.0000127575795,0.000032678807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016153102,0.00040414327,0.0005977978,0.00031266917,0.0001891113,0.00036886698,0.00028389908,0.00027777636,0.0010568398],"category_scores_gemma":[0.00014582877,0.00017517207,0.00039540214,0.00023242163,0.00015568873,0.0002496154,0.00014078492,0.00088404096,0.00030628953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017289788,0.00058820186,0.00055934355,0.00012008005,0.000049732393,0.00009853317,0.000040846844,0.00071361946,0.98816633,0.00013090225,0.00060944183,0.007194075],"study_design_scores_gemma":[0.0002016208,0.0068816,0.007943025,0.000012189605,0.00009601199,0.00044455082,0.000058582747,0.0032359748,0.9766759,0.00003743322,0.004398224,0.000014785111],"about_ca_topic_score_codex":0.0026157247,"about_ca_topic_score_gemma":0.005072848,"teacher_disagreement_score":0.0026157247,"about_ca_system_score_codex":0.0004484622,"about_ca_system_score_gemma":0.0005405966,"threshold_uncertainty_score":0.0052010417},"labels":[],"label_agreement":null},{"id":"W2138124620","doi":"10.1158/1535-7163.mct-10-0249","title":"Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Docetaxel; Ovarian cancer; Chemotherapy; Medicine; Debulking; Oncology; Internal medicine; Cancer; Angiogenesis; Tumor microenvironment; Cancer research; Pharmacology","score_opus":0.021881203073399767,"score_gpt":0.3033659557191305,"score_spread":0.28148475264573075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138124620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842741,0.006417051,0.0046543586,0.00038712317,0.00017515615,0.0001272986,0.0009669965,0.0002980885,0.0026997924],"genre_scores_gemma":[0.98867166,0.0031421937,0.0027706341,0.00007240984,0.000047938276,0.000104742685,0.00074552547,0.00005990485,0.0043849926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977535,0.000049370363,0.000019280278,0.00004221727,0.000060808874,0.000052944648],"domain_scores_gemma":[0.99972314,0.00004945072,0.000091840746,0.000030883904,0.000020497444,0.00008416496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025311753,0.0005284764,0.00049606076,0.0005652816,0.00020103906,0.0004370585,0.00031990584,0.00034099826,0.0012256701],"category_scores_gemma":[0.00021314123,0.0001875072,0.0002424269,0.0002359929,0.0004018678,0.00036995817,0.00018560143,0.0011158963,0.000253174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012315795,0.0010542126,0.00034517463,0.00011262857,0.000019316478,0.000068953465,0.00005849343,0.0007254157,0.98614305,0.00024799837,0.00049796124,0.009495236],"study_design_scores_gemma":[0.00041833395,0.010615302,0.003899571,0.000024563742,0.00007463197,0.0002975669,0.00003833428,0.002811091,0.9752914,0.00012495203,0.0063890624,0.0000151243785],"about_ca_topic_score_codex":0.0011223097,"about_ca_topic_score_gemma":0.0023640594,"teacher_disagreement_score":0.0012256701,"about_ca_system_score_codex":0.00047731056,"about_ca_system_score_gemma":0.00036158296,"threshold_uncertainty_score":0.0041003227},"labels":[],"label_agreement":null},{"id":"W2138465485","doi":"10.1158/1535-7163.mct-05-0361","title":"AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Nucleolin; IκB kinase; IκBα; NF-κB; Biology; Phosphorylation; Cancer research; Kinase; Transcription factor; Cell biology; Molecular biology; Signal transduction; Biochemistry; Cytoplasm; Gene","score_opus":0.012420503632412521,"score_gpt":0.24124494833509222,"score_spread":0.2288244447026797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138465485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875996,0.004852513,0.0050540143,0.00010500286,0.000061249026,0.00002803003,0.00014664083,0.00017975277,0.001973174],"genre_scores_gemma":[0.9933695,0.0016556062,0.002329631,0.000053482057,0.000013429056,0.000033866345,0.0003063764,0.000017034154,0.0022211417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999113,0.000013800832,0.000009221277,0.000019527328,0.000028838498,0.000017313689],"domain_scores_gemma":[0.9999485,0.000009911107,0.000017860506,0.0000061852893,0.0000042237693,0.000013368968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007588059,0.0002709347,0.00021070678,0.00012832656,0.00007570554,0.00014732973,0.00014789698,0.00016077698,0.00062287756],"category_scores_gemma":[0.00008244746,0.00009946012,0.00016867238,0.00008718317,0.00017012932,0.000097796226,0.00013743718,0.00039545566,0.00018548607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006371186,0.000035327084,0.00008130884,0.000028591669,0.0000040948507,0.000018203235,0.0000045004717,0.000027195909,0.9988016,0.000032327156,0.00002223108,0.0008809891],"study_design_scores_gemma":[0.000026115886,0.00046176784,0.0022446606,0.000004585533,0.000011744731,0.0002475666,0.00000873039,0.00061770214,0.99351925,0.00003261277,0.0028228406,0.000002408726],"about_ca_topic_score_codex":0.00024216586,"about_ca_topic_score_gemma":0.00039386612,"teacher_disagreement_score":0.00062287756,"about_ca_system_score_codex":0.00015739724,"about_ca_system_score_gemma":0.00010649434,"threshold_uncertainty_score":0.0020837188},"labels":[],"label_agreement":null},{"id":"W2138590199","doi":"10.1158/1535-7163.mct-07-0482","title":"Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":435,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Glycolysis; Chemistry; Intracellular; NAD+ kinase; Flux (metallurgy); Biochemistry; Cell culture; Enzyme; Cell growth; Transfection; Cancer cell; Growth inhibition; Kinase; Molecular biology; Biology; Cancer; Gene","score_opus":0.019702526442697908,"score_gpt":0.24644757474416887,"score_spread":0.22674504830147096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138590199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930327,0.002709686,0.0020086942,0.00009081849,0.000035051668,0.000045924604,0.0003027517,0.00014712883,0.0016272869],"genre_scores_gemma":[0.9949528,0.00184424,0.001228104,0.000030165967,0.000008273685,0.000040437226,0.00058282225,0.000015952279,0.0012972458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993205,0.0000075151106,0.0000046594305,0.000011416047,0.000022720065,0.000021601627],"domain_scores_gemma":[0.99996185,0.000009109587,0.000012170681,0.0000035259054,0.0000033271267,0.000010014977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009036532,0.0003451563,0.00027162087,0.00015995752,0.00011122749,0.00024715933,0.00021283844,0.00018561097,0.00070028286],"category_scores_gemma":[0.00008120952,0.00011500232,0.00022862328,0.00011614694,0.00016011074,0.00013202862,0.000118898126,0.0005027022,0.00019556875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003128595,0.00015261113,0.00013672879,0.000059089984,0.00001386537,0.000044958004,0.000009330065,0.00048725834,0.9942708,0.0001637286,0.00009791658,0.0042508757],"study_design_scores_gemma":[0.00008367389,0.0011022474,0.0011951046,0.0000037887764,0.000022200276,0.00016621921,0.00000776367,0.0015852227,0.99324965,0.00003078901,0.0025489777,0.0000043994523],"about_ca_topic_score_codex":0.0004964484,"about_ca_topic_score_gemma":0.001117087,"teacher_disagreement_score":0.00070028286,"about_ca_system_score_codex":0.00025781363,"about_ca_system_score_gemma":0.00021545375,"threshold_uncertainty_score":0.002342701},"labels":[],"label_agreement":null},{"id":"W2138642497","doi":"10.1158/1535-7163.mct-13-0420","title":"Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Paracrine signalling; Hedgehog; Hedgehog signaling pathway; Cancer research; Stromal cell; Smoothened; Sonic hedgehog; Biology; GLI1; Autocrine signalling; Cell biology; Signal transduction; Cell culture; Receptor; Genetics","score_opus":0.02851572192640275,"score_gpt":0.30492392390308837,"score_spread":0.27640820197668564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138642497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992523,0.0016310036,0.0020090232,0.00011497489,0.000022602277,0.00006673047,0.00027608362,0.00014182104,0.0032147912],"genre_scores_gemma":[0.9954921,0.0007945398,0.001630719,0.000079917125,0.000010734079,0.000029595716,0.0005238269,0.000008451204,0.0014302365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992466,0.000011792595,0.000006300796,0.000013505354,0.000019981062,0.000023742406],"domain_scores_gemma":[0.9999554,0.000008905323,0.000010578127,0.0000055594005,0.000005896763,0.000013664189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015223424,0.0004188961,0.0002636804,0.00018713088,0.00008305784,0.00020849986,0.00023831983,0.00028299296,0.0013958932],"category_scores_gemma":[0.00008069947,0.00013284772,0.00021154743,0.00010863513,0.00013010151,0.00013131698,0.00010166356,0.00048763235,0.00030663252],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031444788,0.00017434676,0.0003070647,0.00005540065,0.0000134472175,0.000049726696,0.000010297878,0.00021539937,0.99062514,0.00010316599,0.00015239953,0.0079791285],"study_design_scores_gemma":[0.00020463466,0.0050288755,0.00454887,0.000009066827,0.00008306374,0.0007577396,0.00001387417,0.0018285755,0.98334265,0.000048445567,0.0041257166,0.000008355134],"about_ca_topic_score_codex":0.0006959504,"about_ca_topic_score_gemma":0.0013315312,"teacher_disagreement_score":0.0013958932,"about_ca_system_score_codex":0.0002996669,"about_ca_system_score_gemma":0.00020926066,"threshold_uncertainty_score":0.0046696663},"labels":[],"label_agreement":null},{"id":"W2138761399","doi":"10.1158/1535-7163.mct-06-0169","title":"Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Metastasis; Angiogenesis; Cancer research; Matrix metalloproteinase; Small interfering RNA; Lung cancer; Matrix metalloproteinase inhibitor; Biology; Tumor progression; RNA interference; Extracellular matrix; Gene silencing; Cancer; Medicine; Pathology; RNA; Cell culture; Transfection; Cell biology; Gene; Biochemistry","score_opus":0.010935803983070654,"score_gpt":0.24499564020017997,"score_spread":0.23405983621710932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138761399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96180165,0.0062452033,0.016097385,0.0009931792,0.0005624273,0.0006343369,0.0041835764,0.002452403,0.007029872],"genre_scores_gemma":[0.9561129,0.004010803,0.015735773,0.0004086647,0.00012241423,0.00088772865,0.0044443957,0.00029101298,0.017986191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994049,0.000100281875,0.000064530475,0.00014893487,0.00014096123,0.00014036789],"domain_scores_gemma":[0.99956137,0.000083112194,0.00012249041,0.000057970832,0.000034086803,0.00014101653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006156831,0.0012920605,0.0008028483,0.0014733311,0.00029198657,0.0005959867,0.0007237418,0.0011520683,0.0021735448],"category_scores_gemma":[0.0002565506,0.0005387518,0.0007651789,0.00043146632,0.0005589685,0.0004367499,0.0002653912,0.0021755002,0.0007932588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048791248,0.00043448465,0.00011274302,0.000055874418,0.000017800521,0.000063576,0.00002344543,0.00014076516,0.9961283,0.00030509089,0.00026027882,0.0019696618],"study_design_scores_gemma":[0.00060711947,0.0043984535,0.0027816666,0.000028759774,0.00007764473,0.00040753098,0.00003992781,0.004370739,0.97916085,0.00019059633,0.007912165,0.000024519739],"about_ca_topic_score_codex":0.0016634278,"about_ca_topic_score_gemma":0.0024721469,"teacher_disagreement_score":0.0021735448,"about_ca_system_score_codex":0.0007393612,"about_ca_system_score_gemma":0.00059169484,"threshold_uncertainty_score":0.00727123},"labels":[],"label_agreement":null},{"id":"W2139514479","doi":"10.1158/1535-7163.1513.3.12","title":"The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical–dependent and Jun NH2-terminal kinase–dependent mechanism","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Apoptosis; Kinase; Chemistry; Caspase; Mitochondrion; Cell biology; Cancer research; Programmed cell death; Biology; Biochemistry","score_opus":0.011366418037141553,"score_gpt":0.25635340888952596,"score_spread":0.2449869908523844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139514479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973132,0.001166081,0.0007078908,0.000050038983,0.000013495336,0.000023223354,0.00008567803,0.000031088315,0.00060913526],"genre_scores_gemma":[0.99749774,0.0006299066,0.00083027745,0.000032098054,0.000007937964,0.000026074238,0.00025563687,0.0000053857034,0.00071489526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981576,0.000039901286,0.000014726043,0.000022596598,0.000054322336,0.000052650714],"domain_scores_gemma":[0.9999176,0.000017568947,0.00002015072,0.000012010016,0.000011329117,0.000021339883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018717852,0.00034862553,0.00034251148,0.00016969968,0.00016125586,0.0003136365,0.00020996215,0.00022903825,0.0006721975],"category_scores_gemma":[0.0001114071,0.00016876408,0.00029866863,0.00018836142,0.00014225242,0.00016174186,0.00020062315,0.00044665928,0.00028054565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029311606,0.00007100232,0.0002668048,0.000024194833,0.000010864638,0.0000533012,0.000017147235,0.000053845062,0.99813473,0.00003833215,0.000029504603,0.0010072859],"study_design_scores_gemma":[0.00006256306,0.0008866405,0.0041720322,0.0000032472935,0.000025525016,0.00020274625,0.000021841159,0.0008126267,0.9923959,0.000020617514,0.0013928859,0.0000034148218],"about_ca_topic_score_codex":0.0006568985,"about_ca_topic_score_gemma":0.0015322887,"teacher_disagreement_score":0.0006721975,"about_ca_system_score_codex":0.00033624427,"about_ca_system_score_gemma":0.00024313803,"threshold_uncertainty_score":0.002439618},"labels":[],"label_agreement":null},{"id":"W2139966699","doi":"10.1158/1535-7163.mct-10-0677","title":"Notch Signaling Pathway as a Therapeutic Target in Breast Cancer","year":2010,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; University of California, Davis; Cancer Research Coordinating Committee; Office of Research and Development; Purdue University","keywords":"Notch signaling pathway; Cancer; Breast cancer; Signal transduction; Cancer research; Medicine; Disease; Biology; Bioinformatics; Pharmacology; Internal medicine; Genetics","score_opus":0.022170255742610258,"score_gpt":0.314756041743817,"score_spread":0.2925857860012067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139966699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017270536,0.9974711,0.00019998667,0.00032640688,0.00023850691,0.00000760625,0.000017182489,0.000012730251,0.0015538653],"genre_scores_gemma":[0.0010511102,0.9967398,0.00033449553,0.00035805764,0.00019544232,0.000012871213,0.000039156817,0.0000031058782,0.0012659493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986994,0.000025334051,0.000014758758,0.000021143505,0.00005480663,0.000013993675],"domain_scores_gemma":[0.9998679,0.000052517655,0.00001905602,0.0000054453367,0.000037196154,0.000017815382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053046254,0.0008180263,0.0012961878,0.0015037698,0.00022941548,0.0006741889,0.0009931121,0.0010938847,0.0033649537],"category_scores_gemma":[0.00035928082,0.00024284517,0.00036635375,0.0013224739,0.00040930984,0.0010057474,0.0005346235,0.0022419398,0.0032673033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106128864,0.00010032883,0.000109636516,0.006611484,0.000077037614,0.0004023064,0.000038013255,0.00051539834,0.0035408018,0.0047199004,0.05355859,0.93022037],"study_design_scores_gemma":[0.00004335199,0.00010466524,0.0004844698,0.0012260529,0.00006752793,0.0020297782,0.000028024684,0.00014318926,0.00064633344,0.0017527535,0.9934602,0.000013565532],"about_ca_topic_score_codex":0.00073562714,"about_ca_topic_score_gemma":0.0016270803,"teacher_disagreement_score":0.0033649537,"about_ca_system_score_codex":0.0005899992,"about_ca_system_score_gemma":0.00055974745,"threshold_uncertainty_score":0.011256874},"labels":[],"label_agreement":null},{"id":"W2139995836","doi":"10.1158/1535-7163.mct-07-2217","title":"Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor–induced angiogenesis","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Pharmacology; RHOA; Angiogenesis; Vascular endothelial growth factor; Chemistry; Naltrexone; Protein kinase B; Cancer research; Medicine; Receptor; Opioid; Signal transduction; Biochemistry","score_opus":0.026847572037158148,"score_gpt":0.2854884292025764,"score_spread":0.25864085716541824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139995836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904925,0.0051061916,0.00142537,0.00012518036,0.00007211553,0.000090335125,0.00010048917,0.000041627038,0.002546098],"genre_scores_gemma":[0.99551857,0.0015375294,0.0019190427,0.00006408698,0.000020281583,0.000041086718,0.00009930918,0.000003456974,0.00079670525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998385,0.000043370004,0.000014277802,0.000021757474,0.000038540067,0.00004355624],"domain_scores_gemma":[0.9999236,0.000021569967,0.00002046815,0.0000061639835,0.000006656426,0.000021455713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018834596,0.00035722545,0.00040847395,0.0002339417,0.00009368745,0.00021147625,0.00015501711,0.00021645219,0.00084005244],"category_scores_gemma":[0.0001494795,0.00014924024,0.0003545908,0.00011385305,0.00013641603,0.00016511675,0.00020571417,0.00042539646,0.00012891895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005893239,0.00018858186,0.00031456235,0.00008729959,0.000030415607,0.000080557336,0.00001770312,0.00032876342,0.9905511,0.0000863175,0.000108176195,0.0076170787],"study_design_scores_gemma":[0.00023292897,0.007749851,0.008678185,0.000021234218,0.00013578129,0.0006286846,0.0000450384,0.0036725602,0.9752774,0.000056012297,0.0034874415,0.000014877039],"about_ca_topic_score_codex":0.00059312617,"about_ca_topic_score_gemma":0.0025110934,"teacher_disagreement_score":0.00084005244,"about_ca_system_score_codex":0.00018534517,"about_ca_system_score_gemma":0.00023911259,"threshold_uncertainty_score":0.0028101802},"labels":[],"label_agreement":null},{"id":"W2140081727","doi":"10.1158/1535-7163.mct-12-0060","title":"Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"","keywords":"Bivalent (engine); Ectodomain; Antibody; Receptor; Potency; In vivo; Chemistry; Immunoglobulin light chain; In vitro; Linker; Transforming growth factor; Molecular biology; Biology; Biochemistry; Cell biology; Immunology; Genetics","score_opus":0.01984387045036865,"score_gpt":0.2575980395753182,"score_spread":0.23775416912494954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140081727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93692046,0.0060823876,0.053307965,0.0002929324,0.00011653157,0.00028218736,0.00028342314,0.0002076273,0.0025065292],"genre_scores_gemma":[0.97179836,0.00270534,0.023126185,0.00012797445,0.000018576231,0.00013510777,0.0002251211,0.000022055105,0.0018413028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998895,0.0000178663,0.0000069936214,0.000025512803,0.000034429788,0.000025686357],"domain_scores_gemma":[0.99995184,0.0000058418595,0.000019784857,0.0000028387337,0.000006463741,0.000013227431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014947039,0.000337005,0.00019318332,0.00016458391,0.00007447082,0.0002302886,0.00023304363,0.00039228686,0.0005186059],"category_scores_gemma":[0.00007963314,0.00013702983,0.0002517771,0.00008426271,0.00010940359,0.00014123361,0.00023972068,0.0004230548,0.00021191829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037778882,0.000030463285,0.000064876695,0.00005561982,0.000009439633,0.00004968295,0.000010669965,0.0004345734,0.9953773,0.00015668548,0.00006722628,0.0037056392],"study_design_scores_gemma":[0.000053714237,0.0009335675,0.00057536655,0.000013710413,0.00004484993,0.0007154481,0.0000218283,0.0046291766,0.9855979,0.00007503561,0.0073301196,0.000009289821],"about_ca_topic_score_codex":0.00016367713,"about_ca_topic_score_gemma":0.0002474838,"teacher_disagreement_score":0.0005186059,"about_ca_system_score_codex":0.00019016385,"about_ca_system_score_gemma":0.00011034549,"threshold_uncertainty_score":0.001734972},"labels":[],"label_agreement":null},{"id":"W2140280994","doi":"10.1158/1535-7163.mct-11-0402","title":"ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research","keywords":"Ovarian cancer; Debulking; Medicine; Cancer; Stage (stratigraphy); Ovarian tumor; Internal medicine; Asymptomatic; Disease; Malignancy; Cancer research; Oncology; Pathology; Biology","score_opus":0.045531385289772235,"score_gpt":0.2908881867137836,"score_spread":0.24535680142401134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140280994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425393,0.0013324984,0.0024112086,0.00018140246,0.00007125589,0.000075793214,0.0005051024,0.00012709424,0.0010416814],"genre_scores_gemma":[0.98911333,0.0020608273,0.0024861547,0.00009847478,0.00003020773,0.00013695436,0.0009644921,0.000039506176,0.0050701182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979967,0.000039870516,0.000023486306,0.000034695782,0.000055482047,0.000046726895],"domain_scores_gemma":[0.9998006,0.000025572188,0.00007033958,0.000020996406,0.000017025053,0.00006548734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022044635,0.0005573034,0.00035920047,0.000568951,0.00017661205,0.00021154461,0.00025867217,0.00045786332,0.0010639096],"category_scores_gemma":[0.00010840323,0.00022797265,0.00035447182,0.00021921915,0.00025429286,0.00028194158,0.00014330796,0.001272981,0.0002899048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004058238,0.00047282272,0.00021431594,0.000038747894,0.000010904848,0.00007302038,0.00001788186,0.00016174869,0.99652594,0.00009322977,0.00009836458,0.0018871578],"study_design_scores_gemma":[0.00016756779,0.0067645945,0.0035404533,0.00001212604,0.000036427402,0.0003397887,0.000028451812,0.0020848853,0.9845517,0.00007578623,0.0023899258,0.000008283796],"about_ca_topic_score_codex":0.00064478465,"about_ca_topic_score_gemma":0.0009915971,"teacher_disagreement_score":0.0010639096,"about_ca_system_score_codex":0.00029127175,"about_ca_system_score_gemma":0.00023523226,"threshold_uncertainty_score":0.0035591722},"labels":[],"label_agreement":null},{"id":"W2140445067","doi":"10.1158/1535-7163.mct-06-0593","title":"A novel three-dimensional model to quantify metastatic melanoma invasion","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institutes of Health; National Heart, Lung, and Blood Institute; Achievement Rewards for College Scientists Foundation","keywords":"In vivo; Metastasis; Melanoma; Cancer research; Metastatic melanoma; Cell culture; In vitro; Biology; Cell; Cancer; Matrix (chemical analysis); Chemistry; Biotechnology; Genetics","score_opus":0.08281787466730878,"score_gpt":0.3430587174017718,"score_spread":0.260240842734463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140445067","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09508519,0.0005647027,0.8911503,0.00037548566,0.00011882188,0.00017630559,0.0016047182,0.0013249031,0.009599557],"genre_scores_gemma":[0.6415502,0.0011863874,0.34476683,0.0001274148,0.000028755197,0.00053163926,0.0012711472,0.0001840753,0.01035358],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998635,0.000023245266,0.000010787325,0.000026959633,0.00006314424,0.000012221542],"domain_scores_gemma":[0.99985886,0.00005880759,0.000020130941,0.00002177257,0.000025485175,0.000014840328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001764949,0.00050802866,0.00024023619,0.00042790815,0.00019949312,0.0007316672,0.0005403218,0.00075154303,0.0021400487],"category_scores_gemma":[0.00031419465,0.00025240926,0.00054717384,0.00034959384,0.00030882232,0.00039496078,0.0004817847,0.0006056787,0.0005153853],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118993434,0.00013148181,0.0010597269,0.00019403087,0.000033996286,0.0003296141,0.00012663538,0.4832373,0.47903427,0.0135811595,0.0015712703,0.020581542],"study_design_scores_gemma":[0.000015087109,0.00009004702,0.0009963267,0.000011146996,0.000014765048,0.0002357663,0.000023490345,0.9551475,0.034330662,0.0017037876,0.007394799,0.000036591202],"about_ca_topic_score_codex":0.0038474568,"about_ca_topic_score_gemma":0.0045812516,"teacher_disagreement_score":0.0038474568,"about_ca_system_score_codex":0.00050224765,"about_ca_system_score_gemma":0.00068487326,"threshold_uncertainty_score":0.007650137},"labels":[],"label_agreement":null},{"id":"W2141129148","doi":"10.1158/1535-7163.mct-08-0569","title":"A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"GLUT1; Programmed cell death; Apoptosis; Receptor; Glucose transporter; Cell biology; Fas ligand; Cancer cell; Intracellular; Glucose uptake; Biology; Mechanism of action; Tumor necrosis factor alpha; Chemistry; Biochemistry; Pharmacology; In vitro; Endocrinology; Cancer; Insulin; Genetics","score_opus":0.030223424061894526,"score_gpt":0.2658304461202831,"score_spread":0.2356070220583886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141129148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888498,0.0038931048,0.003837473,0.0001233322,0.000042920354,0.00006580716,0.00010843851,0.00009735542,0.0029817733],"genre_scores_gemma":[0.9904165,0.0023723703,0.004552682,0.000053081763,0.000009094801,0.000037195023,0.00029770736,0.000009884588,0.0022514604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994993,0.000010274317,0.000004284819,0.00001137645,0.00001297545,0.000011159741],"domain_scores_gemma":[0.9999745,0.0000071198647,0.000006286579,0.0000031378308,0.000002955071,0.0000059275985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000777088,0.00031929216,0.00019357126,0.00016118544,0.00012591082,0.00019180404,0.00018823771,0.00018657626,0.0008150774],"category_scores_gemma":[0.000066704815,0.00009082872,0.00012839044,0.00012265552,0.00016134829,0.00013948344,0.00011098656,0.00035163548,0.00013969348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013625855,0.000057350113,0.00007920651,0.00005007841,0.0000052891855,0.000067233545,0.000010230058,0.00018938891,0.99516594,0.00025136032,0.000051395124,0.0039361506],"study_design_scores_gemma":[0.00005789806,0.00089310313,0.0008670207,0.000005982639,0.000010642246,0.00036929222,0.000008157873,0.0009105505,0.99240804,0.000040233266,0.004424208,0.000004819755],"about_ca_topic_score_codex":0.00040104362,"about_ca_topic_score_gemma":0.0010371454,"teacher_disagreement_score":0.0008150774,"about_ca_system_score_codex":0.00031462716,"about_ca_system_score_gemma":0.000193845,"threshold_uncertainty_score":0.002726674},"labels":[],"label_agreement":null},{"id":"W2141293359","doi":"10.1158/1535-7163.mct-07-0471","title":"WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; DNA damage; Cell cycle; Radioresistance; Apoptosis; Cancer research; DNA repair; Molecular biology; Transfection; Cancer cell; Programmed cell death; Cancer; Cell cycle checkpoint; Tumor suppressor gene; Carcinogenesis; Cell culture; DNA; Genetics","score_opus":0.01783123944710964,"score_gpt":0.26757718047156304,"score_spread":0.2497459410244534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141293359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954047,0.00095336,0.0018997013,0.00009404988,0.000019208372,0.00002973227,0.00037788125,0.00012441856,0.0010968915],"genre_scores_gemma":[0.996845,0.0003236502,0.0008587953,0.000028716548,0.0000060405528,0.000025646983,0.000551686,0.000025221207,0.0013353736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998185,0.000021825703,0.000022309176,0.000040654864,0.000064545115,0.000032211603],"domain_scores_gemma":[0.999828,0.000027881866,0.000046291767,0.00004904067,0.000017515113,0.00003135276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104803694,0.00028489335,0.00032473757,0.00021124631,0.00014409091,0.0003295584,0.00023956144,0.00028885668,0.001633757],"category_scores_gemma":[0.00014738481,0.0001579844,0.00026345125,0.00021085552,0.00022425168,0.00022136171,0.00023101055,0.000649701,0.00063387805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044488082,0.000021066151,0.00018093525,0.000013061236,0.0000026001183,0.00004928869,0.0000055079213,0.000042052678,0.9988508,0.000065469874,0.000023703387,0.0007008917],"study_design_scores_gemma":[0.000012168416,0.00023791149,0.0033261434,0.0000027402332,0.0000075133707,0.0004726251,0.000015529364,0.0005956367,0.99387616,0.000040535328,0.0014107368,0.0000023231626],"about_ca_topic_score_codex":0.00052881095,"about_ca_topic_score_gemma":0.00072516676,"teacher_disagreement_score":0.001633757,"about_ca_system_score_codex":0.00028894923,"about_ca_system_score_gemma":0.00021738808,"threshold_uncertainty_score":0.0054655075},"labels":[],"label_agreement":null},{"id":"W2141323228","doi":"10.1158/1535-7163.mct-11-0826","title":"Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Prostate cancer; Cancer; Prostate; Cancer research; Medicine; Gene; Chromoplexy; DNA sequencing; Internal medicine; Oncology; Biology; PCA3; Genetics","score_opus":0.08997307342824663,"score_gpt":0.33383762010003104,"score_spread":0.24386454667178442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141323228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661244,0.00092646043,0.007564478,0.00040835267,0.00003534328,0.00004924635,0.002403523,0.0001829445,0.0018172961],"genre_scores_gemma":[0.9840546,0.0006124429,0.01099996,0.00023357978,0.000015896365,0.000026738824,0.0024750312,0.000043499273,0.001538163],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99993324,0.000008707929,0.000004642594,0.000019803405,0.00002054101,0.000013103065],"domain_scores_gemma":[0.99991703,0.000028187114,0.0000107458445,0.000008734377,0.0000120344985,0.000023309982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010086913,0.00022194163,0.0002569954,0.00031790376,0.00024231298,0.00025157098,0.00012211554,0.00042438105,0.0013358067],"category_scores_gemma":[0.00024637705,0.00012308691,0.00025631368,0.00019376204,0.00011062151,0.00008020953,0.000117186886,0.000336585,0.00023456058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057708845,0.00008414081,0.03353075,0.000108638815,0.000092410955,0.008795189,0.00024340129,0.0007911572,0.93060476,0.0004485561,0.0014102476,0.023313688],"study_design_scores_gemma":[0.00007360683,0.0011664644,0.23127693,0.00003247737,0.0003799367,0.06014062,0.0003517696,0.011245462,0.66290116,0.0009900623,0.031403188,0.000038383554],"about_ca_topic_score_codex":0.001186519,"about_ca_topic_score_gemma":0.0035247717,"teacher_disagreement_score":0.0013358067,"about_ca_system_score_codex":0.00021240479,"about_ca_system_score_gemma":0.00020586957,"threshold_uncertainty_score":0.0044686794},"labels":[],"label_agreement":null},{"id":"W2141787758","doi":"10.1158/1535-7163.targ-09-b54","title":"Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Juravinski Cancer Centre","funders":"","keywords":"Pharmacokinetics; Medicine; Dosing; Tolerability; Cmax; Capsule; Adverse effect; Pharmacology; Internal medicine; Gastroenterology","score_opus":0.027314768822341542,"score_gpt":0.3634590329814251,"score_spread":0.3361442641590836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141787758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351406,0.0013404835,0.00045858178,0.00030003296,0.00006950226,0.0017706207,0.0012653832,0.00010643763,0.0011748703],"genre_scores_gemma":[0.98638725,0.0016151696,0.0021187568,0.0008478624,0.00011975292,0.002432027,0.0028431716,0.000054141223,0.0035819055],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996363,0.00016047125,0.000021712865,0.0000718643,0.000041460622,0.00006819175],"domain_scores_gemma":[0.99947613,0.00007595545,0.00010037524,0.00004746381,0.000044972556,0.0002552543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011532711,0.0013896313,0.0020589875,0.00042080018,0.00042332226,0.0007819471,0.0007269879,0.0010055887,0.0057248157],"category_scores_gemma":[0.0007272322,0.0006382674,0.0009665816,0.0003686726,0.0005843839,0.00071246846,0.0003311741,0.0029696373,0.0017143526],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5508303,0.09444934,0.013210535,0.0013793776,0.0013199667,0.0007392884,0.00039300357,0.003033436,0.20225686,0.00028776814,0.007856268,0.12424384],"study_design_scores_gemma":[0.26149634,0.70818055,0.018825108,0.00003882733,0.00037769385,0.0005867479,0.00006165242,0.0012000392,0.005486629,0.00012376648,0.003584572,0.00003821265],"about_ca_topic_score_codex":0.0011098561,"about_ca_topic_score_gemma":0.0019724043,"teacher_disagreement_score":0.0057248157,"about_ca_system_score_codex":0.0008064282,"about_ca_system_score_gemma":0.0014979509,"threshold_uncertainty_score":0.01915145},"labels":[],"label_agreement":null},{"id":"W2142067446","doi":"10.1158/1535-7163.mct-09-0495","title":"Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Receptor; Histone deacetylase; Apoptosis; Programmed cell death; HDAC6; Histone; Histone deacetylase inhibitor; Biology; Chemistry; Cancer research; Cell biology; Pharmacology; Gene; Biochemistry","score_opus":0.014746398252306281,"score_gpt":0.31615507126264547,"score_spread":0.3014086730103392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142067446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380326,0.0011702243,0.0035040367,0.00006180846,0.000010602243,0.000022831826,0.0001155047,0.00006321902,0.0012485738],"genre_scores_gemma":[0.9959598,0.0010247461,0.0020284469,0.000023947752,0.000004462955,0.000019051415,0.00014686742,0.000008759418,0.000783887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999341,0.000008394561,0.0000045100237,0.000013688417,0.000019582862,0.000019788942],"domain_scores_gemma":[0.999966,0.0000076208994,0.000011023699,0.000006132301,0.000003134311,0.0000061496307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005171022,0.00021783212,0.00023756188,0.00019266992,0.00009207762,0.00020395796,0.00013149955,0.00012500248,0.00069181377],"category_scores_gemma":[0.00007255683,0.00012547479,0.0001893612,0.00011655111,0.0001623008,0.0001377723,0.00013829996,0.0002931595,0.00016018876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003008994,0.0000072502235,0.00011566157,0.000010939892,0.0000033258043,0.000016014057,0.000005268079,0.00009545269,0.99852306,0.000068953064,0.000010563912,0.0011133975],"study_design_scores_gemma":[0.0000068496515,0.00012104545,0.0019478614,0.0000011673844,0.000006820384,0.000070977505,0.000009354224,0.0005114479,0.9964766,0.000031562893,0.0008150116,0.0000013432181],"about_ca_topic_score_codex":0.0003389912,"about_ca_topic_score_gemma":0.00089458964,"teacher_disagreement_score":0.00069181377,"about_ca_system_score_codex":0.000233488,"about_ca_system_score_gemma":0.00011227745,"threshold_uncertainty_score":0.0023143291},"labels":[],"label_agreement":null},{"id":"W2143782801","doi":"10.1158/1535-7163.mct-06-0557","title":"Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Trace Elements in Health","field":"Nursing","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency","keywords":"Metallothionein; Transcription factor; Gene; Biology; Gene expression; Gallium; Transporter; Molecular biology; Cancer research; Genetics; Chemistry","score_opus":0.02408011798436612,"score_gpt":0.2993019458024416,"score_spread":0.2752218278180755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143782801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953472,0.0007774395,0.0019493962,0.000055191103,0.000011476281,0.000030363142,0.0011869209,0.000045878554,0.00059616345],"genre_scores_gemma":[0.9858188,0.00085415586,0.0038960609,0.00012157237,0.000011907226,0.000116908865,0.004847783,0.000023261182,0.004309667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998312,0.000017321878,0.000013016964,0.000050981504,0.000049549537,0.000037858932],"domain_scores_gemma":[0.99992347,0.000018791117,0.000016127678,0.000009609506,0.000012714707,0.000019308898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008041417,0.00025946135,0.00036248847,0.0004003677,0.00015078277,0.00026979024,0.00012783802,0.0002965528,0.001054705],"category_scores_gemma":[0.000108778695,0.00013141845,0.0003923121,0.00043041736,0.00017425814,0.00013923482,0.00013877104,0.00027665703,0.0003427199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000637652,0.0000086008495,0.00042807782,0.000009679727,0.0000038179946,0.000016506914,0.00001346591,0.000016243715,0.9990983,0.000010258804,0.0000069188836,0.00032453184],"study_design_scores_gemma":[0.000020157802,0.0005365949,0.06580003,0.000004676424,0.00004035494,0.00031263876,0.00012090899,0.0012751932,0.9305031,0.00004701092,0.0013291171,0.000010205565],"about_ca_topic_score_codex":0.0012528087,"about_ca_topic_score_gemma":0.001572394,"teacher_disagreement_score":0.0012528087,"about_ca_system_score_codex":0.00022390106,"about_ca_system_score_gemma":0.0001370212,"threshold_uncertainty_score":0.0035283566},"labels":[],"label_agreement":null},{"id":"W2143814205","doi":"10.1158/1535-7163.mct-13-0649","title":"KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"London Health Sciences Centre","keywords":"KRAS; Pemetrexed; Antifolate; Cancer research; Gene knockdown; Biology; Mutant; Cancer; Cell culture; Antimetabolite; Gene; Genetics; Colorectal cancer; Chemotherapy","score_opus":0.012331464038611479,"score_gpt":0.2861007131037423,"score_spread":0.27376924906513084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143814205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970385,0.001040417,0.00070245634,0.000055954013,0.000011059677,0.000014377828,0.0004420651,0.00004253011,0.00065277214],"genre_scores_gemma":[0.99718374,0.0004982591,0.0004584875,0.00002404606,0.000002408199,0.000015236289,0.0005957761,0.000006216571,0.0012158689],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986625,0.000015954343,0.000020077501,0.000025926056,0.00004596965,0.000025803143],"domain_scores_gemma":[0.99989617,0.0000201754,0.00003081011,0.000016816954,0.000015814165,0.000020216943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077807716,0.0002001596,0.00019830953,0.0003252969,0.00016941447,0.0002679024,0.000113659524,0.00023890748,0.0014878021],"category_scores_gemma":[0.00010556921,0.00013979475,0.00025294357,0.0002742823,0.00010902316,0.000116972195,0.00012659548,0.00021733441,0.00032255333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087619745,0.000020321213,0.0015501494,0.000018611461,0.000005604356,0.00012134751,0.0000118902135,0.00002446097,0.99723756,0.000036127738,0.0000234886,0.00086288806],"study_design_scores_gemma":[0.000011796836,0.00048379131,0.11393835,0.0000067668498,0.000032637934,0.001911185,0.00009740942,0.0013367063,0.87932634,0.000084989886,0.0027589216,0.0000110816045],"about_ca_topic_score_codex":0.0015452169,"about_ca_topic_score_gemma":0.0025580577,"teacher_disagreement_score":0.0015452169,"about_ca_system_score_codex":0.00019777118,"about_ca_system_score_gemma":0.00019745763,"threshold_uncertainty_score":0.0049771667},"labels":[],"label_agreement":null},{"id":"W2143972162","doi":"10.1158/1535-7163.mct-06-0663","title":"Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Kruppel-like factors research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"","keywords":"Epigenetics; Biology; DNA methylation; Cancer epigenetics; Cancer research; Estrogen receptor; MCF-7; Cisplatin; Histone H3; Cancer cell; Histone; Vorinostat; Cancer; Histone methyltransferase; Gene expression; Genetics; Breast cancer; Histone deacetylase; Gene","score_opus":0.026268298539420306,"score_gpt":0.3103611688220568,"score_spread":0.28409287028263647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143972162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937425,0.001738107,0.0021719234,0.000067071145,0.000008098434,0.000019760051,0.0010179444,0.000051815223,0.0011829068],"genre_scores_gemma":[0.9926472,0.0011646713,0.0026628312,0.000055406996,0.000005484864,0.000028639968,0.0017203045,0.00000820361,0.0017072759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999603,0.0000043840087,0.0000027891554,0.00000901432,0.00001688653,0.0000065798213],"domain_scores_gemma":[0.99996305,0.000005221707,0.000009198855,0.000004360712,0.000012405345,0.0000057854068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005712268,0.00009505357,0.00013949633,0.00029075734,0.00009157343,0.00010945315,0.000067911154,0.00010683438,0.0005309782],"category_scores_gemma":[0.00008224917,0.000066281944,0.00008884357,0.00021300653,0.00006382044,0.000051345076,0.00006374173,0.00012713514,0.00014746831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036516172,0.000004841842,0.0014945255,0.000015329706,0.000003823227,0.000029787892,0.000018384528,0.00003731079,0.996819,0.000020035679,0.000019938125,0.0015005852],"study_design_scores_gemma":[0.000007842593,0.0002669438,0.14251089,0.00000544544,0.000053624404,0.000646057,0.000114045026,0.0012955955,0.85182816,0.00006712614,0.0031965324,0.000007801974],"about_ca_topic_score_codex":0.0010257126,"about_ca_topic_score_gemma":0.0017691406,"teacher_disagreement_score":0.0010257126,"about_ca_system_score_codex":0.00012268686,"about_ca_system_score_gemma":0.00009449298,"threshold_uncertainty_score":0.0020395517},"labels":[],"label_agreement":null},{"id":"W2144520265","doi":"10.1158/1535-7163.mct-05-0539","title":"Promise of vitamin D analogues in the treatment of hyperproliferative conditions","year":2006,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Calcitriol; Vitamin D and neurology; Calcitriol receptor; Pharmacology; Cancer; Cancer research; Steroid hormone; Medicine; Calcipotriol; Angiogenesis; Endocrinology; Internal medicine; Biology; Psoriasis; Hormone; Immunology","score_opus":0.09284472894735561,"score_gpt":0.4210077713324955,"score_spread":0.3281630423851399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144520265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012389957,0.99501204,0.0004715069,0.0006340748,0.00050882035,0.000012195902,0.000037347763,0.000026384054,0.0020586692],"genre_scores_gemma":[0.006819879,0.98758906,0.0009921584,0.00081547175,0.00061499234,0.00002209547,0.000116442,0.000009064989,0.0030207816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998498,0.00003098843,0.000020749345,0.00002528305,0.000057747773,0.000015490485],"domain_scores_gemma":[0.99991965,0.000033550008,0.000012198158,0.0000032800856,0.000021401414,0.00000986377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029325928,0.00038819006,0.0008744577,0.0007230507,0.00019745575,0.0006457172,0.00043503364,0.0006831377,0.0042063943],"category_scores_gemma":[0.00030203926,0.00014102003,0.0005014488,0.00042229187,0.00019406728,0.00064716965,0.00037433676,0.0013840781,0.0013310461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070906064,0.00021161586,0.00039160138,0.012125156,0.00024724362,0.0006426771,0.00015971136,0.0005626283,0.02918167,0.0068168733,0.030712461,0.9182393],"study_design_scores_gemma":[0.0000737163,0.0004946984,0.00074381847,0.00060908706,0.00016630313,0.0012445074,0.000065884684,0.0001503153,0.0050634937,0.0018481183,0.9895238,0.000016193724],"about_ca_topic_score_codex":0.00029404685,"about_ca_topic_score_gemma":0.000767927,"teacher_disagreement_score":0.0042063943,"about_ca_system_score_codex":0.0003377755,"about_ca_system_score_gemma":0.00035180533,"threshold_uncertainty_score":0.014071763},"labels":[],"label_agreement":null},{"id":"W2144900656","doi":"10.1158/1535-7163.mct-08-1068","title":"Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"U.S. Department of Veterans Affairs","keywords":"KRAS; Lung cancer; Medicine; Epidermal growth factor receptor; Immunohistochemistry; Paclitaxel; Internal medicine; Fluorescence in situ hybridization; Targeted therapy; Cancer; Oncology; Cancer research; Biology; Colorectal cancer; Gene","score_opus":0.008356432669197871,"score_gpt":0.31058050054610215,"score_spread":0.30222406787690426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144900656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867463,0.00074145466,0.000105527426,0.000101032994,0.00000951599,0.000035359128,0.000032410957,0.000010033918,0.00029000692],"genre_scores_gemma":[0.99937075,0.00015048985,0.00013430596,0.00006593088,0.000027346818,0.000017548908,0.00010709234,0.0000027888004,0.00012380634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997348,0.00010630728,0.000029148312,0.000041643754,0.00004759169,0.00004048842],"domain_scores_gemma":[0.9993388,0.00028419952,0.00017671593,0.000024488047,0.000037594327,0.00013819204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058218517,0.0002732229,0.000709548,0.00038774253,0.00018847191,0.00037104395,0.00018760235,0.00039363618,0.0004591623],"category_scores_gemma":[0.001212194,0.00013061888,0.0003615909,0.0003488817,0.00018262361,0.00020966827,0.00009529144,0.00047955796,0.00014040284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03324608,0.0020918245,0.794843,0.00014446623,0.00044296135,0.0018088211,0.00024336785,0.0017240077,0.07177849,0.00006454512,0.00063278637,0.09297968],"study_design_scores_gemma":[0.0012876625,0.029341714,0.9517031,0.000013400908,0.0003383803,0.002941562,0.00009910462,0.0035124484,0.009323799,0.00009891304,0.0013178259,0.000022021684],"about_ca_topic_score_codex":0.0002758984,"about_ca_topic_score_gemma":0.0006055367,"teacher_disagreement_score":0.000709548,"about_ca_system_score_codex":0.000359779,"about_ca_system_score_gemma":0.00024117852,"threshold_uncertainty_score":0.0030789375},"labels":[],"label_agreement":null},{"id":"W2145353373","doi":"10.1158/1535-7163.mct-05-0033","title":"Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute","keywords":"Identification (biology); Gene; Biology; Cancer; Genetics; Computational biology; Cancer research","score_opus":0.01877441894176379,"score_gpt":0.2866875490502745,"score_spread":0.2679131301085107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145353373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97281283,0.015440739,0.00826257,0.00027578024,0.00002932186,0.00008623238,0.0017024291,0.00010008866,0.0012898968],"genre_scores_gemma":[0.9689493,0.011593292,0.013599249,0.00016118633,0.000034044984,0.00010036292,0.0025125127,0.000015983493,0.0030340408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992144,0.000007914627,0.0000045302486,0.00002773857,0.000018307692,0.000019977646],"domain_scores_gemma":[0.99990606,0.000020701595,0.000026318685,0.00000685074,0.000018728211,0.000021351869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013044525,0.00022423414,0.00024385772,0.0005759293,0.00016086746,0.0003066059,0.00010220869,0.00023260056,0.0011681754],"category_scores_gemma":[0.00013119946,0.000103130544,0.00021671921,0.00043840945,0.00017612285,0.00027045672,0.00018120286,0.0003445425,0.0002951484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021215461,0.0000306322,0.0073169298,0.0001993124,0.00001091982,0.00010908157,0.000037884744,0.000092758295,0.9791589,0.00020006101,0.00006274311,0.012568613],"study_design_scores_gemma":[0.000029951754,0.0008180447,0.47121403,0.000087567874,0.00011929351,0.0014818995,0.00066359644,0.0024876718,0.50965697,0.0014065886,0.012008725,0.000025641164],"about_ca_topic_score_codex":0.00044509833,"about_ca_topic_score_gemma":0.00071959913,"teacher_disagreement_score":0.0011681754,"about_ca_system_score_codex":0.00019353731,"about_ca_system_score_gemma":0.00033286438,"threshold_uncertainty_score":0.003907919},"labels":[],"label_agreement":null},{"id":"W2146004287","doi":"10.1158/1535-7163.mct-10-0643","title":"Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; La Trobe University; McGill University; University of Michigan","keywords":"Radiosensitizer; Apoptosis; Cancer research; Head and neck squamous-cell carcinoma; Gene knockdown; Caspase; Radioresistance; Cell culture; Caspase 3; Activator (genetics); Inhibitor of apoptosis; Caspase-9; Medicine; Cancer cell; Chemistry; Programmed cell death; Caspase 8; Cancer; Head and neck cancer; Biology; Radiation therapy; Internal medicine; Biochemistry","score_opus":0.02162316544434196,"score_gpt":0.24553467346716087,"score_spread":0.22391150802281892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146004287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545103,0.002127358,0.0012738685,0.000047336856,0.000024800906,0.000042752526,0.00013547714,0.000031351607,0.00086599006],"genre_scores_gemma":[0.9964353,0.0011354637,0.0011432839,0.000025707515,0.0000063234993,0.00003078651,0.0002655772,0.0000039227193,0.0009535724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999535,0.000009196443,0.0000057141124,0.000008092954,0.000013031425,0.000010529273],"domain_scores_gemma":[0.99997747,0.000003477422,0.0000061064075,0.0000033088131,0.000004376285,0.0000053036542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010183529,0.00024854034,0.00016049379,0.00015941546,0.00008724704,0.00011843678,0.00010179918,0.00017523438,0.000732583],"category_scores_gemma":[0.000051855746,0.000067600435,0.00022968273,0.00008303052,0.000091112386,0.00010607375,0.00008989167,0.00036474754,0.00015471675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056062803,0.00003291578,0.00007188741,0.000029762123,0.0000033482613,0.000023973522,0.000004951171,0.00004624522,0.9987398,0.000029066641,0.00001623572,0.0009457225],"study_design_scores_gemma":[0.000012492053,0.00050268695,0.001445453,0.0000026878245,0.000010568032,0.00013951353,0.000011093373,0.0003896284,0.9964881,0.000010992976,0.0009849387,0.0000018548862],"about_ca_topic_score_codex":0.0003409505,"about_ca_topic_score_gemma":0.0006665032,"teacher_disagreement_score":0.000732583,"about_ca_system_score_codex":0.00016746197,"about_ca_system_score_gemma":0.00017622096,"threshold_uncertainty_score":0.0024507046},"labels":[],"label_agreement":null},{"id":"W2146553113","doi":"10.1158/1535-7163.mct-14-0547","title":"Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research","keywords":"Docetaxel; Pharmacology; Transporter; Chemistry; Organic anion transporter 1; Organic anion-transporting polypeptide; Pharmacokinetics; Transfection; In vivo; Biochemistry; Biology; Internal medicine; Medicine; Cancer; Gene","score_opus":0.021909245701659804,"score_gpt":0.2826174546863057,"score_spread":0.2607082089846459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146553113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493474,0.002712366,0.0015830826,0.000064345346,0.000008735661,0.000011828268,0.000145748,0.00002366485,0.000515461],"genre_scores_gemma":[0.99756706,0.0008661306,0.00064563163,0.000020877736,0.0000053935155,0.000007944225,0.00020505434,0.000014232547,0.000667828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998264,0.00003924104,0.00001650013,0.000031207193,0.000048966052,0.000037753256],"domain_scores_gemma":[0.9998281,0.000033779983,0.000052362833,0.000017047536,0.000034948494,0.000033814566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015884344,0.00018406201,0.00028009826,0.00017769226,0.000096687116,0.0005616696,0.00007808876,0.00020809112,0.00064610754],"category_scores_gemma":[0.00038459152,0.00014022035,0.00020406183,0.00014008017,0.00016972491,0.00019344784,0.000095470976,0.00026363367,0.00022322389],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011732116,0.00002813516,0.00979719,0.000057530644,0.00002195511,0.00022117233,0.000035155233,0.00018621166,0.9835715,0.000115313116,0.000052292107,0.004740425],"study_design_scores_gemma":[0.0000514886,0.0005523312,0.12884197,0.000014182691,0.00011657871,0.0014225085,0.00014288783,0.005104389,0.8603753,0.0001486249,0.0032072975,0.0000224322],"about_ca_topic_score_codex":0.0021998086,"about_ca_topic_score_gemma":0.0011564399,"teacher_disagreement_score":0.0021998086,"about_ca_system_score_codex":0.00049451983,"about_ca_system_score_gemma":0.0002577969,"threshold_uncertainty_score":0.0043740273},"labels":[],"label_agreement":null},{"id":"W2146832982","doi":"10.1158/1535-7163.mct-08-1090","title":"Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Etoposide; DNA damage; Topoisomerase; Hypoxia (environmental); Biology; Cancer research; Cancer cell; DNA repair; Tumor hypoxia; Molecular biology; Pharmacology; DNA; Chemistry; Cancer; Medicine; Internal medicine; Chemotherapy; Biochemistry; Genetics; Oxygen; Radiation therapy","score_opus":0.0356408677871664,"score_gpt":0.30391991231239,"score_spread":0.2682790445252236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146832982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775904,0.012009912,0.006278313,0.00031994027,0.0000899684,0.00011005606,0.0005109553,0.00020805415,0.0028824422],"genre_scores_gemma":[0.9890192,0.0034981854,0.0032045334,0.00014171285,0.00003496094,0.00009525172,0.00088624825,0.000015850144,0.0031040139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999318,0.000016039894,0.0000081275375,0.0000129000255,0.000016066731,0.00001506787],"domain_scores_gemma":[0.999941,0.000012282174,0.000019185813,0.000006850411,0.000008471084,0.000012182225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008692226,0.0002454406,0.00026992607,0.00013188079,0.00012675324,0.00015944419,0.00014827357,0.00014779661,0.0009915342],"category_scores_gemma":[0.000097082906,0.000101919715,0.000159286,0.00009061279,0.000096718104,0.00013163441,0.000119404074,0.00033568568,0.00029500268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012305903,0.000040913463,0.00018102243,0.000069515416,0.0000068235945,0.000022217382,0.00001334836,0.000048642134,0.9972385,0.000038364848,0.000089482186,0.0021281284],"study_design_scores_gemma":[0.000025513915,0.0005559157,0.01075945,0.000013972128,0.000019294854,0.00020163361,0.000016635962,0.0007843141,0.9828452,0.000030176083,0.0047433297,0.0000045410284],"about_ca_topic_score_codex":0.0006028616,"about_ca_topic_score_gemma":0.0010939477,"teacher_disagreement_score":0.0009915342,"about_ca_system_score_codex":0.00013787743,"about_ca_system_score_gemma":0.00017382782,"threshold_uncertainty_score":0.0033169985},"labels":[],"label_agreement":null},{"id":"W2147186597","doi":"10.1158/1535-7163.mct-12-1166","title":"PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Moffitt Cancer Center","keywords":"Multiple myeloma; Apoptosis; Dexamethasone; Cancer research; Gene knockdown; In vivo; Gene silencing; Cell culture; Doxorubicin; Chemistry; Medicine; Biology; Immunology; Internal medicine; Chemotherapy","score_opus":0.018219872193544838,"score_gpt":0.26820796506068445,"score_spread":0.2499880928671396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147186597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942409,0.0026754574,0.0016442407,0.00008512923,0.0000270904,0.000036974834,0.00021631754,0.00010636333,0.00096745224],"genre_scores_gemma":[0.9955533,0.00089587865,0.0017705939,0.000031780608,0.000009915199,0.000031271455,0.00050261983,0.000011281423,0.0011932957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988496,0.00001878821,0.000011683902,0.000017168966,0.00004509508,0.000022370526],"domain_scores_gemma":[0.99992764,0.000008967066,0.00002093257,0.0000080919735,0.000008542124,0.000025736208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012499676,0.00031880883,0.00035858992,0.00025787213,0.00012192006,0.00024123509,0.0001510104,0.00021721674,0.0007414861],"category_scores_gemma":[0.00008404532,0.00010741674,0.00023515242,0.0001885082,0.00012582513,0.00012247087,0.00013837001,0.00057403115,0.00020511853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002213749,0.000093365874,0.00019015092,0.00003647588,0.000007727392,0.000053689804,0.000008071352,0.00011184965,0.9964562,0.000045331893,0.000060933166,0.0027146828],"study_design_scores_gemma":[0.000029895691,0.00096815074,0.0016976941,0.0000018239566,0.00001624497,0.00029298573,0.0000049634305,0.0004806157,0.995037,0.000013348445,0.001454765,0.0000025706586],"about_ca_topic_score_codex":0.000315988,"about_ca_topic_score_gemma":0.0004101428,"teacher_disagreement_score":0.0007414861,"about_ca_system_score_codex":0.00019949142,"about_ca_system_score_gemma":0.00017042841,"threshold_uncertainty_score":0.002480507},"labels":[],"label_agreement":null},{"id":"W2147195140","doi":"10.1158/1535-7163.targ-09-a196","title":"Abstract A196: Characterization of stability and biological activity of the cancer gene therapy biologic SNS01 following storage at ambient and freezing temperatures","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Molecular biology; Agarose gel electrophoresis; Biology; In vivo; Apoptosis; Cancer cell; In vitro; Transfection; Polyethylenimine; Biochemistry; Cell biology; Cancer; Gene","score_opus":0.026881084944715982,"score_gpt":0.2819565397507381,"score_spread":0.2550754548060221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147195140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386615,0.0011441548,0.0031169301,0.000041199295,0.000028133387,0.000027555423,0.00046796197,0.000045641442,0.0012622532],"genre_scores_gemma":[0.9922982,0.0005994598,0.0024413601,0.000029947676,0.000010458544,0.000042309908,0.001503864,0.00003172319,0.0030426888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993193,0.000008932758,0.0000065703534,0.000014685567,0.000027863525,0.000009954953],"domain_scores_gemma":[0.99982786,0.000040392257,0.00004153419,0.000016052167,0.000052956824,0.000021282973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017157578,0.0002396615,0.00009307091,0.00022307794,0.00014163158,0.0001562451,0.00013617922,0.00014338423,0.001845374],"category_scores_gemma":[0.00023532577,0.00005813727,0.0001586232,0.00017270555,0.00015441225,0.00013819424,0.000072102295,0.00021010994,0.00043189002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014472149,0.000017168795,0.00043229043,0.000021072028,0.000004527054,0.000037970764,0.000018956282,0.00008918065,0.9966619,0.000027004511,0.00004230261,0.002502955],"study_design_scores_gemma":[0.0000057343295,0.00026162097,0.0032193377,0.0000039352053,0.000009798384,0.000099110905,0.00001430906,0.00051645824,0.9946924,0.0000136509225,0.0011591777,0.0000044780336],"about_ca_topic_score_codex":0.0006647735,"about_ca_topic_score_gemma":0.00038628816,"teacher_disagreement_score":0.001845374,"about_ca_system_score_codex":0.00018388168,"about_ca_system_score_gemma":0.000129896,"threshold_uncertainty_score":0.0061733723},"labels":[],"label_agreement":null},{"id":"W2147471000","doi":"10.1158/1535-7163.mct-05-0082","title":"Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Urokinase receptor; Cancer research; Metastasis; Angiogenesis; Matrix metalloproteinase; Zymography; Lung cancer; Biology; Cancer cell; Cancer; Molecular biology; Pathology; Chemistry; Plasminogen activator; Medicine; Internal medicine; Endocrinology; Biochemistry","score_opus":0.008975766653876045,"score_gpt":0.22871856950205932,"score_spread":0.2197428028481833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147471000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872327,0.0028054256,0.0071792835,0.00015934742,0.00015313977,0.00015203531,0.00052014843,0.00012312029,0.0016747641],"genre_scores_gemma":[0.9847244,0.002486605,0.008685455,0.000052864798,0.000026034282,0.0001701308,0.0008961101,0.000020716589,0.0029375888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997317,0.000044169723,0.000040068222,0.000044457007,0.000079913945,0.000059635808],"domain_scores_gemma":[0.999907,0.000025861575,0.000020643987,0.000018025883,0.00001008312,0.000018332254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003335302,0.00055196334,0.000354234,0.0002355121,0.0001631864,0.0003027733,0.00031912784,0.00029013096,0.0008770771],"category_scores_gemma":[0.000115303425,0.00022342999,0.00051555876,0.00019715099,0.00031084928,0.00026663137,0.00017939588,0.0010294293,0.00024207537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073956486,0.0000920069,0.00006512766,0.000043747037,0.000007101749,0.000024445659,0.000014343383,0.000059220907,0.99846375,0.00015237504,0.00003875281,0.00096521765],"study_design_scores_gemma":[0.000049805723,0.0008584538,0.0012749754,0.0000055974183,0.000028605793,0.00013826865,0.000019857558,0.001648743,0.9937516,0.00003665128,0.0021825128,0.000005111743],"about_ca_topic_score_codex":0.001197076,"about_ca_topic_score_gemma":0.0019130717,"teacher_disagreement_score":0.001197076,"about_ca_system_score_codex":0.0003688682,"about_ca_system_score_gemma":0.0004126248,"threshold_uncertainty_score":0.0029341578},"labels":[],"label_agreement":null},{"id":"W2147582215","doi":"10.1158/1535-7163.mct-10-0312","title":"Small Interfering RNA Targeting 14-3-3ζ Increases Efficacy of Chemotherapeutic Agents in Head and Neck Cancer Cells","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"14-3-3 protein interactions","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Small interfering RNA; Propidium iodide; Transfection; Cancer research; Cisplatin; Cancer cell; Molecular biology; Doxorubicin; Apoptosis; Annexin; Cancer; Head and neck squamous-cell carcinoma; Paclitaxel; Biology; Flow cytometry; Cell culture; Programmed cell death; Head and neck cancer; Chemotherapy; Biochemistry","score_opus":0.027621851449162894,"score_gpt":0.3059244296367972,"score_spread":0.2783025781876343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147582215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891151,0.0039350768,0.0035033692,0.00015772342,0.00012696527,0.000104178645,0.0004307112,0.00017908082,0.0024477048],"genre_scores_gemma":[0.9904884,0.002305093,0.002893956,0.000089815214,0.000017218179,0.000107186206,0.00085506553,0.000029430534,0.0032138296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981076,0.000021937301,0.000020534284,0.000037936006,0.000069873015,0.000039087707],"domain_scores_gemma":[0.9999236,0.00002157756,0.000013262716,0.0000121085795,0.000014728418,0.000014736934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016349478,0.00031028493,0.00046391247,0.00021042813,0.00020322013,0.00030849274,0.00023807409,0.00026383883,0.0011221718],"category_scores_gemma":[0.00014869023,0.00010978576,0.00029382465,0.00023689846,0.00022744465,0.00015385979,0.00015784075,0.0005192665,0.00034544928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011630923,0.00008715197,0.00018666133,0.00003851104,0.000006990311,0.000021107964,0.000014457128,0.00008482037,0.9968051,0.000055054094,0.00010324337,0.0024806145],"study_design_scores_gemma":[0.00002919725,0.00048669745,0.003231886,0.0000042535607,0.000019756451,0.00006878451,0.000013849086,0.0011500028,0.9925841,0.00003063174,0.0023775203,0.0000033262984],"about_ca_topic_score_codex":0.0015255758,"about_ca_topic_score_gemma":0.0020979163,"teacher_disagreement_score":0.0015255758,"about_ca_system_score_codex":0.0004391322,"about_ca_system_score_gemma":0.00041942933,"threshold_uncertainty_score":0.0037540793},"labels":[],"label_agreement":null},{"id":"W2148047944","doi":"10.1158/1535-7163.mct-14-0521","title":"Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transactivation; Androgen receptor; CYP17A1; Enzalutamide; LNCaP; Prostate cancer; In vivo; Chemistry; Reporter gene; Luciferase; Androgen deprivation therapy; Cancer research; Internal medicine; Pharmacology; Biology; Cancer; Transfection; Medicine; Gene expression; Gene; Biochemistry","score_opus":0.07939099133391246,"score_gpt":0.38985684938807197,"score_spread":0.3104658580541595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148047944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789084,0.0063776537,0.0018729268,0.00012474527,0.000059809667,0.000102269056,0.0010526783,0.00021772234,0.0023012427],"genre_scores_gemma":[0.98786783,0.00470024,0.0016136365,0.000062195926,0.000018128949,0.00006356402,0.0017481048,0.00002594703,0.0039003144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989843,0.000020615145,0.00000796868,0.000014463292,0.00003408243,0.00002443649],"domain_scores_gemma":[0.99991965,0.000009048311,0.000024249915,0.000008375106,0.00001230583,0.000026471791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000144003,0.00037898944,0.00046128588,0.00043592614,0.00014961496,0.00031077163,0.00024738637,0.00020661624,0.001369216],"category_scores_gemma":[0.000105781335,0.0001880793,0.00030630032,0.00039108063,0.00012822614,0.00019106914,0.00010255449,0.00058810465,0.00026626937],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001770825,0.00075156277,0.0006084104,0.00020601679,0.00007010659,0.000097500306,0.00002812366,0.0009630068,0.97843665,0.00015393567,0.0004194854,0.016494347],"study_design_scores_gemma":[0.0005894465,0.017836882,0.010744139,0.000025496514,0.00019230963,0.0009264102,0.00006583095,0.002781771,0.9550583,0.000082273145,0.011670724,0.000026480971],"about_ca_topic_score_codex":0.0019988157,"about_ca_topic_score_gemma":0.005710814,"teacher_disagreement_score":0.0019988157,"about_ca_system_score_codex":0.00036329005,"about_ca_system_score_gemma":0.00038660775,"threshold_uncertainty_score":0.004580438},"labels":[],"label_agreement":null},{"id":"W2148098988","doi":"10.1158/1535-7163.mct-06-0230","title":"High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m–labeled anti-DR5 antibody in breast tumor xenografts","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Single-photon emission computed tomography; Biodistribution; Emission computed tomography; Nuclear medicine; Chemistry; Distribution (mathematics); Antibody; Monoclonal antibody; Molecular biology; Cancer research; Positron emission tomography; Medicine; Biology; In vitro; Immunology; Biochemistry","score_opus":0.015791139513509824,"score_gpt":0.30285195562941397,"score_spread":0.28706081611590417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148098988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841426,0.0014308179,0.010721714,0.000092418304,0.000014993268,0.00008255851,0.0004776826,0.00014306657,0.0028941184],"genre_scores_gemma":[0.978683,0.00091755844,0.015528468,0.00009002318,0.0000066755224,0.00013976893,0.0009911843,0.000040833304,0.0036026314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987483,0.00002451827,0.000006372289,0.000024510693,0.00004247097,0.00002741039],"domain_scores_gemma":[0.999925,0.000014810402,0.000014716913,0.00001185905,0.000017074653,0.000016645512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027101662,0.00027706908,0.00029755506,0.0003248602,0.00009091755,0.00027267952,0.00032106473,0.0004200043,0.0011655398],"category_scores_gemma":[0.00015199302,0.00028547848,0.00016620067,0.00022318558,0.00014705423,0.00021074417,0.00012390145,0.0005368167,0.00049165083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018149312,0.000045626904,0.00045692944,0.000024012252,0.0000059997888,0.00016251864,0.000017474184,0.0002528431,0.9975562,0.00008743243,0.00006422109,0.0011453595],"study_design_scores_gemma":[0.000095936,0.001095916,0.030306203,0.000017349172,0.000043908123,0.0035543425,0.0000920348,0.020238437,0.9414148,0.000091011076,0.0030322955,0.000017837032],"about_ca_topic_score_codex":0.0021255638,"about_ca_topic_score_gemma":0.0020600175,"teacher_disagreement_score":0.0021255638,"about_ca_system_score_codex":0.00040466312,"about_ca_system_score_gemma":0.0003016292,"threshold_uncertainty_score":0.0042263865},"labels":[],"label_agreement":null},{"id":"W2148135357","doi":"10.1158/1535-7163.mct-06-0134","title":"Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Ontario Genomics","funders":"National Institutes of Health","keywords":"Apoptosis; Pharmacology; Traditional medicine; Medicine; Biology; Genetics","score_opus":0.019980352863682875,"score_gpt":0.2784638712500205,"score_spread":0.2584835183863376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148135357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540965,0.023799405,0.014172514,0.00041465875,0.00011442606,0.0001822802,0.00026727022,0.0002887244,0.0066642812],"genre_scores_gemma":[0.9822969,0.0066651953,0.0081251785,0.000113215945,0.000033354285,0.00004202022,0.00023653932,0.00001487203,0.0024727941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987006,0.000037288366,0.000009207486,0.000028126828,0.000032069744,0.000023311888],"domain_scores_gemma":[0.999902,0.000022897726,0.00002277505,0.0000091054635,0.000022846969,0.000020270096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021754547,0.0004047424,0.00022639659,0.00033577724,0.00012881303,0.0002565232,0.00030535914,0.00030893803,0.0004887897],"category_scores_gemma":[0.00012739617,0.000111327354,0.00022238605,0.00019112472,0.00018655723,0.00020552595,0.00018223486,0.0002935273,0.00018246105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012097476,0.000042781692,0.00025164636,0.00007437595,0.0000106815805,0.0000995245,0.000012317261,0.00019668414,0.99301344,0.00025888826,0.00005772734,0.0058609415],"study_design_scores_gemma":[0.000021701488,0.00090205605,0.00080184214,0.000004427291,0.000018432205,0.00021460168,0.000008802888,0.0005089814,0.99504745,0.000036133653,0.0024318357,0.0000038615517],"about_ca_topic_score_codex":0.00085155136,"about_ca_topic_score_gemma":0.0014452835,"teacher_disagreement_score":0.00085155136,"about_ca_system_score_codex":0.00040923164,"about_ca_system_score_gemma":0.00032379501,"threshold_uncertainty_score":0.0029692054},"labels":[],"label_agreement":null},{"id":"W2148148974","doi":"10.1158/1535-7163.mct-14-0337","title":"Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Pharmacology; Gemcitabine; Sunitinib; Pazopanib; Cytotoxicity; Axitinib; Nucleoside; Medicine; Nucleoside analogue; Erlotinib; Tyrosine kinase; Cancer research; Chemistry; Cancer; Biochemistry; Internal medicine; In vitro; Receptor; Epidermal growth factor receptor","score_opus":0.026876852741158724,"score_gpt":0.34438449292463374,"score_spread":0.317507640183475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148148974","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021616489,0.870867,0.013228738,0.08056891,0.0035649755,0.00012592012,0.00021526881,0.00026603707,0.00954665],"genre_scores_gemma":[0.20604487,0.6635626,0.03402455,0.06392446,0.01697676,0.0006640924,0.00070051214,0.0003606696,0.013741502],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957218,0.0018475489,0.0003481079,0.00059810275,0.0010330968,0.00045133653],"domain_scores_gemma":[0.992735,0.004258506,0.0006608728,0.00039380463,0.0012501891,0.0007016819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010302941,0.0012016927,0.0061191204,0.0011129042,0.00078321743,0.0045852894,0.0021005515,0.0028827419,0.008635022],"category_scores_gemma":[0.0050488524,0.00091712514,0.0017727958,0.0013474617,0.0023874433,0.010878818,0.002962174,0.010180036,0.002796183],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002730814,0.0009462052,0.0046954406,0.0046529304,0.0011546966,0.0008224126,0.00034799502,0.0022005325,0.01055972,0.017330207,0.059808686,0.8947504],"study_design_scores_gemma":[0.0023236978,0.0112194605,0.008256889,0.005208021,0.0020741597,0.009147975,0.0018811292,0.009518432,0.0124504315,0.08834401,0.8491454,0.00043042746],"about_ca_topic_score_codex":0.0007052987,"about_ca_topic_score_gemma":0.0032705907,"teacher_disagreement_score":0.010302941,"about_ca_system_score_codex":0.0021013983,"about_ca_system_score_gemma":0.0016591257,"threshold_uncertainty_score":0.054487824},"labels":[],"label_agreement":null},{"id":"W2148192822","doi":"10.1158/1535-7163.mct-07-0155","title":"The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Glioma; Cancer research; PI3K/AKT/mTOR pathway; Protein kinase B; Cell growth; Kinase; Biology; Cell cycle; Cyclin-dependent kinase 6; Signal transduction; Cell; Protein kinase A; Cell biology; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.01031715399708017,"score_gpt":0.254356103785512,"score_spread":0.24403894978843182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148192822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135923,0.0051290602,0.00137788,0.0001305006,0.000055915876,0.00006379439,0.00016806973,0.00014173314,0.0015739005],"genre_scores_gemma":[0.99288046,0.002927369,0.002406226,0.000064294785,0.000027876717,0.00005323453,0.00035024958,0.000013754961,0.0012763609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998679,0.000023220178,0.000014310421,0.0000193865,0.000045646844,0.000029485172],"domain_scores_gemma":[0.9999298,0.000013705837,0.00002211165,0.000005561236,0.000004885578,0.000023983117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014379827,0.00054567464,0.00044595264,0.0003599814,0.00010960104,0.00028090723,0.00024803044,0.00031157027,0.0010249048],"category_scores_gemma":[0.00009826034,0.00014498287,0.00033960358,0.00020032913,0.00020502429,0.00021616492,0.00014625225,0.0007393788,0.00035758084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089882524,0.0006293734,0.00044274327,0.0001313644,0.00005849425,0.00007883161,0.000014274336,0.0004626678,0.9806246,0.00014261676,0.00025563964,0.016260665],"study_design_scores_gemma":[0.0002953329,0.009418257,0.0073422636,0.000009340771,0.00012355638,0.0007954101,0.00002009758,0.0017571659,0.9762779,0.00005337213,0.0038894766,0.00001773683],"about_ca_topic_score_codex":0.0004250126,"about_ca_topic_score_gemma":0.0017292127,"teacher_disagreement_score":0.0010249048,"about_ca_system_score_codex":0.0002216967,"about_ca_system_score_gemma":0.0002926702,"threshold_uncertainty_score":0.003428638},"labels":[],"label_agreement":null},{"id":"W2149564446","doi":"10.1158/1535-7163.mct-06-0106","title":"Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Immunohistochemistry; Biology; Glioma; Methylation; DNA methylation; O-6-methylguanine-DNA methyltransferase; Molecular biology; Methyltransferase; DNA; Cancer research; Pathology; Immunology; Biochemistry; Gene; Medicine; Gene expression","score_opus":0.01899061330498693,"score_gpt":0.3014807369575591,"score_spread":0.2824901236525722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149564446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884362,0.0018784887,0.008244945,0.000028590284,0.000013022884,0.00006663346,0.00034879326,0.00011908496,0.0008641628],"genre_scores_gemma":[0.9851677,0.0006950248,0.01221031,0.00002547353,0.000012033968,0.00018234449,0.0007004857,0.000020108353,0.0009866216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994205,0.00016131556,0.00003729699,0.000096611766,0.0002321053,0.00005214255],"domain_scores_gemma":[0.999572,0.00014720229,0.000113834954,0.00003914372,0.000093222596,0.000034719185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055341754,0.00029433012,0.00023382214,0.00095481536,0.000108874796,0.00023109493,0.00015832915,0.00030555745,0.0006844117],"category_scores_gemma":[0.0011021218,0.00018216744,0.00012859004,0.00052348344,0.00027913638,0.00017575597,0.00015117305,0.00027295575,0.00026873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047056936,0.000044307806,0.014027005,0.00010232568,0.0000256718,0.000062671825,0.000098441786,0.00015589775,0.9758439,0.00005201408,0.000040441442,0.009076718],"study_design_scores_gemma":[0.000029464816,0.0012712921,0.22186783,0.00001743204,0.000073602256,0.0011982333,0.00011782499,0.0044619464,0.76877844,0.00012828187,0.0020369792,0.0000186744],"about_ca_topic_score_codex":0.00051424734,"about_ca_topic_score_gemma":0.00068336003,"teacher_disagreement_score":0.00095481536,"about_ca_system_score_codex":0.0002372952,"about_ca_system_score_gemma":0.000114142844,"threshold_uncertainty_score":0.0029267669},"labels":[],"label_agreement":null},{"id":"W2150186278","doi":"10.1158/1535-7163.271.4.2","title":"Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"AKT2; Protein kinase B; AKT1; AKT3; PI3K/AKT/mTOR pathway; Pleckstrin homology domain; Biology; Cancer research; Cell biology; Kinase; Phosphorylation; Signal transduction; Proto-Oncogene Proteins c-akt; Cell growth; Chemistry; Biochemistry","score_opus":0.014561717447437315,"score_gpt":0.26588085075826956,"score_spread":0.2513191333108322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150186278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737854,0.004256559,0.0040057222,0.00014099355,0.000060174458,0.00008558096,0.00039989623,0.0001889268,0.003483712],"genre_scores_gemma":[0.9895163,0.003547783,0.0035199844,0.00006527428,0.000018466217,0.00010411422,0.0007440647,0.000021395543,0.0024625345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986804,0.00001880716,0.000015347616,0.000023405959,0.000039090093,0.000035238856],"domain_scores_gemma":[0.9999416,0.000014812427,0.000013456458,0.000010106459,0.000005330211,0.000014656509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101154044,0.0005331132,0.00034184032,0.0002963219,0.00015364017,0.00023484456,0.00013511923,0.00015134815,0.0012563792],"category_scores_gemma":[0.00007346765,0.00011845678,0.00022628177,0.00024314522,0.00016287535,0.00013141443,0.00015184323,0.00077500613,0.0003463226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000164207,0.0001375104,0.0001761311,0.000081242084,0.000012671694,0.000041684027,0.000020529173,0.0002081093,0.99478227,0.00021522958,0.00009600057,0.004064354],"study_design_scores_gemma":[0.00002666644,0.0006034124,0.0018674162,0.0000047948006,0.000016553638,0.00025388008,0.000009909244,0.0005879421,0.9939633,0.0000442655,0.0026186553,0.0000031807392],"about_ca_topic_score_codex":0.0002461305,"about_ca_topic_score_gemma":0.0005442366,"teacher_disagreement_score":0.0012563792,"about_ca_system_score_codex":0.00024249672,"about_ca_system_score_gemma":0.0002507243,"threshold_uncertainty_score":0.0042030215},"labels":[],"label_agreement":null},{"id":"W2150625778","doi":"10.1158/1535-7163.mct-06-0174","title":"Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Curcumin; Cancer; Pharmacology; Chemistry; In vivo; Cancer cell; Oncogene; Cyclin D1; Phytochemical; In vitro; Cancer research; Biochemistry; Biology; Cell cycle; Apoptosis; Biotechnology","score_opus":0.028360169432652592,"score_gpt":0.32228043699161596,"score_spread":0.2939202675589634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150625778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97192365,0.014302143,0.0057183667,0.00017773647,0.000072819945,0.00030752047,0.0006652405,0.00007887881,0.006753564],"genre_scores_gemma":[0.9783342,0.008223802,0.0092806695,0.000100670935,0.000042059524,0.00011712095,0.00083398476,0.00002409294,0.0030433538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999598,0.000010639617,0.0000039820866,0.000008922433,0.000007578359,0.000009090623],"domain_scores_gemma":[0.9999335,0.000012006073,0.000018638459,0.000007872415,0.0000112295265,0.00001680873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093469454,0.00032566738,0.00030340816,0.0002914676,0.00012037258,0.00012165157,0.00014521781,0.00015921418,0.001759507],"category_scores_gemma":[0.00015496138,0.0001144849,0.00023391268,0.0001731861,0.0001310523,0.00018418666,0.00008945104,0.00023225482,0.00034282837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026104596,0.00012726708,0.00009564682,0.00024916237,0.000014898319,0.00018581608,0.000024319203,0.0005463137,0.9898499,0.00021610163,0.00009785603,0.008331643],"study_design_scores_gemma":[0.00024733058,0.0035479406,0.002903838,0.000032755463,0.000092332506,0.00078854366,0.000031408825,0.00065706327,0.9758184,0.00012944503,0.015722826,0.000028125762],"about_ca_topic_score_codex":0.0003262883,"about_ca_topic_score_gemma":0.0006006145,"teacher_disagreement_score":0.001759507,"about_ca_system_score_codex":0.00019731084,"about_ca_system_score_gemma":0.000185171,"threshold_uncertainty_score":0.0058861375},"labels":[],"label_agreement":null},{"id":"W2150670449","doi":"10.1158/1535-7163.mct-06-0468","title":"Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Myofibroblast; Cancer research; Docetaxel; Epithelial–mesenchymal transition; Medicine; Fibroblast; Stromal cell; Cancer; Pathology; Biology; Internal medicine; Cell culture; Metastasis; Fibrosis","score_opus":0.004249424430683317,"score_gpt":0.23868883065374175,"score_spread":0.23443940622305842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150670449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940665,0.0038165683,0.0007270775,0.000062514366,0.000019157063,0.000036768248,0.00017130905,0.00006360878,0.0010365119],"genre_scores_gemma":[0.9975248,0.0011097975,0.00045472718,0.000025122517,0.0000057632697,0.00001941114,0.00014411034,0.0000040267887,0.0007122762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999571,0.000007928228,0.0000032958524,0.000005172648,0.000009368706,0.000017116727],"domain_scores_gemma":[0.9999331,0.000017354037,0.000014011038,0.0000064951714,0.0000058272553,0.000023062436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008377773,0.00032670726,0.0002254963,0.00017499962,0.00008934601,0.00014675641,0.00014108594,0.00018217282,0.0009802618],"category_scores_gemma":[0.000073320254,0.00008047845,0.00016407871,0.0001040108,0.00013633085,0.0001033079,0.00009152393,0.0003106875,0.000114445174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003245611,0.00007362052,0.000276596,0.000067008594,0.000007995757,0.000052626354,0.000010205063,0.00019334168,0.9957913,0.000068532405,0.000055039767,0.0030791766],"study_design_scores_gemma":[0.000052203544,0.0011378308,0.006473211,0.0000069088546,0.000023682165,0.00013482057,0.000010703634,0.00064829417,0.98954844,0.000030155436,0.0019295292,0.000004040798],"about_ca_topic_score_codex":0.0010781306,"about_ca_topic_score_gemma":0.0021353746,"teacher_disagreement_score":0.0010781306,"about_ca_system_score_codex":0.00023276427,"about_ca_system_score_gemma":0.00024465093,"threshold_uncertainty_score":0.0032792687},"labels":[],"label_agreement":null},{"id":"W2150852167","doi":"10.1158/1535-7163.mct-08-0444","title":"Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibroblast growth factor receptor; Cancer research; Fibroblast growth factor receptor 1; Biology; Epidermal growth factor receptor; Fibroblast growth factor; Receptor; Cell growth; Growth factor receptor; Epidermal growth factor; Cancer cell; Lung cancer; Cancer; Signal transduction; Cell biology; Internal medicine; Medicine; Biochemistry; Genetics","score_opus":0.01746676278443335,"score_gpt":0.26264557398758875,"score_spread":0.2451788112031554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150852167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856367,0.01030822,0.0019620745,0.00014250712,0.00003047233,0.00006862776,0.00013045066,0.00005942944,0.0016616612],"genre_scores_gemma":[0.99499655,0.0030064217,0.0009060263,0.000023764771,0.000013029598,0.000031211817,0.000113231676,0.000005844238,0.0009039673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985635,0.00003974639,0.000011568073,0.000014584793,0.00004667837,0.000030953073],"domain_scores_gemma":[0.9999416,0.000017722305,0.0000123632935,0.0000066784005,0.000007117485,0.000014515765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019565584,0.00050549704,0.0003119391,0.0001804401,0.000102966136,0.00019038828,0.00014943832,0.00022048692,0.0010623221],"category_scores_gemma":[0.000077162666,0.000090318885,0.00028148928,0.00009458998,0.00012697375,0.00016357136,0.00014808381,0.00035967544,0.000162486],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016630895,0.000052321404,0.0003507673,0.000079361125,0.000007059248,0.000104263025,0.00001046455,0.000071884875,0.9954554,0.00007986862,0.00003366546,0.003588687],"study_design_scores_gemma":[0.000039113707,0.0010895364,0.009103039,0.00000871144,0.000049966402,0.0007230811,0.0000253025,0.0011377637,0.9847639,0.000053462045,0.0030011781,0.000004894002],"about_ca_topic_score_codex":0.00021291291,"about_ca_topic_score_gemma":0.0006379608,"teacher_disagreement_score":0.0010623221,"about_ca_system_score_codex":0.00016392328,"about_ca_system_score_gemma":0.0001737705,"threshold_uncertainty_score":0.0035538673},"labels":[],"label_agreement":null},{"id":"W2151135547","doi":"10.1158/1535-7163.mct-08-0136","title":"Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pomegranate: compositions and health benefits","field":"Nursing","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of California, Los Angeles; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Prostate cancer; Androgen; Apoptosis; Cancer; Cancer research; Internal medicine; Prostate; Endocrinology; Viability assay; Medicine; Chemistry; Hormone; Biochemistry","score_opus":0.03845215773367282,"score_gpt":0.301945314570622,"score_spread":0.2634931568369492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151135547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910768,0.0052180295,0.0012311742,0.00014991651,0.00005087031,0.000040072227,0.00019067353,0.00007234895,0.001969924],"genre_scores_gemma":[0.990879,0.0047963546,0.0013612194,0.000084637555,0.0000474081,0.000034536304,0.00033326398,0.0000149177185,0.0024487406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994695,0.000012602277,0.0000038059843,0.0000060480165,0.000016704063,0.000013860627],"domain_scores_gemma":[0.99994206,0.000014466075,0.000015922886,0.000005468796,0.0000046009386,0.00001736242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010034876,0.0005108331,0.00025474446,0.00039512705,0.00017246792,0.00019679265,0.00019505329,0.0002033364,0.0016985395],"category_scores_gemma":[0.00015165267,0.00011266956,0.00026721953,0.0001463171,0.00025796314,0.00019044,0.0001818072,0.0006470818,0.0002616704],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015058717,0.00071886246,0.00027066952,0.00014601386,0.000025262965,0.00010703743,0.00001354445,0.00013583848,0.98549795,0.00009892096,0.000091692804,0.011388241],"study_design_scores_gemma":[0.00040702889,0.008561006,0.008120297,0.000022930119,0.000056205405,0.00046533815,0.000031548465,0.00062026945,0.97784495,0.00016208466,0.0037004778,0.000007870166],"about_ca_topic_score_codex":0.00032324353,"about_ca_topic_score_gemma":0.0006877299,"teacher_disagreement_score":0.0016985395,"about_ca_system_score_codex":0.00011647634,"about_ca_system_score_gemma":0.00020205101,"threshold_uncertainty_score":0.00568223},"labels":[],"label_agreement":null},{"id":"W2151701983","doi":"10.1158/1535-7163.mct-09-0962","title":"SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis <i>In vitro</i> and <i>In vivo</i> through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Bosutinib; Cancer; Metastasis; Cancer research; Prostate cancer; Matrigel; Bone metastasis; Cancer cell; Medicine; Biology; Pathology; Internal medicine; Angiogenesis","score_opus":0.020053318019657988,"score_gpt":0.28311392525580115,"score_spread":0.26306060723614316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151701983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752526,0.016829105,0.0018897686,0.00033810834,0.00012741664,0.00006500647,0.0009297049,0.0002213003,0.0043468866],"genre_scores_gemma":[0.9853967,0.009186364,0.0012267699,0.000108276974,0.000041976633,0.000054147393,0.0014488003,0.000024200812,0.0025127945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999118,0.000012545523,0.000007717566,0.000010872455,0.000024450337,0.000032655695],"domain_scores_gemma":[0.99995816,0.000004677651,0.000014460943,0.0000028665056,0.000005337777,0.000014502749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012844225,0.00056080136,0.0003773912,0.00027118874,0.00014142915,0.00026815053,0.00020672126,0.00015470627,0.0013570556],"category_scores_gemma":[0.000061105275,0.00011023801,0.0003157459,0.000218469,0.0002048658,0.00013068118,0.000081894796,0.00068806426,0.0004519495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025485968,0.00019508948,0.00028945066,0.00019951619,0.000017794084,0.000045859586,0.0000084824505,0.00019497583,0.99379385,0.00006939624,0.00022308811,0.004707669],"study_design_scores_gemma":[0.00011727992,0.0026527112,0.006685009,0.0000119888755,0.00007352423,0.0003702129,0.000023165781,0.0007979355,0.9851391,0.000033995555,0.0040872144,0.000007853189],"about_ca_topic_score_codex":0.0009774729,"about_ca_topic_score_gemma":0.0025741055,"teacher_disagreement_score":0.0013570556,"about_ca_system_score_codex":0.00025771238,"about_ca_system_score_gemma":0.000331815,"threshold_uncertainty_score":0.004539788},"labels":[],"label_agreement":null},{"id":"W2151876400","doi":"10.1158/1535-7163.mct-12-0950","title":"RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval","keywords":"Olaparib; PARP inhibitor; Cancer research; DNA damage; Cancer; DNA repair; Medicine; Biology; Poly ADP ribose polymerase; Internal medicine; DNA; Polymerase","score_opus":0.02604159606197083,"score_gpt":0.29894876053579533,"score_spread":0.2729071644738245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151876400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98031104,0.0058959136,0.0064552017,0.00032725895,0.00011686128,0.00007720215,0.0031135546,0.00040484767,0.0032980824],"genre_scores_gemma":[0.99105084,0.001336169,0.0017538193,0.0001469509,0.000009441455,0.00006347885,0.0028409732,0.000031675092,0.002766611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997465,0.00003209454,0.00003801922,0.00006423113,0.00008111232,0.000038038772],"domain_scores_gemma":[0.9998398,0.000024166047,0.000051121675,0.000038325445,0.000022921799,0.000023662971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104324194,0.00042467625,0.0004872465,0.00033331342,0.00018997681,0.00045298424,0.00019827587,0.00037577358,0.0013793802],"category_scores_gemma":[0.00018875192,0.00015156536,0.00029259155,0.0003484443,0.00019558385,0.0001915476,0.00018345244,0.00068388483,0.0008226654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008763336,0.000017142951,0.00035316008,0.000027775674,0.0000070934598,0.00010017268,0.000006681825,0.00007595891,0.9975533,0.00005490774,0.0001237174,0.0015924216],"study_design_scores_gemma":[0.00001942194,0.00026593334,0.012478662,0.0000065525705,0.000023776478,0.0008899122,0.000032287193,0.0010552524,0.9802213,0.00008854774,0.0049082013,0.000010251719],"about_ca_topic_score_codex":0.0005116952,"about_ca_topic_score_gemma":0.00041691994,"teacher_disagreement_score":0.0013793802,"about_ca_system_score_codex":0.00025009993,"about_ca_system_score_gemma":0.00016499496,"threshold_uncertainty_score":0.0046144724},"labels":[],"label_agreement":null},{"id":"W2151970029","doi":"10.1158/1535-7163.mct-12-0299","title":"A New Nonestrogenic Steroidal Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type I Blocks the Estrogen-Dependent Breast Cancer Tumor Growth Induced by Estrone","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Centre Hospitalier Universitaire de Québec","keywords":"Estrone; Estrogen; In vivo; Endocrinology; Internal medicine; Hydroxysteroid dehydrogenase; Breast cancer; Steroid; Chemistry; Cell growth; IC50; Estrogen receptor; Cancer; Pharmacology; Dehydrogenase; Hormone; Biology; Medicine; In vitro; Enzyme; Biochemistry","score_opus":0.008911511635038087,"score_gpt":0.25048146752405615,"score_spread":0.24156995588901806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151970029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9554568,0.025462702,0.009239206,0.0002589464,0.00015755011,0.00034522451,0.0011933229,0.0004681809,0.007418196],"genre_scores_gemma":[0.9666795,0.015351132,0.0065619415,0.00018670424,0.000042058182,0.00018379356,0.0014335228,0.00003459579,0.009526608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999224,0.000014049583,0.0000069123053,0.000018660805,0.000018367622,0.000019627412],"domain_scores_gemma":[0.99995327,0.000008470986,0.000012302724,0.000006530426,0.000005549028,0.000013879259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011428334,0.00039123034,0.00032843646,0.00023581565,0.00010370745,0.00011734971,0.0004567809,0.00021043916,0.0013060507],"category_scores_gemma":[0.000105836414,0.00015302362,0.00021950735,0.00016195668,0.00016713639,0.00016405495,0.00011993194,0.00062049594,0.00039899565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004345479,0.00019778611,0.00013454529,0.00015659993,0.00001460462,0.000095654344,0.000014722717,0.00023166294,0.9864841,0.00019963399,0.00017331372,0.011862834],"study_design_scores_gemma":[0.00020786426,0.004253107,0.002651154,0.00001350976,0.000045565972,0.0006160444,0.000012241176,0.00058422756,0.9781728,0.000033818735,0.013396109,0.0000135354485],"about_ca_topic_score_codex":0.0005320297,"about_ca_topic_score_gemma":0.0010868049,"teacher_disagreement_score":0.0013060507,"about_ca_system_score_codex":0.00013978714,"about_ca_system_score_gemma":0.00025691578,"threshold_uncertainty_score":0.0043691993},"labels":[],"label_agreement":null},{"id":"W2152324247","doi":"10.1158/1535-7163.mct-09-0365","title":"Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute","keywords":"Rhabdomyosarcoma; PLK1; Polo-like kinase; Biology; Kinase; Cancer research; Small interfering RNA; Propidium iodide; Molecular biology; Sarcoma; Apoptosis; Cell cycle; Cell culture; Cell biology; Medicine; Pathology; Programmed cell death; Biochemistry; Genetics; Transfection","score_opus":0.049664839311527584,"score_gpt":0.31208443345900094,"score_spread":0.26241959414747335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152324247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98212457,0.0047247587,0.0068364814,0.00016627707,0.00004468672,0.0002799157,0.002654847,0.0003018807,0.002866498],"genre_scores_gemma":[0.9673779,0.006357746,0.013550772,0.00018613345,0.000020310335,0.00030609997,0.0076692486,0.00006436656,0.0044674473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999876,0.000015297894,0.000012888755,0.000025838266,0.0000496807,0.000020303636],"domain_scores_gemma":[0.99992204,0.000029482437,0.000018346804,0.0000052710043,0.000010363018,0.000014498104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020372064,0.0005434368,0.00067638216,0.0003775382,0.00013319947,0.00031365085,0.00026811857,0.00028569822,0.0010130241],"category_scores_gemma":[0.00013521551,0.00020755749,0.00035066484,0.00028977767,0.000114815506,0.00010305907,0.00013237316,0.00034694074,0.00034972635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014756835,0.00006245155,0.00023996129,0.000060759838,0.000015417605,0.000092302864,0.000009259747,0.0003575646,0.99616456,0.000047814905,0.00011436928,0.0026878424],"study_design_scores_gemma":[0.00009046852,0.001462483,0.0043222154,0.000009791543,0.00012032994,0.00050076074,0.000021407122,0.0026607823,0.9865833,0.00003769254,0.004180682,0.000010147007],"about_ca_topic_score_codex":0.0006128583,"about_ca_topic_score_gemma":0.001935135,"teacher_disagreement_score":0.0010130241,"about_ca_system_score_codex":0.00029669673,"about_ca_system_score_gemma":0.00026495708,"threshold_uncertainty_score":0.0033888817},"labels":[],"label_agreement":null},{"id":"W2152445171","doi":"10.1158/1535-7163.1193.3.10","title":"Targeting heterogeneous nuclear ribonucleoparticule A1 and A2 proteins by RNA interference promotes cell death in transformed but not in normal mouse cell lines","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Gene knockdown; RNA interference; Biology; HeLa; Telomere; Telomerase; Molecular biology; Cell biology; Cell culture; Small interfering RNA; RNA; Complementary DNA; Nuclear protein; Cell; Transfection; Gene; Genetics; Transcription factor","score_opus":0.017867742682679266,"score_gpt":0.25116947067901785,"score_spread":0.23330172799633858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152445171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904811,0.0017711731,0.0051054507,0.000111171335,0.00003693146,0.000034942866,0.00041556614,0.00022148248,0.001822172],"genre_scores_gemma":[0.98754275,0.0013311028,0.004742578,0.000056295365,0.000016671425,0.00008405915,0.0012059725,0.0000528901,0.0049676537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997354,0.000039535335,0.00003395636,0.00005859332,0.00008462711,0.00004785779],"domain_scores_gemma":[0.9997726,0.000051572304,0.000059513026,0.000038713457,0.000020882691,0.000056745932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022968731,0.000428568,0.0002848222,0.0005627461,0.0001893529,0.00040475844,0.00024042043,0.00029452887,0.0011140757],"category_scores_gemma":[0.00017284047,0.00020082697,0.00033610372,0.00022319706,0.0002806928,0.00018046678,0.00017019309,0.00067828904,0.0004452265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060984436,0.000019055382,0.000062498606,0.000009334854,0.000005412222,0.000031066338,0.000009128532,0.000029066687,0.9993111,0.00009338127,0.00002390915,0.0003451368],"study_design_scores_gemma":[0.000019366822,0.00029168482,0.0015410229,0.0000034140553,0.000014800028,0.00025422574,0.000014446325,0.0007233644,0.99527586,0.000044442808,0.0018147301,0.000002659678],"about_ca_topic_score_codex":0.00053291663,"about_ca_topic_score_gemma":0.0009795228,"teacher_disagreement_score":0.0011140757,"about_ca_system_score_codex":0.00030049542,"about_ca_system_score_gemma":0.0002321678,"threshold_uncertainty_score":0.0037269592},"labels":[],"label_agreement":null},{"id":"W2152545151","doi":"10.1158/1535-7163.911.3.8","title":"The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; Montreal General Hospital","funders":"","keywords":"Exonuclease; Cancer cell; DNA repair; DNA damage; Biology; Cisplatin; Cancer research; DNA; Molecular biology; Chemistry; Cancer; Biochemistry; Genetics; DNA polymerase; Chemotherapy","score_opus":0.01797271554480728,"score_gpt":0.28399503031428797,"score_spread":0.2660223147694807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152545151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8009324,0.1571772,0.028828036,0.0024193407,0.00040139048,0.00018307472,0.0005417475,0.00033673123,0.009180107],"genre_scores_gemma":[0.948158,0.034029722,0.011182727,0.00039989845,0.00006609658,0.00005928759,0.00055545376,0.000021524702,0.0055272076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990714,0.000018477096,0.0000067763663,0.000019753223,0.00003257318,0.000015231086],"domain_scores_gemma":[0.99994624,0.000009673428,0.0000153563,0.000006902694,0.000010464947,0.00001135395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018248663,0.0002787157,0.000296024,0.00016651665,0.00007783317,0.00030991156,0.00018768411,0.00037364117,0.0008093817],"category_scores_gemma":[0.00007376896,0.000090797286,0.00013888528,0.00013348185,0.00015740775,0.00016559291,0.00015447101,0.0005610877,0.00024169324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001140262,0.00004651829,0.0002393617,0.00015614112,0.000010411994,0.000093132236,0.000012878376,0.000162839,0.98879015,0.00041020568,0.0002264412,0.00973802],"study_design_scores_gemma":[0.00004718951,0.0011369744,0.0022069262,0.000026972035,0.000066594606,0.001650122,0.000018865518,0.0008205517,0.96231735,0.0001840829,0.031517033,0.0000073044325],"about_ca_topic_score_codex":0.00017356334,"about_ca_topic_score_gemma":0.00035965964,"teacher_disagreement_score":0.0008093817,"about_ca_system_score_codex":0.0002760984,"about_ca_system_score_gemma":0.00016933437,"threshold_uncertainty_score":0.0027076006},"labels":[],"label_agreement":null},{"id":"W2153507021","doi":"10.1158/1535-7163.mct-08-0248","title":"Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; University of Chicago","keywords":"International HapMap Project; Carboplatin; Biology; Genetics; Single-nucleotide polymorphism; Gene; Genotype","score_opus":0.02559635144748617,"score_gpt":0.2469385469462732,"score_spread":0.22134219549878703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153507021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985507,0.00010815713,0.00066013314,0.000011298125,0.0000027813987,0.000014255143,0.00043082374,0.000008650157,0.00021320234],"genre_scores_gemma":[0.9978436,0.0001525509,0.00087367423,0.000023505563,0.0000032334042,0.000026348442,0.0007239092,0.000018288249,0.00033496003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998115,0.000036180387,0.000018312716,0.000060575898,0.00003902743,0.0000344681],"domain_scores_gemma":[0.999772,0.00007067673,0.00007384788,0.000040476647,0.000019831583,0.000023142436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018275932,0.00023585862,0.0002812095,0.00069069024,0.0002955753,0.00027770485,0.00014508908,0.00023395196,0.0018430066],"category_scores_gemma":[0.00045250758,0.0001556629,0.00034919917,0.00073117507,0.00020106339,0.00007722221,0.00026877713,0.00030385566,0.0001968925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013504369,0.00009574944,0.14375542,0.000063928186,0.00020409355,0.0016477597,0.0005922585,0.0003606664,0.8439375,0.0002672473,0.00013313921,0.0075917463],"study_design_scores_gemma":[0.0000390186,0.00039119404,0.94586414,0.000015105157,0.00015219717,0.0036340025,0.0003397831,0.0009823322,0.04652609,0.00017294275,0.0018628488,0.000020399948],"about_ca_topic_score_codex":0.0018802161,"about_ca_topic_score_gemma":0.0020100225,"teacher_disagreement_score":0.0018802161,"about_ca_system_score_codex":0.00013524941,"about_ca_system_score_gemma":0.00009139625,"threshold_uncertainty_score":0.006165445},"labels":[],"label_agreement":null},{"id":"W2154040159","doi":"10.1158/1535-7163.mct-08-0021","title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":636,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"Oak Ridge Institute for Science and Education","keywords":"microRNA; Cancer research; Cancer cell; Doxorubicin; Breast cancer chemotherapy; Cancer; Transfection; Biology; Epigenetics; Breast cancer; MCF-7; Drug resistance; Gene silencing; Multiple drug resistance; Cell culture; Gene; Chemotherapy; Genetics","score_opus":0.012762503057607403,"score_gpt":0.25152260790769804,"score_spread":0.23876010485009064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154040159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848279,0.00883351,0.0022832742,0.00027223412,0.00008226487,0.00003248862,0.0005059695,0.0001417311,0.0030207057],"genre_scores_gemma":[0.9946333,0.0021368647,0.0014458902,0.00009425586,0.000009741229,0.000023263708,0.0004279347,0.000012778134,0.0012159735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998789,0.000021207246,0.000013416392,0.000025720845,0.000039469876,0.00002124502],"domain_scores_gemma":[0.99994826,0.000009809061,0.000015784883,0.0000060870943,0.000009509254,0.000010541284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011358401,0.00018807662,0.00025418476,0.0002397648,0.00016222608,0.00027606077,0.00007702503,0.0002498628,0.0005812357],"category_scores_gemma":[0.00013319158,0.00013885667,0.00022176882,0.00010132318,0.00012182605,0.000097638556,0.00011413632,0.00022490347,0.00033378086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006704775,0.000011318799,0.0005592775,0.000027660208,0.000005670396,0.0001016268,0.000024358655,0.00004769757,0.99774444,0.000081277096,0.000055305303,0.0012742706],"study_design_scores_gemma":[0.000008698691,0.00017494446,0.017661983,0.00000771081,0.00003268887,0.000665705,0.000055891884,0.0012842268,0.9748045,0.00006817937,0.005227048,0.000008380462],"about_ca_topic_score_codex":0.00051839044,"about_ca_topic_score_gemma":0.00048925023,"teacher_disagreement_score":0.0005812357,"about_ca_system_score_codex":0.0002476035,"about_ca_system_score_gemma":0.00016116793,"threshold_uncertainty_score":0.0019444227},"labels":[],"label_agreement":null},{"id":"W2154252904","doi":"10.1158/1535-7163.mct-07-2164","title":"Arsenic trioxide decreases AKT protein in a caspase-dependent manner","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Protein kinase B; Arsenic trioxide; Cancer research; Chemistry; Phosphorylation; Caspase; Cell biology; Apoptosis; Kinase; Acute promyelocytic leukemia; Biology; Biochemistry; Programmed cell death; Retinoic acid","score_opus":0.01950918625296531,"score_gpt":0.26461104711954453,"score_spread":0.24510186086657923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154252904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905365,0.002888594,0.0031456957,0.0002599199,0.000075111224,0.00003227094,0.00041712722,0.00014919981,0.0024955226],"genre_scores_gemma":[0.98976445,0.0025802916,0.0021494464,0.00009247321,0.0000137421775,0.000038777693,0.00041437396,0.000019241308,0.004927333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999176,0.00001530647,0.000009352812,0.000014911411,0.000026671672,0.000016177448],"domain_scores_gemma":[0.99995685,0.0000057593707,0.000014651533,0.000004689964,0.000008956866,0.000009088846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008718907,0.00026410437,0.00016095907,0.00019673149,0.00012871627,0.0001948986,0.00011159604,0.00016684836,0.0015198165],"category_scores_gemma":[0.00006657556,0.00008941608,0.00019616431,0.00019161556,0.00018782268,0.00016353096,0.0000757121,0.00032894313,0.00027005374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019432913,0.000042374344,0.000078849764,0.00003408123,0.00000844935,0.000020151138,0.000008316349,0.000044154975,0.9985128,0.00006899676,0.0000731101,0.00091436494],"study_design_scores_gemma":[0.00003743128,0.00028408528,0.0019206477,0.0000026679886,0.00001674832,0.0001380821,0.000019089059,0.00047874264,0.9945152,0.00007994445,0.0025042682,0.0000030773442],"about_ca_topic_score_codex":0.0006219228,"about_ca_topic_score_gemma":0.0011215995,"teacher_disagreement_score":0.0015198165,"about_ca_system_score_codex":0.0002523717,"about_ca_system_score_gemma":0.00026328425,"threshold_uncertainty_score":0.005084336},"labels":[],"label_agreement":null},{"id":"W2154416389","doi":"10.1158/1535-7163.mct-11-0659","title":"Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Eli Lilly and Company","keywords":"Medicine; Gemcitabine; Pharmacology; Prodrug; Chemotherapy; Paclitaxel; Vinblastine; Topotecan; Cyclophosphamide; Bone marrow; Cancer research; Internal medicine","score_opus":0.022541055487687794,"score_gpt":0.2668235972590885,"score_spread":0.2442825417714007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154416389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806136,0.0005582424,0.0005252558,0.000033853008,0.000018033445,0.000039863495,0.0002269908,0.00004622249,0.0004901122],"genre_scores_gemma":[0.99748886,0.00037328262,0.0007001166,0.000018869088,0.000009340635,0.00003704521,0.00046679046,0.00001102389,0.00089467276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989843,0.000024892235,0.000010045793,0.000016627599,0.000021999522,0.000027964254],"domain_scores_gemma":[0.9999225,0.000016917966,0.000019503981,0.000011485246,0.000006813485,0.00002277669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104054256,0.0003384455,0.0004414869,0.00022111576,0.0000804285,0.00017387193,0.00015860627,0.00023053901,0.0010070292],"category_scores_gemma":[0.000105533574,0.000096377,0.0001673855,0.0001960753,0.00015922831,0.00013847165,0.00008248905,0.0005578067,0.00017839951],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001701483,0.00040798512,0.00037595283,0.00005801334,0.000014275731,0.000058576952,0.000017905282,0.0002428751,0.9918069,0.000066859924,0.0001091868,0.0051399157],"study_design_scores_gemma":[0.00015273433,0.010768753,0.003126876,0.0000035324836,0.000029812398,0.00022019641,0.000013702609,0.0007182068,0.9838464,0.000016950698,0.0010981702,0.0000047471926],"about_ca_topic_score_codex":0.0004621617,"about_ca_topic_score_gemma":0.00096610654,"teacher_disagreement_score":0.0010070292,"about_ca_system_score_codex":0.00020582952,"about_ca_system_score_gemma":0.00025021107,"threshold_uncertainty_score":0.003368795},"labels":[],"label_agreement":null},{"id":"W2155021489","doi":"10.1158/1535-7163.mct-07-2282","title":"Cyclooxygenase inhibitors block uterine tumorigenesis in <i>HMGA1a</i> transgenic mice and human xenografts","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Sulindac; Celecoxib; Cyclooxygenase; Cancer; Cancer research; Carcinogenesis; Medicine; Pharmacology; Internal medicine; Biology; Enzyme; Biochemistry","score_opus":0.017437790963481456,"score_gpt":0.2817271344254578,"score_spread":0.26428934346197636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155021489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840539,0.0018499488,0.0056616366,0.0005377205,0.00016304773,0.00018234133,0.0027894315,0.00053611683,0.004225897],"genre_scores_gemma":[0.9774341,0.0019393738,0.0057948222,0.00016994645,0.00004959104,0.00023812574,0.0036344538,0.00015993,0.010579623],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967456,0.000059908973,0.00003979738,0.0000663657,0.00007475428,0.000084690415],"domain_scores_gemma":[0.99970263,0.000059000504,0.000084347645,0.0000480252,0.000017588538,0.00008828369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004109251,0.00054371683,0.00045281975,0.0005607503,0.00021004445,0.00030988583,0.00041092353,0.0004654965,0.0024402693],"category_scores_gemma":[0.00017621995,0.0003611303,0.0005949113,0.00027236826,0.00031547179,0.0002520913,0.0001921806,0.0011428457,0.00061909563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060856796,0.0002680475,0.00028589836,0.000038614908,0.000015577956,0.00009581868,0.000038513772,0.00013821728,0.9962352,0.00039550284,0.00030904173,0.0015710762],"study_design_scores_gemma":[0.00016357393,0.0018602692,0.0029087851,0.000012957242,0.000036599708,0.00049404707,0.000045023306,0.0022854921,0.985903,0.00010209053,0.0061808713,0.000007335616],"about_ca_topic_score_codex":0.0018585206,"about_ca_topic_score_gemma":0.0027185162,"teacher_disagreement_score":0.0024402693,"about_ca_system_score_codex":0.0004373686,"about_ca_system_score_gemma":0.00041826666,"threshold_uncertainty_score":0.008163512},"labels":[],"label_agreement":null},{"id":"W2155136577","doi":"10.1158/1535-7163.mct-13-1053","title":"Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"U.S. Food and Drug Administration","keywords":"Bevacizumab; Ovarian cancer; Medicine; Cancer research; Stromal cell; Minimal residual disease; Autocrine signalling; Cancer; Progenitor cell; Protein kinase B; Immunology; Oncology; Internal medicine; Biology; Stem cell; Bone marrow; Chemotherapy; Signal transduction; Cell biology","score_opus":0.019901269408656233,"score_gpt":0.29186653579912675,"score_spread":0.27196526639047053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155136577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949142,0.0031110756,0.000743672,0.00011604345,0.000009444929,0.000009143118,0.000047439324,0.000011487676,0.0010375644],"genre_scores_gemma":[0.9987445,0.00054434483,0.00021092947,0.00001881791,0.0000039299543,0.0000037318832,0.00003596594,0.0000014080548,0.00043634634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992776,0.000019967543,0.0000054373386,0.000010893887,0.000019425932,0.000016419795],"domain_scores_gemma":[0.9999411,0.00001221431,0.000019363028,0.000007765346,0.0000061294822,0.000013544142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013557237,0.00008043687,0.0001222655,0.00016982396,0.0000842775,0.00024988852,0.00007114684,0.00015140286,0.0007932331],"category_scores_gemma":[0.00012991222,0.000078397214,0.000100041114,0.00009705856,0.00015052606,0.00015536662,0.00010321899,0.00028618154,0.00011109468],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063685875,0.00008866882,0.008112476,0.00007740664,0.000018289978,0.00043063797,0.00004578649,0.00016460508,0.9786258,0.00076872413,0.00011062408,0.010920128],"study_design_scores_gemma":[0.0001530107,0.0023275465,0.28396115,0.000036210688,0.00012829211,0.010244052,0.00030113693,0.005078346,0.68068874,0.0018868577,0.015171914,0.000022722195],"about_ca_topic_score_codex":0.0002573686,"about_ca_topic_score_gemma":0.00034350314,"teacher_disagreement_score":0.0007932331,"about_ca_system_score_codex":0.00016364733,"about_ca_system_score_gemma":0.00017555967,"threshold_uncertainty_score":0.0026535988},"labels":[],"label_agreement":null},{"id":"W2155321348","doi":"10.1158/1535-7163.mct-05-0099","title":"Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Protein kinase B; Kinase; Integrin-linked kinase; MAPK/ERK pathway; Cancer research; Wortmannin; PI3K/AKT/mTOR pathway; Protein kinase A; Phosphatidylinositol; Chemistry; Biology; Cell biology; Molecular biology; Signal transduction; Cyclin-dependent kinase 2","score_opus":0.0073327816817469645,"score_gpt":0.21447004087722632,"score_spread":0.20713725919547935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155321348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922127,0.0029685993,0.002244437,0.00010273646,0.0000500772,0.000072628514,0.00029257932,0.00010500301,0.0019513143],"genre_scores_gemma":[0.9918481,0.0016445385,0.0042415285,0.00005023958,0.000012733532,0.000108445485,0.0004972746,0.000011079598,0.0015859158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996921,0.000046550504,0.00003739361,0.000035962283,0.000118952295,0.00006911732],"domain_scores_gemma":[0.9999268,0.000011935782,0.000014683656,0.000009681122,0.00001241009,0.000024480196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023378739,0.0006160966,0.00069995795,0.00042886043,0.00018023874,0.00030670327,0.00022454523,0.00022177768,0.0007216102],"category_scores_gemma":[0.00007264642,0.00020792315,0.0005229351,0.0003648232,0.00014271164,0.00016656684,0.00025243594,0.00053109945,0.00029709982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022684128,0.00018204574,0.00039069846,0.000086980406,0.00003788426,0.000051283172,0.00002840026,0.00014263719,0.99461985,0.000083117375,0.00012688688,0.0040233587],"study_design_scores_gemma":[0.000038035352,0.0011680828,0.003325734,0.0000051418633,0.00007105933,0.00018029888,0.00002749716,0.0007724353,0.9927025,0.00002242815,0.0016820384,0.0000049148207],"about_ca_topic_score_codex":0.0011263894,"about_ca_topic_score_gemma":0.0033973872,"teacher_disagreement_score":0.0011263894,"about_ca_system_score_codex":0.0002998461,"about_ca_system_score_gemma":0.0003480009,"threshold_uncertainty_score":0.002413988},"labels":[],"label_agreement":null},{"id":"W2155784435","doi":"10.1158/1535-7163.mct-06-0596","title":"Radiation-induced cell signaling: inside-out and outside-in","year":2007,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Cell biology; Paracrine signalling; Signal transduction; Autocrine signalling; Biology; Cell signaling; Kinase; Protein kinase B; Intracellular; Receptor; Biochemistry","score_opus":0.07123259998810326,"score_gpt":0.38355879384918684,"score_spread":0.31232619386108357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155784435","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78342277,0.082323916,0.04623115,0.002564667,0.002247911,0.0004017885,0.0014680892,0.0014202852,0.07991946],"genre_scores_gemma":[0.95785546,0.014970032,0.005406657,0.00088544056,0.0002633189,0.000107184096,0.0006859491,0.00013135449,0.0196947],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99957365,0.000069088834,0.000023486304,0.000113312206,0.00013326597,0.000087224435],"domain_scores_gemma":[0.99979514,0.000024238527,0.000046327783,0.000043577034,0.000049042803,0.000041768093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033300024,0.0007849617,0.00061593077,0.00036632892,0.00054389745,0.0015151917,0.00052300765,0.0010106335,0.00586711],"category_scores_gemma":[0.00019705908,0.00030751576,0.00078262505,0.0002412452,0.00041489772,0.0013171321,0.00048226072,0.0010391873,0.0021966435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003481928,0.00015952432,0.0005233201,0.00044517577,0.000036064896,0.00044288777,0.00013477437,0.0003178313,0.9707139,0.0061738286,0.0009876608,0.019716714],"study_design_scores_gemma":[0.000061564926,0.0008529045,0.007352991,0.000121010984,0.00008920492,0.0017565609,0.00022732985,0.002195876,0.9373416,0.0018385581,0.048122186,0.000040215284],"about_ca_topic_score_codex":0.000119057186,"about_ca_topic_score_gemma":0.00016064367,"teacher_disagreement_score":0.00586711,"about_ca_system_score_codex":0.00075796904,"about_ca_system_score_gemma":0.00027753253,"threshold_uncertainty_score":0.019627512},"labels":[],"label_agreement":null},{"id":"W2155841399","doi":"10.1158/1535-7163.mct-10-0321","title":"PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Natural Science Foundation of China; Prostate Cancer Canada; Ontario Institute for Cancer Research","keywords":"Kinase; Cancer research; Cell growth; Cell culture; STAT5; Cancer cell; Downregulation and upregulation; Phosphorylation; Prostate cancer; Biology; Molecular biology; Chemistry; Cancer; Cell biology; Biochemistry","score_opus":0.013961841674693744,"score_gpt":0.28505471495867224,"score_spread":0.2710928732839785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155841399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856146,0.0030063184,0.0025952775,0.00017693918,0.000075556265,0.00010490591,0.002388106,0.00036190602,0.0056764157],"genre_scores_gemma":[0.9893254,0.0021089336,0.0022669756,0.000117813564,0.000017231321,0.00007748111,0.0028393234,0.000022143651,0.0032245752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999882,0.000011893377,0.000008709782,0.0000141507935,0.00004204257,0.00004115209],"domain_scores_gemma":[0.9999571,0.000007762961,0.000010906232,0.0000036602478,0.0000057009115,0.000014937648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093748495,0.00051424635,0.00031065848,0.00029343634,0.00014820135,0.00027604788,0.00014396566,0.00019015532,0.0013879866],"category_scores_gemma":[0.000074543714,0.00011855396,0.00033002687,0.00024111781,0.0001279412,0.00008336787,0.00014630916,0.00044173503,0.00050454534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001593264,0.00007109593,0.000260844,0.00007390396,0.000017255003,0.000051152445,0.000008304543,0.00021078995,0.9955362,0.000075044736,0.00024946514,0.0032866478],"study_design_scores_gemma":[0.000035289675,0.0005472065,0.00532829,0.0000047360386,0.000037267357,0.00020651604,0.000014435351,0.0011349174,0.9889887,0.000031009637,0.0036664312,0.0000051719508],"about_ca_topic_score_codex":0.00065387477,"about_ca_topic_score_gemma":0.001561883,"teacher_disagreement_score":0.0013879866,"about_ca_system_score_codex":0.00036060569,"about_ca_system_score_gemma":0.0002528182,"threshold_uncertainty_score":0.0046432614},"labels":[],"label_agreement":null},{"id":"W2155927815","doi":"10.1158/1535-7163.mct-14-0751","title":"The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Ministero dello Sviluppo Economico; Mitacs; McGill University","keywords":"Cancer research; Metastasis; In vivo; Angiogenesis; Receptor; Cancer; Cell growth; Biology; Medicine; Internal medicine; Biochemistry","score_opus":0.04735227450325679,"score_gpt":0.287548949260484,"score_spread":0.24019667475722722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155927815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8325641,0.09830055,0.05342561,0.0015292843,0.00048430957,0.0004427615,0.0009856641,0.0009633631,0.011304296],"genre_scores_gemma":[0.9428185,0.01989183,0.022206977,0.00033587983,0.00015849157,0.00016406139,0.0011726606,0.000040006507,0.0132116955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995685,0.000004757963,0.0000015709907,0.0000083688055,0.000017058073,0.000011454739],"domain_scores_gemma":[0.9999738,0.0000044494814,0.00000531259,0.0000012476183,0.000004812473,0.000010415205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010602188,0.00043028116,0.000178026,0.00023944154,0.00014431668,0.00022332245,0.00024626194,0.00028724733,0.00097332447],"category_scores_gemma":[0.00006768319,0.000077300894,0.00016422616,0.000110257664,0.0001619468,0.00019091053,0.00016650427,0.0005741992,0.00030035625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021602387,0.00010278816,0.00027675784,0.00020472593,0.00001734135,0.00033781878,0.000021161812,0.00028449853,0.95562464,0.0006652163,0.0012235224,0.041025583],"study_design_scores_gemma":[0.00022044477,0.0018095433,0.0028641976,0.000022885046,0.000070061506,0.003855374,0.000020214791,0.002570557,0.9372756,0.00014455107,0.0511203,0.000026307967],"about_ca_topic_score_codex":0.000873401,"about_ca_topic_score_gemma":0.001695712,"teacher_disagreement_score":0.00097332447,"about_ca_system_score_codex":0.0003386616,"about_ca_system_score_gemma":0.00033014044,"threshold_uncertainty_score":0.0032560825},"labels":[],"label_agreement":null},{"id":"W2156678982","doi":"10.1158/1535-7163.mct-06-0517","title":"Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Calcitriol receptor; Chemotherapy; Cancer research; Medicine; Apoptosis; Cancer; Vitamin D and neurology; Cancer cell; Internal medicine; Oncology; Biology; Biochemistry","score_opus":0.021886781490850743,"score_gpt":0.3042405412308481,"score_spread":0.2823537597399973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156678982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964437,0.0017539539,0.00071941974,0.000118846525,0.000017093062,0.000023152974,0.0001357156,0.00004481798,0.0007433936],"genre_scores_gemma":[0.99757993,0.00053028145,0.00073607685,0.000038210495,0.0000074760133,0.000017607186,0.00019052411,0.0000054111792,0.00089445285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977463,0.000057500984,0.000021302103,0.000039407954,0.00007027647,0.000036757763],"domain_scores_gemma":[0.9998493,0.000040698713,0.000032709915,0.000023953804,0.000010832841,0.00004247418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015106585,0.00019738235,0.00039644912,0.00027837552,0.00011232854,0.0002904595,0.00015842383,0.00021401749,0.00091502856],"category_scores_gemma":[0.00015364119,0.00015948676,0.00030361649,0.0001718299,0.00016998989,0.00011381114,0.00020515492,0.00033419064,0.0001916872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003250656,0.000051205458,0.00064375415,0.000025081741,0.000012226173,0.00007704868,0.000009244391,0.00006511016,0.9972402,0.000036714897,0.000047323854,0.0014670407],"study_design_scores_gemma":[0.000081181206,0.0021447248,0.022779709,0.0000067257665,0.000053692722,0.0013288583,0.00005973764,0.0012039952,0.96789336,0.000042939926,0.0043971487,0.000007902453],"about_ca_topic_score_codex":0.00045143886,"about_ca_topic_score_gemma":0.0012249863,"teacher_disagreement_score":0.00091502856,"about_ca_system_score_codex":0.00025964942,"about_ca_system_score_gemma":0.00020815482,"threshold_uncertainty_score":0.0030610561},"labels":[],"label_agreement":null},{"id":"W2157107922","doi":"10.1158/1535-7163.mct-07-0514","title":"Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Retinoic acid; Acute promyelocytic leukemia; Myeloid leukemia; Myeloid; Cellular differentiation; Biology; Differentiation therapy; Cancer research; Cell biology; Kinase; Proto-oncogene tyrosine-protein kinase Src; Cell culture; Gene; Biochemistry; Genetics","score_opus":0.015529573131299747,"score_gpt":0.26698234068904575,"score_spread":0.251452767557746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157107922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874079,0.004467823,0.0027822256,0.00012259645,0.000041231993,0.000031042706,0.00022348235,0.00012729158,0.004796533],"genre_scores_gemma":[0.9891889,0.0029120964,0.0024560064,0.000041812847,0.000014993297,0.000032036987,0.00040413396,0.0000197971,0.0049301954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998692,0.000024839954,0.0000123743475,0.000016583645,0.000042998417,0.000033883167],"domain_scores_gemma":[0.99994123,0.000016051368,0.000011862861,0.000008211876,0.0000056828594,0.00001690638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110394634,0.00027658002,0.00024033815,0.00019732627,0.000083869265,0.00019217783,0.000101024394,0.00012143184,0.0014291077],"category_scores_gemma":[0.00010315453,0.000078527024,0.00017779633,0.00012898743,0.00017751884,0.00013888846,0.00012919153,0.00040916746,0.000456858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007487782,0.000021155376,0.000057508467,0.000024430166,0.0000022609827,0.000021278356,0.0000059687245,0.000055924622,0.9980679,0.000093540526,0.000022083681,0.0015531463],"study_design_scores_gemma":[0.000014242632,0.0001965467,0.0012785764,0.0000030691567,0.000006449929,0.00010146432,0.000006265972,0.00046506035,0.9954513,0.000027443259,0.0024483914,0.0000012528227],"about_ca_topic_score_codex":0.00037842896,"about_ca_topic_score_gemma":0.0007471293,"teacher_disagreement_score":0.0014291077,"about_ca_system_score_codex":0.00022535812,"about_ca_system_score_gemma":0.0001969541,"threshold_uncertainty_score":0.004780829},"labels":[],"label_agreement":null},{"id":"W2157322564","doi":"10.1158/1535-7163.targ-11-c235","title":"Abstract C235: Interleukin-6 secreted by cancer-associated fibroblasts mediates gemcitabine resistance in pancreatic cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic cancer; Cancer research; Adenocarcinoma; CA19-9; Cancer; Cancer-Associated Fibroblasts; Internal medicine; Medicine; Tumor microenvironment; Cytokine; Pancreatic tumor; Endocrinology; Oncology; Biology","score_opus":0.022191067881289783,"score_gpt":0.29085276455719167,"score_spread":0.2686616966759019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157322564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923873,0.0016883465,0.0014802602,0.00016222328,0.00007616649,0.000039717386,0.0025398,0.0000920766,0.001534144],"genre_scores_gemma":[0.9880023,0.0012111808,0.0018945449,0.00010203917,0.000053893,0.00008118198,0.0036587352,0.000018804989,0.0049772463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984455,0.000015414085,0.000014877668,0.000042519165,0.00004407733,0.000038496295],"domain_scores_gemma":[0.9998996,0.000016456392,0.00002366992,0.000008293391,0.000012888087,0.00003899277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001015901,0.0003825469,0.00028579327,0.00026389898,0.00021469504,0.00032708375,0.00012510885,0.00021226167,0.0028565042],"category_scores_gemma":[0.00009225331,0.00009511885,0.00026558936,0.0003147517,0.00019524772,0.00013703451,0.00012617777,0.0005098238,0.00070576166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004283473,0.000050540788,0.0012510363,0.00007930334,0.000007062549,0.00011687949,0.000019478986,0.00003784691,0.9963845,0.00003535173,0.00015858574,0.0014310995],"study_design_scores_gemma":[0.00004257832,0.0007162795,0.03812048,0.0000119821725,0.000050874256,0.0009048743,0.00009148149,0.00067795155,0.955259,0.000059606016,0.0040580747,0.000006782186],"about_ca_topic_score_codex":0.00042465844,"about_ca_topic_score_gemma":0.00035725083,"teacher_disagreement_score":0.0028565042,"about_ca_system_score_codex":0.00024548647,"about_ca_system_score_gemma":0.00018365635,"threshold_uncertainty_score":0.009555936},"labels":[],"label_agreement":null},{"id":"W2157433648","doi":"10.1158/1535-7163.mct-07-2421","title":"Tumor necrosis factor-α–induced accentuation in cryoinjury: mechanisms <i>in vitro</i> and <i>in vivo</i>","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; University of Minnesota","keywords":"In vivo; LNCaP; Tumor necrosis factor alpha; Cytokine; Apoptosis; Cancer research; In vitro; Cancer; Cancer cell; Medicine; Biology; Chemistry; Pathology; Immunology; Internal medicine; Biochemistry","score_opus":0.02066774793588567,"score_gpt":0.26087438075131864,"score_spread":0.24020663281543297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157433648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827146,0.0058416314,0.009289914,0.000107679916,0.00006316071,0.00008258902,0.00018408523,0.00011596279,0.0016003407],"genre_scores_gemma":[0.9942783,0.0017185878,0.0024129942,0.00004801627,0.000015644062,0.000051244544,0.0001946106,0.000013816003,0.0012667172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983406,0.000046529858,0.000013374846,0.000029497984,0.000032197975,0.000044341345],"domain_scores_gemma":[0.9997719,0.00004759527,0.000089897156,0.00003758147,0.000029106199,0.000024052208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038882656,0.00053123996,0.00019400883,0.00012816391,0.00013397369,0.0002888682,0.00019312881,0.0002594537,0.0012585903],"category_scores_gemma":[0.00017111294,0.00020293373,0.00040431204,0.00009219288,0.00038843197,0.0003572338,0.00015000952,0.00052072224,0.00028019174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024496834,0.000038534206,0.00019806363,0.00006014967,0.000007978395,0.00003336305,0.000021886866,0.00007200648,0.9983878,0.00006133374,0.000018547706,0.00085537584],"study_design_scores_gemma":[0.000007125395,0.0005749586,0.002707283,0.0000052576656,0.000014949525,0.00015745779,0.00001718597,0.00022249941,0.9958918,0.000018667439,0.000381136,0.0000016943189],"about_ca_topic_score_codex":0.00035569404,"about_ca_topic_score_gemma":0.00039563212,"teacher_disagreement_score":0.0012585903,"about_ca_system_score_codex":0.00032003975,"about_ca_system_score_gemma":0.00014674746,"threshold_uncertainty_score":0.004210353},"labels":[],"label_agreement":null},{"id":"W2157901482","doi":"10.1158/1535-7163.mct-08-0562","title":"Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Resveratrol; Gene knockdown; Melanoma; Molecular biology; Chemistry; Cancer research; Nitric oxide synthase; AP site; DNA-(apurinic or apyrimidinic site) lyase; DNA damage; Biology; Apoptosis; Biochemistry; Enzyme; DNA","score_opus":0.028085088972556755,"score_gpt":0.30485036226430223,"score_spread":0.2767652732917455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157901482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724246,0.007852328,0.0025354153,0.00018180793,0.000101819904,0.000070251815,0.00023998511,0.0000936912,0.0016822803],"genre_scores_gemma":[0.99340266,0.0023356127,0.0015335417,0.000070926115,0.000021952006,0.00005842887,0.0003486747,0.0000074052527,0.0022208313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989796,0.000023833241,0.000009106981,0.000022953056,0.000023203896,0.0000229403],"domain_scores_gemma":[0.9999461,0.000008571538,0.000016804006,0.0000051400275,0.000009170626,0.0000142169965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014817959,0.00039532993,0.00024454738,0.00019204686,0.000116578354,0.00015155697,0.00015398572,0.00020509194,0.000734952],"category_scores_gemma":[0.00009658501,0.00014581584,0.00035485474,0.0000796279,0.0001485484,0.00016908348,0.00013006567,0.0005507413,0.00018548519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020874134,0.000071817274,0.00014895778,0.000053692558,0.000007414072,0.000043670727,0.000017953686,0.00002753493,0.9981785,0.00006776361,0.000043357955,0.0011307353],"study_design_scores_gemma":[0.00007906648,0.0014983725,0.010206439,0.0000139015865,0.000034937188,0.00028476625,0.00004000712,0.0010997643,0.9838398,0.00011454829,0.0027803082,0.000008109767],"about_ca_topic_score_codex":0.0006278875,"about_ca_topic_score_gemma":0.00089570094,"teacher_disagreement_score":0.000734952,"about_ca_system_score_codex":0.00015327115,"about_ca_system_score_gemma":0.00017107313,"threshold_uncertainty_score":0.0024586916},"labels":[],"label_agreement":null},{"id":"W2158343538","doi":"10.1158/1535-7163.mct-13-0749","title":"Glioblastoma Cells Containing Mutations in the Cohesin Component <i>STAG2</i> Are Sensitive to PARP Inhibition","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Institute for Advanced Research","keywords":"Poly ADP ribose polymerase; Mutant; Biology; Cancer research; Molecular biology; Mutation; DNA repair; DNA damage; PARP inhibitor; Cancer cell; DNA; Cancer; Gene; Genetics; Polymerase","score_opus":0.026576075252569154,"score_gpt":0.3001990841337632,"score_spread":0.27362300888119406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158343538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961404,0.0011216373,0.0011386134,0.000053520267,0.000022189406,0.000037293394,0.00033993396,0.00007597165,0.0010703809],"genre_scores_gemma":[0.9967691,0.00055928546,0.0011246663,0.000057782545,0.0000056165086,0.000051617873,0.0007677879,0.000015441754,0.0006488344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997758,0.000036772744,0.000038205962,0.00002736766,0.000070617774,0.000051066076],"domain_scores_gemma":[0.9998129,0.000026093567,0.000051348532,0.000038694052,0.000027053407,0.00004391725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016648315,0.00034050774,0.00052451313,0.00031462446,0.00017470383,0.0003298073,0.00015026062,0.00021908229,0.0006648876],"category_scores_gemma":[0.00022622397,0.00014858693,0.00026512562,0.00026318865,0.00015655141,0.00013318003,0.00016357307,0.00039119524,0.00021605918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033606144,0.00005622224,0.0017784975,0.000023794852,0.000023846009,0.00014054736,0.00002308296,0.000111392685,0.993982,0.00006556392,0.0001180234,0.0033410715],"study_design_scores_gemma":[0.000052324576,0.0016558241,0.030355757,0.0000055555265,0.000049166436,0.001038472,0.00004769626,0.000600493,0.9644518,0.000051472205,0.0016847602,0.000006573373],"about_ca_topic_score_codex":0.0015686712,"about_ca_topic_score_gemma":0.0023494062,"teacher_disagreement_score":0.0015686712,"about_ca_system_score_codex":0.00029271265,"about_ca_system_score_gemma":0.00020835837,"threshold_uncertainty_score":0.003119111},"labels":[],"label_agreement":null},{"id":"W2158453396","doi":"10.1158/1535-7163.mct-05-0066","title":"Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Health and Medical Research Council; Medical Research Council; University of Alberta","keywords":"Gefitinib; Epidermal growth factor receptor; Tumor hypoxia; In vivo; Cancer research; Epidermal growth factor; Hypoxia (environmental); A431 cells; Medicine; Pharmacology; Chemistry; Pathology; Cancer; Internal medicine; Biology; Radiation therapy; Receptor; Cell cycle; Oxygen; Molecular medicine","score_opus":0.020034396896466414,"score_gpt":0.2636662241664722,"score_spread":0.24363182727000576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158453396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98979,0.0016294685,0.007151013,0.0000749865,0.000020906275,0.000031190626,0.00010972538,0.00008021665,0.0011123801],"genre_scores_gemma":[0.9931377,0.0010589522,0.004129694,0.000027855074,0.000013684172,0.00006228079,0.00023322212,0.000017702556,0.0013189216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999192,0.000021120884,0.0000037825362,0.000017919287,0.000017520486,0.000020488838],"domain_scores_gemma":[0.9999608,0.000009877146,0.000012953496,0.000004749151,0.0000046435102,0.0000069318207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001386315,0.00028707404,0.00024929456,0.00012610693,0.00008737242,0.0002568274,0.0001689072,0.00022993401,0.00076972006],"category_scores_gemma":[0.00009223194,0.00013349675,0.00013020106,0.00007167364,0.00015776356,0.00022684688,0.000068222456,0.00029646826,0.00016093973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014560315,0.000018387584,0.0001291038,0.00001213389,0.0000040168284,0.000016856025,0.000004277385,0.00005166106,0.9985196,0.000019270517,0.000020695259,0.0010584211],"study_design_scores_gemma":[0.000021148031,0.000666382,0.0048135477,0.0000015901991,0.000019964777,0.00025843698,0.000016635142,0.0015928972,0.991499,0.000017955632,0.0010888815,0.0000035990565],"about_ca_topic_score_codex":0.00057906145,"about_ca_topic_score_gemma":0.0011498184,"teacher_disagreement_score":0.00076972006,"about_ca_system_score_codex":0.00020474025,"about_ca_system_score_gemma":0.00011699139,"threshold_uncertainty_score":0.0025750399},"labels":[],"label_agreement":null},{"id":"W2158521269","doi":"10.1158/1535-7163.targ-09-b51","title":"Abstract B51: A phase I dose-escalation study of MGCD265 in patients with advanced malignancies (study 265-102)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Medicine; Cohort; Neutropenia; Toxicity; Internal medicine; Gastroenterology; Surgery","score_opus":0.011750247194241975,"score_gpt":0.2832393718980667,"score_spread":0.2714891247038247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158521269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533075,0.0007910411,0.00035692748,0.0002531964,0.000045755238,0.0012399469,0.0007586887,0.00007682543,0.0011468077],"genre_scores_gemma":[0.9925355,0.0008376673,0.0011805374,0.00052314985,0.000100690086,0.00089151243,0.0020420873,0.000021088466,0.0018677379],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997267,0.00012257599,0.000015984355,0.00004752853,0.000032226922,0.000055061442],"domain_scores_gemma":[0.9995309,0.00005909465,0.00008287902,0.00003861775,0.000033153836,0.0002553467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226473,0.0013288701,0.001096938,0.00035638476,0.00036186574,0.0007231302,0.0005631509,0.00077665295,0.0033247056],"category_scores_gemma":[0.00046673903,0.0004703933,0.00075233664,0.00034907617,0.0005952785,0.00036784072,0.00026848746,0.0025754464,0.0008893268],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53600043,0.106674396,0.020031374,0.0012986248,0.0013638152,0.00072496047,0.00064307987,0.005122918,0.20466802,0.00061162945,0.010670955,0.1121899],"study_design_scores_gemma":[0.46212342,0.49864185,0.02367097,0.000051440067,0.00036194455,0.00044677078,0.00006388073,0.0013340401,0.008689859,0.00014345312,0.0044354177,0.000037049478],"about_ca_topic_score_codex":0.0012083654,"about_ca_topic_score_gemma":0.002235884,"teacher_disagreement_score":0.0033247056,"about_ca_system_score_codex":0.00068218453,"about_ca_system_score_gemma":0.001456366,"threshold_uncertainty_score":0.011122286},"labels":[],"label_agreement":null},{"id":"W2158594431","doi":"10.1158/1535-7163.mct-08-0959","title":"Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"RAD51; Imatinib; Cancer research; Clonogenic assay; Gemcitabine; Imatinib mesylate; Mitomycin C; Chemistry; DNA repair; Biology; Molecular biology; Cell; Cancer; Medicine; Internal medicine; DNA; Biochemistry","score_opus":0.026343124940142452,"score_gpt":0.3143477273620954,"score_spread":0.2880046024219529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158594431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949051,0.0009714479,0.002268875,0.000073066025,0.000015388761,0.00004277303,0.00029943557,0.000083232364,0.0013406678],"genre_scores_gemma":[0.9963721,0.00048190658,0.0015935937,0.000020029904,0.0000037233594,0.000030314279,0.00028697823,0.000014438973,0.0011969658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998117,0.000030312909,0.00002311966,0.000039891915,0.000053227457,0.000041766198],"domain_scores_gemma":[0.99993896,0.000012607801,0.000024713356,0.000008080205,0.000004276632,0.000011385138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013891324,0.00022776211,0.0002896755,0.00013824261,0.00007311931,0.00020528896,0.00014206955,0.00022833417,0.0013484053],"category_scores_gemma":[0.00008874568,0.000107402506,0.00014949276,0.00015664787,0.00017456614,0.00017264513,0.00015405327,0.00044958535,0.00025663865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005668068,0.000021670077,0.000051993382,0.000015301062,0.0000024334283,0.000019636276,0.000005436923,0.000098608434,0.998904,0.00006453037,0.000022644213,0.0007371396],"study_design_scores_gemma":[0.000009655483,0.00022536988,0.0011189411,0.0000016235011,0.0000070535134,0.00014673843,0.0000049560313,0.0006312643,0.997059,0.000015678226,0.00077791774,0.0000018472663],"about_ca_topic_score_codex":0.00027636703,"about_ca_topic_score_gemma":0.00038786215,"teacher_disagreement_score":0.0013484053,"about_ca_system_score_codex":0.00019167001,"about_ca_system_score_gemma":0.00011500419,"threshold_uncertainty_score":0.0045108795},"labels":[],"label_agreement":null},{"id":"W2159087758","doi":"10.1158/1535-7163.mct-06-0109","title":"Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); inVentiv Health Clinical","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"CD8; Adoptive cell transfer; Cytotoxic T cell; Immune system; Tumor microenvironment; Cancer research; Biology; Transforming growth factor beta; Immunology; T cell; Transforming growth factor; In vitro; Cell biology","score_opus":0.010743989676033659,"score_gpt":0.24567069555011886,"score_spread":0.2349267058740852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159087758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403507,0.0016279005,0.0019492646,0.000065519744,0.00004217088,0.000054681797,0.00007857143,0.00011716,0.0020296401],"genre_scores_gemma":[0.9957833,0.00070554717,0.0014477917,0.00007083092,0.000025619622,0.000074039715,0.00015834697,0.000012906506,0.001721552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999207,0.000015530428,0.0000061220435,0.000014119351,0.000015085215,0.000028421655],"domain_scores_gemma":[0.99995434,0.0000094445195,0.000012226406,0.0000056965428,0.0000039542765,0.000014291936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009727668,0.00025257774,0.00017808443,0.000102366015,0.00007226695,0.00017627439,0.00012161539,0.00017375393,0.001266404],"category_scores_gemma":[0.00007043781,0.00008518908,0.00014175588,0.000051927003,0.00012406685,0.000099319,0.000101915546,0.00058382633,0.00038138116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000288506,0.00012417165,0.00022559954,0.0000375634,0.000003017249,0.00004821056,0.00000955391,0.00010419322,0.9949654,0.00011560999,0.0000630379,0.0040152147],"study_design_scores_gemma":[0.00015728053,0.0016480021,0.0028671583,0.000012890121,0.000018943638,0.00043013893,0.000013971812,0.0015894817,0.9894051,0.00011554139,0.0037388944,0.0000026950297],"about_ca_topic_score_codex":0.00008378293,"about_ca_topic_score_gemma":0.00016404853,"teacher_disagreement_score":0.001266404,"about_ca_system_score_codex":0.000122328,"about_ca_system_score_gemma":0.00011735339,"threshold_uncertainty_score":0.0042365193},"labels":[],"label_agreement":null},{"id":"W2159560706","doi":"10.1158/1535-7163.mct-06-0443","title":"Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy","year":2007,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"XIAP; Apoptosis; Inhibitor of apoptosis; Melanoma; Cancer research; Caspase; Chemotherapy; Immune system; Malignancy; Small molecule; Pharmacology; Chemistry; Medicine; Immunology; Programmed cell death; Biochemistry; Internal medicine","score_opus":0.03438674536190695,"score_gpt":0.32339435661293103,"score_spread":0.2890076112510241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159560706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005380875,0.99365956,0.00068908045,0.0004463055,0.00036039116,0.000015348198,0.000019525416,0.000026730873,0.004245008],"genre_scores_gemma":[0.0019623297,0.99319893,0.0009835969,0.00033519627,0.00017442022,0.000018442355,0.00004783596,0.0000038953262,0.0032752624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999114,0.000015006744,0.000009396033,0.000013300667,0.000041218616,0.00000956057],"domain_scores_gemma":[0.9999368,0.00001943404,0.000010056377,0.0000026055106,0.000019948367,0.000011237964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026609196,0.0006826483,0.0008715289,0.0016087291,0.00022966781,0.00060068176,0.00051503046,0.00084741355,0.0026788244],"category_scores_gemma":[0.00018163619,0.00017974208,0.00024303906,0.0013645302,0.0003063269,0.0007933064,0.0003551267,0.001336126,0.0027640632],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008150991,0.00014599205,0.00016489449,0.0058223708,0.00005276601,0.0007749229,0.000058962214,0.0004977099,0.014724461,0.0059724622,0.032394495,0.93930954],"study_design_scores_gemma":[0.000029515413,0.00012864145,0.00049560994,0.0006931537,0.000040194205,0.0033040221,0.000033683813,0.0001247177,0.0021272684,0.0013782621,0.99163085,0.000014053507],"about_ca_topic_score_codex":0.00050594343,"about_ca_topic_score_gemma":0.0011583396,"teacher_disagreement_score":0.0026788244,"about_ca_system_score_codex":0.00055065384,"about_ca_system_score_gemma":0.0006154117,"threshold_uncertainty_score":0.008961499},"labels":[],"label_agreement":null},{"id":"W2160694221","doi":"10.1158/1535-7163.mct-09-0673","title":"Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Cancer Institute; McGill University Health Centre","keywords":"Biology; Epidermal growth factor receptor; Molecular biology; DNA damage; Kinase; Tyrosine kinase; Transfection; DNA repair; Phosphorylation; DNA; Cell biology; Biochemistry; Signal transduction; Receptor; Gene","score_opus":0.01278670995869844,"score_gpt":0.23818011937805522,"score_spread":0.2253934094193568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160694221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216765,0.0013883839,0.00503082,0.00005569473,0.000013355778,0.000022948896,0.000112738344,0.000060848175,0.0011475686],"genre_scores_gemma":[0.993654,0.00045401487,0.0042238827,0.00003087092,0.0000044064386,0.000030462705,0.00012621794,0.000012569727,0.0014635534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999192,0.000012164127,0.0000035856622,0.000024416311,0.000024306004,0.000016317845],"domain_scores_gemma":[0.99993014,0.000014536141,0.000019032197,0.000006147528,0.000012528655,0.000017625522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091434515,0.00023751115,0.00017216855,0.00014119524,0.00010215422,0.0002603244,0.00021502076,0.00039586468,0.0007879208],"category_scores_gemma":[0.00007003434,0.00009044239,0.00014284179,0.00010160222,0.00018208635,0.00015802115,0.000094068804,0.0002932979,0.00028023927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030778105,0.000009760895,0.00006326722,0.000013191222,0.0000034126183,0.000020646756,0.000005052646,0.00004642628,0.99921846,0.000047557354,0.000010081231,0.0005314286],"study_design_scores_gemma":[0.000003855879,0.000121676276,0.0004883042,7.9290203e-7,0.0000059227227,0.00006290061,0.0000051496877,0.0004301745,0.99840707,0.0000076196197,0.0004651497,0.0000014233308],"about_ca_topic_score_codex":0.000432469,"about_ca_topic_score_gemma":0.00053202995,"teacher_disagreement_score":0.0007879208,"about_ca_system_score_codex":0.00038841733,"about_ca_system_score_gemma":0.000112778995,"threshold_uncertainty_score":0.0028181672},"labels":[],"label_agreement":null},{"id":"W2160846997","doi":"10.1158/1535-7163.mct-12-0227","title":"First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Ligue Contre le Cancer; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Ceramide; Sphingosine kinase 1; Prostate cancer; Sphingosine; Cancer; Cancer cell; Cancer research; Sphingosine kinase; Sphingosine-1-phosphate; Gene silencing; Apoptosis; Biology; Medicine; Internal medicine; Biochemistry","score_opus":0.028473161347986223,"score_gpt":0.3228567867164746,"score_spread":0.2943836253684884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160846997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526398,0.030555055,0.010155865,0.0006988733,0.00009300998,0.000097624135,0.0011198792,0.00041060476,0.0042293374],"genre_scores_gemma":[0.98753136,0.006653054,0.002355068,0.00017442326,0.000048167178,0.00003836569,0.0010156351,0.000023606275,0.0021601652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998987,0.000014670688,0.00000825445,0.000024776758,0.000033791806,0.000019919851],"domain_scores_gemma":[0.999806,0.000046751215,0.00004615775,0.000027345213,0.000039032166,0.000034822497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013550722,0.00023521474,0.00024307083,0.0003158058,0.0001132157,0.0003022066,0.00011759861,0.00027179287,0.0012578275],"category_scores_gemma":[0.00018731922,0.00009542974,0.0002343815,0.00023012637,0.00023575181,0.00014030983,0.0002077228,0.00049040513,0.00033270227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034942644,0.000052539956,0.005426476,0.00019105128,0.00002648729,0.0003510273,0.000039216076,0.00006341095,0.98090017,0.00011339532,0.0003073847,0.01217946],"study_design_scores_gemma":[0.000020131916,0.0012751423,0.08644603,0.000018042227,0.00010608051,0.004792302,0.000083958774,0.0007304534,0.8868619,0.00015315707,0.019498896,0.000013921397],"about_ca_topic_score_codex":0.00041749526,"about_ca_topic_score_gemma":0.0005126352,"teacher_disagreement_score":0.0012578275,"about_ca_system_score_codex":0.00017630887,"about_ca_system_score_gemma":0.00023813017,"threshold_uncertainty_score":0.004207909},"labels":[],"label_agreement":null},{"id":"W2161336797","doi":"10.1158/1535-7163.mct-11-0421","title":"Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Ontario Institute for Cancer Research","keywords":"Digitoxin; Kinase; Pharmacology; Cancer cell; Biology; Signal transduction; Kinome; Cancer; Cancer research; Chemistry; Biochemistry; Heart failure; Internal medicine; Medicine; Digoxin","score_opus":0.03812928380603275,"score_gpt":0.27108474907897845,"score_spread":0.2329554652729457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161336797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99116373,0.0025187791,0.0039230455,0.00010799378,0.000017661945,0.000034710127,0.00045339842,0.00007506337,0.0017057067],"genre_scores_gemma":[0.9948702,0.0016062598,0.0019299517,0.000071213886,0.000004978113,0.000032359992,0.00047265788,0.0000047214517,0.001007673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998976,0.000012204488,0.000008821906,0.000024134622,0.0000382682,0.000019012405],"domain_scores_gemma":[0.9999473,0.000009952714,0.000022047436,0.0000052643404,0.000008654815,0.000006717794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009301324,0.0002611022,0.00021926407,0.00019358308,0.0001628092,0.00025521804,0.000086930886,0.00017684443,0.0007218328],"category_scores_gemma":[0.00007906578,0.000071131304,0.00022635775,0.00022976704,0.00011575354,0.00016983095,0.00016912622,0.00025736418,0.0002079957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011066038,0.000011999745,0.00072328845,0.000046529083,0.000005993253,0.000053283977,0.000011894173,0.0001244346,0.996594,0.00006897267,0.000021884536,0.0022271692],"study_design_scores_gemma":[0.000017180597,0.000250711,0.024825396,0.0000068418085,0.000024528857,0.00031514053,0.000052638654,0.0027022937,0.9703371,0.00012660118,0.001335471,0.0000060113075],"about_ca_topic_score_codex":0.00024834255,"about_ca_topic_score_gemma":0.00047867742,"teacher_disagreement_score":0.0007218328,"about_ca_system_score_codex":0.00027163333,"about_ca_system_score_gemma":0.00014640448,"threshold_uncertainty_score":0.0024148226},"labels":[],"label_agreement":null},{"id":"W2161709887","doi":"10.1158/1535-7163.mct-11-0077","title":"Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen's University; Sunnybrook Health Science Centre; Lawson Health Research Institute","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Biology; Carcinogenesis; Gene knockdown; Oncogene; Cancer research; Downregulation and upregulation; Cell cycle; Small hairpin RNA; Gene; Transgene; Molecular biology; Cell biology; Genetics","score_opus":0.045084547340752734,"score_gpt":0.26068970851791384,"score_spread":0.2156051611771611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161709887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882587,0.0017573377,0.013345446,0.0003200826,0.000064190135,0.00015418339,0.0024545004,0.0003876185,0.0026907725],"genre_scores_gemma":[0.9766519,0.0016003567,0.009845051,0.00021751174,0.000024455045,0.00019919038,0.0035174557,0.00012044224,0.007823567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998356,0.000018003226,0.000017863344,0.000045093628,0.00004212715,0.00004127477],"domain_scores_gemma":[0.99983656,0.00001747897,0.000051122046,0.000022076088,0.000020898351,0.000051854455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001766102,0.00031250645,0.00022861129,0.0005775476,0.00020657801,0.0002790707,0.00028183137,0.00045054767,0.0016559868],"category_scores_gemma":[0.00011101112,0.00017319518,0.00046641505,0.00021786243,0.00024861735,0.00019596428,0.00016916798,0.0007771497,0.0007529222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044296863,0.00001806035,0.00013387609,0.000018039746,0.0000034902837,0.000051632836,0.000006463384,0.000029220557,0.99895775,0.00009515689,0.000034753026,0.0006073163],"study_design_scores_gemma":[0.000011251118,0.00024922483,0.003134035,0.000006401151,0.000022450375,0.0005334977,0.000019153877,0.0007439933,0.99191463,0.00004622118,0.0033155119,0.0000036231163],"about_ca_topic_score_codex":0.00058324594,"about_ca_topic_score_gemma":0.0006031104,"teacher_disagreement_score":0.0016559868,"about_ca_system_score_codex":0.0003915508,"about_ca_system_score_gemma":0.0001565241,"threshold_uncertainty_score":0.0055398345},"labels":[],"label_agreement":null},{"id":"W2162160107","doi":"10.1158/1535-7163.mct-10-0471","title":"RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Downregulation and upregulation; Apoptosis; Mdm2; Cancer research; Cytotoxic T cell; Multiple myeloma; Caspase; Biology; Cell culture; Caspase 8; Programmed cell death; Gene; Immunology; In vitro; Genetics","score_opus":0.023995870911143767,"score_gpt":0.27871922280274636,"score_spread":0.2547233518916026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162160107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347574,0.002737056,0.001606071,0.00007682162,0.000028643435,0.000058015987,0.000292182,0.00019952614,0.0015260249],"genre_scores_gemma":[0.9940798,0.0018197268,0.0020296248,0.000037162943,0.000013879031,0.0000611537,0.0005163159,0.000014925186,0.0014275287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980456,0.000045940782,0.00002631393,0.000024817416,0.00005844323,0.000039921695],"domain_scores_gemma":[0.99993527,0.00001192521,0.000017399812,0.000010685133,0.00000766004,0.00001704772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015477075,0.00048650044,0.0005524992,0.00044497996,0.00010914152,0.00021600543,0.0002710233,0.00017642153,0.00090019364],"category_scores_gemma":[0.00011884507,0.0001439625,0.00035081917,0.00023220434,0.0001691562,0.00014514555,0.00022361391,0.0005785225,0.00028744817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002529788,0.000105353814,0.00027010165,0.00005700484,0.000020083018,0.000039873827,0.000014033784,0.00009078499,0.9952058,0.000050131643,0.00007060026,0.0038232482],"study_design_scores_gemma":[0.00005772622,0.0016540451,0.0065404805,0.0000061386604,0.000049732324,0.00025026058,0.000012181458,0.0010975453,0.988165,0.000025064739,0.002137617,0.000004242295],"about_ca_topic_score_codex":0.00032482768,"about_ca_topic_score_gemma":0.0010502753,"teacher_disagreement_score":0.00090019364,"about_ca_system_score_codex":0.00026118584,"about_ca_system_score_gemma":0.00018067597,"threshold_uncertainty_score":0.0030114055},"labels":[],"label_agreement":null},{"id":"W2162351740","doi":"10.1158/1535-7163.mct-04-0310","title":"Strongylophorine-26, a Rho-dependent inhibitor of tumor cell invasion that reduces actin stress fibers and induces nonpolarized lamellipodial extensions","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Silk-based biomaterials and applications","field":"Materials Science","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lamellipodium; Membrane ruffling; Motility; Stress fiber; Cell biology; Actin; Focal adhesion; Cell migration; Cell; Chemistry; Myofibroblast; Cytoskeleton; Biology; Fibrosis; Medicine; Signal transduction; Biochemistry; Pathology","score_opus":0.026564290346850882,"score_gpt":0.2714589183366407,"score_spread":0.24489462798978984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162351740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97965413,0.0057914355,0.0071463753,0.00016151641,0.000036159396,0.00009889065,0.00037466135,0.00010918214,0.0066275736],"genre_scores_gemma":[0.9846987,0.0041977796,0.0033646575,0.00005299218,0.000009757035,0.000050269457,0.0005030744,0.000015061432,0.0071076984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996376,0.000006277034,0.0000025026532,0.000006586323,0.00001147114,0.000009466196],"domain_scores_gemma":[0.99997234,0.000004675558,0.000008088392,0.000002625248,0.000003238677,0.000009006326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080162274,0.0003559279,0.00011508746,0.00015292998,0.000072668525,0.00012393466,0.00010147992,0.00014518763,0.0008674907],"category_scores_gemma":[0.00004009423,0.00006699379,0.00013423173,0.00007616862,0.00012298896,0.00010616664,0.00010521535,0.0002647965,0.00020476562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005055919,0.000021155001,0.000045183166,0.000036104157,0.0000032811427,0.000031550124,0.0000026691712,0.000072467745,0.9977525,0.00009817581,0.000034567558,0.0018517502],"study_design_scores_gemma":[0.000015878371,0.00022206282,0.0011683512,0.0000023172634,0.000004957276,0.00013200537,0.0000042875677,0.00029199186,0.99508435,0.000024280163,0.0030475736,0.0000017825253],"about_ca_topic_score_codex":0.00015475761,"about_ca_topic_score_gemma":0.00057074556,"teacher_disagreement_score":0.0008674907,"about_ca_system_score_codex":0.00016725628,"about_ca_system_score_gemma":0.00014430816,"threshold_uncertainty_score":0.002902031},"labels":[],"label_agreement":null},{"id":"W2162579298","doi":"10.1158/1535-7163.mct-13-1086","title":"Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Veterinary medicine and infectious diseases","field":"Veterinary","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Ottawa Hospital Research Institute","keywords":"Erlotinib; EGFR inhibitors; Epidermal growth factor receptor; Pharmacology; Monensin; Cancer research; Cytotoxicity; Chemistry; Medicine; Internal medicine; Receptor; In vitro; Biochemistry","score_opus":0.03595096515547805,"score_gpt":0.29235425184590286,"score_spread":0.2564032866904248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162579298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896271,0.0065554855,0.00091125333,0.00018333785,0.00005722236,0.00008806668,0.00049909356,0.0000952901,0.0019831008],"genre_scores_gemma":[0.99361163,0.0022976645,0.0014327824,0.00011410142,0.00001460969,0.00003535749,0.00059669156,0.000011403,0.0018857787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984705,0.000026665417,0.000012581444,0.000023505254,0.00004470577,0.0000454145],"domain_scores_gemma":[0.9999299,0.000013019502,0.000011992172,0.0000075284224,0.000013264242,0.00002424073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018273389,0.0002505864,0.0004631794,0.00029878598,0.00017284807,0.00034105792,0.00017902012,0.00021536916,0.000828046],"category_scores_gemma":[0.00012564864,0.00010808172,0.00032098853,0.00020662392,0.00013576045,0.00014681184,0.00026580595,0.0004038939,0.000273069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091905845,0.000175294,0.0012185302,0.00019189533,0.000045443543,0.00016635626,0.000029475545,0.0003540055,0.98237497,0.000050259558,0.0003986206,0.014076044],"study_design_scores_gemma":[0.00015054314,0.0031218282,0.019957423,0.000025246447,0.00016072989,0.0010962825,0.00008940064,0.0013696918,0.96285176,0.000045100496,0.011108352,0.000023611945],"about_ca_topic_score_codex":0.001077091,"about_ca_topic_score_gemma":0.0076705334,"teacher_disagreement_score":0.001077091,"about_ca_system_score_codex":0.0003831749,"about_ca_system_score_gemma":0.0002946856,"threshold_uncertainty_score":0.0027800798},"labels":[],"label_agreement":null},{"id":"W2164897814","doi":"10.1158/1535-7163.mct-09-0042","title":"Niacin status and treatment-related leukemogenesis","year":2009,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Bone marrow; Apoptosis; Cancer research; Biology; DNA damage; Haematopoiesis; Poly ADP ribose polymerase; Leukemia; Chromosomal translocation; Cancer; Chemotherapy; Immunology; Stem cell; Endocrinology; Genetics; DNA","score_opus":0.07197418825721326,"score_gpt":0.3812024341047375,"score_spread":0.30922824584752423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164897814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019878366,0.99877065,0.00004349657,0.0001349868,0.000054134984,0.000002640784,0.000008104345,0.0000037288573,0.00078344654],"genre_scores_gemma":[0.0014049453,0.9974976,0.00009220145,0.00012117745,0.000057947167,0.0000055933697,0.000025797854,9.350526e-7,0.0007937737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998877,0.000022369819,0.00001791503,0.000019762356,0.000041482755,0.000010781651],"domain_scores_gemma":[0.99985075,0.00006417548,0.00003159875,0.000004676595,0.000034911413,0.00001391359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033209287,0.00064707256,0.0012200861,0.0013772564,0.00024400912,0.00067431194,0.00074088323,0.000987131,0.0037676645],"category_scores_gemma":[0.0004005687,0.00021294075,0.00032107116,0.0016927272,0.00035415162,0.0006936124,0.0004454071,0.0010567241,0.0016911317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015508923,0.00011425011,0.0003686161,0.007659791,0.00009313145,0.00031350824,0.000043638593,0.000249044,0.0019497791,0.0017943941,0.01529009,0.9719688],"study_design_scores_gemma":[0.000059817572,0.00024311127,0.002943454,0.0029653006,0.00017214347,0.00328038,0.000082331804,0.00014342963,0.0012807613,0.002466186,0.9863419,0.000021352851],"about_ca_topic_score_codex":0.0012032802,"about_ca_topic_score_gemma":0.0031702996,"teacher_disagreement_score":0.0037676645,"about_ca_system_score_codex":0.0005831073,"about_ca_system_score_gemma":0.0006013935,"threshold_uncertainty_score":0.012604117},"labels":[],"label_agreement":null},{"id":"W2165551720","doi":"10.1158/1535-7163.mct-14-0166","title":"Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Nanocapsules; Cancer research; RNA interference; Basal cell; Cancer; Cell; Mechanism (biology); Chemistry; Biology; Medicine; Nanotechnology; Biochemistry; Internal medicine; Gene; Materials science; Nanoparticle; Genetics; RNA","score_opus":0.014140979963202276,"score_gpt":0.24905761870376056,"score_spread":0.2349166387405583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165551720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414235,0.0011185374,0.0032524283,0.000066468565,0.000021964186,0.000059870654,0.00008434472,0.000056704073,0.0011973622],"genre_scores_gemma":[0.9956448,0.00054477825,0.0020659966,0.00004638128,0.0000043188033,0.00007109772,0.0000845269,0.0000090245385,0.0015290839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992716,0.000010317363,0.0000058499772,0.000016793723,0.000021879325,0.000017983115],"domain_scores_gemma":[0.999964,0.000009395901,0.000008870496,0.0000036961542,0.0000061502283,0.000007834279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016242047,0.0002417172,0.00017702495,0.00012891747,0.00009550631,0.00013647406,0.00016730717,0.00025022827,0.0004843509],"category_scores_gemma":[0.000078257755,0.00011670303,0.00021334842,0.00005124685,0.00018991179,0.00013903169,0.00010432221,0.00020065643,0.00015109639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072193914,0.000023704784,0.00006763248,0.000039062572,0.0000052542105,0.00002364299,0.000010751381,0.00018340965,0.99800795,0.00008054512,0.00003807085,0.0014477619],"study_design_scores_gemma":[0.000013512458,0.00038278964,0.000797004,0.0000026264886,0.000010699718,0.000057176156,0.0000065733234,0.001074963,0.9969856,0.000013805523,0.0006520071,0.00000324889],"about_ca_topic_score_codex":0.001209524,"about_ca_topic_score_gemma":0.0019424278,"teacher_disagreement_score":0.001209524,"about_ca_system_score_codex":0.00039678844,"about_ca_system_score_gemma":0.00026811374,"threshold_uncertainty_score":0.0028789043},"labels":[],"label_agreement":null},{"id":"W2165570750","doi":"10.1158/1535-7163.mct-07-0455","title":"Calcitrol (1α,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Université Laval","keywords":"LNCaP; Calcitriol; Prostate cancer; Dihydrotestosterone; Androgen receptor; Calcitriol receptor; Endocrinology; Internal medicine; Androgen; Cancer research; Chemistry; Cancer; Biology; Vitamin D and neurology; Medicine; Hormone","score_opus":0.027047234613975252,"score_gpt":0.2925756800418609,"score_spread":0.2655284454278857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165570750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639356,0.020889368,0.006565318,0.0003577913,0.00015532038,0.00015602706,0.0014690245,0.00056065974,0.0059109055],"genre_scores_gemma":[0.97223693,0.010439415,0.005023369,0.00023825766,0.000035669003,0.00012169858,0.002684273,0.00005669687,0.0091635855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984956,0.000023226108,0.000011677785,0.000028031132,0.000060402028,0.000027069676],"domain_scores_gemma":[0.99994755,0.00001143515,0.000008892074,0.000009186308,0.0000087364015,0.000014217153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001049371,0.00033598967,0.0004026345,0.0003178298,0.00021909416,0.0002645184,0.00022942401,0.00017988267,0.0011615293],"category_scores_gemma":[0.00007070039,0.0001341561,0.00040432846,0.00038546984,0.00017986963,0.000068961184,0.00013433826,0.00041853607,0.00052178296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011664125,0.000058639656,0.0001418477,0.00006523286,0.000009111859,0.00003941644,0.000019824765,0.00006474658,0.9972281,0.000062928215,0.000088008914,0.0021055057],"study_design_scores_gemma":[0.00005747914,0.0005932398,0.0051908246,0.0000055010655,0.000025896195,0.000211267,0.000028312563,0.00073478813,0.98371214,0.00002930673,0.009404216,0.0000069933963],"about_ca_topic_score_codex":0.0044457177,"about_ca_topic_score_gemma":0.0063931956,"teacher_disagreement_score":0.0044457177,"about_ca_system_score_codex":0.00039861928,"about_ca_system_score_gemma":0.0005563479,"threshold_uncertainty_score":0.008839726},"labels":[],"label_agreement":null},{"id":"W2165769610","doi":"10.1158/1535-7163.1239.3.10","title":"The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Sulforaphane; Apoptosis; Isothiocyanate; Oxidative stress; Cell cycle; Glutathione; Cyclin B1; Pancreatic cancer; Molecular biology; Growth inhibition; Biology; Cyclin-dependent kinase 1; Chemistry; Cancer research; Biochemistry; Cancer","score_opus":0.009102891551533127,"score_gpt":0.23282500371783427,"score_spread":0.22372211216630114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165769610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943182,0.0030617807,0.0009360586,0.000072269555,0.0000137313855,0.000047354606,0.0003030673,0.000062707855,0.0011848195],"genre_scores_gemma":[0.99436957,0.00201406,0.0013595637,0.00003192552,0.000008771124,0.000062922874,0.0005224652,0.000009560308,0.0016210759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999038,0.000019852136,0.000008645867,0.000017011096,0.000026413269,0.00002417421],"domain_scores_gemma":[0.9999355,0.000008817445,0.000024411587,0.0000109360235,0.0000069310377,0.000013434642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108035245,0.00043306992,0.00030339425,0.00027701334,0.00012502859,0.00020474044,0.00016716667,0.0002515657,0.0008489908],"category_scores_gemma":[0.00010045704,0.00014441511,0.00019219783,0.00023970127,0.00017786602,0.00016612763,0.00014432248,0.00038845773,0.00015063878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034783833,0.00004305848,0.00035960996,0.000040771032,0.000008690875,0.00003643698,0.0000070105325,0.0000720131,0.9966017,0.0000401291,0.000030224117,0.0024125406],"study_design_scores_gemma":[0.00003984737,0.0013366833,0.0053194473,0.000005962073,0.000029888535,0.00026123584,0.000016322385,0.0003503253,0.9908289,0.00002147715,0.0017875487,0.000002361303],"about_ca_topic_score_codex":0.0006739724,"about_ca_topic_score_gemma":0.0020727147,"teacher_disagreement_score":0.0008489908,"about_ca_system_score_codex":0.0002765141,"about_ca_system_score_gemma":0.0002745528,"threshold_uncertainty_score":0.0028401017},"labels":[],"label_agreement":null},{"id":"W2166435610","doi":"10.1158/1535-7163.mct-13-0032","title":"Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bicalutamide; LNCaP; Prostate cancer; Androgen receptor; Protein kinase B; Antiandrogen; Cancer research; In vivo; PI3K/AKT/mTOR pathway; Medicine; Growth inhibition; Androgen; Internal medicine; Pharmacology; Endocrinology; Cell growth; Cancer; Apoptosis; Chemistry; Biology; Biochemistry","score_opus":0.02192626339959827,"score_gpt":0.3056647247005957,"score_spread":0.28373846130099745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166435610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889081,0.0045954078,0.002746347,0.0002018902,0.00010145803,0.000068340894,0.00036621766,0.0003097686,0.0027024762],"genre_scores_gemma":[0.994682,0.0014172837,0.001836169,0.000054304106,0.000018616229,0.000045661272,0.0003853271,0.000015115904,0.0015454738],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987817,0.0000133914555,0.000010301855,0.000020761592,0.00003430047,0.000043142976],"domain_scores_gemma":[0.9999591,0.000004174685,0.000013572198,0.0000043306477,0.0000034471366,0.000015340336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009480834,0.0004186356,0.00041721156,0.00021864341,0.00013340385,0.0003294428,0.00021931632,0.00017256514,0.0009673587],"category_scores_gemma":[0.00006219042,0.0001426632,0.00030924834,0.00016897453,0.00017796594,0.00017933533,0.00013725291,0.00078815396,0.0002561505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091004244,0.00034335422,0.0003807543,0.00010339557,0.000035535213,0.00005629862,0.000012582471,0.00036861203,0.9888278,0.00022979795,0.00032461018,0.008407223],"study_design_scores_gemma":[0.00011964436,0.0032201186,0.0044385795,0.000007732571,0.00006213186,0.00030895186,0.000015933392,0.0018246901,0.986139,0.00007049418,0.0037838633,0.000008744987],"about_ca_topic_score_codex":0.00075713417,"about_ca_topic_score_gemma":0.0024752603,"teacher_disagreement_score":0.0009673587,"about_ca_system_score_codex":0.00037242495,"about_ca_system_score_gemma":0.00045754836,"threshold_uncertainty_score":0.003236115},"labels":[],"label_agreement":null},{"id":"W2167968468","doi":"10.1158/1535-7163.mct-13-0267","title":"Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Basis Foundation","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; Androgen; LNCaP; Antiandrogen; Androgen Receptor Antagonists; Cancer research; Endocrinology; Medicine; Internal medicine; Pharmacology; Cancer; Hormone","score_opus":0.014741834600917476,"score_gpt":0.29646458112044477,"score_spread":0.2817227465195273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167968468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97116345,0.010450308,0.009573624,0.0002835175,0.000078466044,0.0008275215,0.0019420654,0.00021749426,0.0054635545],"genre_scores_gemma":[0.976581,0.005653755,0.011162166,0.00027587725,0.000037677913,0.00021362242,0.0030086085,0.000029496443,0.0030377235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998944,0.000013160225,0.000006673279,0.000018532732,0.000046020425,0.000021182896],"domain_scores_gemma":[0.9999286,0.0000075546354,0.000011924915,0.0000056989606,0.000015190764,0.000031147825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000168913,0.00041524053,0.00058419956,0.000335855,0.00013429344,0.00028931198,0.00027233007,0.00025405196,0.0012897704],"category_scores_gemma":[0.00012790265,0.0001260991,0.0003148171,0.00033873442,0.0001430536,0.00016550074,0.00012904058,0.00047345113,0.0003912508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020479789,0.00032536875,0.00038104685,0.00018598043,0.000021617223,0.00014937736,0.000020743946,0.0011846572,0.9809169,0.00017581644,0.0002872081,0.016146494],"study_design_scores_gemma":[0.0006398158,0.016145151,0.009094258,0.00004866457,0.00020750257,0.001562224,0.000052289884,0.006062223,0.9356435,0.00018517683,0.03031089,0.000048412752],"about_ca_topic_score_codex":0.00083943154,"about_ca_topic_score_gemma":0.0019651991,"teacher_disagreement_score":0.0012897704,"about_ca_system_score_codex":0.00017942222,"about_ca_system_score_gemma":0.00049441843,"threshold_uncertainty_score":0.0043147802},"labels":[],"label_agreement":null},{"id":"W2168213980","doi":"10.1158/1535-7163.mct-14-0866","title":"Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Erlotinib; A549 cell; Lung cancer; Medicine; Pharmacology; Hsp27; Cancer research; Cancer; Internal medicine; Biology; Epidermal growth factor receptor; Heat shock protein; Hsp70","score_opus":0.01952114444822322,"score_gpt":0.2950278219370564,"score_spread":0.2755066774888332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168213980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940013,0.0017301713,0.0006918966,0.00011024647,0.0000540259,0.00007902423,0.0004354809,0.00013364272,0.002764255],"genre_scores_gemma":[0.9933728,0.0015809953,0.000733897,0.000074838885,0.00000998222,0.00008031989,0.0010723299,0.00002013491,0.0030547632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999907,0.0000139526155,0.0000097815855,0.0000150189335,0.00002320694,0.00003096893],"domain_scores_gemma":[0.9999627,0.0000046821933,0.0000070817096,0.000006702539,0.000005749175,0.00001312883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086051834,0.00038167395,0.0004346241,0.00020899007,0.00015973666,0.00022630379,0.00015622006,0.00022672601,0.0016676029],"category_scores_gemma":[0.000053552885,0.00017832349,0.00034505545,0.00021942887,0.0001740149,0.00014431738,0.00021280983,0.0005569434,0.00040289253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041736345,0.00021614826,0.00021688045,0.00009982081,0.000026456266,0.000080375365,0.000032128642,0.000350459,0.99409866,0.000087875,0.00037066877,0.004003194],"study_design_scores_gemma":[0.000110103385,0.0021435742,0.0077189794,0.000011928294,0.000034984856,0.00024209502,0.000063293475,0.0014549311,0.9832487,0.000040448875,0.004918116,0.000012905732],"about_ca_topic_score_codex":0.0012393963,"about_ca_topic_score_gemma":0.0026608594,"teacher_disagreement_score":0.0016676029,"about_ca_system_score_codex":0.00021637276,"about_ca_system_score_gemma":0.00026966908,"threshold_uncertainty_score":0.005578637},"labels":[],"label_agreement":null},{"id":"W2168586185","doi":"10.1158/1535-7163.mct-08-0374","title":"HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Max Kade Foundation","keywords":"Cancer research; Protein kinase B; Tyrosine kinase; MAPK/ERK pathway; Receptor tyrosine kinase; PI3K/AKT/mTOR pathway; Biology; Kinase; Signal transduction; Chemistry; Cell biology","score_opus":0.035953202806409824,"score_gpt":0.2968964523811407,"score_spread":0.26094324957473086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168586185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856097,0.0002888949,0.00025232346,0.00003154818,0.000011266564,0.000024169136,0.00016083181,0.000024850835,0.00064512057],"genre_scores_gemma":[0.99798286,0.00024454555,0.0005228098,0.000022379218,0.000003830233,0.000022580309,0.00036955503,0.0000065861013,0.00082478335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978596,0.00004537995,0.00003384456,0.000031690706,0.000052970157,0.00005025963],"domain_scores_gemma":[0.99991345,0.000020758822,0.000014079045,0.000020199197,0.0000076708975,0.000023904542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013994225,0.00027269122,0.00033413747,0.00020018918,0.000092375056,0.00028165922,0.00018974853,0.00022344469,0.0010695073],"category_scores_gemma":[0.00013444744,0.00021693319,0.00029610642,0.00019767803,0.00012381889,0.00011444626,0.00019957207,0.0004592733,0.00026298498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021841626,0.000109825014,0.0006351125,0.000027421715,0.000012108324,0.00013548523,0.00002228071,0.00022824954,0.9966543,0.00014264802,0.00006647282,0.0017476701],"study_design_scores_gemma":[0.00010211735,0.0020041724,0.013775777,0.000007489152,0.00003993824,0.0011888004,0.000055253076,0.004518713,0.97600114,0.000054856093,0.0022426804,0.000009021725],"about_ca_topic_score_codex":0.00082713756,"about_ca_topic_score_gemma":0.0010682814,"teacher_disagreement_score":0.0010695073,"about_ca_system_score_codex":0.00027290007,"about_ca_system_score_gemma":0.00017080778,"threshold_uncertainty_score":0.003577888},"labels":[],"label_agreement":null},{"id":"W2169031119","doi":"10.1158/1535-7163.mct-05-0358","title":"Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CHEK1; G2-M DNA damage checkpoint; DNA repair; DNA damage; Cell cycle checkpoint; Biology; Cell cycle; Cell biology; Cancer research; Cancer cell; Checkpoint Kinase 2; DNA; Molecular biology; Cancer; Genetics","score_opus":0.004450107327435434,"score_gpt":0.24522990227486224,"score_spread":0.24077979494742682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169031119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580634,0.0018194778,0.00036071264,0.00006168347,0.000059664922,0.000033071046,0.00025949636,0.00007688288,0.0015225433],"genre_scores_gemma":[0.9937401,0.0014660599,0.0009574095,0.000063249616,0.00006396778,0.000057491427,0.0006888042,0.000050082926,0.0029129002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997961,0.000033685385,0.000015597896,0.000044195658,0.000039637365,0.000070776165],"domain_scores_gemma":[0.9997322,0.00006539261,0.00004156334,0.000031583524,0.000013801663,0.00011539472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018104605,0.0007434258,0.00068367214,0.00038649666,0.00020255889,0.0004136257,0.00048761445,0.00035203798,0.0029953995],"category_scores_gemma":[0.0002274726,0.0002089072,0.0003261468,0.00026257106,0.00033233548,0.00025559205,0.00030842068,0.0008291521,0.00063159585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067631905,0.0014589702,0.0005841538,0.00019498469,0.00011120895,0.00017997812,0.00003541013,0.0009561296,0.9788761,0.00023224513,0.00039643963,0.010211134],"study_design_scores_gemma":[0.0005930613,0.009648574,0.004843088,0.000024560173,0.0001229661,0.00042850696,0.0000285849,0.0016789755,0.97827756,0.00009073353,0.0042450526,0.000018431701],"about_ca_topic_score_codex":0.00089668034,"about_ca_topic_score_gemma":0.0022174572,"teacher_disagreement_score":0.0029953995,"about_ca_system_score_codex":0.00032827895,"about_ca_system_score_gemma":0.0005464457,"threshold_uncertainty_score":0.010020614},"labels":[],"label_agreement":null},{"id":"W2169157708","doi":"10.1158/1535-7163.mct-05-0362","title":"Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Apoptosis; Caspase 8; Cycloheximide; Cytotoxic T cell; Cancer cell; Cancer research; Caspase; Cell culture; Biology; Chemistry; Molecular biology; Cell biology; Programmed cell death; Cancer; In vitro; Biochemistry; Genetics","score_opus":0.012569205567210723,"score_gpt":0.2612088494725402,"score_spread":0.24863964390532947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169157708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946778,0.0025122615,0.0015751495,0.000070071525,0.000010959829,0.000027302189,0.00026724485,0.00004169869,0.00081756536],"genre_scores_gemma":[0.9971943,0.00084008643,0.00087177445,0.000025145779,0.000005511702,0.000017366221,0.0004065127,0.0000059941926,0.0006334116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986684,0.00002300498,0.000022194954,0.00002131923,0.000042178555,0.00002447789],"domain_scores_gemma":[0.99986386,0.00002559364,0.000039606573,0.000026219921,0.000025150319,0.000019602357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013959881,0.00015930772,0.00024269796,0.00016981071,0.00010253443,0.00032238918,0.000097704775,0.00017420981,0.0010585014],"category_scores_gemma":[0.00022582723,0.00009273329,0.00021850858,0.00020205429,0.00011833213,0.00017137926,0.0001292683,0.00045955795,0.00030467196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012514697,0.0000262513,0.0010099037,0.000031785497,0.0000073844917,0.00013686852,0.000023432487,0.000042890602,0.9967527,0.00008567063,0.000036669382,0.001721353],"study_design_scores_gemma":[0.00006401429,0.000849377,0.02632397,0.000008358729,0.000026510334,0.003075021,0.000040335635,0.0007323617,0.96500576,0.00011757648,0.0037487156,0.00000799177],"about_ca_topic_score_codex":0.00026299775,"about_ca_topic_score_gemma":0.00030712198,"teacher_disagreement_score":0.0010585014,"about_ca_system_score_codex":0.0002017653,"about_ca_system_score_gemma":0.00017575378,"threshold_uncertainty_score":0.0035409927},"labels":[],"label_agreement":null},{"id":"W2169541841","doi":"10.1158/1535-7163.mct-08-0446","title":"Identification and characterization of small-molecule inhibitors of hepsin","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Serine protease; Chemistry; Small molecule; Cancer research; Cancer; Serine; Metastasis; Prostate cancer; Cancer cell; Tumor progression; Transmembrane protein; Cytotoxicity; Protease; In vitro; Biochemistry; Biology; Enzyme; Gene; Genetics; Receptor","score_opus":0.025046880798219363,"score_gpt":0.2705939419360608,"score_spread":0.24554706113784142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169541841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734528,0.012594818,0.008279972,0.0002491333,0.000062609375,0.00040962512,0.0013293781,0.00015904495,0.0034625728],"genre_scores_gemma":[0.9661497,0.013398546,0.009352756,0.00021135715,0.00005217685,0.00022306186,0.0047056563,0.000035213696,0.00587152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993336,0.000011645598,0.000006146369,0.000011102624,0.000019532525,0.000018178245],"domain_scores_gemma":[0.9998989,0.000025025996,0.000019078925,0.000008178594,0.000020843285,0.000027885175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014974599,0.00046123637,0.00056584086,0.00030455666,0.00013579281,0.00030693406,0.00028026148,0.00019832351,0.0012431879],"category_scores_gemma":[0.0002158681,0.0001575438,0.00021513723,0.00024708136,0.00017715868,0.00017245789,0.00017503032,0.0005208947,0.00042565123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003747367,0.00026054398,0.0006284143,0.00015305611,0.00003618311,0.00024422843,0.00003422731,0.000797454,0.9805079,0.0001681536,0.00029779616,0.016497234],"study_design_scores_gemma":[0.0003527988,0.0035165336,0.0047651166,0.000026405207,0.00012263487,0.0010915401,0.000036249625,0.0017679753,0.9771155,0.00007366985,0.011112398,0.000019096491],"about_ca_topic_score_codex":0.00051174546,"about_ca_topic_score_gemma":0.0014600097,"teacher_disagreement_score":0.0012431879,"about_ca_system_score_codex":0.00026429654,"about_ca_system_score_gemma":0.000245508,"threshold_uncertainty_score":0.0041588545},"labels":[],"label_agreement":null},{"id":"W2170102261","doi":"10.1158/1535-7163.mct-07-2284","title":"Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics","year":2008,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); Université de Montréal","funders":"U.S. Food and Drug Administration","keywords":"Histone; Acetylation; Histone deacetylase; Epigenetics; Chromatin; Cancer epigenetics; HDAC11; Biology; Histone deacetylase 5; Histone-modifying enzymes; Cell biology; Chromatin remodeling; Cancer research; Chemistry; Histone methyltransferase; Biochemistry; DNA; Gene","score_opus":0.07793731805207046,"score_gpt":0.39850757749240584,"score_spread":0.32057025944033535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170102261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009514096,0.9978765,0.00022024085,0.00050690403,0.00039718888,0.000002034047,0.000004356936,0.0000065239215,0.0008911694],"genre_scores_gemma":[0.00066420774,0.9977076,0.00022621764,0.0002715971,0.00028885208,0.0000033424412,0.000010288338,0.0000012563368,0.0008266967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998765,0.000025271043,0.000013372291,0.000025285606,0.000044001292,0.00001563898],"domain_scores_gemma":[0.9997702,0.00009128586,0.000023672093,0.000010894746,0.000066542794,0.000037376885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006318119,0.00089467445,0.0012223952,0.00124753,0.00035320618,0.0008304881,0.0011583962,0.0014114215,0.0025939657],"category_scores_gemma":[0.00047575202,0.00023739842,0.00036068304,0.0018399574,0.0011541344,0.002336595,0.0006467236,0.002027202,0.001979762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119490345,0.00006736933,0.00020525657,0.008073184,0.000063484695,0.00045608132,0.000105516665,0.0007458667,0.0046735653,0.013052116,0.037073504,0.9353646],"study_design_scores_gemma":[0.000021182717,0.00007440236,0.00068056455,0.0009648975,0.00003777175,0.0014804249,0.000070765454,0.000115084076,0.0005928686,0.006624697,0.9893205,0.00001681077],"about_ca_topic_score_codex":0.0010891042,"about_ca_topic_score_gemma":0.0020664895,"teacher_disagreement_score":0.0025939657,"about_ca_system_score_codex":0.001028813,"about_ca_system_score_gemma":0.000807948,"threshold_uncertainty_score":0.008677661},"labels":[],"label_agreement":null},{"id":"W2170220266","doi":"10.1158/1535-7163.mct-07-2117","title":"Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Paclitaxel; Clonogenic assay; In vivo; Ovarian cancer; Chemotherapy; Medicine; Apoptosis; Cancer; Cancer research; Internal medicine; Oncology; Biology","score_opus":0.026150746924365,"score_gpt":0.30451623315443827,"score_spread":0.2783654862300733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170220266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976767,0.0014823461,0.00038740196,0.000026127733,0.000014812204,0.00001544042,0.000044510136,0.000020473284,0.00033215378],"genre_scores_gemma":[0.99779934,0.0008590827,0.0007527392,0.000022195729,0.000016672193,0.000029938197,0.00007924512,0.0000065840986,0.0004341113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999205,0.00001830441,0.000006906111,0.000012337427,0.000017701443,0.000024136809],"domain_scores_gemma":[0.99990475,0.000028715962,0.000025629957,0.0000133149315,0.000006570476,0.000021040507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011708881,0.00017034782,0.00025507063,0.00019077842,0.00008498567,0.00018041447,0.00014084158,0.00016568595,0.0006541836],"category_scores_gemma":[0.00016325925,0.000070107504,0.00016701405,0.00018705844,0.0001135278,0.000177624,0.00010571034,0.0003491617,0.0000770542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005337696,0.0012146396,0.0022565925,0.00020214071,0.00004879049,0.00015339094,0.000064752145,0.00060078665,0.91930497,0.00013934766,0.00021712607,0.070459865],"study_design_scores_gemma":[0.00055266573,0.04787099,0.044133916,0.000033025215,0.00018692456,0.00075172825,0.00009538326,0.003903338,0.89656615,0.00011835078,0.005767753,0.000019786303],"about_ca_topic_score_codex":0.00026652793,"about_ca_topic_score_gemma":0.0006398765,"teacher_disagreement_score":0.0006541836,"about_ca_system_score_codex":0.00016656429,"about_ca_system_score_gemma":0.00015181211,"threshold_uncertainty_score":0.0021885037},"labels":[],"label_agreement":null},{"id":"W2170236489","doi":"10.1158/1535-7163.targ-13-a66","title":"Abstract A66: Ablative radiotherapy increases invasion potential in EGFR-wildtype non-small cell lung cancer cells compared to fractionated radiotherapy.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Clonogenic assay; Lung cancer; Radiation therapy; Cancer research; Epidermal growth factor receptor; Medicine; Cancer; Cell growth; Metastasis; Oncology; A549 cell; Cell culture; Internal medicine; Biology; Pathology","score_opus":0.03235643899308948,"score_gpt":0.27934911123444567,"score_spread":0.24699267224135618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170236489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969144,0.0040753502,0.0016149195,0.00012627033,0.00013324509,0.000063125255,0.0010320316,0.00018091027,0.0030827057],"genre_scores_gemma":[0.98528636,0.0019643616,0.0021581228,0.00009626446,0.000038472073,0.00008040482,0.002781571,0.000030865926,0.007563571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998605,0.000025881218,0.000015335958,0.000031015315,0.000041994266,0.000025236539],"domain_scores_gemma":[0.99990475,0.000027583917,0.000017450364,0.000013505318,0.000011190984,0.000025547155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015545776,0.00042606893,0.00031926384,0.00022642832,0.00013407938,0.00018078797,0.00021427538,0.00028226836,0.005831277],"category_scores_gemma":[0.0000969999,0.0001635174,0.00052536774,0.00024979157,0.00017430019,0.00017974208,0.00012499127,0.0006172833,0.0007188538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052140007,0.00022227973,0.00014767339,0.00014726077,0.000013417679,0.000045025085,0.000022040367,0.00008941268,0.9955995,0.00005331082,0.00021483359,0.0029238553],"study_design_scores_gemma":[0.000112842914,0.005154418,0.009150908,0.000017380042,0.000038228965,0.00042063917,0.00002874133,0.0006516957,0.9816595,0.000038934184,0.0027177618,0.0000089709565],"about_ca_topic_score_codex":0.0006941169,"about_ca_topic_score_gemma":0.00059922854,"teacher_disagreement_score":0.005831277,"about_ca_system_score_codex":0.0001410678,"about_ca_system_score_gemma":0.00020412878,"threshold_uncertainty_score":0.019507527},"labels":[],"label_agreement":null},{"id":"W2171131568","doi":"10.1158/1535-7163.1221.3.10","title":"Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Kinase; CHEK1; G2-M DNA damage checkpoint; Chemistry; Biochemistry; Protein kinase A; DNA damage; Biology; Cell cycle checkpoint; DNA; Cell cycle; Cell","score_opus":0.011659954915534138,"score_gpt":0.25386121016399404,"score_spread":0.2422012552484599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171131568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154025,0.0035277996,0.0015433775,0.00010920815,0.000023823344,0.000041241874,0.0005147745,0.00012707438,0.0025723781],"genre_scores_gemma":[0.99317896,0.002120982,0.0017565709,0.000059452985,0.0000069211474,0.000041129955,0.0012224751,0.000025255351,0.0015883072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995065,0.0000055522737,0.000003717251,0.000009588531,0.000017747157,0.000012739377],"domain_scores_gemma":[0.9999627,0.000005981715,0.000014054879,0.0000038395037,0.000003198723,0.0000102484855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053211712,0.00032837194,0.00022563762,0.00011528748,0.000078712656,0.0002170859,0.00023830937,0.00015450666,0.0009852932],"category_scores_gemma":[0.00008900892,0.00009842229,0.00015476026,0.000116763804,0.00013387292,0.000113758186,0.00013589696,0.00040733855,0.00033515357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002990633,0.000058936872,0.00022530329,0.000062607556,0.000009202139,0.000036018453,0.000009569614,0.00049407396,0.9939242,0.00009485346,0.00016910442,0.0046169907],"study_design_scores_gemma":[0.0000768034,0.00034498505,0.0038414048,0.0000073123197,0.000010948508,0.00019186766,0.000009759728,0.0015229468,0.9903015,0.000041801195,0.0036455027,0.0000051312472],"about_ca_topic_score_codex":0.00057801243,"about_ca_topic_score_gemma":0.0012499302,"teacher_disagreement_score":0.0009852932,"about_ca_system_score_codex":0.000560823,"about_ca_system_score_gemma":0.00022916298,"threshold_uncertainty_score":0.0040690303},"labels":[],"label_agreement":null},{"id":"W2171369497","doi":"10.1158/1535-7163.mct-14-0208","title":"Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Agilent Technologies","keywords":"Sunitinib; Renal cell carcinoma; Epigenetics; Clear cell renal cell carcinoma; Cancer research; Medicine; Acquired resistance; Oncology; Transient (computer programming); Internal medicine; Pharmacology; Cancer; Biology; Genetics; Gene; Computer science","score_opus":0.025707271109698168,"score_gpt":0.2549107071518875,"score_spread":0.22920343604218935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171369497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984609,0.00050735375,0.00049044355,0.000024955185,0.000008544039,0.000030327463,0.00008301301,0.000043828633,0.00035062438],"genre_scores_gemma":[0.9984068,0.00027979544,0.00056175666,0.000021716563,0.000004860671,0.000022750255,0.00018189439,0.000007678237,0.00051278295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989724,0.000014740382,0.000009845991,0.000022970122,0.00002915483,0.000025893378],"domain_scores_gemma":[0.9999485,0.000010096894,0.000016125037,0.000009673967,0.0000059708814,0.000009697041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001292402,0.00016763597,0.00039200517,0.00016270755,0.00008307218,0.00019587517,0.00017106548,0.00013618235,0.0007871313],"category_scores_gemma":[0.000115921226,0.00009768215,0.00025816093,0.00013934984,0.00009542583,0.00016698157,0.000099559846,0.00044891084,0.0000921826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063976203,0.00037235388,0.0012080263,0.00007602799,0.000028863244,0.00006911627,0.0000355483,0.0007117082,0.9763594,0.00008528994,0.00017800258,0.02023578],"study_design_scores_gemma":[0.00015951852,0.009656717,0.031151272,0.0000069388557,0.00008953735,0.00075397687,0.000039415543,0.0036125819,0.95116895,0.00009563068,0.0032519314,0.00001355226],"about_ca_topic_score_codex":0.00027327082,"about_ca_topic_score_gemma":0.0008562433,"teacher_disagreement_score":0.0007871313,"about_ca_system_score_codex":0.00021352811,"about_ca_system_score_gemma":0.00015318947,"threshold_uncertainty_score":0.002633214},"labels":[],"label_agreement":null},{"id":"W2171387031","doi":"10.1158/1535-7163.1659.3.12","title":"Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor–related apoptosis-inducing ligand–mediated cell death","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Institute of Cancer Research; Canadian Institutes of Health Research","keywords":"Camptothecin; TRADD; FADD; Apoptosis; Death domain; Programmed cell death; Biology; Fas receptor; Tumor necrosis factor alpha; Molecular biology; Cell biology; Chemistry; Cancer research; Immunology; Biochemistry; Caspase","score_opus":0.017765968466216912,"score_gpt":0.25370379354166994,"score_spread":0.23593782507545302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171387031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553597,0.0011825623,0.0014503254,0.000062382984,0.000019380199,0.000043046533,0.00040624035,0.000067190726,0.0012329647],"genre_scores_gemma":[0.9934809,0.0008059072,0.0016174,0.000045751673,0.000009703191,0.00005713846,0.0010841775,0.000009799114,0.002889296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998803,0.00002075273,0.000016583212,0.000019087962,0.000036336896,0.000026875243],"domain_scores_gemma":[0.99994564,0.000010589853,0.000011012767,0.000012771696,0.0000065222102,0.000013422432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097134944,0.00025220282,0.00020716048,0.00017807644,0.00012033437,0.00018833375,0.00011150839,0.00016892201,0.0011448],"category_scores_gemma":[0.000092690236,0.00013388238,0.00022054873,0.00016255185,0.00012710241,0.00012966384,0.00010502088,0.00047097183,0.0004892232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015066491,0.00003054493,0.00015693814,0.000019167705,0.0000046552254,0.000059951915,0.000016639966,0.000043248387,0.99859434,0.00006311354,0.000030900566,0.0008297531],"study_design_scores_gemma":[0.00003826248,0.0002605439,0.005091547,0.00000366727,0.000008509274,0.00036014186,0.000015087329,0.0009940551,0.9915168,0.00004577895,0.001662809,0.0000028130007],"about_ca_topic_score_codex":0.00086870865,"about_ca_topic_score_gemma":0.0009922698,"teacher_disagreement_score":0.0011448,"about_ca_system_score_codex":0.00033027958,"about_ca_system_score_gemma":0.00022746285,"threshold_uncertainty_score":0.0038297176},"labels":[],"label_agreement":null},{"id":"W2172092066","doi":"10.1158/1535-7163.mct-11-0977","title":"O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; University of Alberta; Montreal Neurological Institute and Hospital","funders":"Alberta Cancer Foundation","keywords":"Glioblastoma; Methyltransferase; O-6-methylguanine-DNA methyltransferase; Temozolomide; Effector; Cancer research; DNA; DNA methyltransferase; Chemistry; Biology; Molecular biology; Genetics; Biochemistry; Methylation","score_opus":0.03053477144979372,"score_gpt":0.31220909533392777,"score_spread":0.28167432388413405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172092066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514104,0.012450693,0.0012485462,0.00012634473,0.00001830636,0.00001206354,0.000109790926,0.00005414331,0.00083913805],"genre_scores_gemma":[0.9960951,0.002718679,0.0003932267,0.000025741396,0.0000073724736,0.000006282157,0.00014670007,0.0000025829886,0.00060431974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995875,0.000006203607,0.0000028218242,0.000008397531,0.000014971003,0.000008782906],"domain_scores_gemma":[0.99996614,0.0000034933107,0.000013857773,0.000002199345,0.000006054094,0.000008261465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008911576,0.00022642552,0.00018889307,0.00018208462,0.00010013989,0.00015413291,0.000092260256,0.00013524556,0.00032064444],"category_scores_gemma":[0.000076868455,0.00005866305,0.000106053114,0.000133376,0.0001509128,0.00009547489,0.00013130008,0.00020296662,0.00007868789],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002644821,0.000032259166,0.008111683,0.00013327248,0.000017739692,0.00024077996,0.00003570907,0.00010142587,0.9783201,0.00019312814,0.000137711,0.012411614],"study_design_scores_gemma":[0.00003599332,0.0014602584,0.27195582,0.000029116023,0.0001155949,0.0029067488,0.00013582427,0.001884201,0.7109016,0.00045226427,0.010109543,0.000012986976],"about_ca_topic_score_codex":0.00076840975,"about_ca_topic_score_gemma":0.0012981751,"teacher_disagreement_score":0.00076840975,"about_ca_system_score_codex":0.00022292399,"about_ca_system_score_gemma":0.0001384414,"threshold_uncertainty_score":0.0016174316},"labels":[],"label_agreement":null},{"id":"W2172231359","doi":"10.1158/1535-7163.mct-07-2150","title":"Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Protein kinase B; Biology; Kinase; Geldanamycin; Protein kinase A; p38 mitogen-activated protein kinases; PI3K/AKT/mTOR pathway; Synthetic lethality; Signal transduction; Programmed cell death; Molecular biology; Cell biology; Apoptosis; Cancer research; Heat shock protein; Biochemistry; Hsp90; Mutant","score_opus":0.012887109744977344,"score_gpt":0.24512977138803974,"score_spread":0.2322426616430624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172231359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690163,0.0015501535,0.00074738375,0.000037819853,0.00001220057,0.000014872888,0.00023702173,0.000023166043,0.00047586818],"genre_scores_gemma":[0.99679655,0.0011432648,0.0007417144,0.000020630052,0.0000029381945,0.000030608782,0.00051023974,0.0000045166767,0.0007495787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992144,0.0000137332245,0.000006608228,0.000009953321,0.000019271476,0.000029035222],"domain_scores_gemma":[0.9999733,0.0000031289821,0.0000072857238,0.0000029554114,0.0000053965778,0.000007984857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082788356,0.00046285806,0.00022700006,0.00013087908,0.00013162136,0.00016561708,0.00010366691,0.00014221377,0.0005001213],"category_scores_gemma":[0.00004261145,0.00010592093,0.00029698765,0.00012856159,0.00012877827,0.00013196167,0.00013061054,0.00034861622,0.00017096307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120595694,0.00003814948,0.0002563651,0.000039592764,0.000007659686,0.000040870535,0.000019329456,0.00007850036,0.9985825,0.00006690611,0.000023221797,0.0007263583],"study_design_scores_gemma":[0.000010486936,0.00040562905,0.0040784082,0.0000031015293,0.000016053913,0.00014608787,0.000031363794,0.00049930875,0.9941251,0.000027326107,0.0006546181,0.0000024970236],"about_ca_topic_score_codex":0.00095307303,"about_ca_topic_score_gemma":0.0016161682,"teacher_disagreement_score":0.00095307303,"about_ca_system_score_codex":0.00029189387,"about_ca_system_score_gemma":0.00024985088,"threshold_uncertainty_score":0.0021178722},"labels":[],"label_agreement":null},{"id":"W2172727255","doi":"10.1158/1535-7163.mct-15-0679","title":"GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"Ministry of Health and Welfare; Neurosciences Research Foundation","keywords":"Cetuximab; Panitumumab; Epitope; Monoclonal antibody; Antibody; Cancer research; Epidermal growth factor receptor; EGFR inhibitors; Colorectal cancer; Chemistry; Cancer; In vivo; Pharmacology; Receptor; Biology; Medicine; Biochemistry; Immunology; Internal medicine","score_opus":0.02825514190910116,"score_gpt":0.3251876591008646,"score_spread":0.29693251719176345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172727255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805802,0.00821382,0.0049611125,0.00029180443,0.000052368967,0.00012115974,0.00021304772,0.00012211723,0.005444216],"genre_scores_gemma":[0.98364973,0.0032412612,0.0069262567,0.00022202026,0.000020675121,0.00006325447,0.0008069915,0.000027112605,0.005042773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986565,0.00002415879,0.000008086534,0.000030649222,0.00003981463,0.00003166607],"domain_scores_gemma":[0.9999341,0.000013791067,0.0000138202695,0.000009087893,0.000009152857,0.000020087713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001539446,0.00037586063,0.0002653135,0.00025082566,0.000114089205,0.00030572442,0.00032561613,0.00049630104,0.00094015745],"category_scores_gemma":[0.00013909827,0.00010415005,0.00016139337,0.000227263,0.00028694927,0.00023670589,0.00020949384,0.0007593897,0.00039512632],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017292023,0.00012816401,0.00042146898,0.00010398983,0.000011790645,0.00014687268,0.00002004354,0.00026579943,0.9853837,0.00051223184,0.00035579462,0.0124771865],"study_design_scores_gemma":[0.0001188747,0.001469537,0.0024480023,0.00000984596,0.00002912211,0.0018507343,0.000013063023,0.0011579302,0.98080117,0.00006977841,0.012021106,0.000010829442],"about_ca_topic_score_codex":0.00075492065,"about_ca_topic_score_gemma":0.001238697,"teacher_disagreement_score":0.00094015745,"about_ca_system_score_codex":0.000536678,"about_ca_system_score_gemma":0.00035874825,"threshold_uncertainty_score":0.0038939118},"labels":[],"label_agreement":null},{"id":"W2182736412","doi":"10.1158/1535-7163.1525.3.12","title":"Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Erythropoietin; Erythropoietin receptor; Cancer research; Cisplatin; Cancer cell; Cell culture; Cancer; Ionizing radiation; Biology; Chemotherapy; Endocrinology; Irradiation; Genetics","score_opus":0.021905567914438085,"score_gpt":0.30706195937927583,"score_spread":0.28515639146483773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182736412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946964,0.001786981,0.001198989,0.0000765745,0.00001732477,0.00007477277,0.00024831088,0.00008788944,0.0018126412],"genre_scores_gemma":[0.99524313,0.00083249767,0.0010803369,0.000038916478,0.0000074045956,0.00006321167,0.000589592,0.00002336752,0.0021216152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997954,0.00005698503,0.000025161144,0.000031089814,0.000057295587,0.000034071705],"domain_scores_gemma":[0.99976,0.00007946492,0.00003778936,0.00005733346,0.00002588607,0.000039588405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015422757,0.00026834797,0.0005148226,0.0004229705,0.00015353238,0.00028664357,0.00017002117,0.00025776177,0.001373123],"category_scores_gemma":[0.00027481338,0.0001710314,0.00024165107,0.00021257378,0.0002185217,0.0001263862,0.00019964935,0.00062803057,0.0002968869],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016555621,0.000079123834,0.0003773398,0.000040030074,0.00001648349,0.00007624999,0.000045039527,0.00018450081,0.9964623,0.000101784964,0.000120805795,0.0023307602],"study_design_scores_gemma":[0.00004296031,0.00094399456,0.0062530944,0.0000089256955,0.00002029584,0.0005129278,0.000026854357,0.0010450183,0.9886185,0.000057167643,0.0024657943,0.0000044561857],"about_ca_topic_score_codex":0.0005987358,"about_ca_topic_score_gemma":0.0007210472,"teacher_disagreement_score":0.001373123,"about_ca_system_score_codex":0.00028438616,"about_ca_system_score_gemma":0.00017560352,"threshold_uncertainty_score":0.0045934916},"labels":[],"label_agreement":null},{"id":"W2183162965","doi":"10.1158/1535-7163.mct-04-0137","title":"Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Cytochrome c; Cell biology; Apoptosis; Kinase; Biology; Signal transduction; Phosphorylation; U937 cell; Jurkat cells; Cancer research; Chemistry; Mitochondrion; Biochemistry; Immunology","score_opus":0.019668314881333755,"score_gpt":0.25963659094923064,"score_spread":0.2399682760678969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183162965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993476,0.0039098635,0.00084945577,0.000094956195,0.00003151987,0.000040377934,0.00019831189,0.00008635048,0.0013131758],"genre_scores_gemma":[0.99459344,0.0023003253,0.0013535687,0.000054218755,0.00001394119,0.00007323633,0.00049541076,0.0000061861183,0.0011095664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998011,0.000050941286,0.000026551272,0.000023090375,0.000049147784,0.000049238],"domain_scores_gemma":[0.9999418,0.00000990675,0.00001623105,0.0000075361627,0.000006995616,0.000017501312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013040172,0.00046396995,0.00035817138,0.00023510242,0.0001634284,0.00024466187,0.00012778403,0.00018812646,0.0007777739],"category_scores_gemma":[0.00008945318,0.00013839087,0.0002601775,0.000279485,0.00016453839,0.00012386235,0.00020804371,0.00038099108,0.00028473313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013784454,0.00019528116,0.0005923263,0.00013145927,0.00002926396,0.00012734957,0.000046704085,0.00023955137,0.9905415,0.00015873127,0.00017995221,0.0063792705],"study_design_scores_gemma":[0.00010730955,0.0016726584,0.0068891537,0.000011874589,0.00005226803,0.00052887003,0.00004692395,0.0009916861,0.985551,0.00003635045,0.0041051344,0.000006782308],"about_ca_topic_score_codex":0.0005951764,"about_ca_topic_score_gemma":0.001502131,"teacher_disagreement_score":0.0007777739,"about_ca_system_score_codex":0.00027475366,"about_ca_system_score_gemma":0.00030520602,"threshold_uncertainty_score":0.0026019216},"labels":[],"label_agreement":null},{"id":"W2184357820","doi":"10.1158/1535-7163.1343.3.11","title":"Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cytochrome c; Peptide; Apoptosis; Cell biology; Biology; Mitochondrion; Bcl-xL; Programmed cell death; Apoptosome; Bcl-2-associated X protein; Jurkat cells; Bcl-2 family; Biochemistry; Caspase; Caspase 3; Genetics; T cell","score_opus":0.04765989799492853,"score_gpt":0.31908325764797507,"score_spread":0.27142335965304654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184357820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980793,0.000497258,0.0009271178,0.000018493163,0.000003885586,0.000012540362,0.00006900542,0.0000059900563,0.0003863652],"genre_scores_gemma":[0.9984281,0.0002637259,0.0008708555,0.000018792922,0.0000040802984,0.000011361313,0.00022060944,0.0000064570745,0.00017612387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982846,0.000049349073,0.000018864044,0.0000192117,0.00004453923,0.00003952876],"domain_scores_gemma":[0.99966705,0.00012215722,0.00009023919,0.000023693727,0.000037680304,0.000059203452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016841282,0.00016705146,0.00016087084,0.00011277748,0.0001328884,0.0002613024,0.000104183426,0.00016812787,0.00073195976],"category_scores_gemma":[0.00028575948,0.00013208769,0.0001556212,0.000109886205,0.00017310948,0.00021758964,0.00009430889,0.00029520696,0.00021957915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011258831,0.000011694191,0.00025906018,0.000013686257,0.0000018190241,0.000045263765,0.000009750468,0.00008499737,0.9990891,0.00003589596,0.000003889651,0.00033227302],"study_design_scores_gemma":[0.000023338149,0.00044438493,0.0072059734,0.0000049741984,0.000015742873,0.00063232123,0.000046052082,0.00076232397,0.99003196,0.00006795414,0.00075903843,0.0000060591237],"about_ca_topic_score_codex":0.00027794138,"about_ca_topic_score_gemma":0.00035986255,"teacher_disagreement_score":0.00073195976,"about_ca_system_score_codex":0.00017985591,"about_ca_system_score_gemma":0.00016516463,"threshold_uncertainty_score":0.0024486184},"labels":[],"label_agreement":null},{"id":"W2187655164","doi":"10.1158/1535-7163.187.4.2","title":"Synergistic antitumor effect of combined use of adenoviral-mediated<i>p53</i>gene transfer and antisense oligodeoxynucleotide targeting<i>clusterin</i>gene in an androgen-independent human prostate cancer model","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Clusterin; Cancer research; Biology; Genetic enhancement; Prostate cancer; Antisense therapy; Apoptosis; Pharmacology; Cancer; Molecular biology; Oligonucleotide; Gene; Biochemistry","score_opus":0.024208715790543383,"score_gpt":0.3035869524290446,"score_spread":0.2793782366385012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187655164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939116,0.0020336437,0.0019255719,0.000070197275,0.00006192501,0.00006810829,0.00008822025,0.000088918874,0.0017517282],"genre_scores_gemma":[0.9963638,0.00078602886,0.0015057388,0.000034943278,0.000016710976,0.000034554625,0.0001110422,0.000009324951,0.0011378553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998816,0.0000184231,0.0000082892875,0.000026559439,0.00003174156,0.00003329426],"domain_scores_gemma":[0.9999455,0.000009833086,0.000009678422,0.000007222141,0.0000052632913,0.000022556098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012670767,0.00053581654,0.00046704744,0.0002681316,0.00010922679,0.00019189822,0.00015119079,0.00022409052,0.00065751135],"category_scores_gemma":[0.00006763745,0.00012577379,0.0002599226,0.00013578699,0.00020621101,0.00014282217,0.00016272772,0.00045010162,0.000096374424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040659506,0.00016982485,0.00022132823,0.000058352805,0.000024851339,0.000053419673,0.000017191724,0.00030868454,0.9934255,0.00011855945,0.00006452024,0.005131199],"study_design_scores_gemma":[0.00010673901,0.004067808,0.0025158657,0.000006704616,0.00009273434,0.00027476015,0.00001731446,0.0016336133,0.9891179,0.000051579893,0.0021072782,0.000007780495],"about_ca_topic_score_codex":0.00078685157,"about_ca_topic_score_gemma":0.001686497,"teacher_disagreement_score":0.00078685157,"about_ca_system_score_codex":0.00021540941,"about_ca_system_score_gemma":0.00037464363,"threshold_uncertainty_score":0.0021995306},"labels":[],"label_agreement":null},{"id":"W2202354116","doi":"10.1158/1538-8514.pi3k14-ia05","title":"Abstract IA05: The role of glucose and lipid metabolism in growth and survival of cancer cells","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer cell; Lipid metabolism; Biology; mTORC1; Cancer; Lipogenesis; Cell growth; Carcinogenesis; PI3K/AKT/mTOR pathway; Cancer research; Cell biology; Signal transduction; Biochemistry; Genetics","score_opus":0.014250860325053651,"score_gpt":0.26407760170754646,"score_spread":0.2498267413824928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202354116","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86243945,0.03746773,0.008383214,0.004418145,0.0013803662,0.00015496588,0.010051016,0.0012987488,0.074406445],"genre_scores_gemma":[0.9378671,0.008177892,0.0035488792,0.00037335773,0.00009292443,0.000089255365,0.0076401406,0.00007762705,0.042132825],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998933,0.000011218832,0.000011390441,0.000024803672,0.00003563937,0.000023595732],"domain_scores_gemma":[0.99990535,0.000010778839,0.000017625422,0.000010274878,0.000025112631,0.000030846673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013770492,0.0003677352,0.00024996858,0.0006862859,0.0005019012,0.00097457576,0.0004137807,0.00041924627,0.007774733],"category_scores_gemma":[0.00018305825,0.00008917033,0.00020070751,0.0009472498,0.0002600126,0.00025528838,0.00038084798,0.0005358725,0.0025375988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009672391,0.00015701905,0.0028037974,0.00037340724,0.000029561617,0.0004673136,0.000063882326,0.00047377858,0.9275743,0.0033736047,0.00582253,0.05789366],"study_design_scores_gemma":[0.000066520115,0.0006367229,0.034629516,0.00009356306,0.000077482146,0.0014051556,0.00022910547,0.0026301553,0.8640768,0.0015188935,0.09460659,0.000029434465],"about_ca_topic_score_codex":0.0023171273,"about_ca_topic_score_gemma":0.0013445555,"teacher_disagreement_score":0.007774733,"about_ca_system_score_codex":0.0008950961,"about_ca_system_score_gemma":0.00071245246,"threshold_uncertainty_score":0.026009083},"labels":[],"label_agreement":null},{"id":"W2205644460","doi":"10.1158/1535-7163.mct-15-0409","title":"Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phytochemical compounds biological activities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research","keywords":"EIF4E; Phosphorylation; eIF4A; Protein subunit; Biology; Translation (biology); EIF4G; MAPK/ERK pathway; Initiation factor; Eukaryotic initiation factor; Protein biosynthesis; Cell biology; Eukaryotic translation; Messenger RNA; Cancer research; Molecular biology; Biochemistry; Gene","score_opus":0.034615760157933294,"score_gpt":0.2831360043032137,"score_spread":0.24852024414528037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205644460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98212874,0.007860581,0.0028603086,0.00019800737,0.000059593654,0.000048600436,0.0007887832,0.00019222763,0.0058632237],"genre_scores_gemma":[0.991118,0.0032386757,0.0020988467,0.00011407239,0.000034202076,0.00003667769,0.0009858266,0.000027574102,0.0023460665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998932,0.00002272512,0.000014425913,0.000019949704,0.000024799672,0.000024911935],"domain_scores_gemma":[0.9998679,0.000036855236,0.000040609368,0.000019664449,0.00001693832,0.000017970631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114973824,0.00032785363,0.00032591738,0.0002738976,0.00012984138,0.00020681806,0.00012933314,0.00020487599,0.0019900552],"category_scores_gemma":[0.00013277124,0.00010194849,0.00029018134,0.0001482986,0.0001678314,0.00019330753,0.00012492015,0.00045643773,0.0005385733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034709592,0.000059107002,0.00015782203,0.00006949114,0.000009113724,0.000053392563,0.000007160952,0.000065878216,0.99565035,0.00009820357,0.00006534018,0.0034170458],"study_design_scores_gemma":[0.0000283071,0.00083109067,0.0032536653,0.000007789458,0.000015859034,0.00018844324,0.000011343499,0.00032354976,0.9923826,0.000049668524,0.0029017834,0.0000059075514],"about_ca_topic_score_codex":0.0002078833,"about_ca_topic_score_gemma":0.00049211294,"teacher_disagreement_score":0.0019900552,"about_ca_system_score_codex":0.00016097042,"about_ca_system_score_gemma":0.00014136054,"threshold_uncertainty_score":0.006657362},"labels":[],"label_agreement":null},{"id":"W2211386458","doi":"","title":"Inhibition of EphA2 receptor tyrosine kinase activity by dasatinib in pancreatic cancer.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Axon Guidance and Neuronal Signaling","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research","funders":"","keywords":"EPH receptor A2; Erythropoietin-producing hepatocellular (Eph) receptor; Dasatinib; Cancer research; Ephrin; Tyrosine kinase; Receptor tyrosine kinase; Pancreatic cancer; Proto-oncogene tyrosine-protein kinase Src; Biology; Autophosphorylation; Cancer; Kinase; Cell biology; Signal transduction; Internal medicine; Medicine; Protein kinase A","score_opus":0.043864998937964986,"score_gpt":0.31923569045112005,"score_spread":0.2753706915131551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211386458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98551524,0.0075756987,0.0017957117,0.00027155154,0.00011012599,0.00015900697,0.0014568921,0.00014944475,0.002966372],"genre_scores_gemma":[0.9903992,0.0040071877,0.001955618,0.00006118487,0.000009654853,0.0001228019,0.001847204,0.0000134811,0.001583565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997881,0.00004596277,0.000032891247,0.00003450992,0.000046103603,0.000052434145],"domain_scores_gemma":[0.9999579,0.000008885198,0.000008218602,0.000007655525,0.000005184109,0.000012232071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021298663,0.00043374457,0.00067990704,0.00024439703,0.00016766362,0.00034651053,0.00024608406,0.00029521453,0.0010414281],"category_scores_gemma":[0.00014252329,0.00021368229,0.00045844287,0.0004897864,0.00017684612,0.00022438342,0.00020626155,0.0007456253,0.0003350603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013587275,0.0003699023,0.00069721794,0.00035533233,0.00007625918,0.000244371,0.0000418036,0.0007612693,0.9845783,0.0001852205,0.0005702313,0.010761394],"study_design_scores_gemma":[0.00053082424,0.0039003573,0.008041561,0.000010724498,0.0000772482,0.0015641964,0.000063696505,0.0027472356,0.97477096,0.00009221184,0.008186117,0.0000148824065],"about_ca_topic_score_codex":0.0005929207,"about_ca_topic_score_gemma":0.0011961819,"teacher_disagreement_score":0.0010414281,"about_ca_system_score_codex":0.0003808892,"about_ca_system_score_gemma":0.00038911722,"threshold_uncertainty_score":0.003483951},"labels":[],"label_agreement":null},{"id":"W2216333908","doi":"10.1158/1535-7163.mct-15-0658","title":"Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada)","funders":"Stephenson Cancer Center; University of Oklahoma Health Sciences Center; National Institutes of Health; National Institute of Allergy and Infectious Diseases; American Association for Cancer Research","keywords":"Macrophage migration inhibitory factor; Ovarian cancer; Cancer research; Biology; Human leukocyte antigen; Cancer; Immunology; Antigen; Cytokine","score_opus":0.041341736122792065,"score_gpt":0.3067793309965293,"score_spread":0.26543759487373725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216333908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907692,0.0051101707,0.0024957326,0.00017398557,0.000017299375,0.000051509996,0.000078891164,0.000045282824,0.0012579972],"genre_scores_gemma":[0.9968631,0.0009981558,0.0012923324,0.000049031267,0.000011085616,0.000024945184,0.000102597725,0.000003227123,0.00065566174],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999131,0.000025488795,0.000004988748,0.000012155842,0.000019831126,0.000024504434],"domain_scores_gemma":[0.9999579,0.000010634535,0.000010881506,0.000004662409,0.0000060484635,0.000009887485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015755641,0.00018900062,0.00017809648,0.00018818119,0.00010207894,0.00019974208,0.000097240045,0.0002454329,0.00082689326],"category_scores_gemma":[0.00014837724,0.00006802108,0.00012204174,0.00013881749,0.00013550709,0.00011694555,0.0001568607,0.0003875537,0.00016494477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012188273,0.00003347175,0.0010972805,0.000042138778,0.0000041074386,0.00003910961,0.000009858345,0.000060654904,0.994282,0.000043717973,0.000050296916,0.004215522],"study_design_scores_gemma":[0.000047294237,0.0021820012,0.029537298,0.000019935113,0.000036569065,0.0011390528,0.0000743642,0.0024245002,0.95730543,0.00011015143,0.0071164737,0.0000070003985],"about_ca_topic_score_codex":0.00032769487,"about_ca_topic_score_gemma":0.00046089536,"teacher_disagreement_score":0.00082689326,"about_ca_system_score_codex":0.00018447913,"about_ca_system_score_gemma":0.00014532739,"threshold_uncertainty_score":0.0027662516},"labels":[],"label_agreement":null},{"id":"W2226081785","doi":"10.1158/1535-7163.mct-15-0282","title":"Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"PARP1; Olaparib; Cancer research; Veliparib; Medicine; In vivo; PARP inhibitor; Poly ADP ribose polymerase; DNA damage; Biology; DNA; Polymerase","score_opus":0.025574440247841997,"score_gpt":0.3001339648040031,"score_spread":0.2745595245561611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226081785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935217,0.008056058,0.001387709,0.00007517253,0.000010544596,0.000038202907,0.00022135688,0.000046754893,0.0008120871],"genre_scores_gemma":[0.9929194,0.0042199986,0.0018380301,0.00003322496,0.0000057502234,0.000035405716,0.00061349967,0.000009974933,0.00032462037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991393,0.000015060389,0.000005867019,0.000025502575,0.000021757392,0.000017830855],"domain_scores_gemma":[0.9999373,0.000010543582,0.000020358533,0.0000067482974,0.000009185854,0.000015886633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014117261,0.00020088155,0.00032903848,0.00018173181,0.00007051321,0.00029255223,0.00015561972,0.00018655846,0.00038898393],"category_scores_gemma":[0.0001519678,0.00012691614,0.0002524492,0.0003081491,0.00016880302,0.00017501913,0.000109885994,0.0005135065,0.0001211449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023744572,0.00027415366,0.01989942,0.0005377698,0.00012290764,0.0013660019,0.000118153366,0.0025580912,0.90869963,0.0002620437,0.00041322052,0.063374065],"study_design_scores_gemma":[0.00024588723,0.01395371,0.16276969,0.000042614887,0.00032517812,0.013335818,0.00026098563,0.0062072407,0.7850902,0.00033404803,0.017412985,0.000021724723],"about_ca_topic_score_codex":0.00075497956,"about_ca_topic_score_gemma":0.0014473005,"teacher_disagreement_score":0.00075497956,"about_ca_system_score_codex":0.0003832083,"about_ca_system_score_gemma":0.0002602621,"threshold_uncertainty_score":0.0027804375},"labels":[],"label_agreement":null},{"id":"W2232682640","doi":"10.1158/1535-7163.813.3.7","title":"Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue <i>N</i>1,<i>N</i>11-diethylnorspermine at the level of spermidine/spermine <i>N</i>1-acetyltransferase","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Spermidine; Polyamine; Spermine; Chemistry; Biochemistry; Catabolism; Oxaliplatin; Anticancer drug; Pharmacology; Drug; Enzyme; Biology; Cancer","score_opus":0.047485110370335065,"score_gpt":0.31645435842749275,"score_spread":0.2689692480571577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232682640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927705,0.004765702,0.0012667663,0.00008777367,0.000026176513,0.000030152034,0.00013564865,0.00003214639,0.000885136],"genre_scores_gemma":[0.99623555,0.0012484102,0.0012454974,0.000048228852,0.0000097678885,0.00002614439,0.00026034753,0.0000055162213,0.00092053233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998759,0.00003959938,0.000014796037,0.000025898802,0.000022489236,0.000021257421],"domain_scores_gemma":[0.99992275,0.00002162843,0.000019678304,0.000007125758,0.00000876485,0.000019996009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019053246,0.0002590014,0.00036671312,0.00013985261,0.00010694466,0.0002883405,0.00014321454,0.00027354556,0.00066183216],"category_scores_gemma":[0.00014856411,0.00016013073,0.0003204064,0.00016025828,0.00017953037,0.00022305835,0.00015224308,0.00025114464,0.00014374823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005596973,0.000054043594,0.000866898,0.00006455077,0.000016028425,0.00006533098,0.000013291922,0.0001297366,0.99507636,0.00004368123,0.000022393495,0.0030880177],"study_design_scores_gemma":[0.00003309103,0.0011927407,0.018467251,0.0000056505337,0.000029527782,0.00019896186,0.000017807182,0.0013600461,0.97712827,0.000026623315,0.0015348321,0.000005224663],"about_ca_topic_score_codex":0.0008244889,"about_ca_topic_score_gemma":0.0014760852,"teacher_disagreement_score":0.0008244889,"about_ca_system_score_codex":0.00041242366,"about_ca_system_score_gemma":0.00022819577,"threshold_uncertainty_score":0.002992332},"labels":[],"label_agreement":null},{"id":"W2240322070","doi":"10.1158/1538-8514.pi3k14-a46","title":"Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN)","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Oncology; Internal medicine; Epidermal growth factor receptor; EGFR inhibitors; Cancer; Cancer research; Colorectal cancer","score_opus":0.02081037150155034,"score_gpt":0.29531306301326465,"score_spread":0.2745026915117143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240322070","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988499,0.0024281242,0.001606084,0.0003140433,0.00018294172,0.0004254912,0.0014279087,0.00029583482,0.0048206495],"genre_scores_gemma":[0.9921072,0.0011524233,0.0012128766,0.00010954469,0.000025765577,0.00013377379,0.0015004061,0.000036508718,0.0037214875],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997851,0.000030029838,0.000021884707,0.00005307691,0.00004958937,0.000060311682],"domain_scores_gemma":[0.9999167,0.000008130794,0.000014154618,0.0000132285795,0.000012412995,0.000035357687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028027483,0.00049792323,0.0006539377,0.0003465285,0.0003487045,0.00060576096,0.00045365383,0.00040466603,0.005920087],"category_scores_gemma":[0.00013512967,0.00020741743,0.0006298663,0.00030396346,0.00030394839,0.00033335882,0.0002554712,0.0011987768,0.0014119954],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064944113,0.0029008442,0.0013021502,0.00035186752,0.00012744733,0.00014515132,0.000048558763,0.00090071384,0.9523998,0.00025682268,0.0024699608,0.03260214],"study_design_scores_gemma":[0.004874162,0.03929814,0.012216204,0.000035117835,0.00032038597,0.0012212796,0.00006417865,0.0035174515,0.9257879,0.00014085257,0.012489348,0.00003495918],"about_ca_topic_score_codex":0.0023718916,"about_ca_topic_score_gemma":0.0030303332,"teacher_disagreement_score":0.005920087,"about_ca_system_score_codex":0.0006554783,"about_ca_system_score_gemma":0.000812511,"threshold_uncertainty_score":0.019804657},"labels":[],"label_agreement":null},{"id":"W2241515017","doi":"","title":"Regulation of growth of renal clear cell carcinoma by peroxisome proliferator-activated receptor gamma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Troglitazone; Peroxisome proliferator-activated receptor; Endocrinology; Internal medicine; Receptor; Peroxisome proliferator-activated receptor alpha; Biology; Peroxisome; Chemistry; Biochemistry; Medicine; Nuclear receptor","score_opus":0.010321590877944625,"score_gpt":0.2451649783076107,"score_spread":0.23484338742966607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241515017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589408,0.027429532,0.0023322578,0.00068982714,0.00014607351,0.0000854456,0.0014543454,0.00018337736,0.008738284],"genre_scores_gemma":[0.97341114,0.016231276,0.00228783,0.00024435378,0.000039902785,0.00011866803,0.001269772,0.000024451985,0.006372587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982905,0.00004630851,0.0000140958455,0.000024155994,0.000050156556,0.00003626251],"domain_scores_gemma":[0.99986887,0.00004017501,0.000021186677,0.000017591028,0.000035817175,0.000016428132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012682407,0.00022208304,0.00023935779,0.0003675151,0.00017999334,0.00036402207,0.00019832294,0.00023077149,0.0015922505],"category_scores_gemma":[0.00021676818,0.0001677287,0.00027900818,0.00023164976,0.0002312274,0.00014829336,0.00020095128,0.0003940323,0.0007339854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000458555,0.000081834376,0.001131522,0.00013111811,0.000009354029,0.000119836106,0.00004675169,0.00016490277,0.99104637,0.00015180289,0.0004420076,0.0062159784],"study_design_scores_gemma":[0.00007497705,0.0011816617,0.059011854,0.000033644435,0.000027010097,0.00033873873,0.000256099,0.001593093,0.9239045,0.00014334488,0.013418208,0.000017002596],"about_ca_topic_score_codex":0.0041602384,"about_ca_topic_score_gemma":0.005683487,"teacher_disagreement_score":0.0041602384,"about_ca_system_score_codex":0.0004638649,"about_ca_system_score_gemma":0.0004101481,"threshold_uncertainty_score":0.008271992},"labels":[],"label_agreement":null},{"id":"W2242758687","doi":"","title":"Downregulation of XIAP expression induces apoptosis and sensitizes a panel of pediatric tumor cells to cytotoxic agents","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"XIAP; Inhibitor of apoptosis; Cytotoxic T cell; Cancer research; Apoptosis; Programmed cell death; Cancer; Rhabdomyosarcoma; Cancer cell; Biology; Medicine; Immunology; Caspase; Sarcoma; In vitro; Internal medicine; Pathology","score_opus":0.02462555906816942,"score_gpt":0.27633822474735026,"score_spread":0.2517126656791808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242758687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432325,0.0018151851,0.001213726,0.000066654226,0.000014580095,0.000029496732,0.00073681766,0.00004009119,0.0017601702],"genre_scores_gemma":[0.99094653,0.003330176,0.0016341371,0.000055750566,0.000006320672,0.00004443568,0.0019210884,0.000010044394,0.0020514396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991274,0.000010898605,0.000014908623,0.00001552607,0.000025352685,0.000020524181],"domain_scores_gemma":[0.99993205,0.000014479885,0.000015231378,0.00001059477,0.000012040948,0.000015599704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009256817,0.00022676257,0.0002494912,0.00021523367,0.000098886456,0.00019367466,0.00010318602,0.00010440032,0.001276502],"category_scores_gemma":[0.00009172077,0.00009289721,0.00017857022,0.0002579277,0.00009553737,0.00010013941,0.00013042596,0.0004003858,0.00026375786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016316523,0.00006208127,0.0011181415,0.000046926383,0.000010397256,0.00009219143,0.00003935043,0.00029771656,0.9947495,0.00011222463,0.00019806171,0.0031102034],"study_design_scores_gemma":[0.000026869842,0.0013045233,0.021978108,0.00001329725,0.000036026806,0.0005445265,0.00009349082,0.0010698728,0.9667995,0.00005617176,0.008072586,0.0000050289914],"about_ca_topic_score_codex":0.0012448967,"about_ca_topic_score_gemma":0.0016114817,"teacher_disagreement_score":0.001276502,"about_ca_system_score_codex":0.00024250367,"about_ca_system_score_gemma":0.00023174452,"threshold_uncertainty_score":0.004270315},"labels":[],"label_agreement":null},{"id":"W2243992364","doi":"","title":"Functional synergism between IGF-IR tyrosine kinase and NPM-ALK oncogene identifies a novel role of IGF-IR in malignant lymphoma.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; Anaplastic large-cell lymphoma; Lymphoma; Autocrine signalling; Biology; Tyrosine kinase; BCL10; Oncogene; Receptor tyrosine kinase; Cancer; Signal transduction; Cell culture; Internal medicine; Immunology; Medicine; Cell cycle; Lung cancer; Cell biology; Genetics","score_opus":0.01688563241363388,"score_gpt":0.2621212238248602,"score_spread":0.2452355914112263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243992364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023945,0.0054164142,0.0055616326,0.0003017283,0.00008629817,0.000071580136,0.0004329663,0.00022360847,0.007666242],"genre_scores_gemma":[0.99596894,0.00066161226,0.0017396653,0.00005416176,0.000018031335,0.000023861456,0.0003349197,0.00000584366,0.0011929551],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985945,0.000022909093,0.000007990063,0.000029175308,0.000040931114,0.000039540766],"domain_scores_gemma":[0.99991465,0.000025864607,0.00001638937,0.000011915268,0.0000068045683,0.000024473295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012733544,0.00030779414,0.00016536491,0.0004428553,0.00012448766,0.0002673997,0.00018219072,0.00023578262,0.0027230668],"category_scores_gemma":[0.00010907172,0.00015182485,0.0002906243,0.00014995046,0.00023971131,0.00021205877,0.0002763233,0.00035659038,0.0006224859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009120896,0.000028407661,0.0015666336,0.00003195437,0.0000068636223,0.0005169982,0.0000064567357,0.000028630575,0.99466175,0.00023441642,0.00007471478,0.0027520473],"study_design_scores_gemma":[0.00006507156,0.0007411762,0.04824859,0.000011717221,0.00006728317,0.01281205,0.00007899721,0.0018968752,0.9228008,0.00030628324,0.012957722,0.000013322722],"about_ca_topic_score_codex":0.0004553821,"about_ca_topic_score_gemma":0.0007713998,"teacher_disagreement_score":0.0027230668,"about_ca_system_score_codex":0.00044321103,"about_ca_system_score_gemma":0.00019289069,"threshold_uncertainty_score":0.009109557},"labels":[],"label_agreement":null},{"id":"W2246998135","doi":"","title":"AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Interim analysis; Internal medicine; Phases of clinical research; Renal cell carcinoma; Oncology; Gastroenterology; Neutropenia; Pharmacology; Urology; Surgery; Toxicity; Clinical trial","score_opus":0.06798462123839182,"score_gpt":0.3577161289842715,"score_spread":0.2897315077458797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246998135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97273105,0.012069071,0.00110035,0.0016561503,0.00027869485,0.0029869739,0.003976057,0.00029900478,0.0049025905],"genre_scores_gemma":[0.9702388,0.006286406,0.0026803906,0.0017232073,0.00042592533,0.002276018,0.010746315,0.0000609481,0.0055619655],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995735,0.00019409043,0.000022830056,0.000042314507,0.00005906438,0.00010802729],"domain_scores_gemma":[0.99909914,0.00019738852,0.00016321878,0.000053484644,0.00005084531,0.00043592925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021038144,0.0012167756,0.0016677307,0.0004961421,0.00045427395,0.00086704316,0.0008980412,0.0013611206,0.0041101463],"category_scores_gemma":[0.00093754556,0.0004441117,0.00081273593,0.00039389482,0.0005623933,0.00062477926,0.00030375112,0.002273865,0.0011051581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5797469,0.03690682,0.014199413,0.0015202379,0.0022039004,0.00091950764,0.00023301136,0.0029141787,0.06102395,0.0004997546,0.020101706,0.27973074],"study_design_scores_gemma":[0.57599247,0.36749402,0.030992702,0.00007718656,0.00082561607,0.0013104812,0.00004186922,0.0019424362,0.011533567,0.00023650461,0.009512539,0.000040599156],"about_ca_topic_score_codex":0.0010068776,"about_ca_topic_score_gemma":0.0026205708,"teacher_disagreement_score":0.0041101463,"about_ca_system_score_codex":0.0009532492,"about_ca_system_score_gemma":0.0012092481,"threshold_uncertainty_score":0.013749838},"labels":[],"label_agreement":null},{"id":"W2247744690","doi":"","title":"A monoclonal antibody targeting melanoma-associated chondroitin sulfate proteoglycan demonstrates antitumor activity in human melanoma, ovarian and breast cancer models.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Ovarian cancer; Melanoma; Cancer research; Breast cancer; Chondroitin sulfate proteoglycan; Cancer; Medicine; Metastasis; Immunology; Chondroitin sulfate; Internal medicine; Glycosaminoglycan","score_opus":0.019729038917485755,"score_gpt":0.31578276376009107,"score_spread":0.29605372484260534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247744690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745651,0.008189435,0.007907312,0.00031792463,0.00015141387,0.00018563824,0.00094625406,0.00035317196,0.0073838243],"genre_scores_gemma":[0.9777739,0.004122985,0.0063975262,0.00013547779,0.000029472432,0.00016795809,0.0021528343,0.000022045513,0.009197717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998857,0.000018296198,0.0000061905303,0.00002171623,0.000035288376,0.00003282263],"domain_scores_gemma":[0.9999522,0.0000066487114,0.00000990812,0.0000049632504,0.0000107648075,0.000015535332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017565695,0.00045115256,0.00029651803,0.000304604,0.00009378578,0.00012869663,0.0001802965,0.00035079825,0.0014958419],"category_scores_gemma":[0.00005977701,0.00014698693,0.0002681904,0.00021647263,0.0000979547,0.00011623314,0.00012014415,0.00072689506,0.0003747538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001123721,0.00013340256,0.00008945877,0.000052989373,0.0000116596975,0.000015510404,0.00000712777,0.00003698052,0.9960091,0.000049112572,0.00021253763,0.0032697187],"study_design_scores_gemma":[0.00011927252,0.004255749,0.0063250083,0.000013736715,0.00005600975,0.00045650918,0.000013381342,0.00085556426,0.981126,0.000037506576,0.0067341086,0.0000070563624],"about_ca_topic_score_codex":0.0010773177,"about_ca_topic_score_gemma":0.0021392219,"teacher_disagreement_score":0.0014958419,"about_ca_system_score_codex":0.00020650103,"about_ca_system_score_gemma":0.00018901956,"threshold_uncertainty_score":0.0050040483},"labels":[],"label_agreement":null},{"id":"W2248318148","doi":"","title":"Response of bladder cancer cells and xenografts to treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and gemcitabine","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gemcitabine; Apoptosis; Necrosis; Chemistry; Cell culture; Molecular biology; Cytotoxicity; Bladder cancer; Flow cytometry; Medicine; Cancer cell; Cancer; Pharmacology; Cancer research; Pathology; In vitro; Biology; Internal medicine; Biochemistry","score_opus":0.02166410143764098,"score_gpt":0.2942671363975314,"score_spread":0.2726030349598904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248318148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923844,0.0027560892,0.0009913526,0.00013476681,0.00014559875,0.000072376926,0.001670784,0.00009290953,0.0017516997],"genre_scores_gemma":[0.98614,0.001911527,0.0022833624,0.00011001227,0.000030358144,0.00024153873,0.004461118,0.000028313556,0.004793698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969804,0.00006460422,0.000045500976,0.000051298044,0.000057943053,0.000082652754],"domain_scores_gemma":[0.9996804,0.00010728389,0.00004642662,0.000044675642,0.000046906913,0.00007420608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029436746,0.0003803946,0.0006232841,0.00027873323,0.00018616824,0.00027916968,0.00022255509,0.00049125357,0.0016234384],"category_scores_gemma":[0.00022878485,0.00019259533,0.00042474104,0.00044867984,0.00016406496,0.0002152977,0.0001696293,0.0009005926,0.0005167673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012172955,0.0004236212,0.00086936273,0.00012246218,0.000026804162,0.00011010278,0.00010031236,0.0003917064,0.9943184,0.00006963061,0.00040874354,0.00194154],"study_design_scores_gemma":[0.0001540913,0.009273582,0.014309937,0.000026306612,0.000065893946,0.00060425664,0.00014744047,0.004044242,0.9677669,0.000055576336,0.0035318304,0.000019917547],"about_ca_topic_score_codex":0.0018768116,"about_ca_topic_score_gemma":0.0014889303,"teacher_disagreement_score":0.0018768116,"about_ca_system_score_codex":0.00039143642,"about_ca_system_score_gemma":0.00042436793,"threshold_uncertainty_score":0.0054309964},"labels":[],"label_agreement":null},{"id":"W2252412663","doi":"","title":"Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; CXCR4; Toxicity; CXCR4 antagonist; Metastasis; Internal medicine; Pharmacology; Cancer; Receptor; Oncology; Cancer research; Chemokine","score_opus":0.028047503419849875,"score_gpt":0.3310237124490393,"score_spread":0.3029762090291894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252412663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395186,0.00079295685,0.0006237446,0.00021114001,0.00006792696,0.0025880397,0.0005667091,0.000086322754,0.0011113104],"genre_scores_gemma":[0.9882234,0.00094735477,0.0021786967,0.0004977833,0.0001099054,0.0030359924,0.0018781737,0.000030941344,0.003097836],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996791,0.00013273308,0.000017480734,0.000047610552,0.000040323208,0.00008283764],"domain_scores_gemma":[0.9995585,0.00006724555,0.0000726165,0.00003949612,0.00003332199,0.00022878284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010716323,0.0015109566,0.0016308654,0.00048481234,0.00038166065,0.0007684409,0.0008018631,0.0011835389,0.0028208124],"category_scores_gemma":[0.00057274854,0.00063733733,0.0008248971,0.00039594076,0.00083787076,0.0005585121,0.00033296025,0.0025918358,0.00076776266],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.448239,0.1969966,0.016990159,0.00080576044,0.00082849193,0.0006837139,0.0004990132,0.0058175507,0.20188564,0.00069651206,0.00616422,0.120393366],"study_design_scores_gemma":[0.19918919,0.776618,0.010850869,0.000021978081,0.0001887942,0.00031452364,0.000049198366,0.0015878178,0.00800125,0.00012331543,0.0030346054,0.000020457768],"about_ca_topic_score_codex":0.00093074254,"about_ca_topic_score_gemma":0.0016353233,"teacher_disagreement_score":0.0028208124,"about_ca_system_score_codex":0.0008528904,"about_ca_system_score_gemma":0.001407418,"threshold_uncertainty_score":0.009436607},"labels":[],"label_agreement":null},{"id":"W2257212963","doi":"","title":"The human cathelicidin, LL-37, kills through activation of the mitochondrial-associated pathway of apoptosis in a caspase-independent manner","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Jurkat cells; Cathelicidin; Apoptosis; Biology; Cell biology; Caspase; Programmed cell death; DNA fragmentation; Inhibitor of apoptosis domain; Molecular biology; Innate immune system; Immunology; T cell; Immune system; Biochemistry","score_opus":0.018080799101930445,"score_gpt":0.266549425651146,"score_spread":0.24846862654921553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257212963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865747,0.0040724715,0.006429131,0.00014427752,0.000045216253,0.00006942121,0.0005900914,0.00008704746,0.001987706],"genre_scores_gemma":[0.9929832,0.001567602,0.0026846083,0.00006430254,0.000010590646,0.000047095065,0.0004970743,0.0000054498405,0.0021402205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997626,0.000050561473,0.000029033654,0.000035305977,0.00006037299,0.00006199904],"domain_scores_gemma":[0.99993026,0.000011163065,0.00002032834,0.00001255885,0.000011931737,0.0000136745475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013519824,0.000284766,0.00017778005,0.00014223262,0.00011648612,0.0002681656,0.00013364603,0.00021754713,0.0007808454],"category_scores_gemma":[0.00013043928,0.000067029185,0.00022484729,0.00013740259,0.00017235252,0.00019834621,0.00021072045,0.0003879503,0.00025293248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012625892,0.000022071466,0.0002022667,0.000043926597,0.0000043380087,0.00006996493,0.000013434918,0.00004128691,0.99795735,0.00012726302,0.00003855677,0.0013534158],"study_design_scores_gemma":[0.000025143783,0.00029422468,0.0028655892,0.000011002727,0.000010011584,0.0005357895,0.000021947139,0.0008219404,0.99223375,0.000067088025,0.003110201,0.0000032311423],"about_ca_topic_score_codex":0.00039670695,"about_ca_topic_score_gemma":0.00036834637,"teacher_disagreement_score":0.0007808454,"about_ca_system_score_codex":0.00036773816,"about_ca_system_score_gemma":0.0002166027,"threshold_uncertainty_score":0.0026680827},"labels":[],"label_agreement":null},{"id":"W2263044871","doi":"","title":"Preclinical development of Aneustat (OMN54): a multifunctional multi-targeted natural product derivative with anti-tumor, anti-inflammatory and immuno-modulatory activity","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer research; DU145; Cancer; Angiogenesis; Medicine; Immunology; Lung cancer; Cancer cell; Biology; Pharmacology; In vitro; Internal medicine","score_opus":0.026367161400760748,"score_gpt":0.3045943598324489,"score_spread":0.2782271984316882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263044871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98074496,0.004171685,0.006462563,0.000243989,0.00009570369,0.0007392682,0.0015050289,0.0001703451,0.005866334],"genre_scores_gemma":[0.9777989,0.0050680917,0.006069467,0.00019859702,0.000025790017,0.00053587736,0.0027934236,0.00002663813,0.0074833813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993277,0.000013836606,0.0000039604333,0.000009431661,0.000021693677,0.00001833848],"domain_scores_gemma":[0.9999267,0.000007696669,0.000018235995,0.0000052185705,0.000012758744,0.00002940384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002830766,0.00036181023,0.00023889609,0.00029624987,0.000087803484,0.0001815027,0.0002691913,0.00028000507,0.0023567136],"category_scores_gemma":[0.0000937915,0.00014726752,0.00021303396,0.00013032378,0.00015421199,0.00018242888,0.00013757577,0.0006401294,0.0004417365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015885043,0.0019257544,0.00040593656,0.00033856125,0.000033749246,0.0001888488,0.000033549706,0.0010723857,0.9730306,0.00046208277,0.0008400263,0.02007988],"study_design_scores_gemma":[0.0013877153,0.057004254,0.006319788,0.00007848199,0.00015807903,0.0011362028,0.000057542107,0.0022750979,0.887916,0.00024511045,0.04339873,0.000023064578],"about_ca_topic_score_codex":0.00046432987,"about_ca_topic_score_gemma":0.00083485356,"teacher_disagreement_score":0.0023567136,"about_ca_system_score_codex":0.00022117123,"about_ca_system_score_gemma":0.00034325107,"threshold_uncertainty_score":0.007883966},"labels":[],"label_agreement":null},{"id":"W2263916211","doi":"","title":"Role of human CEACAM5 and CEACAM6 in murine lung tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carcinogenesis; Carcinoembryonic antigen; Lung; Lung cancer; Cancer research; Genetically modified mouse; Transgene; Biology; Medicine; Internal medicine; Cancer; Immunology; Endocrinology; Gene; Genetics","score_opus":0.022325963629060044,"score_gpt":0.3551653968554965,"score_spread":0.33283943322643644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263916211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984634,0.007836871,0.0032160352,0.0002047438,0.000031137915,0.000033963774,0.0004806107,0.00010266575,0.0034599847],"genre_scores_gemma":[0.9924446,0.0015755079,0.0016081693,0.000057294827,0.000010849254,0.000021049545,0.0005432282,0.000021916157,0.0037174278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976367,0.000058235437,0.000015209059,0.00003792333,0.0000662742,0.000058702484],"domain_scores_gemma":[0.9998011,0.000032842458,0.00004541025,0.000027197693,0.0000149607085,0.000078444136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025990378,0.00026889346,0.00020094264,0.0005865112,0.00014240238,0.0002627253,0.00018460125,0.00037635866,0.0017285658],"category_scores_gemma":[0.0001644319,0.00018642492,0.00023607798,0.000108014334,0.0002017257,0.00019749341,0.00023029342,0.00034693742,0.0005029735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027625397,0.00004234985,0.00061441195,0.000022766471,0.0000051424627,0.000080985476,0.000010751575,0.00005599603,0.99640936,0.00025601537,0.00004094187,0.0021850038],"study_design_scores_gemma":[0.000021668591,0.00096819666,0.008366848,0.000010397299,0.00002066685,0.0011117461,0.000027610082,0.00081835664,0.9843277,0.00012574212,0.0041952576,0.0000057204534],"about_ca_topic_score_codex":0.00072275096,"about_ca_topic_score_gemma":0.00071959605,"teacher_disagreement_score":0.0017285658,"about_ca_system_score_codex":0.00030967494,"about_ca_system_score_gemma":0.00017120222,"threshold_uncertainty_score":0.005782604},"labels":[],"label_agreement":null},{"id":"W2264190290","doi":"","title":"Pharmacokinetics of ARRY-543 from a Phase 1 study in cancer patients","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pharmacokinetics; Dosing; Medicine; Pharmacology; Animal science; Chemistry; Internal medicine; Biology","score_opus":0.032733211282353625,"score_gpt":0.412456535462635,"score_spread":0.3797233241802814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264190290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955776,0.0014076452,0.0005853822,0.00016522522,0.00002590524,0.00059862185,0.00068520335,0.00009465681,0.0008598434],"genre_scores_gemma":[0.9916495,0.0010300463,0.0016827094,0.00048761745,0.000066637294,0.0007187914,0.0028588534,0.000042518357,0.0014633692],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953115,0.00017935624,0.000026262067,0.00010692123,0.00008607091,0.00007031613],"domain_scores_gemma":[0.9994355,0.00011955653,0.00014075653,0.000059282498,0.00006662502,0.00017830713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015296807,0.00076358294,0.001397235,0.00040444854,0.00052246655,0.00062293455,0.00046625768,0.0007615359,0.002842349],"category_scores_gemma":[0.0012430282,0.0004214425,0.00067591015,0.00044722293,0.00048523562,0.00044596219,0.0002804336,0.001857142,0.00079397],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31830513,0.029851466,0.058302995,0.0011591833,0.0021935783,0.0017498607,0.0011023779,0.006132542,0.35228592,0.00032398678,0.015261763,0.21333115],"study_design_scores_gemma":[0.093541935,0.66446924,0.18247604,0.00008355797,0.0015893345,0.0045757536,0.00016776563,0.0045263967,0.030243734,0.00030628635,0.017860934,0.00015902585],"about_ca_topic_score_codex":0.00090332027,"about_ca_topic_score_gemma":0.0012377877,"teacher_disagreement_score":0.002842349,"about_ca_system_score_codex":0.0008045393,"about_ca_system_score_gemma":0.0010832703,"threshold_uncertainty_score":0.00950855},"labels":[],"label_agreement":null},{"id":"W2265903980","doi":"10.1158/1535-7163.223.3.3","title":"Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both<i>in vitro</i>and<i>in vivo</i>","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative","keywords":"Clusterin; Cancer research; Paclitaxel; Lung cancer; In vivo; A549 cell; Gene silencing; Apoptosis; Cancer; Small interfering RNA; Biology; Medicine; Molecular biology; Pharmacology; Cell culture; Pathology; Transfection; Internal medicine; Biochemistry","score_opus":0.016024994268128576,"score_gpt":0.28029237430567666,"score_spread":0.26426738003754807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265903980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98979086,0.0028441031,0.0029906554,0.00016636228,0.00007459762,0.00011032566,0.0003800765,0.00018485181,0.003458216],"genre_scores_gemma":[0.988627,0.0019248924,0.0040520695,0.00007631717,0.000013970374,0.00010421556,0.00070982,0.000027644648,0.0044640973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999312,0.000009353778,0.0000062780446,0.000017601218,0.000023002556,0.000012511618],"domain_scores_gemma":[0.99996626,0.0000058774904,0.000009138935,0.0000046504847,0.000006474625,0.0000075872167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083627114,0.0003056565,0.00020821477,0.00015406134,0.00013798698,0.00016358648,0.0001423337,0.00024076633,0.0011971422],"category_scores_gemma":[0.0000664228,0.00009206392,0.00014996447,0.00012791654,0.00013325905,0.00010582037,0.00009150063,0.00031764383,0.00030880346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007229439,0.000027994109,0.000050339975,0.000034348006,0.00000356467,0.000010217886,0.0000062300414,0.00007398699,0.9986337,0.000026977237,0.0000786056,0.0009817654],"study_design_scores_gemma":[0.000018777528,0.0004322169,0.0011594584,0.0000031906804,0.000013502018,0.000066571294,0.000008628709,0.00043802173,0.9960824,0.000010194678,0.0017647091,0.0000021960325],"about_ca_topic_score_codex":0.0011808859,"about_ca_topic_score_gemma":0.0026237397,"teacher_disagreement_score":0.0011971422,"about_ca_system_score_codex":0.00029176645,"about_ca_system_score_gemma":0.00022697714,"threshold_uncertainty_score":0.0040047765},"labels":[],"label_agreement":null},{"id":"W2266099825","doi":"","title":"Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Cancer; Breast cancer; DNA repair; BRCA2 Protein; Biology; Ovarian cancer; Gene; Genetics; Synthetic lethality; Cancer research; Allele; Homologous recombination; Mutation; Prostate cancer; Germline mutation","score_opus":0.08739391783872785,"score_gpt":0.31216636897644845,"score_spread":0.2247724511377206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266099825","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058960687,0.7003656,0.018245488,0.0084002195,0.005732769,0.0008013004,0.0039293896,0.0016588735,0.20190567],"genre_scores_gemma":[0.19014354,0.5342673,0.012750408,0.0048425626,0.0013765629,0.00059671,0.0052421046,0.00022062128,0.25056013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987626,0.000012604606,0.0000050499434,0.000013761577,0.0000731834,0.000019197361],"domain_scores_gemma":[0.9999403,0.000010968727,0.000009624674,0.0000040411383,0.000015120194,0.00001993672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002066521,0.0004846377,0.00029946584,0.0009129142,0.0002221133,0.00038252614,0.0005498278,0.0005936105,0.01747797],"category_scores_gemma":[0.00017585588,0.00012283624,0.0002804908,0.00052083936,0.0002475652,0.00028438313,0.0004728876,0.0012159791,0.0045945547],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077402644,0.00052963424,0.00063631614,0.0021011485,0.000057059817,0.0010936795,0.00011083266,0.00063516543,0.16550256,0.008664928,0.12009589,0.69979876],"study_design_scores_gemma":[0.00017543983,0.0010207023,0.002614517,0.00025806806,0.00003277227,0.0030817396,0.00004212226,0.00035403032,0.046930637,0.0014679076,0.94399863,0.000023474282],"about_ca_topic_score_codex":0.0008648303,"about_ca_topic_score_gemma":0.0028591226,"teacher_disagreement_score":0.01747797,"about_ca_system_score_codex":0.0005206443,"about_ca_system_score_gemma":0.0003583649,"threshold_uncertainty_score":0.058469594},"labels":[],"label_agreement":null},{"id":"W2266877858","doi":"","title":"Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Propidium iodide; Melanoma; In vivo; Doxorubicin; In vitro; Apoptosis; Cancer research; Annexin; Pharmacology; MTT assay; Medicine; Chemistry; Chemotherapy; Molecular biology; Biology; Programmed cell death; Biochemistry; Internal medicine","score_opus":0.006366709458148614,"score_gpt":0.2506000983877784,"score_spread":0.2442333889296298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266877858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896248,0.0035726754,0.0017801882,0.00009763551,0.00007056534,0.00008583932,0.00021982432,0.00011101825,0.0044375146],"genre_scores_gemma":[0.995112,0.000930154,0.0018742712,0.000038640956,0.000014804168,0.000037059286,0.0001713323,0.000012685835,0.0018090648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999404,0.000013462796,0.0000043240707,0.000015562582,0.00001180132,0.000014508827],"domain_scores_gemma":[0.9999654,0.000008492266,0.000006529758,0.0000037893185,0.0000044812464,0.000011220026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008194026,0.0002949498,0.0001991704,0.00022266376,0.00006980311,0.00016016478,0.00010148825,0.00016829533,0.0013575093],"category_scores_gemma":[0.000075606404,0.00006747658,0.00010608022,0.00009484008,0.000086953514,0.0001087898,0.00011395481,0.0002444518,0.00021247003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020033395,0.000087258646,0.00022988276,0.00005369649,0.000008706003,0.000032268003,0.000012039287,0.0001140227,0.9920799,0.00008987592,0.00012790522,0.0069640656],"study_design_scores_gemma":[0.00009038559,0.0041157184,0.005420251,0.000012293993,0.000051599665,0.00046427565,0.000023517474,0.0014245053,0.98070186,0.000048406506,0.0076416903,0.0000054932084],"about_ca_topic_score_codex":0.00029078173,"about_ca_topic_score_gemma":0.0005736109,"teacher_disagreement_score":0.0013575093,"about_ca_system_score_codex":0.00012627248,"about_ca_system_score_gemma":0.00008784678,"threshold_uncertainty_score":0.004541278},"labels":[],"label_agreement":null},{"id":"W2268021342","doi":"","title":"Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration via ERK parthway and proteins involved in focal complexes","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Tissue factor pathway inhibitor; Endothelial stem cell; Cell biology; Focal adhesion; Tissue factor; Biology; Angiogenesis; Cell adhesion; Molecular biology; Chemistry; Cell; Phosphorylation; Biochemistry; Coagulation; Cancer research; In vitro; Internal medicine","score_opus":0.029682458290878577,"score_gpt":0.28060840924240793,"score_spread":0.25092595095152936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268021342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98409986,0.006347272,0.0056261183,0.00020458082,0.00006238268,0.000057695535,0.0005795199,0.00013543777,0.0028870902],"genre_scores_gemma":[0.9889719,0.0027090681,0.0033311732,0.00006527322,0.00001975031,0.000105984866,0.0008634907,0.000016648457,0.0039165895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990666,0.000017429758,0.000008742153,0.000014106502,0.000021161974,0.00003188483],"domain_scores_gemma":[0.9999628,0.000008561314,0.000010446445,0.000003817255,0.0000042517236,0.000010063316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010897534,0.00041232732,0.00017671582,0.00018434144,0.0001270623,0.0001739472,0.00016663308,0.00018043013,0.0023124162],"category_scores_gemma":[0.00012488953,0.00008413786,0.00025316942,0.0001443321,0.00013747925,0.000136763,0.000109770685,0.000427157,0.00036590992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002505784,0.000059599377,0.00006549957,0.00006905319,0.000008242958,0.00003564354,0.000006546438,0.000046399266,0.99768794,0.00006809007,0.000071285,0.0016312003],"study_design_scores_gemma":[0.00003348046,0.00035031806,0.0026591665,0.0000061121846,0.000015186518,0.00019673114,0.000008836365,0.00086685654,0.9941083,0.000046447258,0.0017062477,0.0000022631632],"about_ca_topic_score_codex":0.0005589446,"about_ca_topic_score_gemma":0.00059967814,"teacher_disagreement_score":0.0023124162,"about_ca_system_score_codex":0.00026203287,"about_ca_system_score_gemma":0.00027912282,"threshold_uncertainty_score":0.0077358484},"labels":[],"label_agreement":null},{"id":"W2268487266","doi":"","title":"Classification of anticancer drugs based on tissue penetration using a novel in vitro screening assay","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spheroid; Penetration (warfare); Drug; Tissue culture; In vivo; Cancer research; In vitro; Pharmacology; Biology; Biochemistry; Genetics","score_opus":0.05429729239070638,"score_gpt":0.3505192375143022,"score_spread":0.2962219451235958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268487266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76227474,0.025497599,0.16873671,0.0008228711,0.000686449,0.002806903,0.009351888,0.0021856057,0.027637308],"genre_scores_gemma":[0.86219156,0.011203131,0.10359508,0.0004343969,0.00020873343,0.0015714451,0.0069432375,0.00010069114,0.013751716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818486,0.00047464215,0.000268347,0.00023721278,0.00069757365,0.00013745381],"domain_scores_gemma":[0.9985599,0.00040269867,0.00033118107,0.0000993495,0.00050539477,0.00010142712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008874743,0.0012065731,0.0010272479,0.0032551095,0.0003965213,0.0009967791,0.0005786165,0.0009890859,0.0026504262],"category_scores_gemma":[0.0012044574,0.00028134548,0.0011481761,0.0018522869,0.0004022081,0.00056997605,0.00050559535,0.0007366493,0.0017779692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027697702,0.0001978218,0.0024477532,0.00027613805,0.000041802723,0.000068006186,0.000040343773,0.00040088728,0.98244345,0.00013041748,0.00020132451,0.013475001],"study_design_scores_gemma":[0.000025995807,0.0026980434,0.019907685,0.00005212837,0.00024972484,0.00078983244,0.00007556836,0.0071574063,0.96160626,0.00012963465,0.007255168,0.000052633004],"about_ca_topic_score_codex":0.001280412,"about_ca_topic_score_gemma":0.0013700208,"teacher_disagreement_score":0.0032551095,"about_ca_system_score_codex":0.0004076693,"about_ca_system_score_gemma":0.0003498426,"threshold_uncertainty_score":0.008866608},"labels":[],"label_agreement":null},{"id":"W2269231033","doi":"","title":"Toxicology and pharmacokinetics of chimeric ARH460-16-2, a therapeutic monoclonal antibody targeting CD44","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Monoclonal antibody; Prostate; Cancer; Biology; Antibody; CD44; Medicine; Colorectal cancer; Pathology; Cancer research; Immunology; Internal medicine; In vitro","score_opus":0.02094923130325893,"score_gpt":0.3477244181047692,"score_spread":0.32677518680151024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269231033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074686,0.0025429258,0.0030360247,0.00016376108,0.00007324421,0.00016839977,0.0007281211,0.00018331909,0.0023574547],"genre_scores_gemma":[0.99141604,0.0019025339,0.0015075764,0.00013070925,0.0000740669,0.00017702879,0.00093843037,0.00008647471,0.0037671877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983025,0.00004885439,0.0000054975335,0.00003726918,0.000035148383,0.00004299084],"domain_scores_gemma":[0.999785,0.00004098947,0.000047787555,0.00003115752,0.000036276513,0.0000588945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035946665,0.0004592805,0.00051447115,0.00032178577,0.00018376092,0.00048784085,0.00024575813,0.0004377396,0.0010178307],"category_scores_gemma":[0.000427304,0.0003120105,0.0003919977,0.00024565787,0.0003044237,0.0003986932,0.00011693596,0.0010272699,0.00053802994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013134773,0.0031168305,0.0029791591,0.00017319516,0.00014112299,0.00030738232,0.00025142828,0.00251112,0.9379059,0.00035222035,0.001847776,0.03727907],"study_design_scores_gemma":[0.0013321176,0.12281508,0.033438284,0.000052754647,0.00065407524,0.0019258572,0.00027691407,0.018400807,0.79610455,0.00057481445,0.02432419,0.00010048856],"about_ca_topic_score_codex":0.0016400669,"about_ca_topic_score_gemma":0.0014026306,"teacher_disagreement_score":0.0016400669,"about_ca_system_score_codex":0.00046315845,"about_ca_system_score_gemma":0.0005312043,"threshold_uncertainty_score":0.0034050345},"labels":[],"label_agreement":null},{"id":"W2269888391","doi":"","title":"Intrinsic resistance of prostate cancer to the BH3 mimetic ABT-737 is related to expression of the anti-apoptotic Mcl-1 and additional survival and apoptosis regulating pathways","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"DU145; LNCaP; Apoptosis; Cytotoxic T cell; Viability assay; Cytotoxicity; Cancer research; Prostate cancer; Pharmacology; Chemistry; Cell culture; Cancer; Biology; In vitro; Medicine; Internal medicine; Biochemistry","score_opus":0.016595383567970697,"score_gpt":0.26639896176410943,"score_spread":0.24980357819613874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269888391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102074,0.0041919313,0.0017892448,0.00013162964,0.000023442539,0.000037353795,0.00053118385,0.00013413483,0.0021403215],"genre_scores_gemma":[0.9956583,0.0013148303,0.00073165837,0.000043049196,0.000008565189,0.000021082331,0.00058818614,0.000010052519,0.0016242476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989235,0.00000892543,0.0000050455624,0.000015037001,0.000047434645,0.000031242816],"domain_scores_gemma":[0.99992454,0.000010177938,0.000016598533,0.0000079251195,0.000016534326,0.000024200639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060198494,0.00020536708,0.00019610598,0.00024201398,0.00019083609,0.00022911819,0.00017765364,0.000165881,0.0021870055],"category_scores_gemma":[0.00007555574,0.00008893231,0.00022018839,0.00025260088,0.0001688613,0.00011188596,0.000113497816,0.00053338544,0.00047696463],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014592416,0.000071893584,0.00072209357,0.00006644581,0.000011728494,0.00010804111,0.00001161332,0.00009082975,0.9952295,0.00008041738,0.00013369534,0.0033279131],"study_design_scores_gemma":[0.000017265207,0.0008674284,0.013272508,0.000006144714,0.00003353926,0.0012237829,0.000037179358,0.0005050758,0.98038495,0.00006572037,0.0035787837,0.000007557997],"about_ca_topic_score_codex":0.0014970218,"about_ca_topic_score_gemma":0.0026030925,"teacher_disagreement_score":0.0021870055,"about_ca_system_score_codex":0.0003703421,"about_ca_system_score_gemma":0.00046989095,"threshold_uncertainty_score":0.0073162913},"labels":[],"label_agreement":null},{"id":"W2270912873","doi":"","title":"Low BRCA1 and ERCC1 mRNA expression correlates with improved survival in ovarian cancer patients","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ERCC1; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Stage (stratigraphy); Medicine; Biology; Cisplatin; Cancer; Survival analysis; Cancer research; Nucleotide excision repair; DNA repair; Gene","score_opus":0.012970336250718879,"score_gpt":0.2731652375159512,"score_spread":0.2601949012652323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270912873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993905,0.00030690408,0.000029521587,0.000030115505,0.0000020710177,0.0000017271817,0.00008623544,0.0000025056424,0.00015045078],"genre_scores_gemma":[0.99955946,0.00008748578,0.000028917097,0.000011189254,0.0000035735661,0.00000213879,0.00014308236,6.88036e-7,0.000163478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999237,0.0000118020125,0.000007307637,0.000020053778,0.00001768211,0.000019574816],"domain_scores_gemma":[0.99962795,0.00006546647,0.00018031229,0.000016320591,0.000046462763,0.00006341549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001311942,0.00010511998,0.00017469669,0.00041690623,0.00019112982,0.00026443947,0.00011715494,0.00016457857,0.0009942501],"category_scores_gemma":[0.00063823053,0.000093650204,0.00010027979,0.00034284522,0.00021313514,0.0001445573,0.00010612251,0.00024123395,0.00013090679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032532727,0.000014216393,0.9927735,0.000012619241,0.000020486466,0.00013610999,0.000059762904,0.000056305107,0.0038101648,0.000010389733,0.00015218204,0.0026289572],"study_design_scores_gemma":[0.0000054184165,0.000061126884,0.9985941,0.0000025595325,0.000018082586,0.00038989648,0.000061890554,0.00009309596,0.00056151603,0.000010432066,0.00020029949,0.0000015486183],"about_ca_topic_score_codex":0.0034058627,"about_ca_topic_score_gemma":0.0059902505,"teacher_disagreement_score":0.0034058627,"about_ca_system_score_codex":0.00036144292,"about_ca_system_score_gemma":0.00019989983,"threshold_uncertainty_score":0.006772101},"labels":[],"label_agreement":null},{"id":"W2271878792","doi":"","title":"Identification and characterization of an antibody to the CD9 tetraspanin: Therapeutic implications for cancer treatment.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Biology; Antibody; Tetraspanin; Cancer research; Cytotoxicity; Pancreatic cancer; Cancer; Epitope; Cancer cell; Molecular biology; Flow cytometry; Monoclonal antibody; In vivo; Cell culture; In vitro; Cell; Immunology; Biochemistry","score_opus":0.04728039646817933,"score_gpt":0.39538664588847505,"score_spread":0.3481062494202957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271878792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943198,0.015226892,0.028404009,0.0011038595,0.00028094364,0.0007912625,0.0013832804,0.0002834051,0.009328305],"genre_scores_gemma":[0.94186544,0.008224329,0.030985873,0.0008449237,0.00014273441,0.00042565347,0.0056398343,0.000060154987,0.011811142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999861,0.000023854871,0.000010163576,0.000028437553,0.000037940445,0.00003869938],"domain_scores_gemma":[0.99989724,0.000015121229,0.000015567995,0.00000822785,0.00003520881,0.000028594575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002616831,0.00044512545,0.00023535607,0.0003822857,0.00019796116,0.000265619,0.00043234433,0.00065366074,0.002384026],"category_scores_gemma":[0.00025359532,0.00014317998,0.0003540436,0.00021886178,0.00012529068,0.00024843443,0.00020558594,0.00056637503,0.0011131947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014856248,0.000160523,0.0002574883,0.000064667605,0.000012922549,0.00008486894,0.000011203452,0.00017109142,0.98325574,0.00020227997,0.0004747658,0.015155952],"study_design_scores_gemma":[0.00022270763,0.0037738795,0.008624124,0.00004092388,0.000118761425,0.0024991098,0.00003250289,0.0041519804,0.92222345,0.0004052237,0.057887405,0.000019961451],"about_ca_topic_score_codex":0.00073855,"about_ca_topic_score_gemma":0.00074140204,"teacher_disagreement_score":0.002384026,"about_ca_system_score_codex":0.0005787354,"about_ca_system_score_gemma":0.0004006426,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2275335512","doi":"10.1158/1538-8514.tumang15-b02","title":"Abstract B02: Ultrasound evaluation of anti-angiogenic therapy on patient-derived renal cell carcinoma xenograft tumors in the chicken embryo model","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Matrigel; Medicine; Ultrasound; Chorioallantoic membrane; Angiogenesis; In ovo; Pathology; Urology; Embryo; Cancer research; Radiology; Biology","score_opus":0.08660705833989239,"score_gpt":0.3308428850847941,"score_spread":0.24423582674490169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275335512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452747,0.0019477687,0.0092068575,0.000063913554,0.00004539443,0.0001538861,0.00084871036,0.00017509068,0.0030310005],"genre_scores_gemma":[0.9744455,0.0017763942,0.015579108,0.00005105818,0.0000126432715,0.00018446668,0.0019200285,0.00005624381,0.0059745037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998859,0.000024836958,0.000012966356,0.000025068404,0.00003566583,0.000015587711],"domain_scores_gemma":[0.9998888,0.00003449885,0.000016646956,0.000012716474,0.000026702768,0.000020649812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003056288,0.00034705157,0.00017711816,0.00025855456,0.00009704717,0.00013842834,0.00016096934,0.00027611395,0.0023490677],"category_scores_gemma":[0.000117575844,0.00011247591,0.0001553933,0.00014389827,0.00012489798,0.00012431458,0.00008426399,0.00027301378,0.00039788484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002099133,0.000052866217,0.00019125787,0.00004752243,0.000003272968,0.00004594209,0.000017747712,0.000072338284,0.99801636,0.000035388362,0.00007789595,0.001229568],"study_design_scores_gemma":[0.000020628418,0.0014714304,0.0034321535,0.00000638567,0.000019814239,0.00022800014,0.000020079888,0.000893721,0.99237543,0.000009268971,0.0015183543,0.0000048490288],"about_ca_topic_score_codex":0.0017873879,"about_ca_topic_score_gemma":0.0015015447,"teacher_disagreement_score":0.0023490677,"about_ca_system_score_codex":0.00017269303,"about_ca_system_score_gemma":0.00019053082,"threshold_uncertainty_score":0.007858455},"labels":[],"label_agreement":null},{"id":"W2275754697","doi":"","title":"High-throughput screening for compounds toxic to human leukemic cells derived from lineage-depleted cord blood cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Leukemia; Haematopoiesis; Stem cell; Cancer research; Cancer cell; Biology; Cancer stem cell; Progenitor cell; Population; Cord blood; Cancer; Cell culture; Immunology; Cell biology; Medicine; Genetics","score_opus":0.0304658265468354,"score_gpt":0.29905569904048346,"score_spread":0.2685898724936481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275754697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465669,0.0065216008,0.03143341,0.00040785648,0.00007058693,0.0010769881,0.006150071,0.0010847185,0.0066878987],"genre_scores_gemma":[0.94510996,0.008268463,0.025670836,0.0003905289,0.00002811607,0.0006428272,0.010781251,0.00013625332,0.008971854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999716,0.00004742786,0.000025037814,0.000053770134,0.00012382124,0.000033979897],"domain_scores_gemma":[0.9998895,0.000031909774,0.000016245838,0.000011927383,0.000027948781,0.000022520853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027080585,0.00081725226,0.0006823852,0.00070415327,0.0002018059,0.00047692625,0.00038609045,0.00044232875,0.001805231],"category_scores_gemma":[0.00029477468,0.00019817683,0.00033147956,0.00090036565,0.00017374166,0.00018327359,0.0003407659,0.0004940623,0.000774417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020628967,0.00020659128,0.0005469076,0.00014907157,0.00003344038,0.00009865544,0.000022310924,0.0007291649,0.98595077,0.00008063041,0.00028481576,0.0116913365],"study_design_scores_gemma":[0.00007124724,0.0015486176,0.0017724027,0.000013359679,0.000074968,0.00022360486,0.000022153523,0.0016526252,0.98943526,0.00006655689,0.005106655,0.000012467847],"about_ca_topic_score_codex":0.0006279333,"about_ca_topic_score_gemma":0.0011961744,"teacher_disagreement_score":0.001805231,"about_ca_system_score_codex":0.0002925344,"about_ca_system_score_gemma":0.00037422008,"threshold_uncertainty_score":0.0060390234},"labels":[],"label_agreement":null},{"id":"W2277059326","doi":"","title":"OB-24, a novel selective and potent HO-1 inhibitor, induces a wide spectrum anti-tumor activity in vitro and in vivo and synergizes with chemotherapy drugs","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer research; In vivo; Cancer; Prostate cancer; Colorectal cancer; Pharmacology; Melanoma; Cancer cell; Growth inhibition; Heme oxygenase; Biology; Medicine; In vitro; Heme; Internal medicine; Enzyme; Biochemistry","score_opus":0.007345860065743424,"score_gpt":0.23728908646897937,"score_spread":0.22994322640323595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277059326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681999,0.0212309,0.006058004,0.00019964093,0.00010594642,0.000089579706,0.0004958064,0.0003370745,0.0032831302],"genre_scores_gemma":[0.98259455,0.0090136025,0.002967202,0.00008353131,0.000044680568,0.000062048915,0.0008698822,0.00002644869,0.004338112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999461,0.0000076027736,0.0000040031186,0.000011023783,0.000016772625,0.000014437384],"domain_scores_gemma":[0.99995875,0.0000041707995,0.00001272985,0.0000042644206,0.0000048532124,0.000015110757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006827758,0.00044757134,0.00039323448,0.00030197823,0.00010411261,0.00013893271,0.00017719889,0.00017130427,0.0008700528],"category_scores_gemma":[0.00004902968,0.00011128086,0.0002489205,0.00015758525,0.00014698048,0.00013256882,0.00013233429,0.00052916084,0.00027746137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057084655,0.0002632383,0.00024685173,0.00013324743,0.000019479989,0.00007388741,0.0000090873655,0.0003126447,0.983922,0.000071287664,0.00020338589,0.014174029],"study_design_scores_gemma":[0.0000957874,0.0027266364,0.0030217515,0.000009174475,0.00003426811,0.00051520445,0.000008390325,0.0007602643,0.98388773,0.00003829218,0.008895425,0.0000070988344],"about_ca_topic_score_codex":0.00021583517,"about_ca_topic_score_gemma":0.0004797536,"teacher_disagreement_score":0.0008700528,"about_ca_system_score_codex":0.00011246936,"about_ca_system_score_gemma":0.00013540479,"threshold_uncertainty_score":0.002910614},"labels":[],"label_agreement":null},{"id":"W2278657612","doi":"10.1158/1535-7163.mct-15-0581","title":"The Role of HMGB1 in Radioresistance of Bladder Cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Radioresistance; Gene knockdown; Bladder cancer; Autophagy; Radiation therapy; Cancer research; HMGB1; In vivo; Medicine; Cancer; Radiosensitivity; Biology; Pathology; Cell culture; Internal medicine; Apoptosis; Inflammation","score_opus":0.025624099766628394,"score_gpt":0.33314411984246783,"score_spread":0.30752002007583945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278657612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9394852,0.05698841,0.0017718187,0.00037163732,0.000033374483,0.000030551266,0.00020562788,0.000059789556,0.0010535775],"genre_scores_gemma":[0.99298394,0.005623051,0.0005463448,0.00006665776,0.000011805527,0.00001858331,0.00011350714,0.0000042303736,0.0006319272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999032,0.0000311039,0.00000914665,0.000015804597,0.000020587186,0.000020072424],"domain_scores_gemma":[0.9998807,0.000019299861,0.000052268642,0.00000973632,0.000013961233,0.000024062212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023219947,0.0002378055,0.00026770963,0.0005692887,0.00019696404,0.00037992944,0.00015777846,0.00027803972,0.0005946077],"category_scores_gemma":[0.00019126035,0.00013568578,0.00025771212,0.00028123928,0.0002748844,0.00016954182,0.0002654552,0.00023475723,0.00017009495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009046753,0.00007166329,0.028519657,0.0006422233,0.000109410495,0.00043960067,0.00022082988,0.00037531625,0.94443417,0.00054388057,0.00020995829,0.02352866],"study_design_scores_gemma":[0.000034276,0.0011838208,0.3010731,0.00016736082,0.00021559163,0.0023377389,0.00045686017,0.0019632988,0.6830485,0.00063146435,0.00885278,0.00003523443],"about_ca_topic_score_codex":0.00049074745,"about_ca_topic_score_gemma":0.00046854175,"teacher_disagreement_score":0.0005946077,"about_ca_system_score_codex":0.00028292768,"about_ca_system_score_gemma":0.00018267796,"threshold_uncertainty_score":0.002052784},"labels":[],"label_agreement":null},{"id":"W2278671746","doi":"","title":"Targeted approach towards inhibition of telomere-hnRNP A1 interaction","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA and Nucleic Acid Chemistry","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"","keywords":"Telomere; Telomerase; Small molecule; DNA; Oligonucleotide; Biology; In vitro; Molecular biology; G-quadruplex; Computational biology; Biochemistry; Chemistry; Gene","score_opus":0.016234604581357986,"score_gpt":0.2819143588097175,"score_spread":0.2656797542283595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278671746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775915,0.0063905744,0.009089293,0.00019419339,0.000049524013,0.00044308236,0.001256979,0.0002556532,0.0047292802],"genre_scores_gemma":[0.9755701,0.0060225273,0.0086031,0.00026887123,0.000022962435,0.00029161156,0.001617382,0.00003664061,0.0075668953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998913,0.000015310708,0.000007805923,0.000028552522,0.000025614168,0.000031497704],"domain_scores_gemma":[0.9999484,0.000011079627,0.000011501142,0.0000054137936,0.0000086398895,0.000015117907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010620846,0.00052947795,0.0004484323,0.00043298898,0.00018118437,0.000348751,0.00042972944,0.0003132725,0.001735047],"category_scores_gemma":[0.000104232015,0.00018594702,0.0003586691,0.0003522809,0.00013564179,0.00013617896,0.00029989585,0.0005853382,0.0006057714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017692821,0.00026339683,0.00018205805,0.00016560237,0.000030278863,0.00014277504,0.000025487854,0.00091533066,0.98836213,0.00023596716,0.00022077144,0.009279296],"study_design_scores_gemma":[0.00011920111,0.0031181497,0.0019090082,0.000017666809,0.00008680927,0.00047154306,0.000029266475,0.002144547,0.98158836,0.000082479186,0.010413383,0.00001954348],"about_ca_topic_score_codex":0.00067672326,"about_ca_topic_score_gemma":0.0013227786,"teacher_disagreement_score":0.001735047,"about_ca_system_score_codex":0.0003432686,"about_ca_system_score_gemma":0.00031665328,"threshold_uncertainty_score":0.00580436},"labels":[],"label_agreement":null},{"id":"W2279192913","doi":"","title":"Vinorelbine liposomes injection results in greater tumor drug exposure compared to conventional vinorelbine in tumor-bearing nude mice","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Vinorelbine; Pharmacokinetics; Pharmacology; Liposome; Chemistry; Volume of distribution; Internal medicine; Medicine; Chemotherapy; Biochemistry","score_opus":0.026983872306910076,"score_gpt":0.3224996452426178,"score_spread":0.29551577293570774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279192913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920878,0.0010274717,0.0024128098,0.00017071878,0.000078670324,0.00010397276,0.0017847336,0.00028664467,0.0020473548],"genre_scores_gemma":[0.98103124,0.0011370304,0.0046232436,0.00011096963,0.000048394697,0.0002372711,0.0025582477,0.00012573678,0.010127869],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99962187,0.000029838906,0.000026836851,0.00014802332,0.000074124575,0.00009935589],"domain_scores_gemma":[0.99975044,0.000041226605,0.00009608125,0.00002481645,0.000018474482,0.00006902558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026964568,0.000774957,0.0005922655,0.0008158513,0.00020192159,0.0003942393,0.00038928515,0.00066221034,0.0027839337],"category_scores_gemma":[0.00013791754,0.00031743493,0.0003880363,0.00033016343,0.00037575833,0.0004632752,0.00019632505,0.0012431234,0.0005541933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005955868,0.0001785217,0.0000958717,0.00002422782,0.000008600824,0.00002418306,0.000018806933,0.000069213216,0.99784505,0.000048303038,0.000065507076,0.001026075],"study_design_scores_gemma":[0.000089326946,0.0019818929,0.0020404784,0.0000048820716,0.000026097194,0.00014083463,0.000018486526,0.0008371431,0.9937972,0.000021573996,0.0010349521,0.000007196693],"about_ca_topic_score_codex":0.0018552354,"about_ca_topic_score_gemma":0.0019426367,"teacher_disagreement_score":0.0027839337,"about_ca_system_score_codex":0.00070924987,"about_ca_system_score_gemma":0.00036242022,"threshold_uncertainty_score":0.009313166},"labels":[],"label_agreement":null},{"id":"W2279288073","doi":"10.1158/1535-7163.targ-09-cn08-01","title":"Abstract CN08-01: 3D-QSAR based design of novel inhibitors of topoisomerase II","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Quantitative structure–activity relationship; Chemistry; Steric effects; Stereochemistry; Ligand (biochemistry); Topoisomerase; Computational biology; Computational chemistry; DNA; Biology; Biochemistry","score_opus":0.02881427801376997,"score_gpt":0.2823049288345023,"score_spread":0.25349065082073235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279288073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5968859,0.0025533882,0.3618341,0.0004952217,0.00027095774,0.0011483724,0.003113271,0.001686829,0.032011937],"genre_scores_gemma":[0.90147483,0.00070710306,0.09137356,0.00012290398,0.000021104861,0.0005622668,0.0014272947,0.00006370151,0.0042473106],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998221,0.000045904144,0.000008551013,0.000024580373,0.00006771226,0.000031164323],"domain_scores_gemma":[0.9998883,0.000028336159,0.00001870867,0.000006661913,0.000045043307,0.000012877769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005451143,0.000731195,0.0009608754,0.00043690065,0.00018812719,0.0005776715,0.00059805886,0.00048911595,0.0042541344],"category_scores_gemma":[0.00038499592,0.0002843078,0.0009735461,0.0003690047,0.00018689496,0.00017500279,0.0003189806,0.0005524821,0.00052424415],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002764025,0.00025398054,0.00087265205,0.00032228522,0.00006902272,0.00017118824,0.000028618437,0.89835644,0.065971486,0.0034378434,0.0014644606,0.028775599],"study_design_scores_gemma":[0.00008411692,0.000717294,0.00044639004,0.000012588025,0.000040126397,0.00003008904,0.00001050594,0.9807124,0.014823475,0.00031779107,0.0027887127,0.000016484164],"about_ca_topic_score_codex":0.005193146,"about_ca_topic_score_gemma":0.0043049194,"teacher_disagreement_score":0.005193146,"about_ca_system_score_codex":0.0007103863,"about_ca_system_score_gemma":0.0010417551,"threshold_uncertainty_score":0.014231503},"labels":[],"label_agreement":null},{"id":"W2279294031","doi":"10.1158/1535-7163.mct-15-0714-t","title":"High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Metformin; Medicine; PTEN; Bladder cancer; Cancer; Urothelium; Drug; Cancer research; Urinary system; Pharmacology; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Insulin; Apoptosis","score_opus":0.01740349267522202,"score_gpt":0.259092171826959,"score_spread":0.24168867915173697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279294031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600923,0.00026214577,0.0024251726,0.00010409336,0.0000220713,0.000028516522,0.00039833863,0.00012760879,0.0006228967],"genre_scores_gemma":[0.9944084,0.00029358803,0.0023601726,0.000046590576,0.000007009221,0.000051302202,0.00044785664,0.000031892683,0.0023531772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996942,0.000049094655,0.000042533167,0.000053048607,0.000091195216,0.00006996529],"domain_scores_gemma":[0.9995838,0.0000654139,0.0001346573,0.00006293205,0.000027953349,0.00012521385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024248309,0.00041211492,0.00040109965,0.0005363022,0.00024425192,0.00035555114,0.00025529932,0.0004129778,0.0014822354],"category_scores_gemma":[0.00019829668,0.0002534167,0.00040862567,0.0003481921,0.0003596336,0.00024950807,0.00023940297,0.00082241575,0.00034726536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018506857,0.00008631582,0.00035589645,0.00001274372,0.0000047930394,0.000064626794,0.000017601787,0.000056120356,0.9986749,0.000061107006,0.00003152327,0.0004492312],"study_design_scores_gemma":[0.0000151215045,0.00100812,0.005803859,0.000003657858,0.000014942724,0.0005586839,0.000044371172,0.0014448869,0.99027455,0.00006374519,0.0007603508,0.000007681988],"about_ca_topic_score_codex":0.001338931,"about_ca_topic_score_gemma":0.0016139216,"teacher_disagreement_score":0.0014822354,"about_ca_system_score_codex":0.0003780334,"about_ca_system_score_gemma":0.00027930943,"threshold_uncertainty_score":0.0049586296},"labels":[],"label_agreement":null},{"id":"W2281114779","doi":"10.1158/1535-7163.823.3.7","title":"Role of the transcription factor Ets-1 in cisplatin resistance","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Transcription factor; Cisplatin; Biology; Genetics; Cancer research; Gene","score_opus":0.01929336701741016,"score_gpt":0.2754516404099668,"score_spread":0.25615827339255665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281114779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871063,0.007175274,0.0029016302,0.00040163443,0.000029566254,0.000022312564,0.00025998303,0.00007873875,0.0020245982],"genre_scores_gemma":[0.9957137,0.0017283554,0.00054879085,0.000054129603,0.0000078900375,0.000007792369,0.00028643382,0.0000084145595,0.0016445538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999882,0.000021237085,0.0000076791675,0.000020736345,0.000036723206,0.000031676856],"domain_scores_gemma":[0.99988115,0.000033645225,0.000030285337,0.000013040824,0.00002222675,0.000019714133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014986684,0.00024314102,0.0002066994,0.00026600953,0.00015760916,0.00033132127,0.00015185785,0.0002942872,0.0011304202],"category_scores_gemma":[0.00022361733,0.0001222163,0.00020959612,0.00013038145,0.00023562192,0.00020646381,0.00020091604,0.0004232888,0.00033211568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011488745,0.000023581435,0.0021837316,0.000035255496,0.0000064387873,0.0001633584,0.000033131444,0.00023477263,0.9930155,0.00026488365,0.000087236054,0.0038371312],"study_design_scores_gemma":[0.0000190371,0.0003069679,0.04738959,0.000022730253,0.000035526387,0.0011380132,0.00013790811,0.002570842,0.94148916,0.00045178432,0.006423597,0.000014794696],"about_ca_topic_score_codex":0.000396703,"about_ca_topic_score_gemma":0.0004265566,"teacher_disagreement_score":0.0011304202,"about_ca_system_score_codex":0.00037684353,"about_ca_system_score_gemma":0.00016484006,"threshold_uncertainty_score":0.0037816763},"labels":[],"label_agreement":null},{"id":"W2281508145","doi":"","title":"Novel strategy for targeted photodynamic therapy of breast cancer using a chlorin e6 conjugated-aptamer","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Aptamer; Systematic evolution of ligands by exponential enrichment; MUC1; Oligonucleotide; Cancer research; Cancer; Breast cancer; Photodynamic therapy; Cancer cell; Biology; Molecular biology; Chemistry; Antigen; Immunology; DNA; Biochemistry; Gene","score_opus":0.031668987847209625,"score_gpt":0.3352866331948813,"score_spread":0.30361764534767166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281508145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92695445,0.0039537977,0.06130975,0.0005654937,0.00010445739,0.00034437768,0.0001843409,0.00041647456,0.0061668465],"genre_scores_gemma":[0.955115,0.0015385244,0.036988106,0.00035683753,0.000020292986,0.0001254461,0.00015049658,0.000037473026,0.0056677638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998915,0.000015345797,0.0000073506453,0.000026668078,0.00003973047,0.000019352248],"domain_scores_gemma":[0.9999571,0.000008972788,0.000011730901,0.000004966556,0.0000060354073,0.000011239575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108569584,0.0003507202,0.00026270127,0.00020060247,0.00012820314,0.000275387,0.00030241036,0.0005897313,0.0006287367],"category_scores_gemma":[0.00008157757,0.0001698763,0.00020038188,0.00014356687,0.00019692817,0.00017236764,0.00024859366,0.00056474336,0.00039795655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032485164,0.000026131978,0.00003954227,0.00003360469,0.0000030023573,0.000054140677,0.0000120528575,0.00020447097,0.99699223,0.00012351417,0.000046269026,0.0024326532],"study_design_scores_gemma":[0.000015992904,0.00012409361,0.00023190792,0.000002288527,0.000005230114,0.00034897937,0.00000491613,0.0010971383,0.9961528,0.00002175456,0.0019889812,0.000005812449],"about_ca_topic_score_codex":0.00033642192,"about_ca_topic_score_gemma":0.00036942036,"teacher_disagreement_score":0.0006287367,"about_ca_system_score_codex":0.0003314685,"about_ca_system_score_gemma":0.00016424654,"threshold_uncertainty_score":0.0024049282},"labels":[],"label_agreement":null},{"id":"W2282235435","doi":"","title":"A new brain delivery system for therapeutic molecules to treat brain primary or metastatic tumors","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada); Université du Québec à Montréal","funders":"","keywords":"Paclitaxel; In vivo; Blood–brain barrier; Pharmacology; Brain tumor; Drug delivery; Medicine; P-glycoprotein; In vitro; Glioma; Cytotoxicity; Monoclonal antibody; Pharmacokinetics; Parenchyma; Cancer research; Cancer; Chemistry; Pathology; Immunology; Antibody; Central nervous system; Drug resistance; Internal medicine; Biology; Multiple drug resistance","score_opus":0.028217966232193838,"score_gpt":0.2905396133293675,"score_spread":0.26232164709717365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282235435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6943802,0.045165114,0.22372681,0.0028482983,0.0010880765,0.0013485688,0.0016592317,0.0025603035,0.027223391],"genre_scores_gemma":[0.8467253,0.01682098,0.100434475,0.0015510008,0.00024619908,0.0009953154,0.0014805595,0.00021009837,0.03153612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999151,0.000009683816,0.0000041610188,0.000025712186,0.000030936182,0.000014269708],"domain_scores_gemma":[0.99996054,0.0000075205585,0.000008867369,0.0000031371678,0.000010547024,0.000009529671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014716855,0.00038963376,0.00020420429,0.00042978206,0.00022742794,0.00043280327,0.00029351187,0.00047882597,0.0020215318],"category_scores_gemma":[0.000104458384,0.0001231987,0.0002629398,0.00017926883,0.00018794826,0.00046742026,0.00024114357,0.00063552946,0.0011750158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078756726,0.000060646897,0.00008313721,0.00015024701,0.000012119261,0.00019029553,0.000022319917,0.00014100423,0.96955174,0.0007137955,0.0010662846,0.02792971],"study_design_scores_gemma":[0.00009571171,0.0009395348,0.0014373766,0.000041348205,0.000070675494,0.0020667107,0.000021036685,0.0035527705,0.9217253,0.00030369958,0.06971456,0.00003137382],"about_ca_topic_score_codex":0.0007621926,"about_ca_topic_score_gemma":0.00091740704,"teacher_disagreement_score":0.0020215318,"about_ca_system_score_codex":0.00046127528,"about_ca_system_score_gemma":0.00036044122,"threshold_uncertainty_score":0.0067626834},"labels":[],"label_agreement":null},{"id":"W2282899483","doi":"10.1158/1535-7163.mct-15-0862","title":"<i>In Vitro</i> and <i>In Vivo</i> Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Free Radicals and Antioxidants","field":"Chemistry","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Waterloo","funders":"Canadian Institutes of Health Research; Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"In vivo; Radiation therapy; Cancer; Cancer research; In vitro; Medicine; Ovarian cancer; Cancer cell; Head and neck cancer; Lung cancer; Radiosensitizer; Pharmacology; Oncology; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.02413943694141593,"score_gpt":0.31119714807880317,"score_spread":0.2870577111373872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282899483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.795738,0.093563385,0.043546986,0.0037819303,0.0012115365,0.00084507646,0.0027318792,0.0005905078,0.057990775],"genre_scores_gemma":[0.93096125,0.032080796,0.017080477,0.0011459526,0.0005857899,0.00041293012,0.0024189367,0.00017082461,0.015143161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994504,0.0002977741,0.000027490858,0.00007681181,0.000079793834,0.00006764798],"domain_scores_gemma":[0.9995727,0.00016448792,0.00008138162,0.00006193224,0.00007350639,0.00004594139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012955181,0.0006266049,0.00041901134,0.00065893447,0.0003482042,0.0004931631,0.00039002768,0.00046249072,0.007231826],"category_scores_gemma":[0.00051791186,0.00026932172,0.00053459225,0.00030077802,0.0004943603,0.0004483282,0.00019554357,0.0011531903,0.0014319017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004527075,0.0003667471,0.00023723241,0.0005203783,0.000032334527,0.00006044498,0.000048764072,0.0004947202,0.9886529,0.0013595343,0.0009549176,0.0068193916],"study_design_scores_gemma":[0.000073554475,0.0033140671,0.0010894014,0.000035554513,0.000046318168,0.00024938514,0.000020693284,0.00041121125,0.98354536,0.00018558338,0.011021772,0.0000072363136],"about_ca_topic_score_codex":0.0012807425,"about_ca_topic_score_gemma":0.0010001508,"teacher_disagreement_score":0.007231826,"about_ca_system_score_codex":0.00064798683,"about_ca_system_score_gemma":0.00041990858,"threshold_uncertainty_score":0.02419287},"labels":[],"label_agreement":null},{"id":"W2283778444","doi":"","title":"A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vinorelbine; Pharmacokinetics; Medicine; Pharmacology; Lymphoma; Drug; In vivo; Paclitaxel; Internal medicine; Oncology; Cancer; Chemotherapy; Biology","score_opus":0.0105058140867031,"score_gpt":0.3312848075388701,"score_spread":0.320778993452167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283778444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965501,0.00059473555,0.00044465216,0.0001345905,0.00002907478,0.0012053944,0.0002924872,0.000035343885,0.0007136575],"genre_scores_gemma":[0.99578875,0.0005596882,0.0009094756,0.0002085083,0.00005677713,0.0008288004,0.000640414,0.000011094419,0.0009965344],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996674,0.0001226183,0.000016822472,0.000075455384,0.00004026387,0.000077397766],"domain_scores_gemma":[0.9995401,0.0000828082,0.00007109775,0.000045071527,0.00003545524,0.00022540064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011659364,0.00088234566,0.0012452507,0.00036638218,0.0003629373,0.00065114105,0.00047600653,0.000664414,0.001857729],"category_scores_gemma":[0.0006208958,0.0005525179,0.00069655717,0.00028054192,0.00082621473,0.0006495549,0.0002506772,0.0018680488,0.00059870956],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.434206,0.19447015,0.026376422,0.00067036325,0.0010417048,0.0008988324,0.001184024,0.0033305872,0.21676798,0.0005634908,0.00334055,0.11714983],"study_design_scores_gemma":[0.12935477,0.8197331,0.03434074,0.000017043356,0.00028673687,0.0006159482,0.000118943404,0.001489159,0.010184764,0.00013247158,0.0036912055,0.000035152094],"about_ca_topic_score_codex":0.00087487017,"about_ca_topic_score_gemma":0.0011993273,"teacher_disagreement_score":0.001857729,"about_ca_system_score_codex":0.00076667697,"about_ca_system_score_gemma":0.0010713679,"threshold_uncertainty_score":0.006214738},"labels":[],"label_agreement":null},{"id":"W2291176625","doi":"10.1158/1535-7163.mct-15-0730","title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Venetoclax; Multiple myeloma; Bortezomib; Cancer research; Bcl-xL; Lenalidomide; Medicine; Pharmacology; Biology; Leukemia; Apoptosis; Immunology; Programmed cell death; Chronic lymphocytic leukemia; Genetics","score_opus":0.05085372977947655,"score_gpt":0.3446252469714147,"score_spread":0.29377151719193817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291176625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974087,0.0008281919,0.0007934115,0.00003196527,0.0000080003165,0.000019367313,0.0002417162,0.00004028154,0.0006283867],"genre_scores_gemma":[0.99749076,0.00038886763,0.00073249027,0.000018222669,0.0000035995668,0.000025259362,0.0003740943,0.000005642708,0.00096113165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998784,0.000012518285,0.000007696979,0.000023130247,0.000035758912,0.00004237758],"domain_scores_gemma":[0.999907,0.000012954392,0.000026162927,0.000007212062,0.00001203858,0.00003461684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012558936,0.00015514751,0.00024026574,0.00030534138,0.00017278692,0.00031696408,0.00012967706,0.00024210075,0.001299641],"category_scores_gemma":[0.00013377811,0.00014479348,0.0001482795,0.00029292202,0.00013898053,0.00019236648,0.000105129606,0.000781164,0.00022584813],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038461108,0.00009940216,0.0014680834,0.000011806769,0.0000060798648,0.000015996082,0.000015512232,0.00009156841,0.99677473,0.000026532241,0.000039042592,0.0010666264],"study_design_scores_gemma":[0.00005106391,0.0021702254,0.043256685,0.000005522649,0.00004584049,0.0004522254,0.0000694536,0.0031952525,0.94930387,0.00005249006,0.001387785,0.000009622169],"about_ca_topic_score_codex":0.00089585804,"about_ca_topic_score_gemma":0.0014391944,"teacher_disagreement_score":0.001299641,"about_ca_system_score_codex":0.00034616055,"about_ca_system_score_gemma":0.00014604224,"threshold_uncertainty_score":0.0043477416},"labels":[],"label_agreement":null},{"id":"W2291631976","doi":"10.1158/1538-8514.pi3k14-ia10","title":"Abstract IA10: Nuclear PTEN in regulation of genome integrity","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PTEN; Cowden syndrome; Cancer research; PI3K/AKT/mTOR pathway; Phosphatase; Germline; Cancer; Biology; DNA repair; DNA damage; Medicine; Phosphorylation; Cell biology; Genetics; DNA; Signal transduction; Gene","score_opus":0.04323157160202021,"score_gpt":0.3042399501044616,"score_spread":0.2610083785024414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291631976","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26862425,0.28907046,0.027540084,0.027906965,0.013353916,0.00054969505,0.009307931,0.0038027384,0.35984385],"genre_scores_gemma":[0.5727836,0.090725,0.0055751335,0.0016495424,0.0016160215,0.00013601797,0.0060772034,0.00023811814,0.32119942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999863,0.000019596713,0.000006826582,0.000029627061,0.000056498557,0.00002439411],"domain_scores_gemma":[0.99992216,0.000007850944,0.000015261383,0.0000056394956,0.000020030544,0.000029088178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030963542,0.00086370454,0.00044481055,0.00081042247,0.00038567587,0.001222249,0.0007741695,0.00065911096,0.019886648],"category_scores_gemma":[0.00013223439,0.00023423899,0.00024816336,0.00051669317,0.0006403329,0.00048663194,0.0006440664,0.0009409716,0.0052785017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002463872,0.00046606583,0.0011995351,0.0019947754,0.00006490535,0.0017982239,0.00009740584,0.0017098902,0.64007777,0.02343381,0.104519285,0.22217447],"study_design_scores_gemma":[0.00028576632,0.0012525469,0.011484732,0.00029155766,0.00009993806,0.0042991024,0.0001444246,0.0026637686,0.5140301,0.005130114,0.4602784,0.000039626528],"about_ca_topic_score_codex":0.0011968988,"about_ca_topic_score_gemma":0.0019230911,"teacher_disagreement_score":0.019886648,"about_ca_system_score_codex":0.0012081884,"about_ca_system_score_gemma":0.0008316506,"threshold_uncertainty_score":0.066527426},"labels":[],"label_agreement":null},{"id":"W2293000497","doi":"10.1158/1535-7163.mct-15-0003","title":"Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; SGS (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pancreatic cancer; STAT3; Cancer research; In vivo; Cancer cell; STAT protein; In vitro; Tumor microenvironment; Kinome; Cancer; Growth inhibition; Chemistry; Medicine; Kinase; Biology; Signal transduction; Cell biology; Internal medicine; Biochemistry; Tumor cells","score_opus":0.03599202423389613,"score_gpt":0.29278891903306714,"score_spread":0.256796894799171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293000497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438029,0.028352337,0.019098045,0.00046188664,0.00016779274,0.0002510914,0.0006737182,0.00033258006,0.006859687],"genre_scores_gemma":[0.9791374,0.01105817,0.0072835716,0.00014224966,0.000024672629,0.00008356575,0.00034008393,0.000013310887,0.001917077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999331,0.000015898282,0.000004015853,0.00001076644,0.000020804875,0.000015266529],"domain_scores_gemma":[0.9999714,0.000008990802,0.000008480354,0.0000022484828,0.000002700723,0.000006119756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013519953,0.0002770144,0.00021141031,0.0002646218,0.000094533716,0.0003246707,0.0001222936,0.00023701641,0.00086998893],"category_scores_gemma":[0.00006366531,0.000096727876,0.00027285196,0.00021840465,0.0001610931,0.0001277632,0.00015129823,0.000491968,0.0002219611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025941868,0.00011233015,0.00029625383,0.00016840399,0.000018466892,0.00011137545,0.000020167401,0.000729238,0.9800126,0.0002654536,0.00021084314,0.017795423],"study_design_scores_gemma":[0.000114227594,0.0021582597,0.002625539,0.000018693278,0.000056516892,0.00051338534,0.00002702751,0.0025222558,0.9802736,0.00015305179,0.011528054,0.00000942517],"about_ca_topic_score_codex":0.0002930712,"about_ca_topic_score_gemma":0.0008474458,"teacher_disagreement_score":0.00086998893,"about_ca_system_score_codex":0.00027998025,"about_ca_system_score_gemma":0.00018275635,"threshold_uncertainty_score":0.0029103756},"labels":[],"label_agreement":null},{"id":"W2299417213","doi":"10.1158/1535-7163.mct-15-0843","title":"An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"","keywords":"Cancer; In vivo; Combination therapy; Cancer cell; Pharmacology; Medicine; Computational biology; Cancer therapy; Drug; Cancer research; Cancer treatment; Biology; Internal medicine; Genetics","score_opus":0.03619010624958395,"score_gpt":0.3574481275927425,"score_spread":0.32125802134315856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299417213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8291257,0.02376136,0.08945656,0.0012360251,0.0002243743,0.0060269856,0.023213496,0.0023794456,0.024576016],"genre_scores_gemma":[0.830593,0.014686829,0.11838877,0.0008734662,0.00013320756,0.0030514917,0.018956313,0.00031593844,0.013001063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884725,0.00021494979,0.00009549224,0.0001899228,0.00053238904,0.00011997509],"domain_scores_gemma":[0.9994816,0.0001581579,0.00007141527,0.000075682765,0.0001671419,0.000046087363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010644044,0.0012055788,0.0017479024,0.0021928656,0.00056639453,0.0008022105,0.00057728315,0.0005585641,0.0038068404],"category_scores_gemma":[0.0009556718,0.00052954257,0.0007219304,0.0016304199,0.0002904728,0.00048277446,0.00078334956,0.00071767066,0.0015107054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048021507,0.00088489265,0.005966353,0.00048994104,0.0002326595,0.0004867736,0.000073805706,0.004109488,0.91928864,0.0007221984,0.002507105,0.06475792],"study_design_scores_gemma":[0.0004710019,0.00927552,0.022562418,0.00008784595,0.0010684787,0.0022417877,0.00016341363,0.015675237,0.89308006,0.001154857,0.054112945,0.000106435924],"about_ca_topic_score_codex":0.0007998465,"about_ca_topic_score_gemma":0.0034849953,"teacher_disagreement_score":0.0038068404,"about_ca_system_score_codex":0.00049041165,"about_ca_system_score_gemma":0.001137734,"threshold_uncertainty_score":0.012735128},"labels":[],"label_agreement":null},{"id":"W2304807948","doi":"10.1158/1538-8514.tumang15-b05","title":"Abstract B05: An immune modulatory role for the Fes protein tyrosine kinase","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cell biology; Signal transduction; Biology; Immune system; Receptor; Tyrosine kinase; Cancer research; Immunology; Biochemistry","score_opus":0.035565328596908204,"score_gpt":0.2956219460281028,"score_spread":0.2600566174311946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304807948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96256834,0.013303618,0.006910197,0.0012953925,0.00040422805,0.000072998926,0.0018892165,0.00025853523,0.013297421],"genre_scores_gemma":[0.9855618,0.0020670544,0.0018804554,0.00019087507,0.000050024868,0.000028981287,0.0013857115,0.000015403783,0.008819702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995065,0.000007386625,0.0000030447811,0.000009684603,0.000011984006,0.000017124503],"domain_scores_gemma":[0.9999536,0.0000039834217,0.000010947105,0.0000029112057,0.000007109518,0.000021412123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008394751,0.00030418552,0.00012481549,0.00016279973,0.00020081013,0.00025338965,0.00023540725,0.00036965727,0.004213403],"category_scores_gemma":[0.000071637216,0.00005492095,0.00020699562,0.00008134453,0.00018477453,0.00014482647,0.00017843167,0.00042330028,0.0011780114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051920157,0.000047142235,0.00020167774,0.00007624202,0.0000061121805,0.00019317314,0.0000075024464,0.0000995167,0.9939873,0.0009027159,0.0005136107,0.0034457287],"study_design_scores_gemma":[0.0002883279,0.0010265633,0.018067848,0.000068871814,0.00003929594,0.0024216296,0.00013415016,0.0024495581,0.9297382,0.0009657908,0.044778857,0.000020797259],"about_ca_topic_score_codex":0.00050742587,"about_ca_topic_score_gemma":0.00023707518,"teacher_disagreement_score":0.004213403,"about_ca_system_score_codex":0.00031198698,"about_ca_system_score_gemma":0.00013843838,"threshold_uncertainty_score":0.014095187},"labels":[],"label_agreement":null},{"id":"W2305209678","doi":"","title":"Activity of signaling pathways in hypoxic pancreatic and cervical tumor xenografts","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Angiogenesis; In vivo; Metastasis; Hypoxia (environmental); Cancer research; Immunofluorescence; Pancreatic cancer; Tumor hypoxia; Biology; Pathology; Chemistry; Cancer; Antibody; Internal medicine; Immunology; Medicine; Radiation therapy","score_opus":0.019635694739866698,"score_gpt":0.2690314652262114,"score_spread":0.2493957704863447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305209678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595886,0.00058627815,0.0007633255,0.000040421524,0.000007423458,0.000024549134,0.0010910576,0.000039846043,0.0014881755],"genre_scores_gemma":[0.9907135,0.00056279683,0.0019564093,0.000054685937,0.000005386679,0.000089671455,0.0029144338,0.000023838738,0.003679237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985635,0.000011628233,0.000009202479,0.00002956178,0.00004870828,0.00004453979],"domain_scores_gemma":[0.99992776,0.000012763114,0.000017119131,0.000007748708,0.000008411995,0.000026091786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010898075,0.00023157422,0.00022087155,0.00027669262,0.00017141587,0.000173742,0.00012197612,0.00018947679,0.0020370781],"category_scores_gemma":[0.00007474131,0.00011539822,0.0001620163,0.00025891152,0.00014205967,0.0001574714,0.0001452192,0.00047805248,0.00027765348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014964503,0.000030769403,0.00040929933,0.000014425058,0.0000026779321,0.000023301309,0.0000134015945,0.000039386734,0.9987608,0.000028755197,0.000034769975,0.00049288996],"study_design_scores_gemma":[0.00002325485,0.00077101716,0.02848999,0.0000061545634,0.000013709337,0.0002830833,0.00006774848,0.0009700936,0.9679106,0.00003798537,0.0014220932,0.0000041550397],"about_ca_topic_score_codex":0.0024947086,"about_ca_topic_score_gemma":0.0032462396,"teacher_disagreement_score":0.0024947086,"about_ca_system_score_codex":0.0003826275,"about_ca_system_score_gemma":0.00021359533,"threshold_uncertainty_score":0.0068147182},"labels":[],"label_agreement":null},{"id":"W2305927988","doi":"10.1158/1538-8514.pi3k14-a20","title":"Abstract A20: Insulin receptor signaling in mammary epithelial cells","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Insulin receptor; Insulin; Signal transduction; Insulin receptor substrate; Hyperinsulinemia; Biology; Cancer research; Endocrinology; Cell biology; Gene knockdown; Internal medicine; Medicine; Cell culture; Insulin resistance; Genetics","score_opus":0.025951007523519722,"score_gpt":0.2727540152847231,"score_spread":0.24680300776120337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305927988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8476852,0.031355005,0.03166269,0.0048267753,0.0012446642,0.00047333306,0.03187429,0.0024634625,0.048414636],"genre_scores_gemma":[0.90642315,0.011456666,0.012602104,0.0011873236,0.00012973699,0.0002885049,0.027215825,0.00022288998,0.04047381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950707,0.000067514666,0.000047340684,0.00009240137,0.00019787367,0.000087825254],"domain_scores_gemma":[0.99982387,0.000027709715,0.00003546348,0.000028608298,0.00004529442,0.00003903413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035675,0.00048140073,0.0005047811,0.00066222774,0.00057651335,0.0012002593,0.00051877944,0.00063350296,0.008801802],"category_scores_gemma":[0.0003120724,0.00027122858,0.00077666406,0.0009767504,0.00020994795,0.00039922603,0.0005563993,0.0010627395,0.0048146807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001723421,0.000078324876,0.000448125,0.0001553238,0.000015307176,0.0001812051,0.000021105136,0.00008507893,0.9934242,0.00049700745,0.000966253,0.0039557912],"study_design_scores_gemma":[0.000059088386,0.00061721134,0.018314116,0.000043691456,0.000070185255,0.0015947317,0.00015877685,0.0024719492,0.914577,0.00044817475,0.061620586,0.000024425992],"about_ca_topic_score_codex":0.0016848865,"about_ca_topic_score_gemma":0.0014104835,"teacher_disagreement_score":0.008801802,"about_ca_system_score_codex":0.00088771357,"about_ca_system_score_gemma":0.000519004,"threshold_uncertainty_score":0.029444933},"labels":[],"label_agreement":null},{"id":"W2307983749","doi":"10.1158/1538-8514.pi3k14-b14","title":"Abstract B14: Targeting amino acid transport to block mTORC1 and cell cycle in prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Glutamine; mTORC1; Amino acid transporter; Cell growth; Cancer research; Prostate cancer; Cancer cell; LNCaP; Chemistry; Biology; Cancer; Amino acid; Cell biology; Biochemistry; Signal transduction; PI3K/AKT/mTOR pathway; Transporter","score_opus":0.013547124377689556,"score_gpt":0.2641945683393009,"score_spread":0.2506474439616113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307983749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582175,0.017869746,0.008572931,0.0009813037,0.00052233884,0.00044578096,0.0043542148,0.0011759357,0.007860169],"genre_scores_gemma":[0.9680169,0.008380244,0.008438471,0.000359097,0.000085373664,0.0003265938,0.0049553425,0.000144533,0.009293368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986124,0.000016110691,0.000013816128,0.000026107371,0.000044940185,0.000037781585],"domain_scores_gemma":[0.999933,0.0000065439785,0.000015357473,0.000007594869,0.000013236242,0.000024221463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015718112,0.0006388327,0.0004552256,0.00038191,0.00029678896,0.00034778815,0.00041602048,0.0004048873,0.004655008],"category_scores_gemma":[0.00007754713,0.00016344975,0.00037848525,0.0004433129,0.000243382,0.0001778516,0.00024383771,0.00090551854,0.0013210324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005730649,0.0002518885,0.00015481432,0.00032902966,0.000029388977,0.00006752734,0.000013883376,0.00030277198,0.99010336,0.00023779376,0.0011230396,0.006813497],"study_design_scores_gemma":[0.00020367421,0.0018789707,0.002430808,0.000021961496,0.000062105166,0.00039504105,0.000012604115,0.0012541544,0.97410685,0.0000700879,0.019554911,0.000008731806],"about_ca_topic_score_codex":0.0010238336,"about_ca_topic_score_gemma":0.00160453,"teacher_disagreement_score":0.004655008,"about_ca_system_score_codex":0.0005447379,"about_ca_system_score_gemma":0.00067742757,"threshold_uncertainty_score":0.015572548},"labels":[],"label_agreement":null},{"id":"W2310704577","doi":"10.1158/1535-7163.mct-15-0636","title":"Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"Korea Research Institute of Bioscience and Biotechnology","keywords":"Bladder cancer; Cancer research; Suicide gene; Cancer stem cell; Cancer; Stem cell; Cancer cell; Medicine; Chemotherapy; Genetic enhancement; Immunotherapy; Biology; Internal medicine; Gene; Cell biology","score_opus":0.023495641485548238,"score_gpt":0.278251621309808,"score_spread":0.2547559798242598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2310704577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787097,0.007547466,0.0036892968,0.00038641342,0.00015651163,0.00018081816,0.0007054145,0.00029604678,0.008328493],"genre_scores_gemma":[0.9808678,0.005540251,0.003837036,0.00011042546,0.000024989817,0.000115014125,0.0014907544,0.000026185857,0.007987657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988997,0.000017625487,0.000010758472,0.000010718247,0.000046871173,0.00002409994],"domain_scores_gemma":[0.99994695,0.000014109681,0.000009393518,0.000009545048,0.000007686621,0.000012296429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019271109,0.00035342883,0.00019548951,0.00029427625,0.00011535444,0.00022578395,0.00020796635,0.00020373736,0.0018832441],"category_scores_gemma":[0.00009670205,0.000093432114,0.00028555578,0.00021277979,0.00019020193,0.00011792999,0.00016567347,0.000492916,0.0005596274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032413326,0.0004994239,0.00044210907,0.00017926715,0.000025215622,0.00012132808,0.000057761314,0.000406623,0.970771,0.000600397,0.00086601666,0.02570669],"study_design_scores_gemma":[0.000121082594,0.001790037,0.0026263709,0.000023900813,0.000040940686,0.00028578602,0.000029629247,0.0019022119,0.9806898,0.00011328854,0.012371928,0.000004981312],"about_ca_topic_score_codex":0.0011434244,"about_ca_topic_score_gemma":0.00285543,"teacher_disagreement_score":0.0018832441,"about_ca_system_score_codex":0.00023105483,"about_ca_system_score_gemma":0.00034702278,"threshold_uncertainty_score":0.006300032},"labels":[],"label_agreement":null},{"id":"W2312543879","doi":"10.1158/1535-7163.targ-13-a154","title":"Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"EIF4E; Cancer research; Cancer; Metastasis; Oncogene; Carcinogenesis; Breast cancer; Triple-negative breast cancer; Medicine; Ribavirin; Epithelial–mesenchymal transition; Biology; Cell cycle; Immunology; Internal medicine; Translation (biology); Messenger RNA","score_opus":0.022314147813511237,"score_gpt":0.2965809079215373,"score_spread":0.2742667601080261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312543879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871725,0.004418994,0.0017928015,0.00042777797,0.0004008379,0.00013813486,0.0013291034,0.0002553261,0.0040645725],"genre_scores_gemma":[0.98936355,0.0014014423,0.0020098153,0.0001763978,0.000050263305,0.000120278746,0.0016860522,0.000027665797,0.005164587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999007,0.000017996774,0.000012855767,0.00001739908,0.00002323042,0.000027805901],"domain_scores_gemma":[0.9999449,0.000010213228,0.000012400874,0.000007440393,0.000005852749,0.000019142626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107180495,0.00041457373,0.0003168266,0.00024095719,0.00013455146,0.0001809494,0.00018997338,0.00033739608,0.0029006538],"category_scores_gemma":[0.000106887455,0.00009170354,0.00027788413,0.0001618048,0.00017436186,0.00012347096,0.00010694262,0.00065775303,0.00062832906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012791521,0.0003860243,0.00011396425,0.0000960513,0.000015521611,0.000060890405,0.000010194534,0.00013801015,0.9924407,0.00011021329,0.00042505396,0.004924232],"study_design_scores_gemma":[0.00030289116,0.0050499365,0.0025520069,0.000012268449,0.000033381555,0.00032408017,0.000017379241,0.0007546291,0.98461443,0.000061655905,0.0062694345,0.00000785263],"about_ca_topic_score_codex":0.0003677345,"about_ca_topic_score_gemma":0.00047384773,"teacher_disagreement_score":0.0029006538,"about_ca_system_score_codex":0.00017421976,"about_ca_system_score_gemma":0.00018632025,"threshold_uncertainty_score":0.009703696},"labels":[],"label_agreement":null},{"id":"W2316810850","doi":"10.1158/1535-7163.targ-09-a105","title":"Abstract A105: Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Internal medicine; Hepatocellular carcinoma; Progression-free survival; Cancer; Clinical trial; Lung cancer; Phases of clinical research; Sorafenib; Interim analysis; Nuclear medicine; Urology; Overall survival; Confidence interval","score_opus":0.03472244194285886,"score_gpt":0.3741749619326415,"score_spread":0.33945251998978265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316810850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209154,0.0019570894,0.00084030326,0.00023915114,0.00005016515,0.0016578214,0.001798939,0.000074860414,0.0012901537],"genre_scores_gemma":[0.98930794,0.0005176493,0.002094032,0.00041941434,0.0001507424,0.0017934314,0.0038361272,0.000018422017,0.0018623037],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99837035,0.0011647927,0.00010866348,0.00013517794,0.00013008913,0.00009100681],"domain_scores_gemma":[0.9978756,0.0006958929,0.00061853754,0.00014343242,0.00018037029,0.00048621363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037063898,0.00061783654,0.000796569,0.00038450482,0.00023360134,0.00064655376,0.00043497205,0.00053067214,0.0033242584],"category_scores_gemma":[0.002071636,0.00019344912,0.0009103791,0.00035109752,0.0003944596,0.00046014469,0.00023617902,0.0010759127,0.0004961376],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8205362,0.015120609,0.06200076,0.00078759366,0.0031995785,0.00025653356,0.00013348267,0.0014561004,0.027536832,0.00017780547,0.0036492967,0.065145314],"study_design_scores_gemma":[0.2796108,0.51190406,0.18586013,0.00009455857,0.002755341,0.00054316706,0.00007668519,0.0034334816,0.01014371,0.00030350787,0.0052357414,0.0000387101],"about_ca_topic_score_codex":0.00037705264,"about_ca_topic_score_gemma":0.001049419,"teacher_disagreement_score":0.0037063898,"about_ca_system_score_codex":0.0005865152,"about_ca_system_score_gemma":0.001031224,"threshold_uncertainty_score":0.019601524},"labels":[],"label_agreement":null},{"id":"W2318057464","doi":"10.1158/1535-7163.targ-09-b160","title":"Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intrinsik (Canada); Angiochem (Canada)","funders":"","keywords":"Glioma; Medicine; Tolerability; Neutropenia; Adverse effect; Taxane; Internal medicine; Cancer; Oncology; Gastroenterology; Pharmacology; Cancer research; Breast cancer; Toxicity","score_opus":0.053768399153598656,"score_gpt":0.3395313373520377,"score_spread":0.28576293819843906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318057464","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688996,0.013762738,0.002778703,0.0004503393,0.00016559285,0.0003268748,0.00087721174,0.00035997608,0.01237894],"genre_scores_gemma":[0.9805267,0.0057648006,0.002661447,0.0004849921,0.000062732026,0.000119906654,0.0013500839,0.000030885636,0.008998547],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99995637,0.000007670042,0.0000026889452,0.000007527904,0.000014934632,0.000010816678],"domain_scores_gemma":[0.9999683,0.0000025008273,0.000007453919,0.0000028647146,0.0000039421507,0.0000148554045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001309265,0.00025722486,0.00023763254,0.00030056536,0.00008703747,0.00020824098,0.00021972953,0.00024779263,0.0024834329],"category_scores_gemma":[0.00008239786,0.00008160317,0.00015900405,0.00016069667,0.000104355444,0.00014727285,0.00015616437,0.00058313424,0.00074755726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050835707,0.0022728827,0.0026168218,0.0006496027,0.00013438782,0.00072639703,0.000087416716,0.0012139215,0.7070816,0.00085240416,0.0068770978,0.2724039],"study_design_scores_gemma":[0.0097899465,0.10901067,0.0689631,0.00027383585,0.00051828334,0.01065967,0.00011768354,0.008096583,0.64957887,0.0008104954,0.14208043,0.00010050726],"about_ca_topic_score_codex":0.0005517101,"about_ca_topic_score_gemma":0.0011873184,"teacher_disagreement_score":0.0024834329,"about_ca_system_score_codex":0.00023827417,"about_ca_system_score_gemma":0.00023520713,"threshold_uncertainty_score":0.008307874},"labels":[],"label_agreement":null},{"id":"W2319740689","doi":"10.1158/1535-7163.targ-13-c293","title":"Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Irinotecan; Hypoxia (environmental); Tumor hypoxia; Pharmacokinetics; Medicine; Camptothecin; Colorectal cancer; Pharmacology; Nuclear medicine; Internal medicine; Chemistry; Cancer; Radiation therapy; Oxygen","score_opus":0.026230494577792866,"score_gpt":0.2812783448882339,"score_spread":0.255047850310441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319740689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945141,0.00061703677,0.0019556659,0.00014393294,0.000032253593,0.00004013971,0.00053263345,0.00012103896,0.002043193],"genre_scores_gemma":[0.9934767,0.0003205104,0.0017685797,0.000041686806,0.0000075418816,0.00003654726,0.000737434,0.00003455964,0.003576432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998771,0.000010974207,0.000009393041,0.000030914387,0.000047014542,0.000024635374],"domain_scores_gemma":[0.9999291,0.000010428982,0.00002453279,0.000006666049,0.000009897747,0.00001940041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000793715,0.00030008832,0.0002595561,0.0001967221,0.00012730013,0.00021181809,0.00018208235,0.00036533515,0.002616857],"category_scores_gemma":[0.00009412579,0.00009239029,0.0001535214,0.00016344881,0.00021298113,0.0002536894,0.00009153379,0.000498219,0.0005782146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002629805,0.000056814,0.00008240005,0.000022646338,0.0000037866193,0.0000453306,0.0000069841735,0.000097832795,0.99807787,0.000069731956,0.000094674964,0.0011789122],"study_design_scores_gemma":[0.000017194223,0.00037286128,0.000774259,0.0000015430163,0.000004665468,0.00013486964,0.000006544939,0.00065260916,0.9970591,0.000012930807,0.00096118316,0.0000022830502],"about_ca_topic_score_codex":0.0019508647,"about_ca_topic_score_gemma":0.0011053107,"teacher_disagreement_score":0.002616857,"about_ca_system_score_codex":0.00048955955,"about_ca_system_score_gemma":0.00031809448,"threshold_uncertainty_score":0.008754253},"labels":[],"label_agreement":null},{"id":"W2320984091","doi":"10.1158/1535-7163.targ-13-c225","title":"Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Myeloid leukemia; Medicine; Stem cell; Myelodysplastic syndromes; CD34; Cancer research; Progenitor cell; clone (Java method); Internal medicine; Immunology; Biology; Bone marrow; Genetics","score_opus":0.022164490800552113,"score_gpt":0.28871054114473743,"score_spread":0.2665460503441853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320984091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825361,0.010856206,0.0020378917,0.00035251424,0.00016965561,0.00014371624,0.0010243073,0.00013553524,0.0027442216],"genre_scores_gemma":[0.98999184,0.0026645518,0.0025919979,0.00022475586,0.00003817737,0.00011139961,0.0015359599,0.000021124404,0.0028202548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999224,0.000012899633,0.0000063294433,0.000014492137,0.00002466235,0.00001922819],"domain_scores_gemma":[0.99995923,0.000004411937,0.000011364205,0.0000038394796,0.000007202472,0.000014050047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011846885,0.00028015624,0.0002595618,0.00019116882,0.00013257489,0.00028871268,0.0001956732,0.00030755156,0.0017813314],"category_scores_gemma":[0.00006324994,0.000070848335,0.00018636076,0.0001627797,0.0001533429,0.00010510255,0.00014655659,0.00048784688,0.00048609878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050473865,0.00007688238,0.00039088115,0.00010986019,0.000013225098,0.00007883015,0.000013560832,0.00016411964,0.9898896,0.00020758601,0.00040538714,0.008145257],"study_design_scores_gemma":[0.00017295788,0.0019175572,0.0065486487,0.000024688592,0.0000979398,0.0009300337,0.000024977136,0.0013173932,0.9728224,0.00011449395,0.016019195,0.000009653148],"about_ca_topic_score_codex":0.0003228013,"about_ca_topic_score_gemma":0.0005548769,"teacher_disagreement_score":0.0017813314,"about_ca_system_score_codex":0.00027894485,"about_ca_system_score_gemma":0.000270959,"threshold_uncertainty_score":0.005959213},"labels":[],"label_agreement":null},{"id":"W2322809144","doi":"10.1158/1535-7163.targ-09-a51","title":"Abstract A51: Identification of compounds targeting human leukemia stem cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Leukemia; Stem cell; Cancer research; Cancer stem cell; Haematopoiesis; Cancer cell; Etoposide; Cancer; Biology; Population; Cytotoxic T cell; Progenitor cell; Immunology; Medicine; Cell biology; Chemotherapy; Biochemistry; Genetics; In vitro","score_opus":0.026676936184379333,"score_gpt":0.29793394922597594,"score_spread":0.2712570130415966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322809144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9446136,0.015188496,0.009254273,0.0006656484,0.00016953752,0.001556143,0.008543101,0.00077839213,0.01923071],"genre_scores_gemma":[0.95434636,0.010141684,0.010055824,0.0006057441,0.00004888121,0.00044775888,0.009751674,0.00007848561,0.014523557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988306,0.000013085649,0.000010560751,0.00002967969,0.00003630482,0.000027166507],"domain_scores_gemma":[0.99990785,0.000017881954,0.000014469665,0.000007851011,0.000019197145,0.000032830434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014007014,0.000903898,0.0006109526,0.0017768373,0.00022567612,0.0004310867,0.0003281172,0.0004406537,0.0060383137],"category_scores_gemma":[0.00019505681,0.00019035069,0.00050132093,0.0007387699,0.00020417044,0.00023420503,0.00034194172,0.0005183158,0.0013458072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005647626,0.0004797901,0.0009181797,0.00038660772,0.000051568248,0.00033406809,0.000029335915,0.0010113548,0.9676041,0.00039383306,0.0010858147,0.027140625],"study_design_scores_gemma":[0.00066412584,0.010652434,0.009067885,0.0001320853,0.0002967773,0.0010599621,0.00006556656,0.0023668224,0.9503811,0.00032670982,0.024936441,0.000050048704],"about_ca_topic_score_codex":0.00081607443,"about_ca_topic_score_gemma":0.0017587495,"teacher_disagreement_score":0.0060383137,"about_ca_system_score_codex":0.0003391252,"about_ca_system_score_gemma":0.00050370465,"threshold_uncertainty_score":0.020200133},"labels":[],"label_agreement":null},{"id":"W2322879380","doi":"10.1158/1535-7163.targ-09-a142","title":"Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Quinazolinone synthesis and applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cancer research; Epidermal growth factor receptor; Tyrosine kinase; Quinazoline; Kinase; Biology; Erlotinib; PTEN; Proto-oncogene tyrosine-protein kinase Src; Receptor tyrosine kinase; Biochemistry; Afatinib; Docking (animal); Chemistry; Pharmacology; Signal transduction; Cell biology; PI3K/AKT/mTOR pathway; Receptor; Medicine; Stereochemistry","score_opus":0.039225374973548,"score_gpt":0.2795693104840613,"score_spread":0.2403439355105133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322879380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6678702,0.005234025,0.287772,0.001070864,0.0001840252,0.0008618025,0.0021849563,0.0010030858,0.033819135],"genre_scores_gemma":[0.8862148,0.0029242882,0.104946285,0.00014075938,0.000024161905,0.00076645036,0.0008550742,0.000114074275,0.0040140804],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998367,0.00004932642,0.000007649533,0.000022150916,0.000054035518,0.000030132054],"domain_scores_gemma":[0.9998938,0.000043755786,0.000018260438,0.0000063746706,0.000024502464,0.000013258361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045764106,0.0010642076,0.0010910716,0.0004194327,0.00038788302,0.0006553468,0.0009710121,0.00058198126,0.0031954055],"category_scores_gemma":[0.00041603085,0.00045332828,0.0006726794,0.00041283647,0.00025445706,0.00043017248,0.00037718224,0.0007469652,0.0004766622],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004264085,0.00033259325,0.00081558636,0.0004022426,0.00007533239,0.00041486035,0.000061077924,0.9274956,0.040646862,0.01482087,0.00091836066,0.013590171],"study_design_scores_gemma":[0.00020740295,0.00054025196,0.00015648938,0.000027645525,0.000047413178,0.000051918425,0.00003745397,0.97806305,0.0159428,0.0013220134,0.0035794876,0.000024150044],"about_ca_topic_score_codex":0.002755144,"about_ca_topic_score_gemma":0.0037822095,"teacher_disagreement_score":0.0031954055,"about_ca_system_score_codex":0.00088480953,"about_ca_system_score_gemma":0.0011719961,"threshold_uncertainty_score":0.010689676},"labels":[],"label_agreement":null},{"id":"W2323767515","doi":"10.1158/1535-7163.targ-09-a188","title":"Abstract A188: Proapoptotic <i>versus</i> prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vorinostat; Histone deacetylase inhibitor; Sodium butyrate; DNA damage; Apoptosis; p38 mitogen-activated protein kinases; Cell cycle; Biology; Cell cycle checkpoint; Histone deacetylase; Cancer research; Cell biology; Kinase; Chemistry; Histone; Cell culture; Protein kinase A; Biochemistry; DNA","score_opus":0.022723297742067893,"score_gpt":0.2864238494424917,"score_spread":0.26370055170042384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323767515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907865,0.0032108058,0.0013626958,0.00019524062,0.00009652704,0.000039174305,0.00078484387,0.00013554975,0.0033887555],"genre_scores_gemma":[0.9944741,0.0010496373,0.00089230697,0.000068551235,0.000036910464,0.00004188459,0.00079674425,0.0000149325015,0.0026249783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999443,0.000008724758,0.00000520158,0.000009421116,0.000014699943,0.000017585244],"domain_scores_gemma":[0.9999647,0.000007055373,0.000009094622,0.0000037150846,0.0000042803736,0.000011196204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056952485,0.00028099216,0.00019516583,0.00015423332,0.00010856254,0.00015059397,0.00010871161,0.00013346608,0.003772726],"category_scores_gemma":[0.000055202396,0.000059996135,0.00017674059,0.000115269235,0.00012060224,0.00013827729,0.00006859148,0.00038702777,0.0004575614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042630607,0.00005537122,0.00015755632,0.000057091365,0.0000053525505,0.000086996755,0.0000089282075,0.000031130603,0.9973278,0.00008735441,0.00013345755,0.0016225993],"study_design_scores_gemma":[0.00005230108,0.0009112736,0.0035932725,0.0000050199237,0.000014519717,0.00029132862,0.000022584607,0.00031835175,0.99231476,0.00005544245,0.0024190415,0.0000021899011],"about_ca_topic_score_codex":0.00027929558,"about_ca_topic_score_gemma":0.00022731043,"teacher_disagreement_score":0.003772726,"about_ca_system_score_codex":0.00013396691,"about_ca_system_score_gemma":0.00010977288,"threshold_uncertainty_score":0.012621045},"labels":[],"label_agreement":null},{"id":"W2324692647","doi":"10.1158/1535-7163.targ-11-b12","title":"Abstract B12: The effects of Irinophore C™ on the microenvironment and vasculature of a primary orthotopic model of colorectal cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Irinotecan; Medicine; Cancer; Tumor microenvironment; Primary tumor; Pathology; In vivo; Cancer research; Internal medicine; Metastasis; Biology","score_opus":0.01955027477734175,"score_gpt":0.2508242462791802,"score_spread":0.23127397150183845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324692647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851424,0.0021508401,0.0025294134,0.0002512716,0.00017464299,0.00015796682,0.001878791,0.00030924418,0.0040336587],"genre_scores_gemma":[0.9825021,0.0015824403,0.0043503665,0.00014456133,0.000041588817,0.00022915116,0.0028357783,0.000055860903,0.008258175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977905,0.00003297971,0.000013325643,0.000056899713,0.000050196057,0.00006760521],"domain_scores_gemma":[0.9997477,0.000033638036,0.000046881538,0.000032076772,0.000026162652,0.00011357852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023823713,0.0006086012,0.00042714173,0.0003800399,0.00023887583,0.00028757396,0.00028985424,0.00035539796,0.0029802022],"category_scores_gemma":[0.000087443106,0.00023565,0.00040622617,0.00028989097,0.00025716846,0.00026197167,0.00012532437,0.0012312505,0.00067385455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009589458,0.00043459996,0.000112596696,0.00009219624,0.000008171714,0.0000908384,0.00002378886,0.00008868498,0.99622923,0.00006008159,0.0003337234,0.0015671515],"study_design_scores_gemma":[0.00012352911,0.007352508,0.0063367505,0.000011744103,0.000031921223,0.00044330556,0.00004836275,0.0007582769,0.98124415,0.000025472958,0.0036134478,0.000010537903],"about_ca_topic_score_codex":0.0021833635,"about_ca_topic_score_gemma":0.0028722973,"teacher_disagreement_score":0.0029802022,"about_ca_system_score_codex":0.0004000739,"about_ca_system_score_gemma":0.00046239502,"threshold_uncertainty_score":0.009969771},"labels":[],"label_agreement":null},{"id":"W2328609447","doi":"10.1158/1535-7163.targ-13-b176","title":"Abstract B176: The correlation of clinicopathologic characteristics with oncogenic somatic mutations and Human Papilloma Virus (HPV) in vulvovaginal carcinoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; KRAS; Oncology; Cancer; Internal medicine; Carcinoma; Polymerase chain reaction; Somatic cell; Cervical cancer; Biology; Gene","score_opus":0.0405368688106189,"score_gpt":0.34460547801086316,"score_spread":0.30406860920024426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328609447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809545,0.00047621,0.000063586835,0.000034509438,0.000010401878,0.00001533852,0.00070463424,0.0000039128695,0.00059595495],"genre_scores_gemma":[0.9990338,0.00009690855,0.00007208242,0.000012439358,0.0000082384595,0.000007536474,0.00048951554,0.0000012967364,0.00027819615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980706,0.000024697114,0.000034600875,0.00004364456,0.000051505715,0.00003858902],"domain_scores_gemma":[0.998833,0.0003107602,0.00037965743,0.00007133661,0.00019081874,0.00021437986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003823865,0.00019312458,0.00016236411,0.0010470604,0.0003966062,0.00046843835,0.00028479967,0.0002824186,0.004273111],"category_scores_gemma":[0.0015553803,0.00014696507,0.00021595931,0.00093759823,0.0003402864,0.0002534423,0.00027391146,0.0002767351,0.0006067947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009080473,0.0000068090817,0.99782974,0.000013008857,0.0000081363505,0.0002555684,0.000020346724,0.000017508402,0.00060129265,0.0000053001677,0.00011012865,0.0010412676],"study_design_scores_gemma":[0.000003416671,0.00007878739,0.9963224,0.000009046471,0.000015510073,0.0025512527,0.00010522316,0.000057298057,0.00034934314,0.000012340816,0.00049289176,0.0000024773365],"about_ca_topic_score_codex":0.004624796,"about_ca_topic_score_gemma":0.0051367762,"teacher_disagreement_score":0.004624796,"about_ca_system_score_codex":0.0005256745,"about_ca_system_score_gemma":0.0005012034,"threshold_uncertainty_score":0.014294982},"labels":[],"label_agreement":null},{"id":"W2331427771","doi":"10.1158/1535-7163.targ-09-c218","title":"Abstract C218: Antitumor activities of a novel oral formulation of SN38","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Tolerability; Irinotecan; Pharmacology; Pharmacokinetics; In vivo; Active metabolite; Chemistry; Prodrug; Bioavailability; SN-38; Oral administration; Bioequivalence; Medicine; In vitro; Metabolite; Colorectal cancer; Cancer; Biochemistry; Adverse effect; Internal medicine; Biology","score_opus":0.05436867551825783,"score_gpt":0.3722591213640159,"score_spread":0.3178904458457581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331427771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990961,0.0031690807,0.001974129,0.00011259393,0.000044367946,0.00012768873,0.0004067149,0.000061821775,0.0031425061],"genre_scores_gemma":[0.9900933,0.0018086649,0.0033204206,0.000042441756,0.000027499556,0.00007127484,0.00056798296,0.000016980273,0.0040514395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999547,0.000006829689,0.000003252412,0.000009942845,0.000016641769,0.000008663921],"domain_scores_gemma":[0.99996424,0.0000044790536,0.000009826503,0.000003098818,0.000007509535,0.000010915291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081187834,0.00035114572,0.00016221462,0.00019867651,0.00009578174,0.0001302439,0.00018344352,0.00019231677,0.0020292606],"category_scores_gemma":[0.00008330493,0.000066538996,0.000112163805,0.00012770071,0.00008644151,0.00014674116,0.000103833125,0.00033788182,0.00037511572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046899752,0.0003220073,0.00011474507,0.00011287426,0.000009028644,0.000094639276,0.000014783347,0.00030042874,0.9846976,0.000092135735,0.00026600042,0.013506885],"study_design_scores_gemma":[0.00020634227,0.0055481824,0.0016624908,0.000014842141,0.00003696212,0.00049015565,0.000012909583,0.0014894301,0.98091185,0.000037333284,0.009580856,0.000008608268],"about_ca_topic_score_codex":0.00062877894,"about_ca_topic_score_gemma":0.00075195957,"teacher_disagreement_score":0.0020292606,"about_ca_system_score_codex":0.00024603668,"about_ca_system_score_gemma":0.00019320911,"threshold_uncertainty_score":0.0067886114},"labels":[],"label_agreement":null},{"id":"W2332272456","doi":"10.1158/1535-7163.targ-09-c147","title":"Abstract C147: siRNA targeting TS and TK as an anticancer therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Small interfering RNA; Thymidylate synthase; Biology; Cancer research; Cell growth; Molecular biology; Transfection; Pharmacology; Cancer; Cell culture; Biochemistry","score_opus":0.03276891888321092,"score_gpt":0.3281588253113174,"score_spread":0.2953899064281065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332272456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324536,0.01788523,0.017398039,0.0013341927,0.0012790422,0.00064334896,0.0017274746,0.0009220537,0.026356988],"genre_scores_gemma":[0.9716793,0.0037626808,0.009491393,0.00046454484,0.000115886454,0.0003716504,0.0016666393,0.00007941966,0.012368715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984825,0.000020246074,0.000022160808,0.000028517796,0.000048862163,0.000031897445],"domain_scores_gemma":[0.99993706,0.000013406224,0.000011569348,0.0000067022393,0.00001755954,0.000013779592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015393051,0.00035980213,0.00040348942,0.00033158227,0.00014931553,0.00029640892,0.00022383448,0.0005298465,0.0026974536],"category_scores_gemma":[0.00012521376,0.00008870609,0.00027358235,0.00019275682,0.00015035422,0.00015295549,0.00015166077,0.0004791819,0.0007326964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025934892,0.000076856064,0.00013781105,0.00014140875,0.000010705956,0.000066017805,0.000009935859,0.00012411886,0.98901296,0.0003583166,0.0007421732,0.0090603335],"study_design_scores_gemma":[0.00009358236,0.0009223212,0.0012605507,0.000016961914,0.00005134962,0.000416407,0.000012247854,0.0014217995,0.9829926,0.00007883259,0.012727165,0.000006158544],"about_ca_topic_score_codex":0.0007546872,"about_ca_topic_score_gemma":0.0008373632,"teacher_disagreement_score":0.0026974536,"about_ca_system_score_codex":0.00035106877,"about_ca_system_score_gemma":0.00043545658,"threshold_uncertainty_score":0.009023905},"labels":[],"label_agreement":null},{"id":"W2332604050","doi":"10.1158/1535-7163.targ-11-b23","title":"Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Basal (medicine); Pharmacodynamics; Sorafenib; Peripheral blood mononuclear cell; Cyclophosphamide; Oncology; Pharmacology; MAPK/ERK pathway; Internal medicine; Signal transduction; Pharmacokinetics; Chemotherapy; In vitro; Chemistry","score_opus":0.01558948879398097,"score_gpt":0.28739419483359596,"score_spread":0.271804706039615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332604050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983814,0.0004326653,0.00016126191,0.000059392645,0.000026885036,0.00012697333,0.00039903307,0.000018780884,0.00039358236],"genre_scores_gemma":[0.99779946,0.00012067627,0.0005274785,0.00008817758,0.000030451189,0.00021003767,0.0006928187,0.0000061523856,0.00052479777],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997824,0.000079709964,0.000014357752,0.00006918787,0.000029459912,0.00002493891],"domain_scores_gemma":[0.9995347,0.00007850915,0.00009830186,0.000030178737,0.00004049816,0.00021782429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075760396,0.0006448575,0.00076202006,0.00025833552,0.0002483847,0.00087231316,0.00027463134,0.0005719474,0.0020270408],"category_scores_gemma":[0.0005766892,0.00024572347,0.00040432997,0.0002630963,0.00033014925,0.0003720841,0.0001997617,0.0011050459,0.0005602166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4249545,0.017670555,0.23035069,0.00046885086,0.00092297257,0.0008372647,0.00031985127,0.0032428552,0.22466846,0.00017953807,0.0037558288,0.092628725],"study_design_scores_gemma":[0.044632435,0.34249398,0.53276324,0.00005282225,0.001015337,0.0020775418,0.00028316418,0.011442456,0.05775858,0.00039652828,0.0069520744,0.00013168823],"about_ca_topic_score_codex":0.0003571589,"about_ca_topic_score_gemma":0.00057494454,"teacher_disagreement_score":0.0020270408,"about_ca_system_score_codex":0.0005050816,"about_ca_system_score_gemma":0.00043421367,"threshold_uncertainty_score":0.006781101},"labels":[],"label_agreement":null},{"id":"W2334087039","doi":"10.1158/1535-7163.targ-11-c143","title":"Abstract C143: Combining siRNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5FUdR and pemetrexed.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thymidylate synthase; Thymidine kinase; Cancer research; Gene knockdown; Small interfering RNA; Downregulation and upregulation; Pemetrexed; Cancer cell; Kinase; Cancer; Biology; Chemistry; Pharmacology; Molecular biology; Transfection; Cell culture; Apoptosis; Cell biology; Cisplatin; Biochemistry; Immunology; Chemotherapy; Fluorouracil","score_opus":0.052682980625344725,"score_gpt":0.30001762794600134,"score_spread":0.24733464732065663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334087039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98217577,0.0027028036,0.0034778703,0.00024666238,0.0002520316,0.00028380135,0.0020318308,0.00030806698,0.008521119],"genre_scores_gemma":[0.9825545,0.0008189667,0.0041819154,0.00016094929,0.00003413266,0.00024510024,0.002919865,0.000054459062,0.0090301335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998117,0.000020219844,0.000020708801,0.000054398533,0.000049315593,0.000043636144],"domain_scores_gemma":[0.9999107,0.00002678594,0.000011870047,0.000012082884,0.000012493464,0.000025933763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014798062,0.00048977777,0.0004365418,0.00023232614,0.00017504835,0.00027519147,0.00024704201,0.0005397919,0.0049244612],"category_scores_gemma":[0.00013069213,0.0001379908,0.00039549996,0.00017218268,0.00018527856,0.00012844297,0.00014193008,0.0005619877,0.0009442825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001931213,0.000061898405,0.00006461934,0.000041615996,0.000009071872,0.000034927634,0.000009238314,0.00007512434,0.9980076,0.000060669467,0.00019387956,0.0012483192],"study_design_scores_gemma":[0.000035484285,0.0006190411,0.0011990988,0.0000030743124,0.000016011158,0.00008555633,0.0000071727513,0.00049415487,0.99562967,0.000010358711,0.0018971863,0.000003168884],"about_ca_topic_score_codex":0.002197965,"about_ca_topic_score_gemma":0.0020436973,"teacher_disagreement_score":0.0049244612,"about_ca_system_score_codex":0.0003564381,"about_ca_system_score_gemma":0.0003722803,"threshold_uncertainty_score":0.01647389},"labels":[],"label_agreement":null},{"id":"W2335421053","doi":"10.1158/1535-7163.targ-11-a95","title":"Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Adverse effect; Nausea; Pharmacodynamics; Pharmacokinetics; Tolerability; Internal medicine; Maximum tolerated dose; Pharmacology; Gastroenterology; Oncology","score_opus":0.08630945641426414,"score_gpt":0.38851745837937557,"score_spread":0.30220800196511144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335421053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332136,0.0008186269,0.0010155388,0.00017457953,0.000048063015,0.0018292734,0.0011489384,0.00011850227,0.0015250123],"genre_scores_gemma":[0.9920854,0.00051765115,0.0019886298,0.0003485635,0.00009318551,0.0011979764,0.0021731164,0.000030936975,0.0015645671],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967515,0.0001349536,0.000020543937,0.000064389424,0.000042506043,0.00006249724],"domain_scores_gemma":[0.9992933,0.0001303769,0.00015046155,0.000060436803,0.000037009373,0.00032830433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013273333,0.0012999183,0.0010485976,0.0003964053,0.00031220925,0.00081582804,0.00087604386,0.0012069151,0.004104815],"category_scores_gemma":[0.0007909592,0.00044695273,0.000775254,0.00032557175,0.00075921504,0.0005609251,0.00026823004,0.0029239794,0.0009484532],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59548664,0.09418696,0.010448075,0.0009415597,0.0010071786,0.0008743378,0.0004027181,0.0074983006,0.17237051,0.0007376311,0.00814542,0.10790069],"study_design_scores_gemma":[0.29286575,0.6729344,0.012265281,0.00004491558,0.00027851443,0.0005427506,0.000050682032,0.0026353716,0.014784629,0.00020252696,0.0033609995,0.00003409039],"about_ca_topic_score_codex":0.000997169,"about_ca_topic_score_gemma":0.001473371,"teacher_disagreement_score":0.004104815,"about_ca_system_score_codex":0.00077951164,"about_ca_system_score_gemma":0.001347993,"threshold_uncertainty_score":0.013732016},"labels":[],"label_agreement":null},{"id":"W2336997490","doi":"10.1158/1535-7163.targ-15-c185","title":"Abstract C185: Targeting PARP and DNA as a novel unimolecular combination model for the enhancement of chemosensitivity","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Olaparib; Synthetic lethality; DNA repair; Poly ADP ribose polymerase; Biology; Cancer research; DNA damage; PARP inhibitor; Programmed cell death; DNA; Polymerase; Genetics; Apoptosis","score_opus":0.07282148049106738,"score_gpt":0.3465300539674201,"score_spread":0.2737085734763527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336997490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8918736,0.006944285,0.07250311,0.0010238943,0.0005268154,0.0005391899,0.0008272382,0.00074387423,0.025018007],"genre_scores_gemma":[0.979936,0.0011368273,0.012167942,0.0001742472,0.000038529,0.00015444029,0.00017786803,0.000031208878,0.0061829216],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99988556,0.00001596404,0.0000054563543,0.000035963105,0.00003369752,0.000023243496],"domain_scores_gemma":[0.99994373,0.000008921217,0.0000180617,0.000007005951,0.0000057114194,0.000016452017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015616899,0.00034963485,0.00032768113,0.00032849752,0.00011894461,0.00038523457,0.00052877463,0.00044738306,0.0029225315],"category_scores_gemma":[0.00009026653,0.0001486147,0.00028631417,0.00023127414,0.00022041755,0.000344058,0.00025780578,0.00059678196,0.00049559923],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051146344,0.0003461351,0.00010309243,0.00017925487,0.000032664917,0.00017977273,0.000011876604,0.0038068069,0.97684664,0.0044996087,0.00081045495,0.012672228],"study_design_scores_gemma":[0.00023269591,0.003001276,0.00055400236,0.000013079793,0.000051530395,0.00028431677,0.000007173686,0.026753435,0.9539719,0.0011002574,0.014004075,0.000026327885],"about_ca_topic_score_codex":0.00031260093,"about_ca_topic_score_gemma":0.00026728498,"teacher_disagreement_score":0.0029225315,"about_ca_system_score_codex":0.00042307092,"about_ca_system_score_gemma":0.0001953438,"threshold_uncertainty_score":0.009776831},"labels":[],"label_agreement":null},{"id":"W2337242297","doi":"10.1158/1538-8514.tumang15-b15","title":"Abstract B15: In vivo analysis of repeated siRNA silencing on protein expression levels","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gene silencing; In vivo; Small interfering RNA; RNA interference; Survivin; Cancer research; Angiogenesis; Biology; Cell growth; In vitro; Cell; Cancer; Cell culture; RNA; Transfection; Gene; Genetics","score_opus":0.050338421090548015,"score_gpt":0.31234727140875684,"score_spread":0.2620088503182088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337242297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96068484,0.0037951272,0.022461375,0.0003173894,0.00032890603,0.0002599941,0.0031146733,0.0006202679,0.008417385],"genre_scores_gemma":[0.94796675,0.002269599,0.017537672,0.00029100376,0.000051602015,0.00049494,0.005136958,0.00022133395,0.026030086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977165,0.000026020029,0.000022416765,0.00007486057,0.00006003708,0.000045053603],"domain_scores_gemma":[0.99979883,0.000049908213,0.00004634979,0.000025185262,0.00003636833,0.000043434637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002875485,0.0004427917,0.0002948663,0.00040176322,0.00020899666,0.00030099862,0.0002700522,0.00052170065,0.003600435],"category_scores_gemma":[0.00011346914,0.00015771543,0.00038874242,0.00027628193,0.000248254,0.00021502403,0.000114246075,0.0008710573,0.001081842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012694103,0.00006737211,0.000035792287,0.000021088812,0.0000049796677,0.000025324245,0.000008680083,0.00002277949,0.9988054,0.000036019002,0.0000836592,0.0007619688],"study_design_scores_gemma":[0.000015782885,0.0007121642,0.0017511598,0.0000031737886,0.000015800188,0.00011896885,0.000008269731,0.00043187305,0.99593323,0.000019588897,0.0009859813,0.000004015689],"about_ca_topic_score_codex":0.0011375606,"about_ca_topic_score_gemma":0.0010289546,"teacher_disagreement_score":0.003600435,"about_ca_system_score_codex":0.00033104245,"about_ca_system_score_gemma":0.00024301103,"threshold_uncertainty_score":0.012044728},"labels":[],"label_agreement":null},{"id":"W2337430744","doi":"10.1158/1535-7163.mct-15-0695","title":"Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus","year":2016,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Guizhou University; National Natural Science Foundation of China","keywords":"Oncolytic virus; Virotherapy; Cancer research; Cancer; Immune system; Radiation therapy; Immunotherapy; Cancer cell; Medicine; Biology; Immunology; Virology; Internal medicine","score_opus":0.05086805946299626,"score_gpt":0.3713914075100794,"score_spread":0.3205233480470831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337430744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003208034,0.9974261,0.00040908364,0.00024730922,0.000142246,0.0000071890377,0.000011813764,0.000011977829,0.0014235233],"genre_scores_gemma":[0.0029188592,0.9944354,0.0007025842,0.0003554337,0.00011451797,0.000018432043,0.00004463229,0.0000053122117,0.001404806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984217,0.000035619094,0.000013546833,0.000024913634,0.00005950593,0.00002422527],"domain_scores_gemma":[0.99988365,0.000052837844,0.000015158333,0.0000054228267,0.000028012608,0.000014885771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005988229,0.00066927617,0.0009828209,0.0013624869,0.00020276605,0.000958321,0.0008391329,0.0010419015,0.002254585],"category_scores_gemma":[0.00034871927,0.0002598996,0.00053317985,0.00093040563,0.0005224314,0.0015417777,0.00056741113,0.0022872407,0.0015620064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011049355,0.00011722425,0.00010245877,0.005293743,0.00007696601,0.00024837445,0.00006442346,0.00070056133,0.0063367295,0.00915319,0.014510376,0.9632854],"study_design_scores_gemma":[0.00004440143,0.00020920364,0.0003171722,0.0010063935,0.000063729494,0.0013447276,0.000038220325,0.0002473777,0.0026189052,0.0032122373,0.9908761,0.000021512615],"about_ca_topic_score_codex":0.0006244917,"about_ca_topic_score_gemma":0.0013493192,"teacher_disagreement_score":0.002254585,"about_ca_system_score_codex":0.0008732008,"about_ca_system_score_gemma":0.00061709597,"threshold_uncertainty_score":0.007542312},"labels":[],"label_agreement":null},{"id":"W2346218376","doi":"10.1158/1538-8514.tumang15-pr06","title":"Abstract PR06: Formation of lymph node metastases is not angiogenesis dependent","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lymph node; Lymph; Medicine; Angiogenesis; Lymphatic system; Sprouting angiogenesis; Pathology; Cancer; Oncology; Cancer research; Internal medicine; Neovascularization","score_opus":0.04080303947871639,"score_gpt":0.29816431070110855,"score_spread":0.25736127122239216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346218376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807302,0.0023637703,0.010165402,0.00026366566,0.0000709832,0.00014655427,0.0013100096,0.00026454745,0.004684925],"genre_scores_gemma":[0.979506,0.00092554017,0.0062648747,0.00011894982,0.000018370314,0.00012855373,0.003823051,0.00011119894,0.0091035105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998048,0.000022213759,0.00001684495,0.000052175237,0.000066294575,0.000037713467],"domain_scores_gemma":[0.99959975,0.00008573314,0.000098786906,0.00006627371,0.000045836896,0.00010361293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002477912,0.00032628427,0.00021167618,0.00021254296,0.00015294996,0.0003768293,0.00033864772,0.00036829495,0.003740721],"category_scores_gemma":[0.0002710652,0.00017913365,0.0002749675,0.0001545793,0.00033242864,0.00031418086,0.00023077567,0.0011213821,0.0010819115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018155522,0.00008465831,0.0002519037,0.000055430603,0.0000038570406,0.00009295414,0.0000086516075,0.000039811595,0.99755126,0.00016064313,0.00017692531,0.0013923257],"study_design_scores_gemma":[0.000066986344,0.00142489,0.0055036084,0.000014704327,0.000013490078,0.0015151371,0.000021064361,0.0013822345,0.98438686,0.00009237531,0.0055737854,0.000004946152],"about_ca_topic_score_codex":0.0006212847,"about_ca_topic_score_gemma":0.0006126366,"teacher_disagreement_score":0.003740721,"about_ca_system_score_codex":0.00028154562,"about_ca_system_score_gemma":0.00035971365,"threshold_uncertainty_score":0.012513995},"labels":[],"label_agreement":null},{"id":"W23699658","doi":"10.1158/1535-7163.mct-12-1249","title":"Ionic and Osmotic Mechanisms Of Insect Chill-Coma And Chilling Injury","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Insect behavior and control techniques","field":"Agricultural and Biological Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Insect; Coma (optics); Chemistry; Botany; Biology","score_opus":0.01793487351953992,"score_gpt":0.23361546395093455,"score_spread":0.21568059043139462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23699658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90956205,0.05916914,0.009008464,0.0025033846,0.0006018173,0.0003819429,0.0020785877,0.0006598575,0.016034754],"genre_scores_gemma":[0.98453724,0.008147365,0.0017220721,0.000810867,0.00006628238,0.00012157897,0.0009927629,0.000032546133,0.0035692544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997435,0.00003413778,0.0000237492,0.000032404085,0.00008268095,0.000083459694],"domain_scores_gemma":[0.9998535,0.0000103066905,0.000050301867,0.000011229346,0.00003351511,0.000041126747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025978984,0.00057726307,0.0005485116,0.00030223484,0.00032548953,0.0006309815,0.00042589798,0.00063298544,0.0019471361],"category_scores_gemma":[0.00019691786,0.00018180322,0.0007647291,0.00023666437,0.00046963166,0.0004443897,0.0004936791,0.00083986117,0.00030963542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010916903,0.00007908065,0.0012159456,0.0005794618,0.00008578967,0.00045296235,0.00008412096,0.0004542333,0.98678374,0.0010483494,0.0010671736,0.007057536],"study_design_scores_gemma":[0.00016698724,0.0012712731,0.0503892,0.000088036555,0.00017523777,0.0013650206,0.0002916406,0.003927776,0.92286086,0.0010124488,0.018360801,0.00009066401],"about_ca_topic_score_codex":0.002985563,"about_ca_topic_score_gemma":0.0026410362,"teacher_disagreement_score":0.002985563,"about_ca_system_score_codex":0.0010106065,"about_ca_system_score_gemma":0.0005915615,"threshold_uncertainty_score":0.0073325634},"labels":[],"label_agreement":null},{"id":"W2385366530","doi":"10.1158/1538-8514.tumang15-ia22","title":"Abstract IA22: Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; Breast cancer; Adjuvant therapy; Primary tumor; Chemotherapy; Pazopanib; Clinical trial; Adjuvant; Metastasis; Cancer","score_opus":0.1294528729338554,"score_gpt":0.3981295523672547,"score_spread":0.26867667943339935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2385366530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76824,0.020586504,0.18820067,0.0023940804,0.0007069677,0.0007735283,0.005235574,0.0018475458,0.012015099],"genre_scores_gemma":[0.96193105,0.0051467195,0.025899911,0.00025904604,0.00014371461,0.00042406775,0.0038512645,0.00014403585,0.0022001837],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999655,0.00010532652,0.00002595271,0.00005787644,0.00011684061,0.000039018756],"domain_scores_gemma":[0.9991999,0.00026566035,0.00019037344,0.00008846984,0.00013914371,0.000116474315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010560856,0.0009098831,0.0009245723,0.00052638195,0.00013840644,0.0012096213,0.0006457655,0.00088945386,0.0019954797],"category_scores_gemma":[0.0011297055,0.00027724297,0.00043966854,0.00025779643,0.00021408404,0.0005235369,0.00036222057,0.0013036228,0.00091110024],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025250595,0.0026106297,0.012255674,0.0009582135,0.00023131233,0.0004344019,0.000063426196,0.11555117,0.77347124,0.0036411004,0.009298655,0.078959204],"study_design_scores_gemma":[0.00041185715,0.009552678,0.016884495,0.00014449673,0.00037570932,0.0014760947,0.000041006075,0.5435066,0.39951617,0.0024130656,0.025573634,0.00010415425],"about_ca_topic_score_codex":0.0010692782,"about_ca_topic_score_gemma":0.00046687858,"teacher_disagreement_score":0.0019954797,"about_ca_system_score_codex":0.0007467523,"about_ca_system_score_gemma":0.0005823764,"threshold_uncertainty_score":0.0066755414},"labels":[],"label_agreement":null},{"id":"W2394733107","doi":"10.1158/1535-7163.targ-15-b29","title":"Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Adverse effect; Prednisone; Abiraterone acetate; Internal medicine; Hyponatremia; Enzalutamide; Pharmacokinetics; Cancer; Androgen deprivation therapy; Urology; Pharmacology; Androgen receptor","score_opus":0.08138194030855352,"score_gpt":0.39718238655424015,"score_spread":0.31580044624568665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394733107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902463,0.0018399378,0.0006003658,0.00039827873,0.000097946,0.003993016,0.0016054276,0.000120604054,0.0010980868],"genre_scores_gemma":[0.9874441,0.0016381243,0.0020470216,0.0007495292,0.00019652318,0.0029404985,0.0023567975,0.00003991925,0.002587493],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945587,0.00025031864,0.000028788165,0.00011917715,0.000047597514,0.00009822842],"domain_scores_gemma":[0.9993155,0.00008375247,0.000095154384,0.000049369915,0.00004267972,0.00041361217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017373007,0.0020359706,0.0021124813,0.000572641,0.00058366806,0.00097358326,0.00087286514,0.0013232379,0.004881054],"category_scores_gemma":[0.0007453227,0.0007278597,0.0012587281,0.00045926933,0.0011183615,0.0008692005,0.0003956393,0.0028274609,0.0014501038],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6118406,0.16636288,0.0072628343,0.0012754679,0.0012930799,0.00065538095,0.00049265014,0.0029577177,0.11268755,0.00023749506,0.0047683096,0.090166],"study_design_scores_gemma":[0.4187267,0.56355757,0.010857037,0.000027238397,0.0002874336,0.00029824415,0.00004590008,0.0006650924,0.0035088204,0.00008334591,0.0019070059,0.00003567461],"about_ca_topic_score_codex":0.0013397175,"about_ca_topic_score_gemma":0.0027690397,"teacher_disagreement_score":0.004881054,"about_ca_system_score_codex":0.00072139327,"about_ca_system_score_gemma":0.0019833473,"threshold_uncertainty_score":0.016328752},"labels":[],"label_agreement":null},{"id":"W2394817086","doi":"10.1158/1535-7163.targ-15-b91","title":"Abstract B91: Anti-PD1 blockade increases the activity of tumor infiltrating antigen-specific CD8 T cells induced by a potent peptide vaccine in combination with metronomic cyclophosphamide","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"ELISPOT; Immunogenicity; Immune system; Cytotoxic T cell; CD8; Medicine; Immunology; Tumor microenvironment; Cancer vaccine; Antigen; Cancer research; Tumor antigen; Cancer; Immunotherapy; Pharmacology; Biology; Internal medicine; In vitro","score_opus":0.019080110591711635,"score_gpt":0.2490849723117268,"score_spread":0.23000486172001516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394817086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688596,0.00078379066,0.00081522163,0.00011432643,0.00008332614,0.000063152955,0.00022473246,0.00007937897,0.00095016835],"genre_scores_gemma":[0.9971614,0.00035221287,0.00088311697,0.000057003013,0.00003820904,0.0000642307,0.00027020375,0.000014489893,0.0011592351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983704,0.00003139209,0.000012618015,0.00002966842,0.000027529333,0.00006171647],"domain_scores_gemma":[0.99989545,0.00001675435,0.000022445576,0.00000969795,0.000007712202,0.000047944395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000136894,0.00053814513,0.00045611218,0.00023056034,0.00011083406,0.00030012152,0.0002225759,0.00038269046,0.0016993199],"category_scores_gemma":[0.00013135994,0.00018296069,0.0002234611,0.00014181173,0.00020407351,0.00018463786,0.0001823621,0.0010946973,0.0004318029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021668368,0.00074505334,0.00011924429,0.00008035636,0.000015935639,0.00003437312,0.000013440376,0.0003935604,0.990927,0.000086594264,0.00023354402,0.005184119],"study_design_scores_gemma":[0.0007109623,0.018365268,0.0027594343,0.000018668534,0.000044515393,0.00024587897,0.000019313225,0.00278765,0.9726211,0.000065601904,0.0023513746,0.00001020231],"about_ca_topic_score_codex":0.00039619338,"about_ca_topic_score_gemma":0.00045605042,"teacher_disagreement_score":0.0016993199,"about_ca_system_score_codex":0.00020554634,"about_ca_system_score_gemma":0.00030037056,"threshold_uncertainty_score":0.005684793},"labels":[],"label_agreement":null},{"id":"W2396978951","doi":"10.1158/1535-7163.targ-15-a159","title":"Abstract A159: Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Delmar (Canada)","funders":"","keywords":"Cisplatin; Cytotoxicity; Oxaliplatin; In vivo; Pharmacology; Lung cancer; MTT assay; Medicine; Cancer research; Gemcitabine; Cancer; Oncology; Chemistry; Chemotherapy; Internal medicine; Cell growth; In vitro; Biology; Colorectal cancer; Biochemistry","score_opus":0.021870783041135326,"score_gpt":0.2945530401078155,"score_spread":0.2726822570666802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396978951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577135,0.0016713357,0.0003698793,0.00008394491,0.00004620408,0.000035580157,0.00041199714,0.00006037037,0.0015492954],"genre_scores_gemma":[0.9961777,0.00061707065,0.0006243424,0.000052615957,0.000009797435,0.000019108575,0.0005508216,0.000009922639,0.0019385443],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999449,0.000010191725,0.0000072931916,0.000010743366,0.000015460757,0.000011356231],"domain_scores_gemma":[0.99995923,0.000005724432,0.000009516298,0.0000049072487,0.0000058457817,0.000014769327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006114689,0.00025469757,0.00022490154,0.00016719472,0.00009527108,0.00017747824,0.0001645199,0.00022716571,0.002217072],"category_scores_gemma":[0.00005948699,0.00007879504,0.00021546487,0.00016980294,0.00013638339,0.00013806662,0.0001421773,0.00032666553,0.0004116473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005969647,0.00014708532,0.0002973385,0.00007039036,0.000010056136,0.00005729281,0.000010662683,0.0001098074,0.9949759,0.00004942582,0.00015912029,0.0035160107],"study_design_scores_gemma":[0.00008151103,0.002411279,0.0033186101,0.000004935699,0.00002398997,0.00024252082,0.000013422727,0.00037876665,0.99075794,0.000026192447,0.002736837,0.0000040340324],"about_ca_topic_score_codex":0.00044785047,"about_ca_topic_score_gemma":0.00043833736,"teacher_disagreement_score":0.002217072,"about_ca_system_score_codex":0.00015982428,"about_ca_system_score_gemma":0.00016551021,"threshold_uncertainty_score":0.007416904},"labels":[],"label_agreement":null},{"id":"W2397155186","doi":"10.1158/1535-7163.targ-15-a152","title":"Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital","funders":"","keywords":"Autotaxin; Lysophosphatidic acid; Lysophosphatidylcholine; Receptor; In vitro; Cell growth; Lipid signaling; Biochemistry; Signal transduction; Biology; Cell culture; Cancer cell; In vivo; Cell biology; Chemistry; Cancer; Phospholipid","score_opus":0.02091265378255236,"score_gpt":0.2574952640580346,"score_spread":0.23658261027548222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397155186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855555,0.0037703388,0.0047032414,0.0001927207,0.00008121706,0.00013405507,0.00079455075,0.0001666806,0.0046016662],"genre_scores_gemma":[0.98638797,0.0018210285,0.0040789554,0.000150125,0.000027698656,0.000110521934,0.0021123767,0.000024185476,0.0052871075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998241,0.000031939715,0.000015524813,0.00002399687,0.000050192622,0.000054281416],"domain_scores_gemma":[0.9999064,0.000025712896,0.000017169761,0.00000753226,0.000017378085,0.000025721678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016119728,0.00048161644,0.000259243,0.00022903018,0.00009746796,0.00018099601,0.00032343308,0.00030450412,0.0017011687],"category_scores_gemma":[0.00011114013,0.00015008119,0.0002819424,0.00013984847,0.00011652444,0.00011081367,0.00011579571,0.00068205,0.0006777085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001282847,0.00013595383,0.00008410283,0.000031066513,0.000006635311,0.000036722962,0.000006154817,0.00009253748,0.99772173,0.000045406825,0.00013480568,0.0015765216],"study_design_scores_gemma":[0.00008031399,0.0019312913,0.0024949245,0.000009321976,0.000023140266,0.00035613365,0.000009793834,0.0012401069,0.9907549,0.000025887859,0.0030704197,0.0000036895315],"about_ca_topic_score_codex":0.00080812594,"about_ca_topic_score_gemma":0.0011321439,"teacher_disagreement_score":0.0017011687,"about_ca_system_score_codex":0.0003084198,"about_ca_system_score_gemma":0.00021368229,"threshold_uncertainty_score":0.005690992},"labels":[],"label_agreement":null},{"id":"W2397178591","doi":"10.1158/1535-7163.targ-15-a119","title":"Abstract A119: Investigating PIK3CA mutational status on cisplatin and radiation sensitivity in cervical cancer cell lines: Implications for PI3K inhibitor therapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; University of Calgary","funders":"","keywords":"Cisplatin; PI3K/AKT/mTOR pathway; Cancer research; HeLa; Cervical cancer; Medicine; Cancer; Radiation therapy; Mutation; Chemotherapy; Cell culture; Molecular biology; Biology; Internal medicine; Gene; Signal transduction; Genetics","score_opus":0.049310210053979876,"score_gpt":0.3350010664048908,"score_spread":0.2856908563509109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397178591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828933,0.0025790778,0.0028981278,0.00041743027,0.00014161262,0.00033917377,0.00413021,0.00018915863,0.0064118477],"genre_scores_gemma":[0.98649466,0.0012837009,0.0038346986,0.00019422108,0.000020326965,0.00041027568,0.0034718728,0.000040808165,0.004249446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99949396,0.00008324794,0.000088548884,0.000080110694,0.00018914511,0.00006509042],"domain_scores_gemma":[0.9997435,0.000066625085,0.00003661248,0.000042907115,0.000080137885,0.000030238054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039549507,0.0003502387,0.0007737303,0.00052430766,0.0004229804,0.00062945555,0.00041028572,0.000694196,0.0046860683],"category_scores_gemma":[0.00035321745,0.00025517982,0.00069347984,0.00078447605,0.0002782447,0.0004444594,0.00027141042,0.0011358508,0.0010683001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005237021,0.00042822966,0.0030381614,0.00010844661,0.000035841585,0.00008787402,0.00007283324,0.00025127933,0.9895738,0.0001582538,0.00066891935,0.005052715],"study_design_scores_gemma":[0.00007677559,0.0024354134,0.03312611,0.00001305584,0.00008949044,0.00041364925,0.00013048304,0.002132444,0.9578536,0.00006832758,0.0036433607,0.000017369253],"about_ca_topic_score_codex":0.0040755845,"about_ca_topic_score_gemma":0.0029300747,"teacher_disagreement_score":0.0046860683,"about_ca_system_score_codex":0.0006865898,"about_ca_system_score_gemma":0.00044709802,"threshold_uncertainty_score":0.015676439},"labels":[],"label_agreement":null},{"id":"W2398074214","doi":"10.1158/1535-7163.targ-15-a188","title":"Abstract A188: Diazonamide DZ 2384, a potential therapeutic for pancreatic cancer, binds to tubulin with a unique impact on microtubule dynamics and tubulin curvature","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vinorelbine; Tubulin; Microtubule; Vinca; Mitosis; Cell biology; Biology; Cancer research; Chemistry; Pharmacology; Genetics","score_opus":0.0129217169998951,"score_gpt":0.28508751888489187,"score_spread":0.2721658018849968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398074214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9284119,0.01915527,0.0088343145,0.0017817296,0.0005742434,0.00019256189,0.004574501,0.00047008647,0.0360053],"genre_scores_gemma":[0.94918245,0.00879493,0.005319933,0.00040341262,0.00008423046,0.00008461216,0.0039031864,0.000046467703,0.032180764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999714,0.0000032303699,0.0000017693474,0.0000061480337,0.000011955374,0.000005559161],"domain_scores_gemma":[0.9999819,0.0000017601345,0.000005418924,0.0000010593334,0.000003833577,0.0000061333753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004920421,0.00030246805,0.00016431655,0.00013825974,0.00014524136,0.0001585606,0.00025893524,0.0002296713,0.0063450276],"category_scores_gemma":[0.000053730237,0.00008924315,0.00013920163,0.00012156844,0.000099129094,0.00010238652,0.00013462256,0.00038270725,0.0014524057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004253905,0.00009920235,0.00054536323,0.00024014355,0.000018784238,0.00036924146,0.000014516774,0.00038256767,0.97426605,0.0008225933,0.0029002584,0.019915821],"study_design_scores_gemma":[0.0002908877,0.0015241824,0.0054390887,0.000029237935,0.000068350644,0.0031075622,0.000030873995,0.0014682703,0.87825954,0.0004006776,0.10936755,0.000013788717],"about_ca_topic_score_codex":0.00083508994,"about_ca_topic_score_gemma":0.0007534569,"teacher_disagreement_score":0.0063450276,"about_ca_system_score_codex":0.00036411488,"about_ca_system_score_gemma":0.00023476059,"threshold_uncertainty_score":0.021226227},"labels":[],"label_agreement":null},{"id":"W2399049874","doi":"10.1158/1535-7163.targ-15-c28","title":"Abstract C28: The combination of Acetazolamide and Sulforophane targets the tumor initiating cells in human bronchial carcinoids","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Queen's University","funders":"","keywords":"Clonogenic assay; Cancer research; Cancer stem cell; Stem cell; Cell culture; Biology; Chemistry; Cell biology","score_opus":0.043283800107408316,"score_gpt":0.34102044359066797,"score_spread":0.2977366434832597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399049874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941499,0.0016407415,0.00064132334,0.00014419328,0.000059876704,0.0001101653,0.00094347575,0.00006533205,0.0022450874],"genre_scores_gemma":[0.9952715,0.00065922743,0.000846171,0.000043365308,0.000016704105,0.000056556542,0.0010387797,0.000011141042,0.0020566103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998839,0.000016457121,0.000009511998,0.000024988964,0.00003320156,0.0000318103],"domain_scores_gemma":[0.99994004,0.000010157539,0.000008235166,0.000008501197,0.000010015694,0.000023098342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088961315,0.00030030354,0.00035583548,0.0001898917,0.00015315134,0.0001688365,0.00020246816,0.00023086568,0.0027025857],"category_scores_gemma":[0.00009870999,0.00008310181,0.00027115902,0.0001579103,0.00015527273,0.00009154889,0.00013653003,0.0004255885,0.0004858882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063781417,0.00011799383,0.00033874653,0.000074655625,0.000012330325,0.000091471906,0.00001470456,0.0001908159,0.994152,0.000036257883,0.00026079625,0.0040723644],"study_design_scores_gemma":[0.000119077056,0.0029902598,0.0066998294,0.000008253825,0.00003301017,0.00035215815,0.000026495392,0.00081522367,0.98473144,0.000017472114,0.004200574,0.0000062672257],"about_ca_topic_score_codex":0.0029528476,"about_ca_topic_score_gemma":0.0045590233,"teacher_disagreement_score":0.0029528476,"about_ca_system_score_codex":0.00023922112,"about_ca_system_score_gemma":0.0003855805,"threshold_uncertainty_score":0.009041071},"labels":[],"label_agreement":null},{"id":"W2400062612","doi":"10.1158/1535-7163.targ-15-b34","title":"Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Prodrug; Pharmacology; Drug; Chemistry; Pharmacokinetics; Bioavailability; Toxicity; Distribution (mathematics); Tolerability; Drug delivery; Linker; Medicine; Adverse effect","score_opus":0.03979978382547662,"score_gpt":0.29042508235058256,"score_spread":0.25062529852510596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400062612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679477,0.0014240617,0.0073401444,0.00010802105,0.000033185534,0.00007917065,0.0005845413,0.00032360686,0.0033125035],"genre_scores_gemma":[0.9864153,0.0005694331,0.0054136706,0.000036510173,0.000011888608,0.00006629504,0.000576532,0.00005545771,0.0068549835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991,0.000009069596,0.0000064718593,0.000026035395,0.000030388861,0.000018027175],"domain_scores_gemma":[0.99994385,0.0000068673,0.000018755498,0.0000065382415,0.0000103437815,0.0000136164845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011480357,0.00037526185,0.00024935373,0.00020086755,0.000104786006,0.00019960215,0.0001543335,0.00024080765,0.002576575],"category_scores_gemma":[0.000078030105,0.00012765372,0.00015291291,0.0001328125,0.00016357837,0.00017786077,0.00013990582,0.0004880162,0.00056942116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014633016,0.000043384338,0.000059353053,0.000028025517,0.0000056966564,0.00001217074,0.000005179465,0.000106782216,0.9974837,0.000048643466,0.0001146464,0.0019460478],"study_design_scores_gemma":[0.000015626025,0.0005335925,0.00062383246,0.0000022385457,0.000009370694,0.00004849193,0.000001896567,0.00041387696,0.9967699,0.000009359637,0.0015698627,0.0000019030641],"about_ca_topic_score_codex":0.00096162054,"about_ca_topic_score_gemma":0.0010286807,"teacher_disagreement_score":0.002576575,"about_ca_system_score_codex":0.00032669606,"about_ca_system_score_gemma":0.00024356495,"threshold_uncertainty_score":0.008619547},"labels":[],"label_agreement":null},{"id":"W2400969352","doi":"10.1158/1535-7163.targ-15-lb-c19","title":"Abstract LB-C19: The investigation of structural determinants that mediate selective inhibition of UBA5, the UFM1 activating enzyme","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Linker; Chemistry; Enzyme; Kinome; Stereochemistry; Active site; Biochemistry; IC50; In vitro; Kinase","score_opus":0.04683034237247323,"score_gpt":0.2934551128160076,"score_spread":0.24662477044353437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400969352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923785,0.0015073334,0.003370603,0.000089191686,0.000021722042,0.00008048159,0.00046211403,0.00010530628,0.0019847131],"genre_scores_gemma":[0.9951499,0.00048067878,0.0023016122,0.00004169959,0.000004845652,0.000019788491,0.000628332,0.000021760738,0.0013513265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998808,0.000016706557,0.000009157163,0.000020787958,0.000040092164,0.00003247648],"domain_scores_gemma":[0.9999275,0.00001010491,0.000019482703,0.000005709328,0.000015881964,0.000021416547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012234597,0.00024745785,0.0002798009,0.00014458458,0.00013071719,0.00020769607,0.00044809704,0.00022935992,0.0015501406],"category_scores_gemma":[0.00012150132,0.00008883348,0.00017267838,0.00013262065,0.00016437062,0.0000961885,0.00013883774,0.000356432,0.00042585985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021231,0.00008213822,0.00014721762,0.00002954174,0.000010008486,0.00006129386,0.000004839899,0.00030561766,0.9971909,0.00011617353,0.00008587316,0.0017540591],"study_design_scores_gemma":[0.00003533202,0.00071347883,0.00055830204,0.0000028504742,0.000011284815,0.00010333604,0.0000040750824,0.00077205175,0.9964142,0.00001189644,0.0013704739,0.000002749629],"about_ca_topic_score_codex":0.0022299318,"about_ca_topic_score_gemma":0.0017639415,"teacher_disagreement_score":0.0022299318,"about_ca_system_score_codex":0.00047089622,"about_ca_system_score_gemma":0.00030368887,"threshold_uncertainty_score":0.0051857233},"labels":[],"label_agreement":null},{"id":"W2402002440","doi":"10.1158/1535-7163.targ-15-b173","title":"Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; splice; Cancer research; Androgen; Alternative splicing; Cancer; Biology; Medicine; Internal medicine; Endocrinology; Messenger RNA; Hormone; Gene; Genetics","score_opus":0.22797474971661802,"score_gpt":0.40608981782862924,"score_spread":0.17811506811201122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402002440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322797,0.0018108565,0.0023334606,0.000723952,0.00020615166,0.0002878381,0.004029798,0.00047554108,0.006904485],"genre_scores_gemma":[0.97910666,0.0010831541,0.0016315073,0.00027165102,0.00004097826,0.00031888788,0.00687845,0.00009672419,0.010572061],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99964595,0.00007775929,0.00002391123,0.00005161177,0.00011613137,0.000084536616],"domain_scores_gemma":[0.99971825,0.000051749572,0.000049109276,0.00004624252,0.000031059324,0.00010351735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051115535,0.0007365408,0.00060928316,0.000450195,0.0002787335,0.00055547385,0.0005549864,0.0004825148,0.007636635],"category_scores_gemma":[0.00023522013,0.00022900506,0.0007011009,0.0003072245,0.0004856023,0.00029828018,0.00017082131,0.0025051963,0.0011547051],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077203806,0.0046380768,0.0011254319,0.00018925182,0.00011228904,0.00020235674,0.00006921794,0.00056415197,0.965934,0.00037616838,0.002937888,0.016130926],"study_design_scores_gemma":[0.0026234908,0.043206435,0.010464116,0.000023044327,0.00015366732,0.0010426736,0.000101824226,0.0012310942,0.92825365,0.00015708581,0.012715582,0.00002728636],"about_ca_topic_score_codex":0.002160627,"about_ca_topic_score_gemma":0.0044351355,"teacher_disagreement_score":0.007636635,"about_ca_system_score_codex":0.0006978502,"about_ca_system_score_gemma":0.00079952116,"threshold_uncertainty_score":0.025547087},"labels":[],"label_agreement":null},{"id":"W2402016156","doi":"10.1158/1535-7163.targ-15-b194","title":"Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Cancer; Medicine; Oncology; Pharmacology; Internal medicine; Epidermal growth factor receptor","score_opus":0.04897850486155135,"score_gpt":0.3676255073323042,"score_spread":0.31864700247075284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402016156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92425066,0.04555631,0.001159162,0.0036879939,0.0011898782,0.0035406617,0.010890046,0.00015317036,0.009572175],"genre_scores_gemma":[0.9668559,0.008751941,0.0013964177,0.002323155,0.0013156355,0.0022143833,0.010796398,0.000091365015,0.006254661],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987413,0.0007493095,0.00008470824,0.00012814469,0.00015863933,0.00013797476],"domain_scores_gemma":[0.99875116,0.0003753691,0.00028711857,0.0001511333,0.0001212291,0.00031399698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003670922,0.0013541443,0.0029278037,0.00038800397,0.0003836535,0.0019196329,0.0010168484,0.001241033,0.005814185],"category_scores_gemma":[0.003020441,0.00050559844,0.005338157,0.0005081083,0.00042370558,0.0010696012,0.00044665884,0.003499853,0.0015358003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8976781,0.0043750894,0.0070062135,0.001286188,0.0155868195,0.00019993764,0.0001321545,0.0011964657,0.009861672,0.00028118337,0.013488419,0.048907794],"study_design_scores_gemma":[0.7477081,0.15456542,0.052193552,0.00033995896,0.020769577,0.00044619205,0.00020744842,0.001905451,0.0031568431,0.0009931982,0.01756612,0.00014811919],"about_ca_topic_score_codex":0.0010938601,"about_ca_topic_score_gemma":0.0036052815,"teacher_disagreement_score":0.005814185,"about_ca_system_score_codex":0.0009032626,"about_ca_system_score_gemma":0.0011064612,"threshold_uncertainty_score":0.019450426},"labels":[],"label_agreement":null},{"id":"W2402074372","doi":"10.1158/1535-7163.mct-15-0849","title":"Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Hospital for Sick Children","keywords":"Medulloblastoma; Cancer research; Cell cycle; Radiation therapy; Cell cycle checkpoint; Cancer; Kinase; Radiosensitizer; Medicine; Chemistry; Biology; Cell biology; Internal medicine","score_opus":0.022055733255393846,"score_gpt":0.2898538999910119,"score_spread":0.26779816673561807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402074372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943445,0.0019679354,0.0013695732,0.00009969212,0.000034252178,0.000051035888,0.00024167671,0.00011618578,0.0017751792],"genre_scores_gemma":[0.99413174,0.002270671,0.0018451933,0.000045915927,0.00001055284,0.000059326987,0.0003657277,0.000014268477,0.0012565987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999304,0.000011413001,0.000007926239,0.000009809672,0.000017746783,0.000022740602],"domain_scores_gemma":[0.9999808,0.0000037017478,0.000007021033,0.0000022241973,0.0000017856613,0.00000448949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000928099,0.00033517627,0.00027408937,0.00019383704,0.000108977525,0.000176419,0.00021082476,0.00013775824,0.0010236304],"category_scores_gemma":[0.00005503409,0.000117988486,0.00026665677,0.00013512645,0.00016009515,0.00010526372,0.00013848221,0.0005040418,0.00026281577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021941452,0.00012459335,0.00016972204,0.0000934275,0.00001742667,0.000038106387,0.0000122971915,0.00023270931,0.99493873,0.00015204924,0.00012703972,0.0038744702],"study_design_scores_gemma":[0.00010978244,0.0015245083,0.0040301257,0.000009849354,0.0000494341,0.00023424989,0.000027604921,0.0020172305,0.98734564,0.00005508239,0.0045897095,0.0000066812386],"about_ca_topic_score_codex":0.0007407855,"about_ca_topic_score_gemma":0.0020209153,"teacher_disagreement_score":0.0010236304,"about_ca_system_score_codex":0.00025574345,"about_ca_system_score_gemma":0.00027376265,"threshold_uncertainty_score":0.0034243464},"labels":[],"label_agreement":null},{"id":"W2403532441","doi":"10.1158/1535-7163.targ-15-c169","title":"Abstract C169: ER maleate is a novel anticancer agent in oral cancer cells: Implications for cancer therapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Chemosensitizer; Cancer research; Carboplatin; Syk; Apoptosis; Cancer; In vivo; Cell growth; Cancer cell; Medicine; Biology; Tyrosine kinase; In vitro; Cisplatin; Internal medicine; Cytotoxicity; Chemotherapy; Receptor","score_opus":0.0951377634896796,"score_gpt":0.364094278728318,"score_spread":0.2689565152386384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403532441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94837403,0.02909024,0.003956609,0.0009929177,0.00024399093,0.00017058475,0.0013511769,0.00014965331,0.01567081],"genre_scores_gemma":[0.96594864,0.00952158,0.0017456074,0.00026190424,0.00008790574,0.00006226066,0.0012112387,0.000029059125,0.0211319],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990475,0.000016218719,0.000008753648,0.000018767128,0.000029804087,0.000021798023],"domain_scores_gemma":[0.99996626,0.0000036785552,0.0000096182985,0.0000032549628,0.000009095192,0.000008074217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014508604,0.0004400579,0.00040656378,0.00022487645,0.00017327315,0.0003305278,0.0002490026,0.00033432132,0.0058568646],"category_scores_gemma":[0.00006543693,0.00009779119,0.00026953826,0.00026012343,0.00015831027,0.00019300824,0.00021143856,0.00030359565,0.0011163226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012176249,0.0001549786,0.00050679775,0.00030271482,0.000022456512,0.00034153918,0.000020383923,0.0002465311,0.96962345,0.00090237544,0.00075455057,0.025906684],"study_design_scores_gemma":[0.00014046326,0.0023494808,0.0056508393,0.000028284025,0.000059585513,0.0013859253,0.000037865248,0.00043355132,0.9561341,0.00019729669,0.033570845,0.000011768002],"about_ca_topic_score_codex":0.00043939622,"about_ca_topic_score_gemma":0.0004897411,"teacher_disagreement_score":0.0058568646,"about_ca_system_score_codex":0.00039035094,"about_ca_system_score_gemma":0.00024439237,"threshold_uncertainty_score":0.01959318},"labels":[],"label_agreement":null},{"id":"W2404352909","doi":"10.1158/1535-7163.targ-15-b109","title":"Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in <i>Akt1</i> E17K mutation positive advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"AKT1; Cancer; Protein kinase B; Library science; Medicine; Chemistry; Phosphorylation; Biochemistry; Internal medicine; Computer science","score_opus":0.02893861731283678,"score_gpt":0.30944031885153467,"score_spread":0.2805017015386979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404352909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35902828,0.25734043,0.004134538,0.027112829,0.027509889,0.0017225622,0.020061031,0.0035645873,0.2995259],"genre_scores_gemma":[0.59949845,0.13346471,0.0038424945,0.010079671,0.006390238,0.00055706064,0.020800814,0.000528566,0.22483797],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99986625,0.000022603255,0.000014022587,0.000020082922,0.00004712154,0.00002992318],"domain_scores_gemma":[0.9998871,0.000012553543,0.000017152539,0.00000705274,0.000018659683,0.000057346493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027471804,0.0008324915,0.0008985247,0.00061824336,0.00039194836,0.0010074908,0.00049587,0.0008503238,0.032521006],"category_scores_gemma":[0.00029649682,0.00023825282,0.0005509292,0.00070819724,0.00023207109,0.0003950201,0.00029806985,0.0013916853,0.0138288075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019817723,0.0019146503,0.0024416773,0.0019807955,0.00023840767,0.002338057,0.00007084109,0.0009731397,0.09693427,0.0012502626,0.37500867,0.49703148],"study_design_scores_gemma":[0.01903076,0.036238503,0.05648675,0.0016718404,0.0010730823,0.010732921,0.00016708099,0.0028293475,0.12812842,0.0019249363,0.74159575,0.00012052632],"about_ca_topic_score_codex":0.0010406084,"about_ca_topic_score_gemma":0.0024327948,"teacher_disagreement_score":0.032521006,"about_ca_system_score_codex":0.00079011475,"about_ca_system_score_gemma":0.00086580985,"threshold_uncertainty_score":0.10879362},"labels":[],"label_agreement":null},{"id":"W2405138885","doi":"10.1158/1535-7163.targ-15-a150","title":"Abstract A150: Anti-BIRC6 antisense oligonucleotide inhibits enzalutamide-resistant castration-resistant prostate cancer growth in patient-derived xenograft model by suppressing multiple signaling pathways","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; Spinal Cord Injury BC","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Bicalutamide; Survivin; Apoptosis; Medicine; In vivo; Androgen; LNCaP; Cancer; Biology; Internal medicine; Hormone","score_opus":0.0526247472187007,"score_gpt":0.30567236337101195,"score_spread":0.25304761615231125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405138885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867923,0.0023812172,0.0031167066,0.00020162377,0.00023591414,0.00016471627,0.0014572882,0.00033155992,0.0034317006],"genre_scores_gemma":[0.9830876,0.0015570063,0.0047776136,0.00013716618,0.00003623861,0.00018734936,0.0027333037,0.00003058298,0.0074531063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.000012338722,0.000011979327,0.000027336511,0.000036171572,0.000029735598],"domain_scores_gemma":[0.9999491,0.0000061761275,0.00001036566,0.000005415523,0.000008285659,0.000020613259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013738882,0.0004850187,0.00034192475,0.0003095929,0.0001564996,0.0001855917,0.00022879837,0.00031364098,0.002051585],"category_scores_gemma":[0.000045169556,0.00010883089,0.0003070526,0.00018809509,0.0001596307,0.00014744232,0.0000761923,0.00090809463,0.000456481],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003070145,0.00026510993,0.00009373251,0.00006424655,0.000009065346,0.000036116115,0.000011984392,0.000084133135,0.99718684,0.00009946431,0.00027219314,0.0015700692],"study_design_scores_gemma":[0.00013872722,0.0042291023,0.0021780226,0.0000070767924,0.000038634123,0.00027266273,0.000021014306,0.0011390205,0.98823893,0.000029898985,0.0037000508,0.000006781169],"about_ca_topic_score_codex":0.0010777029,"about_ca_topic_score_gemma":0.0014160587,"teacher_disagreement_score":0.002051585,"about_ca_system_score_codex":0.00025266325,"about_ca_system_score_gemma":0.0003451145,"threshold_uncertainty_score":0.0068632364},"labels":[],"label_agreement":null},{"id":"W2405581107","doi":"10.1158/1535-7163.targ-15-c41","title":"Abstract C41: A phase 1 study of OMN54 in patients with advanced malignancies","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Dosing; Adverse effect; Gastroenterology; Nausea; Vomiting; Cmax; Toxicity; Cancer; Pharmacology","score_opus":0.03311406230783848,"score_gpt":0.3316198073455244,"score_spread":0.2985057450376859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405581107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405175,0.0012605436,0.00038916373,0.00026956078,0.00005124782,0.0011858713,0.0008188008,0.0000838579,0.0018892356],"genre_scores_gemma":[0.98902506,0.0014185169,0.0021135446,0.0007638544,0.00009306778,0.0011578762,0.002373406,0.0000331291,0.0030215178],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99985063,0.00005876315,0.000011393017,0.00003067069,0.000019736159,0.00002873183],"domain_scores_gemma":[0.99972004,0.000037674577,0.000050960865,0.000028616676,0.00003008613,0.00013257177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061885786,0.00076842174,0.0010200891,0.00028494277,0.00028113928,0.00049944647,0.0004324954,0.00061467197,0.0043315515],"category_scores_gemma":[0.00039548826,0.0002670183,0.0005135491,0.00029285892,0.00047402646,0.00041046375,0.0002502173,0.001475648,0.00084015366],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3463697,0.08384596,0.02924687,0.0024723702,0.0011763255,0.0013149161,0.0004886498,0.0040694405,0.24278983,0.0007448391,0.014666841,0.27281427],"study_design_scores_gemma":[0.22319587,0.7067898,0.03871089,0.000096151256,0.0004172138,0.0015967255,0.00012606474,0.0021230732,0.013279906,0.0003119588,0.013304276,0.000048139096],"about_ca_topic_score_codex":0.0005843936,"about_ca_topic_score_gemma":0.0016396709,"teacher_disagreement_score":0.0043315515,"about_ca_system_score_codex":0.00047526907,"about_ca_system_score_gemma":0.001044285,"threshold_uncertainty_score":0.014490485},"labels":[],"label_agreement":null},{"id":"W2405852651","doi":"10.1158/1535-7163.targ-15-lb-a13","title":"Abstract LB-A13: Cellular characterization of the selective inhibition of UBA5 by organometallic, adenosine-based inhibitors","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Endoplasmic reticulum; Unfolded protein response; A549 cell; Cell biology; Cancer cell; Apoptosis; Cell; Cell growth; Cell culture; Cancer; Biology; Chemistry; Cancer research; Biochemistry","score_opus":0.01788890400519245,"score_gpt":0.2401138858856245,"score_spread":0.22222498188043205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405852651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97507817,0.004892276,0.009373589,0.00013735495,0.00006784445,0.00013332478,0.0024043038,0.00025708336,0.0076559978],"genre_scores_gemma":[0.98805654,0.00093707436,0.0035153246,0.00004161005,0.0000069427906,0.00005884411,0.0020380393,0.00003564735,0.005310027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999874,0.000020617275,0.0000115885605,0.000025851843,0.00003697886,0.000031003074],"domain_scores_gemma":[0.99993837,0.000012217632,0.000013264442,0.0000073343867,0.00001475162,0.000014101004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016610719,0.00032191988,0.00025980815,0.00017366697,0.00017400659,0.00025743808,0.00037395407,0.000291292,0.001544813],"category_scores_gemma":[0.000083282444,0.00008891458,0.0002145747,0.0002662973,0.00011646757,0.000103919396,0.00009047793,0.00042825213,0.0007081645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011078898,0.000049174316,0.000028993789,0.000033573713,0.0000053046097,0.00002304424,0.000005655421,0.000090394875,0.9987746,0.000055230463,0.000047888414,0.0007752107],"study_design_scores_gemma":[0.00000591032,0.00023066743,0.00029261445,0.0000019840393,0.000005639441,0.000028630622,0.0000047765507,0.00042050186,0.9982803,0.000005135788,0.0007223922,0.0000015219426],"about_ca_topic_score_codex":0.0029238488,"about_ca_topic_score_gemma":0.0023156782,"teacher_disagreement_score":0.0029238488,"about_ca_system_score_codex":0.0003968034,"about_ca_system_score_gemma":0.00020930795,"threshold_uncertainty_score":0.0058136582},"labels":[],"label_agreement":null},{"id":"W2410015475","doi":"","title":"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Pancreatic cancer; In vivo; Cancer research; Monoclonal antibody; Cancer; Cytotoxicity; Antibody; Signal transduction; Prostate cancer; Colorectal cancer; Biology; In vitro; Immunology; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.041043055824262084,"score_gpt":0.36784482769629,"score_spread":0.3268017718720279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410015475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784494,0.0058476655,0.009142565,0.0002257814,0.00011643631,0.00010284929,0.000746619,0.000488427,0.004880268],"genre_scores_gemma":[0.98041874,0.00317645,0.0072739595,0.00008005568,0.000031189582,0.000111075096,0.0018639965,0.000056121437,0.006988254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998103,0.000031781274,0.000012889186,0.000039771217,0.00006199484,0.000043341865],"domain_scores_gemma":[0.9998869,0.000018086166,0.00003642742,0.000016292033,0.000020608144,0.000021686103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029775483,0.0005215739,0.00036365076,0.00046699628,0.000120254525,0.00019867404,0.00027658715,0.00035178184,0.001644307],"category_scores_gemma":[0.00010382758,0.00018145409,0.0003442611,0.00020251506,0.00016127738,0.0001833138,0.00010969587,0.0006925542,0.0004791513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020447858,0.00014110064,0.00011331594,0.000059779344,0.000010553332,0.000032977605,0.000008882796,0.00006970136,0.99691427,0.000038685295,0.00013759184,0.0022685993],"study_design_scores_gemma":[0.000042980333,0.001908856,0.0017891941,0.000004866449,0.000035392677,0.0004011229,0.0000069206503,0.00061064336,0.99287087,0.0000121023895,0.0023131566,0.0000038532376],"about_ca_topic_score_codex":0.00077096844,"about_ca_topic_score_gemma":0.0008822532,"teacher_disagreement_score":0.001644307,"about_ca_system_score_codex":0.00023072617,"about_ca_system_score_gemma":0.00022866054,"threshold_uncertainty_score":0.0055007935},"labels":[],"label_agreement":null},{"id":"W2486291976","doi":"10.1158/1535-7163.mct-16-0048","title":"Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Doxorubicin; Osteosarcoma; Pharmacology; Cancer research; Mitochondrion; Medicine; Chemistry; Chemotherapy; Internal medicine; Biochemistry","score_opus":0.023481467536507372,"score_gpt":0.2965816286056582,"score_spread":0.2731001610691508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486291976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92432654,0.035773102,0.03220791,0.0011513619,0.00034309697,0.00032269975,0.0003077699,0.00027613319,0.0052913544],"genre_scores_gemma":[0.96244425,0.01943277,0.012845352,0.00030881295,0.00008053156,0.000101225785,0.0003105353,0.000022642602,0.004453905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995804,0.0000070711617,0.0000039699607,0.000013259997,0.000009749803,0.000007926798],"domain_scores_gemma":[0.999984,0.0000016725381,0.0000049312453,0.0000020457237,0.0000021340657,0.000005180607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009864093,0.00029020262,0.00030003427,0.00029992586,0.00011837785,0.0002188937,0.00017463222,0.00022513195,0.00051585835],"category_scores_gemma":[0.000040286326,0.000113832306,0.00020335446,0.00013158222,0.00016745256,0.00033008287,0.00023014986,0.0003604938,0.00014830015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012973884,0.000106900654,0.00024972498,0.00020907787,0.000013031241,0.00016400228,0.00004515675,0.0003241373,0.9761752,0.0010969519,0.0002256247,0.021260424],"study_design_scores_gemma":[0.0003321849,0.0048056967,0.005320129,0.000106739986,0.00020288906,0.0031173062,0.00006029717,0.0038247816,0.90163815,0.00081591756,0.07972193,0.000053928834],"about_ca_topic_score_codex":0.00020240195,"about_ca_topic_score_gemma":0.00065434637,"teacher_disagreement_score":0.00051585835,"about_ca_system_score_codex":0.00019627789,"about_ca_system_score_gemma":0.00014509365,"threshold_uncertainty_score":0.0017256737},"labels":[],"label_agreement":null},{"id":"W2488197870","doi":"10.1158/1535-7163.mct-16-0211","title":"FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; British Lung Foundation; Cancer Research UK; Wellcome Trust; Department of Education and Learning, Northern Ireland","keywords":"Mediator; Lung cancer; Cancer research; Cancer; Flip; Medicine; Oncology; Biology; Immunology; Internal medicine; Genetics; Apoptosis","score_opus":0.009561578925680396,"score_gpt":0.28395312735813805,"score_spread":0.27439154843245767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488197870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96189255,0.025924325,0.0047192797,0.0008402806,0.00018606285,0.00015545289,0.0007824222,0.0002403093,0.0052593173],"genre_scores_gemma":[0.9914874,0.004858017,0.00063018186,0.00015159594,0.000033899352,0.000047430825,0.0006201933,0.000013688296,0.0021575275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999124,0.000016087239,0.0000074958234,0.00001572374,0.000026364422,0.000021997732],"domain_scores_gemma":[0.9999443,0.0000066640087,0.00002063464,0.0000045932247,0.0000090161875,0.000014715344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001731128,0.00027955536,0.000257192,0.00018797998,0.00017981493,0.00032087535,0.00018201639,0.00034178866,0.0017438369],"category_scores_gemma":[0.00013954489,0.000103315106,0.00018497725,0.00012642935,0.0002148699,0.0002612643,0.000179935,0.00060814637,0.00044175374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014403144,0.000040572617,0.0005735112,0.00021427327,0.0000150842125,0.00023118871,0.00001430654,0.000108334374,0.99045676,0.00027516432,0.00033571917,0.007591049],"study_design_scores_gemma":[0.00010456738,0.0011789607,0.021510772,0.00004696279,0.00008836556,0.0035301577,0.000085409076,0.0017172943,0.95348454,0.0003657883,0.017867358,0.000019852912],"about_ca_topic_score_codex":0.00016437891,"about_ca_topic_score_gemma":0.0002594344,"teacher_disagreement_score":0.0017438369,"about_ca_system_score_codex":0.0003429933,"about_ca_system_score_gemma":0.0001771526,"threshold_uncertainty_score":0.0058336854},"labels":[],"label_agreement":null},{"id":"W2499220296","doi":"10.1158/1538-8514.pi3k14-a02","title":"Abstract A02: Biomarkers of drug response to buparlisib: Results of next-generation sequencing in a phase II trial of advanced endometrial carcinoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PTEN; Medicine; Endometrial cancer; PI3K/AKT/mTOR pathway; Oncology; KRAS; Internal medicine; Population; Clinical trial; Cohort; Cancer research; Cancer; Biology; Signal transduction; Colorectal cancer","score_opus":0.06582735248246067,"score_gpt":0.3257918820897812,"score_spread":0.2599645296073205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499220296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294066,0.0014234886,0.0011513901,0.00051737844,0.000038641272,0.0005931859,0.0024111571,0.00005481844,0.00086941087],"genre_scores_gemma":[0.98832244,0.0004974696,0.0031261714,0.00073360995,0.00006813888,0.0007254795,0.0056178835,0.00002117239,0.0008877697],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990909,0.00059303787,0.000048121117,0.000121790385,0.00009867326,0.000047540674],"domain_scores_gemma":[0.9983157,0.00053712487,0.00045134427,0.00015421418,0.00019814077,0.00034339636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003155164,0.00058693293,0.00080458756,0.00024486982,0.0002257803,0.00094973587,0.0003940084,0.000640227,0.0018589746],"category_scores_gemma":[0.0036599892,0.00024059675,0.00067063485,0.0003038922,0.000348163,0.00035448858,0.0003116374,0.0010895758,0.00038730458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49386552,0.008900118,0.16638532,0.0010354342,0.0049770474,0.0005277303,0.0003181318,0.008653055,0.11000538,0.00045084246,0.0089673,0.19591406],"study_design_scores_gemma":[0.25278547,0.26417753,0.39737388,0.00019429508,0.005515332,0.002050384,0.00021896888,0.03065662,0.03474015,0.0016788456,0.010447549,0.00016100485],"about_ca_topic_score_codex":0.00044924414,"about_ca_topic_score_gemma":0.00058049796,"teacher_disagreement_score":0.003155164,"about_ca_system_score_codex":0.0005388555,"about_ca_system_score_gemma":0.000653175,"threshold_uncertainty_score":0.01668626},"labels":[],"label_agreement":null},{"id":"W2528347464","doi":"10.1158/1535-7163.mct-16-0354","title":"Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Prostate Cancer Canada; U.S. Department of Defense","keywords":"Enzalutamide; Androgen receptor; Antiandrogens; Prostate cancer; Tetratricopeptide; Cancer research; Small molecule; Chemistry; Pharmacology; Biology; Cell biology; Medicine; Cancer; Internal medicine; Biochemistry","score_opus":0.03141413035605064,"score_gpt":0.3114934926663247,"score_spread":0.2800793623102741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528347464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916037,0.0023231357,0.003878151,0.00011302932,0.000043822565,0.00003641836,0.00028842906,0.00011204067,0.0016012997],"genre_scores_gemma":[0.9953057,0.0008905476,0.002262058,0.000061291226,0.000008555244,0.000018109688,0.00035380726,0.000011099989,0.0010888464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999325,0.0000069209636,0.0000036764814,0.000013018183,0.000023168897,0.00002073229],"domain_scores_gemma":[0.9999665,0.000006407329,0.000011865899,0.00000346696,0.0000025752959,0.00000907717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007128253,0.00030703328,0.00019654231,0.0000672513,0.00010006257,0.00013749838,0.00016360598,0.0001755826,0.000954231],"category_scores_gemma":[0.000049873135,0.00006341065,0.00026824285,0.00009341341,0.0001729953,0.000101813835,0.00010618133,0.000599741,0.00025521877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006285472,0.000023479546,0.000085536485,0.0000308619,0.0000050734325,0.000034722834,0.000006037251,0.0001399852,0.99803084,0.00010686515,0.000048546055,0.0014251147],"study_design_scores_gemma":[0.000028862985,0.0005394337,0.0021517016,0.0000027823453,0.000012476089,0.00037398833,0.0000075762005,0.00092681317,0.99270916,0.000027286065,0.0032155397,0.000004460203],"about_ca_topic_score_codex":0.00085037935,"about_ca_topic_score_gemma":0.0013619764,"teacher_disagreement_score":0.000954231,"about_ca_system_score_codex":0.00023416484,"about_ca_system_score_gemma":0.00019847107,"threshold_uncertainty_score":0.003192246},"labels":[],"label_agreement":null},{"id":"W2536079445","doi":"10.1158/1535-7163.mct-16-0449","title":"Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Mesothelin; Antibody-drug conjugate; Monoclonal antibody; Cancer research; Immunohistochemistry; Antibody; In vivo; Pancreatic cancer; Cancer; Mesothelioma; Chemistry; Medicine; Immunology; Pathology; Biology; Internal medicine","score_opus":0.024712442906646,"score_gpt":0.3452394585150638,"score_spread":0.32052701560841784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536079445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952142,0.0007371301,0.0023233374,0.00005918329,0.00002831225,0.00008003445,0.00033154603,0.000102865204,0.0011233207],"genre_scores_gemma":[0.9972498,0.00025152275,0.0007869518,0.000018894201,0.00000780192,0.000043734202,0.00040586572,0.000017726741,0.0012176326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973434,0.00006417621,0.00002042189,0.00004116642,0.00007183133,0.00006805934],"domain_scores_gemma":[0.99966323,0.000091395945,0.000086464795,0.00004963665,0.000040332416,0.00006894541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005083842,0.00046006875,0.00032958886,0.00029366667,0.0001261317,0.00030585442,0.00025152974,0.00037059851,0.0011602488],"category_scores_gemma":[0.00041233833,0.00023365501,0.00022605623,0.00019827759,0.0002717408,0.00027817654,0.00012365382,0.00082263525,0.00033980142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012391476,0.00056627125,0.0006234086,0.00002598311,0.000016658825,0.000021234422,0.000027060993,0.0006792615,0.9943159,0.000055256092,0.00010062302,0.0023291155],"study_design_scores_gemma":[0.000081835715,0.0069444072,0.0035149911,0.0000029263847,0.000030829466,0.00006045287,0.000009641275,0.0025524981,0.98614883,0.000018012548,0.0006316674,0.0000039568276],"about_ca_topic_score_codex":0.0008011314,"about_ca_topic_score_gemma":0.00072696677,"teacher_disagreement_score":0.0011602488,"about_ca_system_score_codex":0.00035272396,"about_ca_system_score_gemma":0.00025020345,"threshold_uncertainty_score":0.0038813949},"labels":[],"label_agreement":null},{"id":"W2537108088","doi":"10.1158/1535-7163.mct-16-0325","title":"6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Griffith University; Prostate Cancer Foundation of Australia; Medical Research Council; Movember Foundation; Australian Government; Prostate Cancer Foundation","keywords":"Microtubule polymerization; LNCaP; Vinblastine; Mitosis; Microtubule; Cancer research; Cancer cell; Biology; Vinca; Prostate cancer; Cell biology; Mitotic catastrophe; Cancer; Pharmacology; Tubulin; Chemotherapy; Genetics","score_opus":0.007828536117142175,"score_gpt":0.2517319151267506,"score_spread":0.2439033790096084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537108088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606719,0.019995056,0.009773741,0.00033636254,0.0000808214,0.00019546055,0.001280713,0.00034925522,0.0073166587],"genre_scores_gemma":[0.9752265,0.008802692,0.0075771357,0.00014145885,0.000038535778,0.00006937704,0.0014182404,0.000018980216,0.006707006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999585,0.0000048470315,0.0000027709943,0.0000118584285,0.000014983141,0.0000070022465],"domain_scores_gemma":[0.999969,0.0000029286325,0.00001035249,0.0000036640495,0.0000052700807,0.000008731499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005359146,0.0002513111,0.00018347554,0.00018691654,0.00016695178,0.00015780193,0.00017146803,0.00018576963,0.00067710935],"category_scores_gemma":[0.00003717972,0.000078974976,0.00016015868,0.00013932247,0.00010206814,0.00012011069,0.000116568124,0.00037155332,0.00023680927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058137975,0.000022237593,0.00014799995,0.000065481836,0.0000051140555,0.000055660486,0.000008860176,0.000114457376,0.99310195,0.00008084616,0.00006716626,0.0062721297],"study_design_scores_gemma":[0.000024979207,0.0006822856,0.0077560553,0.000008505509,0.000019723071,0.00079384027,0.000012555604,0.00065890234,0.96807367,0.000070738955,0.021891179,0.000007535694],"about_ca_topic_score_codex":0.00059399824,"about_ca_topic_score_gemma":0.001701026,"teacher_disagreement_score":0.00067710935,"about_ca_system_score_codex":0.00024037641,"about_ca_system_score_gemma":0.00013510893,"threshold_uncertainty_score":0.0022651553},"labels":[],"label_agreement":null},{"id":"W2559479504","doi":"10.1158/1535-7163.mct-16-0416","title":"STAT1 Promotes <i>KRAS</i> Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Cancer Research Society","keywords":"KRAS; Cancer research; Carcinogenesis; Biology; STAT1; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Colorectal cancer; Gene knockdown; Cancer; Signal transduction; Eukaryotic translation; Translation (biology); Messenger RNA; Cell culture; Cell biology; Gene; Genetics","score_opus":0.05675535520054349,"score_gpt":0.33603544510472205,"score_spread":0.2792800899041786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559479504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944352,0.0009481118,0.0011375736,0.000193143,0.000039045568,0.000016426677,0.0003734464,0.00013867949,0.0027184114],"genre_scores_gemma":[0.9972842,0.00040097418,0.00047587242,0.000055890676,0.0000071689833,0.000014833513,0.0004043041,0.000015118679,0.0013415656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998714,0.000022588201,0.0000107622745,0.000016102897,0.0000340524,0.00004511219],"domain_scores_gemma":[0.9999093,0.000014304819,0.000030835177,0.00001058651,0.000007968949,0.000027018807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011596256,0.00021588498,0.00015510789,0.00020876224,0.00012009044,0.0002513782,0.00008412983,0.00012270523,0.0017846505],"category_scores_gemma":[0.00010129111,0.00010802534,0.00019826775,0.0001332898,0.00020208317,0.00011973437,0.00011053411,0.0006000781,0.00043395383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029538287,0.00005307952,0.00035332594,0.000023005503,0.0000041861385,0.000023150254,0.0000064131505,0.0001149683,0.99731916,0.00012760673,0.00010240511,0.0015772829],"study_design_scores_gemma":[0.00002794184,0.0005686554,0.0074710455,0.000006192128,0.000011390305,0.00020463023,0.000023024766,0.001249437,0.98813826,0.00006696439,0.0022290866,0.0000033202348],"about_ca_topic_score_codex":0.00056944875,"about_ca_topic_score_gemma":0.0010501943,"teacher_disagreement_score":0.0017846505,"about_ca_system_score_codex":0.00030355717,"about_ca_system_score_gemma":0.0002629704,"threshold_uncertainty_score":0.0059702396},"labels":[],"label_agreement":null},{"id":"W2563098228","doi":"","title":"SFRP1 promoter methylation and its contribution to endometrial tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"DNA methylation; Carcinogenesis; Endometrial cancer; Microsatellite instability; Epigenetics; Methylation; Biology; Cancer research; Wnt signaling pathway; Bisulfite sequencing; Cancer; Molecular biology; Genetics; Gene; Gene expression; Microsatellite","score_opus":0.021554815787292996,"score_gpt":0.3117308642557196,"score_spread":0.2901760484684266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563098228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735653,0.0017527627,0.00038117802,0.000034696597,0.0000024005806,0.00000525546,0.00012265728,0.000011496839,0.00033303694],"genre_scores_gemma":[0.9992637,0.00027905876,0.00018338962,0.0000056555305,0.0000031929776,0.0000031790312,0.00009570678,0.0000017985678,0.00016424304],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988365,0.000023272953,0.000012153793,0.000027670729,0.000032032523,0.000021160013],"domain_scores_gemma":[0.9997247,0.00006672906,0.00012058289,0.0000233593,0.000028712162,0.000035910714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022539655,0.00016579531,0.00013654838,0.00043115963,0.0001131107,0.00017594024,0.00012511852,0.00013773302,0.0018873204],"category_scores_gemma":[0.0007346001,0.00011976314,0.00014496892,0.00025153812,0.00013697847,0.00009069146,0.00015828748,0.0001538306,0.00023207154],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019289718,0.000047697475,0.54170734,0.00021752599,0.00013681744,0.00076160737,0.00030363703,0.00026181462,0.4189573,0.0001611398,0.00020728087,0.035308946],"study_design_scores_gemma":[0.000028216129,0.00040931217,0.9304494,0.000026556041,0.00012065689,0.005504119,0.00010094875,0.0011398185,0.060271543,0.00018572506,0.0017562091,0.0000076089477],"about_ca_topic_score_codex":0.0009132583,"about_ca_topic_score_gemma":0.0006425376,"teacher_disagreement_score":0.0018873204,"about_ca_system_score_codex":0.00018624868,"about_ca_system_score_gemma":0.00013764558,"threshold_uncertainty_score":0.006313741},"labels":[],"label_agreement":null},{"id":"W2563238632","doi":"","title":"Anticancer activity of a human monoclonal antibody inhibitor of MMP-14","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Matrix metalloproteinase; Immunohistochemistry; Metastasis; Cancer research; Monoclonal antibody; Antibody; Cancer; Tumor progression; Medicine; Phage display; In vitro; Immunology; Pharmacology; Biology; Internal medicine; Biochemistry","score_opus":0.019519780710510498,"score_gpt":0.3232640618103585,"score_spread":0.30374428109984797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563238632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745603,0.0066840732,0.0074489675,0.00018548375,0.0000967643,0.00016820512,0.00055599055,0.00031361383,0.0070909895],"genre_scores_gemma":[0.9828384,0.0030272119,0.0059593795,0.00015325392,0.000024635172,0.000075304946,0.0019120539,0.000023429742,0.005986482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990475,0.000013717131,0.000007008912,0.000017317076,0.000029832667,0.000027404989],"domain_scores_gemma":[0.99996865,0.0000061227806,0.0000048351603,0.0000032551382,0.000004610584,0.000012418814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014088456,0.00035939112,0.00025456698,0.00037225086,0.00011058977,0.00025485473,0.0002338759,0.00024495574,0.0015221693],"category_scores_gemma":[0.0001148281,0.00013419219,0.00024787913,0.00020129493,0.00008917739,0.00009034222,0.00013665976,0.0003206402,0.00054707786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025275294,0.00028613198,0.0003294317,0.0000489749,0.00001837687,0.000050194627,0.000008626366,0.0002633024,0.9854446,0.00013917524,0.00028505616,0.012873411],"study_design_scores_gemma":[0.00018397407,0.0028473968,0.0039691115,0.00000842655,0.000050470422,0.00055804936,0.0000064871365,0.002532916,0.9808818,0.000033246448,0.00892066,0.00000743971],"about_ca_topic_score_codex":0.0007996925,"about_ca_topic_score_gemma":0.000903712,"teacher_disagreement_score":0.0015221693,"about_ca_system_score_codex":0.00028976498,"about_ca_system_score_gemma":0.00025657823,"threshold_uncertainty_score":0.0050922036},"labels":[],"label_agreement":null},{"id":"W2563884867","doi":"10.1158/1535-7163.mct-16-0588","title":"Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; National Institutes of Health","keywords":"Epigenetics; Epigenetic therapy; Vorinostat; Histone deacetylase; Biology; DNA methylation; Cancer research; Cancer; Decitabine; Pharmacology; Histone; Gene expression; Genetics; Gene","score_opus":0.013206137043269965,"score_gpt":0.29976905953115307,"score_spread":0.2865629224878831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563884867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736804,0.010342284,0.0044352054,0.0002752557,0.000065800734,0.0002941129,0.0033136632,0.00032641226,0.007266851],"genre_scores_gemma":[0.9670707,0.00913296,0.011366223,0.00030683182,0.00003384489,0.00022362272,0.005751805,0.000053943102,0.0060599763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977094,0.00003233194,0.000020861955,0.0000535003,0.000079316706,0.00004299349],"domain_scores_gemma":[0.9998721,0.000022265478,0.00003383586,0.000015184576,0.000027398422,0.000029232328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021750605,0.00042353393,0.0007004487,0.001095465,0.00019272577,0.000497295,0.00018729815,0.0002793827,0.0019255962],"category_scores_gemma":[0.0002086872,0.00020341417,0.0004432068,0.0009298858,0.00013673105,0.00022180835,0.00026759453,0.0004505627,0.00064557476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028350294,0.00017647039,0.0018312859,0.00028539184,0.00004657956,0.00018628359,0.000022454999,0.0005731067,0.9712276,0.00012215576,0.00044417058,0.024801107],"study_design_scores_gemma":[0.000118888835,0.0022589967,0.015463359,0.000043202854,0.00031121363,0.0007584301,0.00005521357,0.0021046256,0.9573007,0.00008394243,0.021469427,0.000031957632],"about_ca_topic_score_codex":0.00051715196,"about_ca_topic_score_gemma":0.0020793492,"teacher_disagreement_score":0.0019255962,"about_ca_system_score_codex":0.00036588078,"about_ca_system_score_gemma":0.00043312542,"threshold_uncertainty_score":0.0064417124},"labels":[],"label_agreement":null},{"id":"W2565862397","doi":"","title":"Tumor suppressive role of ING3 in human cutaneous melanoma tumorigenesis and its regulation by ubiquitin-proteasome system","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Melanoma; Carcinogenesis; Cancer research; Apoptosis; Ubiquitin ligase; Immunohistochemistry; Suppressor; Proteasome; Ubiquitin; Pathogenesis; Cell; Cancer; Biology; Chemistry; Medicine; Pathology; Cell biology; Internal medicine; Gene; Genetics","score_opus":0.008894793696357222,"score_gpt":0.25984248071814736,"score_spread":0.25094768702179016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565862397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798125,0.00109077,0.0002747076,0.000020245092,0.000002695096,0.0000029674486,0.0000883862,0.000014467425,0.00052453787],"genre_scores_gemma":[0.9989385,0.00025761419,0.00021246739,0.000008080492,0.0000014961969,0.0000027224512,0.00012898086,0.0000027787478,0.000447376],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99996686,0.0000053664685,0.0000019363574,0.0000059583285,0.000008399714,0.000011549343],"domain_scores_gemma":[0.99996185,0.0000038685475,0.000013138891,0.0000044504895,0.0000059880917,0.0000107194055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068291905,0.00017212391,0.000116294,0.00018201675,0.0001724375,0.00018513268,0.00004997397,0.00007652792,0.0006447401],"category_scores_gemma":[0.000063856714,0.000055430854,0.00011795653,0.000091541915,0.00011785648,0.000050826246,0.00008775728,0.00009994937,0.00018556799],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002408056,0.000016759212,0.0023188072,0.000018087705,0.0000062612116,0.00011997578,0.00001415081,0.000083068575,0.9956365,0.00005801118,0.00003408965,0.0014534574],"study_design_scores_gemma":[0.000024234792,0.00024812118,0.09794635,0.0000061101146,0.000033728087,0.0010424398,0.0000722038,0.0016543148,0.8970858,0.00014527292,0.0017343819,0.000007094011],"about_ca_topic_score_codex":0.001075491,"about_ca_topic_score_gemma":0.0012314217,"teacher_disagreement_score":0.001075491,"about_ca_system_score_codex":0.00021159828,"about_ca_system_score_gemma":0.00011564719,"threshold_uncertainty_score":0.0021568537},"labels":[],"label_agreement":null},{"id":"W2565888311","doi":"","title":"Impaired membrane-type 1 matrix metalloproteinase phosphorylation results in blocking 3D-collagen invasion by tumor cells through cell cycle arrest in G0/G1 phase","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"","keywords":"Matrix metalloproteinase; Cell cycle; Molecular biology; Extracellular matrix; Zymography; Flow cytometry; Type I collagen; Cell growth; Cell biology; Biology; Transfection; Cell culture; Type IV collagen; Wild type; Cell; Chemistry; Mutant; Biochemistry; Laminin","score_opus":0.015086422817382634,"score_gpt":0.28585834157452333,"score_spread":0.2707719187571407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565888311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977738,0.00047466977,0.0006350191,0.000052874995,0.000023608538,0.00002092249,0.00026166823,0.00004917895,0.0007082124],"genre_scores_gemma":[0.99480706,0.0005049864,0.001134604,0.000035611967,0.000007353383,0.000046783152,0.00078937545,0.000021090442,0.002653146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998398,0.000028384493,0.000019711155,0.000026496422,0.000033312812,0.00005244931],"domain_scores_gemma":[0.9998599,0.000035591238,0.000031555497,0.000019923451,0.0000088457755,0.000044101387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011134932,0.00038571394,0.00031362212,0.00016805639,0.00013719757,0.00020363035,0.00023779235,0.00023947055,0.0016721524],"category_scores_gemma":[0.00009048077,0.00015097426,0.00031173814,0.00014697236,0.00021352629,0.00012237432,0.000113580965,0.0006197518,0.00052119046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010847567,0.00008294797,0.00006708803,0.000014411707,0.0000027171018,0.00002358556,0.000008141893,0.000037561626,0.9992163,0.000046947778,0.000028905102,0.00036288347],"study_design_scores_gemma":[0.000028107259,0.00062079116,0.0025325539,0.0000036186261,0.000008099531,0.00013142343,0.000013114179,0.0011050326,0.9945798,0.000021158723,0.0009533715,0.0000030178694],"about_ca_topic_score_codex":0.0013373768,"about_ca_topic_score_gemma":0.0011001623,"teacher_disagreement_score":0.0016721524,"about_ca_system_score_codex":0.0002561141,"about_ca_system_score_gemma":0.00026467582,"threshold_uncertainty_score":0.005593896},"labels":[],"label_agreement":null},{"id":"W2566139700","doi":"","title":"Intramembrane proteolysis of the p75 neurotrophin receptor is required for glioma invasion.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ectodomain; Low-affinity nerve growth factor receptor; Biology; Neurite; Cell biology; Proteolysis; Glioma; Receptor; Neurotrophin; Molecular biology; Cancer research; In vitro; Biochemistry","score_opus":0.028463922027722622,"score_gpt":0.3162503988662543,"score_spread":0.28778647683853165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566139700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380505,0.0020882015,0.0011184656,0.00011915995,0.00002926329,0.000029147397,0.00075418205,0.00009399944,0.0019624499],"genre_scores_gemma":[0.9925398,0.0008470188,0.0012918193,0.00005161746,0.000007193005,0.000027724487,0.0019062704,0.000011916195,0.0033166064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999038,0.000010615103,0.000009292236,0.000012876459,0.00003304645,0.000030334124],"domain_scores_gemma":[0.9998838,0.000013415408,0.000030771145,0.000011321551,0.0000121203775,0.000048550963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059054713,0.00024574946,0.0001812077,0.00014604001,0.00018082143,0.0002550784,0.00013562317,0.00020278885,0.0011937249],"category_scores_gemma":[0.000082551065,0.000103931096,0.0002728483,0.000093842944,0.0001196093,0.0001606593,0.00015659232,0.00040129796,0.0006599315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007289664,0.000022984806,0.00024232602,0.00001995563,0.000002019963,0.00016684647,0.000008585994,0.000013240265,0.9987061,0.00005570448,0.00006270721,0.0006266602],"study_design_scores_gemma":[0.000015768996,0.00038871847,0.043496102,0.0000087510925,0.00001726664,0.0016602062,0.000085816384,0.0009445598,0.9475974,0.00006652697,0.0057111825,0.000007651736],"about_ca_topic_score_codex":0.0016862032,"about_ca_topic_score_gemma":0.0025216988,"teacher_disagreement_score":0.0016862032,"about_ca_system_score_codex":0.00027940905,"about_ca_system_score_gemma":0.00027070154,"threshold_uncertainty_score":0.0039934516},"labels":[],"label_agreement":null},{"id":"W2570216110","doi":"","title":"Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"XIAP; Apoptosis; Programmed cell death; Inhibitor of apoptosis; Pharmacology; Medicine; Cancer; Biology; Caspase; Cancer research; Internal medicine","score_opus":0.05674874129001793,"score_gpt":0.42197239441858936,"score_spread":0.3652236531285714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570216110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812298,0.0036334472,0.0066310237,0.0003003731,0.00017995086,0.0038481813,0.0010763716,0.00022531494,0.002875597],"genre_scores_gemma":[0.9806505,0.001473833,0.009444111,0.0004033428,0.000054860393,0.0030954634,0.0015642989,0.000026743526,0.0032870048],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995415,0.00021576753,0.000022316184,0.000074727366,0.00009322376,0.00005256073],"domain_scores_gemma":[0.99975353,0.00004074285,0.000079702426,0.000021840358,0.000036169873,0.00006807921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012483544,0.00073954614,0.0005724377,0.00028636496,0.00018341676,0.00042898595,0.00037415305,0.00066568394,0.0012612927],"category_scores_gemma":[0.0005204277,0.0003068396,0.00034008114,0.0002623506,0.00030447394,0.00022141745,0.00012959857,0.0013426194,0.00038087703],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084423825,0.026760617,0.0064214747,0.00051934144,0.00023610122,0.00025047013,0.0002600163,0.0042888615,0.7597671,0.00059988303,0.0035263808,0.11294585],"study_design_scores_gemma":[0.04657913,0.61599,0.025970252,0.0000532283,0.00030263246,0.0010226287,0.0000905817,0.006047693,0.29153335,0.0003428328,0.01201493,0.00005280415],"about_ca_topic_score_codex":0.0003181818,"about_ca_topic_score_gemma":0.0009103236,"teacher_disagreement_score":0.0012612927,"about_ca_system_score_codex":0.00052378094,"about_ca_system_score_gemma":0.00063554064,"threshold_uncertainty_score":0.006602049},"labels":[],"label_agreement":null},{"id":"W2580129211","doi":"10.1158/1535-7163.mct-16-0504","title":"Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"DNA damage; CHEK1; Cancer research; Biology; Cancer; DNA repair; Cancer cell; G2-M DNA damage checkpoint; Kinase; Signal transduction; Cell biology; DNA; Cell cycle; Cell cycle checkpoint; Genetics","score_opus":0.025533460785314318,"score_gpt":0.3259974071218004,"score_spread":0.3004639463364861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580129211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156004,0.0015974176,0.0016419769,0.00016615403,0.000024185241,0.000032704127,0.00065628765,0.00013740893,0.004183836],"genre_scores_gemma":[0.99640405,0.0004254679,0.00058104267,0.000022453138,0.0000043423497,0.000019007308,0.00044968186,0.000007803455,0.0020859973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988055,0.000014124711,0.00000711815,0.00001818897,0.00003810978,0.00004177322],"domain_scores_gemma":[0.99994516,0.0000090836265,0.000009328386,0.000008992786,0.0000101748865,0.000017306515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007840723,0.000358252,0.00016183473,0.00030079868,0.0002828864,0.00030607698,0.00012440435,0.00013378041,0.0026610037],"category_scores_gemma":[0.00007940405,0.00013685001,0.00016126754,0.00013649031,0.00017531526,0.00012547766,0.00022985513,0.00048433748,0.00084507186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106394094,0.000031240634,0.00032571622,0.00002289656,0.0000038029164,0.00003528813,0.0000074027716,0.00008832644,0.9976889,0.0001485666,0.00011051204,0.0014309336],"study_design_scores_gemma":[0.000013554931,0.00015916272,0.008026832,0.0000029976245,0.0000054993125,0.00021676,0.000016866552,0.0009866795,0.9876874,0.000058548674,0.0028234029,0.0000022987049],"about_ca_topic_score_codex":0.0013151052,"about_ca_topic_score_gemma":0.0025278474,"teacher_disagreement_score":0.0026610037,"about_ca_system_score_codex":0.000569458,"about_ca_system_score_gemma":0.00033977244,"threshold_uncertainty_score":0.008901894},"labels":[],"label_agreement":null},{"id":"W2580398445","doi":"10.1158/1535-7163.mct-16-0644","title":"Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Texas at El Paso; University of Toronto; Oregon Health and Science University","keywords":"Metastatic breast cancer; Cancer research; Breast cancer; Cancer; Kinome; Metastasis; Triple-negative breast cancer; Cancer cell; Cytotoxicity; Gene knockdown; In vivo; PLK1; Medicine; Chemistry; Biology; Kinase; In vitro; Internal medicine; Apoptosis; Cell cycle; Cell biology; Biochemistry","score_opus":0.028174877008697374,"score_gpt":0.2928454558962161,"score_spread":0.2646705788875187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580398445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981128,0.0027787304,0.013660124,0.00018284816,0.000050338524,0.00006292382,0.0001905955,0.0002358155,0.0017106605],"genre_scores_gemma":[0.99121886,0.0008650928,0.005573556,0.00006516262,0.000010566497,0.000055502835,0.00012669443,0.000013298467,0.002071237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999577,0.0000044571093,0.0000029442479,0.000014379345,0.0000112173075,0.00000927158],"domain_scores_gemma":[0.9999769,0.000002980932,0.000007885651,0.0000017508894,0.000005008321,0.000005543626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070915245,0.0003185606,0.00018399041,0.00014486087,0.000094407056,0.00016070464,0.00014491157,0.00025781192,0.00055623945],"category_scores_gemma":[0.00004556681,0.00010305514,0.000188115,0.000053951266,0.00011433173,0.00014457315,0.00014075755,0.0002376815,0.00020714193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031149262,0.000010409901,0.000035940866,0.00003093773,0.0000032481682,0.000020116271,0.0000050629164,0.00010608747,0.9984862,0.00003929686,0.0000361026,0.0011954588],"study_design_scores_gemma":[0.000010240858,0.0002015145,0.0003431151,0.0000026396838,0.000013045523,0.0000882932,0.0000043176083,0.0012398438,0.996741,0.000016142656,0.00133714,0.00000273105],"about_ca_topic_score_codex":0.00037355573,"about_ca_topic_score_gemma":0.00044691778,"teacher_disagreement_score":0.00055623945,"about_ca_system_score_codex":0.00025959796,"about_ca_system_score_gemma":0.00015670643,"threshold_uncertainty_score":0.0018835068},"labels":[],"label_agreement":null},{"id":"W2581199101","doi":"10.1158/1538-8514.pi3k14-b51","title":"Abstract B51: The tyrphostin, NT157, suppresses insulin receptor substrates and augments therapeutic response of prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"LNCaP; Prostate cancer; IRS1; Cancer research; Protein kinase B; Androgen receptor; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Insulin-like growth factor 1 receptor; Endocrinology; Internal medicine; Signal transduction; Insulin receptor; Growth factor; Biology; Cancer; Receptor; Medicine; Insulin; Insulin resistance; Cell biology","score_opus":0.03238721274005957,"score_gpt":0.30560673511112435,"score_spread":0.2732195223710648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581199101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935947,0.0015807168,0.0007162017,0.00014526867,0.000086299304,0.000084173575,0.00066959276,0.00010816556,0.0030147526],"genre_scores_gemma":[0.9924035,0.001040298,0.00084713346,0.00009614758,0.000021541255,0.00005407415,0.0012103018,0.000018520024,0.0043085306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999949,0.0000071885984,0.000004656262,0.0000082060915,0.000018822933,0.000012083807],"domain_scores_gemma":[0.9999504,0.0000055305422,0.000010453709,0.000005396912,0.000006194256,0.000021959371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092750975,0.0003664947,0.00031488255,0.00020824137,0.00011104056,0.00019349727,0.00024423466,0.000281031,0.0035466028],"category_scores_gemma":[0.00007667861,0.00009673405,0.00020079575,0.00012876684,0.00015104828,0.00014206102,0.000099259625,0.00067701354,0.00067114446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011644036,0.00075498055,0.00022924095,0.000082602804,0.000018318919,0.0000836888,0.0000107190535,0.00029735462,0.9882455,0.00011594289,0.0005014002,0.008495971],"study_design_scores_gemma":[0.0005259652,0.013742689,0.0076716086,0.000025179506,0.000059203652,0.00059528486,0.000024587052,0.0015835268,0.96894705,0.00004314224,0.0067702,0.000011447374],"about_ca_topic_score_codex":0.0008093501,"about_ca_topic_score_gemma":0.0012683403,"teacher_disagreement_score":0.0035466028,"about_ca_system_score_codex":0.00022591681,"about_ca_system_score_gemma":0.00028512432,"threshold_uncertainty_score":0.011864543},"labels":[],"label_agreement":null},{"id":"W2585919465","doi":"10.1158/1535-7163.mct-16-0753","title":"Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Kinase; Cancer; Protein kinase A; Cachexia; Mitogen-activated protein kinase; Cancer research; Pharmacology; Medicine; Cancer cachexia; Chemistry; Biochemistry; Internal medicine","score_opus":0.09000478040142562,"score_gpt":0.3960864685893406,"score_spread":0.306081688187915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585919465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.085549004,0.8733065,0.0037035432,0.0071687954,0.0013428666,0.00019311118,0.0008839989,0.00037079555,0.027481314],"genre_scores_gemma":[0.36636692,0.6024026,0.0051786867,0.0024345762,0.0012838496,0.0002054261,0.0012730339,0.000035564637,0.020819362],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9999634,0.000008489989,0.000002571241,0.000004656418,0.000010879634,0.000009922244],"domain_scores_gemma":[0.9999647,0.000005335196,0.000009763184,0.0000013699225,0.0000071405616,0.000011650095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016765563,0.0003783357,0.00044383467,0.00037794045,0.0001767829,0.00047039558,0.00023094514,0.00036838517,0.0032875703],"category_scores_gemma":[0.0001029904,0.000099084675,0.0002679642,0.00031925837,0.00014391996,0.00033710847,0.00021321318,0.0009975467,0.00096247013],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028645014,0.0013377963,0.0010299955,0.002813007,0.00015716178,0.0008609574,0.00006862878,0.0010671968,0.14665216,0.009090584,0.03041027,0.80364764],"study_design_scores_gemma":[0.0040911296,0.009595012,0.010445801,0.0010453518,0.0005918192,0.0053888187,0.00013217062,0.0031404463,0.104724534,0.007179796,0.8535866,0.000078485326],"about_ca_topic_score_codex":0.0002510278,"about_ca_topic_score_gemma":0.0012890103,"teacher_disagreement_score":0.0032875703,"about_ca_system_score_codex":0.0002738851,"about_ca_system_score_gemma":0.00023116567,"threshold_uncertainty_score":0.01099807},"labels":[],"label_agreement":null},{"id":"W2611439401","doi":"10.1158/1535-7163.mct-16-0819","title":"Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Food science; Substrate (aquarium); Chemistry; Biochemistry; Biology; Ecology","score_opus":0.029365483733206646,"score_gpt":0.3017219061666139,"score_spread":0.27235642243340724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611439401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9423014,0.017253682,0.027106978,0.00033494554,0.00010082977,0.00080037833,0.001706598,0.0002029635,0.010192258],"genre_scores_gemma":[0.95949507,0.0077000596,0.022916645,0.00019131725,0.0000447229,0.00021713557,0.0034495003,0.000051081002,0.005934478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998838,0.000022796234,0.000012261284,0.00001937265,0.00004244357,0.000019383997],"domain_scores_gemma":[0.9999255,0.000010047273,0.00001529098,0.000009735679,0.00001903425,0.000020366508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023844802,0.00045510763,0.0004062525,0.00033900948,0.00014200211,0.0003035213,0.0003771364,0.0002315409,0.0011579016],"category_scores_gemma":[0.00019535405,0.00012617861,0.0002943941,0.00024112035,0.00010514785,0.00022670829,0.00015400803,0.0004487203,0.0005366643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020874223,0.00022003693,0.00042908333,0.000109331755,0.00002558496,0.00012598501,0.000023969955,0.00048213534,0.98121554,0.00036413484,0.00022737223,0.01656805],"study_design_scores_gemma":[0.00013424116,0.002152067,0.0020048844,0.000017309228,0.00007747994,0.0007999933,0.000024569626,0.0023130898,0.97642606,0.00011645367,0.015920658,0.0000132028845],"about_ca_topic_score_codex":0.00036577287,"about_ca_topic_score_gemma":0.0012338625,"teacher_disagreement_score":0.0011579016,"about_ca_system_score_codex":0.0003056058,"about_ca_system_score_gemma":0.00028435767,"threshold_uncertainty_score":0.0038735867},"labels":[],"label_agreement":null},{"id":"W2625910864","doi":"10.1158/1535-7163.mct-17-0009","title":"Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Pancreatic cancer; MEK inhibitor; Cancer research; MAPK/ERK pathway; Medicine; STAT3; Cancer; Ponatinib; KRAS; Kinase; Selumetinib; Metastasis; Internal medicine; Biology; Signal transduction; Dasatinib; Imatinib","score_opus":0.06310484529008194,"score_gpt":0.36081807515836284,"score_spread":0.2977132298682809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625910864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848357,0.0050417134,0.0031582054,0.00028900712,0.00016381062,0.0002443892,0.0006926015,0.0003646386,0.00521009],"genre_scores_gemma":[0.99218243,0.0021847566,0.0022050578,0.00006804065,0.000017686236,0.000103160295,0.000500387,0.000022171347,0.0027162952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987817,0.000014820785,0.000010145487,0.000019831381,0.000038866783,0.00003822194],"domain_scores_gemma":[0.9999645,0.0000040750338,0.0000075495477,0.0000051964284,0.0000043429714,0.00001448023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013146784,0.0004133238,0.00050281937,0.000380564,0.00016311438,0.00034371146,0.00024250783,0.00020734564,0.0016214015],"category_scores_gemma":[0.00005959055,0.00015101732,0.0003435919,0.0003766418,0.000192078,0.00016998599,0.00024780328,0.00069450994,0.00043686733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089157326,0.00067219685,0.00070264767,0.00024123414,0.00007682554,0.00018089983,0.000033447086,0.0009428109,0.9686511,0.0003800682,0.000752157,0.026475111],"study_design_scores_gemma":[0.0005855382,0.008734829,0.013316528,0.00002480494,0.00018521865,0.0011458177,0.00006927263,0.003839815,0.95446765,0.00016582561,0.017442424,0.000022321348],"about_ca_topic_score_codex":0.0011584052,"about_ca_topic_score_gemma":0.003442518,"teacher_disagreement_score":0.0016214015,"about_ca_system_score_codex":0.0004322675,"about_ca_system_score_gemma":0.00043067205,"threshold_uncertainty_score":0.0054240823},"labels":[],"label_agreement":null},{"id":"W2731426244","doi":"10.1158/1535-7163.mct-16-0666","title":"Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Downregulation and upregulation; Colorectal cancer; Cancer research; Cancer; Kinase; Protein kinase domain; Medicine; Chemistry; Biology; Cell biology; Internal medicine; Gene; Genetics","score_opus":0.04300192920630522,"score_gpt":0.3410777621829696,"score_spread":0.2980758329766644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731426244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855025,0.0016781151,0.0031735627,0.00053407496,0.00022712495,0.00011792666,0.0009955914,0.0004305344,0.004292921],"genre_scores_gemma":[0.9878219,0.00077062956,0.0022303266,0.00007656968,0.000019461122,0.00013778982,0.0008689428,0.000051631723,0.008022778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998362,0.000030007297,0.000011604657,0.000028173712,0.000043203338,0.000050867046],"domain_scores_gemma":[0.9998029,0.00003831727,0.00003978063,0.000027091735,0.000013946627,0.00007794019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024133791,0.00057510537,0.00031167187,0.0005081037,0.00020286119,0.00020669033,0.00036411348,0.00033723065,0.0034837204],"category_scores_gemma":[0.00014353388,0.00020009014,0.00024184653,0.00018103897,0.0003827975,0.00022929214,0.00012388952,0.001171516,0.0005216179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012018237,0.0008736631,0.00023946851,0.000073314164,0.000014039209,0.000083896455,0.000014834867,0.00021834299,0.99334466,0.00033866745,0.0004953718,0.003101886],"study_design_scores_gemma":[0.00015003617,0.002531432,0.0016584992,0.000008100365,0.000014749253,0.00020794317,0.000018468225,0.0019821725,0.9909924,0.00007025538,0.0023615286,0.0000044838816],"about_ca_topic_score_codex":0.0013022851,"about_ca_topic_score_gemma":0.0025248218,"teacher_disagreement_score":0.0034837204,"about_ca_system_score_codex":0.0005535513,"about_ca_system_score_gemma":0.00042751076,"threshold_uncertainty_score":0.011654198},"labels":[],"label_agreement":null},{"id":"W2743088462","doi":"10.1158/1535-7163.mct-17-0374","title":"Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Epitope; Cancer research; Biology; Computational biology; Immunology; Antibody","score_opus":0.01655211928093965,"score_gpt":0.2955177967313981,"score_spread":0.27896567745045847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743088462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942873,0.001224763,0.0032473437,0.000046845886,0.000014101102,0.00007139188,0.000054739827,0.000031732685,0.0010218206],"genre_scores_gemma":[0.99586076,0.00041442583,0.0027271037,0.000027245416,0.000006684511,0.000029413055,0.00015039397,0.000004797549,0.00077913766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968433,0.0000705214,0.000025707823,0.000036444915,0.0001103123,0.000072574956],"domain_scores_gemma":[0.9999361,0.000011064772,0.000018179107,0.0000068492996,0.000008454321,0.000019249277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003805502,0.0005102475,0.00036450994,0.0002738757,0.00009185224,0.00033215998,0.00027548496,0.0002426607,0.00072036625],"category_scores_gemma":[0.00014645014,0.00012250543,0.00030520864,0.00014621558,0.00020116042,0.00017888889,0.00029228124,0.00045677982,0.00021566114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022014398,0.000090168214,0.00025945608,0.000039023867,0.000016424563,0.000026419179,0.000006171953,0.00020889218,0.995611,0.00006993662,0.000028514338,0.003423945],"study_design_scores_gemma":[0.000057426532,0.0018689487,0.0017994428,0.0000043395526,0.00003363928,0.00023387127,0.000011379082,0.0011780272,0.9936318,0.000013633013,0.0011644753,0.0000029254352],"about_ca_topic_score_codex":0.0003532131,"about_ca_topic_score_gemma":0.0009314509,"teacher_disagreement_score":0.00072036625,"about_ca_system_score_codex":0.00041108986,"about_ca_system_score_gemma":0.0002992886,"threshold_uncertainty_score":0.002982676},"labels":[],"label_agreement":null},{"id":"W2744273464","doi":"10.1158/1535-7163.mct-17-0259","title":"Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Chemistry; Chromatin; DNA-binding domain; Cancer research; Small molecule; Transcription factor; Pharmacology; Mechanism of action; Cancer; Biology; DNA; Biochemistry; Genetics; In vitro; Gene","score_opus":0.04388678794563423,"score_gpt":0.327327484174485,"score_spread":0.28344069622885076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744273464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92080295,0.033730134,0.020949041,0.0010050128,0.0002987296,0.00062152976,0.0014710927,0.0010833729,0.020038124],"genre_scores_gemma":[0.9782898,0.008909798,0.0054727443,0.00024091674,0.000035481073,0.00015424863,0.00073479634,0.000044282668,0.0061179935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998845,0.000022720416,0.0000066050916,0.000019972944,0.00003986565,0.000026396367],"domain_scores_gemma":[0.9999387,0.000014151313,0.000016341211,0.00000956686,0.000010143509,0.0000111234785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017039705,0.00038308374,0.0003812314,0.00044430624,0.00015439281,0.00038861527,0.0002558071,0.00018075212,0.0025723553],"category_scores_gemma":[0.00010476503,0.00012715187,0.00031818877,0.00023923685,0.00023583116,0.00014754372,0.0002322834,0.00071879453,0.00065766246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017694278,0.00044106686,0.00046608964,0.00034215162,0.00004395168,0.00013348013,0.0000371985,0.0012593245,0.9590415,0.0014674541,0.0013364464,0.035254505],"study_design_scores_gemma":[0.00023171947,0.0033625655,0.004123862,0.000031934454,0.00006952207,0.0006393375,0.000026465934,0.0036962428,0.9532978,0.00027699937,0.03422091,0.000022583627],"about_ca_topic_score_codex":0.00072533294,"about_ca_topic_score_gemma":0.0019211199,"teacher_disagreement_score":0.0025723553,"about_ca_system_score_codex":0.00038201505,"about_ca_system_score_gemma":0.0002733649,"threshold_uncertainty_score":0.008605421},"labels":[],"label_agreement":null},{"id":"W2747905863","doi":"10.1158/1535-7163.mct-17-0292","title":"Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Grand River Hospital; University of Guelph; Regional Municipality of Waterloo; Ontario Institute for Cancer Research; University of Waterloo","funders":"","keywords":"Myeloid leukemia; Estrogen receptor; Leukemia; Cancer research; Haematopoiesis; Gene knockdown; Pharmacology; Biology; Myeloid; Stem cell; Cell culture; Cancer; Immunology; Cell biology; Breast cancer","score_opus":0.013674953197759812,"score_gpt":0.2825024646678262,"score_spread":0.2688275114700664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747905863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8602745,0.10383639,0.012572166,0.0022453028,0.00030449298,0.00034801726,0.0026808558,0.00041276787,0.01732555],"genre_scores_gemma":[0.94845676,0.03360875,0.0047688396,0.000685104,0.00006758342,0.00008543167,0.0027498747,0.000023222367,0.009554457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999131,0.0000124027265,0.000006990213,0.000018358698,0.000035742865,0.000013319247],"domain_scores_gemma":[0.99995744,0.000007988332,0.0000109159755,0.0000049047417,0.000009296688,0.000009409918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019262877,0.00030045016,0.0003396544,0.00028128835,0.00013383554,0.00036029282,0.00023815787,0.00027420148,0.0014058875],"category_scores_gemma":[0.00013278161,0.00011462702,0.00020019471,0.00035233633,0.0001121173,0.00016137768,0.0002121971,0.00042685782,0.0006570989],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002788047,0.000103209015,0.0026960783,0.0003622551,0.000040412222,0.00048534782,0.000025690486,0.00054684276,0.9375037,0.0006457122,0.0017873306,0.055524487],"study_design_scores_gemma":[0.00019542905,0.0011132287,0.015330538,0.00006772597,0.00019742669,0.0045920354,0.00007296225,0.002384309,0.8224016,0.00073292496,0.15289596,0.000015928783],"about_ca_topic_score_codex":0.00032995132,"about_ca_topic_score_gemma":0.00075945305,"teacher_disagreement_score":0.0014058875,"about_ca_system_score_codex":0.00038092895,"about_ca_system_score_gemma":0.00024034774,"threshold_uncertainty_score":0.004703164},"labels":[],"label_agreement":null},{"id":"W2749993682","doi":"10.1158/1535-7163.mct-16-0739","title":"PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Cancer research; Cancer; Annexin A1; Annexin; Predictive marker; Medicine; Biology; Internal medicine; Oncology; Apoptosis","score_opus":0.0220421876638564,"score_gpt":0.31089966051514145,"score_spread":0.28885747285128505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749993682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754095,0.0007611036,0.00093371206,0.000038348306,0.000008800626,0.000012796631,0.00023062018,0.000019101122,0.00045466167],"genre_scores_gemma":[0.9982054,0.00025213792,0.0004547765,0.00002006251,0.0000024489834,0.000014212104,0.0001997632,0.0000039561037,0.00084711245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999167,0.000012866681,0.000008462618,0.00002194898,0.000019007053,0.00002113893],"domain_scores_gemma":[0.9999169,0.000014035806,0.000029292578,0.000008899565,0.0000129097525,0.00001790353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115856354,0.00011197166,0.00016832983,0.00022002995,0.00012232171,0.00028077283,0.00006564781,0.00019205218,0.0015418086],"category_scores_gemma":[0.00011634735,0.000111721565,0.00014075714,0.00016338834,0.00012664727,0.00014472059,0.00009473025,0.00037176113,0.00031450574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001436673,0.000019306433,0.001439458,0.000018115557,0.0000038715148,0.000034356017,0.000014170222,0.000035042016,0.9974131,0.00002700137,0.00002068242,0.0008313304],"study_design_scores_gemma":[0.00001729793,0.00045652367,0.04956883,0.0000060442103,0.000019000343,0.00059393526,0.00011665034,0.0013925934,0.94620717,0.00010216624,0.0015116668,0.000008206591],"about_ca_topic_score_codex":0.0002663379,"about_ca_topic_score_gemma":0.00034714435,"teacher_disagreement_score":0.0015418086,"about_ca_system_score_codex":0.00028577365,"about_ca_system_score_gemma":0.000099334524,"threshold_uncertainty_score":0.005157888},"labels":[],"label_agreement":null},{"id":"W2753735822","doi":"10.1158/1535-7163.mct-17-0397","title":"Death by HDAC Inhibition in Synovial Sarcoma Cells","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health","funders":"","keywords":"Synovial sarcoma; Cancer research; Apoptosis; Sarcoma; Cancer; Histone deacetylase; Histone deacetylase inhibitor; Transcriptome; Biology; Cancer cell; Medicine; Histone; Pathology; Internal medicine; Gene expression; Biochemistry","score_opus":0.02300530319860789,"score_gpt":0.32064326584401637,"score_spread":0.2976379626454085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753735822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787199,0.006037771,0.0051137838,0.00022632291,0.00012288873,0.00010099629,0.0026082832,0.00022107994,0.006849044],"genre_scores_gemma":[0.9904965,0.0017563138,0.0018230974,0.00006706867,0.000012052499,0.00005874903,0.0018042949,0.000011795972,0.003970058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998733,0.000012828557,0.0000140860275,0.000026659047,0.000045130048,0.000027978676],"domain_scores_gemma":[0.99996555,0.0000050389394,0.000007660806,0.000006552091,0.000006930056,0.000008366724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010845514,0.0002478165,0.00029776958,0.00020922214,0.00017282895,0.00024179489,0.00012039083,0.00013714825,0.0021077644],"category_scores_gemma":[0.00006764196,0.000076441196,0.00029362467,0.00023280708,0.00014530383,0.0001068631,0.00013442246,0.00045730767,0.0007116768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023615906,0.000053329593,0.00042979018,0.00007714107,0.000011534235,0.00008099811,0.000025552874,0.00011610855,0.993802,0.00017261758,0.00028323472,0.004711646],"study_design_scores_gemma":[0.000049719394,0.00049749867,0.0051358435,0.000008233747,0.000021274831,0.00034560336,0.000058534228,0.0011041281,0.98720455,0.000098953446,0.0054713194,0.0000042932406],"about_ca_topic_score_codex":0.0012414651,"about_ca_topic_score_gemma":0.0016312165,"teacher_disagreement_score":0.0021077644,"about_ca_system_score_codex":0.00030502363,"about_ca_system_score_gemma":0.00025958804,"threshold_uncertainty_score":0.00705117},"labels":[],"label_agreement":null},{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","score_opus":0.039443511507001754,"score_gpt":0.3106321426094479,"score_spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756647112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97811687,0.009662995,0.004249087,0.0006553855,0.00010170223,0.00038481894,0.0012373454,0.00048677507,0.00510507],"genre_scores_gemma":[0.9880355,0.0053371005,0.002566573,0.00011765951,0.000024849689,0.00015663933,0.0012640683,0.000033227167,0.002464413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989843,0.000018875531,0.0000066597386,0.000012725379,0.000021750686,0.00004157152],"domain_scores_gemma":[0.9999497,0.000005955533,0.000011252017,0.000004727593,0.000008839031,0.000019606581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003809346,0.00094353606,0.0005305328,0.00033381776,0.00023041773,0.00047249603,0.0003602382,0.00041839704,0.0011754698],"category_scores_gemma":[0.00010474665,0.00024613403,0.00042222987,0.00021858171,0.00018754207,0.00029006295,0.00014242847,0.00087605644,0.00041966332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019788889,0.0021218085,0.0005057161,0.0002579084,0.00006229045,0.00015989266,0.000044575518,0.0018513353,0.96250176,0.0002806661,0.0012936166,0.028941533],"study_design_scores_gemma":[0.0019084731,0.030071136,0.0061058444,0.00004141395,0.00018107839,0.001200452,0.00003933995,0.0063434844,0.94498277,0.00016538035,0.0089268135,0.00003382433],"about_ca_topic_score_codex":0.0013178498,"about_ca_topic_score_gemma":0.0028288173,"teacher_disagreement_score":0.0013178498,"about_ca_system_score_codex":0.00056345644,"about_ca_system_score_gemma":0.0005332657,"threshold_uncertainty_score":0.0040881634},"labels":[],"label_agreement":null},{"id":"W2756935441","doi":"10.1158/1535-7163.mct-17-0170","title":"Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Olaparib; PARP inhibitor; Veliparib; Breast cancer; Cancer research; Triple-negative breast cancer; Cancer; Gene signature; Biology; DNA damage; Poly ADP ribose polymerase; Medicine; Molecular biology; Oncology; Internal medicine; Gene expression; Gene; Genetics; DNA","score_opus":0.029570303604162327,"score_gpt":0.32340810719261665,"score_spread":0.2938378035884543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756935441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631506,0.00056824833,0.00075008423,0.000043727265,0.0000043618497,0.000017964043,0.0019584901,0.000031861786,0.00031027466],"genre_scores_gemma":[0.9963085,0.00022538137,0.0009875472,0.00003216357,0.000002466597,0.000028515815,0.0021698594,0.0000048056327,0.00024074785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999002,0.000015162053,0.000007534189,0.000026816742,0.000024598405,0.000025707195],"domain_scores_gemma":[0.9998461,0.00003738696,0.00005682582,0.000009531916,0.000024113113,0.000026038599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013034204,0.00022200619,0.00032422066,0.0007013601,0.00017732498,0.00029487023,0.000096394186,0.00017463922,0.0007210273],"category_scores_gemma":[0.0002571209,0.00007705288,0.00022642378,0.00065213407,0.00011389604,0.00008340843,0.0001754099,0.00018914233,0.00018852636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015082011,0.00013852504,0.302156,0.0002420458,0.00017580901,0.0005678906,0.00009836677,0.00243648,0.672593,0.00009143851,0.0005094057,0.01948292],"study_design_scores_gemma":[0.000028732873,0.0003399613,0.9294523,0.000022072632,0.00018058757,0.0013347126,0.00019012645,0.008252598,0.058632936,0.0002902518,0.0012573418,0.000018384952],"about_ca_topic_score_codex":0.0009187502,"about_ca_topic_score_gemma":0.0011957962,"teacher_disagreement_score":0.0009187502,"about_ca_system_score_codex":0.0002026433,"about_ca_system_score_gemma":0.00020952598,"threshold_uncertainty_score":0.0024120808},"labels":[],"label_agreement":null},{"id":"W2765801571","doi":"10.1158/1538-8514.synthleth-pr01","title":"Abstract PR01: A functional variomic chemi-genetic screen in C. elegans identifies new synthetic lethal interactions with PARP inhibition that are conserved from worm to human","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetics, Aging, and Longevity in Model Organisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Caenorhabditis elegans; Synthetic lethality; Genetics; Olaparib; Model organism; Gene; Genetic screen; Mutation; PARP inhibitor; DNA repair; Poly ADP ribose polymerase; Homologous recombination; Polymerase; Mutant","score_opus":0.04231862433460418,"score_gpt":0.28328139181690526,"score_spread":0.24096276748230108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765801571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765637,0.0010073597,0.008793386,0.00021750703,0.0000730412,0.00037717386,0.0075382455,0.0006641784,0.0047654696],"genre_scores_gemma":[0.9642281,0.00075671315,0.0154217845,0.00024228691,0.000011457398,0.00022856263,0.007203736,0.0002917645,0.011615529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997099,0.000024149498,0.000031349562,0.000073034935,0.000120144345,0.00004141475],"domain_scores_gemma":[0.9997533,0.00005363396,0.00007763152,0.000022044167,0.000039425988,0.0000540457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024544928,0.0008037271,0.00036244077,0.0005685496,0.0003460574,0.00033047487,0.0005544001,0.0005476207,0.0025670012],"category_scores_gemma":[0.00018301338,0.000252467,0.00049639377,0.0002491465,0.00029760046,0.00015042648,0.00029300302,0.00061249506,0.0007072537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007217666,0.000036738653,0.00022283153,0.000035365505,0.000009853838,0.000103019695,0.0000049748155,0.00009773886,0.99801105,0.00005264788,0.00013407283,0.0012194258],"study_design_scores_gemma":[0.00003101513,0.0005830195,0.007760964,0.000015830137,0.000044669716,0.00056016806,0.000023030956,0.0014553382,0.98558205,0.000025648576,0.003901767,0.000016547257],"about_ca_topic_score_codex":0.0023221702,"about_ca_topic_score_gemma":0.004238954,"teacher_disagreement_score":0.0025670012,"about_ca_system_score_codex":0.00043591013,"about_ca_system_score_gemma":0.00036864198,"threshold_uncertainty_score":0.00858742},"labels":[],"label_agreement":null},{"id":"W2766480817","doi":"10.1158/1538-8514.synthleth-b04","title":"Abstract B04: RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"RAD51; Homologous recombination; DNA repair; Ovarian cancer; Biology; Molecular biology; DNA damage; Cancer research; PARP inhibitor; Cancer; Olaparib; Synthetic lethality; Poly ADP ribose polymerase; DNA; Genetics; Polymerase","score_opus":0.05492772240357369,"score_gpt":0.37437744291218916,"score_spread":0.3194497205086155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766480817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031746,0.0021991453,0.0023887744,0.00016995662,0.000022511911,0.00005802264,0.0014364378,0.00013737529,0.003270228],"genre_scores_gemma":[0.9954792,0.00029317272,0.0018793755,0.00009799464,0.000009741252,0.000040235413,0.0011140577,0.000014731509,0.0010715317],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997589,0.000064258755,0.000027813707,0.00005005035,0.00005939926,0.000039724895],"domain_scores_gemma":[0.9995783,0.00012241481,0.00011027294,0.00003431164,0.000108342596,0.000046469137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004634532,0.00015925837,0.00018879476,0.0015988012,0.0002381672,0.00040518792,0.00013116143,0.0003542151,0.0030408448],"category_scores_gemma":[0.0005367226,0.00010796284,0.00014888588,0.0009176579,0.00024985065,0.00012824716,0.00019129299,0.00034129797,0.00056100613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001202677,0.000103616396,0.18571508,0.00022084561,0.0000672763,0.00039978497,0.0000997166,0.0003093621,0.79338634,0.00014843426,0.0014004773,0.016946372],"study_design_scores_gemma":[0.000025355246,0.00046591982,0.8129217,0.000023745699,0.000055882516,0.0015647365,0.00020941494,0.0015321503,0.17942509,0.0001421943,0.00362211,0.000011691694],"about_ca_topic_score_codex":0.0015322127,"about_ca_topic_score_gemma":0.0014553476,"teacher_disagreement_score":0.0030408448,"about_ca_system_score_codex":0.00033030447,"about_ca_system_score_gemma":0.00012762025,"threshold_uncertainty_score":0.010172665},"labels":[],"label_agreement":null},{"id":"W2767374855","doi":"10.1158/1538-8514.synthleth-a04","title":"Abstract A04: Cross-species analysis identifies MUS81, a structure-specific endonuclease, as a novel synthetic lethal interaction with PARP","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Synthetic lethality; Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Homologous recombination; DNA repair; Genetics; Cell biology; DNA damage; Molecular biology; Polymerase; DNA","score_opus":0.0529701463254155,"score_gpt":0.356372261200227,"score_spread":0.3034021148748115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767374855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991614,0.0008229475,0.0045759017,0.00006704228,0.000035588302,0.000041956948,0.0010529272,0.00009190418,0.0016978529],"genre_scores_gemma":[0.9880846,0.0002501362,0.0034453643,0.00012527204,0.000008078478,0.000030521744,0.0024469427,0.00005462062,0.0055543957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998561,0.000014863742,0.00001736442,0.000054808068,0.000033739743,0.000023028835],"domain_scores_gemma":[0.9998185,0.000023290397,0.00007548507,0.000017358901,0.00002113635,0.000044320866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011929105,0.000435609,0.00016269964,0.00043773357,0.00023375038,0.00020299623,0.0003223185,0.000540337,0.0026651237],"category_scores_gemma":[0.00011002471,0.00015783758,0.0003473036,0.00018244366,0.00015590206,0.00014092824,0.00033814687,0.00047295698,0.00064838683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003404343,0.000013351983,0.0003393729,0.000010383611,0.000005559621,0.00010496441,0.0000050073945,0.000011703714,0.999,0.000038815913,0.000032872023,0.00040387324],"study_design_scores_gemma":[0.000009667162,0.00020556625,0.027448116,0.0000063332686,0.000031113388,0.002095653,0.000031959844,0.00068244914,0.965742,0.00004372861,0.0036963518,0.0000070995497],"about_ca_topic_score_codex":0.00058360986,"about_ca_topic_score_gemma":0.00067639153,"teacher_disagreement_score":0.0026651237,"about_ca_system_score_codex":0.00027031032,"about_ca_system_score_gemma":0.000087548564,"threshold_uncertainty_score":0.008915782},"labels":[],"label_agreement":null},{"id":"W2767673199","doi":"10.1158/1538-8514.synthleth-ia06","title":"Abstract IA06: Leveraging genome-wide CRISPR screens and synthetic lethal interactions for novel cancer therapeutics","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CRISPR; Frizzled; Biology; Wnt signaling pathway; Cancer; Genome editing; Computational biology; Cas9; Genome; Context (archaeology); Cancer research; Genetics; Gene","score_opus":0.040523857169522455,"score_gpt":0.35626202916618976,"score_spread":0.3157381719966673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767673199","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38591293,0.007930432,0.46839118,0.0039246585,0.002670457,0.0019246808,0.01757377,0.031087305,0.08058461],"genre_scores_gemma":[0.6668583,0.005881227,0.24177252,0.001270503,0.00015573308,0.0009492819,0.008898241,0.0020898408,0.0721243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990393,0.00013632345,0.00009511067,0.00018982546,0.00041406255,0.00012534631],"domain_scores_gemma":[0.99959,0.00006648507,0.000080788515,0.000079058525,0.00008139257,0.00010235764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087349745,0.0009958426,0.0008899639,0.0011114151,0.00052629143,0.0017421618,0.0011876825,0.001325025,0.0076233745],"category_scores_gemma":[0.0005135202,0.0004887934,0.0007984035,0.00050650677,0.00067831395,0.00044513907,0.0013656757,0.0023511895,0.0033860481],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013045734,0.00006210368,0.00019355582,0.00012684613,0.000028257942,0.00020940395,0.000030409206,0.0010470467,0.9807344,0.0025231682,0.003171657,0.011742588],"study_design_scores_gemma":[0.000042116586,0.0003693522,0.0008450159,0.000028663446,0.000048385784,0.00079155184,0.00003014188,0.0049501895,0.9445918,0.0005187056,0.04774166,0.000042345833],"about_ca_topic_score_codex":0.0009436777,"about_ca_topic_score_gemma":0.0016365141,"teacher_disagreement_score":0.0076233745,"about_ca_system_score_codex":0.0009317789,"about_ca_system_score_gemma":0.0008051205,"threshold_uncertainty_score":0.025502741},"labels":[],"label_agreement":null},{"id":"W2768045733","doi":"10.1158/1538-8514.synthleth-a38","title":"Abstract A38: Genome-wide CRISPR-Cas9 screens reveal modulators of temozolomide sensitivity in glioblastoma","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Temozolomide; MSH6; CRISPR; Cancer research; Biology; Synthetic lethality; Gene; DNA repair; Medicine; Glioblastoma; Genetics; DNA mismatch repair","score_opus":0.014533477766253739,"score_gpt":0.30992175175134634,"score_spread":0.2953882739850926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768045733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872749,0.0007492436,0.0040932703,0.00011314811,0.000022551178,0.0001069869,0.0052909586,0.00041474545,0.0019341765],"genre_scores_gemma":[0.98801583,0.00053158094,0.0048344187,0.000099034194,0.00000398511,0.00006838369,0.0036109346,0.00007105518,0.0027647603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986696,0.000013751427,0.000014013465,0.000029569877,0.00005243883,0.00002317507],"domain_scores_gemma":[0.9999366,0.00001451176,0.000017131759,0.0000057309335,0.000010314489,0.000015603211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012126046,0.0003549324,0.0003425964,0.00028715917,0.00014078036,0.00025056442,0.00023640029,0.00023623488,0.0022172872],"category_scores_gemma":[0.00013853755,0.00010605595,0.00025391395,0.0002213058,0.0001301282,0.0000665005,0.00019758476,0.00027578272,0.00039006467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000758757,0.000023193565,0.00036778132,0.00003617393,0.0000092272585,0.000066991684,0.000009940252,0.00017332232,0.99724674,0.000036312595,0.0001325448,0.0018219324],"study_design_scores_gemma":[0.00003257052,0.0005027473,0.01316744,0.000010299132,0.000051182797,0.00044622913,0.00003473319,0.002718145,0.97863364,0.00005399432,0.004335832,0.000013198856],"about_ca_topic_score_codex":0.002214897,"about_ca_topic_score_gemma":0.0041875676,"teacher_disagreement_score":0.0022172872,"about_ca_system_score_codex":0.00028871212,"about_ca_system_score_gemma":0.00020710558,"threshold_uncertainty_score":0.0074175596},"labels":[],"label_agreement":null},{"id":"W2773439479","doi":"10.1158/1538-8514.synthleth-b18","title":"Abstract B18: Mechanisms of regulation and synthetic lethal strategies against PALB2 and APRIN, two DNA double-strand break repair proteins","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"PALB2; Homologous recombination; DNA repair; Biology; DNA damage; Genetics; Genome instability; Cancer research; Mutation; DNA; Cell biology; Gene; Germline mutation","score_opus":0.019716191837931104,"score_gpt":0.28236122566860666,"score_spread":0.26264503383067556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773439479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96608245,0.007488226,0.017608194,0.00071701204,0.00020547835,0.00012079702,0.0010476992,0.0004297263,0.0063005458],"genre_scores_gemma":[0.9877702,0.0010361845,0.0040197833,0.0001459771,0.000017365646,0.0000639879,0.0007781833,0.000045259905,0.006123087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998599,0.000019072106,0.000011417617,0.000036162615,0.000051836778,0.00002158088],"domain_scores_gemma":[0.99991167,0.000009136971,0.00003403121,0.000009714566,0.000012430927,0.000023056948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016986966,0.00047372535,0.0002338806,0.00016255215,0.00017814114,0.00025959397,0.0004125627,0.00041136687,0.0025978324],"category_scores_gemma":[0.00008845462,0.00013713543,0.00027187166,0.00009413673,0.00025438718,0.00017770531,0.00022212495,0.0006039724,0.0007424191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006182712,0.000021334508,0.00005736809,0.000032812815,0.0000036908998,0.000052875977,0.0000046475448,0.00009949433,0.9982463,0.0003118245,0.00007929959,0.0010283841],"study_design_scores_gemma":[0.000016940608,0.0002188604,0.00071733684,0.0000039254346,0.0000051935117,0.0002454964,0.0000071105796,0.0006679364,0.9938705,0.000085584616,0.004157608,0.0000034557072],"about_ca_topic_score_codex":0.0002856941,"about_ca_topic_score_gemma":0.00017373354,"teacher_disagreement_score":0.0025978324,"about_ca_system_score_codex":0.00035257605,"about_ca_system_score_gemma":0.00014581473,"threshold_uncertainty_score":0.008690655},"labels":[],"label_agreement":null},{"id":"W2785529934","doi":"10.1158/1535-7163.targ-17-b181","title":"Abstract B181: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including low-dose gemcitabine, in preclinical models of cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Cisplatin; Synthetic lethality; Cancer research; DNA damage; Topoisomerase; Biology; Cancer cell; Mitomycin C; Cancer; DNA replication; DNA repair; CHEK1; Cell cycle; Pharmacology; Cell cycle checkpoint; In vitro; DNA; Biochemistry; Genetics; Chemotherapy","score_opus":0.05506971729150969,"score_gpt":0.3484874899095117,"score_spread":0.29341777261800206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785529934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986829,0.0033573562,0.0022421512,0.00032449793,0.00011585667,0.00011880291,0.0016258865,0.00048077526,0.0049055633],"genre_scores_gemma":[0.990159,0.0017381468,0.0017806005,0.00007635827,0.000023384278,0.000116979834,0.0015814818,0.000048718524,0.004475494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982786,0.00002779762,0.00001427603,0.00002381546,0.000056216875,0.000049946706],"domain_scores_gemma":[0.999869,0.00001475085,0.000031202155,0.000013061701,0.000015570704,0.000056297842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015916258,0.00073743035,0.00044895086,0.00060522807,0.0002743202,0.0003055985,0.0002925316,0.00033816282,0.0029702785],"category_scores_gemma":[0.000093092116,0.00017758133,0.0002663958,0.00030820403,0.00023778893,0.0002344555,0.00013498505,0.000999545,0.00055478624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013126143,0.00094282813,0.0003186954,0.00010696543,0.000033982797,0.000065250104,0.00002047492,0.00044695326,0.98696,0.00027916045,0.0010183024,0.0084947925],"study_design_scores_gemma":[0.00009279606,0.00401742,0.0016151157,0.00000856576,0.000040003957,0.00014113054,0.000014673679,0.0008758545,0.99073386,0.00003631826,0.002419086,0.00000505905],"about_ca_topic_score_codex":0.0016284853,"about_ca_topic_score_gemma":0.0030331726,"teacher_disagreement_score":0.0029702785,"about_ca_system_score_codex":0.00037288465,"about_ca_system_score_gemma":0.0005500095,"threshold_uncertainty_score":0.009936571},"labels":[],"label_agreement":null},{"id":"W2786006104","doi":"10.1158/1535-7163.targ-17-a190","title":"Abstract A190: Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Germline; Genetic counseling; Context (archaeology); Cancer; Medicine; Penetrance; Oncology; Internal medicine; Bioinformatics; Genetics; Gene; Biology; Phenotype","score_opus":0.026910687958789307,"score_gpt":0.3418710277015232,"score_spread":0.3149603397427339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786006104","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6852788,0.020542594,0.08211021,0.072482206,0.0043260977,0.0019395684,0.002614878,0.0028467549,0.12785898],"genre_scores_gemma":[0.9377299,0.004827829,0.03141247,0.007597951,0.0027501981,0.00047736705,0.0014484316,0.00039778615,0.013358099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990024,0.00036555904,0.00016162096,0.00015072533,0.00021452135,0.00010522023],"domain_scores_gemma":[0.9972258,0.00061485585,0.00067114114,0.00027264102,0.0006040504,0.00061145646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026060282,0.0003440332,0.00020555143,0.0011056234,0.0011159265,0.001109121,0.0006858181,0.0010280972,0.0059964345],"category_scores_gemma":[0.005954314,0.0001757982,0.00019568794,0.0006441333,0.0007045493,0.0009472774,0.001127892,0.0009800335,0.0023649188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007609875,0.0003185123,0.24066946,0.0005194257,0.00005740265,0.040546134,0.0011788587,0.0009794256,0.014323218,0.003852237,0.14357363,0.55322075],"study_design_scores_gemma":[0.00017342866,0.0018331786,0.3013454,0.0013078249,0.00016003486,0.2857335,0.0040849755,0.0070915977,0.027290365,0.014080488,0.3567794,0.0001198233],"about_ca_topic_score_codex":0.0005806432,"about_ca_topic_score_gemma":0.0010746901,"teacher_disagreement_score":0.0059964345,"about_ca_system_score_codex":0.0007812875,"about_ca_system_score_gemma":0.001222996,"threshold_uncertainty_score":0.020060062},"labels":[],"label_agreement":null},{"id":"W2786998403","doi":"10.1158/1535-7163.targ-17-b011","title":"Abstract B011: Immunoediting in untreated mismatch repair deficient colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Immunoediting; Microsatellite instability; DNA mismatch repair; Colorectal cancer; Cancer; Exome; Biology; Immune checkpoint; Immune system; Exome sequencing; Cancer research; Medicine; Genetics; Gene; Microsatellite; Immunotherapy; Mutation; Allele","score_opus":0.026547168257235767,"score_gpt":0.3139578065377615,"score_spread":0.28741063828052577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786998403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754015,0.0005931879,0.01454392,0.00017438161,0.00005346379,0.00010648162,0.0065364926,0.0009018119,0.0016887356],"genre_scores_gemma":[0.9640271,0.00016128423,0.01829045,0.00012430294,0.000019790612,0.00006797269,0.015773835,0.00019032184,0.0013449399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996822,0.00005586303,0.000027611988,0.000118128024,0.000080495025,0.000035702626],"domain_scores_gemma":[0.9996026,0.00019343216,0.00006217431,0.0000363752,0.000057001325,0.000048443064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008308462,0.0003956029,0.00054209196,0.0012169663,0.00037704041,0.00074013066,0.00044151844,0.0005216862,0.0036424564],"category_scores_gemma":[0.0022161694,0.00017112045,0.000516355,0.00086555746,0.00021063529,0.00020001193,0.0004254212,0.00033199982,0.0009304663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070363176,0.0005986739,0.5925432,0.0008494529,0.00055396196,0.0030681102,0.00022782042,0.030817565,0.10404132,0.0010667433,0.0103182895,0.2488785],"study_design_scores_gemma":[0.00044615532,0.0022236,0.5109812,0.00014312436,0.00045595007,0.006823303,0.00042066025,0.3902586,0.06546332,0.0032042393,0.019484859,0.00009502929],"about_ca_topic_score_codex":0.002810685,"about_ca_topic_score_gemma":0.0036950905,"teacher_disagreement_score":0.0036424564,"about_ca_system_score_codex":0.00037508694,"about_ca_system_score_gemma":0.00037888577,"threshold_uncertainty_score":0.012185276},"labels":[],"label_agreement":null},{"id":"W2787014069","doi":"10.1158/1535-7163.targ-17-b148","title":"Abstract B148: Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SignalChem (Canada)","funders":"","keywords":"Immune system; Cancer research; Tumor microenvironment; Kinase; CD8; Biology; Immunology; Cancer; Pharmacology; Medicine; Internal medicine; Biochemistry","score_opus":0.02416915970491095,"score_gpt":0.26254877021169204,"score_spread":0.23837961050678108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787014069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897059,0.00151748,0.0020484468,0.000502413,0.0001240872,0.00014360965,0.0031167937,0.00028202994,0.0025591496],"genre_scores_gemma":[0.98284966,0.0013711598,0.0019796882,0.00018786125,0.00003990904,0.0002904404,0.002838262,0.000076641256,0.010366368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997149,0.00003137658,0.000024298257,0.00006848036,0.00007257586,0.000088269284],"domain_scores_gemma":[0.99975365,0.000018046268,0.00007866524,0.000022863129,0.000018074206,0.00010864979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022600837,0.0010717777,0.00051615865,0.00079889054,0.00025175142,0.00032066004,0.00042782372,0.0008502392,0.003982372],"category_scores_gemma":[0.00009929172,0.00028249426,0.0006686909,0.0002926284,0.0005696766,0.00041551638,0.00018002972,0.0017036039,0.0013039235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084141694,0.0003063625,0.00011074603,0.00005143763,0.000007044943,0.00014775724,0.000015378795,0.000104111496,0.9973416,0.00015444738,0.00016089727,0.0007588991],"study_design_scores_gemma":[0.00016562473,0.003987405,0.0018948041,0.000015352025,0.000029868499,0.00041210707,0.000034463348,0.00078555907,0.9902062,0.00007553362,0.0023841741,0.000008841624],"about_ca_topic_score_codex":0.0010748083,"about_ca_topic_score_gemma":0.00093825767,"teacher_disagreement_score":0.003982372,"about_ca_system_score_codex":0.000440714,"about_ca_system_score_gemma":0.00041665373,"threshold_uncertainty_score":0.013322353},"labels":[],"label_agreement":null},{"id":"W2787342755","doi":"10.1158/1535-7163.targ-17-a109","title":"Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Delmar (Canada); University of British Columbia","funders":"","keywords":"DNA damage; DNA repair; Olaparib; Topoisomerase; Poly ADP ribose polymerase; Cancer research; Biology; Cancer cell; Homologous recombination; Topoisomerase inhibitor; Molecular biology; DNA; PARP inhibitor; Chemistry; Cancer; Polymerase; Genetics","score_opus":0.011364562012254002,"score_gpt":0.25349216129835606,"score_spread":0.24212759928610206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787342755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95759314,0.022496007,0.0050052726,0.0006848887,0.0002809561,0.00025926443,0.0015110571,0.00073133595,0.011437991],"genre_scores_gemma":[0.98288065,0.004381251,0.0037464628,0.00023483936,0.00003184033,0.00007754326,0.0013536529,0.00003473775,0.007259045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996495,0.0000047341487,0.0000033146398,0.000008275255,0.000009851778,0.000008782943],"domain_scores_gemma":[0.99997056,0.0000021217818,0.0000081844155,0.000002797666,0.0000041279923,0.00001212824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038859635,0.0003861418,0.00023328395,0.00028004753,0.00011962959,0.00017383596,0.00023662555,0.0003064116,0.002396886],"category_scores_gemma":[0.000039232287,0.00009299257,0.00018990437,0.00019330494,0.00010360199,0.00011270695,0.00014558883,0.0005607968,0.00059766223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064845046,0.00025469234,0.0005003602,0.00017897812,0.000023116594,0.00023378327,0.000010558567,0.00019335952,0.97675806,0.00018251337,0.0008787849,0.020137282],"study_design_scores_gemma":[0.00014197499,0.0028281726,0.005561436,0.000019925252,0.00005569926,0.0016378355,0.00001977915,0.00080869196,0.96897817,0.00010878886,0.019830905,0.000008604098],"about_ca_topic_score_codex":0.0004306913,"about_ca_topic_score_gemma":0.0006011202,"teacher_disagreement_score":0.002396886,"about_ca_system_score_codex":0.00020744273,"about_ca_system_score_gemma":0.0001505318,"threshold_uncertainty_score":0.008018374},"labels":[],"label_agreement":null},{"id":"W2787457224","doi":"10.1158/1535-7163.targ-17-a082","title":"Abstract A082: A phase I study of the MDM2 antagonist RO6839921, a pegylated intravenous prodrug of idasanutlin, in patients with AML","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Nausea; Pharmacology; Prodrug; Dosing; Vomiting; Internal medicine; Pharmacodynamics; Phases of clinical research; Pharmacokinetics; Gastroenterology; Toxicity","score_opus":0.015465020455442565,"score_gpt":0.2865701823240733,"score_spread":0.2711051618686307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787457224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961875,0.0007811338,0.00046123718,0.00021374112,0.000033866425,0.00077946874,0.0004547167,0.00006232096,0.0010260714],"genre_scores_gemma":[0.9944858,0.000591448,0.0011435281,0.00031059436,0.00008601099,0.00074882346,0.0010354717,0.000025183122,0.0015730591],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99977237,0.00009616751,0.000015842079,0.000046963956,0.000026102662,0.000042575248],"domain_scores_gemma":[0.9997216,0.000039809504,0.000047028174,0.000026962929,0.000018418992,0.00014607137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000630946,0.0010512072,0.0012111241,0.0002798975,0.00027755,0.0006362728,0.00052989676,0.0007273233,0.0021822855],"category_scores_gemma":[0.00047250616,0.00036077865,0.00057517336,0.00023482261,0.00044848613,0.0004787427,0.00027214165,0.0019090044,0.0008627993],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33949974,0.083680525,0.013345613,0.0010444019,0.001063234,0.0013387386,0.00068445754,0.0043369606,0.3852236,0.00045630935,0.0053250454,0.16400138],"study_design_scores_gemma":[0.21277791,0.73376906,0.020389188,0.000033552893,0.00040571796,0.0013172738,0.000095682335,0.0021135476,0.02348845,0.00018322989,0.005391567,0.000034788085],"about_ca_topic_score_codex":0.00053009304,"about_ca_topic_score_gemma":0.0006580298,"teacher_disagreement_score":0.0021822855,"about_ca_system_score_codex":0.0004960856,"about_ca_system_score_gemma":0.0006975769,"threshold_uncertainty_score":0.0073004365},"labels":[],"label_agreement":null},{"id":"W2787641076","doi":"10.1158/1535-7163.targ-17-a189","title":"Abstract A189: Identification of antibody-drug conjugate targets using curated public data, in-house glycoproteomics, and a surrogate in vitro ADC assay","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Biology; Cancer research; Population; Cancer; Computational biology; Medicine; Genetics","score_opus":0.06927556907969151,"score_gpt":0.3802044517327276,"score_spread":0.3109288826530361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787641076","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3199533,0.0018727798,0.057809986,0.0010555174,0.00022413109,0.0011298283,0.5876675,0.021301458,0.008985525],"genre_scores_gemma":[0.1581778,0.0008785487,0.09779398,0.00047486715,0.00007051185,0.0010685408,0.73745006,0.0009770467,0.0031086365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805826,0.00022532033,0.00016686408,0.00063119107,0.00073767744,0.00018074013],"domain_scores_gemma":[0.99789447,0.00039518066,0.0003892911,0.00039838266,0.0007024215,0.00022018494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017761751,0.0014566969,0.0013105995,0.003613961,0.0007083913,0.0016979438,0.0009036099,0.00073708856,0.0045527583],"category_scores_gemma":[0.0027360052,0.00042024898,0.0011560841,0.0033723018,0.0003369117,0.0006861279,0.0011680385,0.00083072676,0.005667882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032443576,0.0013741485,0.089483365,0.0029140327,0.000831885,0.0015815205,0.00027297117,0.014238628,0.589608,0.0022288132,0.14729734,0.14692484],"study_design_scores_gemma":[0.00073066977,0.0018745022,0.15591711,0.00029275735,0.0006576881,0.0017610394,0.0004673331,0.13231505,0.45238864,0.0043767714,0.2489852,0.00023320984],"about_ca_topic_score_codex":0.0044332137,"about_ca_topic_score_gemma":0.0057532843,"teacher_disagreement_score":0.0045527583,"about_ca_system_score_codex":0.00084914855,"about_ca_system_score_gemma":0.002573158,"threshold_uncertainty_score":0.015230477},"labels":[],"label_agreement":null},{"id":"W2789873517","doi":"10.1158/1535-7163.mct-17-0552","title":"Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of California, San Francisco; National Institutes of Health; Sunnybrook Research Institute","keywords":"Pharmacodynamics; Pharmacology; Biomarker; Medicine; Pharmacokinetics; Drug; Biology","score_opus":0.019470182303289663,"score_gpt":0.3456646254658927,"score_spread":0.32619444316260304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789873517","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2383251,0.007855345,0.7334487,0.0031059454,0.00025626982,0.0013621354,0.00053204,0.0011833602,0.013931183],"genre_scores_gemma":[0.8186698,0.0029165507,0.17449395,0.00075141224,0.000098973294,0.0006219613,0.00019421469,0.00014307321,0.0021101306],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9993063,0.00024328954,0.00004723927,0.00014495333,0.00019138423,0.00006666769],"domain_scores_gemma":[0.9994735,0.0001550334,0.00017694972,0.00006517395,0.00008457945,0.00004479181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018582386,0.0007724859,0.00086493127,0.0006206086,0.00029328783,0.0015916238,0.00096900197,0.0005266066,0.0012753038],"category_scores_gemma":[0.0018279413,0.0004381863,0.00052379066,0.00039233116,0.0006463711,0.0011505998,0.0007816576,0.0017350123,0.0003621415],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014066708,0.001048599,0.0024326332,0.00046392428,0.00012410684,0.00017015563,0.00011873964,0.104046255,0.66107553,0.020708742,0.001927605,0.20647708],"study_design_scores_gemma":[0.00070461753,0.009934397,0.005428582,0.00008957233,0.00019599337,0.000764161,0.000125044,0.3614135,0.5651499,0.01983173,0.036175426,0.00018703817],"about_ca_topic_score_codex":0.000517235,"about_ca_topic_score_gemma":0.0006658112,"teacher_disagreement_score":0.0018582386,"about_ca_system_score_codex":0.0014583187,"about_ca_system_score_gemma":0.00112595,"threshold_uncertainty_score":0.010580897},"labels":[],"label_agreement":null},{"id":"W2791467603","doi":"10.1158/1535-7163.mct-17-1091","title":"Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Government of Canada","keywords":"Immune checkpoint; Cancer research; Cisplatin; CD8; Immune system; Biology; In vivo; Cancer; Cytotoxic T cell; Immunology; Immunotherapy; Chemotherapy; Genetics; In vitro","score_opus":0.027543629945367083,"score_gpt":0.33420471881669817,"score_spread":0.3066610888713311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791467603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99816716,0.0002601505,0.00072265265,0.000030144518,0.000012646268,0.00002850976,0.00019024199,0.00004803918,0.0005405081],"genre_scores_gemma":[0.9977775,0.00017624695,0.0006619426,0.000023460272,0.0000044340263,0.000024316547,0.00023316461,0.000024762143,0.0010742396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975973,0.000058621237,0.000023168652,0.00004544099,0.000059333408,0.000053761723],"domain_scores_gemma":[0.99973875,0.00006707729,0.00007088173,0.000046886034,0.00001960325,0.000056842964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019564315,0.00029667554,0.00023815471,0.00033493477,0.00010947173,0.00020418112,0.00018974672,0.00031897394,0.0017151942],"category_scores_gemma":[0.00014058987,0.00012286224,0.00021112668,0.00011866468,0.00020646008,0.00019265173,0.00018587719,0.0006106386,0.00024507628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112962494,0.00007560625,0.00016209517,0.00001013986,0.0000039436877,0.000015876112,0.000008414927,0.00012463058,0.9989692,0.000033506487,0.000014050319,0.0004695683],"study_design_scores_gemma":[0.000009738493,0.0017437219,0.0018241905,0.0000026034345,0.000007692169,0.000065054024,0.000011624634,0.00055108586,0.9953349,0.000019123314,0.00042774473,0.0000024797835],"about_ca_topic_score_codex":0.00045357033,"about_ca_topic_score_gemma":0.0006840951,"teacher_disagreement_score":0.0017151942,"about_ca_system_score_codex":0.00022239661,"about_ca_system_score_gemma":0.0001259943,"threshold_uncertainty_score":0.005737841},"labels":[],"label_agreement":null},{"id":"W2792862146","doi":"10.1158/1535-7163.mct-17-0559","title":"Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Association for the Study of the Liver","keywords":"Anaplastic thyroid cancer; Telomerase; Telomerase reverse transcriptase; Thyroid cancer; Chemistry; Cancer research; In vivo; Pharmacology; Cancer cell; Cytotoxicity; Poloxamer; Cancer; In vitro; Molecular biology; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.02168774687493087,"score_gpt":0.2887609737655415,"score_spread":0.26707322689061064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792862146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931937,0.0011694485,0.0033459233,0.00006293189,0.00003849801,0.000044512668,0.00019935082,0.00019331477,0.0017523427],"genre_scores_gemma":[0.99173695,0.00056842784,0.003203016,0.00003891015,0.000012100864,0.00004991276,0.00030900803,0.000030025112,0.004051808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999058,0.00001022778,0.000007857969,0.000021830941,0.00003326136,0.000020958441],"domain_scores_gemma":[0.9999341,0.000014394043,0.000018528712,0.000007476823,0.00001176799,0.000013806727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011485023,0.00031051962,0.0002480257,0.00015511765,0.00009145719,0.00015571086,0.00016885469,0.00026118808,0.0007543456],"category_scores_gemma":[0.0000636471,0.000107276916,0.00021210933,0.000087813445,0.00012618727,0.00013477501,0.00008028422,0.000401584,0.00023016807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031400286,0.000021067288,0.00002527361,0.000013249089,0.0000024342914,0.000009900507,0.0000055219884,0.00004423364,0.9992249,0.00002271043,0.00002533336,0.00057403476],"study_design_scores_gemma":[0.000008657492,0.00039235884,0.0007047213,0.0000019004535,0.000011626376,0.000040569445,0.0000051611664,0.00082654785,0.9971812,0.0000071814075,0.00081852975,0.0000016408669],"about_ca_topic_score_codex":0.0014109719,"about_ca_topic_score_gemma":0.002126365,"teacher_disagreement_score":0.0014109719,"about_ca_system_score_codex":0.00023921975,"about_ca_system_score_gemma":0.00017498243,"threshold_uncertainty_score":0.0028054714},"labels":[],"label_agreement":null},{"id":"W2796900308","doi":"10.1158/1535-7163.targ-17-lb-a12","title":"Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<i>BRCA</i> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"PARP inhibitor; Olaparib; Oncology; Medicine; Internal medicine; BRCA mutation; Cancer research; Homologous recombination; Ovarian cancer; Cancer; Genetics; Biology; Gene; Poly ADP ribose polymerase","score_opus":0.023965657891026924,"score_gpt":0.29624467251739556,"score_spread":0.2722790146263686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796900308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937145,0.0016969404,0.00041954403,0.000396434,0.000070675276,0.001016322,0.0016227365,0.00010507974,0.0009577236],"genre_scores_gemma":[0.99263084,0.00065816,0.00096194475,0.0007406571,0.00012405221,0.00080254656,0.002841045,0.000046065477,0.0011946175],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9986761,0.0008049636,0.00008917903,0.0001621832,0.00011417806,0.00015337006],"domain_scores_gemma":[0.997974,0.00048436443,0.0004165281,0.0003032385,0.00018136905,0.0006405145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035994141,0.0010678433,0.0023717834,0.00036411904,0.0004819969,0.0009768389,0.00094145857,0.0013544682,0.0039861696],"category_scores_gemma":[0.0018274166,0.00046785842,0.0027404232,0.00045571057,0.0009533542,0.0007777168,0.0003562808,0.0036195493,0.00081562164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8971577,0.026708305,0.007896012,0.00040207428,0.0020029445,0.00013300897,0.00013673288,0.000593278,0.028504187,0.00005977212,0.0022136653,0.03419221],"study_design_scores_gemma":[0.54037225,0.41253072,0.037289012,0.000041892577,0.0017345636,0.00026947225,0.00006980529,0.00066750066,0.005168164,0.00013574773,0.0016696041,0.00005124794],"about_ca_topic_score_codex":0.0013176742,"about_ca_topic_score_gemma":0.0030658979,"teacher_disagreement_score":0.0039861696,"about_ca_system_score_codex":0.00078820693,"about_ca_system_score_gemma":0.0015155135,"threshold_uncertainty_score":0.019035757},"labels":[],"label_agreement":null},{"id":"W2801224767","doi":"10.1158/1535-7163.mct-17-1066","title":"Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Roswell Park Cancer Institute; U.S. Department of Defense","keywords":"Tumor microenvironment; Biomarker; Immune system; Angiogenesis; Transcriptome; Biology; Antibody; Cancer research; Cancer; Immune checkpoint; Immunology; Immunotherapy; Medicine; Gene; Gene expression; Genetics","score_opus":0.011340171221078185,"score_gpt":0.2542033933345853,"score_spread":0.2428632221135071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801224767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685717,0.0004643745,0.0012756898,0.000030061978,0.000013602431,0.000022449834,0.0007152778,0.000034756697,0.0005866527],"genre_scores_gemma":[0.9965507,0.00026666073,0.0010623022,0.00004497244,0.0000107369315,0.000034565095,0.0007661632,0.000016191483,0.0012478171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998945,0.000014648468,0.000007472863,0.000022312914,0.00003647045,0.00002456268],"domain_scores_gemma":[0.99986005,0.000023772658,0.000054935546,0.000015636786,0.000018882422,0.000026772173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013072629,0.00019355946,0.00022785357,0.000243008,0.00008176137,0.00027696448,0.00005655685,0.00013724886,0.00084983086],"category_scores_gemma":[0.00011064197,0.0000848328,0.0002462528,0.00012250146,0.00015545613,0.00017060367,0.00014896072,0.0003762455,0.00015651871],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001299578,0.0000092919945,0.00046194534,0.000013067496,0.000003846364,0.000014289056,0.0000064047686,0.000031600175,0.9988856,0.000020814081,0.000011382966,0.00041191434],"study_design_scores_gemma":[0.00001619221,0.0005640966,0.056586627,0.0000045705597,0.000027525573,0.00019903874,0.000048800553,0.0014960187,0.93962526,0.000087416294,0.0013393335,0.000004995332],"about_ca_topic_score_codex":0.00012285943,"about_ca_topic_score_gemma":0.00016192332,"teacher_disagreement_score":0.00084983086,"about_ca_system_score_codex":0.00016629847,"about_ca_system_score_gemma":0.000091627844,"threshold_uncertainty_score":0.0028430223},"labels":[],"label_agreement":null},{"id":"W2885489314","doi":"10.1158/1535-7163.targ-17-a184","title":"Abstract A184: Clinical application of whole genome and transcriptome sequencing in cancer care","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Indel; Transcriptome; Computational biology; Personalized medicine; Cancer; Genome; Whole genome sequencing; Personal genomics; Cancer genome sequencing; Genomics; Ensembl; DNA sequencing; Precision medicine; Biology; Gene; Genetics; Bioinformatics; Gene expression","score_opus":0.029734807867320797,"score_gpt":0.3326298229840574,"score_spread":0.3028950151167366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885489314","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19090822,0.027343296,0.3908454,0.06308074,0.0059166546,0.00657376,0.15296641,0.040350232,0.12201539],"genre_scores_gemma":[0.46923554,0.011966388,0.4128723,0.012022868,0.0020764235,0.0032445618,0.06454208,0.0040896623,0.019950155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852645,0.00059926143,0.00013141136,0.00026810268,0.0003875412,0.00008720496],"domain_scores_gemma":[0.99356866,0.002481923,0.00057926186,0.000659678,0.0020306378,0.0006798445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004493388,0.00064213877,0.0004642115,0.0018543731,0.00057896355,0.0023717044,0.00066543336,0.001061126,0.021362517],"category_scores_gemma":[0.009575576,0.0003770503,0.00069821475,0.0018762418,0.00033259857,0.00094370596,0.0013489126,0.001279048,0.008531346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015174069,0.00029533645,0.07007363,0.0013070445,0.00028786564,0.001108792,0.0003890293,0.0040690172,0.017709164,0.0036018244,0.27011308,0.62952775],"study_design_scores_gemma":[0.0014388621,0.0019288765,0.2253223,0.002586829,0.0005886254,0.0048564426,0.001321073,0.051309276,0.043240063,0.03655521,0.63055664,0.00029580278],"about_ca_topic_score_codex":0.0041530854,"about_ca_topic_score_gemma":0.003944337,"teacher_disagreement_score":0.021362517,"about_ca_system_score_codex":0.0010522577,"about_ca_system_score_gemma":0.0023889723,"threshold_uncertainty_score":0.07146472},"labels":[],"label_agreement":null},{"id":"W2885983462","doi":"10.1158/1535-7163.targ-17-a152","title":"Abstract A152: Emerging indications for kinase-targeted therapies: screening for new targets","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SignalChem (Canada)","funders":"","keywords":"Kinome; Kinase; Vandetanib; Tyrosine kinase; Receptor tyrosine kinase; Medicine; Pharmacology; Cabozantinib; Cancer research; Sorafenib; Biology; Cancer; Biochemistry; Signal transduction; Internal medicine","score_opus":0.0617206210391006,"score_gpt":0.37740121309189767,"score_spread":0.3156805920527971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885983462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66436374,0.28072923,0.014313952,0.004545783,0.0007297745,0.0010525066,0.004377651,0.00055027485,0.029337073],"genre_scores_gemma":[0.8341279,0.13076112,0.011626803,0.002364445,0.0003479386,0.00039362177,0.0052546533,0.00008819602,0.015035406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998172,0.000045100107,0.0000137928755,0.000029704435,0.000060178194,0.00003396422],"domain_scores_gemma":[0.9998423,0.00002612182,0.000031094656,0.000010192448,0.000045303288,0.000044978264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005669049,0.000679851,0.0008030437,0.00076527335,0.00015748342,0.0008973744,0.0004769419,0.00068842625,0.0041716583],"category_scores_gemma":[0.00026526165,0.00020159571,0.0005676094,0.0005157062,0.00021619974,0.00046586207,0.00029141756,0.0012635407,0.0014741017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027080588,0.0014351741,0.0023657419,0.0018748974,0.00017897527,0.0008977322,0.0000906157,0.003019995,0.7914581,0.0021839926,0.0070080715,0.1867786],"study_design_scores_gemma":[0.0034140234,0.05116393,0.021691922,0.0010886202,0.0008056808,0.005976566,0.00030614508,0.013156892,0.6675162,0.0030493136,0.23166135,0.00016938795],"about_ca_topic_score_codex":0.0006001524,"about_ca_topic_score_gemma":0.0018550907,"teacher_disagreement_score":0.0041716583,"about_ca_system_score_codex":0.00053890684,"about_ca_system_score_gemma":0.00046104076,"threshold_uncertainty_score":0.013955653},"labels":[],"label_agreement":null},{"id":"W2886557345","doi":"10.1158/1535-7163.targ-17-a100","title":"Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; McMaster University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Phases of clinical research; Clinical Oncology; Population; Oncology; Food and drug administration; Cancer; Drug development; Sample size determination; Drug; Pharmacology","score_opus":0.06756027576180723,"score_gpt":0.4308483398892855,"score_spread":0.36328806412747827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886557345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7616736,0.1682402,0.012876422,0.0014706887,0.00032717566,0.0037715875,0.044535425,0.00020903606,0.006895869],"genre_scores_gemma":[0.96127623,0.0146442475,0.0045597684,0.0011270612,0.00034682342,0.0028128312,0.014534269,0.00011383539,0.0005849036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.94299805,0.017761953,0.025320241,0.0043687257,0.008665863,0.00088512775],"domain_scores_gemma":[0.7029062,0.1049112,0.14660661,0.019900568,0.021375854,0.0042996868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03823971,0.00053121493,0.0013295372,0.009090607,0.00064638007,0.0025908526,0.0010011871,0.0007944661,0.0027505464],"category_scores_gemma":[0.10925901,0.0006728788,0.0021935157,0.012400217,0.0010758588,0.0024655506,0.0015986894,0.0009998427,0.00094013417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025252437,0.00011706695,0.9530248,0.0050971154,0.0031706213,0.00050931476,0.00028968384,0.0004136723,0.0007729043,0.0004993068,0.0051329834,0.02844723],"study_design_scores_gemma":[0.0006398152,0.00146237,0.94688374,0.0040602814,0.004868295,0.0049526333,0.0006817532,0.00079076993,0.0014581837,0.0005030187,0.033614162,0.00008484297],"about_ca_topic_score_codex":0.0010983722,"about_ca_topic_score_gemma":0.0012905619,"teacher_disagreement_score":0.03823971,"about_ca_system_score_codex":0.0010194936,"about_ca_system_score_gemma":0.0022426066,"threshold_uncertainty_score":0.20223331},"labels":[],"label_agreement":null},{"id":"W2887451076","doi":"10.1158/1535-7163.targ-17-b056","title":"Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; University of Toronto","funders":"","keywords":"Trametinib; Dabrafenib; Vemurafenib; Melanoma; Cancer research; MAPK/ERK pathway; MEK inhibitor; Medicine; Kinase; Targeted therapy; Mutant; V600E; In vivo; Cell culture; Cell growth; Metastatic melanoma; Cancer; Biology; Internal medicine; Cell biology; Biochemistry; Genetics","score_opus":0.017198359884491442,"score_gpt":0.28795492942818246,"score_spread":0.27075656954369104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887451076","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8628037,0.066339396,0.016686177,0.004426397,0.00068223604,0.001416745,0.0023145596,0.00061065436,0.044720102],"genre_scores_gemma":[0.9671738,0.01572299,0.0073562344,0.00069064874,0.00011543186,0.00021159432,0.0011694523,0.000044717963,0.0075151175],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999012,0.00002534521,0.00000805909,0.0000143984835,0.000026916436,0.000024029088],"domain_scores_gemma":[0.9999336,0.000009579465,0.000013147731,0.0000055411138,0.0000132069845,0.000024983154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027840683,0.00048629922,0.00045229407,0.0004367124,0.00017971825,0.0004640907,0.00043007592,0.00039490397,0.0043408484],"category_scores_gemma":[0.00014992972,0.00015975312,0.00031630447,0.00022303284,0.0002143469,0.00026208136,0.0002622846,0.0009971125,0.0011128834],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004708792,0.0028917328,0.0020923156,0.0011676728,0.00021288339,0.0017305819,0.00012620419,0.0056196842,0.776816,0.0049682613,0.0115253525,0.18814038],"study_design_scores_gemma":[0.008558138,0.031657122,0.013212893,0.0005294831,0.0005620073,0.008277983,0.00021149499,0.017529583,0.7137689,0.0049017677,0.20067264,0.000118012336],"about_ca_topic_score_codex":0.00041029663,"about_ca_topic_score_gemma":0.0011958224,"teacher_disagreement_score":0.0043408484,"about_ca_system_score_codex":0.00036146838,"about_ca_system_score_gemma":0.00027825212,"threshold_uncertainty_score":0.014521599},"labels":[],"label_agreement":null},{"id":"W2890293509","doi":"10.1158/1535-7163.mct-18-0348","title":"Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"SMARCA4; Biology; EZH2; Cancer research; Histone deacetylase; Histone Acetyltransferases; Acetylation; Histone; Epigenetics; Chromatin remodeling; Genetics; Gene","score_opus":0.01518160534608104,"score_gpt":0.25976281553028563,"score_spread":0.2445812101842046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890293509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369895,0.003160416,0.00064888445,0.00009749195,0.00005641734,0.000086800246,0.00020005403,0.00007639069,0.0019746176],"genre_scores_gemma":[0.9971384,0.001133925,0.00040992757,0.00003837907,0.000011510866,0.000036411984,0.00024340945,0.000005596551,0.0009824483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999548,0.0000056354265,0.0000042378047,0.0000072002426,0.000010825639,0.000017175702],"domain_scores_gemma":[0.9999734,0.000005006145,0.0000051774896,0.00000345111,0.0000033172514,0.000009714017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008593671,0.00021054433,0.0002782967,0.0002561754,0.00009696633,0.00016043181,0.00016190896,0.00013062797,0.0012105365],"category_scores_gemma":[0.00006913021,0.000077640056,0.00019428704,0.00017831994,0.00011507144,0.00012753364,0.00009443352,0.00036375804,0.00012140787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013325188,0.0006838223,0.0007897714,0.000147168,0.000048899645,0.00011711379,0.000025773834,0.00035969669,0.97421885,0.00026449826,0.00047405311,0.021537768],"study_design_scores_gemma":[0.00089291617,0.010519188,0.016308106,0.000012586943,0.000119961616,0.0006763488,0.00005326103,0.0019050688,0.958409,0.00010852263,0.010985393,0.000009697205],"about_ca_topic_score_codex":0.00056631106,"about_ca_topic_score_gemma":0.002153503,"teacher_disagreement_score":0.0012105365,"about_ca_system_score_codex":0.00020955535,"about_ca_system_score_gemma":0.0002343098,"threshold_uncertainty_score":0.004049659},"labels":[],"label_agreement":null},{"id":"W2892613404","doi":"10.1158/1535-7163.mct-18-0107","title":"Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia","keywords":"Gene knockdown; Gene silencing; Cancer research; In vivo; Biology; Apoptosis; Bladder cancer; Cancer; Gene; Biochemistry; Genetics","score_opus":0.014284392125237026,"score_gpt":0.262702458021119,"score_spread":0.248418065895882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892613404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942016,0.0023512323,0.0014968441,0.00014477235,0.000054255055,0.000027687287,0.00042380198,0.00015125045,0.0011484969],"genre_scores_gemma":[0.9958216,0.0007893979,0.0005903221,0.00005477292,0.000006113359,0.000024775994,0.0004702936,0.00001742308,0.0022253392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990046,0.000017241231,0.000008233631,0.000012672457,0.000032326014,0.00002910117],"domain_scores_gemma":[0.99991584,0.000014193996,0.000018172135,0.0000108572885,0.000015186662,0.000025880356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011686328,0.0003053929,0.00037059002,0.00018438871,0.00013214009,0.00028619927,0.0002019759,0.00020889823,0.0016172865],"category_scores_gemma":[0.00013212927,0.00013035149,0.00029492337,0.00016150606,0.00013342255,0.00014535371,0.00019048613,0.00051013,0.00027819828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050123717,0.00013252109,0.0008189916,0.00010769821,0.00002571789,0.000031613068,0.000019492616,0.00019453182,0.99324566,0.000054693897,0.00023315407,0.0046347864],"study_design_scores_gemma":[0.00007376299,0.0020466058,0.012207435,0.000013888407,0.00009538496,0.00019068725,0.00006368143,0.002684029,0.97786385,0.00006349931,0.004689994,0.0000071771065],"about_ca_topic_score_codex":0.0015576778,"about_ca_topic_score_gemma":0.0019747787,"teacher_disagreement_score":0.0016172865,"about_ca_system_score_codex":0.000378346,"about_ca_system_score_gemma":0.0003263076,"threshold_uncertainty_score":0.005410373},"labels":[],"label_agreement":null},{"id":"W2894608512","doi":"10.1158/1535-7163.mct-18-0341","title":"Immune Effector Functions of Human IgG2 Antibodies against EGFR","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"KWF Kankerbestrijding","keywords":"Antibody-dependent cell-mediated cytotoxicity; Panitumumab; Effector; Antibody; Immune system; Immunology; Isotype; Biology; Cetuximab; Cancer research; Monoclonal antibody","score_opus":0.03897247107650753,"score_gpt":0.35629938265856026,"score_spread":0.31732691158205273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894608512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98200154,0.0047996114,0.0060408316,0.00016496463,0.00002998267,0.000056912417,0.00015813451,0.00010463513,0.006643372],"genre_scores_gemma":[0.99508023,0.00089118304,0.0013049989,0.0001057034,0.000013313896,0.000017240785,0.00018997223,0.00000908672,0.0023881942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997886,0.00006511773,0.000010265323,0.000021388121,0.000041318668,0.00007332159],"domain_scores_gemma":[0.9999324,0.000019135889,0.000010144025,0.000011220448,0.000015525664,0.000011623683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046194988,0.00053423335,0.00018098339,0.00024118954,0.00009401814,0.00037314623,0.00021940818,0.00026987586,0.0012833489],"category_scores_gemma":[0.0002449359,0.00008218575,0.00024849034,0.000111364825,0.00015495002,0.00022014222,0.00020418815,0.00028483983,0.00024646116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037519413,0.00010887489,0.0010001857,0.0001135803,0.00002112674,0.0001313565,0.000029444971,0.00039715398,0.9848024,0.00053790945,0.00019290944,0.012289753],"study_design_scores_gemma":[0.00007235715,0.00093677524,0.005780587,0.000017938675,0.000052564592,0.00046335981,0.000022717346,0.0016340407,0.9844431,0.00011464706,0.006457375,0.0000045684174],"about_ca_topic_score_codex":0.0017399638,"about_ca_topic_score_gemma":0.0016501915,"teacher_disagreement_score":0.0017399638,"about_ca_system_score_codex":0.00061021507,"about_ca_system_score_gemma":0.0003163401,"threshold_uncertainty_score":0.004427433},"labels":[],"label_agreement":null},{"id":"W2898886729","doi":"10.1158/1535-7163.mct-17-1261","title":"TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Fondation du cancer du sein du Québec; Qatar Foundation","keywords":"Anoikis; Focal adhesion; Cancer research; Cancer; Signal transduction; Cell adhesion; Cell biology; Biology; Immunology; Cancer cell; Cell; Genetics","score_opus":0.020287511333151355,"score_gpt":0.2846268657186688,"score_spread":0.2643393543855174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898886729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955153,0.0017581398,0.0013645178,0.000041757925,0.000009081758,0.000013173329,0.00019887672,0.000050177037,0.0010489215],"genre_scores_gemma":[0.99857235,0.0002379841,0.00027905992,0.000009310019,0.0000042926654,0.000007643998,0.00020126978,0.0000033117192,0.00068478915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985766,0.000029225104,0.000011715426,0.00002410477,0.000034712688,0.00004266294],"domain_scores_gemma":[0.99984205,0.00001880244,0.00005073983,0.00001915291,0.000027091606,0.000042089832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016793977,0.0003742021,0.00014450961,0.000563725,0.00022251224,0.00043467566,0.000154252,0.00021727724,0.00096949236],"category_scores_gemma":[0.00015503232,0.00011056773,0.00021525912,0.0002654734,0.0001522682,0.00015016079,0.00021457161,0.00019547311,0.0002877089],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113279464,0.000017671086,0.0013553879,0.000015618996,0.000008123501,0.00007636526,0.000005994855,0.00006619194,0.99776304,0.00006142174,0.00003409444,0.0004828859],"study_design_scores_gemma":[0.000040136554,0.00035109083,0.08749748,0.000006479447,0.000047093934,0.0018068807,0.00008524472,0.0032803067,0.90358096,0.00017986995,0.0031122502,0.00001226089],"about_ca_topic_score_codex":0.0005921823,"about_ca_topic_score_gemma":0.00044514608,"teacher_disagreement_score":0.00096949236,"about_ca_system_score_codex":0.00035505457,"about_ca_system_score_gemma":0.00012450511,"threshold_uncertainty_score":0.0032433271},"labels":[],"label_agreement":null},{"id":"W2911547717","doi":"10.1158/1535-7163.mct-18-0831","title":"First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Pharmacokinetics; Adverse effect; Pharmacodynamics; Cancer; Phases of clinical research; Lung cancer; Dosing; Internal medicine; Pharmacology; GiST; Gastroenterology; Oncology; Chemotherapy; Stromal cell","score_opus":0.014303057858761273,"score_gpt":0.33164271540461165,"score_spread":0.31733965754585036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911547717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287355,0.0015462976,0.000978853,0.00026637752,0.00013978397,0.0019580338,0.00086487166,0.00011522806,0.0012569999],"genre_scores_gemma":[0.9912798,0.0015391436,0.0015253718,0.00045588205,0.00015730766,0.0012570585,0.001630444,0.000037235077,0.0021176815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958104,0.00017089049,0.00002254059,0.00006277209,0.000050635233,0.00011219613],"domain_scores_gemma":[0.9994573,0.000066497094,0.00007888477,0.000061994164,0.00004644145,0.0002888147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013429751,0.00177274,0.0028267335,0.00034503522,0.0005757284,0.00094579975,0.00069882214,0.000686316,0.0023273947],"category_scores_gemma":[0.0005560642,0.0007929489,0.0014165316,0.0004017268,0.0010292575,0.00082161365,0.00033580136,0.0040476182,0.00077864784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43790755,0.1630535,0.014377652,0.001260743,0.0019761072,0.0008988735,0.00081828784,0.005823346,0.22498861,0.0006805107,0.0077372,0.14047767],"study_design_scores_gemma":[0.15070641,0.8177061,0.011822524,0.000017146654,0.00046006558,0.00039705864,0.000069549926,0.0017674571,0.013711699,0.00013305414,0.003177204,0.000031797546],"about_ca_topic_score_codex":0.0011762617,"about_ca_topic_score_gemma":0.0021968412,"teacher_disagreement_score":0.0028267335,"about_ca_system_score_codex":0.0008963451,"about_ca_system_score_gemma":0.0016219345,"threshold_uncertainty_score":0.0077858567},"labels":[],"label_agreement":null},{"id":"W2946097255","doi":"10.1158/1535-7163.mct-18-1241","title":"17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Autophagy; Wortmannin; Cancer; Colorectal cancer; Cancer research; Function (biology); Biology; Medicine; Pharmacology; Internal medicine; Cell biology; PI3K/AKT/mTOR pathway; Apoptosis; Biochemistry; Signal transduction","score_opus":0.026037454798142574,"score_gpt":0.3021730784373269,"score_spread":0.2761356236391843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946097255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981828,0.0008384324,0.00030363014,0.000051034618,0.000018029878,0.000015383785,0.00015202086,0.000049952912,0.0003887863],"genre_scores_gemma":[0.99678504,0.00071996514,0.00084444694,0.000054205833,0.000009542064,0.00002700759,0.0005210463,0.000011157345,0.001027558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992037,0.000010032523,0.000013335282,0.00001061858,0.000020962983,0.000024608053],"domain_scores_gemma":[0.9999279,0.000008062734,0.00001860259,0.000009721414,0.000008325204,0.000027378454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009795517,0.0002670341,0.0004208403,0.0003033234,0.00010383461,0.00014287599,0.000101902035,0.0001575782,0.0007842623],"category_scores_gemma":[0.000087455286,0.00013793976,0.00022053884,0.00016186529,0.00012318508,0.000102631086,0.00010509302,0.00043651788,0.00020571062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003219061,0.000086567,0.00037332342,0.000041226263,0.000009955732,0.00008365194,0.000010672418,0.00006541341,0.996789,0.000029241215,0.000060515056,0.0021285878],"study_design_scores_gemma":[0.000112996124,0.002585549,0.014249756,0.000008256048,0.000044912475,0.0009841213,0.00003362586,0.001287301,0.9776913,0.000039588955,0.0029553291,0.0000072520943],"about_ca_topic_score_codex":0.0007395613,"about_ca_topic_score_gemma":0.000948478,"teacher_disagreement_score":0.0007842623,"about_ca_system_score_codex":0.00020262845,"about_ca_system_score_gemma":0.00030914397,"threshold_uncertainty_score":0.002623558},"labels":[],"label_agreement":null},{"id":"W2953753155","doi":"10.1158/1535-7163.mct-19-0105","title":"Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Institut universitaire de cardiologie et de pneumologie de Québec; IGNIS Innovation (Canada); Jewish General Hospital","funders":"Pfizer Canada; Astex Pharmaceuticals","keywords":"Crizotinib; Anaplastic lymphoma kinase; Fusion gene; Oncology; KRAS; Exome sequencing; Lung cancer; Cancer research; Mutation; Internal medicine; Exome; Biology; Medicine; Gene; Genetics","score_opus":0.024932329947555787,"score_gpt":0.34800049562069807,"score_spread":0.3230681656731423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953753155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993519,0.00015761687,0.00007429811,0.000020446538,0.0000011136628,0.0000021877302,0.00018715968,0.0000037327575,0.00020162524],"genre_scores_gemma":[0.9995746,0.000037166097,0.000059400943,0.000008635573,0.0000021843894,0.0000019577453,0.00022851591,0.0000010810893,0.000086453496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999075,0.000016296937,0.000011067431,0.000026110769,0.000020192201,0.000018902689],"domain_scores_gemma":[0.9998319,0.000042107473,0.000060474682,0.000008852373,0.000018871971,0.000037851558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121183715,0.00014359575,0.00018860979,0.000432414,0.00015348847,0.00026688163,0.00011063661,0.00017603942,0.0014637044],"category_scores_gemma":[0.00040693002,0.00006310812,0.0001444815,0.00031997476,0.00012384038,0.00016172737,0.00020784425,0.00015699344,0.00018352295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005935818,0.000028669969,0.9672962,0.000017647177,0.00006650982,0.00043906653,0.000040391868,0.00026154102,0.022552652,0.000029449222,0.00013922514,0.008535226],"study_design_scores_gemma":[0.0000073497067,0.00017633091,0.99519014,0.0000030663039,0.000034201697,0.0017358838,0.00007271902,0.000618464,0.0017939594,0.0000770376,0.0002880787,0.0000027498234],"about_ca_topic_score_codex":0.00054633373,"about_ca_topic_score_gemma":0.00089667185,"teacher_disagreement_score":0.0014637044,"about_ca_system_score_codex":0.0001530112,"about_ca_system_score_gemma":0.0000976758,"threshold_uncertainty_score":0.004896581},"labels":[],"label_agreement":null},{"id":"W2956215750","doi":"10.1158/1535-7163.mct-18-0873","title":"Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; Canadian Nuclear Laboratories; University of Ottawa","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Government of Canada","keywords":"Triple-negative breast cancer; Cancer research; Wnt signaling pathway; Medicine; Cancer stem cell; Breast cancer; Cancer; Carcinogenesis; Paclitaxel; Chemistry; Internal medicine; Signal transduction","score_opus":0.01803710046393301,"score_gpt":0.30022522338139024,"score_spread":0.2821881229174572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956215750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97585356,0.003863119,0.015445074,0.00021583645,0.00008538797,0.00014434259,0.00026927324,0.0002708058,0.0038526414],"genre_scores_gemma":[0.9890877,0.0015081583,0.006008761,0.00008402206,0.000015369911,0.0001280707,0.00020708777,0.00003609569,0.0029246882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989355,0.000013051263,0.000005796082,0.00002482275,0.00004205284,0.000020630305],"domain_scores_gemma":[0.9999609,0.000007085804,0.000010258568,0.000006245988,0.0000066701273,0.000008782153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010844562,0.0003131862,0.00031095065,0.00020223083,0.000083339255,0.00022280203,0.00018390255,0.00029113263,0.00067122636],"category_scores_gemma":[0.00009468275,0.00012321844,0.00024433064,0.00012111197,0.00013071744,0.0001987773,0.00017736555,0.00045774796,0.00022848837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009507522,0.00008045148,0.00016296312,0.000077306075,0.000012656872,0.000064783686,0.000020963578,0.00048415188,0.98935705,0.00018540077,0.00020848868,0.009250849],"study_design_scores_gemma":[0.000050043793,0.00088571646,0.0012434399,0.000008029312,0.000037130278,0.0004804188,0.000016343234,0.004447364,0.9861509,0.00007277788,0.0065976465,0.000010047682],"about_ca_topic_score_codex":0.00036336257,"about_ca_topic_score_gemma":0.0009867596,"teacher_disagreement_score":0.00067122636,"about_ca_system_score_codex":0.00023590111,"about_ca_system_score_gemma":0.00015575823,"threshold_uncertainty_score":0.0022454858},"labels":[],"label_agreement":null},{"id":"W2963802995","doi":"10.1158/1535-7163.mct-18-1337","title":"GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Ferring; U.S. Department of Defense","keywords":"Prostate cancer; Testosterone (patch); Castration; Internal medicine; Endocrinology; Leuprorelin; Androgen deprivation therapy; LNCaP; Luteinizing hormone; Hormone; Medicine; Androgen; Enzalutamide; Chemistry; Androgen receptor; Cancer; Gonadotropin-releasing hormone","score_opus":0.01493351646129815,"score_gpt":0.30932913083751007,"score_spread":0.2943956143762119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963802995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932208,0.0029598903,0.00043939287,0.000068666304,0.00004402017,0.000022440952,0.00032529977,0.000093838076,0.0028256457],"genre_scores_gemma":[0.9938261,0.0014755494,0.00058100047,0.000045151355,0.00001605821,0.000019088428,0.0007546491,0.00001943931,0.003262915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999915,0.000014298626,0.0000060537495,0.000011142007,0.000027762766,0.000025722902],"domain_scores_gemma":[0.9999579,0.000007293551,0.000010663428,0.0000056779863,0.000005001462,0.000013491115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064805434,0.00022925825,0.00020787834,0.0001448958,0.00008370746,0.0002667481,0.00017572395,0.00010581018,0.0016095594],"category_scores_gemma":[0.00006405921,0.00008932787,0.00020398929,0.00011007687,0.00012755625,0.00007052351,0.000077909135,0.0003826996,0.0003981093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029068702,0.00007605171,0.00016384597,0.00003703171,0.000009321485,0.000038069524,0.000008155247,0.00005517799,0.99644864,0.000046930527,0.00013798938,0.002688068],"study_design_scores_gemma":[0.000081274244,0.0024541037,0.005836116,0.000007673151,0.00003608866,0.00036578346,0.000038245464,0.00045908918,0.98635477,0.000020694011,0.004341492,0.0000047112426],"about_ca_topic_score_codex":0.000783969,"about_ca_topic_score_gemma":0.0015360563,"teacher_disagreement_score":0.0016095594,"about_ca_system_score_codex":0.00014396799,"about_ca_system_score_gemma":0.00020447474,"threshold_uncertainty_score":0.005384505},"labels":[],"label_agreement":null},{"id":"W2965511029","doi":"10.1158/1535-7163.mct-19-0132","title":"Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Pembrolizumab; Immunotherapy; Medicine; Adverse effect; Internal medicine; Oncology; Blockade; Antibody; Multiplex; Immune checkpoint; Toxicity; Immune system; Immunology; Cancer; Receptor; Bioinformatics; Biology","score_opus":0.0194290354595217,"score_gpt":0.27511367244459595,"score_spread":0.25568463698507427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965511029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975405,0.0010666902,0.0004584567,0.000043805605,0.00001182364,0.000014772532,0.0001410684,0.000020578967,0.00070237654],"genre_scores_gemma":[0.9992422,0.00015273807,0.00019124805,0.000035473517,0.000014178862,0.000009195512,0.00017657099,0.0000022345519,0.0001761431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961567,0.00007961888,0.00005081598,0.000101957805,0.00010138815,0.00005056132],"domain_scores_gemma":[0.9994374,0.00020690086,0.00017781043,0.000044174918,0.00005524567,0.00007848907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042732948,0.00035465267,0.0005679573,0.0005803345,0.0002573502,0.0004799096,0.00014827313,0.0002966003,0.0009913793],"category_scores_gemma":[0.0011362848,0.00015022108,0.0002564574,0.00039069122,0.00023472322,0.00022039675,0.00016845748,0.0004890272,0.00028480156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00187493,0.00016515094,0.89153045,0.00008382071,0.00014569156,0.0011353962,0.00009642987,0.00018874955,0.08477491,0.00004636331,0.00025181434,0.019706443],"study_design_scores_gemma":[0.000028244247,0.0010085893,0.9783633,0.000011944242,0.00010822296,0.003909057,0.00006511773,0.00074664794,0.014749503,0.00006235529,0.00094195234,0.000005199931],"about_ca_topic_score_codex":0.00034896302,"about_ca_topic_score_gemma":0.00037497413,"teacher_disagreement_score":0.0009913793,"about_ca_system_score_codex":0.00021773783,"about_ca_system_score_gemma":0.00013124764,"threshold_uncertainty_score":0.003316462},"labels":[],"label_agreement":null},{"id":"W2966417378","doi":"10.1158/1535-7163.mct-18-0864","title":"Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Samuel Waxman Cancer Research Foundation; American Cancer Society","keywords":"Lung cancer; MAPK/ERK pathway; Cancer research; Apoptosis; Kinase; Cancer; Biology; Adenocarcinoma; Tyrosine kinase; Medicine; Signal transduction; Internal medicine; Cell biology; Biochemistry","score_opus":0.0060368601078012556,"score_gpt":0.24139905025273745,"score_spread":0.2353621901449362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966417378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501437,0.0017463769,0.00076850137,0.00008653618,0.0000279539,0.000033213495,0.00043800753,0.000113804446,0.001771127],"genre_scores_gemma":[0.9956594,0.0008419523,0.0006460341,0.000035946217,0.000007542049,0.000037430593,0.00056459976,0.000012720043,0.0021942127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990094,0.000010536574,0.0000089391115,0.000019138555,0.000030334586,0.000030130255],"domain_scores_gemma":[0.9999335,0.000011257706,0.000016334192,0.000008370191,0.0000061576343,0.000024346022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087369845,0.0003465979,0.00026891194,0.00024547082,0.00009669827,0.00019047088,0.0001562892,0.00018680053,0.0015296042],"category_scores_gemma":[0.00006683605,0.00009292627,0.00017003462,0.00014239465,0.00016793128,0.0001343913,0.00011709931,0.0006043709,0.00026708655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015278585,0.000051889503,0.00011220165,0.000027432236,0.000004966765,0.000022953805,0.000004353564,0.00005947278,0.9978034,0.000048910708,0.000059192007,0.0016524385],"study_design_scores_gemma":[0.000037619735,0.0012419112,0.003991118,0.0000046536043,0.000016934742,0.00018235808,0.000014896833,0.00059350295,0.9920333,0.000028573302,0.0018522698,0.0000027889598],"about_ca_topic_score_codex":0.0004603559,"about_ca_topic_score_gemma":0.0009129337,"teacher_disagreement_score":0.0015296042,"about_ca_system_score_codex":0.00022667824,"about_ca_system_score_gemma":0.00019002284,"threshold_uncertainty_score":0.0051170588},"labels":[],"label_agreement":null},{"id":"W2967512896","doi":"10.1158/1535-7163.mct-19-0162","title":"eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Neurological Institute and Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Institute of General Medical Sciences; Government of Canada","keywords":"Palbociclib; Cancer research; Cancer; Cancer cell; Downregulation and upregulation; KRAS; Cell cycle; Cyclin D1; Estrogen receptor; Medicine; Cyclin-dependent kinase 6; Breast cancer; Pharmacology; Biology; Internal medicine; Metastatic breast cancer; Colorectal cancer","score_opus":0.012868211759400505,"score_gpt":0.28810024795350697,"score_spread":0.27523203619410647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967512896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908305,0.005491887,0.0014677953,0.00018137571,0.00006289176,0.0000663383,0.00027312528,0.00015498271,0.0032186857],"genre_scores_gemma":[0.99584526,0.0011842165,0.0010956746,0.000044782097,0.000018209827,0.000028692948,0.00025721017,0.000011859806,0.0015141832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992037,0.000017488639,0.000008233842,0.000010635201,0.000017153387,0.00002605817],"domain_scores_gemma":[0.99995077,0.000010798662,0.000011812128,0.000007658712,0.0000074009613,0.000011545324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015057903,0.0002537126,0.00031930587,0.00028346822,0.00012357261,0.00021263701,0.00016545135,0.00015680627,0.001585574],"category_scores_gemma":[0.000107057,0.000096678545,0.00018391166,0.0001326223,0.00010951192,0.00012502812,0.00012033953,0.00045194908,0.0002985798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006398451,0.00030251188,0.00071539375,0.0000790234,0.000022771586,0.00008717728,0.0000099459785,0.00049050996,0.98037946,0.00024138992,0.00042427678,0.016607663],"study_design_scores_gemma":[0.00017787499,0.0025851477,0.006706092,0.0000070465876,0.00003177723,0.00054483186,0.000018149165,0.0024023042,0.9788152,0.00008427682,0.008621914,0.0000055029077],"about_ca_topic_score_codex":0.00034580234,"about_ca_topic_score_gemma":0.0008171697,"teacher_disagreement_score":0.001585574,"about_ca_system_score_codex":0.00024940795,"about_ca_system_score_gemma":0.00018023702,"threshold_uncertainty_score":0.005304277},"labels":[],"label_agreement":null},{"id":"W2970508726","doi":"10.1158/1535-7163.mct-19-0299","title":"Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Minicircle; Microvesicle; Prodrug; Genetic enhancement; Gene delivery; Cancer; DNA; Biology; Medicine; Pharmacology; Gene; Cancer research; Biochemistry; Genetics; Microvesicles; microRNA","score_opus":0.009704326669691708,"score_gpt":0.26292250647217813,"score_spread":0.2532181798024864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970508726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773631,0.0016854833,0.019036628,0.00008965246,0.000058793834,0.000097014185,0.00018198887,0.00018716173,0.0013001522],"genre_scores_gemma":[0.9905285,0.00050239655,0.006886401,0.00003122971,0.000007511287,0.000037915375,0.00016970113,0.000028487195,0.0018076438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985707,0.00002091495,0.000015683872,0.000033537865,0.00004844015,0.000024274634],"domain_scores_gemma":[0.9998728,0.000031435393,0.00004454188,0.000013501177,0.000017833216,0.000019775409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021807378,0.0002717237,0.00024429313,0.00020126057,0.00007582699,0.0003010394,0.00012481013,0.00034097943,0.00059052714],"category_scores_gemma":[0.00019851631,0.00011126049,0.00018285502,0.00011020353,0.00019749266,0.00021046786,0.00017828253,0.00040359944,0.00021346012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029089988,0.00001485454,0.000045331813,0.00001871718,0.000003284665,0.000017352957,0.000008209254,0.0000926303,0.998216,0.00013551052,0.000018614111,0.0014004263],"study_design_scores_gemma":[0.0000053040944,0.0001395213,0.00026826267,0.0000016864875,0.0000053489125,0.00004907514,0.0000022658185,0.00046123972,0.9982395,0.000016472748,0.00080958736,0.0000016633362],"about_ca_topic_score_codex":0.00026318713,"about_ca_topic_score_gemma":0.00026098223,"teacher_disagreement_score":0.00059052714,"about_ca_system_score_codex":0.0002699662,"about_ca_system_score_gemma":0.00020295153,"threshold_uncertainty_score":0.0019755363},"labels":[],"label_agreement":null},{"id":"W2970593485","doi":"10.1158/1535-7163.mct-18-1215","title":"Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Natural Science Foundation of China","keywords":"Protein kinase B; DNA repair; Cancer research; Biology; Cancer cell; DNA damage; Transcription factor; Cell growth; Cancer; Signal transduction; Cell biology; DNA; Gene; Biochemistry; Genetics","score_opus":0.006340465986751245,"score_gpt":0.2394554376583952,"score_spread":0.23311497167164394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970593485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874049,0.0046863356,0.0022364059,0.00032083387,0.00024168576,0.000074631724,0.00060993,0.00022611619,0.004199184],"genre_scores_gemma":[0.99297273,0.0019198509,0.0011541813,0.00009224706,0.000016237138,0.000056534074,0.00046641036,0.000010892256,0.0033108145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999915,0.000009219762,0.000009106581,0.000015807043,0.000023235427,0.000027636574],"domain_scores_gemma":[0.99997413,0.0000042748247,0.000004949453,0.000004026664,0.0000035744895,0.000009032499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007575233,0.00031770772,0.00028734814,0.00023418984,0.00012552051,0.00020848354,0.00016321037,0.0001961443,0.0024627997],"category_scores_gemma":[0.000060539645,0.00012515037,0.00022691957,0.00015922131,0.00017722374,0.00019636398,0.00012089713,0.00065154384,0.00036283486],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053313526,0.00029859552,0.0005043533,0.00012275892,0.000024830608,0.000060613045,0.000017109043,0.00031947062,0.9904011,0.00038195652,0.0005067306,0.0068292874],"study_design_scores_gemma":[0.00010074536,0.0011019269,0.004306133,0.000010740536,0.000028907885,0.00021272217,0.00002592982,0.002033885,0.98526937,0.00017757744,0.006725151,0.000006979981],"about_ca_topic_score_codex":0.0005097888,"about_ca_topic_score_gemma":0.0007754091,"teacher_disagreement_score":0.0024627997,"about_ca_system_score_codex":0.00022917565,"about_ca_system_score_gemma":0.00028877737,"threshold_uncertainty_score":0.008238912},"labels":[],"label_agreement":null},{"id":"W2974766534","doi":"10.1158/1535-7163.mct-18-0986","title":"PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Cancer Research Society","keywords":"Abscopal effect; Bladder cancer; Immune system; Cancer research; In situ; Medicine; Cancer; Immune checkpoint; Immunology; Chemistry; Internal medicine; Immunotherapy","score_opus":0.0077958635843792725,"score_gpt":0.2630815545146738,"score_spread":0.2552856909302945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974766534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993361,0.003150138,0.0017139062,0.00012146978,0.000043948527,0.000044775985,0.00011057281,0.00010575319,0.0013484664],"genre_scores_gemma":[0.99686265,0.0010636399,0.00084576284,0.000042317264,0.000019863573,0.000047211746,0.00010746947,0.0000115780795,0.0009996295],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998579,0.000038624563,0.000009389896,0.00002515288,0.000025768353,0.000043101798],"domain_scores_gemma":[0.9999465,0.000007746564,0.000015429921,0.000008716759,0.0000045619813,0.000017149401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023194856,0.00040064298,0.00056151865,0.00030060546,0.00011201118,0.00030847185,0.00022034148,0.00023361269,0.0015144214],"category_scores_gemma":[0.0000889491,0.00014256366,0.00039660413,0.00018796798,0.00023073012,0.0002001512,0.00018213723,0.0007097252,0.00021997497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015738341,0.00058607734,0.00042058498,0.0002702783,0.000041788426,0.00004213554,0.000028391949,0.00038276898,0.98231536,0.00013712577,0.00017357829,0.014028032],"study_design_scores_gemma":[0.00022164425,0.010462891,0.004773768,0.000025679486,0.00013927245,0.00036154888,0.00003322529,0.0014321686,0.97963333,0.00007224622,0.0028359294,0.000008331068],"about_ca_topic_score_codex":0.00021199448,"about_ca_topic_score_gemma":0.00039394325,"teacher_disagreement_score":0.0015144214,"about_ca_system_score_codex":0.00017305784,"about_ca_system_score_gemma":0.00022925608,"threshold_uncertainty_score":0.0050662756},"labels":[],"label_agreement":null},{"id":"W2976358175","doi":"10.1158/1535-7163.mct-19-0386","title":"Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Northern Alberta Institute of Technology; University of Alberta Hospital; University of Alberta","funders":"Canadian Cancer Society Research Institute","keywords":"Autotaxin; Breast cancer; Chemotherapy; Radiation therapy; Cancer; Medicine; Internal medicine; Oncology; Cancer research; Pharmacology; Biology; Receptor; Lysophosphatidic acid","score_opus":0.009515745732182383,"score_gpt":0.24897653042427426,"score_spread":0.23946078469209187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976358175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347746,0.001699713,0.0015843792,0.0002981835,0.00014360393,0.00011507602,0.0009864763,0.0002610307,0.0014341084],"genre_scores_gemma":[0.988624,0.0018432082,0.0029576619,0.00015610893,0.000044949807,0.00028125907,0.0013601221,0.00005569389,0.0046770256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969125,0.0000566628,0.000028193142,0.000054791817,0.00007995088,0.000089091416],"domain_scores_gemma":[0.9997912,0.000020206457,0.00006900929,0.000022419235,0.00001747248,0.000079693644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003097792,0.0008364373,0.00084762916,0.00071237946,0.00019526112,0.0003051263,0.00044878913,0.0006038391,0.0017328447],"category_scores_gemma":[0.00009062757,0.0003095755,0.00057108514,0.0003775722,0.00039934175,0.00034275255,0.00017059814,0.0018982802,0.00046683094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001140047,0.00056414946,0.00010193025,0.00006350311,0.00001660472,0.000029982904,0.000019434037,0.00018335499,0.99577516,0.00006593242,0.000155505,0.0018844713],"study_design_scores_gemma":[0.0002441707,0.0070468253,0.0020856275,0.0000142626495,0.00004942274,0.00013965426,0.000034085842,0.0012162463,0.9872995,0.000042706073,0.0018162824,0.000011173699],"about_ca_topic_score_codex":0.0007569805,"about_ca_topic_score_gemma":0.0011344424,"teacher_disagreement_score":0.0017328447,"about_ca_system_score_codex":0.0004789869,"about_ca_system_score_gemma":0.00036077743,"threshold_uncertainty_score":0.005796969},"labels":[],"label_agreement":null},{"id":"W2990311629","doi":"10.1158/1535-7163.targ-19-b006","title":"Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; EZH2; Cancer research; Cancer; Interferon; Immunotherapy; Biology; CD8; Medicine; Immunology; Gene expression; Antigen; Internal medicine; Gene","score_opus":0.018336811812654997,"score_gpt":0.29934188399017714,"score_spread":0.28100507217752213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990311629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910205,0.0020193006,0.0022246789,0.00032051204,0.00013359923,0.00008693012,0.0008379999,0.00031042052,0.0030461117],"genre_scores_gemma":[0.9925269,0.0006961179,0.00163008,0.00009628158,0.000028466266,0.00008646542,0.0008067727,0.00002456765,0.004104171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998746,0.000020144222,0.0000069428797,0.000020299156,0.00003959325,0.000038468053],"domain_scores_gemma":[0.9999449,0.0000067831206,0.000011171983,0.000004270096,0.0000045308043,0.000028310023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013050869,0.0003758624,0.00040102433,0.0002811878,0.00011874777,0.0002579968,0.0002060457,0.0003209558,0.0028934043],"category_scores_gemma":[0.000068845155,0.00011082666,0.00018450481,0.0001889354,0.00020097465,0.0001537951,0.00013002165,0.001091671,0.0004547169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012767608,0.0005548178,0.00010310644,0.000068506735,0.000013172449,0.000023686045,0.000009881744,0.00017071966,0.9933947,0.0000997821,0.0003682075,0.003916776],"study_design_scores_gemma":[0.00019824428,0.0061204396,0.002676585,0.000007145303,0.000026010115,0.00011717167,0.00001966067,0.0013044111,0.98603463,0.000053220676,0.0034363214,0.0000061372725],"about_ca_topic_score_codex":0.00041484452,"about_ca_topic_score_gemma":0.00080164993,"teacher_disagreement_score":0.0028934043,"about_ca_system_score_codex":0.00022863787,"about_ca_system_score_gemma":0.00022597391,"threshold_uncertainty_score":0.009679437},"labels":[],"label_agreement":null},{"id":"W2992010002","doi":"10.1158/1535-7163.targ-19-b057","title":"Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Mesothelin; Nivolumab; Medicine; Mesothelioma; Pharmacology; Pharmacokinetics; Antibody-drug conjugate; Ovarian cancer; Cancer; Internal medicine; Monoclonal antibody; Oncology; Antibody; Immunology; Immunotherapy; Pathology","score_opus":0.013724104482352615,"score_gpt":0.33586451875733075,"score_spread":0.32214041427497814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992010002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971413,0.0009718892,0.00018159852,0.00010466126,0.000029220239,0.00013107448,0.00026685387,0.000056592587,0.0011167898],"genre_scores_gemma":[0.99740916,0.0004228262,0.00029886948,0.000088399254,0.000034217926,0.00009473044,0.00071559503,0.000007981985,0.00092830486],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999908,0.00002665021,0.0000071681707,0.00001682084,0.000017127706,0.000024223651],"domain_scores_gemma":[0.99989367,0.000016119297,0.000014653821,0.0000074139816,0.000008344194,0.00005976305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023692017,0.00035843957,0.0007039922,0.0001850877,0.00015498327,0.00034597708,0.00019627415,0.00028629915,0.0029751922],"category_scores_gemma":[0.00018549987,0.00012449194,0.0002852309,0.00018263722,0.00018707254,0.0002517363,0.0001520394,0.00092445954,0.00066200714],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16651349,0.024063576,0.015790619,0.0006579202,0.0005212811,0.0004967772,0.00018902347,0.0018917155,0.5332355,0.0002733566,0.007882682,0.248484],"study_design_scores_gemma":[0.102024354,0.53243965,0.12202369,0.00008586941,0.00086958497,0.0022625315,0.0001496514,0.005652122,0.21348442,0.00023938301,0.020730015,0.000038779006],"about_ca_topic_score_codex":0.0004402473,"about_ca_topic_score_gemma":0.0007901321,"teacher_disagreement_score":0.0029751922,"about_ca_system_score_codex":0.00029452887,"about_ca_system_score_gemma":0.0004291737,"threshold_uncertainty_score":0.009953022},"labels":[],"label_agreement":null},{"id":"W2992028221","doi":"10.1158/1535-7163.targ-19-b058","title":"Abstract B058: CD73 siRNA therapy regulates glioblastoma immune microenvironment","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Immune system; Tumor microenvironment; Glioma; In vivo; Gene knockdown; Cancer research; Medicine; Small hairpin RNA; Cancer; Brain tumor; In vitro; Pharmacology; Apoptosis; Biology; Immunology; Pathology; Internal medicine","score_opus":0.009754058284271675,"score_gpt":0.24300462953699847,"score_spread":0.2332505712527268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992028221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833454,0.004241671,0.0044485624,0.00037674737,0.00026059346,0.00015534413,0.0006446891,0.00035976924,0.006167127],"genre_scores_gemma":[0.9893461,0.001824639,0.002359073,0.00017544361,0.000036504945,0.00017620134,0.0005266286,0.000028021093,0.005527356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999032,0.000010101937,0.000006855635,0.000018498074,0.00002802192,0.00003330025],"domain_scores_gemma":[0.99997294,0.000002943125,0.000005859872,0.0000019663205,0.0000056028025,0.000010737317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008399252,0.00032512634,0.00033070968,0.00027872634,0.00016393985,0.00022595881,0.00013607007,0.00031254938,0.0021964076],"category_scores_gemma":[0.00005633105,0.00007791501,0.00022489445,0.00014182457,0.00021614842,0.00019148407,0.00011117596,0.00061576784,0.0004111377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000548596,0.00021559949,0.00012563748,0.00012215922,0.000008659226,0.00005082709,0.00002175288,0.00010326312,0.991156,0.00020185996,0.00050511264,0.006940597],"study_design_scores_gemma":[0.000110834575,0.0022764509,0.0017276969,0.000011164906,0.00003926147,0.00015465582,0.000049462415,0.0010851239,0.988372,0.000074499,0.0060914475,0.000007347369],"about_ca_topic_score_codex":0.0010638715,"about_ca_topic_score_gemma":0.0016108213,"teacher_disagreement_score":0.0021964076,"about_ca_system_score_codex":0.00023678195,"about_ca_system_score_gemma":0.00035453335,"threshold_uncertainty_score":0.007347703},"labels":[],"label_agreement":null},{"id":"W2992330814","doi":"10.1158/1535-7163.targ-19-cn06-01","title":"Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Prostate; Exome sequencing; Adenocarcinoma; Somatic evolution in cancer; DNA methylation; Biology; Cancer; Epigenomics; Copy number analysis; Chromoplexy; Liquid biopsy; Medicine; Phenotype; Copy-number variation; PCA3; Genetics; Gene; Genome","score_opus":0.02010044019727532,"score_gpt":0.3109422800884922,"score_spread":0.29084183989121687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992330814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808276,0.0037388674,0.0025824227,0.00036940325,0.00009315656,0.000074189826,0.0044073095,0.0002090228,0.0076978733],"genre_scores_gemma":[0.9839715,0.000847969,0.0020269176,0.00027559703,0.0000187571,0.000050246173,0.0050877533,0.000065221495,0.0076561123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997429,0.00003111446,0.000012962487,0.00005695672,0.000114117596,0.000041779018],"domain_scores_gemma":[0.99966824,0.000038514405,0.00006552957,0.00004587511,0.00008067442,0.00010117248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032205804,0.00022376512,0.0002542788,0.00045644815,0.00034264426,0.0005012151,0.0004061518,0.00036820085,0.0044859946],"category_scores_gemma":[0.00034211858,0.00013459534,0.00022813832,0.0005667493,0.00023680227,0.00019958806,0.00028847743,0.00071239035,0.0008488913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005779203,0.00013448925,0.02145156,0.0001857549,0.000028586555,0.0005187533,0.00007864816,0.00041387108,0.95834166,0.00086349004,0.0020271465,0.015378106],"study_design_scores_gemma":[0.00009412462,0.0016858709,0.52077466,0.00007423337,0.00007385847,0.010779576,0.00021410367,0.005073603,0.41113907,0.00087394123,0.049154617,0.000062281906],"about_ca_topic_score_codex":0.0029828956,"about_ca_topic_score_gemma":0.003827957,"teacher_disagreement_score":0.0044859946,"about_ca_system_score_codex":0.00062265585,"about_ca_system_score_gemma":0.000414888,"threshold_uncertainty_score":0.015007138},"labels":[],"label_agreement":null},{"id":"W2992420236","doi":"10.1158/1535-7163.targ-19-c031","title":"Abstract C031: Ras processing by RRSP protease as a strategy to inhibit Ras-driven tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"KRAS; Cancer research; Biology; Epidermal growth factor receptor; Cancer; Cell growth; Cetuximab; Cancer cell; Colorectal cancer; Molecular biology; Genetics","score_opus":0.01686012876723437,"score_gpt":0.31852805887283403,"score_spread":0.30166793010559967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992420236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98570883,0.0041991775,0.005420372,0.00027022418,0.00012291383,0.0001575248,0.0010781866,0.00018643486,0.0028562846],"genre_scores_gemma":[0.98742676,0.0015534853,0.005449178,0.00016750925,0.000019180328,0.00005349191,0.0017243901,0.00003435921,0.0035716787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988735,0.000016002818,0.000010343198,0.000022643,0.000035627094,0.000027954933],"domain_scores_gemma":[0.99994814,0.0000063669363,0.00001176562,0.000006623257,0.000013439246,0.000013555363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116962714,0.0003401048,0.00027765083,0.00018065995,0.00008728915,0.00020794751,0.00022224762,0.0003696097,0.0013078705],"category_scores_gemma":[0.00008665279,0.00009468925,0.00038302425,0.00020486543,0.000105562365,0.000106210886,0.000119525954,0.0006064325,0.00057861843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017236092,0.00006213982,0.000046687986,0.00003729646,0.0000068141007,0.000038186387,0.0000052133682,0.00009521951,0.9973955,0.000047786867,0.00012776458,0.0019649863],"study_design_scores_gemma":[0.000036736146,0.00066368846,0.00075137184,0.000005290613,0.000011922991,0.00020056254,0.0000070666783,0.0006467095,0.9951356,0.000014965623,0.0025224055,0.000003663694],"about_ca_topic_score_codex":0.00064728875,"about_ca_topic_score_gemma":0.00050796254,"teacher_disagreement_score":0.0013078705,"about_ca_system_score_codex":0.00019098536,"about_ca_system_score_gemma":0.00017968124,"threshold_uncertainty_score":0.004375279},"labels":[],"label_agreement":null},{"id":"W2992593954","doi":"10.1158/1535-7163.targ-19-b075","title":"Abstract B075: eIF4A regulates ERK activation by controlling the translation of DUSP6","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"ATP Synthase and ATPases Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"DUSP6; MAPK/ERK pathway; Kinase; Neuroblastoma RAS viral oncogene homolog; Molecular biology; Biology; Western blot; Phosphatase; Cancer research; Cell biology; Phosphorylation; KRAS; Protein phosphatase 2; Genetics; Gene; Mutation","score_opus":0.020847619617093815,"score_gpt":0.30224239951864657,"score_spread":0.28139477990155276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992593954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97938013,0.0046064523,0.006031895,0.00049225416,0.00028588818,0.00005941299,0.003949671,0.00039951518,0.00479487],"genre_scores_gemma":[0.9844826,0.0013898086,0.0032994498,0.00018942058,0.000042225198,0.000057616893,0.0037577546,0.00008230861,0.00669873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998864,0.0000134802085,0.000012922341,0.00003621845,0.000027682261,0.000023403933],"domain_scores_gemma":[0.99993765,0.0000063325347,0.000019923022,0.0000077974155,0.000009191658,0.000019153716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011377132,0.0003538791,0.00024618238,0.0001628536,0.0002717685,0.00029657484,0.00021863423,0.00031281705,0.0043188646],"category_scores_gemma":[0.00008721885,0.00013423429,0.00032269946,0.00015998773,0.00018243288,0.00018983668,0.0002216447,0.0005731586,0.0014473689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003212437,0.0000339449,0.00016566181,0.00007395301,0.000005414562,0.000044039458,0.000006218586,0.00005689723,0.9976192,0.00011634486,0.00022819072,0.0013288939],"study_design_scores_gemma":[0.000049587754,0.00029302784,0.006689724,0.000014763994,0.000019410752,0.00022472256,0.000027552143,0.0012417055,0.9838568,0.00009806267,0.0074775517,0.0000070267574],"about_ca_topic_score_codex":0.00048352702,"about_ca_topic_score_gemma":0.0006011282,"teacher_disagreement_score":0.0043188646,"about_ca_system_score_codex":0.00032849406,"about_ca_system_score_gemma":0.00023491823,"threshold_uncertainty_score":0.014448047},"labels":[],"label_agreement":null},{"id":"W2993545890","doi":"10.1158/1535-7163.targ-19-c027","title":"Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta","funders":"","keywords":"Blockade; Medicine; Antibody; Monoclonal antibody; Immune checkpoint; Lung cancer; Cancer; Cancer research; Internal medicine; T cell; Oncology; Immune system; Pharmacology; Immunology; Receptor","score_opus":0.01862583428759236,"score_gpt":0.3292702647812341,"score_spread":0.31064443049364177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993545890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913629,0.0010429642,0.00052409014,0.0005295834,0.00008304098,0.0025470066,0.0016691798,0.00013365928,0.002107529],"genre_scores_gemma":[0.98023933,0.0012343116,0.0033140322,0.0014572636,0.00016421992,0.0034325267,0.0057361424,0.000059637532,0.004362501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995167,0.00017390533,0.000021744623,0.00008720832,0.00006728559,0.00013316258],"domain_scores_gemma":[0.9991278,0.00009858971,0.00009242059,0.000054293556,0.00006588262,0.00056107563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013066386,0.002216491,0.0019032186,0.0007213047,0.00065400754,0.0012625728,0.0012050311,0.0015583743,0.0037210772],"category_scores_gemma":[0.0006953199,0.0006206293,0.0010643486,0.0005373975,0.0010337697,0.0006632345,0.0003920672,0.004182502,0.0012919792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53662056,0.17593822,0.0090704635,0.0009938994,0.0015741654,0.00066803844,0.00060377055,0.005069822,0.14145714,0.0005411246,0.015223196,0.11223957],"study_design_scores_gemma":[0.40300116,0.5655014,0.013949077,0.000035274483,0.00050844083,0.00041890302,0.00008224464,0.001731615,0.01066584,0.00014755508,0.0039045648,0.000053933243],"about_ca_topic_score_codex":0.004586643,"about_ca_topic_score_gemma":0.00917504,"teacher_disagreement_score":0.004586643,"about_ca_system_score_codex":0.0016041991,"about_ca_system_score_gemma":0.003737092,"threshold_uncertainty_score":0.012448251},"labels":[],"label_agreement":null},{"id":"W2993613817","doi":"10.1158/1535-7163.targ-19-c048","title":"Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; In vivo; Immune system; Immunotherapy; Medicine; Hepatocellular carcinoma; Cancer; Immunology; Pharmacology; Biology; Internal medicine","score_opus":0.034315951275988264,"score_gpt":0.280333360489796,"score_spread":0.24601740921380774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993613817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868805,0.0019435083,0.004182242,0.0003090624,0.00013567143,0.00014928856,0.0009844977,0.0003727547,0.003234959],"genre_scores_gemma":[0.9877973,0.00095515733,0.0037455403,0.00009283213,0.000023353878,0.00017862523,0.0010233226,0.00002966346,0.006154219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998907,0.000012850073,0.0000093865065,0.000023783798,0.000037489775,0.000025757356],"domain_scores_gemma":[0.9999472,0.000004440444,0.000012253352,0.000006796132,0.0000087799135,0.000020521678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017341232,0.0005380456,0.00038525916,0.0003512706,0.00015700466,0.00023333466,0.000295129,0.00039493668,0.0020468],"category_scores_gemma":[0.00005210841,0.000111224945,0.00023369245,0.00015999537,0.00024188713,0.00023061357,0.000110231915,0.00091673195,0.00052787777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057663047,0.0002614165,0.00006152916,0.000070536466,0.000008194795,0.000036842244,0.000011182693,0.00010575971,0.99498665,0.00010372165,0.00031252153,0.0034650648],"study_design_scores_gemma":[0.000117101175,0.001640662,0.0007566236,0.000004534854,0.000023394652,0.00015342595,0.000009373943,0.0006535978,0.9944564,0.00002252319,0.0021580332,0.0000043500772],"about_ca_topic_score_codex":0.0009769097,"about_ca_topic_score_gemma":0.001276347,"teacher_disagreement_score":0.0020468,"about_ca_system_score_codex":0.00041578125,"about_ca_system_score_gemma":0.00039829526,"threshold_uncertainty_score":0.006847203},"labels":[],"label_agreement":null},{"id":"W2993657848","doi":"10.1158/1535-7163.targ-19-a072","title":"Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy","score_opus":0.012321276851566318,"score_gpt":0.2545202610382896,"score_spread":0.2421989841867233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993657848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945314,0.001715492,0.0004068267,0.00024531336,0.000037419042,0.00043269093,0.0009734948,0.00007008194,0.0015870784],"genre_scores_gemma":[0.9906232,0.0015348601,0.000714117,0.0006974019,0.00011221675,0.00047172443,0.0038431785,0.000036832564,0.0019666117],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996606,0.00017067492,0.000023719187,0.00004348342,0.000040710052,0.000060792154],"domain_scores_gemma":[0.9995925,0.00008706601,0.000050694856,0.000038047714,0.000036763897,0.00019500474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000816975,0.0010872616,0.0012423623,0.000270433,0.00038396983,0.00079591875,0.00044556358,0.00066519814,0.0028665413],"category_scores_gemma":[0.0005686986,0.00031172417,0.0011549774,0.0002983806,0.00041598463,0.0004967284,0.0003541923,0.0019774975,0.00092484546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38373747,0.07581504,0.03491214,0.0013776433,0.0025467402,0.0022113025,0.0011170484,0.0062140306,0.22341621,0.00026770044,0.011956725,0.25642806],"study_design_scores_gemma":[0.1431293,0.7585021,0.06813559,0.000057486162,0.0010823666,0.0016306723,0.0002382358,0.0027178586,0.017429523,0.00022539005,0.006793652,0.000057823992],"about_ca_topic_score_codex":0.001082511,"about_ca_topic_score_gemma":0.0016973878,"teacher_disagreement_score":0.0028665413,"about_ca_system_score_codex":0.0006279444,"about_ca_system_score_gemma":0.00071952067,"threshold_uncertainty_score":0.009589493},"labels":[],"label_agreement":null},{"id":"W2993673395","doi":"10.1158/1535-7163.targ-19-b117","title":"Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; In vivo; Cancer research; Biology; Androgen; Cancer; Chemistry; Pharmacology; Biochemistry; Genetics; Hormone","score_opus":0.031789674954218174,"score_gpt":0.3149602222976824,"score_spread":0.2831705473434642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993673395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97194135,0.008727135,0.0028124629,0.00022915074,0.0001261769,0.00026155138,0.001418345,0.0003185268,0.014165316],"genre_scores_gemma":[0.9843907,0.002873161,0.0021951436,0.00014610498,0.000023258426,0.00007170887,0.0017010828,0.000017527525,0.008581443],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996185,0.0000053299427,0.000002689019,0.0000051019856,0.000010177726,0.000014865214],"domain_scores_gemma":[0.99997437,0.0000028755878,0.0000042600445,0.0000022492916,0.000004580449,0.000011700468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007248284,0.00034458042,0.00023015359,0.00020708663,0.00011060918,0.00019314447,0.00018850964,0.00018090213,0.0030125899],"category_scores_gemma":[0.000053160435,0.00006288878,0.00015327318,0.00015256206,0.00009276363,0.000087521024,0.0000859041,0.00045857488,0.00069616263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030660252,0.0011186261,0.0009020564,0.00043729975,0.00004518677,0.00049948535,0.000030402101,0.0009997666,0.9022506,0.0004921248,0.002262062,0.08789644],"study_design_scores_gemma":[0.0009819114,0.01768085,0.015157226,0.000047502403,0.00014394695,0.0023057137,0.000028769657,0.00318842,0.9384575,0.00009227279,0.021893872,0.000022041973],"about_ca_topic_score_codex":0.0012769441,"about_ca_topic_score_gemma":0.00202726,"teacher_disagreement_score":0.0030125899,"about_ca_system_score_codex":0.00022904655,"about_ca_system_score_gemma":0.00031165165,"threshold_uncertainty_score":0.010078132},"labels":[],"label_agreement":null},{"id":"W2993755223","doi":"10.1158/1535-7163.targ-19-b049","title":"Abstract B049: Hyperprogressive disease after two cycles of immunotherapy in HER-2 positive metastatic gastric cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pembrolizumab; Medicine; Nivolumab; Cancer; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Regimen; Immunohistochemistry; Stomach; Gastroenterology; Disease; Progressive disease","score_opus":0.009132067387983691,"score_gpt":0.28665847441968845,"score_spread":0.2775264070317048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993755223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440575,0.0011036829,0.00031907094,0.0009052059,0.0000486769,0.00006466198,0.00032070308,0.000039593477,0.002792676],"genre_scores_gemma":[0.9979621,0.00022475504,0.00023247386,0.00036228765,0.000042338655,0.000011028122,0.00023732208,0.0000059729196,0.00092177506],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99990225,0.0000112657635,0.000009382355,0.000030645315,0.000014140935,0.000032226435],"domain_scores_gemma":[0.9997842,0.00003672644,0.00003866498,0.000012729969,0.000019699515,0.00010813511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013712313,0.0003362146,0.00043868241,0.00043994674,0.00069202774,0.00038230504,0.000286303,0.0009957113,0.0013806486],"category_scores_gemma":[0.0003543132,0.00015528903,0.00038190745,0.0002489601,0.00028838776,0.00025155826,0.00024906837,0.0008393311,0.0003454091],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013733824,0.00035273866,0.12608315,0.0001499228,0.000054092834,0.8361621,0.00039064276,0.0003922525,0.016437335,0.00019624141,0.0025077683,0.015900392],"study_design_scores_gemma":[0.00010776193,0.0021908258,0.23953699,0.000045586126,0.00008135322,0.74729145,0.00028837763,0.0021513433,0.0041192435,0.00025052868,0.0039085387,0.000028012175],"about_ca_topic_score_codex":0.001873841,"about_ca_topic_score_gemma":0.0027559574,"teacher_disagreement_score":0.001873841,"about_ca_system_score_codex":0.00064407126,"about_ca_system_score_gemma":0.0002665081,"threshold_uncertainty_score":0.0046731234},"labels":[],"label_agreement":null},{"id":"W2993844726","doi":"10.1158/1535-7163.targ-19-c128","title":"Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Biology; Reprogramming; Transcription factor; SOX2; Androgen receptor; Cancer; Gene silencing; Androgen deprivation therapy; TMPRSS2; Prostate; Internal medicine; Genetics; Medicine; Cell","score_opus":0.032841490813874503,"score_gpt":0.3118384028705806,"score_spread":0.2789969120567061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993844726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898254,0.0037072918,0.0016203969,0.0003128187,0.00013781368,0.000023254173,0.0007022089,0.000113987524,0.0035567926],"genre_scores_gemma":[0.9956066,0.0006673854,0.0003910799,0.0000681034,0.000018104092,0.000014704057,0.00037829633,0.000015671387,0.0028399848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991834,0.000008586403,0.0000057197453,0.000025084953,0.000020478976,0.000021783339],"domain_scores_gemma":[0.99995136,0.000003245244,0.000010808973,0.0000044208864,0.0000064920882,0.000023653183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061412786,0.0001626486,0.00015195172,0.00010916932,0.00024013405,0.00028302777,0.00016885599,0.00018091266,0.0038745147],"category_scores_gemma":[0.00007203687,0.00006319936,0.00018016125,0.00012213452,0.00021444584,0.00016415291,0.00022972935,0.00042709024,0.00056134735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020982539,0.000024068198,0.00076922413,0.00007546319,0.000004914604,0.000108826185,0.000024242352,0.000054039436,0.99587125,0.00021423661,0.0002508916,0.0023931242],"study_design_scores_gemma":[0.00007038785,0.0005486684,0.051854134,0.000035372854,0.000037303784,0.0009975322,0.0002216311,0.0022731633,0.93081737,0.00035652547,0.012767218,0.000020734271],"about_ca_topic_score_codex":0.00077856437,"about_ca_topic_score_gemma":0.0011857423,"teacher_disagreement_score":0.0038745147,"about_ca_system_score_codex":0.00026453202,"about_ca_system_score_gemma":0.00021208668,"threshold_uncertainty_score":0.012961507},"labels":[],"label_agreement":null},{"id":"W2994334473","doi":"10.1158/1535-7163.targ-19-c077","title":"Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"","keywords":"GiST; Medicine; PDGFRA; Response Evaluation Criteria in Solid Tumors; Internal medicine; Trabectedin; Phases of clinical research; Dosing; Gastroenterology; Oncology; Surgery; Pharmacology; Stromal cell; Clinical trial","score_opus":0.01661905398869492,"score_gpt":0.3009924335799647,"score_spread":0.2843733795912698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994334473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52081597,0.036648747,0.0051848046,0.0076452107,0.0016931474,0.010257879,0.36421445,0.0014747382,0.052065056],"genre_scores_gemma":[0.48153797,0.012776385,0.0134916315,0.0119553,0.0013095649,0.00501774,0.4596127,0.000742922,0.013555791],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.997182,0.0009399949,0.00023433227,0.0003406935,0.0010201047,0.00028300635],"domain_scores_gemma":[0.9933456,0.0011299518,0.0014837938,0.00059007504,0.002438795,0.001011816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006753144,0.0011170891,0.002107947,0.00101845,0.00059178733,0.0022908975,0.001654532,0.001384581,0.0075560575],"category_scores_gemma":[0.0061162007,0.0004892162,0.0018487348,0.0014250014,0.00034834765,0.0010919996,0.00067438267,0.0025892968,0.0028008537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14481042,0.0071078106,0.054597054,0.005731513,0.009962389,0.0010146239,0.00037913903,0.0056927972,0.049804192,0.0008837056,0.3417662,0.37825015],"study_design_scores_gemma":[0.16831873,0.10712908,0.27498218,0.0013398811,0.01836425,0.0058840187,0.00023354852,0.0044531883,0.029576661,0.0016257549,0.38767165,0.00042111322],"about_ca_topic_score_codex":0.0039371443,"about_ca_topic_score_gemma":0.0102804,"teacher_disagreement_score":0.0075560575,"about_ca_system_score_codex":0.0018893424,"about_ca_system_score_gemma":0.0041588084,"threshold_uncertainty_score":0.035714507},"labels":[],"label_agreement":null},{"id":"W2999172547","doi":"10.1158/1535-7163.targ-19-lb-a06","title":"Abstract LB-A06: A high-throughput functional screen discovered that endogenous DNA damage underlies mechanisms of selected gene susceptibility factors predisposing to lung cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Biology; Candidate gene; Genome-wide association study; Genetics; Carcinogenesis; Gene; Lung cancer; DNA repair; DNA damage; Genome instability; Expression quantitative trait loci; Cancer; Single-nucleotide polymorphism; DNA; Genotype; Medicine; Pathology","score_opus":0.032821973962103755,"score_gpt":0.27215793891343004,"score_spread":0.23933596495132628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999172547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96183264,0.00228124,0.01168407,0.00056934485,0.00013124743,0.00014682021,0.01962956,0.0010839817,0.0026411072],"genre_scores_gemma":[0.9651349,0.0010979827,0.008294797,0.00072743226,0.000047497007,0.00010767041,0.018429605,0.00023625413,0.005923889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965155,0.000059942227,0.00003305819,0.00008338631,0.00011784344,0.000054213746],"domain_scores_gemma":[0.99960655,0.00012546842,0.00006551622,0.00004529567,0.000052018586,0.00010511602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000513506,0.0006368516,0.0007317073,0.0008983907,0.00045929608,0.0005582189,0.00064503297,0.00063900504,0.004325419],"category_scores_gemma":[0.00041192267,0.00019926766,0.000954643,0.00068566354,0.0002970978,0.00015248003,0.00057740393,0.00082142575,0.0011316318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006817654,0.00020742835,0.005687723,0.00012877383,0.00013417561,0.0004896059,0.000019621726,0.0003352422,0.9861558,0.00017284047,0.000834308,0.0051527857],"study_design_scores_gemma":[0.0008088506,0.0036594337,0.19616523,0.00007245661,0.0017236901,0.006976656,0.00020768879,0.016839677,0.74408835,0.0011065983,0.028197063,0.00015435948],"about_ca_topic_score_codex":0.0016303282,"about_ca_topic_score_gemma":0.003291124,"teacher_disagreement_score":0.004325419,"about_ca_system_score_codex":0.00030384757,"about_ca_system_score_gemma":0.00043424207,"threshold_uncertainty_score":0.014469981},"labels":[],"label_agreement":null},{"id":"W3000670779","doi":"10.1158/1535-7163.targ-19-pl03-01","title":"Abstract PL03-01: Targeting DNA Repair and Defective DNA repair","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Genome instability; DNA repair; DNA damage; Synthetic lethality; Cancer research; Cancer; Immune system; Biology; Medicine; DNA; Immunology; Genetics","score_opus":0.009671563450140181,"score_gpt":0.25208394996784766,"score_spread":0.2424123865177075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000670779","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12739703,0.14288042,0.032398395,0.022650233,0.013457466,0.0020008748,0.025508698,0.008718389,0.62498856],"genre_scores_gemma":[0.2763099,0.07983684,0.0155815715,0.006023351,0.0015468448,0.00083429704,0.023114298,0.00081653666,0.59593636],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997917,0.000027826452,0.000012671345,0.00003824193,0.000067978195,0.00006168842],"domain_scores_gemma":[0.999843,0.000017895958,0.000027145841,0.000016816395,0.000023918954,0.00007118464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005115482,0.001052526,0.00044896477,0.0009580681,0.00028763706,0.0011373434,0.0011080449,0.0011023213,0.04922213],"category_scores_gemma":[0.00019999688,0.00038058736,0.000479289,0.0007828313,0.00039138197,0.0005635714,0.00045835375,0.0017975775,0.024050357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002770947,0.0014471504,0.0007059315,0.0013969208,0.00007254802,0.0013620816,0.00007564231,0.0010885218,0.33451673,0.013080828,0.32145923,0.32202348],"study_design_scores_gemma":[0.00070071087,0.00294246,0.0046672286,0.00019644773,0.00007305496,0.004322318,0.000031282052,0.0011412057,0.19685785,0.0017954241,0.78723603,0.00003595721],"about_ca_topic_score_codex":0.0014214735,"about_ca_topic_score_gemma":0.0019532468,"teacher_disagreement_score":0.04922213,"about_ca_system_score_codex":0.0015355123,"about_ca_system_score_gemma":0.0013266861,"threshold_uncertainty_score":0.16466445},"labels":[],"label_agreement":null},{"id":"W3005081400","doi":"10.1158/1535-7163.mct-19-1015","title":"Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Education and Early Childhood Development","funders":"Genentech","keywords":"Antibody; Chemistry; Molecular biology; Cancer research; Biology; Virology; Immunology","score_opus":0.032291007926630415,"score_gpt":0.32976001119495113,"score_spread":0.2974690032683207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005081400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982805,0.00040767548,0.00090377266,0.0000175243,0.000008804228,0.000012826188,0.00003377923,0.000031177824,0.00030395712],"genre_scores_gemma":[0.9979103,0.00027584704,0.0010186603,0.000029183127,0.000005495969,0.000014353434,0.000057357807,0.000020285106,0.0006685804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998715,0.000026310847,0.000009887781,0.000027278918,0.000025998268,0.000038967584],"domain_scores_gemma":[0.9998016,0.00007414137,0.000051720723,0.000015234475,0.000021465867,0.00003585102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021336022,0.000384551,0.00021324184,0.000083540406,0.000055475382,0.00023338581,0.00022996275,0.00023058696,0.00077432883],"category_scores_gemma":[0.0002872049,0.000118149714,0.00010213766,0.00006974622,0.00016123957,0.0001687401,0.0001556577,0.00034458173,0.0001335873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017150314,0.00003532315,0.00006595849,0.000016388221,0.000004178285,0.000015449612,0.000005996795,0.00009416328,0.99891245,0.000020614349,0.00001195135,0.00064607],"study_design_scores_gemma":[0.000007787471,0.00044333987,0.0005190551,0.0000013303595,0.0000091302645,0.000025988655,0.0000029674186,0.000826026,0.99794644,0.0000032524242,0.00021288889,0.0000018164706],"about_ca_topic_score_codex":0.00080243294,"about_ca_topic_score_gemma":0.00085343275,"teacher_disagreement_score":0.00080243294,"about_ca_system_score_codex":0.00024949454,"about_ca_system_score_gemma":0.00017039281,"threshold_uncertainty_score":0.0025903583},"labels":[],"label_agreement":null},{"id":"W3009135015","doi":"10.1158/1535-7163.targ-19-b001","title":"Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Oncology; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Metastatic breast cancer; Paclitaxel; Breast cancer; Phases of clinical research; Colorectal cancer","score_opus":0.0167205724280495,"score_gpt":0.3281169170133715,"score_spread":0.31139634458532195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009135015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935343,0.0029109113,0.00041856442,0.0001912459,0.00004009183,0.00033492595,0.0004554365,0.000069764865,0.0020447231],"genre_scores_gemma":[0.995784,0.0012009263,0.0005054859,0.00017308757,0.000042452546,0.00017857175,0.00088190136,0.000012153744,0.0012213113],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998702,0.000054982338,0.000011967248,0.000023016293,0.000020702075,0.000019197594],"domain_scores_gemma":[0.9998461,0.000029245899,0.000037497583,0.000010167884,0.000011457786,0.00006544356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003948518,0.00050189137,0.0006261417,0.0002645542,0.00014924721,0.00037535772,0.00031142653,0.00034525484,0.0028633384],"category_scores_gemma":[0.0005260775,0.00017588372,0.00043381326,0.00020242395,0.00025155852,0.0003782394,0.00020451432,0.0009513507,0.00054652285],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33644953,0.015450634,0.016387325,0.0012743573,0.0014898675,0.0007034811,0.0002753226,0.0031863824,0.1617514,0.00035590152,0.0064853993,0.45619047],"study_design_scores_gemma":[0.1955151,0.6337738,0.09171682,0.00017510036,0.0018779284,0.0019539318,0.00015717135,0.005778693,0.052056,0.00028689206,0.016647717,0.00006091095],"about_ca_topic_score_codex":0.00056516466,"about_ca_topic_score_gemma":0.0015591714,"teacher_disagreement_score":0.0028633384,"about_ca_system_score_codex":0.00048001943,"about_ca_system_score_gemma":0.00055216695,"threshold_uncertainty_score":0.009578824},"labels":[],"label_agreement":null},{"id":"W3009819010","doi":"10.1158/1535-7163.targ-19-lb-b04","title":"Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Neuroblastoma; Cancer research; Biology; Immunotherapy; Flow cytometry; Cell culture; Molecular biology; Cancer; Genetics","score_opus":0.02274710327787047,"score_gpt":0.3251311079405694,"score_spread":0.3023840046626989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009819010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897076,0.0015497102,0.002590663,0.000159479,0.000022699904,0.000026952921,0.0048677325,0.00010716832,0.0017048472],"genre_scores_gemma":[0.98330873,0.0010393754,0.0033999383,0.0002184707,0.00001214624,0.000040178027,0.008471191,0.000050233695,0.0034596636],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999267,0.0000047736175,0.000004424341,0.000023869661,0.000024059418,0.000016119398],"domain_scores_gemma":[0.999944,0.0000069168,0.0000148046665,0.000006366036,0.000012222851,0.000015679641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014253116,0.00020616813,0.00026763257,0.00043465578,0.00026060824,0.0002972599,0.0001803892,0.00023559047,0.0018395178],"category_scores_gemma":[0.00009046611,0.0000972687,0.0002560179,0.0003955239,0.00016169513,0.0001717701,0.00028454806,0.00037599483,0.0006145876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018795121,0.00001511117,0.0032082372,0.00004796525,0.000014995776,0.00007440135,0.00001835496,0.00007747814,0.99399513,0.00004957324,0.00018737439,0.0021234294],"study_design_scores_gemma":[0.000058586902,0.00058048964,0.29527748,0.000029730405,0.00014786422,0.002561321,0.0002847659,0.0031938183,0.6803179,0.00035248083,0.017173788,0.000021829386],"about_ca_topic_score_codex":0.0014765841,"about_ca_topic_score_gemma":0.0019370643,"teacher_disagreement_score":0.0018395178,"about_ca_system_score_codex":0.0004188925,"about_ca_system_score_gemma":0.00023628626,"threshold_uncertainty_score":0.006153822},"labels":[],"label_agreement":null},{"id":"W3011044624","doi":"10.1158/1535-7163.mct-19-0745","title":"Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University","funders":"Nova Scotia Health Research Foundation; Canadian Institutes of Health Research; Cancer Research Society; Natural Sciences and Engineering Research Council of Canada; Dalhousie Medical Research Foundation","keywords":"Decitabine; Cancer research; DNA methylation; Triple-negative breast cancer; Cancer; Breast cancer; Demethylating agent; Biology; Azacitidine; Medicine; Oncology; Internal medicine; Gene; Genetics; Gene expression","score_opus":0.01684294837552151,"score_gpt":0.28332691116307607,"score_spread":0.26648396278755454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011044624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907398,0.0040227585,0.001381085,0.00016394525,0.000017685397,0.000037125745,0.0010351881,0.000090995,0.0025112394],"genre_scores_gemma":[0.9936698,0.0012203534,0.0009767135,0.0000666757,0.0000033886358,0.000040251238,0.0010781606,0.000017354227,0.002927392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998745,0.000014972797,0.000013480768,0.000032293316,0.000036151763,0.00002870102],"domain_scores_gemma":[0.99989974,0.000015913922,0.000027548866,0.000024789642,0.000017674087,0.000014349553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008856366,0.00018524093,0.00039804704,0.00022764965,0.00021894673,0.00043613726,0.00013003976,0.00020910788,0.002246048],"category_scores_gemma":[0.000215663,0.00013944447,0.00017139119,0.00030251706,0.00014861625,0.00022751448,0.00020144257,0.0004107722,0.0006084382],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018791379,0.000020603906,0.0012654815,0.000053491665,0.000008640415,0.00005742092,0.000018145742,0.00011386302,0.9935044,0.000078926445,0.00007232406,0.0046186554],"study_design_scores_gemma":[0.000016929065,0.0002915899,0.035927292,0.000011320787,0.000024964625,0.00082532445,0.00006510589,0.0006016951,0.9546676,0.00013099353,0.00742984,0.0000073595265],"about_ca_topic_score_codex":0.0008027966,"about_ca_topic_score_gemma":0.0021198157,"teacher_disagreement_score":0.002246048,"about_ca_system_score_codex":0.00051665993,"about_ca_system_score_gemma":0.0002211168,"threshold_uncertainty_score":0.007513821},"labels":[],"label_agreement":null},{"id":"W3012015863","doi":"10.1158/1535-7163.targ-19-pl03-03","title":"Abstract PL03-03: Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Gene; Genome; Computational biology; Genome editing; Biology; Cancer; Drug response; Human genome; CRISPR; DNA; Genetics; Drug; Pharmacology","score_opus":0.011009322859606855,"score_gpt":0.30987547611098887,"score_spread":0.298866153251382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012015863","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17235436,0.074561104,0.2052125,0.060852606,0.014028049,0.0013847786,0.022428866,0.019052219,0.43012556],"genre_scores_gemma":[0.47370732,0.03986692,0.07365352,0.009490712,0.0014509229,0.0005197231,0.011290146,0.0013981863,0.3886226],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976236,0.000033373126,0.000011796237,0.000046551555,0.000105543775,0.000040307918],"domain_scores_gemma":[0.9998461,0.000030368146,0.000024787887,0.000013846124,0.00003187785,0.00005308724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044482286,0.00057296176,0.00045674373,0.0005507085,0.0004787089,0.0019621674,0.00074477954,0.0008283652,0.026160277],"category_scores_gemma":[0.00031771712,0.0002754768,0.00033858587,0.00040768538,0.00060651026,0.00055912946,0.0007127268,0.0016209856,0.008918879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056231115,0.00014599276,0.0003377677,0.0004980589,0.000025251175,0.0005045219,0.00006636341,0.0016435172,0.73298836,0.017762832,0.1508179,0.09464724],"study_design_scores_gemma":[0.00018895419,0.0004654991,0.0018185406,0.00007795066,0.00003306855,0.0015424219,0.000066078,0.0039708577,0.49086848,0.0047987844,0.49612868,0.000040674742],"about_ca_topic_score_codex":0.0010488523,"about_ca_topic_score_gemma":0.0021144433,"teacher_disagreement_score":0.026160277,"about_ca_system_score_codex":0.0015408209,"about_ca_system_score_gemma":0.0007949762,"threshold_uncertainty_score":0.08751482},"labels":[],"label_agreement":null},{"id":"W3012106145","doi":"10.1158/1535-7163.mct-19-1117","title":"Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ATCO (Canada)","funders":"National Cancer Institute; National Institute on Aging; American Society of Clinical Oncology","keywords":"FOLFIRI; Irinotecan; KRAS; Bevacizumab; Colorectal cancer; Medicine; Oxaliplatin; Cancer research; Cytotoxic T cell; Pharmacodynamics; Internal medicine; Pharmacology; Immunology; Oncology; Cancer; Biology; Pharmacokinetics; Chemotherapy","score_opus":0.021005429558043586,"score_gpt":0.3223750773659806,"score_spread":0.301369647807937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012106145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950983,0.0011736264,0.00088888576,0.0003202104,0.000051568422,0.00084723043,0.00042906034,0.00007551343,0.0011155411],"genre_scores_gemma":[0.9950381,0.000599356,0.0013343535,0.00051419873,0.000065493965,0.0007769502,0.0008958032,0.000022973034,0.0007528873],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954456,0.00021748683,0.000026837077,0.000083095576,0.0000427242,0.0000852905],"domain_scores_gemma":[0.9994111,0.00010947611,0.000111273315,0.000051547217,0.000053885287,0.00026275957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015868827,0.00067047094,0.0012265951,0.0002557415,0.00025924054,0.00092743617,0.00041063162,0.00069679687,0.0016478349],"category_scores_gemma":[0.0011080069,0.00033144132,0.00078883546,0.00033077179,0.00045003646,0.00080786954,0.00024284287,0.002371262,0.0003469968],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5822802,0.05116539,0.012073039,0.00070100813,0.0017710795,0.00035017164,0.0005086893,0.008969982,0.14587891,0.00065852137,0.0053704507,0.19027244],"study_design_scores_gemma":[0.21439302,0.7364632,0.021573547,0.00003560358,0.00076135,0.00046761104,0.00009900557,0.0052223126,0.015416217,0.00039643687,0.005114081,0.000057657817],"about_ca_topic_score_codex":0.0003048899,"about_ca_topic_score_gemma":0.00073278195,"teacher_disagreement_score":0.0016478349,"about_ca_system_score_codex":0.00059567636,"about_ca_system_score_gemma":0.00066443306,"threshold_uncertainty_score":0.008392334},"labels":[],"label_agreement":null},{"id":"W3021366882","doi":"10.1158/1535-7163.mct-20-0087","title":"Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Optometric Education Trust Fund; Paraza Pharma (Canada)","funders":"National Cancer Institute; National Institute of General Medical Sciences; Genentech","keywords":"Bromodomain; Nut; BRD4; Biology; Cancer research; Medicine; Pharmacology; Chemistry; Genetics; Histone; DNA","score_opus":0.011698964360440794,"score_gpt":0.2392130122808768,"score_spread":0.227514047920436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021366882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942263,0.0016803611,0.0015383888,0.00013758765,0.000043285036,0.00009259573,0.0003337338,0.00009893842,0.0018487656],"genre_scores_gemma":[0.9970029,0.0005564171,0.0010970829,0.0000331004,0.0000068792,0.000040208783,0.0003013643,0.000008010831,0.00095398823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998989,0.000013346369,0.000007359987,0.000016489183,0.000033533575,0.000030349744],"domain_scores_gemma":[0.9999653,0.0000051874363,0.000005409065,0.000004151928,0.0000031063012,0.000016875136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013879935,0.00030632163,0.00045697516,0.00027762726,0.000120362245,0.00024475498,0.0003312464,0.00024202577,0.0007974405],"category_scores_gemma":[0.00007189961,0.00013747782,0.0002578215,0.00018789252,0.00019341224,0.0001774696,0.00021252269,0.0006879974,0.00024055412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011658092,0.00048066498,0.00047912152,0.00009474739,0.000038499176,0.000117253985,0.000017005897,0.00049341796,0.9860858,0.00018652732,0.00035707897,0.0104840305],"study_design_scores_gemma":[0.0004291549,0.0041126898,0.005311585,0.000005781233,0.000078386125,0.00059066934,0.000029992229,0.0033701207,0.98172367,0.00006869298,0.00426897,0.00001021176],"about_ca_topic_score_codex":0.0008858379,"about_ca_topic_score_gemma":0.0027937016,"teacher_disagreement_score":0.0008858379,"about_ca_system_score_codex":0.00038233728,"about_ca_system_score_gemma":0.00033644435,"threshold_uncertainty_score":0.0027740598},"labels":[],"label_agreement":null},{"id":"W3033074253","doi":"10.1158/1535-7163.mct-19-0977","title":"NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Breast Cancer Research Alliance; National Cancer Institute; Ovarian Cancer Research Alliance; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"ERBB3; Neuregulin 1; In vivo; Ovarian cancer; Cancer research; Downregulation and upregulation; Biomarker; Cancer; Sine; Biology; Signal transduction; Medicine; Pharmacology; Gene; Internal medicine; Cell biology; Biochemistry; Genetics","score_opus":0.01907139910147032,"score_gpt":0.25107729773700266,"score_spread":0.23200589863553234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033074253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664813,0.0007865348,0.001167953,0.00007989822,0.000011767491,0.00001875686,0.00025407688,0.00007041089,0.00096242066],"genre_scores_gemma":[0.99806446,0.00032366716,0.00040664265,0.00003172499,0.0000023168825,0.0000137110665,0.00024866173,0.0000100519255,0.00089876604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998611,0.000031046406,0.000012767814,0.000024715744,0.000035800913,0.000034622484],"domain_scores_gemma":[0.99990964,0.000018911705,0.00002410009,0.000022494947,0.0000090458125,0.00001575119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015323052,0.00019323398,0.00025429117,0.00016393016,0.00007449525,0.00023938036,0.00013588867,0.00017203663,0.0012513936],"category_scores_gemma":[0.00011679833,0.00010684609,0.00018818119,0.00012585944,0.00016087192,0.00011262209,0.00011725842,0.0005649692,0.00020215333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008742414,0.000041065476,0.00044263477,0.000015474883,0.0000072925086,0.00003390945,0.000006908123,0.00008486119,0.99813443,0.00005991956,0.00004779956,0.0010382765],"study_design_scores_gemma":[0.000024487965,0.00045822925,0.009971798,0.0000031739305,0.000012984763,0.0003502287,0.00002659457,0.0013092005,0.9863534,0.000049868624,0.0014372914,0.0000027552403],"about_ca_topic_score_codex":0.00048119723,"about_ca_topic_score_gemma":0.00088715425,"teacher_disagreement_score":0.0012513936,"about_ca_system_score_codex":0.00026319592,"about_ca_system_score_gemma":0.00013760739,"threshold_uncertainty_score":0.004186332},"labels":[],"label_agreement":null},{"id":"W3033597903","doi":"10.1158/1535-7163.mct-20-0094","title":"Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Terry Fox Research Institute; University Health Network; Ontario Institute for Cancer Research; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Pancreas Centre (Canada)","funders":"Canada Research Chairs; Canadian Institutes of Health Research; Genome British Columbia; Canada Foundation for Innovation","keywords":"Biology; Immunogenicity; Pancreatic cancer; Endogenous retrovirus; Cancer; Cancer research; Epigenetics; Colorectal cancer; Epigenomics; Breast cancer; Molecular mimicry; Immunology; Gene; DNA methylation; Gene expression; Genetics; Antibody; Genome","score_opus":0.061660860817377,"score_gpt":0.2671429476222009,"score_spread":0.20548208680482394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033597903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991241,0.00013822259,0.00024627402,0.000011062262,0.0000015844167,0.0000037133495,0.00027956953,0.000007248598,0.0001882509],"genre_scores_gemma":[0.99934226,0.000044938282,0.00015566428,0.000007428799,0.0000023473735,0.000005161388,0.00031600322,0.0000034961756,0.00012268718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982387,0.000025468078,0.00001865432,0.000058712903,0.000038486025,0.00003478442],"domain_scores_gemma":[0.99956864,0.00010244032,0.00017644331,0.00003944653,0.000047536694,0.00006550218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018722976,0.00011503732,0.00021610636,0.0006287804,0.00015556914,0.0004422315,0.00013049613,0.00020380205,0.0013510643],"category_scores_gemma":[0.0006280156,0.000099970435,0.00015155062,0.00042993858,0.00018080021,0.00012755602,0.00025582637,0.00023957147,0.00016294929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011913182,0.00005011465,0.7528413,0.000045887726,0.00010988815,0.00051863916,0.00013709007,0.00034292543,0.23847683,0.00013386676,0.00012875475,0.006023298],"study_design_scores_gemma":[0.00001117469,0.00020121128,0.98393345,0.000005483832,0.000049341637,0.0016480219,0.00020476521,0.0009245283,0.01241749,0.00015837327,0.00043969526,0.0000064986802],"about_ca_topic_score_codex":0.00036098147,"about_ca_topic_score_gemma":0.0004840405,"teacher_disagreement_score":0.0013510643,"about_ca_system_score_codex":0.00014462389,"about_ca_system_score_gemma":0.000079058766,"threshold_uncertainty_score":0.0045197606},"labels":[],"label_agreement":null},{"id":"W3034998325","doi":"10.1158/1535-7163.mct-19-0993","title":"Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions","year":2020,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Clinical trial; Selection (genetic algorithm); Antibody-drug conjugate; Drug development; Medicine; Biomarker; Drug; Expression (computer science); Computational biology; Computer science; Pharmacology; Antibody; Machine learning; Internal medicine; Monoclonal antibody; Biology; Immunology","score_opus":0.0828555232670809,"score_gpt":0.3865256745269056,"score_spread":0.3036701512598247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034998325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000320053,0.99588364,0.0010892261,0.001316497,0.00015386946,0.000052241434,0.000016678092,0.000009278835,0.0011585715],"genre_scores_gemma":[0.003211505,0.99244213,0.0024014509,0.0011032865,0.00024283346,0.00010846046,0.000029943109,0.0000052551013,0.00045506688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990466,0.00044797518,0.00013800008,0.00010902679,0.00019805055,0.000060263395],"domain_scores_gemma":[0.99718744,0.0020219549,0.00024845722,0.00006944249,0.00039056447,0.00008215227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005266952,0.0008287517,0.0018674085,0.0013789613,0.0002002432,0.0015511645,0.0010053086,0.0013122257,0.0034802577],"category_scores_gemma":[0.0045528277,0.0003029757,0.0010522573,0.0014171947,0.0007326073,0.0017233619,0.0006920208,0.0029675472,0.0009873756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020571638,0.0001720796,0.00016983818,0.020260384,0.00015451339,0.00009111222,0.0000721052,0.00086339004,0.0009827445,0.011146782,0.0072713955,0.95861],"study_design_scores_gemma":[0.0004783546,0.0014514289,0.0016422144,0.029376697,0.00094987074,0.0013149416,0.00016265931,0.0012502264,0.002114254,0.015019245,0.94615424,0.00008587851],"about_ca_topic_score_codex":0.0006184042,"about_ca_topic_score_gemma":0.0013030358,"teacher_disagreement_score":0.005266952,"about_ca_system_score_codex":0.001067559,"about_ca_system_score_gemma":0.0020712456,"threshold_uncertainty_score":0.027854621},"labels":[],"label_agreement":null},{"id":"W3080241619","doi":"10.1158/1535-7163.mct-19-1031","title":"Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Terry Fox Research Institute","keywords":"Bladder cancer; Gene silencing; Biology; Cancer research; Slug; Metastasis; Cancer; Gene; Genetics","score_opus":0.044195244923870614,"score_gpt":0.2920252293583531,"score_spread":0.2478299844344825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080241619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970932,0.0008482058,0.0011063144,0.000075043994,0.00000940712,0.000007922677,0.00027565932,0.000029387566,0.0005547947],"genre_scores_gemma":[0.9971476,0.00050045445,0.00073294254,0.000035122877,0.0000035394212,0.0000063973025,0.00046844684,0.0000076041247,0.0010978575],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999429,0.00001069381,0.0000039055144,0.000013615109,0.00001588457,0.000013000799],"domain_scores_gemma":[0.9999323,0.000011675276,0.000025588848,0.000006137278,0.0000065608265,0.000017762342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008882975,0.00012914385,0.00009326618,0.00012727547,0.00006398143,0.00018214574,0.00006180842,0.00011030015,0.0010679247],"category_scores_gemma":[0.0001234606,0.00006768487,0.00009498488,0.00013112841,0.000098983066,0.00009085055,0.00011192459,0.00020808616,0.00014459397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020763621,0.000027440608,0.0060395575,0.000040919935,0.00001152097,0.00007432254,0.000012241106,0.00010396787,0.98740953,0.000070247756,0.00012771909,0.0058748433],"study_design_scores_gemma":[0.000034454253,0.0011018965,0.13660216,0.000015497348,0.000071157454,0.0016023993,0.0000781289,0.0026584086,0.84718966,0.0001256318,0.010512911,0.000007632854],"about_ca_topic_score_codex":0.00044673207,"about_ca_topic_score_gemma":0.0009852997,"teacher_disagreement_score":0.0010679247,"about_ca_system_score_codex":0.00017589562,"about_ca_system_score_gemma":0.0001228592,"threshold_uncertainty_score":0.0035725832},"labels":[],"label_agreement":null},{"id":"W3087748453","doi":"10.1158/1535-7163.mct-20-0227","title":"Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Physiotherapy Foundation of Canada; U.S. Department of Defense","keywords":"Prostate cancer; DU145; Cancer research; Microparticle; Metastasis; Prostate; PLGA; In vivo; Cancer; Medicine; Chemistry; Pharmacology; In vitro; Internal medicine; Biology; LNCaP; Biochemistry","score_opus":0.14216629894576716,"score_gpt":0.3733259680806046,"score_spread":0.23115966913483743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087748453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005693,0.0016252585,0.0066453773,0.000074029864,0.00005900189,0.00014989282,0.00039225936,0.00019012163,0.00080700684],"genre_scores_gemma":[0.9912923,0.00076485047,0.00540331,0.000031919615,0.000012895385,0.00012650435,0.00033680888,0.000024704008,0.0020066223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985933,0.000020267084,0.000008209574,0.00002879454,0.000047849942,0.00003556909],"domain_scores_gemma":[0.9999082,0.000016842258,0.000026442622,0.000008837476,0.000013326665,0.000026344856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020852093,0.0004371162,0.00039559274,0.0003068849,0.00011013756,0.00019981655,0.00025478212,0.00041721217,0.00045669533],"category_scores_gemma":[0.00009064451,0.00014311064,0.00030107785,0.00016310101,0.00012785094,0.00015817326,0.00011733886,0.00055454863,0.00019156662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013046504,0.00010466637,0.00002697919,0.000039738505,0.0000046185237,0.000029543433,0.000007735339,0.00014379458,0.9986461,0.000026151276,0.00002753979,0.0008126339],"study_design_scores_gemma":[0.000022327491,0.0016138166,0.0006877135,0.0000036441224,0.000015764595,0.00007557775,0.0000049892637,0.0015369363,0.99543023,0.0000074859017,0.0005974335,0.0000040472705],"about_ca_topic_score_codex":0.00090862776,"about_ca_topic_score_gemma":0.0010671772,"teacher_disagreement_score":0.00090862776,"about_ca_system_score_codex":0.00028537834,"about_ca_system_score_gemma":0.00022003855,"threshold_uncertainty_score":0.0020705462},"labels":[],"label_agreement":null},{"id":"W3093982502","doi":"10.1158/1535-7163.mct-20-0333","title":"TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université du Québec à Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; McGill University","funders":"Merck Sharp and Dohme; McGill University Health Centre; Meso Scale Diagnostics; Merck","keywords":"Apoptosis; Oxidative stress; Programmed cell death; Chemistry; Protein kinase B; Cancer cell; Cancer research; Cell culture; Biology; Biochemistry; Cancer; Cell biology; Genetics","score_opus":0.040839858531741394,"score_gpt":0.29106520153573406,"score_spread":0.2502253430039927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093982502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741247,0.008683118,0.007851253,0.00021580364,0.00008957929,0.00012199023,0.0005518381,0.00024366716,0.008118006],"genre_scores_gemma":[0.9883986,0.0034962022,0.0039492245,0.00009281973,0.00003063148,0.000039052768,0.0005154605,0.000013803661,0.0034641775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99997735,0.0000030686585,0.0000017473939,0.0000049434543,0.000006820562,0.000006085304],"domain_scores_gemma":[0.999974,0.0000022328256,0.000008698438,0.0000030622898,0.000004614242,0.0000073995734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005466007,0.00029923808,0.00013836184,0.00028369747,0.00012185615,0.00014862136,0.00015698864,0.00020863288,0.0008558652],"category_scores_gemma":[0.000036389,0.00006866066,0.000120418386,0.00017238704,0.00011323567,0.00015136835,0.00011743534,0.00030672931,0.00022519442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011291392,0.000074308686,0.000118069554,0.00008352264,0.000005342098,0.000120337085,0.000008617603,0.00008292366,0.99235195,0.00017268589,0.00013981183,0.0067296023],"study_design_scores_gemma":[0.00003862531,0.0013079385,0.0014930418,0.000005928593,0.00002894414,0.0009788675,0.000005761878,0.00032292216,0.9883913,0.000040952258,0.0073809493,0.000004730542],"about_ca_topic_score_codex":0.00014147029,"about_ca_topic_score_gemma":0.00030865188,"teacher_disagreement_score":0.0008558652,"about_ca_system_score_codex":0.00010986211,"about_ca_system_score_gemma":0.0001037394,"threshold_uncertainty_score":0.0028631687},"labels":[],"label_agreement":null},{"id":"W3094632508","doi":"10.1158/1535-7163.mct-20-0259","title":"Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre; McGill University Health Centre; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reprogramming; Biology; Epigenetics; Cancer research; Kinase; BET inhibitor; Cancer; MEK inhibitor; Genetics; Bioinformatics; MAPK/ERK pathway; Cell; Gene; Bromodomain","score_opus":0.028912408390285946,"score_gpt":0.2730069190894758,"score_spread":0.24409451069918983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094632508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189293,0.0020280194,0.0018916681,0.00013228889,0.000056291603,0.000058607184,0.00026064742,0.000059928963,0.0036195235],"genre_scores_gemma":[0.99807274,0.00044336004,0.00039060655,0.000023463655,0.000005986191,0.000016120599,0.00011764555,0.0000036009733,0.0009264532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994385,0.00000947428,0.0000038771354,0.000009615276,0.000014696012,0.000018483872],"domain_scores_gemma":[0.9999682,0.0000079050615,0.000008609299,0.0000038507496,0.0000029838582,0.0000084521325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101448866,0.00019266496,0.00020883829,0.00015756031,0.000086297296,0.0002469417,0.000120987774,0.00013070597,0.001975648],"category_scores_gemma":[0.00008723406,0.00006626526,0.00016120267,0.000098907956,0.00012610776,0.00011237043,0.00017510461,0.0002942106,0.0002133889],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050961773,0.00016658695,0.0005570335,0.00007068455,0.000019439125,0.00008843342,0.000010787109,0.00035475462,0.9864607,0.0003157658,0.00017978261,0.011266507],"study_design_scores_gemma":[0.000087208864,0.0022609853,0.0067869807,0.000010090943,0.000036857353,0.0003728906,0.000032849235,0.002375556,0.9826089,0.00016651445,0.005255437,0.0000056701983],"about_ca_topic_score_codex":0.00019896787,"about_ca_topic_score_gemma":0.000773323,"teacher_disagreement_score":0.001975648,"about_ca_system_score_codex":0.0001738658,"about_ca_system_score_gemma":0.00017511562,"threshold_uncertainty_score":0.0066092014},"labels":[],"label_agreement":null},{"id":"W3106906902","doi":"10.1158/1535-7163.mct-20-0130","title":"Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells <i>In Vitro</i> and <i>In Vivo</i>","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Hong Kong Polytechnic University; University Grants Committee","keywords":"Chemistry; Cancer research; Breast cancer; Peptide; Cancer cell; Cytotoxicity; In vitro; Biochemistry; Cancer; Internal medicine; Medicine","score_opus":0.018288676461397656,"score_gpt":0.2798321028020886,"score_spread":0.26154342634069094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106906902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956098,0.0007926254,0.0019944427,0.00006772563,0.000034258042,0.000020820744,0.00037887105,0.000059144793,0.0010421851],"genre_scores_gemma":[0.9921314,0.00046877185,0.002966569,0.00006444676,0.000007005554,0.000038597373,0.0015899431,0.000018172046,0.0027151855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998869,0.000019612775,0.000010909399,0.000023989225,0.000028943043,0.000029639183],"domain_scores_gemma":[0.9999398,0.0000144167925,0.000016483442,0.0000065179565,0.000007371415,0.000015379635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010048884,0.00035237547,0.00022183056,0.00009127762,0.00011422429,0.00013896794,0.00017605133,0.00022128936,0.0009351132],"category_scores_gemma":[0.00007938165,0.000113817325,0.00023910619,0.00011659747,0.00014724674,0.000105245155,0.00010882622,0.00037285622,0.0003197933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007734911,0.000019184563,0.000051112358,0.000012997598,0.0000032380249,0.000021997435,0.0000029615226,0.000047393576,0.99951935,0.000017290222,0.000031090152,0.00019609765],"study_design_scores_gemma":[0.0000059974805,0.00020180985,0.00064440747,0.0000011669135,0.00000448288,0.000093884846,0.0000047696985,0.0004943986,0.99801624,0.000005461138,0.00052574975,0.0000015645913],"about_ca_topic_score_codex":0.00068930996,"about_ca_topic_score_gemma":0.0006694781,"teacher_disagreement_score":0.0009351132,"about_ca_system_score_codex":0.0003225552,"about_ca_system_score_gemma":0.0001653758,"threshold_uncertainty_score":0.0031282306},"labels":[],"label_agreement":null},{"id":"W3133986190","doi":"10.1158/1535-7163.mct-20-0510","title":"Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"Janssen Research and Development","keywords":"Prostate cancer; Androgen receptor; Cancer research; Antagonist; Cancer; Internal medicine; Medicine; Receptor; Endocrinology; Pharmacology; Biology","score_opus":0.06884914067294168,"score_gpt":0.3620688245716197,"score_spread":0.29321968389867803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133986190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9400693,0.024848733,0.00972908,0.0025028677,0.0005528295,0.0006582902,0.0013447535,0.000449219,0.019844964],"genre_scores_gemma":[0.96520764,0.014330981,0.0068321996,0.0013466692,0.000085544445,0.00015153785,0.0018045979,0.00003806906,0.0102029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998952,0.000010975515,0.000006330726,0.000015484336,0.000040888805,0.000031074123],"domain_scores_gemma":[0.999943,0.000005164038,0.000009073763,0.00000382049,0.000010116617,0.000028755156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026496113,0.00039098944,0.00048637687,0.00032160146,0.00018804612,0.000495659,0.00037067273,0.0005152554,0.001106953],"category_scores_gemma":[0.0001445154,0.0001872344,0.00036256967,0.00017581832,0.0002453882,0.00024202645,0.0002492418,0.0009393244,0.0005028659],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005680864,0.0008003704,0.0012608784,0.00029909282,0.00007218215,0.0012418715,0.00009952894,0.0016250164,0.90635633,0.003281922,0.004412045,0.07998262],"study_design_scores_gemma":[0.002445656,0.01685665,0.015224584,0.00017729102,0.00029083752,0.009409244,0.000093562216,0.008501812,0.8455353,0.0011404919,0.100232914,0.00009167717],"about_ca_topic_score_codex":0.001157762,"about_ca_topic_score_gemma":0.004327101,"teacher_disagreement_score":0.001157762,"about_ca_system_score_codex":0.0004438332,"about_ca_system_score_gemma":0.0007532322,"threshold_uncertainty_score":0.0037031174},"labels":[],"label_agreement":null},{"id":"W3170601186","doi":"","title":"The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Metastasis; Apoptosis; In vivo; Cancer research; In vitro; Medicine; Cancer; Melanoma; Pathology; Cell culture; Cancer cell; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.02368258694422533,"score_gpt":0.3100096398386744,"score_spread":0.2863270528944491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170601186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511707,0.0010793216,0.0007927913,0.0001356993,0.000057895824,0.00006726161,0.0005655831,0.00013829448,0.002046122],"genre_scores_gemma":[0.9918751,0.0014024959,0.001310956,0.000072055154,0.000022152879,0.000111659865,0.0010664727,0.000022046363,0.0041169967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999021,0.000015984568,0.000010786424,0.000014061429,0.000021493795,0.00003564145],"domain_scores_gemma":[0.9998697,0.000020278083,0.000030996616,0.000014875417,0.000015489892,0.000048586175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010720319,0.00051481574,0.00045325875,0.00048822258,0.00015083684,0.0002043917,0.00025804897,0.00032280097,0.0015220605],"category_scores_gemma":[0.00012896383,0.00011197465,0.00024687906,0.00029283154,0.00023027122,0.00016430698,0.00012878368,0.000737696,0.00029936022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068155315,0.00043267058,0.00016841367,0.000055693552,0.000007232754,0.000051353316,0.000015758633,0.00016463478,0.9957087,0.00007822206,0.0001396282,0.0024960798],"study_design_scores_gemma":[0.00018022892,0.004357624,0.002961592,0.0000089108,0.000022483744,0.00012411832,0.000029712897,0.0012051376,0.9889888,0.000032939653,0.00208134,0.0000070081483],"about_ca_topic_score_codex":0.0015124513,"about_ca_topic_score_gemma":0.002675953,"teacher_disagreement_score":0.0015220605,"about_ca_system_score_codex":0.00032023934,"about_ca_system_score_gemma":0.00037186476,"threshold_uncertainty_score":0.0050917864},"labels":[],"label_agreement":null},{"id":"W3174270804","doi":"10.1158/1535-7163.mct-21-0159","title":"Current Development of Glioblastoma Therapeutic Agents","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"National Cancer Institute","keywords":"Glioblastoma; Tyrosine kinase; Receptor tyrosine kinase; Targeted therapy; Phenotype; Growth factor receptor; Precision medicine; Drug development; Receptor","score_opus":0.043008722865672325,"score_gpt":0.3326312226341538,"score_spread":0.2896224997684815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174270804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005852201,0.9659864,0.0035365473,0.004231365,0.0011083629,0.0001170827,0.00031597257,0.00018150611,0.018670643],"genre_scores_gemma":[0.035432003,0.94278777,0.0046615885,0.0042856494,0.0008523283,0.0002557447,0.0012245253,0.000037622434,0.010462739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998167,0.000029699295,0.000019155968,0.00003311695,0.000063298816,0.000038066046],"domain_scores_gemma":[0.99983156,0.000025482193,0.000035542267,0.000009278282,0.000064048116,0.000034157852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005420584,0.00061279896,0.00066602346,0.00096359965,0.0002892811,0.001036927,0.0007636677,0.0009215974,0.0054606833],"category_scores_gemma":[0.0004295302,0.00022464522,0.0004896505,0.0005139041,0.00030917994,0.0009988196,0.0006114895,0.0017767332,0.0032152063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002595745,0.00027619785,0.0003591307,0.0032886916,0.000070339265,0.00029718192,0.000074080395,0.00050990586,0.025950205,0.009396855,0.03378191,0.92573583],"study_design_scores_gemma":[0.00012670828,0.0006591629,0.0008246301,0.0009069681,0.000108862485,0.0011406412,0.00004298327,0.0004216237,0.013532473,0.0031630874,0.97904944,0.000023399145],"about_ca_topic_score_codex":0.0006414225,"about_ca_topic_score_gemma":0.0015261911,"teacher_disagreement_score":0.0054606833,"about_ca_system_score_codex":0.0008480884,"about_ca_system_score_gemma":0.000785773,"threshold_uncertainty_score":0.01826781},"labels":[],"label_agreement":null},{"id":"W3199957122","doi":"10.1158/1535-7163.mct-20-0144","title":"Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Canadian Institute for Military and Veteran Health Research; Mitacs","keywords":"Cancer research; Immunotherapy; Tumor microenvironment; Medicine; Blockade; Metastasis; Immune system; Pancreatic cancer; Immunology; Biology; Cancer; Internal medicine; Receptor","score_opus":0.024979566459188366,"score_gpt":0.3042864441328752,"score_spread":0.27930687767368684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199957122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948992,0.0017301651,0.0013824388,0.00013117008,0.00006477883,0.000044866327,0.00008827759,0.00007077837,0.001588309],"genre_scores_gemma":[0.9969626,0.0009103962,0.0010269597,0.000048547216,0.000033432585,0.00002638306,0.000076465716,0.0000061363544,0.0009091832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993324,0.00001297511,0.0000039205224,0.000009101867,0.000015681087,0.000024949763],"domain_scores_gemma":[0.99996614,0.0000060369707,0.000008650159,0.0000026368841,0.0000023855093,0.000014066367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009027824,0.00036536754,0.00027368462,0.00017652888,0.000087156404,0.00019154194,0.00012347827,0.00015616676,0.0006741407],"category_scores_gemma":[0.0000494045,0.000051765135,0.00013818068,0.00008243661,0.00016589099,0.00013231448,0.00014699633,0.0006615042,0.000119189855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058057165,0.00037397596,0.00024758303,0.00007845472,0.000011148808,0.000053566415,0.000014770308,0.000433144,0.9856697,0.00013864976,0.00011942307,0.012279057],"study_design_scores_gemma":[0.00020489318,0.008098283,0.004860109,0.000014043658,0.00007212422,0.00038440197,0.000030439613,0.0022334394,0.9795313,0.000107521664,0.0044540726,0.000009341141],"about_ca_topic_score_codex":0.00024713413,"about_ca_topic_score_gemma":0.00085769425,"teacher_disagreement_score":0.0006741407,"about_ca_system_score_codex":0.00012867368,"about_ca_system_score_gemma":0.00018766013,"threshold_uncertainty_score":0.0022552013},"labels":[],"label_agreement":null},{"id":"W3204325537","doi":"10.1158/1535-7163.mct-21-0368","title":"IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NorQuest College","funders":"National Institute for Occupational Safety and Health; National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health","keywords":"Pancreatic cancer; Medicine; Immunoglobulin E; Immunotherapy; Cancer research; Ovalbumin; Immunology; Cancer; Cancer immunotherapy; Antigen; Antibody; Immune system; Internal medicine","score_opus":0.043125097673283985,"score_gpt":0.3266197887092266,"score_spread":0.2834946910359426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204325537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903881,0.0027914308,0.0020885218,0.0003555702,0.00018175693,0.0002187036,0.0006097894,0.00030253225,0.0030636564],"genre_scores_gemma":[0.99267864,0.0019776186,0.0014477809,0.00021015384,0.000060262642,0.0002342176,0.0008230704,0.000023224944,0.0025451034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978834,0.00004161815,0.000019175437,0.000031342515,0.00005149581,0.00006802402],"domain_scores_gemma":[0.99991024,0.000012810522,0.000020787005,0.000010380036,0.000009655522,0.000036160094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028763292,0.0005380625,0.00060295465,0.0004360855,0.00013647562,0.0002842983,0.00033833244,0.0004664724,0.0012631256],"category_scores_gemma":[0.00013783707,0.00016784068,0.00034759194,0.00026314848,0.00019249895,0.00025780356,0.00019524492,0.0019414158,0.00025523434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016819263,0.003727112,0.000254031,0.00021915596,0.000048080416,0.00010120394,0.00005057006,0.0010597806,0.97966653,0.00018473766,0.00070549664,0.012301405],"study_design_scores_gemma":[0.00084429473,0.03742036,0.005595783,0.000038875944,0.00016639948,0.00038922188,0.00006179092,0.0045258864,0.9440539,0.00021528045,0.0066669984,0.00002114713],"about_ca_topic_score_codex":0.0005177122,"about_ca_topic_score_gemma":0.0011545874,"teacher_disagreement_score":0.0012631256,"about_ca_system_score_codex":0.00027438794,"about_ca_system_score_gemma":0.00033862045,"threshold_uncertainty_score":0.004225552},"labels":[],"label_agreement":null},{"id":"W3216161881","doi":"10.1158/1535-7163.mct-21-0411","title":"Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Palbociclib; Prostate; Androgen receptor; Medicine; Cyclin-dependent kinase 4; Internal medicine; Kinase; Cancer research; Androgen; Oncology; Endocrinology; Prostate cancer; Pharmacology; Breast cancer; Biology; Cancer; Cyclin-dependent kinase 2; Hormone; Cell cycle; Metastatic breast cancer; Biochemistry","score_opus":0.014216953938682468,"score_gpt":0.2829275605301325,"score_spread":0.2687106065914501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216161881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9318079,0.045846116,0.0026471028,0.0010842584,0.00042455914,0.0004893408,0.0010458871,0.00056033256,0.016094469],"genre_scores_gemma":[0.98560137,0.0070805983,0.0017968802,0.00019274068,0.00008005892,0.00014865198,0.00086429826,0.000036139074,0.00419929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999181,0.000014490333,0.00000572287,0.000011072912,0.000026543798,0.000024082605],"domain_scores_gemma":[0.99996245,0.0000041967974,0.0000071939007,0.0000035592698,0.000006240235,0.000016438102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011584675,0.00034832105,0.0005490742,0.0004909758,0.00017371085,0.0002604083,0.0003737436,0.00021785848,0.0021153039],"category_scores_gemma":[0.0000719317,0.00013226591,0.00029239495,0.00030448614,0.00016277008,0.00013605437,0.00014131295,0.0008574933,0.00050458405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049943523,0.0020312106,0.0009429319,0.00050871144,0.00014186066,0.00036489405,0.000049499668,0.0009104782,0.84333265,0.00054758723,0.004543968,0.14163192],"study_design_scores_gemma":[0.0033826416,0.018517824,0.01723114,0.00007431241,0.00035819298,0.0026873825,0.000068887195,0.004185678,0.87464285,0.00024918484,0.078553066,0.00004877865],"about_ca_topic_score_codex":0.0012358881,"about_ca_topic_score_gemma":0.0042187897,"teacher_disagreement_score":0.0021153039,"about_ca_system_score_codex":0.0005014237,"about_ca_system_score_gemma":0.00042819782,"threshold_uncertainty_score":0.0070764422},"labels":[],"label_agreement":null},{"id":"W4200008328","doi":"10.1158/1535-7163.targ-21-p096","title":"Abstract P096: Using CRISPR-Cas9 screens to identify microRNA involved in aggressive prostate cancer phenotypes","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"CRISPR; microRNA; DU145; Prostate cancer; Cas9; Biology; Cancer research; In silico; Computational biology; Cancer; Gene knockout; Metastasis; Guide RNA; Phenotype; Gene; Bioinformatics; Genetics; LNCaP","score_opus":0.025782153819473522,"score_gpt":0.36377515183888737,"score_spread":0.33799299801941385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200008328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78512293,0.0018180492,0.16216968,0.0009519389,0.00041728467,0.0010388548,0.021120405,0.0097587,0.01760222],"genre_scores_gemma":[0.8803301,0.0009307679,0.0848649,0.0005107313,0.000033239165,0.00054354954,0.014025856,0.0015201847,0.017240651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99942243,0.00006512165,0.000063247615,0.00013390875,0.0002503205,0.000065035005],"domain_scores_gemma":[0.9995449,0.00012728387,0.000101298916,0.00005035958,0.00007295035,0.00010326416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005265205,0.000847907,0.00060843915,0.0005561069,0.00042458074,0.0008203154,0.00063847477,0.00075511663,0.004277573],"category_scores_gemma":[0.0004159836,0.00038395115,0.0006639906,0.0003488383,0.00038063474,0.00023070065,0.0006171662,0.0011948688,0.0018259196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013566331,0.00004612407,0.00041222002,0.00012366606,0.000028109434,0.00019582988,0.00002199423,0.00047870172,0.9948114,0.00025799184,0.00069590064,0.0027922823],"study_design_scores_gemma":[0.000046919085,0.00041128983,0.0035571298,0.00001825877,0.00006512113,0.00083780783,0.00003227196,0.0051184995,0.9780999,0.00014511704,0.0116348555,0.000032805285],"about_ca_topic_score_codex":0.0011688086,"about_ca_topic_score_gemma":0.0022569976,"teacher_disagreement_score":0.004277573,"about_ca_system_score_codex":0.0005230817,"about_ca_system_score_gemma":0.0005019703,"threshold_uncertainty_score":0.014309943},"labels":[],"label_agreement":null},{"id":"W4200026444","doi":"10.1158/1535-7163.targ-21-lba020","title":"Abstract LBA020: Targeting FGFR2c isoform, a novel therapeutic target with FGFR inhibitor in endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endometrial cancer; Oncology; Cancer; Medicine; Internal medicine; Gene isoform; Cohort; Clinical trial; Disease; Alternative splicing; Cancer research; Biology; Gene","score_opus":0.02507841938843143,"score_gpt":0.3026499582272994,"score_spread":0.277571538838868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200026444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801676,0.011702374,0.001688632,0.00047321696,0.000072371644,0.00018179938,0.00081582495,0.00015067328,0.0047475477],"genre_scores_gemma":[0.9883255,0.0037291322,0.0023982238,0.00023790161,0.000022278826,0.000098618046,0.0012600918,0.000016901546,0.00391138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999349,0.000009438699,0.0000050251756,0.000011750248,0.000019633815,0.000019247453],"domain_scores_gemma":[0.9999647,0.000003679202,0.000007049212,0.0000036506783,0.0000073934457,0.000013576973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022477936,0.00024602798,0.00029209736,0.00023326838,0.00018255833,0.00044756065,0.00031312677,0.00033371404,0.0015139133],"category_scores_gemma":[0.0000955761,0.00011249039,0.00025130008,0.00021199448,0.00017478167,0.00014075915,0.00016952484,0.000621325,0.00035514394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018957151,0.00045385404,0.002015731,0.00024599512,0.00005324682,0.00028956382,0.000051442104,0.0005125018,0.96369386,0.00032193534,0.0011676245,0.029298512],"study_design_scores_gemma":[0.0016889423,0.016539726,0.030861232,0.00007206414,0.00031611003,0.0033303695,0.00014157673,0.0047103176,0.89988065,0.00017861987,0.04224485,0.00003558579],"about_ca_topic_score_codex":0.0023321519,"about_ca_topic_score_gemma":0.0048727742,"teacher_disagreement_score":0.0023321519,"about_ca_system_score_codex":0.0005916649,"about_ca_system_score_gemma":0.00047117146,"threshold_uncertainty_score":0.0050646067},"labels":[],"label_agreement":null},{"id":"W4200042354","doi":"10.1158/1535-7163.targ-21-cc06-01","title":"Abstract CC06-01: Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androgen receptor; Oncology; Prostatectomy; Internal medicine; Disease; Prostate; Circulating tumor cell; Cancer; Liquid biopsy; Metastasis; Bioinformatics; Biology","score_opus":0.04885802728738338,"score_gpt":0.3650282655748881,"score_spread":0.31617023828750473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200042354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9055196,0.014156801,0.0070771277,0.0011090202,0.00022958273,0.00050905364,0.06353761,0.0004949962,0.0073662032],"genre_scores_gemma":[0.92610806,0.0033735973,0.017868383,0.0010939371,0.00016309909,0.0005362578,0.04705102,0.000084439045,0.0037212986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995221,0.00009051085,0.00003568952,0.00013766435,0.00015556258,0.00005833107],"domain_scores_gemma":[0.99914455,0.00029422384,0.00019436865,0.00003436105,0.00021944805,0.00011303276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050992996,0.0003754427,0.0005313167,0.0010618101,0.0003072286,0.00094498997,0.00032162876,0.0005356807,0.0032743504],"category_scores_gemma":[0.0013043638,0.00013130422,0.000395209,0.001424597,0.00020236104,0.0001729374,0.00032384592,0.0004582845,0.0011189203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005224198,0.0004918363,0.6418106,0.002281861,0.00040279562,0.00096657174,0.00027428643,0.003278377,0.17912006,0.0007253268,0.024651922,0.14077216],"study_design_scores_gemma":[0.00018865599,0.0021550094,0.8766579,0.00044319575,0.00040812505,0.0028988062,0.0006151084,0.008532218,0.064665094,0.0008535094,0.042497363,0.000084980486],"about_ca_topic_score_codex":0.0020201278,"about_ca_topic_score_gemma":0.0034934927,"teacher_disagreement_score":0.0032743504,"about_ca_system_score_codex":0.00038717853,"about_ca_system_score_gemma":0.0006934795,"threshold_uncertainty_score":0.010953784},"labels":[],"label_agreement":null},{"id":"W4200048265","doi":"10.1158/1535-7163.targ-21-p058","title":"Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Weyerhauser (Canada)","funders":"","keywords":"In vivo; Medicine; Cancer research; Immunohistochemistry; Cancer; DNA damage; Internal medicine; Oncology; Pathology; Biology; DNA","score_opus":0.021527253508414817,"score_gpt":0.26002207716267794,"score_spread":0.23849482365426314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200048265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949485,0.0007399263,0.0014470974,0.00009685832,0.000058457095,0.00008551688,0.0013488122,0.0001295906,0.0011451986],"genre_scores_gemma":[0.99240804,0.0006933507,0.0022183212,0.00004410701,0.000017077593,0.00010596334,0.0021727788,0.00002106982,0.0023193639],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985754,0.000029668801,0.000016736403,0.00003271087,0.000032517684,0.000030869563],"domain_scores_gemma":[0.99988186,0.000025659841,0.00002639456,0.000019942745,0.000011603482,0.000034598048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024740264,0.00046938373,0.0004064357,0.00026445786,0.00012651342,0.00022843893,0.0002627321,0.0002897412,0.0023537187],"category_scores_gemma":[0.000096372125,0.00012228532,0.00026761903,0.00021430032,0.00013797739,0.00025874324,0.00012480441,0.0010441273,0.00048680592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018834764,0.0015981481,0.00075641676,0.00011769966,0.000029609038,0.000103373,0.000024778616,0.000558834,0.98798054,0.00014722969,0.0006207872,0.006179119],"study_design_scores_gemma":[0.00025783444,0.013783785,0.006328531,0.000007555365,0.000056363955,0.0004849729,0.000028352824,0.0025876448,0.9743893,0.000042178235,0.0020270138,0.000006407888],"about_ca_topic_score_codex":0.0005341646,"about_ca_topic_score_gemma":0.0006925783,"teacher_disagreement_score":0.0023537187,"about_ca_system_score_codex":0.00023126489,"about_ca_system_score_gemma":0.00024585423,"threshold_uncertainty_score":0.007874012},"labels":[],"label_agreement":null},{"id":"W4200094785","doi":"10.1158/1535-7163.targ-21-p154","title":"Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Salivary gland; Cohort; Medicine; Profiling (computer programming); Clinical trial; Oncology; Internal medicine; Pathology; Computer science","score_opus":0.10994641830223084,"score_gpt":0.3807383389832205,"score_spread":0.2707919206809897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200094785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018914,0.0030131855,0.00050731935,0.00044235427,0.00016583524,0.0007288176,0.0026645137,0.000052468207,0.0022363507],"genre_scores_gemma":[0.99189925,0.0005748015,0.000509927,0.00059880235,0.0002091195,0.00063291634,0.004590858,0.000017635315,0.0009666766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813795,0.0011346332,0.000089399386,0.00033936018,0.00014671759,0.00015196664],"domain_scores_gemma":[0.9987174,0.00025662503,0.00032887323,0.000218458,0.00007994273,0.00039880496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039750873,0.0007442584,0.0013442674,0.00033464303,0.00022975412,0.0010081668,0.0005535996,0.00084935816,0.0038690749],"category_scores_gemma":[0.0029113174,0.00023884917,0.0021062053,0.00037406175,0.0005489753,0.00077029434,0.00063760765,0.0011683844,0.0007661526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8553638,0.00799773,0.042320643,0.0006839337,0.006443592,0.0002623573,0.00015052783,0.0023808891,0.010212725,0.0004212842,0.005838235,0.06792433],"study_design_scores_gemma":[0.28087837,0.5105833,0.17713346,0.00012861952,0.00767453,0.00074004906,0.00019439239,0.003744459,0.006124393,0.0016774485,0.011033452,0.00008746998],"about_ca_topic_score_codex":0.00030853096,"about_ca_topic_score_gemma":0.00053511554,"teacher_disagreement_score":0.0039750873,"about_ca_system_score_codex":0.00056711055,"about_ca_system_score_gemma":0.0007239977,"threshold_uncertainty_score":0.021022558},"labels":[],"label_agreement":null},{"id":"W4200113851","doi":"10.1158/1535-7163.targ-21-p136","title":"Abstract P136: Response to alpelisib in an adolescent with <i>PIK3CA</i>-mutated metastatic gastrointestinal stromal tumour","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"PDGFRA; SDHB; Stromal tumor; Sunitinib; GiST; Cancer; CD117; Germline; Cancer research; Germline mutation; Pathology; Imatinib; Internal medicine; Biology; Medicine; Oncology; Stromal cell; Mutation; CD34; Genetics; Gene","score_opus":0.0441469780952872,"score_gpt":0.3455051166161648,"score_spread":0.30135813852087756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200113851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96772736,0.0032591547,0.001344808,0.014691724,0.0005461308,0.00016978667,0.0005995077,0.00014495476,0.011516571],"genre_scores_gemma":[0.996566,0.0005120665,0.0003330311,0.0014054829,0.00017803223,0.000013403769,0.00015028175,0.000012667363,0.0008290843],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998282,0.000018543458,0.000019510402,0.000048327318,0.000030275589,0.000055014018],"domain_scores_gemma":[0.99956566,0.000082515326,0.000051053492,0.000012201111,0.000040570692,0.00024813725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015978572,0.00044936533,0.0005630828,0.00060522574,0.0008658659,0.00042317802,0.0004591932,0.0017591369,0.0017879019],"category_scores_gemma":[0.00085727265,0.00018715407,0.00054965966,0.00037228086,0.00044443124,0.0005817145,0.0003471025,0.002142085,0.0004935591],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015983773,0.000117195894,0.029057005,0.000045997014,0.00001861644,0.96218115,0.00016202056,0.00027535536,0.0018589456,0.00020116285,0.0014232352,0.004499408],"study_design_scores_gemma":[0.0000689208,0.00090859405,0.06355542,0.00012476888,0.000046001787,0.92801493,0.00038201635,0.001971638,0.0010051442,0.00057805993,0.0033158916,0.00002864377],"about_ca_topic_score_codex":0.0024428312,"about_ca_topic_score_gemma":0.0036823365,"teacher_disagreement_score":0.0024428312,"about_ca_system_score_codex":0.0010364426,"about_ca_system_score_gemma":0.00052157714,"threshold_uncertainty_score":0.007519901},"labels":[],"label_agreement":null},{"id":"W4200167174","doi":"10.1158/1535-7163.targ-21-p081","title":"Abstract P081: <i>In vitro</i> activity and efficacy of novel dual PARP-HDAC inhibitors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer research; Molecular biology; Synthetic lethality; Chemistry; Histone; Biology; Polymerase; DNA; Biochemistry","score_opus":0.03704472708377646,"score_gpt":0.3269870545350563,"score_spread":0.2899423274512798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200167174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96291727,0.0124809835,0.00458242,0.000570209,0.00026877876,0.00020854364,0.005446769,0.00058304507,0.012941812],"genre_scores_gemma":[0.98067456,0.0037260829,0.0030727403,0.00020043625,0.00006719397,0.00017375834,0.005284691,0.0000681764,0.0067322324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982774,0.000028977702,0.000019978708,0.000035867346,0.000047703084,0.000039667626],"domain_scores_gemma":[0.9998777,0.000023237815,0.000031968488,0.000012544544,0.000020926575,0.000033598997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000257635,0.00062011403,0.00045694335,0.00023815992,0.00014982598,0.000369506,0.0005037075,0.0003657873,0.0048691565],"category_scores_gemma":[0.0001642849,0.00015299532,0.0002721842,0.00026015122,0.00016129583,0.00028117117,0.00015476691,0.00109618,0.0015742853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017340862,0.0006177976,0.00042377374,0.00036247028,0.000049058013,0.00009383942,0.000023674065,0.00095621776,0.9790756,0.00024330462,0.0030221087,0.01339812],"study_design_scores_gemma":[0.00027532488,0.0055344114,0.0025063679,0.000024238238,0.00007526145,0.00044304386,0.000016071132,0.0020769327,0.98221636,0.000052895957,0.0067663486,0.00001272139],"about_ca_topic_score_codex":0.000887541,"about_ca_topic_score_gemma":0.0009098216,"teacher_disagreement_score":0.0048691565,"about_ca_system_score_codex":0.00043751957,"about_ca_system_score_gemma":0.00029352697,"threshold_uncertainty_score":0.016288996},"labels":[],"label_agreement":null},{"id":"W4200172388","doi":"10.1158/1535-7163.targ-21-p200","title":"Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Biotechnology Research Institute","funders":"","keywords":"Lung cancer; Cancer; Antibody; Immunotherapy; Cancer research; Medicine; CD47; Immune system; Immunology; Receptor; Biology; Oncology; Internal medicine","score_opus":0.06606885790911159,"score_gpt":0.41531484241515276,"score_spread":0.34924598450604116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200172388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265559,0.009001176,0.025522163,0.0020030416,0.0005019344,0.0026597735,0.0025156592,0.00082439714,0.030416112],"genre_scores_gemma":[0.95709944,0.0034231513,0.013032019,0.0010608258,0.000122491,0.0007463681,0.00363922,0.00008297361,0.020793485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998603,0.000021750937,0.000007023575,0.000018563374,0.000045051755,0.00004733863],"domain_scores_gemma":[0.9998647,0.000013933755,0.000011954965,0.00000915224,0.000038244867,0.000061975625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039647182,0.0004280299,0.00025384617,0.00030784166,0.0001758034,0.00037607335,0.00042473947,0.0006418221,0.0043012416],"category_scores_gemma":[0.00016896229,0.00016560365,0.0003154372,0.0001247843,0.00014246296,0.00026444427,0.00021959902,0.0010763351,0.0013645517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008995179,0.0019316314,0.0008537754,0.0001913468,0.000043119617,0.00027808448,0.000058792128,0.0006214595,0.934089,0.0005907253,0.004848765,0.055593725],"study_design_scores_gemma":[0.0011296729,0.023564598,0.006415509,0.000033258042,0.00009833361,0.001595667,0.000032797616,0.003079174,0.9141286,0.00022492245,0.049681053,0.00001636532],"about_ca_topic_score_codex":0.0008828936,"about_ca_topic_score_gemma":0.0012010118,"teacher_disagreement_score":0.0043012416,"about_ca_system_score_codex":0.0004542674,"about_ca_system_score_gemma":0.00060327735,"threshold_uncertainty_score":0.014389098},"labels":[],"label_agreement":null},{"id":"W4200262298","doi":"10.1158/1535-7163.targ-21-p035","title":"Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Medicine; Pharmacokinetics; MEK inhibitor; Internal medicine; Dosing; Cancer; Oncology; Gastroenterology; Pharmacology; Kinase; MAPK/ERK pathway","score_opus":0.03730481211282161,"score_gpt":0.3268553980221237,"score_spread":0.2895505859093021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200262298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946313,0.0006082369,0.00040318188,0.00027705397,0.00007047907,0.0015765477,0.0012515389,0.00009066606,0.0010909513],"genre_scores_gemma":[0.99154025,0.00055204175,0.0010103557,0.0005780279,0.00012936634,0.0015466847,0.0023254508,0.000026944152,0.0022908046],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954236,0.0001934192,0.00002746333,0.00009182904,0.00004505087,0.00009992581],"domain_scores_gemma":[0.9994523,0.00006011987,0.0000836718,0.00003494882,0.000035601504,0.0003334212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001247656,0.0014252192,0.0017135596,0.00040047936,0.00047391173,0.0010092133,0.0008152149,0.0010259188,0.0041576456],"category_scores_gemma":[0.00067212636,0.00048362912,0.0012911113,0.00045617434,0.0009092903,0.0007238725,0.00037812802,0.0030384304,0.0008572205],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.795603,0.07210412,0.008338307,0.00049426046,0.0010290795,0.00049749797,0.00024999978,0.002389676,0.05710321,0.00023494942,0.0057480684,0.056207824],"study_design_scores_gemma":[0.40997294,0.5648303,0.016645025,0.00002056775,0.00041987692,0.00030521184,0.000052021,0.0015806354,0.0041603446,0.00013897731,0.0018418105,0.00003230766],"about_ca_topic_score_codex":0.0017976664,"about_ca_topic_score_gemma":0.00330531,"teacher_disagreement_score":0.0041576456,"about_ca_system_score_codex":0.0010838278,"about_ca_system_score_gemma":0.002306717,"threshold_uncertainty_score":0.013908684},"labels":[],"label_agreement":null},{"id":"W4200263052","doi":"10.1158/1535-7163.targ-21-p072","title":"Abstract P072: Combining ATR inhibitors with carboplatin in chemoresistant TNBC conditionally reprogrammed cells and patient-derived xenografts","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carboplatin; Triple-negative breast cancer; Cancer research; Medicine; Chemotherapy; Breast cancer; Cancer; Oncology; Internal medicine; Cisplatin","score_opus":0.00993659552053282,"score_gpt":0.23665763558083086,"score_spread":0.22672104006029803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200263052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97840786,0.0016565825,0.008432013,0.0003640143,0.00015005204,0.00036419206,0.0047383304,0.00047670776,0.0054101846],"genre_scores_gemma":[0.97630465,0.0011795751,0.008625887,0.00019724449,0.000015558708,0.00023754434,0.0065228767,0.00013770726,0.006778932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971074,0.000035685098,0.000045462344,0.00006635177,0.000099737554,0.00004200383],"domain_scores_gemma":[0.9998573,0.000030448236,0.000025987016,0.000030758947,0.000023077802,0.0000323331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002910724,0.00037669984,0.00035133408,0.0002411921,0.00016986884,0.0003823874,0.00027621503,0.0004659984,0.0022178148],"category_scores_gemma":[0.00017269798,0.000155313,0.00036155953,0.00023320211,0.00018514946,0.00016333601,0.0001828885,0.001112672,0.0007519499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001038076,0.00008324503,0.00026608523,0.000046153786,0.000011855838,0.00013144854,0.000027248114,0.00021184165,0.9969562,0.00011475703,0.0003324737,0.001714845],"study_design_scores_gemma":[0.000034492656,0.00063513225,0.0024658549,0.000007698767,0.00003535089,0.00074736844,0.000024636758,0.0014969222,0.98802733,0.000027871216,0.0064916736,0.000005671909],"about_ca_topic_score_codex":0.0012371759,"about_ca_topic_score_gemma":0.0011975152,"teacher_disagreement_score":0.0022178148,"about_ca_system_score_codex":0.00031570738,"about_ca_system_score_gemma":0.00026222432,"threshold_uncertainty_score":0.0074194074},"labels":[],"label_agreement":null},{"id":"W4200284612","doi":"10.1158/1535-7163.targ-21-p054","title":"Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent","funders":"","keywords":"In vivo; DNA damage; Kinase; Pharmacology; Cancer research; Chemistry; Biology; Biochemistry; DNA; Genetics","score_opus":0.01768560921090383,"score_gpt":0.292498156566137,"score_spread":0.27481254735523314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200284612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971085,0.0069947583,0.006607254,0.00045605988,0.00012475136,0.0003596367,0.0023102448,0.0011802963,0.010881937],"genre_scores_gemma":[0.98165923,0.0026104916,0.0039007375,0.00019269524,0.0000385582,0.00014073582,0.0027863637,0.000037980364,0.008633271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999292,0.000012679616,0.0000064024966,0.000016054604,0.000019239766,0.000016491018],"domain_scores_gemma":[0.99995244,0.000005103884,0.000012177672,0.0000044304593,0.000005987704,0.000019857305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014450989,0.00064063375,0.00028299564,0.00031045775,0.00011019533,0.00029589335,0.00043729565,0.00031170546,0.0031706763],"category_scores_gemma":[0.00007880225,0.00015165354,0.00020251835,0.00018051807,0.00020576204,0.00022013801,0.00013846147,0.00082843547,0.0008771085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023388537,0.0011160681,0.00029064692,0.00025904324,0.000043269287,0.00023913228,0.00002715424,0.00068915496,0.9572325,0.00026386586,0.0029829843,0.034517404],"study_design_scores_gemma":[0.0012095935,0.02406165,0.006093897,0.000026660171,0.00013318521,0.0021334363,0.000022634631,0.002232595,0.9456578,0.00010723249,0.018299192,0.000022096558],"about_ca_topic_score_codex":0.0006122625,"about_ca_topic_score_gemma":0.0008525898,"teacher_disagreement_score":0.0031706763,"about_ca_system_score_codex":0.0003141641,"about_ca_system_score_gemma":0.00028625468,"threshold_uncertainty_score":0.010606945},"labels":[],"label_agreement":null},{"id":"W4200320387","doi":"10.1158/1535-7163.targ-21-p196","title":"Abstract P196: Novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Profound Medical (Canada)","funders":"","keywords":"In vivo; Conjugate; Linker; Pharmacokinetics; Chemistry; Camptothecin; Drug; Potency; Pharmacology; Combinatorial chemistry; Pharmacodynamics; In vitro; Biochemistry; Medicine; Biology","score_opus":0.04894244771709914,"score_gpt":0.32794026793012554,"score_spread":0.2789978202130264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810827,0.0014474707,0.012115325,0.00018744593,0.00004948072,0.00010527507,0.0004950057,0.00015694318,0.004360383],"genre_scores_gemma":[0.98606306,0.0006034195,0.0072316974,0.000101684396,0.000016097709,0.000048957336,0.00048752705,0.000038011978,0.0054095984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993956,0.0000076181614,0.0000050657522,0.00001327424,0.000020936634,0.00001350607],"domain_scores_gemma":[0.9999435,0.0000058063297,0.000024872665,0.0000038423937,0.000008821704,0.000013131846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092107475,0.00035665274,0.00011516332,0.000104159495,0.000071614675,0.0001842325,0.0001593284,0.00023933084,0.0020823346],"category_scores_gemma":[0.00009250498,0.00008671107,0.000108059656,0.00011655867,0.00015936318,0.00025121603,0.00018003881,0.00034909215,0.00035065215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006374103,0.000023675202,0.000048305195,0.00002772913,0.0000025382187,0.000052689487,0.000004894869,0.00015874532,0.9975356,0.00019075707,0.000068341564,0.0018230085],"study_design_scores_gemma":[0.00002375044,0.00023056792,0.00047705512,0.000002180626,0.0000052127484,0.00013846265,0.0000027304657,0.0004430046,0.9955408,0.000024044362,0.003108627,0.0000034993768],"about_ca_topic_score_codex":0.00024719234,"about_ca_topic_score_gemma":0.00032117587,"teacher_disagreement_score":0.0020823346,"about_ca_system_score_codex":0.00022570064,"about_ca_system_score_gemma":0.00016006693,"threshold_uncertainty_score":0.0069661736},"labels":[],"label_agreement":null},{"id":"W4200320597","doi":"10.1158/1535-7163.targ-21-p239","title":"Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Internal medicine; Pharmacodynamics; Cancer; Pharmacokinetics; Gastroenterology; Oncology; Adverse effect; Pharmacology; Immunotherapy","score_opus":0.01232018435498204,"score_gpt":0.3024308497985526,"score_spread":0.29011066544357056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971083,0.0010428204,0.00017585282,0.000103938066,0.000027189239,0.00035882866,0.00033416826,0.000031107964,0.00081774197],"genre_scores_gemma":[0.9972687,0.000522982,0.0003936378,0.00016174579,0.000047392772,0.00031479372,0.0005390789,0.000010530175,0.0007410738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997931,0.00006540995,0.000014353045,0.000052849235,0.00003274862,0.000041529103],"domain_scores_gemma":[0.9997658,0.00002332638,0.000038322865,0.000018004543,0.00001713908,0.00013729472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004906001,0.0008119282,0.0013304859,0.00020447103,0.00040619285,0.00074464746,0.0004319787,0.00049787934,0.0024677352],"category_scores_gemma":[0.00036847248,0.00029589812,0.0006512987,0.0002765083,0.00049731776,0.00038195096,0.00023928362,0.0017395531,0.0008051597],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5321897,0.08577164,0.021380035,0.001158661,0.001860579,0.0012116474,0.00038547372,0.0049530743,0.16147065,0.00018704298,0.007172159,0.18225938],"study_design_scores_gemma":[0.22266808,0.69747555,0.04360189,0.00006586501,0.0009062708,0.0014281148,0.00013760752,0.0038034627,0.023538003,0.0002157648,0.006097144,0.00006227624],"about_ca_topic_score_codex":0.0012796334,"about_ca_topic_score_gemma":0.0017263743,"teacher_disagreement_score":0.0024677352,"about_ca_system_score_codex":0.00094880036,"about_ca_system_score_gemma":0.0011097112,"threshold_uncertainty_score":0.0082553625},"labels":[],"label_agreement":null},{"id":"W4200326442","doi":"10.1158/1535-7163.targ-21-lba026","title":"Abstract LBA026: Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital","funders":"","keywords":"Survivin; Immune system; T cell; Medicine; Antigen; Ovarian cancer; ELISPOT; Cancer research; Immunology; Cancer; Internal medicine","score_opus":0.016343360451750596,"score_gpt":0.2675560092356468,"score_spread":0.2512126487838962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200326442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972287,0.00082869816,0.00079067395,0.00007507287,0.00004736024,0.000030978194,0.00009607004,0.000052705833,0.0008498977],"genre_scores_gemma":[0.9971961,0.0002117207,0.00053598627,0.0000637152,0.000013216854,0.000023645078,0.00017644554,0.000010513044,0.0017686866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999244,0.0000126897885,0.000005897024,0.000019087218,0.000018457267,0.0000195144],"domain_scores_gemma":[0.9999534,0.0000073060905,0.0000097672355,0.0000034040174,0.000007114617,0.000018958004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011420218,0.00022836118,0.00020914736,0.00012845412,0.00008310712,0.00025444443,0.00010203281,0.00025230434,0.0018925716],"category_scores_gemma":[0.00014771812,0.00009747296,0.00013807451,0.00009496713,0.000122043486,0.00015405606,0.0001303321,0.0006537377,0.00041692393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008895861,0.00025869033,0.00030118012,0.000042682663,0.000007486102,0.00005877515,0.000026704192,0.0001532479,0.9929121,0.000041973428,0.00031840763,0.004989117],"study_design_scores_gemma":[0.00042657505,0.015168623,0.0064998884,0.000012398973,0.00005501946,0.00058152515,0.000064664826,0.00276435,0.9697534,0.00005592939,0.004607806,0.000009823458],"about_ca_topic_score_codex":0.0007084838,"about_ca_topic_score_gemma":0.0004985542,"teacher_disagreement_score":0.0018925716,"about_ca_system_score_codex":0.00019133605,"about_ca_system_score_gemma":0.00015191769,"threshold_uncertainty_score":0.006331265},"labels":[],"label_agreement":null},{"id":"W4200371948","doi":"10.1158/1535-7163.targ-21-p064","title":"Abstract P064: Novel engineering of therapeutic <i>Fusobacterium nucleatum</i> phage for colorectal cancer treatment","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bacteriophages and microbial interactions","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brantford Energy (Canada)","funders":"","keywords":"Fusobacterium nucleatum; Biology; Computational biology; Genome; Gene; Bacteria; Genetics","score_opus":0.01874106915550633,"score_gpt":0.26708564430504544,"score_spread":0.24834457514953912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200371948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592791,0.0019273588,0.030896973,0.00022507794,0.00016730042,0.00020048326,0.00041750024,0.00039360524,0.006492462],"genre_scores_gemma":[0.97207975,0.0008554679,0.023259496,0.00006369584,0.00001967213,0.00011903015,0.00032526124,0.00006759004,0.0032100126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989426,0.000011701149,0.0000049454156,0.000021625752,0.00003925939,0.00002829728],"domain_scores_gemma":[0.99994314,0.000007648786,0.000017697708,0.000003161923,0.000011588997,0.000016814278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014366684,0.00040828495,0.00029343355,0.00020290937,0.00021251074,0.00039501145,0.00026202414,0.00043466408,0.0011696272],"category_scores_gemma":[0.00014300083,0.000122614,0.00037262257,0.00017257765,0.00013083951,0.00016168697,0.0002559303,0.000384367,0.0003617254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018006926,0.00011513172,0.00031429384,0.00013914487,0.000015662235,0.00014134646,0.000021801256,0.0040084124,0.985754,0.00048281607,0.00040650074,0.008420928],"study_design_scores_gemma":[0.000047390702,0.0008378685,0.0011805291,0.000017601495,0.000045616023,0.00019173148,0.000024465655,0.026324669,0.96189994,0.0001287514,0.00928183,0.000019657395],"about_ca_topic_score_codex":0.00083092466,"about_ca_topic_score_gemma":0.0008377255,"teacher_disagreement_score":0.0011696272,"about_ca_system_score_codex":0.0004797431,"about_ca_system_score_gemma":0.00022053528,"threshold_uncertainty_score":0.003912747},"labels":[],"label_agreement":null},{"id":"W4200442084","doi":"10.1158/1535-7163.targ-21-lba030","title":"Abstract LBA030: DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Université Laval","funders":"","keywords":"Survivin; Immunotherapy; Immunogenicity; Bladder cancer; Cystectomy; T cell; Cancer immunotherapy; Medicine; Cancer research; Antigen; Immune system; Immunology; Major histocompatibility complex; Cancer; Internal medicine","score_opus":0.04251056014399972,"score_gpt":0.30769736813059273,"score_spread":0.265186807986593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200442084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799279,0.0035980472,0.010176643,0.0002201081,0.00014918279,0.0001521768,0.0008646092,0.00040246098,0.0045088474],"genre_scores_gemma":[0.9890082,0.0009705927,0.0029268079,0.0001075427,0.000015566722,0.00012263411,0.00084896554,0.000023823184,0.0059758034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998946,0.000014689039,0.0000057362263,0.0000252413,0.000028435037,0.000031178773],"domain_scores_gemma":[0.9999608,0.0000039565316,0.000010529099,0.0000042822026,0.000006583176,0.0000139002805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016789879,0.00036059538,0.0002069611,0.00016451236,0.00009861186,0.00018996577,0.00020514202,0.00038867793,0.0018097087],"category_scores_gemma":[0.0000632894,0.00011051693,0.00020641717,0.00012769012,0.00012253464,0.00019334511,0.00012317004,0.00082968245,0.00051634066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041874516,0.00024777153,0.00011798505,0.00009075088,0.000007697422,0.00003030838,0.000013627408,0.00020742501,0.9930935,0.00010401039,0.00041520424,0.00525303],"study_design_scores_gemma":[0.000104904924,0.004073182,0.001313083,0.00001044396,0.000022796112,0.00023189983,0.000013259385,0.0017017799,0.98727244,0.000046778467,0.005204043,0.000005381933],"about_ca_topic_score_codex":0.00051051966,"about_ca_topic_score_gemma":0.00045565242,"teacher_disagreement_score":0.0018097087,"about_ca_system_score_codex":0.00020912442,"about_ca_system_score_gemma":0.00021621477,"threshold_uncertainty_score":0.0060541034},"labels":[],"label_agreement":null},{"id":"W4200454923","doi":"10.1158/1535-7163.targ-21-p175","title":"Abstract P175: Investigating inositol polyphosphate-4-phosphatase, type II (INPP4B) signaling and role in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gene knockdown; Lysosome; Myeloid leukemia; Biology; Cancer research; Leukemia; Inositol; Cell biology; Gene; Biochemistry; Immunology; Enzyme; Receptor","score_opus":0.01787392291850707,"score_gpt":0.26711645911801035,"score_spread":0.2492425361995033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200454923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633076,0.024768358,0.0034058283,0.0010122316,0.00016598063,0.00016343492,0.0017269595,0.00013096095,0.0053187297],"genre_scores_gemma":[0.9769155,0.010910909,0.00295721,0.00041107592,0.00007420294,0.00012884218,0.0018766721,0.000027731367,0.006697958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999219,0.000013358264,0.000005782135,0.000016230091,0.000020535548,0.000022121601],"domain_scores_gemma":[0.9999504,0.000005710406,0.000010966391,0.0000026332796,0.000009102492,0.000021221975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020443751,0.00037857474,0.00027702918,0.00036339255,0.0002631071,0.00039171433,0.00026242615,0.0004156974,0.0025462129],"category_scores_gemma":[0.00009683641,0.00010301839,0.00028368394,0.00035408107,0.00022024992,0.00023238065,0.00019340799,0.00048730636,0.0008139733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000577092,0.00007762042,0.0013977959,0.0002964454,0.00001760831,0.00026509305,0.000028559092,0.000118675955,0.99060893,0.00024130968,0.0004752188,0.00589563],"study_design_scores_gemma":[0.00018449097,0.0020068435,0.034402,0.00005725591,0.00012913135,0.0018151903,0.0002468576,0.0014927974,0.92454463,0.00047036767,0.034636322,0.0000141035825],"about_ca_topic_score_codex":0.0005066738,"about_ca_topic_score_gemma":0.00049892307,"teacher_disagreement_score":0.0025462129,"about_ca_system_score_codex":0.000429812,"about_ca_system_score_gemma":0.00036204726,"threshold_uncertainty_score":0.008517981},"labels":[],"label_agreement":null},{"id":"W4200466845","doi":"10.1158/1535-7163.mct-21-0519","title":"Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Cancer Research Society","keywords":"Prostate cancer; Prostate; Cancer; Senescence; Cell growth; Cancer cell; Phenotype","score_opus":0.017693203283027186,"score_gpt":0.2687015989948471,"score_spread":0.2510083957118199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200466845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135804,0.0042710393,0.0024401068,0.00010293067,0.000025073437,0.00003370208,0.00014032495,0.000104840954,0.0015239626],"genre_scores_gemma":[0.99540013,0.0018101408,0.0009003158,0.000028358725,0.000006895489,0.000021880887,0.00014103959,0.0000071316435,0.0016841782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991333,0.000013944244,0.000007996348,0.0000160156,0.000025302264,0.00002344312],"domain_scores_gemma":[0.9999552,0.0000066851567,0.000013947621,0.000005684776,0.0000034341786,0.0000150194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015079083,0.00032322257,0.00023374459,0.0002303156,0.00015730796,0.00023438217,0.00020452465,0.00016811152,0.0007399885],"category_scores_gemma":[0.00006457539,0.00012125341,0.00020512207,0.00016562025,0.0001660928,0.00013920148,0.00014544578,0.0004937716,0.0001818268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107139334,0.000063172614,0.00027430805,0.000059645725,0.000005863127,0.000052205483,0.000011733196,0.00012246481,0.99687684,0.00009190466,0.00003187698,0.0023028133],"study_design_scores_gemma":[0.000029697232,0.00082974986,0.005591539,0.000006571541,0.000024848629,0.00054646423,0.000020983995,0.00062249915,0.99019027,0.00006342737,0.002069879,0.0000040055756],"about_ca_topic_score_codex":0.00055907696,"about_ca_topic_score_gemma":0.0013568973,"teacher_disagreement_score":0.0007399885,"about_ca_system_score_codex":0.00027980842,"about_ca_system_score_gemma":0.0002657943,"threshold_uncertainty_score":0.0024755},"labels":[],"label_agreement":null},{"id":"W4200468047","doi":"10.1158/1535-7163.targ-21-cc04-01","title":"Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Zygosity; Germline; Medicine; Internal medicine; Neutropenia; Biomarker; Cancer research; Oncology; Biology; Genetics; Chemotherapy; Gene","score_opus":0.010232009975896364,"score_gpt":0.30269688500943903,"score_spread":0.2924648750335427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200468047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928543,0.0008707574,0.00043713255,0.00027451906,0.000042629126,0.0013268186,0.0017966363,0.00016855919,0.0022287148],"genre_scores_gemma":[0.9878131,0.0005402477,0.0013904786,0.00058816746,0.000066475404,0.0013133812,0.0037484516,0.000042244024,0.0044974],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980193,0.00007210001,0.000009609815,0.00004113247,0.000025284635,0.00004993584],"domain_scores_gemma":[0.9997613,0.00002359453,0.000043540414,0.000018022982,0.000017591416,0.00013592107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005659981,0.0009778575,0.00077398354,0.0003088971,0.00027242902,0.00068070483,0.0005094621,0.00072290696,0.005917001],"category_scores_gemma":[0.00038577424,0.00025979898,0.00046255972,0.00025835153,0.0004156683,0.00035959826,0.00026769022,0.0013491645,0.0011031312],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4806394,0.043911226,0.0189339,0.0012332248,0.0013695777,0.0007681898,0.00037187588,0.0059099803,0.2485105,0.00085576205,0.015229243,0.18226713],"study_design_scores_gemma":[0.2414735,0.6856776,0.036505368,0.00008148851,0.00070033537,0.0013072689,0.00011186937,0.0029764578,0.020165745,0.0003508399,0.010587494,0.00006205873],"about_ca_topic_score_codex":0.00085454714,"about_ca_topic_score_gemma":0.002608316,"teacher_disagreement_score":0.005917001,"about_ca_system_score_codex":0.00088573864,"about_ca_system_score_gemma":0.0009715067,"threshold_uncertainty_score":0.019794405},"labels":[],"label_agreement":null},{"id":"W4200471492","doi":"10.1158/1535-7163.targ-21-lba029","title":"Abstract LBA029: Development of computational tools for evaluating differential protein expression relative to spatial oxygen gradients using imaging mass cytometry","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Hypoxia (environmental); Tumor hypoxia; Biology; Mass cytometry; Flow cytometry; Immunohistochemistry; Pathology; Cancer research; Phenotype; Chemistry; Immunology; Medicine; Radiation therapy; Oxygen; Internal medicine; Gene; Biochemistry","score_opus":0.05323106642199492,"score_gpt":0.34676904839407935,"score_spread":0.2935379819720844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200471492","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0379796,0.0006399497,0.75157905,0.0008423826,0.0004300131,0.0005264268,0.014296181,0.18681817,0.006888252],"genre_scores_gemma":[0.14390308,0.0006256359,0.8032794,0.0011065591,0.00012467775,0.0029030752,0.022720065,0.019681487,0.005656011],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950504,0.00010165623,0.000039916475,0.00013180071,0.00016843328,0.000053096264],"domain_scores_gemma":[0.998752,0.0007999202,0.00007605302,0.00008371363,0.00019009547,0.000098171215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00225957,0.0020019277,0.0016939241,0.0012320922,0.00090929243,0.0022290312,0.0038654834,0.0016041449,0.01897568],"category_scores_gemma":[0.004230868,0.0009977487,0.0020885456,0.0008994773,0.00087622716,0.0013595737,0.0017790351,0.002436246,0.0049734437],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019819145,0.001050127,0.016242007,0.0031073387,0.0013222874,0.001082644,0.00069459644,0.55893177,0.045845322,0.04438827,0.14450835,0.18084547],"study_design_scores_gemma":[0.00010708786,0.00003159889,0.0004633866,0.000030288911,0.000026672731,0.000036245412,0.000026733289,0.9798535,0.0042239195,0.0059162215,0.0092544705,0.000029832867],"about_ca_topic_score_codex":0.008725223,"about_ca_topic_score_gemma":0.008275271,"teacher_disagreement_score":0.01897568,"about_ca_system_score_codex":0.0013573839,"about_ca_system_score_gemma":0.0023811269,"threshold_uncertainty_score":0.06347996},"labels":[],"label_agreement":null},{"id":"W4200494616","doi":"10.1158/1535-7163.targ-21-lba018","title":"Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; Medicine; Cancer; Epitope; In vivo; Immunology; Monoclonal antibody; Biology; Internal medicine","score_opus":0.07663870833426535,"score_gpt":0.3582199704934611,"score_spread":0.28158126215919577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200494616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371559,0.02319444,0.01781479,0.0010318239,0.00027860666,0.00037496793,0.0016222191,0.00063601055,0.017891238],"genre_scores_gemma":[0.9696092,0.006719149,0.009712411,0.00056270655,0.000066336084,0.00017696338,0.0018653867,0.000044604923,0.011243184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993896,0.000010241569,0.0000034305287,0.000009099558,0.000017987135,0.000020276664],"domain_scores_gemma":[0.9999645,0.000003226933,0.0000055319492,0.0000018835048,0.000008520155,0.00001649802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013623145,0.00037372328,0.00016045844,0.00030085232,0.00009679237,0.00023306296,0.00022886973,0.00035168245,0.0015973762],"category_scores_gemma":[0.000090725975,0.00009384222,0.0002256049,0.00013763677,0.00007665778,0.00013256882,0.00017319864,0.0004831635,0.0006099746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001609499,0.000113635644,0.00029611716,0.00013607462,0.00001487854,0.0001731382,0.000020959425,0.00029072832,0.97788507,0.00026577915,0.0011169547,0.019525575],"study_design_scores_gemma":[0.00021178984,0.0023261032,0.002960353,0.000041962572,0.00006385854,0.0012797912,0.000020809543,0.0024333184,0.95483124,0.00013385434,0.035679698,0.000017112518],"about_ca_topic_score_codex":0.00048254122,"about_ca_topic_score_gemma":0.00057856244,"teacher_disagreement_score":0.0015973762,"about_ca_system_score_codex":0.00027169546,"about_ca_system_score_gemma":0.0001785823,"threshold_uncertainty_score":0.005343735},"labels":[],"label_agreement":null},{"id":"W4200501854","doi":"10.1158/1535-7163.targ-21-p230","title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"T790M; Osimertinib; Medicine; Epidermal growth factor receptor; Exon; Cancer research; EGFR inhibitors; Mutant; Lung cancer; Mutation; Gefitinib; Cancer; Oncology; Internal medicine; Erlotinib; Gene; Biology; Genetics","score_opus":0.010582206417046503,"score_gpt":0.289737410597893,"score_spread":0.2791552041808465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200501854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747677,0.0052289614,0.0021610812,0.0008892143,0.00022991047,0.005509057,0.004512989,0.0005703291,0.0061307615],"genre_scores_gemma":[0.97645026,0.0029888023,0.0022626163,0.0013268548,0.00014301963,0.0028794457,0.0053198347,0.00011191255,0.0085172085],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996923,0.00009890258,0.000011396147,0.000068992864,0.000038696173,0.000089582594],"domain_scores_gemma":[0.9997317,0.000024325376,0.0000312747,0.000015647727,0.000023453957,0.0001736275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010370471,0.001912867,0.0014702219,0.0004909575,0.00048431972,0.0013175431,0.0011883242,0.0012330149,0.0055519072],"category_scores_gemma":[0.00048422578,0.00066484226,0.0011580961,0.0003808808,0.00078385766,0.0008398784,0.00032610638,0.0028197356,0.0016692708],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38185507,0.11406201,0.008718358,0.0019404527,0.0032250897,0.0014855013,0.0006550137,0.007006511,0.21321368,0.0011621146,0.029452568,0.2372237],"study_design_scores_gemma":[0.37301138,0.58544374,0.01196823,0.000055882443,0.0009485883,0.0010199959,0.0001400255,0.002718438,0.01598053,0.00045177687,0.0081809545,0.00008046081],"about_ca_topic_score_codex":0.0027407426,"about_ca_topic_score_gemma":0.005468279,"teacher_disagreement_score":0.0055519072,"about_ca_system_score_codex":0.0010181527,"about_ca_system_score_gemma":0.0018336707,"threshold_uncertainty_score":0.018572986},"labels":[],"label_agreement":null},{"id":"W4200504528","doi":"10.1158/1535-7163.mct-21-0615","title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","year":2021,"lang":"en","type":"letter","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent; Telesta Therapeutics (Canada); Aegera Therapeutics (Canada)","funders":"","keywords":"Kinase; Olaparib; Pharmacology; In vivo; DNA damage; PARP inhibitor; PI3K/AKT/mTOR pathway; Cancer research; Chemistry; Biology; Biochemistry; Signal transduction; DNA; Poly ADP ribose polymerase","score_opus":0.04383461660618057,"score_gpt":0.33004020380099386,"score_spread":0.28620558719481326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200504528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96257234,0.011961071,0.00947498,0.00044642412,0.00013522837,0.00054024276,0.0025465582,0.0019528687,0.010370366],"genre_scores_gemma":[0.9768876,0.005372581,0.008042499,0.00023473274,0.00004886806,0.00027907788,0.0035129634,0.00006520804,0.005556362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989474,0.000018686662,0.000008072177,0.000025516489,0.000029754174,0.00002309985],"domain_scores_gemma":[0.9999366,0.0000065175873,0.000018027671,0.000006624102,0.0000073675046,0.000024869054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022573207,0.0007816066,0.00048718354,0.0004994927,0.00014553138,0.00035206118,0.00056850654,0.00043383494,0.0021360402],"category_scores_gemma":[0.00009581527,0.00026057742,0.0002761329,0.00026665602,0.00024182991,0.00038589473,0.0001509688,0.00092705013,0.0006746417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001698165,0.001375921,0.0002454688,0.00023913627,0.000044584875,0.00015723928,0.000024603845,0.0008382381,0.9600377,0.0002707196,0.002253439,0.032814693],"study_design_scores_gemma":[0.0018854156,0.046029754,0.008392169,0.00004561155,0.00023314872,0.0030304901,0.00002889004,0.0043288325,0.9096185,0.00016000666,0.0261994,0.000047747053],"about_ca_topic_score_codex":0.00056463486,"about_ca_topic_score_gemma":0.0015024545,"teacher_disagreement_score":0.0021360402,"about_ca_system_score_codex":0.00032750904,"about_ca_system_score_gemma":0.0003537563,"threshold_uncertainty_score":0.007145822},"labels":[],"label_agreement":null},{"id":"W4200516710","doi":"10.1158/1535-7163.targ-21-p061","title":"Abstract P061: <i>De novo</i> design of importin-<i>a</i>-specific NLS sequences for nuclear-targeted therapeutics","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"NLS; Nuclear localization sequence; Importin; Nuclear transport; In silico; Computational biology; Amino acid; Chemistry; Biology; Biochemistry; Cell biology; Cell nucleus; Gene","score_opus":0.029122613546647753,"score_gpt":0.2737225353320046,"score_spread":0.24459992178535683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200516710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55389065,0.00050920545,0.43067607,0.00037625924,0.00013757119,0.0006630963,0.00087929127,0.0017777941,0.011090051],"genre_scores_gemma":[0.69957113,0.00048507593,0.29480088,0.00013216631,0.000019018005,0.00048797939,0.0010447627,0.0002692855,0.0031896783],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999002,0.000018121318,0.0000061543187,0.000023168415,0.00003275269,0.00001954246],"domain_scores_gemma":[0.9998549,0.00004229156,0.000035417022,0.000011817147,0.00003414224,0.000021402682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003812154,0.00045840137,0.00044458944,0.00022642402,0.00024088206,0.00066802395,0.00056213146,0.00058411126,0.002633363],"category_scores_gemma":[0.0005058983,0.0002839884,0.0005314309,0.00020329241,0.00025144508,0.00033919053,0.00034517143,0.00063391577,0.0007549195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047465917,0.00043097735,0.0024571472,0.0006034798,0.00009326901,0.00071792543,0.00009468675,0.62909544,0.31800056,0.010879215,0.0017792404,0.035373364],"study_design_scores_gemma":[0.000100808575,0.00047894302,0.0003972933,0.000023123435,0.000042768814,0.00016227385,0.000041840198,0.8940453,0.09672038,0.0012539157,0.006710194,0.000023155235],"about_ca_topic_score_codex":0.00076639245,"about_ca_topic_score_gemma":0.0008367546,"teacher_disagreement_score":0.002633363,"about_ca_system_score_codex":0.00059862883,"about_ca_system_score_gemma":0.00078788254,"threshold_uncertainty_score":0.008809447},"labels":[],"label_agreement":null},{"id":"W4200523372","doi":"10.1158/1535-7163.targ-21-p246","title":"Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Street Contxt (Canada)","funders":"","keywords":"Cancer research; Allosteric regulation; Mutation; Fibroblast growth factor receptor 1; Gene; Cancer; Biology; Drug discovery; Genetics; Bioinformatics; Fibroblast growth factor; Receptor","score_opus":0.02203547535401564,"score_gpt":0.3028328847848733,"score_spread":0.2807974094308577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200523372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95296174,0.010289571,0.017823275,0.00090733985,0.0001772575,0.0010711375,0.0050936365,0.0004916174,0.011184492],"genre_scores_gemma":[0.9636506,0.0049139797,0.01590849,0.00040097724,0.000050750983,0.00040389982,0.005058684,0.00011671696,0.00949593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998361,0.000017973965,0.000011682707,0.00003620606,0.00007173137,0.000026260483],"domain_scores_gemma":[0.99991596,0.00000740561,0.000017805962,0.000008095893,0.000018559873,0.000032227643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002438189,0.000644319,0.0003915206,0.0005054236,0.00020795049,0.0004509554,0.00055480475,0.0004547464,0.0027552343],"category_scores_gemma":[0.0002767388,0.00015726582,0.00040606858,0.00038113564,0.00019335176,0.00019980627,0.0002408081,0.0006926351,0.0009395673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004283174,0.00030577029,0.0005991469,0.00015917118,0.00004609512,0.0003942749,0.000026826317,0.0018863291,0.97240126,0.0005169914,0.0016965171,0.021539321],"study_design_scores_gemma":[0.00072569656,0.0057022125,0.0030621295,0.000031237174,0.000109615525,0.0020232,0.000029991805,0.0045368364,0.95439845,0.00036026878,0.028984785,0.000035687688],"about_ca_topic_score_codex":0.0006872126,"about_ca_topic_score_gemma":0.00095563225,"teacher_disagreement_score":0.0027552343,"about_ca_system_score_codex":0.0003673813,"about_ca_system_score_gemma":0.0005130945,"threshold_uncertainty_score":0.009217143},"labels":[],"label_agreement":null},{"id":"W4200525569","doi":"10.1158/1535-7163.targ-21-lba013","title":"Abstract LBA013: Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Drug resistance; Oncology; Midostaurin; Population; Medicine; Cancer; Internal medicine; Cancer research; Biology; Pharmacology; Genetics","score_opus":0.015226976321128209,"score_gpt":0.28659163156104833,"score_spread":0.27136465523992015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200525569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749124,0.00046520503,0.0007228951,0.00004645418,0.000004626621,0.000016741025,0.0008389986,0.000047842437,0.0003660147],"genre_scores_gemma":[0.9968424,0.00011447036,0.0013522028,0.000028183345,0.000005683419,0.000018673536,0.0013319481,0.0000072138596,0.00029925452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988735,0.000018634684,0.0000118042735,0.0000303294,0.000030841766,0.000020946325],"domain_scores_gemma":[0.9998678,0.000029357137,0.000043193497,0.000006374298,0.000018483664,0.000034854056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025849938,0.0002560416,0.00038229628,0.00072606327,0.00015761306,0.00042185432,0.00013129607,0.00021059632,0.0016186676],"category_scores_gemma":[0.000349188,0.000081030514,0.00022335011,0.00047813568,0.00013532385,0.00016384562,0.00019508248,0.00021174419,0.0004395106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005317366,0.00019872216,0.16097188,0.00018165473,0.000121397556,0.00030170285,0.000044898556,0.0012550344,0.80518466,0.000059170146,0.0006443694,0.025719069],"study_design_scores_gemma":[0.00011616607,0.0012947575,0.78566235,0.000018323295,0.0002007633,0.0020968632,0.000086813234,0.017683668,0.1911036,0.00020000139,0.0015150261,0.00002171393],"about_ca_topic_score_codex":0.00058377313,"about_ca_topic_score_gemma":0.0007192399,"teacher_disagreement_score":0.0016186676,"about_ca_system_score_codex":0.00026705497,"about_ca_system_score_gemma":0.00015664713,"threshold_uncertainty_score":0.005414963},"labels":[],"label_agreement":null},{"id":"W4200541805","doi":"10.1158/1535-7163.targ-21-p229","title":"Abstract P229: Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stornoway Diamond (Canada)","funders":"","keywords":"Cancer research; Mutation; Allosteric regulation; Mutant; Oncogene; In vivo; HEK 293 cells; V600E; Biology; Cancer; Chemistry; Computational biology; Cell culture; Gene; Genetics; Cell cycle; Receptor","score_opus":0.12276256465408687,"score_gpt":0.40031708090822754,"score_spread":0.2775545162541407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200541805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96018785,0.006904779,0.0076435604,0.0013440561,0.00034402765,0.0019895504,0.003885674,0.0006766126,0.01702393],"genre_scores_gemma":[0.9774655,0.003198875,0.0039392943,0.0007912506,0.00006452117,0.00071812375,0.0033931162,0.00009015745,0.010339137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988663,0.000020507485,0.0000054498646,0.000021504698,0.000031035772,0.00003481375],"domain_scores_gemma":[0.99990284,0.000010635775,0.000012723518,0.000007396902,0.000016917731,0.00004942589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003335884,0.0005511603,0.00054153084,0.00018232297,0.00021255168,0.00076079165,0.00043353892,0.0005925462,0.005249655],"category_scores_gemma":[0.00024059492,0.0001921029,0.00031207327,0.00013193802,0.00023710457,0.0003658426,0.00022522428,0.0014494495,0.0015695057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013592731,0.010118899,0.0023987219,0.00055119745,0.00025710452,0.000905358,0.00017293147,0.0035943924,0.8297977,0.0009974074,0.012989832,0.124623775],"study_design_scores_gemma":[0.014043238,0.22510968,0.015416158,0.00012220895,0.00046354797,0.003946549,0.00018076545,0.011118003,0.64295894,0.00082826894,0.08572417,0.00008849178],"about_ca_topic_score_codex":0.00076223974,"about_ca_topic_score_gemma":0.0024222084,"teacher_disagreement_score":0.005249655,"about_ca_system_score_codex":0.0005138233,"about_ca_system_score_gemma":0.0007011747,"threshold_uncertainty_score":0.017561853},"labels":[],"label_agreement":null},{"id":"W4200563501","doi":"10.1158/1535-7163.targ-21-lba021","title":"Abstract LBA021: Immune resistance interrogation study (IRIS): Initial report of next generation sequencing (NGS) results in patients with primary versus acquired resistance to anti-PD1/L1 antibodies","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Antibody; Cancer; Biopsy; Liquid biopsy; Internal medicine; Oncology; Pathology; Immunology","score_opus":0.03779555001429525,"score_gpt":0.29310929680525416,"score_spread":0.2553137467909589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200563501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946548,0.00028317078,0.00031715378,0.00011311336,0.000008662589,0.00007566536,0.0027377363,0.00002189484,0.0017878078],"genre_scores_gemma":[0.99695337,0.000033992776,0.0002595241,0.00010534112,0.000012428427,0.000045402157,0.0021800196,0.00000867951,0.00040123795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992124,0.0001995129,0.00008588843,0.00026168837,0.00015368263,0.00008681819],"domain_scores_gemma":[0.9987294,0.00038020284,0.00042660933,0.0001009375,0.00017634091,0.00018657383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011491292,0.00019724236,0.0003785121,0.00039256533,0.0002762161,0.0007163409,0.0002110476,0.0004530097,0.002505188],"category_scores_gemma":[0.0025057492,0.00015518023,0.00024982324,0.00038811826,0.0002291136,0.00030261488,0.00035543067,0.0004854232,0.00056614703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006050476,0.00014637677,0.97504437,0.000056699006,0.000080412654,0.0007472163,0.00014847897,0.00016822848,0.008701408,0.00007125919,0.0015126428,0.007272421],"study_design_scores_gemma":[0.00026826115,0.0018948483,0.98811996,0.000022579956,0.00009869218,0.0034367072,0.0001663463,0.0009409423,0.0029514497,0.00007192927,0.0020143334,0.000014004045],"about_ca_topic_score_codex":0.0007465606,"about_ca_topic_score_gemma":0.000772196,"teacher_disagreement_score":0.002505188,"about_ca_system_score_codex":0.00047906613,"about_ca_system_score_gemma":0.00017467803,"threshold_uncertainty_score":0.0083806515},"labels":[],"label_agreement":null},{"id":"W4200592628","doi":"10.1158/1535-7163.targ-21-p062","title":"Abstract P062: The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Linker; Cytotoxicity; Chemistry; Conjugate; Trastuzumab; Conjugated system; Antibody-drug conjugate; Internalization; Prodrug; Endosome; Cancer cell; Biophysics; Combinatorial chemistry; Biochemistry; Monoclonal antibody; Cancer; In vitro; Antibody; Biology; Intracellular; Cell","score_opus":0.03613944612334209,"score_gpt":0.33726379957734026,"score_spread":0.3011243534539982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200592628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961689,0.00039743102,0.001328598,0.000052802887,0.000020374458,0.000017218055,0.0002621703,0.000094278126,0.0016581768],"genre_scores_gemma":[0.99362355,0.0001721825,0.0012654113,0.000026621277,0.0000049441956,0.000015047736,0.00049767544,0.000027469889,0.004367107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.00001421323,0.000008763283,0.00003272329,0.000037312766,0.00003129179],"domain_scores_gemma":[0.99993217,0.00000898038,0.000018572056,0.000006047875,0.00001657702,0.000017647963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010790335,0.00027825584,0.00014624208,0.000120699464,0.00008514312,0.00019411262,0.00018986111,0.00026040978,0.0029360696],"category_scores_gemma":[0.0001084022,0.00007338677,0.00012083224,0.00013084638,0.00011699998,0.00019866001,0.00009651394,0.00029231273,0.0005259191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026278157,0.000036146925,0.000061001454,0.000017675975,0.0000028122151,0.000029565634,0.000007878633,0.00006863526,0.9984106,0.00003121309,0.000091526534,0.0009800484],"study_design_scores_gemma":[0.000011002611,0.00031552574,0.000433773,0.0000012810902,0.000002216381,0.000039069295,0.0000037068546,0.00045988764,0.9981816,0.0000053675953,0.00054506183,0.0000015625212],"about_ca_topic_score_codex":0.000908778,"about_ca_topic_score_gemma":0.0006369317,"teacher_disagreement_score":0.0029360696,"about_ca_system_score_codex":0.0003289996,"about_ca_system_score_gemma":0.00017371301,"threshold_uncertainty_score":0.00982213},"labels":[],"label_agreement":null},{"id":"W4200594151","doi":"10.1158/1535-7163.targ-21-p251","title":"Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"","keywords":"Allosteric regulation; PI3K/AKT/mTOR pathway; Mutant; Gene isoform; Kinase; Protein kinase B; P110α; Protein kinase domain; Small molecule; Chemistry; Phosphoinositide 3-kinase; Pharmacology; Biochemistry; Biology; Phosphorylation; Enzyme; Signal transduction; Gene","score_opus":0.01830301609038135,"score_gpt":0.28625230891469156,"score_spread":0.2679492928243102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200594151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97772527,0.0028874415,0.012144794,0.00024125558,0.000057273504,0.0002535351,0.0016953443,0.00019182109,0.004803437],"genre_scores_gemma":[0.9765577,0.0015617149,0.010221175,0.00013649334,0.000017768225,0.00012298052,0.0045148106,0.000076885364,0.006790522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999268,0.0000061270625,0.0000052468054,0.00001852605,0.000026199476,0.000017014603],"domain_scores_gemma":[0.9999397,0.000003442973,0.000011752735,0.0000044758817,0.000011432399,0.000029122106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016819041,0.0004154229,0.0002431306,0.00015124456,0.00016029755,0.00025101897,0.00044960575,0.00025914417,0.0011531569],"category_scores_gemma":[0.00017616888,0.00012748427,0.00022093747,0.00017399913,0.000185021,0.00015499492,0.00013417978,0.000493581,0.0008073431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022174264,0.00014894665,0.00046011168,0.0000758247,0.000016605687,0.0002893849,0.00003273394,0.002582091,0.9891972,0.00037484933,0.0008249553,0.0057755997],"study_design_scores_gemma":[0.00012968255,0.0015767105,0.0017921146,0.00001276381,0.00003213823,0.00050712697,0.000020964502,0.007353754,0.9730652,0.00011825322,0.015372995,0.000018282426],"about_ca_topic_score_codex":0.0012506085,"about_ca_topic_score_gemma":0.00091867405,"teacher_disagreement_score":0.0012506085,"about_ca_system_score_codex":0.00040586814,"about_ca_system_score_gemma":0.00038432542,"threshold_uncertainty_score":0.0038577318},"labels":[],"label_agreement":null},{"id":"W4210445101","doi":"10.1158/1535-7163.mct-21-0216","title":"Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"EZH2; Phenotype; Histone methyltransferase; Chromatin remodeling; Chromatin; Acquired resistance; Drug resistance; Immune system","score_opus":0.025262360970294405,"score_gpt":0.28925851494496996,"score_spread":0.2639961539746756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210445101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490803,0.00084220356,0.0011645303,0.00011173127,0.000018937331,0.000027700647,0.0013105765,0.00013794997,0.0014783114],"genre_scores_gemma":[0.99350995,0.0005108099,0.0012069826,0.000083066836,0.0000045485385,0.00003743341,0.0026159114,0.000017760063,0.0020135934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989426,0.000011804141,0.000011045268,0.000021330146,0.000040483294,0.000021018146],"domain_scores_gemma":[0.9999664,0.0000065582726,0.00000755276,0.00000539584,0.00000603969,0.00000803141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008144458,0.00016038623,0.00017736776,0.00013056447,0.000103252954,0.00022968731,0.00010588628,0.0001465739,0.001200328],"category_scores_gemma":[0.000077917306,0.000081848346,0.00017434424,0.00020773825,0.00009049139,0.00007337335,0.00010052335,0.00040147838,0.00031300468],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015098427,0.00005358917,0.0007202689,0.00003879139,0.000010135449,0.00006044611,0.000022228696,0.00024836467,0.995904,0.000087040906,0.0003295382,0.0023745731],"study_design_scores_gemma":[0.0000613934,0.0004871455,0.017130679,0.0000058398837,0.000025885342,0.00026899084,0.000058595233,0.0037319176,0.9728678,0.000057599336,0.005297881,0.000006354156],"about_ca_topic_score_codex":0.0018817273,"about_ca_topic_score_gemma":0.002756711,"teacher_disagreement_score":0.0018817273,"about_ca_system_score_codex":0.00028042076,"about_ca_system_score_gemma":0.00017480584,"threshold_uncertainty_score":0.0040154457},"labels":[],"label_agreement":null},{"id":"W4220863628","doi":"10.1158/1535-7163.mct-21-0550","title":"Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Robert H. Lurie Comprehensive Cancer Center; Hospital for Sick Children; National Cancer Institute; Frederick National Laboratory for Cancer Research","keywords":"KRAS; Pancreatic cancer; Cancer research; In vivo; Cancer; MAPK/ERK pathway; Cell growth; Biology; Medicine; Internal medicine; Signal transduction; Colorectal cancer","score_opus":0.03958382700937004,"score_gpt":0.355408717971385,"score_spread":0.315824890962015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220863628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950047,0.0008702258,0.0017780681,0.00007846431,0.000027282942,0.000049430266,0.0007168574,0.0001057335,0.0013693322],"genre_scores_gemma":[0.9931149,0.0009813191,0.0020132796,0.00005035626,0.0000066948382,0.00004468479,0.0014521092,0.000027052547,0.0023096588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998392,0.00002580006,0.000019363788,0.000032549447,0.000056437268,0.000026631864],"domain_scores_gemma":[0.9998808,0.000028601087,0.000028930917,0.000020989919,0.000015158492,0.00002546076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023603225,0.00029252854,0.00031276068,0.00014107613,0.00009244396,0.0002701516,0.00016407232,0.0002583035,0.0011675896],"category_scores_gemma":[0.00014214666,0.0001290983,0.00021520985,0.00018195358,0.00009294878,0.00015673945,0.00011144769,0.00086203014,0.0003142327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002218552,0.00020381229,0.00036452303,0.000035052348,0.000012466253,0.00006973418,0.000024039462,0.00021857215,0.99625814,0.00006393099,0.00015975151,0.002368168],"study_design_scores_gemma":[0.000038747312,0.0023093706,0.0040482753,0.000006971753,0.00002298276,0.0007672312,0.000030179372,0.0019180315,0.98805004,0.000029979718,0.0027741743,0.0000041097587],"about_ca_topic_score_codex":0.00041467312,"about_ca_topic_score_gemma":0.000679149,"teacher_disagreement_score":0.0011675896,"about_ca_system_score_codex":0.00017689166,"about_ca_system_score_gemma":0.00018135202,"threshold_uncertainty_score":0.0039060116},"labels":[],"label_agreement":null},{"id":"W4225531330","doi":"10.1158/1535-7163.mct-21-0442","title":"Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust; National Institute on Handicapped Research","keywords":"Medicine; Drug; KRAS; Combination therapy; Targeted therapy; EGFR inhibitors; Pharmacology; Oncology; Computational biology; Cancer research; Cancer; Internal medicine; Biology; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.04739014557391607,"score_gpt":0.32061531870945986,"score_spread":0.2732251731355438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225531330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98085004,0.0004738177,0.017960997,0.00008618819,0.000008852669,0.000032105407,0.00009182196,0.00010651879,0.00038954744],"genre_scores_gemma":[0.99224585,0.00016424897,0.00734563,0.000024344334,0.000005193123,0.000016429807,0.000093519775,0.000004001752,0.00010074369],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997749,0.00006918068,0.00002190994,0.000044175926,0.00006942959,0.000020374862],"domain_scores_gemma":[0.99966955,0.0001525147,0.00009806529,0.000028190192,0.000029627176,0.00002196137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005385079,0.0003879773,0.0006003962,0.00047741926,0.00009182194,0.0004282866,0.00014816022,0.00023703133,0.0002568188],"category_scores_gemma":[0.0009356515,0.00017553306,0.00035415837,0.0003172637,0.0001880377,0.00024755154,0.00019989278,0.00037892713,0.000064459906],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018565309,0.00049069425,0.11160327,0.00018798334,0.00037050853,0.00023105463,0.00009746329,0.14557011,0.62905866,0.00040305135,0.00024208818,0.10988854],"study_design_scores_gemma":[0.000029838242,0.0011524466,0.0975025,0.000009044638,0.00014328286,0.00022354195,0.00004305378,0.7603915,0.13936631,0.0006107309,0.0004908531,0.00003700487],"about_ca_topic_score_codex":0.0006430988,"about_ca_topic_score_gemma":0.0008419289,"teacher_disagreement_score":0.0006430988,"about_ca_system_score_codex":0.000334876,"about_ca_system_score_gemma":0.00023079413,"threshold_uncertainty_score":0.0028479695},"labels":[],"label_agreement":null},{"id":"W4232401843","doi":"10.1158/1535-7163.targ-09-a9","title":"Abstract A9: Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pazopanib; Topotecan; Ovarian cancer; Medicine; Pharmacology; Paclitaxel; Chemotherapy; Ovarian carcinoma; Cancer; Bevacizumab; Oncology; Cancer research; Internal medicine; Sunitinib","score_opus":0.03545390850934368,"score_gpt":0.3495010082494963,"score_spread":0.31404709974015266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232401843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936144,0.0017268171,0.00067543983,0.00026566008,0.00013276868,0.000263241,0.0012292376,0.00009819877,0.0019942701],"genre_scores_gemma":[0.99406177,0.0011489209,0.0011429572,0.000088258574,0.000046512767,0.00014702391,0.0016237239,0.000019452247,0.0017213806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982363,0.000041691877,0.000014266538,0.000026140122,0.00003336378,0.00006087616],"domain_scores_gemma":[0.9998265,0.00002531537,0.000024777097,0.000016367012,0.00001711007,0.00008985783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026418947,0.0005160947,0.00077263644,0.00040635688,0.0002297219,0.0004962998,0.0003855472,0.0003900554,0.0017365564],"category_scores_gemma":[0.00019779701,0.00020252878,0.00040935574,0.000287206,0.0002676397,0.00030821728,0.00015009279,0.0014376752,0.00032689856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018298572,0.0149849495,0.0010022541,0.0002893354,0.00013772867,0.00025318822,0.000076776945,0.0016515796,0.9337694,0.0003414329,0.0021532024,0.027041646],"study_design_scores_gemma":[0.005406508,0.15632454,0.01037908,0.000025522926,0.0003067295,0.0006199434,0.000067024615,0.0032605838,0.8162324,0.00015285522,0.0071910447,0.000033797587],"about_ca_topic_score_codex":0.0019243931,"about_ca_topic_score_gemma":0.0029812483,"teacher_disagreement_score":0.0019243931,"about_ca_system_score_codex":0.00037263165,"about_ca_system_score_gemma":0.0008843767,"threshold_uncertainty_score":0.0058093667},"labels":[],"label_agreement":null},{"id":"W4282930398","doi":"10.1158/1535-7163.mct-21-0984","title":"Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Immune system; Aryl hydrocarbon receptor; Proinflammatory cytokine; Biology; Tumor microenvironment; Cancer research; Cytokine; Pharmacology; Chemistry; Immunology; Transcription factor; Inflammation; Biochemistry","score_opus":0.0140388904798786,"score_gpt":0.24125740306119572,"score_spread":0.22721851258131712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282930398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953758,0.024062524,0.0109485,0.00030147796,0.00013015418,0.0004612936,0.0012234288,0.00020341382,0.008911085],"genre_scores_gemma":[0.9778677,0.00869757,0.0068272217,0.00024519852,0.000055818637,0.000110832065,0.0021455379,0.000021711858,0.0040283604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995124,0.000005016495,0.000004594202,0.000008070261,0.000015849882,0.000015206445],"domain_scores_gemma":[0.99996257,0.000003096237,0.00000963363,0.0000029792127,0.000007969556,0.000013702992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012310629,0.00047218511,0.0003060058,0.00033217712,0.00013673966,0.0002835374,0.00031975153,0.00019950017,0.00095427973],"category_scores_gemma":[0.000092123286,0.0000986194,0.00031755693,0.0002126496,0.0001469334,0.00018531973,0.000119356475,0.00046318516,0.00035639768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018774836,0.00018598518,0.00023184226,0.00016405871,0.000029123035,0.00016233923,0.000025763025,0.00052865496,0.9846769,0.00036822166,0.00029083056,0.013148632],"study_design_scores_gemma":[0.00023912752,0.0049160495,0.0031912238,0.000026410267,0.0001729485,0.0010657232,0.000031498785,0.001417786,0.96383446,0.00014132954,0.024936693,0.000026810541],"about_ca_topic_score_codex":0.00060623256,"about_ca_topic_score_gemma":0.0010968732,"teacher_disagreement_score":0.00095427973,"about_ca_system_score_codex":0.00026952542,"about_ca_system_score_gemma":0.00035618947,"threshold_uncertainty_score":0.0031923652},"labels":[],"label_agreement":null},{"id":"W4283329314","doi":"10.1158/1535-7163.mct-22-0037","title":"Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA and protein synthesis mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Radiosensitivity; Radioresistance; Polysome; Initiation factor; Clonogenic assay; Biology; Translational efficiency; Protein biosynthesis; Cancer research; Cell culture; Gene knockdown; eIF4A; Molecular biology; Translation (biology); Cell biology; Messenger RNA; Medicine; RNA; Radiation therapy; Ribosome; Gene; Biochemistry; Genetics; Internal medicine","score_opus":0.021699739588702433,"score_gpt":0.2512214470314223,"score_spread":0.22952170744271985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283329314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328643,0.0022002903,0.0017608057,0.00010138299,0.00005735721,0.00005091565,0.0004104539,0.000143275,0.001989145],"genre_scores_gemma":[0.9919274,0.001782796,0.0022019704,0.000054493674,0.000016502725,0.000073228475,0.00081453176,0.00003263519,0.003096437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986565,0.0000204736,0.00001771616,0.000023505065,0.000040239487,0.00003226597],"domain_scores_gemma":[0.99990416,0.000028601866,0.000020717827,0.0000133034755,0.00001338999,0.00001981783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016345488,0.00043173524,0.0004781915,0.00026357835,0.00012735864,0.00025460485,0.0001946386,0.00028263516,0.0013817422],"category_scores_gemma":[0.000103842234,0.0001543229,0.00030622937,0.00018390955,0.00014296238,0.00016024057,0.00017276815,0.0006839559,0.00044010652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008650875,0.000059374597,0.000065086286,0.00003797286,0.0000053463696,0.000014452927,0.000007158423,0.000077684505,0.9985245,0.00003827127,0.00004517731,0.0010384703],"study_design_scores_gemma":[0.000012253709,0.00046430202,0.0013095284,0.000002316725,0.000008290271,0.00004054361,0.0000075755293,0.0005364045,0.9963856,0.000011239619,0.0012194762,0.000002445927],"about_ca_topic_score_codex":0.0004266776,"about_ca_topic_score_gemma":0.00060206855,"teacher_disagreement_score":0.0013817422,"about_ca_system_score_codex":0.00025516475,"about_ca_system_score_gemma":0.00017566048,"threshold_uncertainty_score":0.0046224594},"labels":[],"label_agreement":null},{"id":"W4289950574","doi":"10.1158/1535-7163.1.4.1","title":"Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"National Cancer Institute; Hospital for Sick Children","keywords":"Apigenin; Apoptosis; Programmed cell death; Neuroblastoma; Caspase; Cancer research; Biology; Caspase 3; Cell culture; Pharmacology; Flavonoid; Chemistry; Molecular biology; Biochemistry; Genetics","score_opus":0.012731329094541836,"score_gpt":0.2625937425773251,"score_spread":0.24986241348278326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289950574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456894,0.002149208,0.0013737705,0.000045486497,0.000021417316,0.000051169358,0.0006420644,0.000040424864,0.0011074725],"genre_scores_gemma":[0.9946845,0.0014892935,0.001291224,0.0000323253,0.000005827092,0.00007235296,0.0011598833,0.000007195333,0.0012574847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999249,0.00001667317,0.000009760552,0.000013405115,0.000018559405,0.000016616974],"domain_scores_gemma":[0.9999453,0.000014085887,0.00001008043,0.000008980575,0.000011180642,0.000010309092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013864512,0.00025517156,0.0002274533,0.00028802425,0.00013907399,0.00017058903,0.00013390675,0.00018073867,0.0012242986],"category_scores_gemma":[0.00011235156,0.00008356351,0.00022041399,0.00021643568,0.0001227716,0.00017332601,0.000108576416,0.00035766177,0.00024561526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030028468,0.000053920037,0.00023189382,0.00005058502,0.0000072230605,0.000073678166,0.000017285662,0.00009061454,0.9979634,0.00003811638,0.000042458923,0.0011305651],"study_design_scores_gemma":[0.00006626636,0.00086509273,0.008927164,0.0000097400925,0.000018965744,0.00028997805,0.000049457667,0.0008633763,0.98713547,0.00004659212,0.0017235667,0.000004424501],"about_ca_topic_score_codex":0.0011088147,"about_ca_topic_score_gemma":0.0013186302,"teacher_disagreement_score":0.0012242986,"about_ca_system_score_codex":0.0003472834,"about_ca_system_score_gemma":0.00018117765,"threshold_uncertainty_score":0.004095733},"labels":[],"label_agreement":null},{"id":"W4293022944","doi":"10.1158/1535-7163.23.4.1","title":"(−)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institutes of Health; University of Pittsburgh; U.S. Department of Defense","keywords":"Gossypol; Jurkat cells; Apoptosis; Mitochondrion; Transfection; Biology; Bcl-xL; Programmed cell death; Etoposide; Cytochrome c; Cell biology; Molecular biology; Cell culture; Biochemistry; T cell; Immunology","score_opus":0.013904997928625488,"score_gpt":0.2572712026939176,"score_spread":0.24336620476529214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293022944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944772,0.0015809231,0.0016270133,0.00007781865,0.00004791745,0.000049868955,0.0002802269,0.00008524582,0.0017737721],"genre_scores_gemma":[0.9951349,0.0008894264,0.0015774595,0.000053250333,0.000015559102,0.000019624798,0.00039123662,0.000009514854,0.0019090676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999232,0.000014973956,0.0000089427895,0.000011543026,0.000022061819,0.000019212861],"domain_scores_gemma":[0.99995434,0.0000064275946,0.000015415026,0.000006891555,0.00000526839,0.000011738458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007182279,0.00037707365,0.00013608979,0.00013977436,0.00009957294,0.00025338915,0.00014972113,0.00017250246,0.0010449985],"category_scores_gemma":[0.000066139815,0.00008202462,0.0001804346,0.00010156153,0.00015128106,0.00016612936,0.00013542494,0.00039292197,0.00026359144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045299053,0.000011548906,0.00004837983,0.00001855332,0.0000030438619,0.000020105146,0.0000040192617,0.000029884135,0.9991893,0.00006817063,0.000018693308,0.0005429304],"study_design_scores_gemma":[0.000007780059,0.00018799074,0.0004399028,0.0000019079168,0.0000050362496,0.00008181109,0.0000062859235,0.00014457032,0.99784505,0.000012744889,0.0012658427,0.0000011529118],"about_ca_topic_score_codex":0.00049034576,"about_ca_topic_score_gemma":0.0005798949,"teacher_disagreement_score":0.0010449985,"about_ca_system_score_codex":0.00019617741,"about_ca_system_score_gemma":0.00012886511,"threshold_uncertainty_score":0.0034958124},"labels":[],"label_agreement":null},{"id":"W4296078948","doi":"10.1158/1535-7163.mct-21-0875","title":"BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Cancer research; Pharmacology; Conjugate; Clinical trial; Cancer; Antibody; Oncology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.03166265876332708,"score_gpt":0.327637395701249,"score_spread":0.2959747369379219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296078948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956138,0.015696608,0.015958307,0.000388347,0.00010883953,0.0003054836,0.00052725954,0.0004276009,0.010449521],"genre_scores_gemma":[0.98736763,0.0032901391,0.00514304,0.00009592389,0.000011532827,0.00006415248,0.0004977192,0.000019425514,0.0035103601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995625,0.000007162995,0.0000031206769,0.0000067737074,0.00001642565,0.000010231378],"domain_scores_gemma":[0.99997973,0.0000021373744,0.000005260998,0.0000016599062,0.0000032463079,0.000008051734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006968692,0.0002274724,0.00015947521,0.00020725257,0.00009644135,0.00012213347,0.00018556886,0.00026665654,0.0009766797],"category_scores_gemma":[0.000050337472,0.00008229664,0.000098648736,0.00016002954,0.00010595527,0.00014695498,0.0001404508,0.0004032245,0.00044938485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002102654,0.00009033593,0.0001813718,0.000079451966,0.0000075752628,0.00013813049,0.00001648686,0.00050968543,0.97404826,0.00029642083,0.00041801756,0.024003968],"study_design_scores_gemma":[0.00021744981,0.0043065087,0.0036954004,0.000020517593,0.00002972429,0.0027375713,0.000014392985,0.0030014098,0.96074075,0.00017181234,0.025049957,0.000014326676],"about_ca_topic_score_codex":0.0005972907,"about_ca_topic_score_gemma":0.0009837651,"teacher_disagreement_score":0.0009766797,"about_ca_system_score_codex":0.0004108834,"about_ca_system_score_gemma":0.00019299812,"threshold_uncertainty_score":0.0032673478},"labels":[],"label_agreement":null},{"id":"W4296465570","doi":"10.1158/1535-7163.1207.3.10","title":"Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Docetaxel; Doxorubicin; Confidence interval; Medicine; Odds ratio; Internal medicine; Breast cancer; Chemotherapy; Cancer; Oncology; Paclitaxel; Population; Topoisomerase; Pharmacology; Chemistry; In vitro","score_opus":0.019418069999127794,"score_gpt":0.3001555046830174,"score_spread":0.28073743468388956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296465570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99949443,0.0002160343,0.00008496919,0.000021517228,0.000011130652,0.000020147416,0.000044614546,0.0000017113254,0.000105505125],"genre_scores_gemma":[0.99964845,0.000052012976,0.00004950666,0.00002950753,0.000024668576,0.000019005654,0.00011035801,7.262975e-7,0.00006561308],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99937695,0.00023376745,0.000045575638,0.00019209555,0.00009495554,0.000056652923],"domain_scores_gemma":[0.99880254,0.0005062068,0.0002850777,0.00008489589,0.000062775376,0.00025860875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010024895,0.00029451342,0.00076107157,0.0003380065,0.00027803998,0.00048508047,0.00019314335,0.0004503864,0.001041192],"category_scores_gemma":[0.00242287,0.00023388526,0.00057641475,0.00019597512,0.00041843296,0.00033696613,0.0002514312,0.0005342537,0.00020435936],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05403247,0.0008958776,0.92655855,0.00004918667,0.0007221345,0.00022312357,0.000079579164,0.00055130845,0.0062018563,0.000046232646,0.00020972796,0.010429947],"study_design_scores_gemma":[0.0036851938,0.02614863,0.9623059,0.00001635443,0.00081731036,0.0011190682,0.00013322415,0.0033084895,0.0015309451,0.000153759,0.00075956876,0.000021641341],"about_ca_topic_score_codex":0.00033515962,"about_ca_topic_score_gemma":0.00030864187,"teacher_disagreement_score":0.001041192,"about_ca_system_score_codex":0.00021094702,"about_ca_system_score_gemma":0.00021775132,"threshold_uncertainty_score":0.005301714},"labels":[],"label_agreement":null},{"id":"W4302027542","doi":"10.1158/1535-7163.mct-22-0004","title":"NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Oncode Institute; Janet D. Cottrelle Foundation; BC Cancer Foundation; China Scholarship Council; Ovarian Cancer Canada; VGH and UBC Hospital Foundation","keywords":"Trametinib; MEK inhibitor; Cancer research; KRAS; Gene knockdown; Selumetinib; Synthetic lethality; MAPK/ERK pathway; Medicine; Downregulation and upregulation; Ovarian cancer; Serous fluid; Cell culture; Biology; Cancer; Internal medicine; Mutant; Gene; Signal transduction; Genetics; Colorectal cancer","score_opus":0.03380773318638299,"score_gpt":0.30289646492390804,"score_spread":0.26908873173752507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302027542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957482,0.0014314601,0.00043576976,0.00009970822,0.000022361968,0.00002408697,0.00032877977,0.000054986653,0.0018547416],"genre_scores_gemma":[0.99777645,0.0005423292,0.00029918432,0.000047707606,0.0000031591726,0.000014280924,0.00033894976,0.000008225817,0.0009696022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998802,0.000012888624,0.00001421057,0.000018319422,0.000037648428,0.000036694953],"domain_scores_gemma":[0.99990237,0.000022850723,0.000015117602,0.000012084328,0.00001473225,0.000032723412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014585965,0.00015398438,0.00026932659,0.00015559762,0.00009108155,0.00048198318,0.00016955522,0.00016831618,0.0017509451],"category_scores_gemma":[0.00022183648,0.0001111502,0.00020856508,0.0001233341,0.00012605594,0.00016114688,0.00023830438,0.0005361622,0.00031670582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009002772,0.00017309026,0.002667689,0.00018135933,0.000025015619,0.000086440414,0.000049103357,0.0005198636,0.977853,0.00017059423,0.00043702705,0.016936531],"study_design_scores_gemma":[0.00014278699,0.002136358,0.021087186,0.000025008672,0.00006742445,0.0006752886,0.00015530363,0.00287336,0.962475,0.000116330586,0.010233129,0.000012847606],"about_ca_topic_score_codex":0.00080583175,"about_ca_topic_score_gemma":0.0020547104,"teacher_disagreement_score":0.0017509451,"about_ca_system_score_codex":0.00029321905,"about_ca_system_score_gemma":0.00035263033,"threshold_uncertainty_score":0.0058575273},"labels":[],"label_agreement":null},{"id":"W4313857431","doi":"10.1158/1535-7163.mct-22-0159","title":"Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Research Nova Scotia; Canadian Institutes of Health Research; Li Ka Shing Foundation","keywords":"TMPRSS2; Prostate cancer; Erg; Cancer; Prostate; Medicine; Biology; Cancer research; Ophthalmology; Internal medicine; Coronavirus disease 2019 (COVID-19); Retinal; Disease","score_opus":0.03742462221571558,"score_gpt":0.35936550688908914,"score_spread":0.32194088467337356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313857431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847602,0.0065309647,0.003188028,0.00021784836,0.000070005306,0.000112204936,0.000521538,0.00020438063,0.004394862],"genre_scores_gemma":[0.9932227,0.0019490457,0.0015803947,0.00006691203,0.000007682699,0.000030489322,0.0006660379,0.000010446628,0.002466339],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993885,0.000008483776,0.0000033020972,0.000010121361,0.000021472704,0.000017702947],"domain_scores_gemma":[0.99998176,0.0000034581433,0.0000051063903,0.000002002126,0.0000032629168,0.0000044935077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009076578,0.00035094126,0.00031998177,0.00021080948,0.00013001682,0.00030368712,0.00028606234,0.00019652357,0.0013683452],"category_scores_gemma":[0.000074184325,0.000083894374,0.00033713676,0.00015474597,0.00010855747,0.00013000157,0.0001601434,0.00037628977,0.0002303169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035796931,0.00022678036,0.0004916512,0.00018798315,0.000040259125,0.00016231238,0.000023900926,0.0012022057,0.9802587,0.0002784545,0.0004207767,0.016348902],"study_design_scores_gemma":[0.00010835446,0.0014694604,0.0027553802,0.000008706372,0.00006280921,0.00054748025,0.000028694762,0.0038560203,0.9809703,0.00007812537,0.010103635,0.0000109801595],"about_ca_topic_score_codex":0.0008551401,"about_ca_topic_score_gemma":0.0023795506,"teacher_disagreement_score":0.0013683452,"about_ca_system_score_codex":0.00031249603,"about_ca_system_score_gemma":0.00021428989,"threshold_uncertainty_score":0.004577577},"labels":[],"label_agreement":null},{"id":"W4318754916","doi":"10.1158/1535-7163.mct-22-0092","title":"Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"Warren Y. Soper Charitable Trust; Fonds de Recherche du Québec - Santé; Fondation De Famille Alvin Segal; Jewish General Hospital; Canadian Institutes of Health Research; Cancer Research Society; Genome Canada; Faculty of Medicine, McGill University; McGill University","keywords":"Palbociclib; Cancer research; EIF4E; Clonogenic assay; Melanoma; Cancer; Survivin; Medicine; Downregulation and upregulation; Cell cycle; Breast cancer; Pharmacology; Biology; Cell; Translation (biology); Internal medicine; Messenger RNA; Metastatic breast cancer; Biochemistry","score_opus":0.0161072384513956,"score_gpt":0.28223943783779337,"score_spread":0.26613219938639776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909253,0.0035198755,0.0013579493,0.00027420293,0.00009684523,0.000074180985,0.00075697876,0.00016692713,0.0028276343],"genre_scores_gemma":[0.992898,0.0014804148,0.0012854635,0.00008851623,0.000015089511,0.000079774276,0.0008369838,0.000014908594,0.0033008885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991155,0.000011273349,0.0000063243065,0.000015202621,0.000024197578,0.000031499334],"domain_scores_gemma":[0.9999739,0.00000270473,0.00000600331,0.0000030069916,0.000003664228,0.000010766561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009101244,0.00044296612,0.00032002662,0.0003040933,0.00015360149,0.00021977456,0.00016574014,0.00019770028,0.0017185318],"category_scores_gemma":[0.000059455062,0.0001171651,0.00019064642,0.00015712807,0.00012719528,0.00013638235,0.00010561019,0.00075325015,0.00032366597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082003383,0.00033835514,0.00033649144,0.00011537639,0.000016701708,0.0000418895,0.000008946705,0.00029888508,0.98883855,0.00012478197,0.00031897757,0.008741028],"study_design_scores_gemma":[0.00021174025,0.0026856929,0.0104234135,0.000012006763,0.00004163373,0.00025923815,0.000024066567,0.0021643331,0.97777414,0.00008143153,0.006314699,0.000007553739],"about_ca_topic_score_codex":0.0007444648,"about_ca_topic_score_gemma":0.0022005758,"teacher_disagreement_score":0.0017185318,"about_ca_system_score_codex":0.0004367174,"about_ca_system_score_gemma":0.0002959966,"threshold_uncertainty_score":0.005749047},"labels":[],"label_agreement":null},{"id":"W4320486696","doi":"10.1158/1535-7163.mct-22-0583","title":"A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Institute, University of Pittsburgh; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; University of Texas MD Anderson Cancer Center; Pfizer; Yale Cancer Center; Merck KGaA; Princess Margaret Cancer Foundation; Johns Hopkins University; Dana-Farber/Harvard Cancer Center; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Regeneron Pharmaceuticals; California Space Grant Consortium","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Radium-223; Cancer; Adverse effect; Urology; Bone metastasis","score_opus":0.047131900191674674,"score_gpt":0.35707104660009653,"score_spread":0.30993914640842185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320486696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950447,0.0011253679,0.00045274606,0.00019954606,0.00005734526,0.0019864305,0.00030302533,0.000060051712,0.0007708606],"genre_scores_gemma":[0.99347806,0.0007667684,0.0018047823,0.00038493262,0.0000895045,0.0017320539,0.0005653693,0.0000138049245,0.0011646406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999451,0.00030115506,0.000025987409,0.00007956592,0.000049699946,0.00009268089],"domain_scores_gemma":[0.99948525,0.00007669386,0.000089962276,0.00004801256,0.000031124662,0.00026890222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012299394,0.0012877801,0.0019036896,0.0005485017,0.00043515014,0.00072516326,0.0009113398,0.0010777757,0.0018905496],"category_scores_gemma":[0.00063474313,0.0008139966,0.0011914661,0.00043999054,0.0007664107,0.00045846426,0.00033722853,0.0020547132,0.00043866676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60686225,0.1687554,0.008606729,0.0008422792,0.0016980958,0.00055209623,0.00045661652,0.0041813888,0.089421645,0.0003918314,0.0021370759,0.11609452],"study_design_scores_gemma":[0.30321306,0.68338627,0.006775819,0.000015084647,0.00030963126,0.00023267003,0.00003501427,0.00087422883,0.0037797296,0.00009063771,0.0012647897,0.000022998507],"about_ca_topic_score_codex":0.00076839584,"about_ca_topic_score_gemma":0.0020080246,"teacher_disagreement_score":0.0019036896,"about_ca_system_score_codex":0.00055114954,"about_ca_system_score_gemma":0.0012341841,"threshold_uncertainty_score":0.006504655},"labels":[],"label_agreement":null},{"id":"W4366083752","doi":"10.1158/1535-7163.mct-22-0676","title":"Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Bundesministerium für Digitalisierung und Wirtschaftsstandort; Bundesministerium für Verkehr, Innovation und Technologie; Österreichische Forschungsförderungsgesellschaft","keywords":"Macrophage migration inhibitory factor; Monoclonal antibody; Macrophage; Cancer research; Inhibitory postsynaptic potential; Pharmacology; Chemistry; Biology; Immunology; Antibody; In vitro; Biochemistry; Cytokine; Neuroscience","score_opus":0.06691227969315192,"score_gpt":0.3560835251783305,"score_spread":0.2891712454851786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366083752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434423,0.0016770742,0.0020098374,0.00009335761,0.00005598202,0.00013452138,0.00019380171,0.000054383654,0.0014367956],"genre_scores_gemma":[0.9958014,0.0011443209,0.0012491181,0.0000527505,0.000021666689,0.00009100902,0.0004759413,0.000010557184,0.0011530904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992454,0.000017739318,0.000003020322,0.0000103799075,0.000017018721,0.000027288275],"domain_scores_gemma":[0.99993193,0.000008770985,0.000018197783,0.00000599442,0.000010677561,0.000024342224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022514483,0.0005075732,0.00030287754,0.0002083502,0.00011130314,0.00017522034,0.0003297064,0.0003326661,0.00074409385],"category_scores_gemma":[0.00012588238,0.0000942571,0.00020379273,0.00012689605,0.00017099388,0.0001443208,0.00009532761,0.0006163506,0.00013673966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018414657,0.0022751226,0.0004788069,0.00010092733,0.000029588118,0.000086239925,0.000038794085,0.0013367181,0.9817935,0.00018146003,0.0003421735,0.011495148],"study_design_scores_gemma":[0.00056976324,0.059543632,0.004055488,0.000021618873,0.000167601,0.00037102558,0.000034032255,0.0037705998,0.9232992,0.000117330186,0.008036747,0.000012823743],"about_ca_topic_score_codex":0.0011339935,"about_ca_topic_score_gemma":0.0011659336,"teacher_disagreement_score":0.0011339935,"about_ca_system_score_codex":0.00029026737,"about_ca_system_score_gemma":0.00041236627,"threshold_uncertainty_score":0.0024892688},"labels":[],"label_agreement":null},{"id":"W4368361249","doi":"10.1158/1535-7163.mct-22-0237","title":"Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Transactivation; Prostate cancer; Enzalutamide; Cancer research; Androgen; Chemistry; Transcription factor; Biology; Cell biology; Cancer; Endocrinology; Gene; Genetics; Biochemistry; Hormone","score_opus":0.0386941703284861,"score_gpt":0.33365179603329276,"score_spread":0.29495762570480666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368361249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92174715,0.05222873,0.014482382,0.00064414716,0.0002010435,0.00043733735,0.00066333887,0.0004575417,0.009138288],"genre_scores_gemma":[0.9582459,0.025740976,0.008201401,0.00046539042,0.000041436022,0.0001768184,0.0011863189,0.000021024665,0.005920704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996734,0.0000035976043,0.0000022224754,0.0000060079215,0.000011349015,0.000009454951],"domain_scores_gemma":[0.99998415,0.000001671344,0.0000037362909,0.0000010814002,0.000003531382,0.000005880382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009436007,0.00034201014,0.00031087178,0.00022556983,0.000107631335,0.00018030991,0.00023189813,0.00020266167,0.0008198594],"category_scores_gemma":[0.00004572809,0.00009818447,0.00027083448,0.00015976393,0.00010696067,0.00014002969,0.00014309058,0.00050076575,0.00026916177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018095822,0.00020058693,0.0003176258,0.00040385305,0.000041827465,0.0002864023,0.000031576128,0.00058030407,0.96351784,0.0007476557,0.00074820424,0.032943256],"study_design_scores_gemma":[0.0011088145,0.0069321827,0.006995059,0.0000959592,0.00029308262,0.0027087068,0.000054056745,0.008988008,0.8983296,0.00031916986,0.07410664,0.00006870948],"about_ca_topic_score_codex":0.00049509236,"about_ca_topic_score_gemma":0.0011776177,"teacher_disagreement_score":0.0008198594,"about_ca_system_score_codex":0.00018527944,"about_ca_system_score_gemma":0.0002477657,"threshold_uncertainty_score":0.0027427077},"labels":[],"label_agreement":null},{"id":"W4381715051","doi":"10.1158/1535-7163.mct-23-0041","title":"A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; BC Children's Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Glutamine; GPX4; Lipid peroxidation; Glutathione; Biochemistry; Metabolism; Homeostasis; Chemistry; Cell biology; Glutathione peroxidase; Biology; Enzyme; Amino acid","score_opus":0.014710784035728829,"score_gpt":0.2607522654575003,"score_spread":0.24604148142177146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381715051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029714,0.0028775209,0.0037494672,0.0003072521,0.000043366883,0.00003426986,0.0003266872,0.00013789198,0.0022264146],"genre_scores_gemma":[0.99675673,0.00054657634,0.0007605734,0.00006305011,0.000004445953,0.000015251566,0.00017342428,0.000007307279,0.0016727885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994314,0.000008744839,0.0000037651137,0.000012465913,0.000016337464,0.000015524749],"domain_scores_gemma":[0.9999641,0.0000031860322,0.000012142421,0.0000020512898,0.00000565451,0.000012833468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073485586,0.00017854059,0.00015011727,0.0001238568,0.00015615692,0.00019280058,0.00010008806,0.00019408524,0.0010489508],"category_scores_gemma":[0.00004830928,0.00006383766,0.00013889825,0.00008016059,0.0001641313,0.00009658898,0.00012964665,0.00023918418,0.00013971959],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006868634,0.0000074412937,0.00043230932,0.000021397018,0.0000038667195,0.00005879067,0.0000095981,0.00005822328,0.9979729,0.0001450782,0.000075780124,0.0011460138],"study_design_scores_gemma":[0.000031585336,0.00031011325,0.028453313,0.000010524295,0.000035640394,0.00041062376,0.00011203796,0.002652481,0.96095747,0.00020375366,0.0068151373,0.0000073738715],"about_ca_topic_score_codex":0.0014568329,"about_ca_topic_score_gemma":0.0025901156,"teacher_disagreement_score":0.0014568329,"about_ca_system_score_codex":0.00039727255,"about_ca_system_score_gemma":0.000277806,"threshold_uncertainty_score":0.0035091043},"labels":[],"label_agreement":null},{"id":"W4385196540","doi":"10.1158/1535-7163.mct-23-0196","title":"A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Division of Chemistry; National Cancer Institute; National Science Foundation; National Institutes of Health; School of Medicine, New York University; KU Leuven; New York State Department of Health","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Cancer research; Chemistry; Cancer; Biology; Cell biology; Genetics","score_opus":0.05644194386507937,"score_gpt":0.3467204731395425,"score_spread":0.2902785292744631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385196540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996894,0.00063314114,0.0015680111,0.00003231481,0.000013425992,0.000025274168,0.00007598549,0.00003986056,0.000717884],"genre_scores_gemma":[0.9978332,0.00028135497,0.0009823813,0.000022442946,0.0000040598543,0.000010776247,0.000085068095,0.0000046062696,0.00077612256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999577,0.000005988866,0.0000030031483,0.000011454564,0.000009986579,0.000011931257],"domain_scores_gemma":[0.9999732,0.0000044879616,0.00000880922,0.000002179589,0.0000028822562,0.000008511182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006656642,0.0001911105,0.00012226013,0.00008468279,0.00005738382,0.000126315,0.00008908798,0.00014865522,0.00080973044],"category_scores_gemma":[0.00004556785,0.000060490773,0.00010633341,0.000071758775,0.000089164896,0.00012645456,0.00008841103,0.00030863364,0.00012515478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007257878,0.0000217623,0.00006291728,0.000014920012,0.0000021472474,0.000012798498,0.0000042014613,0.00012840767,0.9986517,0.000050881994,0.000016172398,0.0009615054],"study_design_scores_gemma":[0.00002052021,0.0008060595,0.0012954377,0.0000014877626,0.000009473517,0.00010328385,0.0000057726334,0.00083407864,0.99577713,0.000013677857,0.0011302467,0.0000027933327],"about_ca_topic_score_codex":0.000190841,"about_ca_topic_score_gemma":0.00025524967,"teacher_disagreement_score":0.00080973044,"about_ca_system_score_codex":0.00016721386,"about_ca_system_score_gemma":0.00010125093,"threshold_uncertainty_score":0.0027087927},"labels":[],"label_agreement":null},{"id":"W4385217389","doi":"10.1158/1535-7163.mct-23-0065","title":"First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Adaptive Biotechnologies; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Anemia; Gastroenterology; Mucositis; Neutropenia; Combination therapy; Refractory (planetary science); Pharmacokinetics; Olaparib; Cancer; Diarrhea; Toxicity; Pharmacology","score_opus":0.012174103357139603,"score_gpt":0.249141873966883,"score_spread":0.2369677706097434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385217389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983132,0.0068415296,0.0010484449,0.00054513314,0.00019005183,0.0028958323,0.0021306435,0.00017389399,0.003042426],"genre_scores_gemma":[0.9842202,0.004418667,0.0015235847,0.001354951,0.00033464038,0.0017203598,0.0029771992,0.00006289445,0.0033874668],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99928916,0.000333444,0.000036671794,0.00010808538,0.000059590933,0.00017304458],"domain_scores_gemma":[0.9990759,0.00016468596,0.00015190736,0.00011727659,0.00005820864,0.0004320261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021864532,0.0018733587,0.0030628415,0.000512676,0.0005676329,0.0013456187,0.0009926145,0.0012944846,0.0032164566],"category_scores_gemma":[0.0010456648,0.0009160654,0.0021621122,0.00047757698,0.0011585811,0.0012303208,0.0004867435,0.003970495,0.0011343485],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5017945,0.19026005,0.014858734,0.0013322344,0.0033670578,0.0011716293,0.0006424022,0.003236453,0.076972924,0.00047050318,0.0075447797,0.19834879],"study_design_scores_gemma":[0.2627344,0.7106238,0.012283899,0.0000408013,0.00088630675,0.00048005514,0.00009195207,0.00095941016,0.0064278897,0.00020427966,0.0052210703,0.00004614618],"about_ca_topic_score_codex":0.0009270687,"about_ca_topic_score_gemma":0.003331152,"teacher_disagreement_score":0.0032164566,"about_ca_system_score_codex":0.0013527857,"about_ca_system_score_gemma":0.0015824497,"threshold_uncertainty_score":0.011563182},"labels":[],"label_agreement":null},{"id":"W4387475515","doi":"10.1158/1535-7163.mct-23-0158","title":"Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Tumor microenvironment; Cancer research; Extracellular matrix; Flow cytometry; Biomarker; Chemistry; Pathology; Cancer; Medicine; Immunology; Internal medicine; Biochemistry; Tumor cells","score_opus":0.019380802925599804,"score_gpt":0.2850677300030378,"score_spread":0.265686927077438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387475515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821847,0.002937264,0.013366324,0.00009977487,0.00001763077,0.00007405113,0.00021142271,0.000114852875,0.0009938868],"genre_scores_gemma":[0.9838277,0.0022242826,0.012007153,0.00008448598,0.000014241803,0.00006641133,0.00025209316,0.00001655889,0.0015071924],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993134,0.0000128855345,0.0000045816587,0.000015959597,0.000017860473,0.000017434859],"domain_scores_gemma":[0.9999269,0.000011870839,0.000029496841,0.0000054691304,0.000010348095,0.000015907464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016120558,0.00040534517,0.00022708277,0.00034615886,0.00007452708,0.0001600486,0.00012240198,0.00030346168,0.0006240901],"category_scores_gemma":[0.00008226542,0.0001218702,0.00019061497,0.00013936007,0.00019576708,0.00033174892,0.00015199852,0.000349186,0.00013839231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008639067,0.000023216502,0.000088643035,0.00002129487,0.0000026087548,0.000020390211,0.0000034913257,0.000034616216,0.9982482,0.000029271207,0.000011459905,0.0014303982],"study_design_scores_gemma":[0.000012791177,0.00028462883,0.0014942712,0.0000020159948,0.000008626053,0.00014482607,0.000008128249,0.0006199441,0.99681723,0.000024493274,0.00057912426,0.0000038287662],"about_ca_topic_score_codex":0.00017789232,"about_ca_topic_score_gemma":0.0002785178,"teacher_disagreement_score":0.0006240901,"about_ca_system_score_codex":0.00012218472,"about_ca_system_score_gemma":0.00011697935,"threshold_uncertainty_score":0.002087772},"labels":[],"label_agreement":null},{"id":"W4388510152","doi":"10.1158/1535-7163.mct-23-0102","title":"Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; University of Toronto","funders":"Merck KGaA","keywords":"Biology; Cancer research; Angiogenesis; Cell growth; Cancer; Clear cell renal cell carcinoma; Renal cell carcinoma; Internal medicine; Biochemistry; Medicine; Genetics","score_opus":0.025521641462663426,"score_gpt":0.26833662115125356,"score_spread":0.24281497968859014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388510152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347794,0.0022506225,0.0019084889,0.00015088357,0.000042651875,0.000094917355,0.00027792738,0.00015709247,0.0016395212],"genre_scores_gemma":[0.99506384,0.0013003151,0.0017017396,0.00005890033,0.000010782372,0.00007831855,0.00042919526,0.000012197932,0.0013447383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999132,0.000015558151,0.000007081697,0.000013839567,0.000025879128,0.00002448584],"domain_scores_gemma":[0.99996257,0.0000037286675,0.000012602641,0.000003970812,0.0000046781483,0.0000123902755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014051508,0.00036281758,0.0004452441,0.00023226767,0.00010284398,0.00021061902,0.0002618713,0.00021492278,0.0008494516],"category_scores_gemma":[0.00008076344,0.000118863885,0.00025472188,0.00013678895,0.00011671605,0.00016387593,0.00011558853,0.00068945676,0.00018019424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012693898,0.00067409134,0.0004371358,0.000076369,0.000043586053,0.000081603364,0.000012899,0.0003805497,0.9836435,0.0001382645,0.00036979732,0.012872794],"study_design_scores_gemma":[0.0003841658,0.0067407093,0.003924027,0.000008392664,0.000068081834,0.00054148014,0.000017909882,0.0023397454,0.9815714,0.000057590947,0.00433761,0.00000893963],"about_ca_topic_score_codex":0.0003975701,"about_ca_topic_score_gemma":0.0011587577,"teacher_disagreement_score":0.0008494516,"about_ca_system_score_codex":0.00024256657,"about_ca_system_score_gemma":0.00025632296,"threshold_uncertainty_score":0.002841711},"labels":[],"label_agreement":null},{"id":"W4389081332","doi":"10.1158/1535-7163.mct-23-0460","title":"Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (<i>IDH1/2</i>) Mutant Cholangiocarcinoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Trinity College; Princess Margaret Cancer Centre","funders":"","keywords":"Isocitrate dehydrogenase; IDH1; Biomarker; Glioma; Cancer research; Internal medicine; Biology; Chemistry; Mutant; Medicine; Biochemistry; Enzyme; Gene","score_opus":0.045130157489544055,"score_gpt":0.3297217594717431,"score_spread":0.284591601982199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389081332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823594,0.0008933628,0.00032313765,0.00003503843,0.0000083554705,0.00001019657,0.00011967068,0.000019299507,0.00035498495],"genre_scores_gemma":[0.99923074,0.00010853913,0.00031592124,0.00002714604,0.000010341267,0.000008404432,0.00016958156,0.0000027942583,0.00012649805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974304,0.00006748991,0.000028598948,0.00006180125,0.00006278764,0.00003618861],"domain_scores_gemma":[0.99948454,0.00010622413,0.00020316691,0.000040300252,0.000088151544,0.00007762405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042578738,0.0003447347,0.00040935574,0.0007049848,0.0001744638,0.00063564966,0.00022434663,0.00033224458,0.0004642011],"category_scores_gemma":[0.000988483,0.00019165705,0.00021995905,0.00061135984,0.00020281672,0.00021733234,0.00022662595,0.00033054576,0.00016119468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011318946,0.00004005289,0.977017,0.000033672957,0.00006554752,0.00032781358,0.00005849008,0.00014969562,0.017377198,0.000044698038,0.00012050059,0.0036334503],"study_design_scores_gemma":[0.000032456304,0.0005606693,0.9859964,0.000012772565,0.00012301233,0.0018811537,0.00013622445,0.0017161036,0.008777447,0.0000898565,0.000663974,0.000009851658],"about_ca_topic_score_codex":0.0010442884,"about_ca_topic_score_gemma":0.0016330899,"teacher_disagreement_score":0.0010442884,"about_ca_system_score_codex":0.00027382138,"about_ca_system_score_gemma":0.00016801138,"threshold_uncertainty_score":0.0022518039},"labels":[],"label_agreement":null},{"id":"W4389227449","doi":"10.1158/1535-7163.targ-23-ia003","title":"Abstract IA003: Refining our understanding of ADCs: Drug development insights from 40 years of data","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Magic bullet; Medicine; Drug; Linker; Pharmacology; Computational biology; Computer science; Bioinformatics; Biology","score_opus":0.2877227097958665,"score_gpt":0.4243710880456244,"score_spread":0.1366483782497579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227449","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01250753,0.8545232,0.016849706,0.07858441,0.002810938,0.00012276355,0.0020208783,0.00032023457,0.032260347],"genre_scores_gemma":[0.08564906,0.85528797,0.017204748,0.022896925,0.0040264945,0.0001416474,0.0031175094,0.00019016875,0.011485505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99805284,0.0006056518,0.00016059031,0.0001827802,0.000822447,0.0001756632],"domain_scores_gemma":[0.99177074,0.0033394075,0.0006733333,0.00071704737,0.0028268453,0.0006727351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065076477,0.0008008437,0.001138089,0.0024911596,0.00055821944,0.0050129117,0.0014616874,0.002049567,0.008643974],"category_scores_gemma":[0.010176361,0.00037762584,0.0010338781,0.002971469,0.0018541771,0.007465143,0.0020267882,0.00666031,0.003425581],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067164935,0.00036725122,0.0041713975,0.006299055,0.0002340751,0.0005370458,0.00072416436,0.0035325466,0.010672027,0.08066203,0.117420234,0.77470845],"study_design_scores_gemma":[0.00006208137,0.00058865757,0.0023167483,0.0045427913,0.0001787772,0.0006471637,0.00039661012,0.0030533443,0.0068691275,0.059356194,0.9218984,0.00009007941],"about_ca_topic_score_codex":0.002444626,"about_ca_topic_score_gemma":0.0026938207,"teacher_disagreement_score":0.008643974,"about_ca_system_score_codex":0.0029934424,"about_ca_system_score_gemma":0.0043501197,"threshold_uncertainty_score":0.03441614},"labels":[],"label_agreement":null},{"id":"W4389227464","doi":"10.1158/1535-7163.targ-23-lb_c11","title":"Abstract LB_C11: Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP1; PARP inhibitor; Histone deacetylase; Pharmacology; Cancer research; Vorinostat; DNA repair; Poly ADP ribose polymerase; Synthetic lethality; Biology; Polymerase; Histone; Enzyme; Biochemistry; DNA","score_opus":0.04751386002510425,"score_gpt":0.32016666766537677,"score_spread":0.2726528076402725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8173666,0.09005043,0.034988474,0.001713509,0.0010584132,0.000893956,0.0134357745,0.0030522372,0.03744065],"genre_scores_gemma":[0.9418808,0.01696135,0.011828678,0.00063276925,0.000099964214,0.00035491903,0.008832254,0.00007452914,0.019334828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998517,0.000020589543,0.000012578096,0.000033262826,0.00004537458,0.000036371912],"domain_scores_gemma":[0.9999366,0.0000068855597,0.000013165449,0.000006549552,0.00001182834,0.00002506525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021421879,0.0006875173,0.00041149312,0.00050086767,0.00020252916,0.0003697278,0.00050980435,0.00048627416,0.0046360423],"category_scores_gemma":[0.00009565122,0.00015447734,0.00030387598,0.00050138787,0.00021770938,0.00033525997,0.000187959,0.0009875181,0.0015686151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011541096,0.00045739874,0.00034792695,0.00051055744,0.00005370849,0.00021790931,0.00001914637,0.0006568848,0.9513683,0.0006522281,0.005139605,0.039422188],"study_design_scores_gemma":[0.00058283063,0.0037588591,0.003658231,0.000051610456,0.00010581218,0.0012910826,0.000021739936,0.0029854465,0.95354986,0.00010654083,0.033847895,0.000040070146],"about_ca_topic_score_codex":0.0011175005,"about_ca_topic_score_gemma":0.0013714704,"teacher_disagreement_score":0.0046360423,"about_ca_system_score_codex":0.0006586466,"about_ca_system_score_gemma":0.00037075367,"threshold_uncertainty_score":0.015509129},"labels":[],"label_agreement":null},{"id":"W4389227549","doi":"10.1158/1535-7163.targ-23-c163","title":"Abstract C163: KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"KRAS; Cyclin-dependent kinase 1; Cancer research; Biology; Cell cycle; Cell growth; Mutation; Mutant; Kinase; Molecular biology; Cancer; Genetics; Gene","score_opus":0.040011646229417434,"score_gpt":0.30921393146085024,"score_spread":0.2692022852314328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929173,0.0011418726,0.0012189195,0.00015981,0.00006993803,0.000114920134,0.00080024044,0.00017306794,0.0034039048],"genre_scores_gemma":[0.9952409,0.0003901541,0.0016074232,0.000058840116,0.000014770674,0.000073041694,0.0008072655,0.000023521674,0.0017840979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998197,0.00003094143,0.000026144855,0.00002975983,0.00005457533,0.000038911796],"domain_scores_gemma":[0.9999093,0.000017188127,0.00002081462,0.000012602234,0.0000090443855,0.000031024458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017042336,0.00048581458,0.00041171323,0.0003626167,0.00018731385,0.00026788708,0.00025203,0.00040703692,0.003527685],"category_scores_gemma":[0.00012396148,0.00013790044,0.00025237194,0.0002386623,0.00021638926,0.0001330465,0.00017619357,0.00069246045,0.00068204256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081873074,0.00025128282,0.0003889857,0.000055312332,0.000014236031,0.0002834595,0.000011619089,0.00017629126,0.9939838,0.00015795957,0.000337485,0.003520854],"study_design_scores_gemma":[0.000118136064,0.0027003668,0.0033679807,0.000005963785,0.000028376431,0.001428043,0.000014829322,0.0007797657,0.98880696,0.000032850843,0.0027106034,0.0000061180403],"about_ca_topic_score_codex":0.0005786593,"about_ca_topic_score_gemma":0.0008686155,"teacher_disagreement_score":0.003527685,"about_ca_system_score_codex":0.00032035416,"about_ca_system_score_gemma":0.00030104542,"threshold_uncertainty_score":0.011801243},"labels":[],"label_agreement":null},{"id":"W4389227554","doi":"10.1158/1535-7163.targ-23-b154","title":"Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Tolerability; ALK inhibitor; Crizotinib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Internal medicine; Pharmacodynamics; Lung cancer; Refractory (planetary science); Pharmacokinetics; Oncology; Pharmacology; Clinical trial; Phases of clinical research","score_opus":0.008498528870247834,"score_gpt":0.28725035057182013,"score_spread":0.2787518217015723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914409,0.0033850453,0.0005620827,0.0002899887,0.00006403579,0.00028949822,0.0009708242,0.00012914655,0.0028684225],"genre_scores_gemma":[0.99662614,0.0005845264,0.00031157647,0.00027235263,0.000038563587,0.00008253829,0.001059312,0.00000992755,0.001014962],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998178,0.000067558074,0.000020828758,0.00003259479,0.000029910916,0.000031315416],"domain_scores_gemma":[0.99973744,0.000042601507,0.000059035763,0.000018946843,0.000025317122,0.00011680011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005967066,0.00042532224,0.0006253258,0.00019083482,0.00024244034,0.0005725676,0.00025233632,0.000418273,0.0023189809],"category_scores_gemma":[0.00055802206,0.00016255543,0.00046921865,0.00018174446,0.00021187929,0.00035199217,0.00016102707,0.0011684813,0.0006501566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2544563,0.026777394,0.04804307,0.001475827,0.0012867219,0.0014754724,0.00046100115,0.0040468634,0.1722307,0.0004867543,0.013885018,0.4753749],"study_design_scores_gemma":[0.09395256,0.67903495,0.14763276,0.00024758693,0.001165144,0.0032932914,0.00024331927,0.005234599,0.043692682,0.00038784608,0.025046177,0.000069161644],"about_ca_topic_score_codex":0.0008448891,"about_ca_topic_score_gemma":0.0015504749,"teacher_disagreement_score":0.0023189809,"about_ca_system_score_codex":0.0005941239,"about_ca_system_score_gemma":0.00067620655,"threshold_uncertainty_score":0.007757783},"labels":[],"label_agreement":null},{"id":"W4389227555","doi":"10.1158/1535-7163.targ-23-b045","title":"Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Gemcitabine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacology; Oncology; Clinical trial; Cancer; Phases of clinical research; Adverse effect","score_opus":0.010640445084492668,"score_gpt":0.2818753531656338,"score_spread":0.2712349080811411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914976,0.0030711172,0.0003098712,0.00028404832,0.00004276489,0.00046152837,0.00093326747,0.000099979996,0.003299757],"genre_scores_gemma":[0.9932209,0.0013602661,0.00086320005,0.00022938244,0.000052115563,0.0003001977,0.0018884415,0.000017618087,0.0020679294],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99981314,0.00007374247,0.000016362064,0.000030417348,0.000029120478,0.00003725713],"domain_scores_gemma":[0.9998273,0.000025501973,0.000037403588,0.00001104908,0.000013243175,0.00008550115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005037174,0.00048511717,0.0008506893,0.00042705683,0.00020442971,0.0004819928,0.0004896755,0.0003926632,0.004381392],"category_scores_gemma":[0.00035076248,0.00016539978,0.0003910476,0.00035935565,0.0002579169,0.0003285686,0.00024105345,0.0010608415,0.00068187097],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31774825,0.029469352,0.012517477,0.0018653459,0.0012390944,0.0006309733,0.00027994506,0.0039483747,0.26115182,0.00057612796,0.010947057,0.3596262],"study_design_scores_gemma":[0.17355813,0.6765706,0.06390296,0.00023164199,0.0013945394,0.0016045877,0.00014993819,0.005406528,0.059339017,0.00033850758,0.017442062,0.00006152394],"about_ca_topic_score_codex":0.00095318566,"about_ca_topic_score_gemma":0.002929912,"teacher_disagreement_score":0.004381392,"about_ca_system_score_codex":0.0005404369,"about_ca_system_score_gemma":0.0006085186,"threshold_uncertainty_score":0.014657199},"labels":[],"label_agreement":null},{"id":"W4389227665","doi":"10.1158/1535-7163.targ-23-pr008","title":"Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with <i>CCNE1</i> amplification or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nausea; Internal medicine; Rash; Oncology; Gastroenterology; Adverse effect; Pharmacology","score_opus":0.028046193371300807,"score_gpt":0.31586548706828144,"score_spread":0.2878192936969806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732963,0.0024341035,0.0008841419,0.001432424,0.00022410875,0.0050360104,0.007083997,0.0005565274,0.009052455],"genre_scores_gemma":[0.97171426,0.0010930054,0.0028067476,0.0018472411,0.00019999847,0.0033452997,0.008267012,0.00009350552,0.010632937],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997955,0.00006375488,0.000007950568,0.000042822885,0.000023207935,0.00006675187],"domain_scores_gemma":[0.99968684,0.000027261396,0.000046682515,0.000021661017,0.000017697052,0.00019978608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000927548,0.0011513574,0.0013004297,0.0003601441,0.00039088062,0.0008106596,0.0008681241,0.0012113629,0.011256283],"category_scores_gemma":[0.0004791456,0.0004658792,0.00077262725,0.000252249,0.0006246426,0.0007666247,0.00038699713,0.0030084422,0.0017845673],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6905413,0.036569454,0.0056372345,0.0011263329,0.0009881057,0.00040332897,0.00021513095,0.0029578917,0.074724846,0.0012901999,0.034877416,0.15066878],"study_design_scores_gemma":[0.5216651,0.44333917,0.012741449,0.00007155055,0.0004221489,0.0006324177,0.00004841833,0.0014720609,0.008013615,0.00047700937,0.0110734645,0.000043677454],"about_ca_topic_score_codex":0.00094898115,"about_ca_topic_score_gemma":0.003001749,"teacher_disagreement_score":0.011256283,"about_ca_system_score_codex":0.0011208256,"about_ca_system_score_gemma":0.0014879027,"threshold_uncertainty_score":0.03765601},"labels":[],"label_agreement":null},{"id":"W4389227710","doi":"10.1158/1535-7163.targ-23-a123","title":"Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; PALB2; Cancer research; Biology; CHEK2; BRCA2 Protein; Internal medicine; Oncology; Genetics; Medicine; Germline mutation; Mutation; Gene; Poly ADP ribose polymerase","score_opus":0.05445792351080183,"score_gpt":0.3262254619171759,"score_spread":0.2717675384063741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9479559,0.009790144,0.0030235068,0.0018096538,0.00021149461,0.0011217265,0.01603121,0.0005797161,0.01947651],"genre_scores_gemma":[0.9738548,0.0015548022,0.005187604,0.0010077537,0.00023436133,0.00078709726,0.012778129,0.00008199239,0.004513331],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99920696,0.00034874713,0.00007156627,0.00017141108,0.00014279164,0.000058467656],"domain_scores_gemma":[0.9987212,0.0003537764,0.00036653993,0.00008071615,0.00022778274,0.00025000275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017022833,0.00038794312,0.000697218,0.00036477626,0.00019788076,0.0007330432,0.0003636764,0.00043409286,0.009176145],"category_scores_gemma":[0.0014436803,0.00016295022,0.00043700708,0.0004833952,0.00025772958,0.0003330723,0.0002909137,0.000735041,0.001444795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1192684,0.0015193758,0.2266818,0.002014509,0.0011806337,0.0006355432,0.00019063649,0.0022729295,0.1138373,0.0009153223,0.041701093,0.4897824],"study_design_scores_gemma":[0.030478613,0.08373244,0.65506816,0.0007152431,0.0036224592,0.0066552917,0.0002445088,0.009983543,0.10777139,0.0020000008,0.099600606,0.00012773415],"about_ca_topic_score_codex":0.00048179575,"about_ca_topic_score_gemma":0.0012862207,"teacher_disagreement_score":0.009176145,"about_ca_system_score_codex":0.00051628903,"about_ca_system_score_gemma":0.0005880444,"threshold_uncertainty_score":0.030697227},"labels":[],"label_agreement":null},{"id":"W4389239758","doi":"10.1158/1535-7163.targ-23-b114","title":"Abstract B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Cmax; Pharmacology; Gastroenterology; Internal medicine; Dosing; Adverse effect","score_opus":0.014724666737021675,"score_gpt":0.28811517428666833,"score_spread":0.27339050754964667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438274,0.0014014465,0.00045771094,0.00035646494,0.0000662629,0.0012003588,0.0008791181,0.000080978454,0.0011750153],"genre_scores_gemma":[0.9917373,0.0012375104,0.0016991429,0.0005663885,0.000104784485,0.00091150403,0.0015709281,0.000030051218,0.0021424738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999522,0.00026323696,0.00002363608,0.00007802165,0.00004361672,0.00006952446],"domain_scores_gemma":[0.9995227,0.00008487765,0.00009635893,0.0000385491,0.000030910363,0.00022664235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015600399,0.0014128078,0.0017019544,0.00047073534,0.00033246985,0.00093339116,0.0007210881,0.00095200446,0.0036862327],"category_scores_gemma":[0.00091627706,0.0006288586,0.0015080774,0.00038838145,0.0007859063,0.00084256125,0.00035410502,0.0032144166,0.00090580113],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6933102,0.09084331,0.010731743,0.0010527751,0.0023175203,0.00024076,0.00036740935,0.006101091,0.04996692,0.0003468035,0.0049159788,0.1398054],"study_design_scores_gemma":[0.40207493,0.5718309,0.015664106,0.000034821165,0.0007324706,0.00025287797,0.000074573254,0.0023289537,0.0039010688,0.00019978662,0.0028706552,0.000034703804],"about_ca_topic_score_codex":0.00090313354,"about_ca_topic_score_gemma":0.0026315276,"teacher_disagreement_score":0.0036862327,"about_ca_system_score_codex":0.0009480006,"about_ca_system_score_gemma":0.0015331571,"threshold_uncertainty_score":0.012331605},"labels":[],"label_agreement":null},{"id":"W4389239811","doi":"10.1158/1535-7163.targ-23-b020","title":"Abstract B020: <i>SF3B1 </i>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; Mutant; DNA repair; DNA damage; Cancer research; DNA replication; Transcriptome; Genetics; DNA; Gene; Gene expression","score_opus":0.06120906213030747,"score_gpt":0.3779009795185503,"score_spread":0.3166919173882428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868384,0.0016661554,0.0039201467,0.00016448974,0.000054311186,0.00005360753,0.0035673762,0.00026013787,0.0034753422],"genre_scores_gemma":[0.9908336,0.000561957,0.0020608502,0.00010233851,0.000009574656,0.000030125108,0.002854501,0.000075931435,0.00347125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997658,0.000032499138,0.0000320362,0.00005006621,0.0000738997,0.000045700504],"domain_scores_gemma":[0.99983335,0.000033981163,0.000046602483,0.000024300023,0.000017340526,0.00004441271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001940819,0.00040275315,0.0003935996,0.00025404617,0.0001893854,0.00030599444,0.00021037394,0.0003481695,0.0035361738],"category_scores_gemma":[0.00016347764,0.00015740008,0.0002820002,0.0002520978,0.00020002185,0.000108965265,0.00017754459,0.0006681367,0.0013097622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089729176,0.000016598908,0.00014685422,0.000013298581,0.0000044258336,0.000033006465,0.000003879498,0.000033736836,0.99895406,0.000026015068,0.0000793612,0.0005990783],"study_design_scores_gemma":[0.000010591387,0.00036505976,0.0061839046,0.0000051100774,0.000013792735,0.000554008,0.000014604756,0.00041572834,0.98967546,0.000024784862,0.0027319922,0.000004882584],"about_ca_topic_score_codex":0.0020560394,"about_ca_topic_score_gemma":0.0016256294,"teacher_disagreement_score":0.0035361738,"about_ca_system_score_codex":0.00031556233,"about_ca_system_score_gemma":0.00019377735,"threshold_uncertainty_score":0.011829674},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4389239817","doi":"10.1158/1535-7163.targ-23-c053","title":"Abstract C053: BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Metastasis; Brain metastasis; Cancer research; Adenocarcinoma; Lung cancer; Cancer; In vivo; Medicine; Biology; Internal medicine; Genetics","score_opus":0.021694790002659597,"score_gpt":0.3243851626453038,"score_spread":0.3026903726426442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7873733,0.023267085,0.051573116,0.0063677533,0.0033086715,0.0016565636,0.022801885,0.0066050487,0.09704653],"genre_scores_gemma":[0.8903035,0.0071624443,0.020273887,0.0011661323,0.00013568022,0.00038505602,0.009424863,0.0003286339,0.07081988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997272,0.000024958517,0.000019483963,0.00004500273,0.00013567919,0.000047731686],"domain_scores_gemma":[0.9998914,0.000019498988,0.000020885152,0.000011357389,0.00002510292,0.000031768886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002791292,0.0005770381,0.00040685185,0.00054611405,0.00032836004,0.0006066594,0.0004355951,0.0007178786,0.008433161],"category_scores_gemma":[0.00017520363,0.00021816466,0.00041422076,0.0002924008,0.00031662613,0.00022037007,0.00031139207,0.0012411157,0.002734872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017649989,0.000107745174,0.00020006142,0.00009775465,0.00001649934,0.00018701881,0.000015132921,0.00017776462,0.9859751,0.0007357193,0.004422092,0.007888612],"study_design_scores_gemma":[0.000070657414,0.0006033287,0.002168777,0.00001799802,0.00003295252,0.00082739425,0.00002170104,0.0012254624,0.9612792,0.00020319733,0.033536155,0.0000130654225],"about_ca_topic_score_codex":0.0023484218,"about_ca_topic_score_gemma":0.0033843478,"teacher_disagreement_score":0.008433161,"about_ca_system_score_codex":0.0009004746,"about_ca_system_score_gemma":0.0006623981,"threshold_uncertainty_score":0.028211713},"labels":[],"label_agreement":null},{"id":"W4389239845","doi":"10.1158/1535-7163.targ-23-c051","title":"Abstract C051: Alteration of protein translation by eIF4A1 inhibition exquisitely primes lymphoma cells to induction of ferroptosis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bioinformatics Solutions (Canada)","funders":"","keywords":"Transcriptome; GPX4; Cancer research; Biology; Diffuse large B-cell lymphoma; Cancer cell; Cell biology; Lymphoma; Glutathione; Cancer; Gene expression; Biochemistry; Immunology; Gene; Glutathione peroxidase; Genetics","score_opus":0.02214157215039006,"score_gpt":0.27714127663917787,"score_spread":0.25499970448878784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98222256,0.0028999846,0.0036605094,0.00039835775,0.00015600122,0.00009323826,0.0069014286,0.0005463511,0.0031215143],"genre_scores_gemma":[0.98637855,0.000888111,0.0028765812,0.00021400118,0.000020990556,0.000114910705,0.006037758,0.00008253471,0.0033864782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983704,0.000013854477,0.000015349951,0.000046492027,0.00004544806,0.0000417526],"domain_scores_gemma":[0.99992275,0.000014896748,0.000015314492,0.000010190391,0.000013227866,0.000023627887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013799475,0.00033843648,0.000448555,0.00021454768,0.00024772837,0.0003081726,0.00023171227,0.0003279502,0.004384555],"category_scores_gemma":[0.0001278735,0.00009355399,0.00035341518,0.00025092828,0.00024105895,0.00017211275,0.00015884494,0.0006708957,0.0007598396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000513114,0.000054380078,0.0002253854,0.00010404738,0.000010383243,0.000032071213,0.000008243618,0.000109451634,0.99613345,0.00006896461,0.00041321112,0.002327408],"study_design_scores_gemma":[0.00004405638,0.00044875155,0.002960334,0.0000066509224,0.000014740357,0.00009367249,0.000019680563,0.00081962056,0.9914532,0.000035200894,0.0040987474,0.0000052961846],"about_ca_topic_score_codex":0.0012598303,"about_ca_topic_score_gemma":0.0015194584,"teacher_disagreement_score":0.004384555,"about_ca_system_score_codex":0.00042204137,"about_ca_system_score_gemma":0.00035060165,"threshold_uncertainty_score":0.014667749},"labels":[],"label_agreement":null},{"id":"W4389239940","doi":"10.1158/1535-7163.targ-23-a109","title":"Abstract A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pyrimidine metabolism; Dihydroorotate dehydrogenase; Metastasis; Cancer research; Biology; Cancer; Biochemistry; Pyrimidine; Purine; Enzyme; Genetics","score_opus":0.036327890488446965,"score_gpt":0.3446842506897804,"score_spread":0.30835636020133345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9047318,0.034785274,0.021898005,0.006281427,0.0019768798,0.00051918975,0.0026466132,0.002132083,0.025028756],"genre_scores_gemma":[0.96150136,0.012304327,0.0059987265,0.0007139654,0.00010479904,0.0001249015,0.0010922926,0.00007492864,0.018084781],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998858,0.00001203293,0.000010398915,0.000026170683,0.000043099717,0.000022526314],"domain_scores_gemma":[0.99991417,0.000013376161,0.000017378401,0.000006665778,0.000015516574,0.000032912772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017393628,0.00035380336,0.00048100602,0.0003368632,0.00022486337,0.00063623337,0.00038994406,0.0006619309,0.004592887],"category_scores_gemma":[0.0001368842,0.00013544405,0.0002814128,0.0002465091,0.00036307832,0.00034632394,0.00038955428,0.0012383236,0.0008271648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018857063,0.00008226971,0.0002237099,0.00023754593,0.0000145048025,0.00022757547,0.000018152421,0.00014400031,0.98737794,0.0007716328,0.0013027925,0.009411306],"study_design_scores_gemma":[0.00014783586,0.0014519889,0.003363489,0.00005164003,0.000068770125,0.001682118,0.00006739017,0.0016801845,0.94935834,0.0006345327,0.04147069,0.00002298503],"about_ca_topic_score_codex":0.00089606293,"about_ca_topic_score_gemma":0.0011364141,"teacher_disagreement_score":0.004592887,"about_ca_system_score_codex":0.0004395923,"about_ca_system_score_gemma":0.0004928147,"threshold_uncertainty_score":0.015364766},"labels":[],"label_agreement":null},{"id":"W4389239942","doi":"10.1158/1535-7163.targ-23-a158","title":"Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster University","funders":"","keywords":"Medulloblastoma; BMI1; Context (archaeology); Biology; CRISPR; Cancer research; PI3K/AKT/mTOR pathway; Cancer; Gene; Signal transduction; Genetics","score_opus":0.022646037020298843,"score_gpt":0.28626446070610195,"score_spread":0.2636184236858031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96088094,0.008060966,0.016263716,0.00053565647,0.00017415156,0.0005623027,0.0017471658,0.0005135336,0.011261574],"genre_scores_gemma":[0.9812429,0.0037910147,0.01065104,0.00017408583,0.000017089893,0.00015343387,0.00072568667,0.00003803234,0.0032068088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994206,0.0000059359827,0.0000036110494,0.000012930654,0.000022881202,0.000012604811],"domain_scores_gemma":[0.99996674,0.000003787488,0.000009103996,0.0000029843832,0.000006011867,0.0000114106515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010590163,0.0002784538,0.00027136566,0.00030825107,0.00012341328,0.000207644,0.00027823861,0.00022658423,0.002284735],"category_scores_gemma":[0.00010198039,0.00011695837,0.00029855306,0.000177384,0.00014417914,0.00016225316,0.0002336501,0.0005588316,0.00045137343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004102118,0.00024853778,0.00039737218,0.00027574901,0.000031908337,0.00016015372,0.00003021461,0.0018050205,0.9748061,0.00070334034,0.0008267577,0.020304604],"study_design_scores_gemma":[0.00025699037,0.004751601,0.003505442,0.00005335265,0.00014392432,0.00052585267,0.000040401217,0.0063288817,0.95853716,0.00041287718,0.02541398,0.000029482091],"about_ca_topic_score_codex":0.0006665143,"about_ca_topic_score_gemma":0.0019679405,"teacher_disagreement_score":0.002284735,"about_ca_system_score_codex":0.00026302508,"about_ca_system_score_gemma":0.00030251304,"threshold_uncertainty_score":0.007643223},"labels":[],"label_agreement":null},{"id":"W4389239948","doi":"10.1158/1535-7163.targ-23-a161","title":"Abstract A161: A differentiation based therapeutic approach for KMT2A rearranged leukemia in infants and children","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Leukemia; Cancer research; Biology; Cellular differentiation; Childhood leukemia; Immunology; Medicine; Gene; Genetics","score_opus":0.023317490521837108,"score_gpt":0.27921369683628583,"score_spread":0.2558962063144487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97117597,0.017497243,0.0041520693,0.0006293804,0.000109565975,0.00019190808,0.0009335258,0.00030100934,0.005009343],"genre_scores_gemma":[0.97367305,0.012286811,0.007311766,0.00026718035,0.000050427996,0.00018036086,0.0011923194,0.00003502953,0.005003161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994457,0.000010371586,0.0000051458665,0.000011835723,0.000015159487,0.000012945123],"domain_scores_gemma":[0.99996495,0.0000034920743,0.000010542476,0.0000025404968,0.000005048297,0.000013499434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012171738,0.0002989008,0.00027198964,0.00030170052,0.00015577293,0.00021316826,0.00022527475,0.00023747106,0.0017187807],"category_scores_gemma":[0.000076509525,0.000081834456,0.000208509,0.00021956806,0.00014584379,0.00011859409,0.00022778014,0.000522185,0.00048520626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031105492,0.00086874445,0.009043418,0.0005958825,0.00007178833,0.0021952642,0.00012754207,0.00083449675,0.83261645,0.00080692244,0.002990697,0.14673825],"study_design_scores_gemma":[0.00093696703,0.01751779,0.092754394,0.0002323187,0.00025149676,0.024145864,0.00028319907,0.0025414338,0.7607866,0.00063339615,0.09986774,0.00004890085],"about_ca_topic_score_codex":0.00041343353,"about_ca_topic_score_gemma":0.0007352827,"teacher_disagreement_score":0.0017187807,"about_ca_system_score_codex":0.00030129091,"about_ca_system_score_gemma":0.00038902822,"threshold_uncertainty_score":0.005749941},"labels":[],"label_agreement":null},{"id":"W4389239952","doi":"10.1158/1535-7163.targ-23-a150","title":"Abstract A150: Effects of radioimmunotherapy on human and canine osteosarcoma microenvironment","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Radioimmunotherapy; Medicine; Tumor microenvironment; Osteosarcoma; Cancer research; Cancer; Oncology; Immune system; Internal medicine; Immunology; Antibody; Monoclonal antibody","score_opus":0.014507093166392402,"score_gpt":0.27712896738402265,"score_spread":0.2626218742176302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963379,0.0013636341,0.00043186624,0.000053072115,0.000045953704,0.000043017248,0.00023388171,0.00003803256,0.0014526555],"genre_scores_gemma":[0.99679023,0.00048330385,0.00068022805,0.00003866296,0.000014435146,0.000034797413,0.0006765359,0.000010580334,0.0012712092],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999001,0.00001737075,0.000007670633,0.000023522087,0.000023208571,0.00002810981],"domain_scores_gemma":[0.9999244,0.00002349524,0.000014862519,0.000007730017,0.000011390707,0.00001794914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015154338,0.00019894454,0.00025026716,0.00015753372,0.00012487822,0.0002047096,0.00015366757,0.00020190043,0.0016314649],"category_scores_gemma":[0.00008045298,0.00008437013,0.00021724676,0.00013174504,0.00017311625,0.00011423584,0.0001017491,0.00040841496,0.00029422884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002214873,0.0005618191,0.00060497376,0.00012810915,0.000017809814,0.00010869259,0.000060546405,0.00035754475,0.99052435,0.000120115925,0.00035273374,0.004948582],"study_design_scores_gemma":[0.0001238548,0.012490743,0.010225684,0.000010739485,0.000055890403,0.0005156489,0.000093110575,0.0013512425,0.96932226,0.000045781373,0.0057551907,0.000009736547],"about_ca_topic_score_codex":0.0017188265,"about_ca_topic_score_gemma":0.0013738994,"teacher_disagreement_score":0.0017188265,"about_ca_system_score_codex":0.00024536994,"about_ca_system_score_gemma":0.00021358064,"threshold_uncertainty_score":0.0054578185},"labels":[],"label_agreement":null},{"id":"W4389240120","doi":"10.1158/1535-7163.targ-23-b086","title":"Abstract B086: Targeting ATR to overcome Carboplatin resistance in triple-negative breast cancer patient-derived models","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Carboplatin; Triple-negative breast cancer; DNA damage; Cancer research; Olaparib; Apoptosis; Cancer; Biology; Molecular biology; Breast cancer; Chemotherapy; Cisplatin; Poly ADP ribose polymerase; DNA; Polymerase; Genetics","score_opus":0.01619635138061313,"score_gpt":0.27038447573317664,"score_spread":0.2541881243525635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97994256,0.0021492713,0.0052556386,0.0007047199,0.00013303431,0.00037276556,0.006493451,0.0003614086,0.004587074],"genre_scores_gemma":[0.9777909,0.001577619,0.0049550934,0.00021883339,0.000019151983,0.00037779193,0.0057648355,0.0000782563,0.009217519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973303,0.00004404914,0.00002816092,0.00005191613,0.000096278054,0.00004660865],"domain_scores_gemma":[0.99988794,0.000016053176,0.000021096272,0.000019862084,0.000015368707,0.000039655224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003953473,0.00046711136,0.00049503904,0.00044570147,0.00026837178,0.0004597181,0.0004987222,0.00066483434,0.004118111],"category_scores_gemma":[0.00012562935,0.00023314606,0.00047602213,0.00030819376,0.000269684,0.000205826,0.00022215102,0.001604905,0.0013961457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065642735,0.0005243574,0.0004196692,0.00009954841,0.000027657254,0.00017662912,0.00004146634,0.00047284205,0.9927141,0.00022891494,0.0009993488,0.003639035],"study_design_scores_gemma":[0.00031682572,0.003984604,0.0041435556,0.000024598865,0.00007008974,0.0016526579,0.00007454614,0.0033499007,0.9716959,0.00013619152,0.014536082,0.000015053885],"about_ca_topic_score_codex":0.0015625613,"about_ca_topic_score_gemma":0.0017156164,"teacher_disagreement_score":0.004118111,"about_ca_system_score_codex":0.0005960953,"about_ca_system_score_gemma":0.00050470454,"threshold_uncertainty_score":0.013776481},"labels":[],"label_agreement":null},{"id":"W4389240124","doi":"10.1158/1535-7163.targ-23-c003","title":"Abstract C003: A quantitative mass spectrometry workflow for highly multiplexed measurement of immunomodulatory proteins to support immunotherapy clinical trials","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FuelCell Energy (Canada)","funders":"","keywords":"Peptide; Chemistry; Immunotherapy; Mass spectrometry; Selected reaction monitoring; Computational biology; Biomarker; Tandem mass spectrometry; Antibody; Chromatography; Biomarker discovery; Quantitative proteomics; Sample preparation; Immune system; Proteomics; Biology; Biochemistry; Immunology","score_opus":0.16647023828762625,"score_gpt":0.4365019973843337,"score_spread":0.27003175909670746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240124","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052796964,0.0024499747,0.8358567,0.001805892,0.0008567933,0.005277498,0.017835721,0.06995578,0.01316484],"genre_scores_gemma":[0.13025597,0.0007607554,0.8435517,0.0018103132,0.00038352393,0.0067230226,0.009044694,0.0030655724,0.0044045206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932121,0.0012918685,0.00059427106,0.0014850098,0.0030359593,0.00038069527],"domain_scores_gemma":[0.99332994,0.0018182022,0.00077902566,0.0006892636,0.0027111927,0.0006722952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010069452,0.0027670602,0.0014462196,0.0065450664,0.001543107,0.003725767,0.0026271222,0.0028220478,0.011954495],"category_scores_gemma":[0.009167219,0.0012188089,0.0011567236,0.0018136995,0.0011270135,0.0014494779,0.0024091066,0.002413827,0.008457691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025875263,0.0006561361,0.0069364663,0.0010211096,0.0004023856,0.0005903499,0.00026037436,0.003601465,0.8234106,0.0049781455,0.047752153,0.10780342],"study_design_scores_gemma":[0.00085853453,0.001101708,0.013637368,0.00038688738,0.00021545726,0.0019126459,0.00013086713,0.1515863,0.73699886,0.006641892,0.085979804,0.0005496786],"about_ca_topic_score_codex":0.0018119705,"about_ca_topic_score_gemma":0.0025097667,"teacher_disagreement_score":0.011954495,"about_ca_system_score_codex":0.0020405205,"about_ca_system_score_gemma":0.0053046495,"threshold_uncertainty_score":0.053252935},"labels":[],"label_agreement":null},{"id":"W4389240146","doi":"10.1158/1535-7163.targ-23-a034","title":"Abstract A034: Synthesis and biological activities of a novel series of “combi-molecules” designed to delay metabolic dealkylation prior to crossing the blood brain barrier in the context of optimizing their potency against glioblastoma multiforme","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gefitinib; Temozolomide; Pharmacology; Context (archaeology); Cancer research; In vivo; Tyrosine kinase; Epidermal growth factor receptor; U87; Potency; Chemistry; Medicine; Cancer; Biology; Internal medicine; In vitro; Signal transduction; Glioma; Biochemistry; Genetics","score_opus":0.034743075980362505,"score_gpt":0.2932496063632243,"score_spread":0.25850653038286175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891383,0.0030162004,0.0031002518,0.000107376276,0.00006420663,0.00013305245,0.0006002076,0.00012201536,0.0039427266],"genre_scores_gemma":[0.9905377,0.0014409823,0.004197521,0.000106445645,0.000019917916,0.00008440837,0.0007251763,0.000017658433,0.0028701678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999665,0.000004758812,0.0000032805553,0.000009222621,0.0000074718055,0.000008623088],"domain_scores_gemma":[0.9999654,0.000003680384,0.0000096165295,0.0000026722482,0.000006262228,0.000012293795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076552446,0.0003240161,0.00015702698,0.00019455492,0.00007931543,0.0001421373,0.00032246142,0.00024204193,0.0019057137],"category_scores_gemma":[0.00008431713,0.00007879624,0.00017520682,0.00012579729,0.00009093878,0.00016225995,0.000077244826,0.00022924755,0.0003952582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048605242,0.00029579393,0.00014485315,0.00016154422,0.000019460313,0.000072848896,0.00001846423,0.0004899975,0.98363054,0.0002715326,0.00037937032,0.014029604],"study_design_scores_gemma":[0.00042947938,0.008323103,0.0036712415,0.000018552657,0.00006896515,0.00034526177,0.000020597645,0.0034042823,0.9729024,0.000079050915,0.010707357,0.000029670453],"about_ca_topic_score_codex":0.00049126975,"about_ca_topic_score_gemma":0.0006632449,"teacher_disagreement_score":0.0019057137,"about_ca_system_score_codex":0.00017325481,"about_ca_system_score_gemma":0.00014575385,"threshold_uncertainty_score":0.006375253},"labels":[],"label_agreement":null},{"id":"W4389240186","doi":"10.1158/1535-7163.targ-23-a045","title":"Abstract A045: EZH2 inhibition re-sensitizes drug resistant triple-negative breast cancer PDX models to Eribulin","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Eribulin; Medicine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Cancer; Drug resistance; Triple-negative breast cancer; Cancer research; Biology","score_opus":0.033048788028452444,"score_gpt":0.29665449180796155,"score_spread":0.2636057037795091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735642,0.0011865065,0.008020315,0.0006001699,0.00025470246,0.00020618665,0.0094456365,0.00052484067,0.0061974213],"genre_scores_gemma":[0.9681845,0.0008265929,0.004546335,0.00036030464,0.000023381755,0.0003282134,0.007190109,0.00013310452,0.018407382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997503,0.000022183332,0.000023035425,0.00006663991,0.00008932827,0.00004841322],"domain_scores_gemma":[0.99986887,0.00001652568,0.000028705239,0.000020818403,0.000018971268,0.00004612039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021852588,0.00032171185,0.00038078427,0.00032200766,0.0002554856,0.00046085537,0.00030033247,0.0004742463,0.0041917376],"category_scores_gemma":[0.00012289059,0.00014467686,0.00037967836,0.0002006396,0.00034427783,0.0002186136,0.00020353541,0.0013718519,0.00094877725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005122415,0.00020480233,0.00042861362,0.00008167049,0.000018579662,0.000089434485,0.00004603807,0.0003596584,0.99310803,0.00045712857,0.0012429076,0.003450877],"study_design_scores_gemma":[0.00009829104,0.0015856466,0.0051013087,0.000018411749,0.00004498796,0.00034517405,0.00011443869,0.003426921,0.9743524,0.00016981534,0.014729154,0.000013572632],"about_ca_topic_score_codex":0.0011884487,"about_ca_topic_score_gemma":0.0014534489,"teacher_disagreement_score":0.0041917376,"about_ca_system_score_codex":0.0005011492,"about_ca_system_score_gemma":0.00030579232,"threshold_uncertainty_score":0.014022708},"labels":[],"label_agreement":null},{"id":"W4389241514","doi":"10.1158/1535-7163.targ-23-b130","title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Trastuzumab; Pharmacokinetics; Internal medicine; Population; Cancer; Pharmacology; Adverse effect; Antibody-drug conjugate; Oncology; Breast cancer; Antibody; Gastroenterology; Immunology; Monoclonal antibody","score_opus":0.040658240370309094,"score_gpt":0.36794027471688073,"score_spread":0.32728203434657166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922312,0.001473055,0.00069690205,0.00023618818,0.000026763155,0.0013022502,0.0018946409,0.00007115637,0.0020677801],"genre_scores_gemma":[0.9885462,0.0013464408,0.0020576157,0.00042729935,0.00006353503,0.00076725567,0.003677061,0.00003825984,0.0030763762],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997662,0.0001090558,0.000011918885,0.000036819587,0.000039178216,0.000036834725],"domain_scores_gemma":[0.99975437,0.00004140613,0.000070439695,0.000016960706,0.000017052524,0.00009982621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008169634,0.0007835844,0.00089417683,0.00027851964,0.00021410608,0.0005639048,0.0004378145,0.00052933063,0.002862718],"category_scores_gemma":[0.00056041585,0.00034139806,0.00047959868,0.00026212234,0.0004145065,0.00044605744,0.0002514995,0.0017647468,0.0006363498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34211245,0.048313566,0.024697997,0.001007485,0.0008146818,0.00064982835,0.00042206515,0.0061472952,0.3441686,0.0007237726,0.010373119,0.2205691],"study_design_scores_gemma":[0.22373797,0.63168806,0.07862903,0.0000743191,0.0006331598,0.0013980909,0.00014144962,0.0050386507,0.04373886,0.0005096051,0.014347584,0.000063302854],"about_ca_topic_score_codex":0.001052895,"about_ca_topic_score_gemma":0.0024771104,"teacher_disagreement_score":0.002862718,"about_ca_system_score_codex":0.00072421366,"about_ca_system_score_gemma":0.0011007494,"threshold_uncertainty_score":0.009576738},"labels":[],"label_agreement":null},{"id":"W4389241633","doi":"10.1158/1535-7163.targ-23-c082","title":"Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; McMaster University","funders":"","keywords":"Medulloblastoma; In vivo; Biology; Lipid metabolism; Cancer research; Wnt signaling pathway; Transcriptome; Enzyme; In vitro; Chemistry; Biochemistry; Gene; Genetics; Gene expression","score_opus":0.02090510750237412,"score_gpt":0.28368864123222604,"score_spread":0.2627835337298519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030626,0.004533117,0.0013012127,0.00023522874,0.000071026865,0.00007672412,0.0013459733,0.00015350568,0.0019768078],"genre_scores_gemma":[0.99348736,0.0017337145,0.0013199862,0.00012244366,0.000016893782,0.00004123236,0.001390297,0.000016573347,0.00187133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999635,0.000004415627,0.0000028226502,0.0000068510417,0.000011786779,0.0000104908195],"domain_scores_gemma":[0.99997675,0.0000028354195,0.0000052003347,0.0000019270842,0.000003566854,0.000009645736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006889782,0.0002480548,0.00022430363,0.00022795265,0.00012132778,0.00019141617,0.00013875596,0.00023521116,0.001257782],"category_scores_gemma":[0.00005185095,0.000054770422,0.00015551233,0.00017436135,0.000107480475,0.00007654521,0.00011364445,0.00047964574,0.00033582235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075847807,0.00011255335,0.0005170822,0.00007485496,0.000015417289,0.00009330458,0.000011397566,0.00017946036,0.98885113,0.00009262202,0.00042766685,0.008866023],"study_design_scores_gemma":[0.00015543096,0.0016313775,0.006818091,0.000010627016,0.000047790458,0.00052469684,0.00002515689,0.00092612155,0.9805397,0.00006933962,0.009244997,0.0000067334026],"about_ca_topic_score_codex":0.0009040418,"about_ca_topic_score_gemma":0.0018590754,"teacher_disagreement_score":0.001257782,"about_ca_system_score_codex":0.0002630459,"about_ca_system_score_gemma":0.0002543714,"threshold_uncertainty_score":0.0042076707},"labels":[],"label_agreement":null},{"id":"W4389241646","doi":"10.1158/1535-7163.targ-23-b169","title":"Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring <i>CCNE1</i> amplification and/or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Medicine; Oncology; Biomarker; Tolerability; Cyclin E1; Concordance; Fluorescence in situ hybridization; Cancer research; Cancer; Biology; Cyclin D1; Cell cycle; Adverse effect; Gene; Genetics","score_opus":0.03904351749104924,"score_gpt":0.35771871629521995,"score_spread":0.3186751988041707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98616993,0.0018582733,0.0012131131,0.00029668259,0.000054926208,0.00063282566,0.0068629812,0.00007736218,0.0028338905],"genre_scores_gemma":[0.9831186,0.0003502999,0.0014937607,0.00051542115,0.000072944276,0.00044278885,0.012995729,0.000033208056,0.0009773202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921477,0.00024071737,0.00006799368,0.00023311155,0.00015420564,0.00008913273],"domain_scores_gemma":[0.99902904,0.00017513448,0.0002738035,0.00013227487,0.000092263515,0.00029743285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017044602,0.00057865266,0.0010036563,0.00027393288,0.0005958499,0.0010531503,0.00038272436,0.00054572977,0.0028319492],"category_scores_gemma":[0.0015730553,0.00030219997,0.00057373254,0.00038583475,0.0004090557,0.0007214528,0.00041440557,0.0011467913,0.0008754394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24769117,0.0072994474,0.5545618,0.00080406066,0.0022558465,0.0024644039,0.00036522863,0.0035686665,0.06296146,0.0008014738,0.0148626845,0.102363735],"study_design_scores_gemma":[0.020457532,0.118210115,0.8043705,0.000130012,0.002339106,0.0053483197,0.00023535285,0.0043439646,0.018594595,0.0010932855,0.024748622,0.00012861918],"about_ca_topic_score_codex":0.0004877274,"about_ca_topic_score_gemma":0.000979423,"teacher_disagreement_score":0.0028319492,"about_ca_system_score_codex":0.0006849082,"about_ca_system_score_gemma":0.001024139,"threshold_uncertainty_score":0.009473741},"labels":[],"label_agreement":null},{"id":"W4389241863","doi":"10.1158/1535-7163.targ-23-c028","title":"Abstract C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Radioimmunotherapy; Cancer research; Leukapheresis; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Pharmacology; Antibody; Stem cell; Internal medicine; Biology; CD34","score_opus":0.056765147181907914,"score_gpt":0.3818371142617724,"score_spread":0.3250719670798645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835677,0.00086132076,0.00074640906,0.00042202,0.00015611287,0.0052931383,0.0019223457,0.00016698962,0.0020748626],"genre_scores_gemma":[0.9795681,0.0009567006,0.0021675301,0.0013449299,0.00025745563,0.0060136914,0.003455522,0.00006562862,0.0061703795],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995722,0.00016018789,0.00001981486,0.0000870938,0.000053577372,0.0001070402],"domain_scores_gemma":[0.9991979,0.000100514044,0.000106898326,0.000069121896,0.00008468249,0.00044088354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016014064,0.0016445301,0.0016850284,0.00047015617,0.0006632876,0.00095133344,0.00096732733,0.0019170329,0.004745844],"category_scores_gemma":[0.00071063824,0.0005535212,0.0009966271,0.0003387247,0.00095278845,0.0007146363,0.0002699047,0.0035021254,0.0015178446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5034016,0.23618758,0.005808079,0.0009135888,0.00080721057,0.00079524826,0.00046366343,0.0020201763,0.1653221,0.00039894538,0.010504571,0.07337738],"study_design_scores_gemma":[0.16083528,0.82529235,0.0045783804,0.000017303915,0.0001748097,0.0002658112,0.000054854496,0.00075655465,0.0055442755,0.000101487894,0.0023586506,0.000020189811],"about_ca_topic_score_codex":0.0015883029,"about_ca_topic_score_gemma":0.0027394877,"teacher_disagreement_score":0.004745844,"about_ca_system_score_codex":0.0009514917,"about_ca_system_score_gemma":0.0020289025,"threshold_uncertainty_score":0.015876412},"labels":[],"label_agreement":null},{"id":"W4389241939","doi":"10.1158/1535-7163.targ-23-pr003","title":"Abstract PR003: Repotrectinib in patients with <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; ROS1; Cohort; Clinical endpoint; Lung cancer; Oncology; Cancer; Clinical trial; Adenocarcinoma","score_opus":0.013758122112712929,"score_gpt":0.317288329426474,"score_spread":0.30353020731376107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387819,0.028879715,0.001553471,0.0035488466,0.0004562488,0.001911653,0.008216796,0.00063354685,0.016017819],"genre_scores_gemma":[0.9681461,0.010146721,0.0015863848,0.002395813,0.00035490832,0.0012100053,0.01034438,0.000066597335,0.0057492545],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99981385,0.00008159136,0.00001186841,0.000027055368,0.0000346328,0.000030882173],"domain_scores_gemma":[0.9997496,0.000048246155,0.000081334096,0.0000145005815,0.000035705514,0.000070569746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008401093,0.0005144827,0.00063931756,0.0001697759,0.00014703585,0.0006268621,0.0005198759,0.0004588512,0.0065383976],"category_scores_gemma":[0.0005308365,0.00011456986,0.0008924838,0.00027078955,0.00022247342,0.0004382216,0.00023107928,0.0013980649,0.00090428686],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35680208,0.005797239,0.015893234,0.004549926,0.0030422327,0.0005634669,0.00019373048,0.0018978936,0.07035629,0.0009681107,0.06956553,0.47037023],"study_design_scores_gemma":[0.5607756,0.24990062,0.09152028,0.0007488895,0.004382747,0.002737539,0.00020874059,0.0037386387,0.020718709,0.0014939724,0.063661315,0.00011302099],"about_ca_topic_score_codex":0.00057662,"about_ca_topic_score_gemma":0.0018773056,"teacher_disagreement_score":0.0065383976,"about_ca_system_score_codex":0.0005952771,"about_ca_system_score_gemma":0.0005683123,"threshold_uncertainty_score":0.021873116},"labels":[],"label_agreement":null},{"id":"W4389242040","doi":"10.1158/1535-7163.targ-23-b125","title":"Abstract B125: Neutralizing acidosis with L-DOS47 urease immunoconjugate enhances responses to anti-PD1 checkpoint blockade in a preclinical orthotopic model of pancreatic adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada); University of Calgary","funders":"","keywords":"Cancer research; Medicine; Pancreatic cancer; Tumor microenvironment; Cancer; Immunoconjugate; Pharmacology; Internal medicine; Immunology; Antibody","score_opus":0.04433827230524842,"score_gpt":0.32572716228300996,"score_spread":0.28138888997776157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650276,0.0006460075,0.001235894,0.00008093415,0.000041330815,0.00005374754,0.00027923097,0.00009902103,0.0010611293],"genre_scores_gemma":[0.9952642,0.00047138042,0.00134956,0.000052408628,0.000014062716,0.00006529167,0.00043053628,0.000016252552,0.0023362355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999087,0.000011906586,0.000006846447,0.00001822786,0.000027503174,0.000026839201],"domain_scores_gemma":[0.9999442,0.0000070852266,0.00001468198,0.000005714146,0.0000074065256,0.000020976462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013655398,0.0003456242,0.00031781103,0.00021590371,0.00008225435,0.00019585203,0.00015080276,0.00026713492,0.0014607941],"category_scores_gemma":[0.00007468531,0.000111928115,0.00021655273,0.00013058675,0.00016126462,0.00016953729,0.00009131601,0.00060170714,0.00026346708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000503904,0.00020318353,0.00008917668,0.000036795518,0.000006581916,0.0000150399,0.000007646319,0.0001193967,0.9975399,0.000021505724,0.00007953777,0.0013774576],"study_design_scores_gemma":[0.00007561132,0.0034499534,0.0013956843,0.0000031370223,0.000019317356,0.000059554783,0.000011775682,0.0008973944,0.9932736,0.000012350016,0.0007987942,0.0000027111616],"about_ca_topic_score_codex":0.00058393984,"about_ca_topic_score_gemma":0.00054949906,"teacher_disagreement_score":0.0014607941,"about_ca_system_score_codex":0.00019508564,"about_ca_system_score_gemma":0.00019699034,"threshold_uncertainty_score":0.004886806},"labels":[],"label_agreement":null},{"id":"W4389242080","doi":"10.1158/1535-7163.targ-23-b035","title":"Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Chimeric antigen receptor; Pneumonitis; Internal medicine; T cell; Pharmacokinetics; Leukapheresis; Immunotherapy; Refractory (planetary science); Oncology; Gastroenterology; Pharmacology; Cancer; Immunology; Immune system; Lung; Stem cell","score_opus":0.07208883215688347,"score_gpt":0.3961923356484441,"score_spread":0.3241035034915606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699075,0.0017816757,0.00065016595,0.0007321367,0.00015209026,0.0029303783,0.0028908227,0.0001784016,0.0036936582],"genre_scores_gemma":[0.9827387,0.0012741083,0.0018496827,0.0016744396,0.00016672205,0.002583923,0.0055302405,0.00004810753,0.0041339872],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995906,0.00020681182,0.000022339489,0.00006082327,0.00004108908,0.000078350626],"domain_scores_gemma":[0.9994228,0.00008569917,0.00008238104,0.000045334968,0.000030364004,0.00033355382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016891806,0.0011418402,0.0013280476,0.00038782516,0.00043255519,0.0008860518,0.0008974107,0.0011095924,0.0066430448],"category_scores_gemma":[0.0006468879,0.00040637274,0.00085627876,0.00038144077,0.00077641953,0.0005865576,0.00029816304,0.0027134211,0.0017169596],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73792887,0.07720813,0.0065394454,0.0008637152,0.00129984,0.00052328204,0.00022306756,0.0018445009,0.05884608,0.00056039775,0.011479546,0.10268306],"study_design_scores_gemma":[0.5823302,0.40124145,0.0067500058,0.00004687752,0.0002982868,0.00030353363,0.000053684842,0.0016019929,0.0043450855,0.00024877157,0.0027595572,0.000020547504],"about_ca_topic_score_codex":0.0015726628,"about_ca_topic_score_gemma":0.002617477,"teacher_disagreement_score":0.0066430448,"about_ca_system_score_codex":0.0008861004,"about_ca_system_score_gemma":0.0017753596,"threshold_uncertainty_score":0.022223234},"labels":[],"label_agreement":null},{"id":"W4389242188","doi":"10.1158/1535-7163.targ-23-c097","title":"Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; McMaster University","funders":"","keywords":"Pyrimidine metabolism; Metabolomics; Transcriptome; Dihydroorotate dehydrogenase; Biology; Medulloblastoma; Cancer research; CRISPR; Pyrimidine; Biochemistry; Computational biology; Genetics; Enzyme; Bioinformatics; Gene; Purine; Gene expression","score_opus":0.023224252692736997,"score_gpt":0.30126416254341226,"score_spread":0.2780399098506753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952827,0.0008463012,0.0012753223,0.00007471959,0.0000074266154,0.000025463087,0.0016292982,0.00009288747,0.00076584285],"genre_scores_gemma":[0.99590164,0.00056966796,0.0012711181,0.00005328572,0.0000023028224,0.000014622011,0.0013783684,0.000025937656,0.00078306114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994516,0.0000036151405,0.0000027585388,0.000013855541,0.000022237566,0.000012270846],"domain_scores_gemma":[0.9999496,0.0000062273607,0.000016032762,0.0000046454866,0.0000069465204,0.000016617005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000648839,0.00027275283,0.00021177951,0.00030233082,0.00015201939,0.0002477742,0.00015019301,0.0002657654,0.0009717497],"category_scores_gemma":[0.00008421708,0.0000861107,0.00021597598,0.00027698642,0.00020465243,0.00009343986,0.00017323729,0.00031249662,0.00022699856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018810321,0.00001594218,0.0015796929,0.000034332374,0.00000896551,0.00011950001,0.000008439233,0.0001482841,0.9961414,0.00006151087,0.000055640434,0.0016383217],"study_design_scores_gemma":[0.00001885538,0.00048450078,0.06405012,0.000011941854,0.000041744894,0.0013036202,0.000054102802,0.0020855167,0.9284115,0.00021105398,0.003316135,0.000010961367],"about_ca_topic_score_codex":0.0036533892,"about_ca_topic_score_gemma":0.0048831156,"teacher_disagreement_score":0.0036533892,"about_ca_system_score_codex":0.0006618504,"about_ca_system_score_gemma":0.0002940833,"threshold_uncertainty_score":0.007264197},"labels":[],"label_agreement":null},{"id":"W4390743751","doi":"10.1158/1535-7163.mct-23-0747","title":"PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; CancerCare Manitoba Foundation; Strong; Research Manitoba","keywords":"Cancer; Protein degradation; Proteasome; Ubiquitin; Computational biology; Cancer therapy; Medicine; Bioinformatics; Biology; Cell biology; Genetics","score_opus":0.016959634164403457,"score_gpt":0.32957666936802354,"score_spread":0.3126170352036201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390743751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018879738,0.92744917,0.021756375,0.011864438,0.0012034627,0.00010418116,0.00034111246,0.00057858037,0.017822906],"genre_scores_gemma":[0.12684861,0.83245635,0.019908048,0.0057924055,0.00072176184,0.00013701693,0.00075379235,0.00008929981,0.013292639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979657,0.000037412465,0.000012074479,0.000041187475,0.000073187766,0.000039646762],"domain_scores_gemma":[0.999744,0.000063854124,0.000053908887,0.000017619754,0.00005892815,0.000061751285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086554757,0.00061974506,0.00060773233,0.00058550754,0.0003455512,0.0015501722,0.0005654007,0.0011304629,0.003682226],"category_scores_gemma":[0.00043177532,0.00021391835,0.000464,0.000508822,0.0008757347,0.0017239199,0.0007127305,0.0020454496,0.001476156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007253162,0.0003278615,0.0009135876,0.0037815957,0.00012207554,0.0008126723,0.0002183462,0.0030306461,0.12501195,0.050906215,0.03240331,0.7817464],"study_design_scores_gemma":[0.00013027288,0.0015902498,0.000933036,0.0006138178,0.00011398027,0.0028878634,0.0001745388,0.0023610652,0.060929816,0.015732173,0.91445136,0.00008184168],"about_ca_topic_score_codex":0.00045257527,"about_ca_topic_score_gemma":0.0010067482,"teacher_disagreement_score":0.003682226,"about_ca_system_score_codex":0.0008233473,"about_ca_system_score_gemma":0.0008241208,"threshold_uncertainty_score":0.0123182535},"labels":[],"label_agreement":null},{"id":"W4391805157","doi":"10.1158/1535-7163.mct-23-0822","title":"Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Camptothecin; Drug; Conjugate; Pharmacology; Payload (computing); Antibody; Chemistry; Medicine; Immunology; Biochemistry; Computer science","score_opus":0.12025473286422184,"score_gpt":0.44940770754084514,"score_spread":0.3291529746766233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391805157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835003,0.001392121,0.007722209,0.00009140724,0.000016858114,0.00042522384,0.00029041406,0.000044096898,0.0016675892],"genre_scores_gemma":[0.98794496,0.0011345681,0.008630668,0.000035531328,0.000008207376,0.00010598494,0.00046974747,0.000009643556,0.0016606518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999143,0.000015579728,0.000007439363,0.000018621311,0.000026601472,0.000017532453],"domain_scores_gemma":[0.99994695,0.0000061074097,0.000016555683,0.000004471328,0.000011466998,0.000014423648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016654968,0.00030459353,0.00017858265,0.00017956598,0.00014067462,0.000184706,0.00022769698,0.00026502958,0.000528358],"category_scores_gemma":[0.00014847404,0.00010786056,0.00013168815,0.00012755686,0.00013869285,0.00019066149,0.00013376305,0.00027448896,0.00020437884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017827336,0.00014192387,0.00029519,0.00006415332,0.000008379128,0.00008426829,0.00002538633,0.0020199122,0.9886827,0.00032284923,0.00008323413,0.008093662],"study_design_scores_gemma":[0.00008204547,0.0019724504,0.0012156387,0.000004853675,0.000014483627,0.00019925846,0.000008327541,0.0018921323,0.9904715,0.00003240411,0.0041007698,0.000006117998],"about_ca_topic_score_codex":0.0004413884,"about_ca_topic_score_gemma":0.00062690116,"teacher_disagreement_score":0.000528358,"about_ca_system_score_codex":0.00043825922,"about_ca_system_score_gemma":0.00025220524,"threshold_uncertainty_score":0.0031797886},"labels":[],"label_agreement":null},{"id":"W4392123900","doi":"10.1158/1535-7163.mct-23-0868","title":"Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Victoria; National Research Council Canada","funders":"National Cancer Institute; National Institute of General Medical Sciences; University of Nebraska-Lincoln; National Institutes of Health; American Cancer Society","keywords":"Antibody; Cancer; Pancreatic cancer; Humanized antibody; Medicine; Humanized mouse; Immunology; Cancer research; Pharmacology; Immune system; Internal medicine; Monoclonal antibody","score_opus":0.10186513711662239,"score_gpt":0.38613226941365764,"score_spread":0.28426713229703526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392123900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930998,0.000637141,0.0044301804,0.00008074089,0.000017532057,0.00002778617,0.0001160472,0.000036977508,0.0015536803],"genre_scores_gemma":[0.9974462,0.00018979497,0.0014719929,0.00005653059,0.0000029390553,0.0000069429875,0.00019116722,0.0000068393106,0.0006275512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994147,0.000011453558,0.0000039298757,0.00001176498,0.000014093614,0.000017261222],"domain_scores_gemma":[0.9999664,0.000004379305,0.00001003753,0.0000029692342,0.0000068378113,0.000009512882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008429414,0.00018704758,0.00011327001,0.000055188862,0.00008842224,0.00014225581,0.00030910596,0.00019840863,0.000994784],"category_scores_gemma":[0.00008119674,0.00010112849,0.00020181977,0.000041289146,0.000114394104,0.000091802765,0.00016375737,0.00032234736,0.00029834305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096385746,0.000029799767,0.00024216795,0.00002258034,0.0000061780624,0.0000791028,0.000010097628,0.0002493508,0.9979109,0.00024252065,0.00004248415,0.0010683825],"study_design_scores_gemma":[0.0000444311,0.0004905208,0.004619963,0.0000064165356,0.000018783016,0.00071780966,0.000021787891,0.0039918884,0.9866182,0.000129372,0.0033348955,0.0000057401553],"about_ca_topic_score_codex":0.00034870996,"about_ca_topic_score_gemma":0.000295299,"teacher_disagreement_score":0.000994784,"about_ca_system_score_codex":0.00018942368,"about_ca_system_score_gemma":0.000123796,"threshold_uncertainty_score":0.0033278465},"labels":[],"label_agreement":null},{"id":"W4392243634","doi":"10.1158/1535-7163.mct-23-0876","title":"ATPase Copper Transporting Beta (ATP7B) Is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chao Family Comprehensive Cancer Center; National Cancer Institute; National Institutes of Health; National Institute of General Medical Sciences; Canadian Institute for Advanced Research; U.S. Department of Veterans Affairs","keywords":"Disulfiram; Docetaxel; Cancer; Prostate cancer; Copper; Pharmacology; Medicine; Cancer research; Internal medicine; Chemistry","score_opus":0.022507716593409412,"score_gpt":0.30820903045262193,"score_spread":0.28570131385921255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392243634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98149925,0.011958755,0.0035574366,0.0003513794,0.00009691062,0.000060956732,0.00035757324,0.00017797177,0.00193984],"genre_scores_gemma":[0.98917073,0.0041603004,0.002628162,0.0001012968,0.000022691442,0.00005197145,0.00070636085,0.00002718466,0.0031313205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994326,0.0000062453187,0.0000034524608,0.000013856875,0.00002214394,0.000011037175],"domain_scores_gemma":[0.99997866,0.0000018012112,0.000005310286,0.0000016631051,0.0000053083413,0.0000071798913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093033465,0.00027441568,0.00035192326,0.00017205434,0.00017581278,0.00022423948,0.00020131624,0.00020252858,0.0010761602],"category_scores_gemma":[0.000065622145,0.00014067878,0.00020176242,0.00019877125,0.00013792845,0.00009986382,0.0001138854,0.00032564005,0.00024176699],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002766185,0.000054401662,0.00046267614,0.00013608752,0.000015562646,0.00005341516,0.000017410432,0.00013452437,0.9870703,0.000107668144,0.00035975158,0.011311701],"study_design_scores_gemma":[0.0001526121,0.0013948247,0.009564979,0.000016391878,0.00011018518,0.00046541844,0.00004309169,0.0028477428,0.9672756,0.00008541501,0.018031675,0.000011889972],"about_ca_topic_score_codex":0.0013725766,"about_ca_topic_score_gemma":0.0029382284,"teacher_disagreement_score":0.0013725766,"about_ca_system_score_codex":0.00035123498,"about_ca_system_score_gemma":0.00023694051,"threshold_uncertainty_score":0.0036001205},"labels":[],"label_agreement":null},{"id":"W4394750689","doi":"10.1158/1535-7163.mct-23-0761","title":"Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Beetle Biology and Toxicology Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network; Telesta Therapeutics (Canada)","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; U.S. Department of Defense","keywords":"RNase P; Biology; Leiomyosarcoma; Immunohistochemistry; Copy number analysis; Copy-number variation; Microarray; Molecular biology; Cancer research; Andrology; Gene; Pathology; Medicine; Genetics; Immunology; Gene expression; RNA","score_opus":0.01985373473061958,"score_gpt":0.2875097695471899,"score_spread":0.2676560348165703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394750689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992403,0.00012876611,0.00024378674,0.000009777916,8.2348714e-7,0.0000050024505,0.00010905708,0.000015653,0.000246969],"genre_scores_gemma":[0.99892247,0.00008182066,0.00052898197,0.000013129665,0.0000042454776,0.000010446749,0.00025527648,0.0000068045165,0.00017684676],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998442,0.000019966257,0.000024606858,0.000041390696,0.000035730493,0.000034142005],"domain_scores_gemma":[0.99968433,0.00006322191,0.00011224219,0.000042718075,0.0000314408,0.00006605782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002369929,0.00018229862,0.00025512412,0.00092122296,0.0001504932,0.00022865988,0.00013536116,0.00018203132,0.0008429033],"category_scores_gemma":[0.0005075739,0.00015119267,0.00014548932,0.00032092,0.00028631336,0.00014956575,0.00024675505,0.0001254395,0.00027485663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070345897,0.000039081886,0.562119,0.000055240955,0.000032470085,0.003368366,0.0002002325,0.00012319467,0.42214864,0.000085407475,0.00023195634,0.010892865],"study_design_scores_gemma":[0.000019032128,0.0003217132,0.93744063,0.0000074224254,0.000043821787,0.020162126,0.00020164944,0.00080765766,0.039905716,0.00009707409,0.0009857416,0.000007512497],"about_ca_topic_score_codex":0.00035101705,"about_ca_topic_score_gemma":0.00087896234,"teacher_disagreement_score":0.00092122296,"about_ca_system_score_codex":0.00012114951,"about_ca_system_score_gemma":0.00009356826,"threshold_uncertainty_score":0.0028197765},"labels":[],"label_agreement":null},{"id":"W4398256048","doi":"10.1158/1535-7163.mct-23-0681","title":"Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Etoposide; DNA; DNA damage; Cancer research; Sensitization; Chemistry; Biology; Molecular biology; Pharmacology; Pathology; Chemotherapy; Immunology; Medicine; Biochemistry","score_opus":0.006169938039703382,"score_gpt":0.24723507276119552,"score_spread":0.24106513472149213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398256048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98377913,0.0083985245,0.0026134704,0.00008838896,0.000050186365,0.000095779746,0.00089457433,0.00014116813,0.003938647],"genre_scores_gemma":[0.98522043,0.0040580654,0.002419569,0.000060095354,0.000017125394,0.00016636022,0.0016160677,0.00003196261,0.0064104493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994823,0.00008129917,0.000038696307,0.00012592642,0.00017781841,0.00009403191],"domain_scores_gemma":[0.9997346,0.00004420626,0.00007933879,0.000041806732,0.000040794763,0.000059256257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002962312,0.0006301597,0.0004924299,0.0006222092,0.00016131168,0.00044210444,0.00022159358,0.00038631464,0.0031014166],"category_scores_gemma":[0.00020590767,0.00025279121,0.0003991612,0.00033139013,0.00031315154,0.0005013453,0.00023048847,0.0010916303,0.00060264324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036491078,0.000103050086,0.00042935758,0.000057914178,0.000014717086,0.00002229031,0.000017056822,0.00009756372,0.99576294,0.00006201078,0.000036418325,0.0030316412],"study_design_scores_gemma":[0.000018664037,0.0022560689,0.015036366,0.000008501207,0.000024958168,0.0002572415,0.00004064299,0.00028951335,0.9801639,0.00003869691,0.0018601259,0.0000053507797],"about_ca_topic_score_codex":0.0004239502,"about_ca_topic_score_gemma":0.0007808644,"teacher_disagreement_score":0.0031014166,"about_ca_system_score_codex":0.00035131534,"about_ca_system_score_gemma":0.00031086142,"threshold_uncertainty_score":0.010375261},"labels":[],"label_agreement":null},{"id":"W4398256251","doi":"10.1158/1535-7163.mct-23-0564","title":"PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; National Institutes of Health; Susan G. Komen; Golfers Against Cancer; Cancer Prevention and Research Institute of Texas; Breast Cancer Research Foundation; Pfizer; Robert and Janice McNair Foundation; Susan G. Komen for the Cure","keywords":"Palbociclib; Gemcitabine; Breast cancer; Cancer research; Estrogen receptor; Cancer; Tamoxifen; Medicine; Internal medicine; Biology; Oncology; Metastatic breast cancer","score_opus":0.019532345515422503,"score_gpt":0.31857852558174427,"score_spread":0.2990461800663218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398256251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888732,0.0045838677,0.003304236,0.00018323258,0.000022462578,0.0000556039,0.0007823006,0.00010211938,0.002092997],"genre_scores_gemma":[0.9952945,0.0008678748,0.0021055136,0.000031389463,0.0000149995785,0.000032891512,0.00054505345,0.0000150067335,0.0010927548],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99977523,0.000044580498,0.000019028415,0.000058410867,0.00007416246,0.000028629478],"domain_scores_gemma":[0.9998006,0.00003607443,0.00009827092,0.000014884535,0.00002082971,0.000029271803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034353032,0.00023961601,0.00030252224,0.00061892014,0.00017050334,0.00042610613,0.00014153884,0.00023622948,0.0016320879],"category_scores_gemma":[0.00043906164,0.00016044635,0.00016422725,0.0003867248,0.00019707413,0.0002569077,0.0001768635,0.0005009579,0.00032771018],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014513949,0.00010548689,0.043005653,0.00015384729,0.00005566461,0.0002956524,0.00005543966,0.00066000334,0.918539,0.00019150804,0.00040360147,0.03508274],"study_design_scores_gemma":[0.00005833333,0.0015805931,0.29390487,0.000024231942,0.00010349849,0.0043739555,0.000106913394,0.0039985725,0.68684465,0.00031788397,0.008668935,0.000017665316],"about_ca_topic_score_codex":0.0002375961,"about_ca_topic_score_gemma":0.0002994016,"teacher_disagreement_score":0.0016320879,"about_ca_system_score_codex":0.00046186178,"about_ca_system_score_gemma":0.0001918192,"threshold_uncertainty_score":0.0054599047},"labels":[],"label_agreement":null},{"id":"W4399504358","doi":"10.1158/1538-8514.synthleth24-b009","title":"Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Oncogene; Biology; Mutation; Cancer; Cancer research; Gene; Mutant; Carcinogenesis; Genetics; Cell cycle","score_opus":0.08243197940406843,"score_gpt":0.3663281620360799,"score_spread":0.28389618263201144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91886157,0.012240566,0.022483364,0.0035770726,0.00027338584,0.00016628722,0.0021626062,0.0005083408,0.03972672],"genre_scores_gemma":[0.97616833,0.0038400195,0.00732388,0.00035979005,0.00007520093,0.00006751177,0.0017175891,0.00005121625,0.010396485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999503,0.0000074610316,0.0000023494467,0.0000130847075,0.000015048158,0.000011751202],"domain_scores_gemma":[0.99995255,0.000011821976,0.000008667639,0.0000026416913,0.0000078776275,0.00001636249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104200015,0.00029076732,0.00016693636,0.00030768002,0.00023803824,0.00042142606,0.00037381184,0.0005469306,0.009637926],"category_scores_gemma":[0.00013449386,0.00008173479,0.00016204518,0.00022880688,0.0002597247,0.00042993657,0.00027427523,0.0005438596,0.0019560365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057137024,0.0000956206,0.00211755,0.00031501654,0.000007741846,0.0012223737,0.000057057066,0.0004739273,0.9647284,0.009516211,0.0016517545,0.019243093],"study_design_scores_gemma":[0.000103263046,0.0019097611,0.027832448,0.00011964977,0.00006140709,0.008378083,0.00041351948,0.007045936,0.87243795,0.018233975,0.063410595,0.00005347396],"about_ca_topic_score_codex":0.00018228161,"about_ca_topic_score_gemma":0.00016308608,"teacher_disagreement_score":0.009637926,"about_ca_system_score_codex":0.00035771434,"about_ca_system_score_gemma":0.00016289057,"threshold_uncertainty_score":0.03224206},"labels":[],"label_agreement":null},{"id":"W4399504365","doi":"10.1158/1538-8514.synthleth24-a013","title":"Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Microtubule; Microtubule polymerization; In vitro; Cancer research; Tubulin; Chemistry; Biophysics; Cell biology; Biology; Biochemistry","score_opus":0.046124812847405355,"score_gpt":0.3743399704367299,"score_spread":0.3282151575893245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843443,0.0010016754,0.0031152694,0.00051912863,0.00014779798,0.00007587288,0.0039829453,0.00029261105,0.006520305],"genre_scores_gemma":[0.9872062,0.00033580998,0.0010663412,0.0001575467,0.00001742788,0.00007113983,0.0020926215,0.00008283257,0.008969967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998179,0.00002478662,0.000025172489,0.00003799928,0.000050578354,0.000043689048],"domain_scores_gemma":[0.9998574,0.000032560132,0.00003733501,0.000016290978,0.000009240233,0.000047072168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119245,0.00035888952,0.00026807282,0.00027671453,0.00023368467,0.00025077208,0.00022544601,0.0004874109,0.008564122],"category_scores_gemma":[0.00013435415,0.00008823667,0.00029429872,0.00015310285,0.0002857306,0.00016483739,0.00016376596,0.0010674288,0.0013804934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035446306,0.00012411104,0.0002249582,0.000026646449,0.000009982636,0.00025777522,0.000012332707,0.0000904311,0.99557376,0.00024655164,0.00042204215,0.0026569106],"study_design_scores_gemma":[0.00008303962,0.00080736534,0.0051814676,0.000016020851,0.0000176011,0.0020041084,0.000048989266,0.0014466562,0.98083305,0.00015472871,0.009397413,0.000009593293],"about_ca_topic_score_codex":0.0009794403,"about_ca_topic_score_gemma":0.00080303726,"teacher_disagreement_score":0.008564122,"about_ca_system_score_codex":0.00041525188,"about_ca_system_score_gemma":0.00021612203,"threshold_uncertainty_score":0.028649807},"labels":[],"label_agreement":null},{"id":"W4399504372","doi":"10.1158/1538-8514.synthleth24-a025","title":"Abstract A025: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Estrogen receptor; Breast cancer; Cancer research; Estrogen; Gene; Medicine; Bioinformatics; Biology; Genetics; Internal medicine","score_opus":0.02197417418845879,"score_gpt":0.2782134374509887,"score_spread":0.2562392632625299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56304467,0.06985243,0.02249715,0.025420932,0.008001317,0.0005703037,0.021204075,0.0045395996,0.2848696],"genre_scores_gemma":[0.6544851,0.012233461,0.0061993888,0.001964948,0.0010081499,0.00016528675,0.009627451,0.0004147889,0.31390145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979216,0.000028321601,0.000008303784,0.000030627103,0.00010633721,0.000034199995],"domain_scores_gemma":[0.9998487,0.000022136697,0.000024263278,0.000009724725,0.000038702965,0.000056391596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003829722,0.00038465165,0.0002470988,0.00052296254,0.00048157308,0.0009284743,0.00037664972,0.00036879332,0.033716563],"category_scores_gemma":[0.0002614796,0.00019247655,0.00020253245,0.00033471992,0.0002622233,0.00038105118,0.000527257,0.00052598875,0.0061502163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019246528,0.00013309956,0.0014161101,0.0005255717,0.0000348147,0.00025845814,0.00012353399,0.00042748754,0.8602452,0.0044094245,0.07883,0.051671665],"study_design_scores_gemma":[0.00021167277,0.0006760499,0.029508434,0.00008447735,0.000056315173,0.00047826848,0.0003343844,0.001626644,0.6683768,0.0021111597,0.29650623,0.00002960345],"about_ca_topic_score_codex":0.0026564205,"about_ca_topic_score_gemma":0.0046548247,"teacher_disagreement_score":0.033716563,"about_ca_system_score_codex":0.0013535171,"about_ca_system_score_gemma":0.0010426476,"threshold_uncertainty_score":0.11279315},"labels":[],"label_agreement":null},{"id":"W4399504382","doi":"10.1158/1538-8514.synthleth24-a006","title":"Abstract A006: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Cancer; Library science; Esophageal adenocarcinoma; Adenocarcinoma; Medicine; Cancer research; Internal medicine; Computer science","score_opus":0.052669354927098115,"score_gpt":0.38190117296881715,"score_spread":0.329231818041719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39214486,0.029009435,0.16967924,0.019366695,0.0056901975,0.004160374,0.04149655,0.005296412,0.33315638],"genre_scores_gemma":[0.6557978,0.017788777,0.07575015,0.0041304273,0.0006755004,0.0010768771,0.024070546,0.00078791735,0.21992193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969804,0.000046926623,0.000016593745,0.00004321591,0.00015505079,0.00004027167],"domain_scores_gemma":[0.9996804,0.000055489345,0.000042066255,0.00002750681,0.00008739513,0.00010716087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071222364,0.00057641254,0.00041580186,0.0012815808,0.000547275,0.0012506876,0.00047775434,0.00063782587,0.02724807],"category_scores_gemma":[0.0005314745,0.00023107268,0.00051097316,0.0004804234,0.00040441053,0.00041465217,0.0008726851,0.0012710522,0.006043356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010225975,0.00020220407,0.0031872098,0.0005072345,0.00003722656,0.0005805544,0.000096739925,0.001079163,0.87255347,0.011094329,0.042918924,0.06672035],"study_design_scores_gemma":[0.0002095595,0.0017385911,0.028730325,0.00020021418,0.00012930474,0.0026654077,0.00037276096,0.0050775176,0.5998315,0.005352249,0.3556173,0.00007520895],"about_ca_topic_score_codex":0.0017673858,"about_ca_topic_score_gemma":0.0032164047,"teacher_disagreement_score":0.02724807,"about_ca_system_score_codex":0.0010301248,"about_ca_system_score_gemma":0.0013654018,"threshold_uncertainty_score":0.0911538},"labels":[],"label_agreement":null},{"id":"W4399504392","doi":"10.1158/1538-8514.synthleth24-a020","title":"Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ovarian cancer; BRCA mutation; Medicine; Olaparib; Oncology; Missense mutation; Internal medicine; Germline mutation; Nonsense mutation; PARP inhibitor; Cancer; Germline; Serous fluid; Mutation; Somatic cell; Cancer research; Genetics; Biology; Gene; Poly ADP ribose polymerase","score_opus":0.020173704639477968,"score_gpt":0.3064825006325342,"score_spread":0.2863087959930562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929345,0.00017687399,0.0000753986,0.00001738468,0.0000037925906,0.000014219186,0.00012625434,0.0000032984492,0.0002892541],"genre_scores_gemma":[0.99963105,0.00006476094,0.00005364812,0.000012080184,0.000012977424,0.00000703415,0.00014616195,0.000001856447,0.00007039938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999508,0.00007629815,0.000064291904,0.00020044342,0.000067932924,0.000082953506],"domain_scores_gemma":[0.9987212,0.0003581937,0.00037770285,0.00018579849,0.00008615451,0.0002709991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038455374,0.00041448834,0.000471782,0.0018644168,0.00067808386,0.0006325551,0.00046616438,0.0007467211,0.0031617668],"category_scores_gemma":[0.0017770437,0.0005638306,0.00047900472,0.0011323354,0.0006321718,0.00043079603,0.0005396627,0.00048341,0.0004917699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001206475,0.000054768298,0.9818242,0.000016388674,0.000031002724,0.016481802,0.00007717641,0.000038841652,0.00037449226,0.000022729218,0.00010273504,0.00085523835],"study_design_scores_gemma":[0.000035607212,0.0003013494,0.902207,0.000020110347,0.00008795985,0.09559389,0.000389201,0.000481954,0.00033872385,0.00007111145,0.0004542363,0.000018868424],"about_ca_topic_score_codex":0.0018727141,"about_ca_topic_score_gemma":0.0015994452,"teacher_disagreement_score":0.0031617668,"about_ca_system_score_codex":0.00042279152,"about_ca_system_score_gemma":0.00037308363,"threshold_uncertainty_score":0.010577142},"labels":[],"label_agreement":null},{"id":"W4399504410","doi":"10.1158/1538-8514.synthleth24-b006","title":"Abstract B006: Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genome instability; Somatic cell; Transcription (linguistics); Genetics; Cancer research; Gene; DNA damage; Cell biology; DNA","score_opus":0.020590134841365283,"score_gpt":0.28168873907034986,"score_spread":0.26109860422898457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8503991,0.033097416,0.082492754,0.0048387963,0.00059177034,0.00012374482,0.014455845,0.0026622275,0.011338344],"genre_scores_gemma":[0.94447726,0.00828855,0.034176365,0.000773166,0.00014863316,0.00007021395,0.008173121,0.0005267192,0.0033659993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997508,0.000027234348,0.0000102121985,0.00006692909,0.000115916046,0.000028807894],"domain_scores_gemma":[0.9995554,0.000098549266,0.0001008936,0.00006146921,0.000084906744,0.000098666715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078393763,0.00036893677,0.00041314473,0.00065248593,0.00023131404,0.000692847,0.0003467749,0.0004742438,0.003631034],"category_scores_gemma":[0.0009318055,0.00019289473,0.00033997916,0.0005426991,0.00032960958,0.00039306676,0.00040738125,0.0011462255,0.0010512893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010029754,0.00009519024,0.022219298,0.00082083617,0.00021959445,0.00038515154,0.000096905096,0.003667778,0.8379164,0.0044187433,0.00859823,0.120558895],"study_design_scores_gemma":[0.00017196656,0.0013055201,0.17179844,0.00042544035,0.0005230037,0.0069346623,0.00028418354,0.061105214,0.5850283,0.021749077,0.15054058,0.00013375422],"about_ca_topic_score_codex":0.0007699864,"about_ca_topic_score_gemma":0.0010251651,"teacher_disagreement_score":0.003631034,"about_ca_system_score_codex":0.0005212223,"about_ca_system_score_gemma":0.0004488786,"threshold_uncertainty_score":0.012147009},"labels":[],"label_agreement":null},{"id":"W4399504411","doi":"10.1158/1538-8514.synthleth24-b011","title":"Abstract B011: Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epistasis; Synthetic lethality; Cancer; Somatic cell; Pairwise comparison; Genotype; Biology; Lethality; Genotype-phenotype distinction; Genetics; Gene; Computer science; Artificial intelligence","score_opus":0.02178582790011043,"score_gpt":0.3228895334487908,"score_spread":0.3011037055486804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6384824,0.0010513584,0.32123554,0.002421944,0.0004153091,0.000577631,0.011976163,0.004286694,0.019552987],"genre_scores_gemma":[0.85760266,0.00040303514,0.124398194,0.0008312426,0.000106917396,0.00024041784,0.010571588,0.0004291899,0.005416657],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987888,0.0003759819,0.00006850049,0.00028760682,0.00037804517,0.000101184254],"domain_scores_gemma":[0.99690634,0.0018610294,0.00031827547,0.00022008401,0.00029650668,0.00039774663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021956791,0.0008502816,0.0011153304,0.0019299542,0.00064324646,0.001428558,0.0006778874,0.0007023658,0.0076237745],"category_scores_gemma":[0.0062190345,0.00033265786,0.0012399117,0.0011137611,0.00051477895,0.00045664463,0.0011154164,0.0012233858,0.0011981981],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004244079,0.0013093002,0.12044948,0.0011088528,0.0011361248,0.0013449872,0.00021326928,0.08943511,0.45535064,0.026190419,0.03406067,0.2651571],"study_design_scores_gemma":[0.00089761365,0.002678895,0.10285227,0.00009491933,0.00085266255,0.0022375823,0.00037576788,0.65039575,0.17579195,0.040660486,0.02284558,0.00031654717],"about_ca_topic_score_codex":0.001313498,"about_ca_topic_score_gemma":0.0017341063,"teacher_disagreement_score":0.0076237745,"about_ca_system_score_codex":0.0005594397,"about_ca_system_score_gemma":0.0011013865,"threshold_uncertainty_score":0.025504053},"labels":[],"label_agreement":null},{"id":"W4399504413","doi":"10.1158/1538-8514.synthleth24-b015","title":"Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; KRAS; Mutant; Cancer drugs; Synthetic lethality; Computational biology; Library science; Biology; Genetics; Computer science; Gene; Colorectal cancer","score_opus":0.024459811909872002,"score_gpt":0.34358106007884665,"score_spread":0.31912124816897464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5925976,0.0058212574,0.20807417,0.0034194344,0.00092015543,0.0017882568,0.019187063,0.008766655,0.15942548],"genre_scores_gemma":[0.7768822,0.0034961526,0.16254535,0.0010503092,0.00011136443,0.00059426116,0.012347862,0.00073360605,0.04223889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997366,0.00006281168,0.00001668934,0.00003990574,0.00011521697,0.000028702647],"domain_scores_gemma":[0.9997893,0.00006270677,0.000027058262,0.000018233472,0.000032146858,0.00007052154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044324808,0.0007912936,0.00042108106,0.0011267692,0.00033981167,0.00077203556,0.00045318893,0.00035751896,0.012239891],"category_scores_gemma":[0.0005608321,0.0002234624,0.0005909737,0.0004997989,0.00032454444,0.00024541534,0.00055464404,0.000639714,0.0020825258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020850846,0.0007990079,0.0027125042,0.0007239773,0.000233544,0.00040917928,0.000067356304,0.02607666,0.7360053,0.023815598,0.05087412,0.15619768],"study_design_scores_gemma":[0.001156683,0.0042737992,0.009324661,0.00017662709,0.0003609429,0.0007614962,0.00012265162,0.13664787,0.74859273,0.010920593,0.08752525,0.00013661054],"about_ca_topic_score_codex":0.0032083688,"about_ca_topic_score_gemma":0.0058551375,"teacher_disagreement_score":0.012239891,"about_ca_system_score_codex":0.00073120993,"about_ca_system_score_gemma":0.0010865554,"threshold_uncertainty_score":0.040946543},"labels":[],"label_agreement":null},{"id":"W4399504416","doi":"10.1158/1538-8514.synthleth24-b014","title":"Abstract B014: Unveiling the future: Exploring cutting-edge technologies for synthetic lethality discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Personalized medicine; Precision medicine; Drug discovery; CRISPR; Identification (biology); Cancer; Computer science; Computational biology; Cancer treatment; Data science; Medicine; Bioinformatics; Biology; DNA repair","score_opus":0.06713313725205455,"score_gpt":0.34101817805531315,"score_spread":0.2738850408032586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504416","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020654412,0.1727172,0.320206,0.22897431,0.01677201,0.00045417872,0.0016314934,0.0036150315,0.23497541],"genre_scores_gemma":[0.32560953,0.209675,0.2954435,0.04912216,0.0061934367,0.00078544137,0.0016606859,0.0014423791,0.11006794],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977748,0.0007048971,0.00009003729,0.0002528585,0.0009415849,0.00023584136],"domain_scores_gemma":[0.9961753,0.0018771017,0.0003316906,0.00043117232,0.0007573382,0.00042743722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054127933,0.00090092083,0.00073927594,0.0018808569,0.0016532046,0.0069944235,0.0013175638,0.0029382035,0.015062762],"category_scores_gemma":[0.006901024,0.0005431403,0.00087636575,0.0012140388,0.0053161923,0.008442449,0.0043035173,0.0054583247,0.005303175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003013486,0.0001311771,0.000699781,0.0013566742,0.000044699384,0.00049003446,0.0005470959,0.002520744,0.027401509,0.58209336,0.10567445,0.27873915],"study_design_scores_gemma":[0.00006354662,0.0002942839,0.0004020827,0.00055419985,0.00004394146,0.0005888814,0.00045911205,0.0030185352,0.033394683,0.30892575,0.6521374,0.000117525735],"about_ca_topic_score_codex":0.00095548335,"about_ca_topic_score_gemma":0.00086475775,"teacher_disagreement_score":0.015062762,"about_ca_system_score_codex":0.002889015,"about_ca_system_score_gemma":0.002514424,"threshold_uncertainty_score":0.050389946},"labels":[],"label_agreement":null},{"id":"W4399504421","doi":"10.1158/1538-8514.synthleth24-b018","title":"Abstract B018: Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Aneuploidy; Chromosome; Citation; Cancer research; Medicine; Biology; Library science; Genetics; Oncology; Computer science; Gene","score_opus":0.02352014157130147,"score_gpt":0.28498421393324036,"score_spread":0.2614640723619389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504421","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2053762,0.14823216,0.035250135,0.05749708,0.01427389,0.002583094,0.033398848,0.0020781255,0.50131047],"genre_scores_gemma":[0.4314307,0.07592457,0.017834453,0.008194204,0.0032858502,0.00073683687,0.016521584,0.00046967485,0.44560218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996201,0.000069488924,0.000011140038,0.000054075517,0.00019447693,0.000050786068],"domain_scores_gemma":[0.9995776,0.00009132172,0.000043251643,0.000023359695,0.00014366582,0.00012077874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010757431,0.0006245152,0.00043220056,0.001606895,0.0007059026,0.0015283964,0.00061530207,0.00095493504,0.054455157],"category_scores_gemma":[0.0009750834,0.00020696502,0.0002935589,0.0010613647,0.00041965413,0.0006575706,0.000993271,0.0011624929,0.006427378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023682613,0.0004141037,0.0051661083,0.0033488257,0.00011746165,0.0011569556,0.0003517643,0.001018376,0.3946992,0.019044416,0.2729753,0.2993392],"study_design_scores_gemma":[0.00035323043,0.0025810413,0.038467005,0.00077631325,0.00020666639,0.002660647,0.0007214694,0.0010886033,0.22416744,0.017366637,0.7115259,0.00008501048],"about_ca_topic_score_codex":0.0025253103,"about_ca_topic_score_gemma":0.0033198758,"teacher_disagreement_score":0.054455157,"about_ca_system_score_codex":0.0014362732,"about_ca_system_score_gemma":0.0017470497,"threshold_uncertainty_score":0.18217069},"labels":[],"label_agreement":null},{"id":"W4399504446","doi":"10.1158/1538-8514.synthleth24-b016","title":"Abstract B016: Discovering novel synthetic lethal relationships with large-scale cellular simulations","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Pairwise comparison; In silico; Computational biology; Computer science; Biology; Artificial intelligence; Gene; Genetics","score_opus":0.019646075350274867,"score_gpt":0.2852439478668929,"score_spread":0.26559787251661804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4844568,0.0009792933,0.48031405,0.002370299,0.00038208268,0.00035493687,0.0027866424,0.005027359,0.023328595],"genre_scores_gemma":[0.8271326,0.00051749544,0.16611795,0.0003218431,0.000066262466,0.00037637213,0.002077909,0.00044300003,0.0029465763],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998012,0.000058104146,0.000010764599,0.000033907305,0.00007355665,0.000022555705],"domain_scores_gemma":[0.9984206,0.0011666124,0.00010542063,0.00010128558,0.000107565495,0.000098416254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000721437,0.0007576091,0.0007936966,0.0006064394,0.0005269804,0.0008853265,0.00086289557,0.0009404151,0.003963456],"category_scores_gemma":[0.002596002,0.0003744765,0.0007839855,0.0004437082,0.0007006877,0.000678343,0.00085773476,0.0011583103,0.00043561496],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010051939,0.000114348644,0.002773585,0.00011926504,0.00005382699,0.00013334384,0.000049325554,0.9683992,0.0066003194,0.009788419,0.00231927,0.00954855],"study_design_scores_gemma":[0.000015169818,0.00002042208,0.00017284366,0.0000037442696,0.000005572665,0.000009765132,0.0000103269085,0.9952384,0.0012557693,0.0024452081,0.00081758824,0.00000517671],"about_ca_topic_score_codex":0.003773708,"about_ca_topic_score_gemma":0.0035706311,"teacher_disagreement_score":0.003963456,"about_ca_system_score_codex":0.00076506694,"about_ca_system_score_gemma":0.00096478703,"threshold_uncertainty_score":0.013259113},"labels":[],"label_agreement":null},{"id":"W4399504454","doi":"10.1158/1538-8514.synthleth24-b026","title":"Abstract B026: Screening non-small cell lung cancer patient-derived organoids with epigenetic probes reveals PRMT5 as an oncogenic target","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Organoid; Cancer research; Matrigel; Epigenetics; Biology; Lung cancer; Cancer; Protein arginine methyltransferase 5; Targeted therapy; Medicine; Bioinformatics; Methyltransferase; Pathology; Cell biology; Gene; Methylation; Genetics; Angiogenesis","score_opus":0.009760627953152426,"score_gpt":0.2628823215821492,"score_spread":0.2531216936289968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699702,0.0038115205,0.017617455,0.00030960934,0.000082695304,0.00023753947,0.004107605,0.0005073398,0.0033560132],"genre_scores_gemma":[0.9707324,0.0015899751,0.013151948,0.00014106679,0.000008347514,0.0001750138,0.0071117273,0.000054454853,0.0070351236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978346,0.00003846429,0.0000125623,0.00006251235,0.000073098,0.000030062483],"domain_scores_gemma":[0.999884,0.000028731585,0.00001702881,0.000020939684,0.00002379557,0.000025367022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026098793,0.00042049584,0.00033049725,0.0003127756,0.00018975939,0.00024003103,0.00027027578,0.0004561213,0.00291239],"category_scores_gemma":[0.00018294046,0.00019960158,0.00043296523,0.0002610245,0.0001792307,0.00014124007,0.0002376312,0.00055781787,0.0010163796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007013362,0.000021521051,0.00035420954,0.00003057268,0.0000049426903,0.000042986416,0.000012635656,0.000117267606,0.9981651,0.000014803974,0.000096637195,0.0010692637],"study_design_scores_gemma":[0.000012864888,0.0005803445,0.004323892,0.000005272725,0.000022285183,0.00035869627,0.000039158705,0.00094233983,0.9914938,0.000018293727,0.0021978742,0.0000050753642],"about_ca_topic_score_codex":0.001284373,"about_ca_topic_score_gemma":0.002072409,"teacher_disagreement_score":0.00291239,"about_ca_system_score_codex":0.00030189904,"about_ca_system_score_gemma":0.0002040988,"threshold_uncertainty_score":0.009742975},"labels":[],"label_agreement":null},{"id":"W4399504457","doi":"10.1158/1538-8514.synthleth24-b025","title":"Abstract B025: A genome-wide CRISPR screen identifies synthetic lethality of double-stranded RNA with BRCA1 loss","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA silencing; Biology; Interferon; RNA; Programmed cell death; CRISPR; Cell biology; RNA interference; Molecular biology; Genetics; Gene; Apoptosis","score_opus":0.01680530824172085,"score_gpt":0.31105312946064945,"score_spread":0.2942478212189286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9489229,0.0019154411,0.020590827,0.00041533596,0.0001662634,0.00041906539,0.018086826,0.002604478,0.0068788226],"genre_scores_gemma":[0.96739936,0.0007978509,0.010012347,0.00033662177,0.000014851684,0.00017190745,0.010645735,0.0003930935,0.010228169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966574,0.000031692183,0.000029576784,0.0000969299,0.00012840806,0.000047618272],"domain_scores_gemma":[0.9998198,0.00004141271,0.000045643035,0.000015024028,0.000017917506,0.0000602741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022247533,0.0006795977,0.00056483166,0.0005433094,0.00026495178,0.00044843103,0.0004478558,0.0006861871,0.003509852],"category_scores_gemma":[0.00020822948,0.00021031259,0.00043023645,0.00032927698,0.00023273451,0.00009772788,0.00036256277,0.0005641722,0.0013307331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006610638,0.00002652055,0.00021718736,0.000046597823,0.0000136563485,0.00019947287,0.000009256559,0.00010128624,0.9978503,0.00005128739,0.00018089163,0.0012373953],"study_design_scores_gemma":[0.00005941455,0.00049115834,0.013856276,0.000029161301,0.00011035934,0.0022604675,0.00007245318,0.003869146,0.9684756,0.00008394239,0.010659236,0.00003273357],"about_ca_topic_score_codex":0.0016116367,"about_ca_topic_score_gemma":0.0025987062,"teacher_disagreement_score":0.003509852,"about_ca_system_score_codex":0.00033370065,"about_ca_system_score_gemma":0.00031630872,"threshold_uncertainty_score":0.011741638},"labels":[],"label_agreement":null},{"id":"W4399504458","doi":"10.1158/1538-8514.synthleth24-b013","title":"Abstract B013: Deep learning-based prediction of synthetic essentialities in <i>CTNNB1</i>-mutated hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gene; Hepatocellular carcinoma; Context (archaeology); Computational biology; Biology; Synthetic lethality; Bioinformatics; Genetics; DNA repair","score_opus":0.011712332517158001,"score_gpt":0.2354377841799214,"score_spread":0.2237254516627634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92685616,0.0013811517,0.055709694,0.00096174714,0.00009232645,0.000102367834,0.010043744,0.0020640306,0.002788765],"genre_scores_gemma":[0.9625982,0.00032641224,0.017332502,0.00018602755,0.000026277017,0.00008947125,0.0174858,0.000058156344,0.0018971632],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99981135,0.000041625575,0.000012797179,0.0000578221,0.000037937185,0.000038529175],"domain_scores_gemma":[0.99951506,0.00025237096,0.00004545119,0.000034723704,0.0001024232,0.000050026738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064469245,0.00069596857,0.00044127693,0.0007529943,0.00020692834,0.00048430474,0.00055209413,0.00058704364,0.0017822694],"category_scores_gemma":[0.0015379171,0.00022031607,0.0006007147,0.00042246844,0.00022289742,0.00027036906,0.0005267326,0.00075854495,0.00047844794],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024238934,0.0009194733,0.16180383,0.0006971908,0.00061456615,0.00097365846,0.00008409665,0.5861182,0.04105066,0.0017377968,0.02424453,0.17933212],"study_design_scores_gemma":[0.000040028084,0.00016648555,0.008368992,0.000019535068,0.00005448851,0.00009629372,0.000019914416,0.98087114,0.00829377,0.0010240702,0.0010333942,0.000011914234],"about_ca_topic_score_codex":0.009288952,"about_ca_topic_score_gemma":0.007976694,"teacher_disagreement_score":0.009288952,"about_ca_system_score_codex":0.0007785329,"about_ca_system_score_gemma":0.0009513072,"threshold_uncertainty_score":0.01846981},"labels":[],"label_agreement":null},{"id":"W4399504463","doi":"10.1158/1538-8514.synthleth24-ia024","title":"Abstract IA024: RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA Helicase A; Interferon; RNA; Biology; Helicase; Cell biology; Molecular biology; Chemistry; Biochemistry; Gene; Genetics","score_opus":0.029176071433605323,"score_gpt":0.3177458225239607,"score_spread":0.2885697510903554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75477827,0.11623142,0.04515102,0.002019503,0.0010776343,0.0011991106,0.023359744,0.004619242,0.051564008],"genre_scores_gemma":[0.9009247,0.028354326,0.021589117,0.00089978037,0.00012363611,0.00049942534,0.020631388,0.0003301264,0.026647553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998043,0.000033481003,0.000016738355,0.00004632366,0.00007062234,0.000028541355],"domain_scores_gemma":[0.9998752,0.000019858384,0.00003272583,0.000015569465,0.000030369438,0.000026204894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003201661,0.000580251,0.00050261256,0.0007903056,0.00014729069,0.00050465355,0.00039684694,0.00050902256,0.003926397],"category_scores_gemma":[0.00023588828,0.0002009618,0.00045157463,0.0004602381,0.00016683467,0.00024973537,0.00024900594,0.00096417544,0.0015869492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005090374,0.0002098133,0.0003439187,0.00048481865,0.00006627794,0.000118263684,0.000020610165,0.0011721345,0.9555537,0.00091099984,0.003510938,0.037099406],"study_design_scores_gemma":[0.00020204666,0.002916403,0.0025451821,0.00007972995,0.00010997215,0.000813948,0.000016413052,0.002086045,0.9090975,0.00032214873,0.081774205,0.000036432568],"about_ca_topic_score_codex":0.00039735192,"about_ca_topic_score_gemma":0.00066704076,"teacher_disagreement_score":0.003926397,"about_ca_system_score_codex":0.00044423723,"about_ca_system_score_gemma":0.00024350992,"threshold_uncertainty_score":0.013135076},"labels":[],"label_agreement":null},{"id":"W4399504483","doi":"10.1158/1538-8514.synthleth24-b017","title":"Abstract B017: Loss of UXS1 selectively kills KEAP1 mutant cancer cell lines by depleting pyrimidines and inducing replication stress","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Mutant; Cancer cell; Molecular biology; Cancer research; Cancer; Biochemistry; Chemistry; Gene; Genetics","score_opus":0.01778759834117769,"score_gpt":0.2980180303979056,"score_spread":0.2802304320567279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98013604,0.0029319343,0.0038217648,0.00036516588,0.00017830076,0.00009476638,0.0071908343,0.0008536249,0.0044274707],"genre_scores_gemma":[0.96888864,0.0011793002,0.0045920443,0.00015555849,0.000018368142,0.00016653501,0.011323042,0.00012948998,0.013547002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999796,0.000017100314,0.000021249134,0.00004221178,0.00007709116,0.000046363846],"domain_scores_gemma":[0.99989235,0.000016869159,0.0000210851,0.000015975738,0.000015072076,0.00003867687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105414896,0.0005063093,0.0004599877,0.00034499017,0.00031496122,0.00032954768,0.00033359573,0.00042021656,0.007018263],"category_scores_gemma":[0.00010329214,0.00015561972,0.00031567097,0.00032348488,0.00021259241,0.00018172419,0.00026970252,0.0007024455,0.0016529395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026153793,0.0000601415,0.0002165663,0.00004980896,0.0000071254785,0.00004597447,0.0000100065445,0.000052664724,0.9969289,0.00008106843,0.0003903783,0.0018958288],"study_design_scores_gemma":[0.000017910828,0.00037713288,0.0025917196,0.00000538342,0.00001114926,0.00017728747,0.00002234922,0.0005267997,0.99246806,0.000031121286,0.0037667067,0.00000446566],"about_ca_topic_score_codex":0.0010978103,"about_ca_topic_score_gemma":0.0009477252,"teacher_disagreement_score":0.007018263,"about_ca_system_score_codex":0.00027725537,"about_ca_system_score_gemma":0.00026423205,"threshold_uncertainty_score":0.023478448},"labels":[],"label_agreement":null},{"id":"W4399504496","doi":"10.1158/1538-8514.synthleth24-a009","title":"Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Sarcoma; Context (archaeology); Cancer research; Biology; Metastasis; Cancer; CRISPR; Mutant; Genetics; Medicine; Gene; Pathology","score_opus":0.022651395863248824,"score_gpt":0.29375279504041024,"score_spread":0.2711013991771614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677806,0.0009768393,0.018410487,0.00029609335,0.00016891175,0.00025651566,0.0058494573,0.000764062,0.0054970854],"genre_scores_gemma":[0.97488797,0.00063860574,0.009865417,0.00015287574,0.000016784217,0.0002014276,0.004756519,0.0002308868,0.0092495615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967575,0.000046836336,0.000042217252,0.000067190354,0.00012572124,0.000042359614],"domain_scores_gemma":[0.99980205,0.00004973822,0.000051610037,0.000027246033,0.0000130368335,0.00005634268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021348271,0.0005298523,0.00031519702,0.00043952398,0.00028588428,0.00036432757,0.00045396612,0.00055900874,0.0036627857],"category_scores_gemma":[0.00016465799,0.00015876742,0.0003326442,0.00025500398,0.00037817922,0.00016515203,0.00048925116,0.0010076948,0.0014878028],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005088635,0.000033960878,0.00013564402,0.000030819363,0.000006682524,0.00016978204,0.000013135081,0.00012642857,0.99812585,0.0002489722,0.000153113,0.0009047718],"study_design_scores_gemma":[0.000020705116,0.00030125695,0.0023763212,0.00001171698,0.000018719003,0.0011706069,0.000031504278,0.001956164,0.9862235,0.00009792159,0.0077798697,0.000011790401],"about_ca_topic_score_codex":0.00091512845,"about_ca_topic_score_gemma":0.0011240618,"teacher_disagreement_score":0.0036627857,"about_ca_system_score_codex":0.00042410687,"about_ca_system_score_gemma":0.00026221483,"threshold_uncertainty_score":0.012253284},"labels":[],"label_agreement":null},{"id":"W4399504508","doi":"10.1158/1538-8514.synthleth24-pr011","title":"Abstract PR011: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Triple-negative breast cancer; EIF4E; Cancer research; Cancer; Gene knockdown; Biology; Carcinogenesis; EIF4EBP1; MAPK/ERK pathway; Kinase; Small hairpin RNA; Metastasis; Breast cancer; Translation (biology); Cell biology; Messenger RNA; Cell culture; Genetics; Gene","score_opus":0.01769327595877911,"score_gpt":0.2959992058422084,"score_spread":0.2783059298834293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715133,0.0068268916,0.004212543,0.0008970656,0.0006389627,0.0003425706,0.0034612713,0.0009924925,0.011114975],"genre_scores_gemma":[0.97465026,0.00288508,0.003771807,0.00030603557,0.000043584805,0.00018325928,0.004779164,0.00006455174,0.013316299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987924,0.000010593807,0.00001399594,0.00002719051,0.00003333933,0.000035616446],"domain_scores_gemma":[0.9999459,0.000008049909,0.000009072768,0.00000796118,0.0000067861743,0.000022194425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001332316,0.00049175724,0.00053202163,0.00030794382,0.00018656842,0.00030246776,0.0003274157,0.00039307596,0.0050147767],"category_scores_gemma":[0.00012419965,0.00017061767,0.0003562134,0.0002400022,0.00024879235,0.00020241468,0.00018910914,0.0010626905,0.0011131497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00106296,0.0003648848,0.000285441,0.00020136905,0.000023884346,0.00016234341,0.000016249232,0.00026573113,0.98614186,0.00020864716,0.0016831395,0.009583501],"study_design_scores_gemma":[0.00031654467,0.0032052277,0.0034377892,0.000015633743,0.000043631226,0.00082308654,0.000032737764,0.0010899374,0.97989196,0.00009377992,0.011033391,0.000016245811],"about_ca_topic_score_codex":0.0008078892,"about_ca_topic_score_gemma":0.0013782366,"teacher_disagreement_score":0.0050147767,"about_ca_system_score_codex":0.0003469151,"about_ca_system_score_gemma":0.00040315473,"threshold_uncertainty_score":0.016776085},"labels":[],"label_agreement":null},{"id":"W4399504518","doi":"10.1158/1538-8514.synthleth24-pr005","title":"Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; DNA repair; DNA damage; Medicine; Cancer; In vivo; Internal medicine; Biology; Oncology; Polymerase; DNA; Genetics","score_opus":0.03612750988906618,"score_gpt":0.3464587231508978,"score_spread":0.31033121326183166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97663456,0.0044948407,0.0012381678,0.0013377812,0.0004532356,0.00084158353,0.0041070133,0.00083272246,0.010060211],"genre_scores_gemma":[0.9844631,0.0016272967,0.0012297152,0.0004834567,0.000108354354,0.00025023968,0.0040902547,0.00003922546,0.0077084354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998147,0.00004184367,0.000017066193,0.000029484361,0.000039032948,0.00005794788],"domain_scores_gemma":[0.99988794,0.000012573659,0.000024865401,0.000013913286,0.000009605418,0.000050985906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002631041,0.0006890354,0.000674679,0.00043414027,0.00023858719,0.0005096945,0.0005865448,0.00058446743,0.009902523],"category_scores_gemma":[0.00017676216,0.00021632737,0.00037432695,0.000337261,0.0003357766,0.0003055216,0.0002463883,0.0016087114,0.0011624752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024481837,0.007283084,0.002290588,0.0007351068,0.00028239473,0.0006469328,0.0000717307,0.0019211342,0.85399103,0.0013431736,0.019905576,0.087047346],"study_design_scores_gemma":[0.048507974,0.18808505,0.039904065,0.00014445628,0.0006891019,0.0031003733,0.0001288701,0.008619189,0.65586513,0.0005411217,0.05431409,0.00010052018],"about_ca_topic_score_codex":0.0021064938,"about_ca_topic_score_gemma":0.004012707,"teacher_disagreement_score":0.009902523,"about_ca_system_score_codex":0.00061355723,"about_ca_system_score_gemma":0.000704775,"threshold_uncertainty_score":0.033127308},"labels":[],"label_agreement":null},{"id":"W4399504527","doi":"10.1158/1538-8514.synthleth24-pr014","title":"Abstract PR014: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Computational biology; Cas9; Biology; Gene; Synthetic lethality; Genetics; Precision medicine; Personalized medicine; KRAS; Drug discovery; Genetic screen; Mutant; Mutation; Bioinformatics","score_opus":0.011146393027114728,"score_gpt":0.32737120774996303,"score_spread":0.3162248147228483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86797297,0.0015950333,0.09983925,0.0006497751,0.0002478666,0.0013813793,0.008287869,0.004341539,0.015684264],"genre_scores_gemma":[0.9127824,0.0008099008,0.06944896,0.00029717057,0.000020607475,0.0005827508,0.0048423186,0.0005276744,0.010688341],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994215,0.000072579205,0.00006561369,0.00009343692,0.00026125734,0.000085654036],"domain_scores_gemma":[0.99977165,0.000053834185,0.00005958816,0.000025611544,0.000032787608,0.00005658058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040512692,0.0008283739,0.00072339736,0.0009872782,0.00025269,0.00060934183,0.0006955738,0.0005245113,0.004073518],"category_scores_gemma":[0.00031645168,0.00036901364,0.00067947205,0.00046648463,0.00041100898,0.00022947475,0.0005064534,0.0011874869,0.001193226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000272616,0.00014479937,0.0002772899,0.00008088434,0.00002426602,0.00013136677,0.000011740906,0.0013911407,0.9911425,0.0005070682,0.00053355575,0.0054828087],"study_design_scores_gemma":[0.0001223794,0.0011796126,0.0012257324,0.00001195703,0.000051104627,0.00035458693,0.000020326914,0.008045402,0.9829488,0.00016227331,0.005853113,0.000024745459],"about_ca_topic_score_codex":0.001021136,"about_ca_topic_score_gemma":0.0020445278,"teacher_disagreement_score":0.004073518,"about_ca_system_score_codex":0.00054034905,"about_ca_system_score_gemma":0.0005339704,"threshold_uncertainty_score":0.013627291},"labels":[],"label_agreement":null},{"id":"W4399504533","doi":"10.1158/1538-8514.synthleth24-b022","title":"Abstract B022: TEAD inhibition overcomes YAP/TAZ-driven resistance to RAS(ON) inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hippo pathway signaling and YAP/TAZ","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hippo signaling pathway; KRAS; Biology; Cancer research; Transcription factor; In vivo; CRISPR; Kinase; Cell biology; Mutation; Genetics; Gene","score_opus":0.01731672147573724,"score_gpt":0.2854520544565914,"score_spread":0.2681353329808541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855621,0.0023935249,0.001855847,0.000514755,0.00022280072,0.00012604939,0.0018764306,0.00040936985,0.0070392294],"genre_scores_gemma":[0.98801875,0.0013642141,0.0012763225,0.0001629323,0.000026130921,0.0000842424,0.001784782,0.00005517969,0.0072273985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998435,0.000017574515,0.0000120405475,0.000022339666,0.00004517766,0.000059346585],"domain_scores_gemma":[0.99993074,0.0000058425553,0.0000127626645,0.000008893604,0.0000096689255,0.000032102875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012852874,0.0004255378,0.0004907813,0.00028328423,0.0001862357,0.0004677842,0.00043203164,0.00032967873,0.003576941],"category_scores_gemma":[0.000113476395,0.00012676253,0.00036654642,0.00021351303,0.00017784533,0.00020518134,0.0002470705,0.0010120253,0.0007933623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010580282,0.0006070304,0.00018206067,0.00011564714,0.000034788234,0.000111078116,0.000025056068,0.00030791803,0.9843615,0.00030581912,0.0015934189,0.011297696],"study_design_scores_gemma":[0.00024577984,0.0038811276,0.003825255,0.00001967712,0.000059662907,0.00042084584,0.000060523445,0.0018817353,0.96402574,0.0001124122,0.025451424,0.0000157699],"about_ca_topic_score_codex":0.0012111512,"about_ca_topic_score_gemma":0.0019573309,"teacher_disagreement_score":0.003576941,"about_ca_system_score_codex":0.00037657414,"about_ca_system_score_gemma":0.00034103045,"threshold_uncertainty_score":0.01196605},"labels":[],"label_agreement":null},{"id":"W4399504538","doi":"10.1158/1538-8514.synthleth24-pr001","title":"Abstract PR001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mitosis; Cell cycle checkpoint; Kinesin; Mitotic catastrophe; Cell cycle; Cell biology; Synthetic lethality; Biology; Genome instability; Cell growth; Chromosome instability; DNA damage; Microtubule; Molecular biology; Apoptosis; DNA repair; Genetics; Chromosome; DNA; Gene","score_opus":0.016252035979291327,"score_gpt":0.2701834701455655,"score_spread":0.2539314341662742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804555,0.002744251,0.002669663,0.00029580854,0.00013385231,0.00014582879,0.0036782017,0.00071194506,0.009164968],"genre_scores_gemma":[0.9710779,0.0016147743,0.0022283895,0.00010670858,0.000020522211,0.00017161289,0.0055399984,0.00006295873,0.019177165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990165,0.000008805079,0.000010466746,0.000020974829,0.000033105684,0.000024902714],"domain_scores_gemma":[0.99994755,0.000007203583,0.000013863147,0.0000046923137,0.0000054172237,0.000021369562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085052314,0.0005052981,0.00028563474,0.00027229113,0.00013736158,0.0002633942,0.00033700455,0.0003497712,0.00592197],"category_scores_gemma":[0.00005994918,0.00013120084,0.00022229635,0.00025367923,0.00019019394,0.00014901513,0.00014608917,0.0008096108,0.0013894724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040141775,0.000172359,0.00009488586,0.00006794042,0.000009253551,0.00007599017,0.000011958461,0.00010389914,0.9952968,0.0001767254,0.0005378562,0.0030508924],"study_design_scores_gemma":[0.00007201169,0.0012326975,0.0017456886,0.0000063986636,0.000012571888,0.00022893735,0.000013979233,0.00051418785,0.991532,0.000028492515,0.004608462,0.0000046283362],"about_ca_topic_score_codex":0.0008412208,"about_ca_topic_score_gemma":0.0009971315,"teacher_disagreement_score":0.00592197,"about_ca_system_score_codex":0.0002708105,"about_ca_system_score_gemma":0.00031646466,"threshold_uncertainty_score":0.019810915},"labels":[],"label_agreement":null},{"id":"W4399504543","doi":"10.1158/1538-8514.synthleth24-ia006","title":"Abstract IA006: Synthetic lethalities for SWI/SNF mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SMARCA4; SWI/SNF; ARID1A; SMARCB1; Cancer research; Biology; Chromatin remodeling; Chromatin; Protein subunit; Cancer; Genetics; Mutation; Gene","score_opus":0.025110584373677736,"score_gpt":0.30821713346379886,"score_spread":0.2831065490901211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451866,0.0014783808,0.015034315,0.0010233806,0.0004659428,0.0001921436,0.008305034,0.002115216,0.026198978],"genre_scores_gemma":[0.9705606,0.00080241245,0.0062231487,0.0002373015,0.000041101288,0.00014032885,0.0035487763,0.0002717675,0.01817459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984443,0.000026978278,0.000016466629,0.000027976828,0.00006157987,0.000022559174],"domain_scores_gemma":[0.999816,0.000029093966,0.00003908463,0.000021029633,0.0000128440915,0.00008188253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012324336,0.0006291212,0.00018562903,0.0007938074,0.00030879083,0.00031382372,0.0003474758,0.00057165284,0.007623158],"category_scores_gemma":[0.00018872313,0.00012494445,0.00033034384,0.00021718652,0.00030726462,0.000092859125,0.00040384673,0.00094661245,0.0017578086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025962095,0.00013185201,0.00078841415,0.000033640943,0.000015201617,0.000823859,0.000023134999,0.00053387386,0.98820066,0.0027866089,0.0015281119,0.004874983],"study_design_scores_gemma":[0.0001300546,0.0015084174,0.010922542,0.000039836938,0.000041180356,0.007752991,0.00010868821,0.006417606,0.921646,0.0012223944,0.05017715,0.000033157958],"about_ca_topic_score_codex":0.0007243137,"about_ca_topic_score_gemma":0.0007489306,"teacher_disagreement_score":0.007623158,"about_ca_system_score_codex":0.00035798366,"about_ca_system_score_gemma":0.00023134779,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4399504544","doi":"10.1158/1538-8514.synthleth24-pr016","title":"Abstract PR016: Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Aneuploidy; Chromosome instability; Cancer research; Carcinogenesis; Cancer; Lung cancer; Chromosome; Metastasis; Genetics; Pathology; Gene; Medicine","score_opus":0.02427322320843445,"score_gpt":0.2893144687131825,"score_spread":0.26504124550474806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321148,0.012694022,0.02090029,0.0013137797,0.00037346146,0.0007324961,0.012838242,0.0012911094,0.017741898],"genre_scores_gemma":[0.949626,0.005231998,0.012423981,0.00045312388,0.0000394185,0.000417688,0.010267023,0.00020317154,0.021337694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965286,0.000029905841,0.000030284198,0.00007819665,0.00015690312,0.000051807663],"domain_scores_gemma":[0.9997564,0.000045582157,0.00005491608,0.000031132156,0.00005205616,0.000059901195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041058369,0.0003728141,0.00043574,0.0007545577,0.00033636275,0.0005385209,0.00044637767,0.00078027823,0.0059731742],"category_scores_gemma":[0.00039463694,0.0002323853,0.00040268496,0.0007069157,0.00028423787,0.00031412128,0.00062180904,0.001053626,0.0013030979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003303968,0.00007386703,0.001727874,0.00027870983,0.000020807433,0.0001908468,0.000031017207,0.00019783608,0.9840428,0.00035782615,0.00081354304,0.011934457],"study_design_scores_gemma":[0.00016204358,0.00349472,0.041998755,0.00009978904,0.00014085253,0.0048668026,0.00024755963,0.002341984,0.90530044,0.0006405612,0.040654443,0.000052036376],"about_ca_topic_score_codex":0.0014122173,"about_ca_topic_score_gemma":0.0016334389,"teacher_disagreement_score":0.0059731742,"about_ca_system_score_codex":0.00046720373,"about_ca_system_score_gemma":0.0005329052,"threshold_uncertainty_score":0.019982219},"labels":[],"label_agreement":null},{"id":"W4399504601","doi":"10.1158/1538-8514.synthleth24-a021","title":"Abstract A021: Hunting for synthetic lethal partners in DNA damage response-altered endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endometrial cancer; Ovarian cancer; ARID1A; Biology; Cancer; Synthetic lethality; Biomarker; Computational biology; Cancer research; Medicine; Gene; Genetics; DNA repair; Mutation","score_opus":0.04197064345278476,"score_gpt":0.35958159737386725,"score_spread":0.31761095392108246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88352865,0.0016104282,0.05779873,0.00057871063,0.00013235334,0.000234046,0.032536745,0.01865369,0.0049265428],"genre_scores_gemma":[0.84981906,0.0005108553,0.10152939,0.00048349675,0.000029422834,0.00021034644,0.043537874,0.0013847164,0.0024949678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969053,0.000052819225,0.000020332229,0.00011262202,0.00009258842,0.000031085783],"domain_scores_gemma":[0.99965155,0.0001611992,0.000058956768,0.000040954776,0.00004418758,0.000043119548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007408755,0.0005591167,0.0006530941,0.000869899,0.00057546806,0.00092893385,0.0005395514,0.0005150415,0.0047727437],"category_scores_gemma":[0.0010728937,0.00031066145,0.00079096266,0.0006589684,0.00019456957,0.00039735247,0.0006968961,0.0005651346,0.0016960067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003402536,0.00039711656,0.08573398,0.0018895752,0.0006491458,0.0017252951,0.00030236834,0.04012855,0.73478186,0.0032740945,0.027981574,0.099733904],"study_design_scores_gemma":[0.00040213933,0.0014247413,0.06351422,0.00012498988,0.0005386312,0.0026007101,0.00024962993,0.44069204,0.4355584,0.0046906946,0.050051846,0.00015196731],"about_ca_topic_score_codex":0.0009360112,"about_ca_topic_score_gemma":0.0017048507,"teacher_disagreement_score":0.0047727437,"about_ca_system_score_codex":0.0003935928,"about_ca_system_score_gemma":0.0005509767,"threshold_uncertainty_score":0.015966475},"labels":[],"label_agreement":null},{"id":"W4399504621","doi":"10.1158/1538-8514.synthleth24-b020","title":"Abstract B020: Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Cancer; Microsatellite instability; Cancer cell; DNA; DNA replication; Biology; DNA damage; In vivo; Molecular biology; Cancer research; Genetics; Microsatellite; Gene","score_opus":0.019242336463347318,"score_gpt":0.28797967615959064,"score_spread":0.2687373396962433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8371769,0.0497695,0.020781985,0.0024961266,0.0015953635,0.0008895529,0.0061163297,0.0032852574,0.07788907],"genre_scores_gemma":[0.8567945,0.019833677,0.01380059,0.0010921222,0.00017804955,0.00036104032,0.005775345,0.00019887125,0.10196589],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993706,0.0000062746153,0.000004655683,0.000015276477,0.00002382649,0.0000128720985],"domain_scores_gemma":[0.99995947,0.0000035924643,0.000007042959,0.0000032787152,0.000009417782,0.000017217404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001208705,0.0005316343,0.0003184452,0.000373623,0.00021649884,0.00050068914,0.00040668395,0.00046141975,0.00543131],"category_scores_gemma":[0.00006963271,0.00015913602,0.00019728488,0.00018778864,0.00014223994,0.00021074577,0.00019667092,0.00049923157,0.001969054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003373785,0.0001411323,0.00014679147,0.00013468492,0.000013857894,0.0001429878,0.0000135715445,0.0002133631,0.9737188,0.00049002614,0.0041286205,0.020518731],"study_design_scores_gemma":[0.00023923167,0.0016711005,0.0025697923,0.000019745688,0.000029680541,0.0007797162,0.000016418093,0.0011521316,0.9496018,0.0001521003,0.043749183,0.000019178555],"about_ca_topic_score_codex":0.0010275147,"about_ca_topic_score_gemma":0.002319899,"teacher_disagreement_score":0.00543131,"about_ca_system_score_codex":0.00032135381,"about_ca_system_score_gemma":0.00035754556,"threshold_uncertainty_score":0.018169582},"labels":[],"label_agreement":null},{"id":"W4399504630","doi":"10.1158/1538-8514.synthleth24-pr004","title":"Abstract PR004: Computational discovery of paralog dependencies drives target identification in lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Druggability; Synthetic lethality; Gene duplication; Lung cancer; Biology; Cancer; Gene; Copy-number variation; Computational biology; Crizotinib; Genetics; Genome; Bioinformatics; Cancer research; Medicine; DNA repair; Oncology","score_opus":0.011426439612726784,"score_gpt":0.2841934073314392,"score_spread":0.27276696771871245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7821586,0.006117718,0.12304456,0.009033025,0.0011033916,0.00052581215,0.033294942,0.01787821,0.02684371],"genre_scores_gemma":[0.85903764,0.0010702539,0.099610575,0.0016956103,0.0002546244,0.0004138034,0.03212716,0.00097333576,0.00481705],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996339,0.00014978669,0.000017092063,0.00010296505,0.000048280064,0.00004801393],"domain_scores_gemma":[0.99774677,0.001879325,0.000060520542,0.000085053674,0.00013084162,0.00009745241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010035827,0.0011532959,0.0011641325,0.0010103042,0.00070177205,0.0011576788,0.002020272,0.0018368765,0.008473152],"category_scores_gemma":[0.004076595,0.00058302947,0.0020495476,0.00086094625,0.000514211,0.0006889582,0.00085888465,0.0016802297,0.0009824781],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009372898,0.00039172862,0.017814392,0.00072858145,0.00041437137,0.0005691798,0.00006361583,0.9108873,0.0011844612,0.006257786,0.027793992,0.03295727],"study_design_scores_gemma":[0.00012371219,0.00007595369,0.00059815723,0.000013511155,0.000040609746,0.00003732813,0.000020831545,0.9936945,0.00019781844,0.0029755116,0.0022150937,0.00000699842],"about_ca_topic_score_codex":0.021987088,"about_ca_topic_score_gemma":0.026251651,"teacher_disagreement_score":0.021987088,"about_ca_system_score_codex":0.001088683,"about_ca_system_score_gemma":0.0024831023,"threshold_uncertainty_score":0.04371822},"labels":[],"label_agreement":null},{"id":"W4399504642","doi":"10.1158/1538-8514.synthleth24-a011","title":"Abstract A011: Enhancing chaperone-mediated autophagy to impede glioblastoma growth","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autophagy; Downregulation and upregulation; Cancer research; Cell growth; Cell; Cell biology; Cancer cell; Gene knockdown; Cell cycle; Lysosome; Glioblastoma; Cell culture; Biology; Cancer; Apoptosis; Biochemistry; Gene; Genetics","score_opus":0.014623750132437874,"score_gpt":0.30705426175059897,"score_spread":0.2924305116181611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9591532,0.010013127,0.0074428483,0.0014828489,0.0011121553,0.0003596654,0.0024428421,0.0017491988,0.016244091],"genre_scores_gemma":[0.9519768,0.0077028447,0.008904649,0.000610333,0.00014489949,0.00023870573,0.0025860323,0.00013785838,0.027697938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993694,0.0000063745447,0.000008326058,0.000011877073,0.000020494243,0.00001592452],"domain_scores_gemma":[0.9999616,0.0000032163177,0.0000075520757,0.000003099679,0.0000082792385,0.000016316155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000973085,0.00042092058,0.00030010263,0.0003860454,0.00018418525,0.00047565656,0.0002615589,0.0003483131,0.004559127],"category_scores_gemma":[0.000067316745,0.00013228547,0.0003024862,0.0003516452,0.00014355838,0.0002190384,0.00023055729,0.00053497223,0.001010402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081773225,0.00032525527,0.00021471015,0.0002811276,0.000023004706,0.00014591178,0.000015273416,0.00025587028,0.975272,0.00048664637,0.0035682074,0.018594252],"study_design_scores_gemma":[0.00026947627,0.0024421515,0.0025893871,0.000030912037,0.000097442986,0.00039625654,0.000025539874,0.0015591591,0.9644627,0.00014784554,0.027960964,0.000018056417],"about_ca_topic_score_codex":0.0011128878,"about_ca_topic_score_gemma":0.0016973069,"teacher_disagreement_score":0.004559127,"about_ca_system_score_codex":0.0003461805,"about_ca_system_score_gemma":0.0005806634,"threshold_uncertainty_score":0.015251815},"labels":[],"label_agreement":null},{"id":"W4399504645","doi":"10.1158/1538-8514.synthleth24-ia018","title":"Abstract IA018: Vulnerabilities of TP53-mutated AML and therapeutic implications","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Biology; Myeloid leukemia; Cancer research; Mutant; Etoposide; Gene; Genetics; Chemotherapy","score_opus":0.020459853698692798,"score_gpt":0.29845115482399365,"score_spread":0.27799130112530085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773521,0.00840516,0.0053094365,0.00063997443,0.00008763683,0.000060961906,0.0014297441,0.00043014355,0.006284989],"genre_scores_gemma":[0.99385464,0.0018515005,0.0011586819,0.00012305996,0.0000107356345,0.000019892865,0.00087462907,0.00003101947,0.002075821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991477,0.0000081957605,0.000006336558,0.000021356596,0.000029265153,0.0000200829],"domain_scores_gemma":[0.9999317,0.00000988847,0.000021188373,0.00000801462,0.000011089252,0.000018096294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012806508,0.00028595736,0.00018805079,0.00030546365,0.00015391599,0.0004707463,0.0002256318,0.0002985556,0.002237883],"category_scores_gemma":[0.00019063531,0.00008278101,0.00017950042,0.00021616758,0.00019655956,0.00019092474,0.00023922409,0.0005723387,0.0006548679],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013146317,0.000029961395,0.0016453878,0.000083773404,0.0000072732073,0.00034098592,0.000016201262,0.00024896464,0.9868851,0.00034920138,0.0003231387,0.009938666],"study_design_scores_gemma":[0.000025078674,0.0006351982,0.018791696,0.000049027123,0.000066887755,0.0065805963,0.00012357572,0.002811058,0.9448659,0.0009895108,0.025046213,0.000015266252],"about_ca_topic_score_codex":0.0002950083,"about_ca_topic_score_gemma":0.00020165819,"teacher_disagreement_score":0.002237883,"about_ca_system_score_codex":0.00036876733,"about_ca_system_score_gemma":0.00015006131,"threshold_uncertainty_score":0.0074864626},"labels":[],"label_agreement":null},{"id":"W4399504649","doi":"10.1158/1538-8514.synthleth24-b030","title":"Abstract B030: Expression patterns of miR181a and miR30d in patients with breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SNC-Lavalin (Canada)","funders":"","keywords":"PTEN; microRNA; Breast cancer; PI3K/AKT/mTOR pathway; Gene expression; Protein kinase B; Fold change; Biology; Cancer research; Gene; RNA extraction; Cancer; Signal transduction; Cell biology; Genetics","score_opus":0.009593150931669644,"score_gpt":0.2787001405741748,"score_spread":0.2691069896425052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969375,0.0007056247,0.00020584888,0.00007827528,0.000014469947,0.0000097322445,0.00081719627,0.000019280342,0.0012121011],"genre_scores_gemma":[0.99817014,0.00015793694,0.0002705847,0.000044264765,0.000012593616,0.000018627641,0.00060688605,0.0000059581707,0.00071297324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985695,0.00002217415,0.000016894899,0.00004590732,0.000033942775,0.00002403027],"domain_scores_gemma":[0.9997266,0.000050752747,0.000115779,0.000011762227,0.000039359715,0.000055770073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017518578,0.00014878741,0.00016930628,0.00080102263,0.00026644385,0.0003285874,0.00016438862,0.000328993,0.002580288],"category_scores_gemma":[0.0004540012,0.0001823068,0.00016856304,0.0007397908,0.0001342421,0.00016248724,0.00016235822,0.00033896425,0.0005915795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013080897,0.00007882619,0.9721788,0.00004908747,0.00005012285,0.00083725754,0.00012231308,0.000057361605,0.017313886,0.00004657563,0.0006888896,0.0072688903],"study_design_scores_gemma":[0.000012845821,0.00013032115,0.9944776,0.0000075825847,0.000031109208,0.0022393963,0.00013824027,0.00024687205,0.0016884388,0.00005777597,0.0009643031,0.0000055418477],"about_ca_topic_score_codex":0.0005983795,"about_ca_topic_score_gemma":0.00067128043,"teacher_disagreement_score":0.002580288,"about_ca_system_score_codex":0.00017008472,"about_ca_system_score_gemma":0.00009316423,"threshold_uncertainty_score":0.008631885},"labels":[],"label_agreement":null},{"id":"W4399504653","doi":"10.1158/1538-8514.synthleth24-a019","title":"Abstract A019: Inhibition of nicotinamide adenine dinucleotide (NAD) production is a potent therapeutic strategy to inactivate homologous recombination in cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"RAD51; Synthetic lethality; Olaparib; DNA repair; Homologous recombination; Genome instability; Biology; Poly ADP ribose polymerase; PALB2; NAD+ kinase; Cancer cell; DNA damage; Cancer research; PARP inhibitor; Nicotinamide phosphoribosyltransferase; Cancer; Cell biology; DNA; Mutation; Genetics; Biochemistry; Germline mutation; Enzyme; Polymerase; Gene","score_opus":0.03737261863275776,"score_gpt":0.3369266505763999,"score_spread":0.29955403194364216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094059,0.02868681,0.025155487,0.000878958,0.0006678185,0.00039369232,0.004345377,0.0011684202,0.029297577],"genre_scores_gemma":[0.95907897,0.0074694273,0.0074518565,0.00020740989,0.000039583363,0.0001642128,0.0022522302,0.000042524494,0.023293823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994123,0.000007734447,0.000004781643,0.0000139255235,0.000020596277,0.000011755679],"domain_scores_gemma":[0.9999765,0.0000027992735,0.000007514828,0.0000022735694,0.0000035997857,0.000007292615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006313051,0.00046832094,0.00023036654,0.00028208946,0.00013530489,0.00021912614,0.00024383728,0.00023589097,0.0033567285],"category_scores_gemma":[0.000038951126,0.000077871104,0.00016934308,0.0002063784,0.0000942864,0.0001052583,0.00013029035,0.0005853162,0.0010170096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017944485,0.00013441323,0.00015384988,0.00013861054,0.000012636765,0.00006536799,0.0000069854236,0.000111682915,0.9857555,0.00026700355,0.0006046994,0.012569693],"study_design_scores_gemma":[0.00003743582,0.00070579344,0.0013835565,0.0000102107615,0.000020911639,0.00025858742,0.0000064533046,0.00035759513,0.97836316,0.000047074886,0.018805474,0.0000037699092],"about_ca_topic_score_codex":0.00059285766,"about_ca_topic_score_gemma":0.0006989611,"teacher_disagreement_score":0.0033567285,"about_ca_system_score_codex":0.00027088975,"about_ca_system_score_gemma":0.00014522349,"threshold_uncertainty_score":0.011229336},"labels":[],"label_agreement":null},{"id":"W4399504661","doi":"10.1158/1538-8514.synthleth24-ia002","title":"Abstract IA002: Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues.","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Reprogramming; Cancer research; Cancer cell; Cancer drugs; Chemistry; Cell; Computational biology; Pharmacology; Biology; Biochemistry; Genetics","score_opus":0.010614817586967583,"score_gpt":0.25642293442096986,"score_spread":0.24580811683400228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.707626,0.12695366,0.032044463,0.012046033,0.0033671756,0.0011429328,0.0049915733,0.0037601786,0.10806804],"genre_scores_gemma":[0.86290133,0.045784585,0.014684087,0.0019961281,0.00020588117,0.00031306397,0.0032761001,0.00033079548,0.07050804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998919,0.000012159921,0.000006077314,0.000016636326,0.000039439048,0.000033815046],"domain_scores_gemma":[0.9999219,0.0000070512438,0.000015005242,0.0000074555355,0.000014906542,0.00003369274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030736395,0.0005538548,0.00041364878,0.00053914345,0.00041897557,0.0009138563,0.00037714897,0.00063155784,0.0035894525],"category_scores_gemma":[0.0002275685,0.00022490324,0.00036356528,0.00029478394,0.00036432254,0.00045904267,0.0005630895,0.0011876373,0.0014406665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011220501,0.00026788245,0.00075246516,0.0004753366,0.000054070795,0.0012826305,0.000120104276,0.00131173,0.88597965,0.0064351503,0.02321402,0.07898482],"study_design_scores_gemma":[0.00023558964,0.002189086,0.0038834335,0.00010936644,0.00011058967,0.0033629346,0.00011932068,0.002228973,0.78520346,0.0015659955,0.20092988,0.00006141475],"about_ca_topic_score_codex":0.0018291649,"about_ca_topic_score_gemma":0.0039079147,"teacher_disagreement_score":0.0035894525,"about_ca_system_score_codex":0.0010590107,"about_ca_system_score_gemma":0.00062617776,"threshold_uncertainty_score":0.012007892},"labels":[],"label_agreement":null},{"id":"W4399504666","doi":"10.1158/1538-8514.synthleth24-a004","title":"Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radiation therapy; In vivo; Cancer research; DNA damage; Pharmacology; Viability assay; Medicine; Cancer; In vitro; Biology; Internal medicine; DNA; Biochemistry","score_opus":0.10184426850061963,"score_gpt":0.40615270182311075,"score_spread":0.30430843332249113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8998562,0.014357009,0.040005364,0.0008954734,0.00073899986,0.0013849444,0.012563662,0.002894309,0.027304035],"genre_scores_gemma":[0.8451581,0.011516937,0.043243784,0.0003916048,0.00016786123,0.0022304554,0.022957832,0.0004187937,0.07391477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999567,0.00010248881,0.000050073348,0.00008235773,0.00014369196,0.000054410222],"domain_scores_gemma":[0.99969804,0.000068554735,0.000063147876,0.00006061109,0.000067525434,0.000042077107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004843931,0.0010091446,0.00061247055,0.00093919813,0.00030785985,0.0004245344,0.00056215987,0.0006340508,0.015105373],"category_scores_gemma":[0.00023161905,0.00030251217,0.00065765803,0.0005612139,0.00031646225,0.00040506953,0.00027790613,0.0015937171,0.0034686662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063781533,0.00051242474,0.00020921475,0.00021192331,0.00001835255,0.000068844674,0.00003385025,0.00025324576,0.9925754,0.00019855224,0.0006818491,0.0045985435],"study_design_scores_gemma":[0.000051728493,0.004392762,0.0017638541,0.000026714206,0.00004117262,0.00030156758,0.000022684444,0.0006031337,0.98182744,0.00009513519,0.010862676,0.000011161304],"about_ca_topic_score_codex":0.0005675818,"about_ca_topic_score_gemma":0.0007225199,"teacher_disagreement_score":0.015105373,"about_ca_system_score_codex":0.00035861848,"about_ca_system_score_gemma":0.00039759386,"threshold_uncertainty_score":0.05053246},"labels":[],"label_agreement":null},{"id":"W4399504672","doi":"10.1158/1538-8514.synthleth24-ia017","title":"Abstract IA017: Synthetic dependencies arising during tumor evolution","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Mechanism (biology); Computational biology; Cancer research; Biology; Medicine; Epistemology; Genetics; Philosophy","score_opus":0.03373505215618335,"score_gpt":0.33982575037990825,"score_spread":0.3060906982237249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80981284,0.01719214,0.087529115,0.0051767994,0.0007566919,0.00018016546,0.0027792193,0.0012144637,0.0753586],"genre_scores_gemma":[0.97200555,0.0036377208,0.009421151,0.0009469971,0.00011177017,0.00009932638,0.001852536,0.00030070817,0.011624232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993549,0.00013270533,0.000030116385,0.00012336171,0.00025453742,0.00010434486],"domain_scores_gemma":[0.9990338,0.00029699667,0.0002097065,0.00013643168,0.00018617739,0.00013689202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095718313,0.00043237276,0.00047556203,0.00055599614,0.0006435028,0.0016079764,0.0006122581,0.0006185127,0.0053215562],"category_scores_gemma":[0.0015405788,0.0002642381,0.00038312774,0.0003735144,0.0010411548,0.0011113611,0.0013037558,0.00224514,0.001187173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056883175,0.00010572018,0.0058891946,0.00047171756,0.000056885154,0.00066116726,0.0003332554,0.011431597,0.83815455,0.07185048,0.0065567144,0.06391995],"study_design_scores_gemma":[0.000039697396,0.0011453886,0.020186197,0.00012711735,0.00012503122,0.0030318084,0.0005478327,0.03159974,0.7144586,0.061638284,0.16694152,0.00015885971],"about_ca_topic_score_codex":0.0005630884,"about_ca_topic_score_gemma":0.0006464432,"teacher_disagreement_score":0.0053215562,"about_ca_system_score_codex":0.0015326733,"about_ca_system_score_gemma":0.00066872244,"threshold_uncertainty_score":0.017802417},"labels":[],"label_agreement":null},{"id":"W4399504681","doi":"10.1158/1538-8514.synthleth24-pr012","title":"Abstract PR012: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chromatin; Cancer research; Epigenetics; Estrogen receptor; Biology; Breast cancer; Cancer; Histone; Transcription factor; Regulation of gene expression; Cell biology; Gene; Genetics","score_opus":0.024792615467604442,"score_gpt":0.2836719021734467,"score_spread":0.25887928670584226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95253587,0.0069110254,0.022622313,0.00084632135,0.00027156938,0.000126956,0.0048073353,0.0013051936,0.010573374],"genre_scores_gemma":[0.9777272,0.000947336,0.006328202,0.00023542723,0.00001772304,0.000057001816,0.0019973277,0.00012353876,0.012566187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997671,0.000020320062,0.000019339435,0.00007286413,0.000084760555,0.000035619443],"domain_scores_gemma":[0.99989474,0.000012118233,0.000035074936,0.000010475501,0.000011076793,0.0000365418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017262602,0.0002550704,0.00028329153,0.00020265704,0.00027823276,0.00041946772,0.00027925405,0.00026330285,0.0042179106],"category_scores_gemma":[0.0001251129,0.00018139198,0.00026162647,0.00015811897,0.0002882715,0.00020038379,0.00045110073,0.00066763576,0.0015011573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016088974,0.000016935612,0.00035779286,0.000057532416,0.0000045288925,0.00004437674,0.000017857845,0.000084645115,0.996675,0.00025231592,0.000272823,0.002055337],"study_design_scores_gemma":[0.000031333224,0.00018911208,0.0070500905,0.000010107463,0.000013681398,0.00026135298,0.00005103307,0.0013516229,0.97973,0.000111380075,0.011192037,0.000008333685],"about_ca_topic_score_codex":0.00072689756,"about_ca_topic_score_gemma":0.001408527,"teacher_disagreement_score":0.0042179106,"about_ca_system_score_codex":0.00051016285,"about_ca_system_score_gemma":0.00026485024,"threshold_uncertainty_score":0.014110386},"labels":[],"label_agreement":null},{"id":"W4399504696","doi":"10.1158/1538-8514.synthleth24-ia020","title":"Abstract IA020: Functional studies of genetic variation using precision genome editing","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genome editing; Genome; Computational biology; Genetics; Indel; Gene; Precision medicine; Genotype; Single-nucleotide polymorphism","score_opus":0.03605868568233169,"score_gpt":0.3466691388137472,"score_spread":0.31061045313141555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57002515,0.003347842,0.3892103,0.0011524319,0.00059533655,0.0005760585,0.0079727685,0.0064181206,0.02070202],"genre_scores_gemma":[0.87125754,0.0014944642,0.10824131,0.00033957645,0.000072730974,0.00031008513,0.0053257477,0.0014218662,0.011536695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999106,0.00018086086,0.00006861169,0.00022706614,0.0003336765,0.00008371663],"domain_scores_gemma":[0.999228,0.00027454077,0.00015342407,0.0001510181,0.000090431946,0.00010258683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015127625,0.0006347598,0.00045981558,0.0006303135,0.0003308759,0.0010789314,0.0010175897,0.000870727,0.0033143451],"category_scores_gemma":[0.0008759888,0.00030800988,0.0004622346,0.00050578045,0.00073544384,0.00031781194,0.0008250472,0.0018073863,0.001401569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007610331,0.00003281605,0.00014604082,0.000050436724,0.000012654948,0.00006707408,0.000023306642,0.00053461536,0.99292576,0.0012563851,0.00031458054,0.0045603346],"study_design_scores_gemma":[0.000026702062,0.00020988843,0.0014252022,0.000011271342,0.000020662916,0.00039555083,0.000014845786,0.006103039,0.9783403,0.0005498705,0.012872887,0.000029744102],"about_ca_topic_score_codex":0.0010636634,"about_ca_topic_score_gemma":0.0008787765,"teacher_disagreement_score":0.0033143451,"about_ca_system_score_codex":0.000684869,"about_ca_system_score_gemma":0.0003898396,"threshold_uncertainty_score":0.011087596},"labels":[],"label_agreement":null},{"id":"W4399504765","doi":"10.1158/1538-8514.synthleth24-ia010","title":"Abstract IA010: Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cancer research; Genome instability; Ovarian cancer; Medicine; Cyclin-dependent kinase 1; Biology; Cell cycle; Synthetic lethality; Chromosome instability; Mitosis; Genome; Genetics; Gene; DNA damage; DNA; DNA repair","score_opus":0.023979100531711532,"score_gpt":0.31970008194537397,"score_spread":0.29572098141366243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504765","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054184765,0.3380595,0.02786464,0.11184367,0.031771857,0.0015448477,0.00841833,0.005489605,0.42082283],"genre_scores_gemma":[0.26105255,0.26486,0.021548899,0.030563394,0.009338599,0.0006923551,0.0073158727,0.000574915,0.4040535],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997676,0.000042594744,0.000011174158,0.000030892497,0.00008375872,0.000063975654],"domain_scores_gemma":[0.99971634,0.000026261447,0.000028840133,0.000015317815,0.00008508611,0.00012814066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093692844,0.00069449836,0.00041364896,0.0008827548,0.00037355747,0.0018840851,0.00074820936,0.0010965264,0.024126722],"category_scores_gemma":[0.00048681008,0.00021975675,0.00029247525,0.0005019531,0.0005967299,0.000724756,0.0007234294,0.0022692645,0.0063908244],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011529827,0.00058323063,0.00065473147,0.00078905385,0.00003770342,0.00033552138,0.00010593544,0.00086266996,0.06635604,0.018948425,0.5041678,0.40600583],"study_design_scores_gemma":[0.000526057,0.0015119703,0.0018669558,0.0003084485,0.000065535525,0.00068139966,0.00005988644,0.0010774822,0.03190414,0.0028363045,0.95912445,0.000037339876],"about_ca_topic_score_codex":0.004471911,"about_ca_topic_score_gemma":0.009526088,"teacher_disagreement_score":0.024126722,"about_ca_system_score_codex":0.0023246882,"about_ca_system_score_gemma":0.0018288341,"threshold_uncertainty_score":0.0807119},"labels":[],"label_agreement":null},{"id":"W4399504818","doi":"10.1158/1538-8514.synthleth24-ia019","title":"Abstract IA019: Identification of metabolic adaptation mechanisms that confer resistance to glutathione depletion in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"GCLM; GCLC; Glutathione; Buthionine sulfoximine; Biochemistry; Cancer cell; Chemistry; Cysteine; HT1080; Cystathionine beta synthase; Oxidative stress; Mitochondrion; Cell biology; Biology; Cell; Cancer; Enzyme","score_opus":0.027716169541918974,"score_gpt":0.28916715189581155,"score_spread":0.2614509823538926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967795,0.00030953626,0.0013419389,0.00006521558,0.0000142112785,0.000037722366,0.0004223337,0.000049735056,0.0009797491],"genre_scores_gemma":[0.9946983,0.00019883159,0.001130315,0.000040569746,0.000005408252,0.00003110926,0.0013080193,0.000017613645,0.0025698373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991477,0.000011219115,0.000012787778,0.000022575183,0.00001716676,0.000021568956],"domain_scores_gemma":[0.9999229,0.000014712137,0.000016756023,0.000014719534,0.000008380117,0.00002258092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116708485,0.00020994953,0.00018037524,0.00024347671,0.00009431671,0.00018802319,0.00017443503,0.00022127668,0.0018998826],"category_scores_gemma":[0.00013820123,0.00009167015,0.00021469052,0.00014147002,0.00013129745,0.00009789083,0.00016590016,0.00047985426,0.0004943588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054594508,0.000023290433,0.000269684,0.000007656537,0.0000020055475,0.000027006248,0.000005593277,0.000023722181,0.9989299,0.000042286614,0.000015613525,0.0005986141],"study_design_scores_gemma":[0.000041550975,0.0011881484,0.019337442,0.000007729423,0.000027554102,0.0008157645,0.000078858306,0.0014857805,0.97275496,0.000102722806,0.0041521504,0.000007309687],"about_ca_topic_score_codex":0.0004261857,"about_ca_topic_score_gemma":0.0002786647,"teacher_disagreement_score":0.0018998826,"about_ca_system_score_codex":0.00015830499,"about_ca_system_score_gemma":0.00009619245,"threshold_uncertainty_score":0.006355703},"labels":[],"label_agreement":null},{"id":"W4399504870","doi":"10.1158/1538-8514.synthleth24-a008","title":"Abstract A008: Pre-diabetic D-glucose exposure promotes EOC progression and cisplatin resistance: Role of BAD associated pathway and potential therapeutic strategy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prediabetes; Cisplatin; Cancer research; Insulin resistance; Ex vivo; Glucose uptake; Medicine; Internal medicine; Tumor progression; Cancer; Endocrinology; In vivo; Diabetes mellitus; Type 2 diabetes; Biology; Oncology; Insulin; Chemotherapy; Biotechnology","score_opus":0.00846297219287443,"score_gpt":0.26245784418486523,"score_spread":0.2539948719919908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93702495,0.04575232,0.003776914,0.0027154896,0.0005201215,0.00019800394,0.0026326491,0.00024270707,0.0071368753],"genre_scores_gemma":[0.9754497,0.015497969,0.0014328959,0.0006151253,0.00008252661,0.00012774527,0.001984053,0.000013217851,0.0047967103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994254,0.000009078632,0.0000055734286,0.000010564633,0.000012578206,0.000019621948],"domain_scores_gemma":[0.9999455,0.0000058837227,0.000015367423,0.0000035591518,0.000010490751,0.000019158198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010191029,0.00029603727,0.00032184224,0.00028915398,0.00019585837,0.00049555465,0.00023469815,0.00040169945,0.0048517114],"category_scores_gemma":[0.000082383245,0.000110605695,0.00044207476,0.00029730893,0.00017225936,0.00021221694,0.0002199171,0.0008364162,0.0005112187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008026241,0.0014762039,0.015991861,0.0032918728,0.0002282042,0.0020581065,0.00010774403,0.00080628897,0.88329476,0.0018566898,0.0074414597,0.07542056],"study_design_scores_gemma":[0.0010191501,0.007910164,0.18067272,0.00038853774,0.0006971056,0.006804184,0.00059339614,0.004339688,0.7281403,0.0027997391,0.066563465,0.0000715798],"about_ca_topic_score_codex":0.0003492659,"about_ca_topic_score_gemma":0.00046246292,"teacher_disagreement_score":0.0048517114,"about_ca_system_score_codex":0.00030274616,"about_ca_system_score_gemma":0.00027622216,"threshold_uncertainty_score":0.016230524},"labels":[],"label_agreement":null},{"id":"W4399504875","doi":"10.1158/1538-8514.synthleth24-b001","title":"Abstract B001: Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytidine; Cancer; Diacylglycerol kinase; Cancer cell; Cancer research; Biology; Biochemistry; Chemistry; Enzyme; Genetics; Protein kinase C","score_opus":0.013493765148433163,"score_gpt":0.28116485368334937,"score_spread":0.2676710885349162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504875","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112775974,0.14503597,0.017358158,0.06982314,0.052751508,0.0011740705,0.022157129,0.0030875048,0.5758364],"genre_scores_gemma":[0.22063377,0.054440126,0.0051900595,0.004873257,0.008607567,0.00024460943,0.013037344,0.00032175632,0.69265145],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984586,0.000021976139,0.0000073735346,0.00001923721,0.00007799678,0.000027590608],"domain_scores_gemma":[0.99982893,0.00002557586,0.000016379074,0.000006895016,0.000049679402,0.00007250465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036429768,0.0007387879,0.00031553916,0.0007304508,0.00042509122,0.0011730667,0.00044784488,0.0007113581,0.092557736],"category_scores_gemma":[0.00033283298,0.00015070214,0.00029119093,0.00043200198,0.00024954925,0.00041142822,0.00047252438,0.0008787024,0.01771936],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023900145,0.00027419915,0.0006346379,0.0015759956,0.000046187204,0.0005826098,0.00007160884,0.0005743151,0.28892425,0.011242673,0.5064596,0.18722391],"study_design_scores_gemma":[0.00030718738,0.001123078,0.0058277855,0.00026093016,0.00007861286,0.0009190932,0.00011356193,0.00092354394,0.21435563,0.00411769,0.77194625,0.000026614518],"about_ca_topic_score_codex":0.0011997552,"about_ca_topic_score_gemma":0.0014075896,"teacher_disagreement_score":0.092557736,"about_ca_system_score_codex":0.0010074889,"about_ca_system_score_gemma":0.0011123207,"threshold_uncertainty_score":0.30963647},"labels":[],"label_agreement":null},{"id":"W4399504877","doi":"10.1158/1538-8514.synthleth24-b021","title":"Abstract B021: CFLAR targeting selectively exploits extrinsic apoptosis signaling in triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Necroptosis; Cancer; Cancer research; Programmed cell death; Cancer cell; Apoptosis; Triple-negative breast cancer; Downregulation and upregulation; Medicine; Breast cancer; Biology; Internal medicine; Biochemistry","score_opus":0.022100990123752995,"score_gpt":0.288813788610542,"score_spread":0.266712798486789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977489,0.0042584515,0.0061051203,0.0005669682,0.00020237936,0.00015265196,0.001703607,0.0003627654,0.009158991],"genre_scores_gemma":[0.9815932,0.0020544808,0.005015916,0.00026921427,0.000024265702,0.000073784686,0.0014045258,0.000067822635,0.009496861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998672,0.000018414858,0.000010975522,0.000023926972,0.000045637193,0.000033771445],"domain_scores_gemma":[0.9999417,0.000009046957,0.000013272383,0.000007542611,0.00001010089,0.000018282744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019753542,0.00029448984,0.00037207274,0.00027409405,0.00020148445,0.00033347422,0.00023763801,0.00038046765,0.002405551],"category_scores_gemma":[0.00008865983,0.00011683798,0.00020809172,0.00016140446,0.00021655994,0.00014995932,0.00022562966,0.0005934335,0.0007808294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013087355,0.0000334953,0.00008590471,0.000028384185,0.0000037370505,0.00008050292,0.000008409519,0.00008298505,0.9966844,0.0001480832,0.00025706794,0.0024563246],"study_design_scores_gemma":[0.000028093942,0.0006572175,0.0011841469,0.0000063813036,0.00001497435,0.0007273732,0.000017967079,0.00041813013,0.9908687,0.000041874984,0.0060288366,0.000006240476],"about_ca_topic_score_codex":0.00078779244,"about_ca_topic_score_gemma":0.0015532736,"teacher_disagreement_score":0.002405551,"about_ca_system_score_codex":0.00040217338,"about_ca_system_score_gemma":0.00029164436,"threshold_uncertainty_score":0.008047402},"labels":[],"label_agreement":null},{"id":"W4399504893","doi":"10.1158/1538-8514.synthleth24-ia015","title":"Abstract IA015: Identifying and targeting synthetic lethalities of aneuploid (cancer) cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aneuploidy; Biology; Cancer cell; Cancer; Cancer research; Gene silencing; Chromosome instability; Genetics; Cell biology; Gene; Chromosome","score_opus":0.020122958474689347,"score_gpt":0.28696961743507254,"score_spread":0.2668466589603832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7705965,0.043482214,0.12528957,0.0037441128,0.0015535627,0.001606267,0.004428705,0.0036007657,0.045698307],"genre_scores_gemma":[0.8482548,0.017817296,0.08151518,0.0013187539,0.00017659126,0.0007035112,0.0074932566,0.00042773396,0.042292964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996278,0.000059043425,0.00004973022,0.00008872703,0.00011755285,0.000057193625],"domain_scores_gemma":[0.99977154,0.000041097966,0.000041226293,0.00003286449,0.000047931873,0.00006536363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006732425,0.0005824424,0.0005134123,0.001236432,0.00045369577,0.001145689,0.0006041679,0.0006946417,0.0034906352],"category_scores_gemma":[0.00033783301,0.00026980127,0.0003233727,0.0005782524,0.00048411824,0.00036297535,0.0007974648,0.0009144438,0.0012734084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018748583,0.00009130875,0.0004667844,0.00013506289,0.000010955634,0.00007969926,0.00002960022,0.00024997673,0.98147595,0.0009299509,0.0013848335,0.014958356],"study_design_scores_gemma":[0.00004319944,0.0005196547,0.0025434569,0.000024174755,0.00003986351,0.00081351737,0.000042780848,0.0013927745,0.96623445,0.00028578466,0.028044544,0.00001576382],"about_ca_topic_score_codex":0.0010038308,"about_ca_topic_score_gemma":0.001339836,"teacher_disagreement_score":0.0034906352,"about_ca_system_score_codex":0.0007211593,"about_ca_system_score_gemma":0.0005772994,"threshold_uncertainty_score":0.011677325},"labels":[],"label_agreement":null},{"id":"W4399504903","doi":"10.1158/1538-8514.synthleth24-a003","title":"Abstract A003: Unwinding the complexities of helicases as compelling drug targets in oncology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Computational biology; Biology; Drug discovery; Drug; Cancer; Genetics; Bioinformatics; Pharmacology; Gene; RNA","score_opus":0.08729093644661247,"score_gpt":0.4190637755425328,"score_spread":0.33177283909592037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8612651,0.080392614,0.0163422,0.0060417783,0.0006732561,0.00047423318,0.0029577145,0.0007735751,0.031079464],"genre_scores_gemma":[0.9441758,0.024882425,0.010752551,0.0014362764,0.0002026107,0.00009750819,0.0018765528,0.00009843026,0.016477838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983203,0.000036698224,0.000013294918,0.000021534635,0.00006557363,0.000030774954],"domain_scores_gemma":[0.99968946,0.00009292588,0.00006608343,0.000024444296,0.000073082774,0.00005401185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044288966,0.0004532088,0.00039761278,0.0003924303,0.0002161181,0.00074997445,0.00030776978,0.00055052637,0.008128571],"category_scores_gemma":[0.000457571,0.00012818933,0.00033287803,0.00046587738,0.00033243024,0.00059187616,0.00029640467,0.0012227212,0.0016605518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008055416,0.00024259882,0.0014428089,0.00048797933,0.000041100622,0.00030384545,0.00008011,0.0013330241,0.94769526,0.0016380504,0.0024987771,0.043430984],"study_design_scores_gemma":[0.0002260359,0.007362826,0.011615575,0.00021241866,0.000100692894,0.0018890393,0.00020024201,0.0028002306,0.89713377,0.0027724213,0.07561867,0.00006798204],"about_ca_topic_score_codex":0.00044316586,"about_ca_topic_score_gemma":0.0010924777,"teacher_disagreement_score":0.008128571,"about_ca_system_score_codex":0.00037602457,"about_ca_system_score_gemma":0.0003701046,"threshold_uncertainty_score":0.027192831},"labels":[],"label_agreement":null},{"id":"W4399504914","doi":"10.1158/1538-8514.synthleth24-a002","title":"Abstract A002: Understanding mechanisms of resistance to WRN small molecule inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genetics; Helicase; Mutation; Cancer research; Cancer; Computational biology; Gene","score_opus":0.05844738360686748,"score_gpt":0.30760596226002596,"score_spread":0.2491585786531585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8600987,0.09514628,0.022060854,0.005452972,0.00023662898,0.0002542431,0.0021960873,0.0005531941,0.0140010575],"genre_scores_gemma":[0.9644376,0.02399607,0.0039402684,0.0005918515,0.00012120127,0.00006832158,0.0012287785,0.000024298046,0.005591515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985135,0.000019260242,0.000011143465,0.000029730589,0.000060000995,0.000028640887],"domain_scores_gemma":[0.9998561,0.000037377067,0.000045532306,0.000011138949,0.000033938923,0.000015799724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048781087,0.00042431266,0.00048717397,0.000413903,0.00016105133,0.00096295954,0.00059061445,0.0007851776,0.0035654553],"category_scores_gemma":[0.00041524315,0.00016958968,0.00034007337,0.00024514826,0.00030098055,0.0012053606,0.00021664938,0.0010461032,0.0009067878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006935693,0.00031290998,0.0031637454,0.0008397081,0.000064634485,0.00027598624,0.00008681195,0.005550937,0.9211891,0.0047474173,0.0027038208,0.06037129],"study_design_scores_gemma":[0.0002392351,0.0031183115,0.02782611,0.00016910858,0.00014481891,0.0018917286,0.0002476306,0.050768428,0.8506162,0.009979301,0.054934178,0.000064905216],"about_ca_topic_score_codex":0.0006533621,"about_ca_topic_score_gemma":0.00047389543,"teacher_disagreement_score":0.0035654553,"about_ca_system_score_codex":0.0006647216,"about_ca_system_score_gemma":0.0002824727,"threshold_uncertainty_score":0.011927664},"labels":[],"label_agreement":null},{"id":"W4399504926","doi":"10.1158/1538-8514.synthleth24-a018","title":"Abstract A018: STRIDE as a technology platform for accurate measurement of DNA breaks and breaks-associated repair proteins","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; DNA damage; DNA; Synthetic lethality; Computational biology; Biology; Genetics","score_opus":0.05037764949518274,"score_gpt":0.3367402551636608,"score_spread":0.28636260566847804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504926","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34058493,0.0064497828,0.57698524,0.0021226532,0.001040174,0.0007621861,0.006313971,0.016298782,0.049442332],"genre_scores_gemma":[0.44136834,0.005325311,0.46098974,0.0014455554,0.00020003683,0.0014509378,0.013390733,0.001906028,0.07392326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993573,0.000077479344,0.00003563817,0.00020201299,0.00026218322,0.00006540226],"domain_scores_gemma":[0.9992772,0.0001679005,0.00010359579,0.00012484282,0.0002084182,0.0001179918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008669094,0.0009190404,0.0004555959,0.0010735784,0.00046868244,0.00087873254,0.0009837628,0.0013712308,0.017923117],"category_scores_gemma":[0.00067713746,0.00056327466,0.00048874214,0.000513039,0.00064296916,0.0011834895,0.00086591626,0.0019210011,0.009347134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062701656,0.000055675006,0.00029714798,0.00015794087,0.000014686362,0.00007608311,0.000036734873,0.00015092915,0.98459446,0.0013072628,0.0023717908,0.010874607],"study_design_scores_gemma":[0.000012442709,0.00020643843,0.0008697311,0.000017897826,0.000012205955,0.00044412963,0.00001845079,0.001911096,0.97008836,0.0002879525,0.026109297,0.000021970764],"about_ca_topic_score_codex":0.00025212351,"about_ca_topic_score_gemma":0.00042203913,"teacher_disagreement_score":0.017923117,"about_ca_system_score_codex":0.00040656555,"about_ca_system_score_gemma":0.0005363689,"threshold_uncertainty_score":0.059958816},"labels":[],"label_agreement":null},{"id":"W4399505041","doi":"10.1158/1538-8514.synthleth24-a016","title":"Abstract A016: Companion Diagnostics (CDx) to identify hallmarks of Alternative Lengthening of Telomeres (ALT)","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Telomere; Telomerase; Cancer; Cancer research; Biomarker; Biology; Computational biology; Molecular biology; Medicine; DNA; Genetics; Gene","score_opus":0.023445458253527066,"score_gpt":0.3276595688487436,"score_spread":0.3042141105952165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505041","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35755032,0.03911901,0.3626809,0.0130100995,0.017188545,0.004665772,0.046602253,0.02980075,0.12938236],"genre_scores_gemma":[0.46964604,0.014110044,0.30799958,0.0051190834,0.0021184273,0.00297401,0.028936781,0.0015781552,0.16751789],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861145,0.00025812982,0.00009942846,0.00039274813,0.0005559861,0.00008228857],"domain_scores_gemma":[0.99788994,0.00048031934,0.00041567915,0.00019891717,0.0007121052,0.00030307565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019831434,0.0010821626,0.0007648639,0.002048007,0.0007280629,0.001635715,0.0007018406,0.0016325463,0.027516628],"category_scores_gemma":[0.0026272235,0.00042404744,0.00044399037,0.0009980277,0.00059186685,0.00088964927,0.0010622749,0.0017206552,0.012311693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014144379,0.0002661319,0.0074707973,0.0013024189,0.00006393665,0.00066711096,0.00025656764,0.00054322573,0.7534837,0.0047043934,0.058618072,0.17120922],"study_design_scores_gemma":[0.00014814746,0.0017911706,0.011525024,0.00025125168,0.00010181094,0.0036725998,0.00017628873,0.0033786788,0.6929523,0.0021455418,0.28373474,0.00012254059],"about_ca_topic_score_codex":0.00043310624,"about_ca_topic_score_gemma":0.00058140437,"teacher_disagreement_score":0.027516628,"about_ca_system_score_codex":0.00064412283,"about_ca_system_score_gemma":0.0007938289,"threshold_uncertainty_score":0.09205228},"labels":[],"label_agreement":null},{"id":"W4399505066","doi":"10.1158/1538-8514.synthleth24-b028","title":"Abstract B028: Expression of NOTCH1 in head and neck tumours at selected hospitals in Ghana","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunohistochemistry; Head and neck; Paranasal sinuses; Head and neck cancer; Pathology; Cancer; Internal medicine; Surgery","score_opus":0.013765133537670424,"score_gpt":0.3027731964715795,"score_spread":0.28900806293390907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993874,0.00015065377,0.000030580268,0.000037671307,0.0000014187923,0.0000064544147,0.00023610675,0.0000015181784,0.00014808023],"genre_scores_gemma":[0.9993949,0.00015514367,0.0000800797,0.000016591543,0.000001904527,0.0000074218397,0.00015586975,8.6154597e-7,0.00018727718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988496,0.000020527663,0.000012057179,0.000024871162,0.000018999455,0.00003858577],"domain_scores_gemma":[0.99961394,0.00004901563,0.0002234094,0.000009053346,0.000047437316,0.00005719719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013288915,0.00013256604,0.00012475182,0.00054743676,0.00034304414,0.0003474155,0.00016390062,0.0002295809,0.0017212172],"category_scores_gemma":[0.0004479514,0.00017087995,0.00011539373,0.00075693073,0.00035417156,0.0002382394,0.00024892783,0.00016045936,0.00021298927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009542232,0.000019126426,0.99010664,0.000074781994,0.000008278233,0.0014715651,0.0008992396,0.00006032484,0.0044890777,0.000020912821,0.00021123055,0.0025433712],"study_design_scores_gemma":[0.000004647663,0.00006749537,0.9913083,0.000025370478,0.000010389171,0.0018937272,0.0050256983,0.000105236366,0.0009007294,0.000017856713,0.00063656655,0.000004023199],"about_ca_topic_score_codex":0.023076668,"about_ca_topic_score_gemma":0.030172264,"teacher_disagreement_score":0.023076668,"about_ca_system_score_codex":0.0008507562,"about_ca_system_score_gemma":0.00052288803,"threshold_uncertainty_score":0.04588467},"labels":[],"label_agreement":null},{"id":"W4399505067","doi":"10.1158/1538-8514.synthleth24-a017","title":"Abstract A017: Characterizing intratumoral heterogeneity of <i>CCNE1</i> amplification in ovarian cancer using digital pathology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Ovarian cancer; Biology; Cancer research; Synthetic lethality; Cancer; Gene; Genetics; DNA repair","score_opus":0.028236156593509535,"score_gpt":0.302029070117898,"score_spread":0.27379291352438845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595047,0.0013594478,0.027513433,0.00024525018,0.000042715466,0.0002121474,0.0035063594,0.0013223968,0.006293689],"genre_scores_gemma":[0.96406573,0.0005352026,0.02974786,0.00010341119,0.000028855156,0.0001541504,0.0030933868,0.00010253111,0.0021689024],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99972314,0.000034788212,0.000024315239,0.00007964825,0.00010787915,0.000030267502],"domain_scores_gemma":[0.9994168,0.00014112837,0.00016096735,0.00005899781,0.00015761102,0.00006450134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007592711,0.00032044397,0.00020012526,0.0023745233,0.0002516871,0.0009865124,0.00027284466,0.00042584195,0.002567376],"category_scores_gemma":[0.0013177025,0.00018412573,0.00019539242,0.00074108096,0.00030778005,0.00039568002,0.0004437693,0.00029966634,0.00066351803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015120795,0.00014598315,0.38747278,0.0005207913,0.00021630307,0.0008140585,0.00024570053,0.007996266,0.40915313,0.0013186719,0.006455958,0.18414831],"study_design_scores_gemma":[0.000059722282,0.00042627472,0.61622787,0.00010122584,0.00023127082,0.005650773,0.0004789295,0.10195153,0.2531526,0.0018800098,0.019759092,0.00008070236],"about_ca_topic_score_codex":0.0015144935,"about_ca_topic_score_gemma":0.0023842405,"teacher_disagreement_score":0.002567376,"about_ca_system_score_codex":0.0004640418,"about_ca_system_score_gemma":0.00028907927,"threshold_uncertainty_score":0.008588731},"labels":[],"label_agreement":null},{"id":"W4399505079","doi":"10.1158/1538-8514.synthleth24-b023","title":"Abstract B023: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Medicine; Biology; Genetics; Gene; DNA repair","score_opus":0.0453209368628729,"score_gpt":0.36038447832171006,"score_spread":0.31506354145883714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57196194,0.05335765,0.019392567,0.012729447,0.0074587786,0.0017788096,0.017036224,0.0043983404,0.31188622],"genre_scores_gemma":[0.6675654,0.017266855,0.006476373,0.001642635,0.00063063495,0.00035580416,0.008310251,0.0003197378,0.29743236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999026,0.000013477728,0.0000042559545,0.000012337465,0.000042655258,0.000024601513],"domain_scores_gemma":[0.9999517,0.0000059034032,0.000006135712,0.0000036084027,0.000010676224,0.000022010432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015699989,0.0004920834,0.00035431556,0.00061650923,0.0003736492,0.00042999518,0.00039790114,0.00039450944,0.020312086],"category_scores_gemma":[0.00012406141,0.00013311376,0.00027942104,0.00026568814,0.0001693565,0.00017014929,0.00025624598,0.00070953113,0.004203982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035146575,0.0006989288,0.00047609716,0.00040131144,0.000049442075,0.00056364853,0.000032952492,0.00074506697,0.83958614,0.0020695021,0.067743115,0.08411924],"study_design_scores_gemma":[0.00054726866,0.0027870815,0.0060112784,0.000043294225,0.00007103201,0.0007436425,0.000036407153,0.0015788107,0.8611006,0.00060528493,0.12645218,0.000023103623],"about_ca_topic_score_codex":0.0030199185,"about_ca_topic_score_gemma":0.005340811,"teacher_disagreement_score":0.020312086,"about_ca_system_score_codex":0.00095812976,"about_ca_system_score_gemma":0.0009783813,"threshold_uncertainty_score":0.067950726},"labels":[],"label_agreement":null},{"id":"W4399505093","doi":"10.1158/1538-8514.synthleth24-a005","title":"Abstract A005: A live cell PRMT5 NanoBRET™ target engagement assay querying competitive and uncompetitive modes of inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protein arginine methyltransferase 5; Uncompetitive inhibitor; Methylation; Methyltransferase; Chemistry; Biochemistry; Non-competitive inhibition; Enzyme; Cell biology; Biology; DNA","score_opus":0.013766816945919797,"score_gpt":0.26511029169682343,"score_spread":0.25134347475090363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505093","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6114891,0.0072613796,0.3227931,0.0009639298,0.00051799807,0.0011157931,0.006941841,0.0044994536,0.044417426],"genre_scores_gemma":[0.7953617,0.003123822,0.15964276,0.0004907212,0.0000939574,0.0013310416,0.009471852,0.00035381087,0.030130377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976877,0.0005514764,0.00016659562,0.0004606872,0.0009642629,0.0001692275],"domain_scores_gemma":[0.9994236,0.00022309096,0.000083211846,0.000071939096,0.00014140065,0.0000568444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010856604,0.0013403703,0.0009241192,0.00069258985,0.0004546577,0.00089374493,0.001419139,0.0013727425,0.0053223916],"category_scores_gemma":[0.0006601693,0.00051136926,0.00056719914,0.0009193171,0.0005401583,0.00069519033,0.0005973054,0.0017673875,0.0019185854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017572597,0.00016582671,0.00023775155,0.00016966612,0.00002097211,0.00005028314,0.00006992263,0.00035845567,0.9922954,0.000651138,0.0006574402,0.005147402],"study_design_scores_gemma":[0.0000340568,0.00051979674,0.0008565338,0.000020541553,0.000024513382,0.000110685105,0.000035316472,0.006054191,0.9879281,0.00016243671,0.004233651,0.00002020275],"about_ca_topic_score_codex":0.0021200185,"about_ca_topic_score_gemma":0.0026155992,"teacher_disagreement_score":0.0053223916,"about_ca_system_score_codex":0.0009834152,"about_ca_system_score_gemma":0.00052240555,"threshold_uncertainty_score":0.017805219},"labels":[],"label_agreement":null},{"id":"W4399505096","doi":"10.1158/1538-8514.synthleth24-b007","title":"Abstract B007: Unexpected synthetic lethality mechanisms in eIF4A-targeted therapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Gene knockdown; Targeted therapy; In vivo; Medicine; Tumor microenvironment; Biology; Cancer; Cell culture; Internal medicine; Tumor cells; Genetics","score_opus":0.04855124951664799,"score_gpt":0.35807060044628053,"score_spread":0.30951935092963256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59956926,0.110021554,0.14215401,0.022042628,0.0051537054,0.00076252077,0.0025903203,0.0025079623,0.1151981],"genre_scores_gemma":[0.93919814,0.021669887,0.012413444,0.002972519,0.0005264566,0.00036976943,0.00080819475,0.00024411801,0.02179747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997063,0.000054150678,0.000015320029,0.000049178147,0.00011687403,0.00005804502],"domain_scores_gemma":[0.99982244,0.000046774283,0.00003715114,0.000019567684,0.000037504993,0.00003656261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006222468,0.000526725,0.0004467146,0.0003296118,0.00036318236,0.0008059281,0.00034920598,0.0009523896,0.004793167],"category_scores_gemma":[0.00044187147,0.00019045036,0.00046985198,0.00021576213,0.0004893067,0.0005589113,0.00055908493,0.0015301453,0.0016035204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011282228,0.0003181681,0.0007700587,0.0011965928,0.000100346166,0.0010175405,0.0001221875,0.0019611362,0.84348357,0.0396709,0.011809036,0.0984222],"study_design_scores_gemma":[0.0003144726,0.0032300001,0.0027553912,0.00019065726,0.0001299887,0.003106659,0.000089582034,0.007837291,0.7989911,0.01999081,0.16330491,0.000059132464],"about_ca_topic_score_codex":0.00018469455,"about_ca_topic_score_gemma":0.00015072095,"teacher_disagreement_score":0.004793167,"about_ca_system_score_codex":0.00063915644,"about_ca_system_score_gemma":0.00032316308,"threshold_uncertainty_score":0.016034722},"labels":[],"label_agreement":null},{"id":"W4399505132","doi":"10.1158/1538-8514.synthleth24-pr002","title":"Abstract PR002: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Synthetic lethality; Olaparib; Cancer research; DNA damage; Biology; DNA ligase; DNA repair; Cancer; Chemistry; Poly ADP ribose polymerase; DNA; Genetics","score_opus":0.04460359950510362,"score_gpt":0.3589815907362381,"score_spread":0.31437799123113447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879126,0.0020480056,0.0044331844,0.00021343549,0.00006885791,0.000120810095,0.0009283743,0.00036078756,0.003913863],"genre_scores_gemma":[0.98825806,0.0006862886,0.003586865,0.00010340293,0.000010496916,0.00005065089,0.0012173872,0.000029170309,0.006057593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999931,0.000011527646,0.0000052032615,0.0000146498405,0.00002513019,0.000012385903],"domain_scores_gemma":[0.9999666,0.000005630116,0.0000082362885,0.0000039905763,0.0000047571025,0.000010783766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008019752,0.00028303938,0.00022969411,0.00017948468,0.00010799208,0.00014619816,0.00017418622,0.00026876712,0.0018176464],"category_scores_gemma":[0.0000729221,0.000080687314,0.00016582014,0.000099220066,0.00012351795,0.00009551086,0.00010124418,0.00040108032,0.00047168107],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011083467,0.000042240597,0.00009062546,0.000020220768,0.000003914629,0.00004383966,0.0000026470057,0.000062891086,0.99840254,0.000042479143,0.00009135131,0.0010864098],"study_design_scores_gemma":[0.00001491089,0.0002814858,0.0012898216,0.0000015377501,0.000004320363,0.00016015314,0.000004574271,0.00054379384,0.99632263,0.00001160825,0.0013632816,0.0000017781161],"about_ca_topic_score_codex":0.00055133743,"about_ca_topic_score_gemma":0.0009110394,"teacher_disagreement_score":0.0018176464,"about_ca_system_score_codex":0.00028729116,"about_ca_system_score_gemma":0.00015780929,"threshold_uncertainty_score":0.0060806274},"labels":[],"label_agreement":null},{"id":"W4399505141","doi":"10.1158/1538-8514.synthleth24-a022","title":"Abstract A022: Synthetic lethality of <i>ERBB2</i> and <i>CCND1</i> in breast cancer at scale","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Institute for Biodiagnostics","funders":"","keywords":"Synthetic lethality; Cyclin D1; Cancer research; Biology; Breast cancer; Cancer; Gene; Gene expression; Invasive lobular carcinoma; Oncology; Medicine; Genetics; Invasive ductal carcinoma; DNA repair; Cell cycle","score_opus":0.013207778565682265,"score_gpt":0.29053109331859234,"score_spread":0.27732331475291006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405933,0.00049516035,0.006870348,0.000117076546,0.000018531478,0.000045480763,0.0063882624,0.00025336933,0.0017523989],"genre_scores_gemma":[0.98911554,0.00015181288,0.0040200893,0.000040891773,0.0000059773033,0.000034321805,0.006157321,0.000033568587,0.000440385],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974483,0.00005648918,0.000015632271,0.00009570768,0.00006201668,0.000025393165],"domain_scores_gemma":[0.99936813,0.00039971268,0.000117432566,0.000034151533,0.000039245202,0.00004139293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006109113,0.00048592617,0.00037600633,0.0005849768,0.0002550244,0.00059369626,0.00032965926,0.00030743016,0.0028152515],"category_scores_gemma":[0.0010839284,0.00013663695,0.0011251416,0.00059636997,0.00024823268,0.00025887328,0.00028820994,0.00027582058,0.0005668422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028146768,0.00047352625,0.6223861,0.001842679,0.0015798485,0.0013482729,0.00010182506,0.1543022,0.17784822,0.0019335989,0.00329,0.032079183],"study_design_scores_gemma":[0.00026282715,0.0024286127,0.506746,0.00012187985,0.0018547161,0.0029200884,0.00029734208,0.37133023,0.09927893,0.004703415,0.009940276,0.00011576078],"about_ca_topic_score_codex":0.0020213625,"about_ca_topic_score_gemma":0.0021026914,"teacher_disagreement_score":0.0028152515,"about_ca_system_score_codex":0.00037989594,"about_ca_system_score_gemma":0.00051066733,"threshold_uncertainty_score":0.009417951},"labels":[],"label_agreement":null},{"id":"W4399505148","doi":"10.1158/1538-8514.synthleth24-ia022","title":"Abstract IA022: Mechanisms of splicing dysregulation and dependency in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA splicing; Biology; Alternative splicing; Splicing factor; RNA-binding protein; Exonic splicing enhancer; Genetics; RNA; Gene; Computational biology; Messenger RNA","score_opus":0.021667386956810735,"score_gpt":0.3223889909467752,"score_spread":0.30072160398996445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505148","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760355,0.00779808,0.007663247,0.0003539172,0.00006269436,0.000042326963,0.0013707733,0.0004164963,0.00625697],"genre_scores_gemma":[0.9925062,0.0012403433,0.0015375591,0.000121180674,0.000023154393,0.000027179756,0.0014386601,0.000047334164,0.003058299],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997967,0.000022947013,0.000013964122,0.000058219477,0.00007877357,0.000029426188],"domain_scores_gemma":[0.9998672,0.000014529156,0.000045554705,0.000024196874,0.000020897158,0.000027678958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024958566,0.0003464106,0.00029079392,0.00061224966,0.00024521817,0.0005821291,0.00044880327,0.0003584259,0.0014658106],"category_scores_gemma":[0.00018629609,0.00019536616,0.00026295186,0.00047125635,0.00030940524,0.0002050798,0.0004032201,0.00041360877,0.0008742627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012566101,0.000024195948,0.003138112,0.000053873122,0.000013738215,0.00018826194,0.000012272088,0.00026173476,0.9904468,0.0007455575,0.00021047832,0.004779399],"study_design_scores_gemma":[0.000034225468,0.000500686,0.10209021,0.000023363415,0.00007589611,0.0032463814,0.00006394104,0.0068952455,0.8737823,0.0018104184,0.011453219,0.000023960702],"about_ca_topic_score_codex":0.0004807262,"about_ca_topic_score_gemma":0.00044029538,"teacher_disagreement_score":0.0014658106,"about_ca_system_score_codex":0.0003718832,"about_ca_system_score_gemma":0.0002163352,"threshold_uncertainty_score":0.004903555},"labels":[],"label_agreement":null},{"id":"W4399505149","doi":"10.1158/1538-8514.synthleth24-a024","title":"Abstract A024: SOX11: An <i>Achilles heel</i> of mantle cell lymphoma enhancing sensitivity to DNA damaging agents by impairing DNA repair","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chromatin; DNA damage; Homologous recombination; Transcription factor; Cell biology; DNA repair; Biology; Histone; DNA-binding domain; Molecular biology; Cancer research; Chemistry; DNA; Genetics; Gene","score_opus":0.017109744278648097,"score_gpt":0.2964902886175709,"score_spread":0.2793805443389228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505149","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528585,0.010006223,0.0053061876,0.010158512,0.0013242388,0.000113563474,0.0019354514,0.0009467609,0.017350525],"genre_scores_gemma":[0.97487134,0.0035213507,0.0017544258,0.0014308396,0.00038364812,0.00005172744,0.0011146924,0.00006727922,0.016804777],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999156,0.0000176404,0.00001197833,0.000016976259,0.00002309258,0.000014762219],"domain_scores_gemma":[0.99991596,0.000011537009,0.00002037529,0.0000065785757,0.000011658174,0.000033846543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017961135,0.00051367044,0.00027723447,0.00023317742,0.00021040105,0.00040211724,0.00035728983,0.00065005035,0.0070705176],"category_scores_gemma":[0.00012321245,0.000119690194,0.00021831905,0.00015775002,0.00040418413,0.00022961592,0.00018745054,0.0006539483,0.0012457216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018721656,0.00016591599,0.0051348773,0.00033217412,0.00006969085,0.0065405755,0.000054352364,0.00013097876,0.9533337,0.0020216685,0.006599909,0.02374409],"study_design_scores_gemma":[0.0006366071,0.0043109125,0.06063921,0.00019703177,0.00035198632,0.06949014,0.00034519823,0.0028211377,0.7566869,0.0031584578,0.10130515,0.00005729267],"about_ca_topic_score_codex":0.00049350434,"about_ca_topic_score_gemma":0.00037976052,"teacher_disagreement_score":0.0070705176,"about_ca_system_score_codex":0.00030869248,"about_ca_system_score_gemma":0.0002044607,"threshold_uncertainty_score":0.02365321},"labels":[],"label_agreement":null},{"id":"W4399505153","doi":"10.1158/1538-8514.synthleth24-pr013","title":"Abstract PR013: Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epistasis; Biology; Mutation rate; Cancer; Pairwise comparison; Genetics; Genotype; Selection (genetic algorithm); Computational biology; Germline mutation; Mutation; Gene; Computer science; Machine learning; Statistics; Mathematics","score_opus":0.011308736983207541,"score_gpt":0.28094719466838086,"score_spread":0.2696384576851733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505153","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521093,0.00031465275,0.24039732,0.00039527996,0.0000517315,0.00011005604,0.0024027405,0.0016936075,0.00252536],"genre_scores_gemma":[0.93757904,0.0000902139,0.05952457,0.0001288388,0.000014799381,0.00006742252,0.0015665198,0.00013269605,0.0008959354],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991794,0.00021962718,0.000053209977,0.00028361054,0.0002047572,0.00005929139],"domain_scores_gemma":[0.9965005,0.0021756282,0.0005720568,0.00028805915,0.0002152455,0.000248481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001652524,0.0003649206,0.0007278378,0.0011041032,0.00039644347,0.00080631685,0.00077171304,0.00065279973,0.0030277977],"category_scores_gemma":[0.0072277114,0.00027059187,0.0008168953,0.0010051214,0.00061744277,0.00047744068,0.0009433383,0.0009368213,0.00037439886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016674851,0.00034219286,0.27898183,0.000642638,0.0007091185,0.0016812269,0.0004328942,0.09738002,0.47026116,0.019257203,0.0038540394,0.12479017],"study_design_scores_gemma":[0.00012988437,0.0010788068,0.17305745,0.00004442257,0.00026597033,0.002373942,0.0003131048,0.7108219,0.07919254,0.028355457,0.004177594,0.0001888302],"about_ca_topic_score_codex":0.0019082713,"about_ca_topic_score_gemma":0.0022274675,"teacher_disagreement_score":0.0030277977,"about_ca_system_score_codex":0.00044273413,"about_ca_system_score_gemma":0.0005776836,"threshold_uncertainty_score":0.010128975},"labels":[],"label_agreement":null},{"id":"W4399505156","doi":"10.1158/1538-8514.synthleth24-ia011","title":"Abstract IA011: Towards mapping the landscape of cancer vulnerabilities","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Resource (disambiguation); Dependency (UML); Citation; Computational biology; Cancer research; Biology; Computer science; Library science; Genetics; Artificial intelligence","score_opus":0.057324274623232245,"score_gpt":0.3432844338601982,"score_spread":0.28596015923696594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505156","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11985522,0.0050674668,0.6975524,0.016765635,0.00046241717,0.00057278486,0.09457934,0.013534702,0.05161009],"genre_scores_gemma":[0.44790146,0.0051800255,0.4716627,0.0019223823,0.00023907806,0.0008520807,0.061168563,0.001892167,0.00918156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937385,0.00026534524,0.000020626545,0.00014364174,0.00015611105,0.000040509945],"domain_scores_gemma":[0.99788886,0.0011720856,0.00019485888,0.00026831272,0.00031134114,0.00016453219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015857363,0.000822558,0.00061934703,0.0029189456,0.00066895917,0.0026034873,0.00091290544,0.0007130645,0.010048431],"category_scores_gemma":[0.0075630266,0.00045318072,0.0009932393,0.0022570181,0.0006520806,0.0013108687,0.002622612,0.0013462155,0.0018607724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051723624,0.00015743478,0.04767414,0.0012903848,0.0003333009,0.00034435946,0.00037561328,0.290472,0.008846824,0.111613795,0.20195933,0.33641568],"study_design_scores_gemma":[0.00008315944,0.00014566985,0.01923037,0.00025198964,0.00013155068,0.00036177973,0.00041704494,0.5564892,0.007017528,0.24193718,0.17385255,0.000081991435],"about_ca_topic_score_codex":0.006291947,"about_ca_topic_score_gemma":0.0058643683,"teacher_disagreement_score":0.010048431,"about_ca_system_score_codex":0.0012075084,"about_ca_system_score_gemma":0.002099496,"threshold_uncertainty_score":0.03361529},"labels":[],"label_agreement":null},{"id":"W4399505157","doi":"10.1158/1538-8514.synthleth24-pr015","title":"Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SMARCA4; Chromatin remodeling; Cancer research; Mutant; Synthetic lethality; Cancer; Cell growth; Chemistry; Gene; Chromatin; Biology; Molecular biology; Genetics; Biochemistry","score_opus":0.019402608017725084,"score_gpt":0.300713497200709,"score_spread":0.2813108891829839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505157","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8667727,0.055939127,0.018791702,0.0046923086,0.001245865,0.002194219,0.0063093696,0.0018997497,0.042154975],"genre_scores_gemma":[0.92477477,0.02590433,0.008512447,0.0020899298,0.00021389229,0.00043554697,0.009140068,0.00007335941,0.028855758],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998636,0.000019041277,0.0000108153445,0.000024673016,0.00004695714,0.000034860157],"domain_scores_gemma":[0.9999237,0.0000045263982,0.000014117873,0.0000032613123,0.000016009304,0.000038493614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031107725,0.00083721086,0.00050193805,0.00047599702,0.00017208404,0.0005296493,0.0006876044,0.00079721137,0.003050901],"category_scores_gemma":[0.00016698951,0.00022447137,0.00043286974,0.0002764429,0.00025923585,0.00029936252,0.0003212071,0.001120467,0.0018749555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002450644,0.001545293,0.0012297067,0.0008419576,0.00016982055,0.0013371516,0.00007466473,0.0015752643,0.836278,0.0017790151,0.013373409,0.13934511],"study_design_scores_gemma":[0.010103795,0.040851716,0.01292436,0.00024634507,0.00047272284,0.008804131,0.00012646713,0.006739018,0.75379705,0.0008439424,0.16496062,0.00012977811],"about_ca_topic_score_codex":0.00076005835,"about_ca_topic_score_gemma":0.0015502278,"teacher_disagreement_score":0.003050901,"about_ca_system_score_codex":0.00055000687,"about_ca_system_score_gemma":0.00077764643,"threshold_uncertainty_score":0.010206282},"labels":[],"label_agreement":null},{"id":"W4399505159","doi":"10.1158/1538-8514.synthleth24-a015","title":"Abstract A015: Exploiting endogenous replication stress with a novel targeted therapy in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Biology; DNA replication factor CDT1; FLI1; Pediatric cancer; Mitosis; FOXM1; Targeted therapy; Medicine; Chromatin remodeling; Cell cycle; Cancer; Bioinformatics; Transcription factor; Genetics; Gene","score_opus":0.04317926041654674,"score_gpt":0.2878575235038117,"score_spread":0.24467826308726498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505159","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8792332,0.06962621,0.023495056,0.002865356,0.0019450686,0.0008208126,0.0011401523,0.00083792175,0.020036172],"genre_scores_gemma":[0.9495088,0.022990407,0.010746458,0.00092285156,0.0002456502,0.00030829164,0.0011043311,0.000047925714,0.014125399],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992275,0.000010987673,0.000008917832,0.000016018563,0.00002399965,0.000017334902],"domain_scores_gemma":[0.9999573,0.0000053560584,0.000009117307,0.000004776168,0.000008837858,0.0000146145585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023183823,0.00040828047,0.0003346258,0.0004905912,0.00022064087,0.00040208717,0.00033830083,0.0004687392,0.0025205703],"category_scores_gemma":[0.00010203729,0.00011742011,0.00042910335,0.0002448159,0.00023353964,0.00041044812,0.00032844365,0.0009021569,0.0007077317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007081589,0.0008783766,0.00065116514,0.0005952966,0.000060924594,0.00060702447,0.000057090532,0.00069251284,0.91278476,0.0025244213,0.0029869645,0.07745321],"study_design_scores_gemma":[0.0005202472,0.008782912,0.003601524,0.00009782527,0.00018606425,0.0028919678,0.000055306347,0.0034286468,0.91389006,0.0011714972,0.06533586,0.000038044425],"about_ca_topic_score_codex":0.00036091128,"about_ca_topic_score_gemma":0.00046164592,"teacher_disagreement_score":0.0025205703,"about_ca_system_score_codex":0.0003051036,"about_ca_system_score_gemma":0.00035873012,"threshold_uncertainty_score":0.00843209},"labels":[],"label_agreement":null},{"id":"W4399505160","doi":"10.1158/1538-8514.synthleth24-ia005","title":"Abstract IA005: Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Cancer research; Cohesin; Biology; DNA repair; RNA splicing; Genetics; Gene; Chromatin; RNA","score_opus":0.023480445135015973,"score_gpt":0.30302701060462456,"score_spread":0.2795465654696086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505160","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96873456,0.012875235,0.003310185,0.0008291787,0.000117827236,0.00013918334,0.00082387234,0.00037631684,0.01279371],"genre_scores_gemma":[0.9940202,0.0018468301,0.0008628877,0.00011220173,0.000021583468,0.000031354295,0.0006257477,0.000010397295,0.0024687466],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999498,0.000008586395,0.00000423416,0.000008066502,0.000013786209,0.000015363474],"domain_scores_gemma":[0.9999428,0.000008695513,0.000012412335,0.000008498262,0.000007670229,0.00002000923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015740895,0.00024075876,0.00021522421,0.00027568647,0.00013863717,0.00034842434,0.00020507336,0.0002683165,0.0023477785],"category_scores_gemma":[0.00012956471,0.000050606093,0.00015324453,0.00017801466,0.00013420831,0.00011392168,0.00023009062,0.00046027784,0.00046421436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000969673,0.0003519656,0.0045962054,0.00023981516,0.00004657154,0.00083427574,0.00006898816,0.00076038786,0.89781684,0.0032041993,0.0027634532,0.08834771],"study_design_scores_gemma":[0.00027102727,0.009398917,0.046656143,0.00010275426,0.00018530442,0.009124919,0.00018384046,0.0040722834,0.837581,0.0016635115,0.09073928,0.000021087615],"about_ca_topic_score_codex":0.00038015933,"about_ca_topic_score_gemma":0.00048018302,"teacher_disagreement_score":0.0023477785,"about_ca_system_score_codex":0.0002894966,"about_ca_system_score_gemma":0.00018368488,"threshold_uncertainty_score":0.007854044},"labels":[],"label_agreement":null},{"id":"W4399505170","doi":"10.1158/1538-8514.synthleth24-pr010","title":"Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"PTEN; Prostate cancer; Synthetic lethality; Cancer research; Prostate; Biology; Cancer; Context (archaeology); Medicine; DNA repair; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.048963146014998474,"score_gpt":0.34636403839556645,"score_spread":0.297400892380568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505170","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96267486,0.0011574586,0.012853344,0.00061377033,0.00018049392,0.00016483918,0.0062575177,0.0018933775,0.014204437],"genre_scores_gemma":[0.97590476,0.00046854853,0.003979978,0.0001538026,0.00001817798,0.000096487165,0.0028237374,0.00046556848,0.016088972],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996747,0.000037390673,0.000031391002,0.00008893493,0.000099999954,0.00006765258],"domain_scores_gemma":[0.9997274,0.000036090336,0.000080658516,0.0000410775,0.000015311047,0.00009940449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015518865,0.00058659987,0.0003077457,0.00035488437,0.00029001923,0.00045714725,0.0004671038,0.0004541581,0.007410039],"category_scores_gemma":[0.0001233247,0.000227062,0.0003190442,0.00023579407,0.00049730093,0.00023313654,0.00032138324,0.0016171002,0.0019134525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017234565,0.00006840684,0.00019308149,0.00003895589,0.000008804967,0.00007719552,0.000014909619,0.000120588666,0.997233,0.00036507312,0.00036945732,0.0013382006],"study_design_scores_gemma":[0.000025743966,0.00030949336,0.0032002728,0.000008287045,0.000016847856,0.0005544049,0.000043600856,0.0012804151,0.9866151,0.0000942375,0.007842229,0.00000929338],"about_ca_topic_score_codex":0.0017966024,"about_ca_topic_score_gemma":0.0025672696,"teacher_disagreement_score":0.007410039,"about_ca_system_score_codex":0.0004774209,"about_ca_system_score_gemma":0.0003802206,"threshold_uncertainty_score":0.024789095},"labels":[],"label_agreement":null},{"id":"W4399505172","doi":"10.1158/1538-8514.synthleth24-pr007","title":"Abstract PR007: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Carcinogenesis; Biology; Synthetic lethality; Computational biology; Gene knockdown; Cancer research; Transcriptome; Gene; Genetics; DNA repair; Gene expression","score_opus":0.05331619994262055,"score_gpt":0.38327893890016274,"score_spread":0.3299627389575422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505172","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461193,0.0010592421,0.04213042,0.00025400575,0.000043643446,0.00020355878,0.00578466,0.0007552545,0.0036498988],"genre_scores_gemma":[0.948593,0.00087339024,0.034493495,0.00017534029,0.000011584319,0.00014401438,0.008410209,0.00037692208,0.0069219987],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970645,0.000030220444,0.00003026183,0.00006594913,0.00012502311,0.000042047057],"domain_scores_gemma":[0.9997311,0.000061498016,0.00008761996,0.00003306804,0.000033592503,0.00005311111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029041103,0.00044159606,0.0003994699,0.00082735234,0.00021495289,0.00046908183,0.0003523608,0.00042975013,0.0032137672],"category_scores_gemma":[0.000260452,0.00028947173,0.0004905024,0.00041866497,0.00029470865,0.00021902003,0.0005202095,0.00073113677,0.0012556855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048120288,0.00001161759,0.00057838997,0.000033830413,0.000005825457,0.00007670469,0.000009154195,0.00012131683,0.9974866,0.00010519221,0.000050754,0.0014724513],"study_design_scores_gemma":[0.000010424904,0.00019537014,0.013454923,0.000008015646,0.000035061694,0.0011517829,0.000048241152,0.0027411825,0.9772679,0.00010863186,0.004966029,0.000012418109],"about_ca_topic_score_codex":0.00084430526,"about_ca_topic_score_gemma":0.0015041736,"teacher_disagreement_score":0.0032137672,"about_ca_system_score_codex":0.0004625941,"about_ca_system_score_gemma":0.0004035646,"threshold_uncertainty_score":0.010751128},"labels":[],"label_agreement":null},{"id":"W4399505173","doi":"10.1158/1538-8514.synthleth24-ia009","title":"Abstract IA009: Single strand DNA GAP accumulation as a functional biomarker for DNA Repair Inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; DNA repair; Cancer research; Homologous recombination; PARP1; Biology; Genome instability; DNA damage; Olaparib; Polymerase; Poly ADP ribose polymerase; Genetics; Gene; DNA","score_opus":0.11938644281047917,"score_gpt":0.37918037371034874,"score_spread":0.2597939308998696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505173","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7510269,0.10755287,0.034937568,0.0030350508,0.0024957934,0.0011482192,0.024057666,0.004676053,0.071069844],"genre_scores_gemma":[0.88650155,0.015522334,0.035541993,0.001494394,0.00034409008,0.0014585895,0.023421468,0.000304489,0.035411075],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994357,0.00013052837,0.000055613596,0.0001205961,0.00017725752,0.00008017628],"domain_scores_gemma":[0.99945956,0.00008882917,0.0001328004,0.000042741518,0.00015087226,0.00012518204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005311278,0.00086792227,0.00060206023,0.0024885566,0.00034687525,0.00095805305,0.00045817703,0.0011608762,0.0070041833],"category_scores_gemma":[0.00075543905,0.00024128087,0.00036446375,0.001305805,0.0003039081,0.00040495105,0.00041309648,0.0012473143,0.0032255168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002266929,0.00048674468,0.010016684,0.00091200205,0.00011941514,0.00043029792,0.000054161323,0.0004236708,0.913756,0.0012525351,0.007086536,0.0631951],"study_design_scores_gemma":[0.0002072323,0.003324782,0.035942156,0.00027374653,0.00023143513,0.0041645733,0.00017140408,0.0037805024,0.884715,0.0014956984,0.065641314,0.00005208942],"about_ca_topic_score_codex":0.00042117122,"about_ca_topic_score_gemma":0.0003958866,"teacher_disagreement_score":0.0070041833,"about_ca_system_score_codex":0.0006057899,"about_ca_system_score_gemma":0.00043978466,"threshold_uncertainty_score":0.023431301},"labels":[],"label_agreement":null},{"id":"W4399505192","doi":"10.1158/1538-8514.synthleth24-b019","title":"Abstract B019: Stearoyl-CoA desaturase is a synthetic lethal target in SMAD4-deficient cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer research; Biology; Mutant; Carcinogenesis; Fatty acid synthesis; CRISPR; In vivo; Cancer; Gene; Genetics","score_opus":0.01588855896612284,"score_gpt":0.28248608657922153,"score_spread":0.2665975276130987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505192","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96861804,0.0023226275,0.014102536,0.00063339935,0.00028860473,0.0001451841,0.005558688,0.0009950361,0.0073358975],"genre_scores_gemma":[0.97232705,0.0013142108,0.0054579773,0.00025237587,0.000026678394,0.00014296954,0.004570894,0.00017593773,0.015731864],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997546,0.000028304716,0.000025337653,0.000050241666,0.00009564382,0.00004576231],"domain_scores_gemma":[0.9998319,0.000022935437,0.000046875113,0.000018777953,0.000018972758,0.000060536655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019103836,0.0005092499,0.00034399898,0.00049910124,0.00028078246,0.0003639332,0.00028435118,0.0005543903,0.005477092],"category_scores_gemma":[0.0001396482,0.00021136597,0.00049580215,0.00019630259,0.00031008205,0.00016735695,0.00036841733,0.0009922212,0.0017124066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018404823,0.000028047321,0.00014614098,0.00003554692,0.000006253579,0.00007652475,0.000005665031,0.00004926793,0.9981912,0.00009765736,0.00012309379,0.001056564],"study_design_scores_gemma":[0.000023782848,0.00025884336,0.0013216177,0.000007720983,0.000016125186,0.0003744885,0.000023572216,0.0003786298,0.99338394,0.000044066215,0.0041624187,0.0000047111307],"about_ca_topic_score_codex":0.00059386523,"about_ca_topic_score_gemma":0.0007578896,"teacher_disagreement_score":0.005477092,"about_ca_system_score_codex":0.00033855927,"about_ca_system_score_gemma":0.00028575733,"threshold_uncertainty_score":0.018322706},"labels":[],"label_agreement":null},{"id":"W4399505200","doi":"10.1158/1538-8514.synthleth24-b012","title":"Abstract B012: Predicting targetable paralog synthetic lethalities and functional redundancies in cancer genomes","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University","funders":"","keywords":"Synthetic lethality; Biology; Breast cancer; Cancer; Genome; Gene; Cancer cell; Genetics; Context (archaeology); Computational biology; Triple-negative breast cancer; Gene duplication; CRISPR; Cancer research; DNA repair","score_opus":0.019180244438083548,"score_gpt":0.3024860092635994,"score_spread":0.2833057648255159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505200","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8297638,0.0012667278,0.12512213,0.0007439482,0.00015820339,0.00020205115,0.022158295,0.015944224,0.004640602],"genre_scores_gemma":[0.8101002,0.00043501466,0.14215933,0.00036057585,0.00004458226,0.00021862485,0.04417435,0.0008104354,0.0016968382],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996427,0.00007665841,0.000019503825,0.00012579936,0.000086206135,0.000049093203],"domain_scores_gemma":[0.99916613,0.00053391093,0.000072524614,0.000060583752,0.00010844654,0.000058486006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059950637,0.00092674507,0.0006442392,0.0012373385,0.00055633835,0.00077732455,0.000712296,0.0009993855,0.0032125285],"category_scores_gemma":[0.0019634725,0.00029604515,0.0012105354,0.00079808093,0.00030086236,0.00046873163,0.0005713987,0.0007556885,0.00077162695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018984636,0.00074074196,0.08426443,0.0014514847,0.00041547106,0.0013251681,0.00019396136,0.6670743,0.0950045,0.004993933,0.024302222,0.11833532],"study_design_scores_gemma":[0.00005674546,0.00027869415,0.0058248136,0.000021491918,0.000055116678,0.00021899043,0.000059197013,0.97905916,0.008740212,0.001963214,0.0036994943,0.000022881497],"about_ca_topic_score_codex":0.00591006,"about_ca_topic_score_gemma":0.0075223586,"teacher_disagreement_score":0.00591006,"about_ca_system_score_codex":0.0006113828,"about_ca_system_score_gemma":0.0009317869,"threshold_uncertainty_score":0.011751354},"labels":[],"label_agreement":null},{"id":"W4399505234","doi":"10.1158/1538-8514.synthleth24-ia023","title":"Abstract IA023: Targeting epigenetic complexes in leukemia","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epigenetics; Myeloid leukemia; Chromatin; Leukemia; Cancer research; Cancer; NPM1; Biology; Computational biology; Medicine; Bioinformatics; Genetics; Gene","score_opus":0.01900543605627948,"score_gpt":0.29165553551237583,"score_spread":0.27265009945609636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505234","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7319195,0.099723145,0.030289099,0.00709425,0.0022344198,0.0015604811,0.007984857,0.0035985801,0.11559564],"genre_scores_gemma":[0.8677811,0.03663677,0.014847716,0.0016573329,0.000320837,0.00039039736,0.0053501604,0.00022186861,0.07279393],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999267,0.000009511089,0.0000040777804,0.000012085567,0.000023413628,0.000024343397],"domain_scores_gemma":[0.99996793,0.0000026660846,0.0000045709417,0.000003005689,0.000006935441,0.000015006005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021597806,0.00041096902,0.00030734198,0.0004906663,0.00023150777,0.0004549506,0.0004444206,0.00037048585,0.005766567],"category_scores_gemma":[0.0000792796,0.00017213525,0.00023474269,0.0003431732,0.00021943098,0.00015621113,0.00034269295,0.00072903215,0.0012900513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010152031,0.00032265115,0.00037244248,0.00039365157,0.000028436622,0.00019933906,0.000044469696,0.0010823392,0.90524083,0.0033341954,0.011629647,0.0763367],"study_design_scores_gemma":[0.00078365614,0.0029448166,0.005916918,0.000060152415,0.000094708514,0.0008758559,0.00003385846,0.0032025443,0.7666433,0.000682293,0.21873438,0.000027558202],"about_ca_topic_score_codex":0.0039002837,"about_ca_topic_score_gemma":0.0067769242,"teacher_disagreement_score":0.005766567,"about_ca_system_score_codex":0.0010631512,"about_ca_system_score_gemma":0.00083367585,"threshold_uncertainty_score":0.019291103},"labels":[],"label_agreement":null},{"id":"W4399505248","doi":"10.1158/1538-8514.synthleth24-pr008","title":"Abstract PR008: Targeting mechanisms of dosage compensation to selectively kill aneuploid cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA regulation and disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Aneuploidy; Cancer cell; Gene dosage; Cellular stress response; RNA-binding protein; Stress granule; Cancer; RNA; Dosage compensation; Genetics; Cell biology; Gene; Gene expression; Cancer research; Translation (biology); Molecular biology; Chromosome; Messenger RNA; Fight-or-flight response","score_opus":0.014409730613178021,"score_gpt":0.2850744484675493,"score_spread":0.2706647178543713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505248","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9299017,0.013401978,0.040313095,0.0013703563,0.00038821742,0.00046259005,0.0016136199,0.0026747168,0.009873766],"genre_scores_gemma":[0.9489368,0.0047768806,0.02794698,0.00040535055,0.00005734197,0.00026022506,0.0025074326,0.0002028263,0.014906235],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989676,0.0000087454355,0.000007851403,0.00003071045,0.000035552926,0.000020325291],"domain_scores_gemma":[0.99995196,0.0000062573677,0.000013548139,0.000005829105,0.000008082614,0.000014253464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013630577,0.0004397503,0.00033529388,0.00031077696,0.00012583005,0.0003711414,0.00045936828,0.0006530119,0.0024791805],"category_scores_gemma":[0.00010528571,0.00017109663,0.00029401545,0.00019230778,0.00020049348,0.00025812056,0.0002939465,0.0008164471,0.0008105781],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013278796,0.000045742032,0.00006660373,0.000092755574,0.0000062958998,0.000046222252,0.00000823207,0.000101909674,0.99203897,0.00022456796,0.0003391572,0.006896738],"study_design_scores_gemma":[0.00012215697,0.0012721475,0.001780158,0.000014985258,0.000038697624,0.00042887346,0.000018346878,0.0019840254,0.9819803,0.00019811362,0.012151733,0.000010404385],"about_ca_topic_score_codex":0.00039314455,"about_ca_topic_score_gemma":0.0004114798,"teacher_disagreement_score":0.0024791805,"about_ca_system_score_codex":0.00027046754,"about_ca_system_score_gemma":0.00024117829,"threshold_uncertainty_score":0.008293629},"labels":[],"label_agreement":null},{"id":"W4399505261","doi":"10.1158/1538-8514.synthleth24-ia008","title":"Abstract IA008: Exploiting tumor selective vulnerabilities with structure based drug design","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; Homologous recombination; Biology; DNA damage; Base excision repair; DNA replication; Genome instability; Cell biology; PARP1; Genetics; DNA; Poly ADP ribose polymerase; Polymerase","score_opus":0.032613292186137746,"score_gpt":0.3090953129435718,"score_spread":0.27648202075743405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505261","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6337621,0.051034864,0.18369664,0.0058585987,0.0014933174,0.0021578022,0.0061128926,0.0045930897,0.111290626],"genre_scores_gemma":[0.8775224,0.02195055,0.070975736,0.0013669565,0.00009137283,0.00076024415,0.003538311,0.00021463458,0.023579888],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998754,0.000020953526,0.000006238466,0.000030317067,0.000038119364,0.000028893399],"domain_scores_gemma":[0.99993074,0.0000086806185,0.000014651933,0.000007711842,0.00001679894,0.000021378884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031347777,0.0004682901,0.00036957837,0.0004698278,0.00016916088,0.00072254165,0.0005351558,0.00052872906,0.0040064175],"category_scores_gemma":[0.00020555947,0.00018770163,0.0003221007,0.00026478688,0.00025975838,0.00032992527,0.0004993846,0.0010147542,0.00096793997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006507629,0.0006859946,0.0005637722,0.0007341183,0.000074006275,0.00039812957,0.000066591325,0.0092699705,0.8205573,0.020113409,0.008583196,0.13830264],"study_design_scores_gemma":[0.0010319847,0.008564683,0.0017134805,0.00022280062,0.00016234058,0.0010972049,0.0000633202,0.027899537,0.6922346,0.008279958,0.25863326,0.00009687894],"about_ca_topic_score_codex":0.00041976856,"about_ca_topic_score_gemma":0.0007720948,"teacher_disagreement_score":0.0040064175,"about_ca_system_score_codex":0.0005337864,"about_ca_system_score_gemma":0.0003494018,"threshold_uncertainty_score":0.01340282},"labels":[],"label_agreement":null},{"id":"W4399505265","doi":"10.1158/1538-8514.synthleth24-ia012","title":"Abstract IA012: Generation and Mining of a Pediatric-focused Cancer Cell Line Atlas to Define Druggable Genetic Interactions in Childhood Malignancies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Druggability; Pediatric cancer; Cancer; Medicine; Computational biology; Bioinformatics; Cancer cell lines; CRISPR; Cancer research; Biology; Cancer cell; Genetics; Gene; Internal medicine","score_opus":0.038638325271009515,"score_gpt":0.3261852411758328,"score_spread":0.2875469159048233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505265","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1933167,0.0039007915,0.15423965,0.0018140244,0.00039227086,0.0015914637,0.5928268,0.021365892,0.03055249],"genre_scores_gemma":[0.14997728,0.0022653167,0.1435714,0.0007291855,0.000054231707,0.0015806113,0.6925186,0.0011117246,0.008191639],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988655,0.00013131565,0.00010719419,0.00027870078,0.00049816776,0.000119172764],"domain_scores_gemma":[0.99758434,0.0005419606,0.00029962635,0.0005626761,0.0007015224,0.00030987014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00198599,0.00071491284,0.0011134275,0.0034333526,0.00094495533,0.0021481314,0.0017085595,0.0007913445,0.0050813532],"category_scores_gemma":[0.0030177846,0.0004799441,0.0009795349,0.003789628,0.00045331207,0.00049642165,0.0016344867,0.0014417849,0.003525803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00188093,0.00048360092,0.11726826,0.0015617359,0.0006471138,0.0021481733,0.00085990666,0.034722388,0.3954059,0.018582175,0.20811135,0.21832848],"study_design_scores_gemma":[0.0003160315,0.00070042204,0.09055546,0.00029521217,0.00067877496,0.0025050328,0.0006407672,0.06826778,0.24996993,0.0069492063,0.5789234,0.0001978516],"about_ca_topic_score_codex":0.011827089,"about_ca_topic_score_gemma":0.019076835,"teacher_disagreement_score":0.011827089,"about_ca_system_score_codex":0.0017572506,"about_ca_system_score_gemma":0.0034861648,"threshold_uncertainty_score":0.023516476},"labels":[],"label_agreement":null},{"id":"W4399505282","doi":"10.1158/1538-8514.synthleth24-pr009","title":"Abstract PR009: Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Cytidine; Biology; Cancer cell; Cell culture; Molecular biology; Gene; Genetics; Biochemistry; DNA repair; Enzyme","score_opus":0.013188119822859976,"score_gpt":0.2813339167505841,"score_spread":0.2681457969277241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505282","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87794137,0.0018604068,0.06438542,0.00042541622,0.00015052734,0.00015028895,0.033924717,0.015262262,0.0058995164],"genre_scores_gemma":[0.91784555,0.0006969268,0.036477745,0.0003655391,0.000018848874,0.00013359335,0.036787406,0.0018651056,0.0058093984],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965525,0.000019231946,0.000018284796,0.0001223352,0.00014947951,0.000035546167],"domain_scores_gemma":[0.9997702,0.00006846038,0.00005892981,0.000031170137,0.00003159536,0.00003964995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031529917,0.00066270534,0.0004938947,0.00046570355,0.00035953932,0.0007391809,0.0003435236,0.0003921268,0.005141045],"category_scores_gemma":[0.00046683341,0.00029869252,0.0005083881,0.00055339833,0.00025349113,0.0002662191,0.0004839738,0.00086178456,0.0023371775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040664754,0.000030074647,0.008409957,0.00036045344,0.00005701769,0.00031072806,0.000046619723,0.0023916306,0.96824574,0.00048150722,0.0022657716,0.016993904],"study_design_scores_gemma":[0.000039027316,0.0002325205,0.03473401,0.000033264125,0.000092959206,0.0010700622,0.00006791067,0.024691636,0.9202477,0.00053144793,0.01822986,0.000029718602],"about_ca_topic_score_codex":0.0010869799,"about_ca_topic_score_gemma":0.0017665505,"teacher_disagreement_score":0.005141045,"about_ca_system_score_codex":0.00044801785,"about_ca_system_score_gemma":0.0003891445,"threshold_uncertainty_score":0.017198503},"labels":[],"label_agreement":null},{"id":"W4399505293","doi":"10.1158/1538-8514.synthleth24-a026","title":"Abstract A026: Single-cell landscape deciphering cancer Single-cell landscape deciphering cancer cell-of-origin and cellular heterogeneity in malignant transformation of 13 major tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Carcinogenesis; Cancer stem cell; Cancer; Malignant transformation; Tumor microenvironment; Cancer research; Stem cell; Cancer cell; Cell; Tumor progression; Immunology; Cell biology; Genetics","score_opus":0.024759803609713,"score_gpt":0.2682939568048664,"score_spread":0.2435341531951534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505293","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86597663,0.013055619,0.06376505,0.001382276,0.00048802217,0.00015739448,0.043602344,0.0020664614,0.009506248],"genre_scores_gemma":[0.9381583,0.0023135918,0.02442231,0.00036130243,0.00027277766,0.00021978772,0.02923294,0.00025613536,0.0047629266],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995485,0.000051223695,0.000042846452,0.00018389696,0.000119860946,0.000053600324],"domain_scores_gemma":[0.9992768,0.00016977871,0.00012064721,0.0001265624,0.0002200545,0.00008616374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008720942,0.0003334129,0.0007596155,0.0014197038,0.00062110747,0.0014712415,0.00047321583,0.0006218458,0.0054466575],"category_scores_gemma":[0.0013600775,0.00029221966,0.0005440968,0.0016612096,0.00038287198,0.00089669874,0.0008815742,0.00050533225,0.001380193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010894068,0.000089053276,0.30620414,0.001768888,0.0007153715,0.0005939824,0.0006797688,0.0079820985,0.5181707,0.0036494643,0.02327505,0.1357821],"study_design_scores_gemma":[0.000061026276,0.00030857336,0.772941,0.00014560857,0.0006689182,0.001414259,0.0008999548,0.04159062,0.09950346,0.0091761565,0.07315336,0.00013716529],"about_ca_topic_score_codex":0.0017273683,"about_ca_topic_score_gemma":0.0029075725,"teacher_disagreement_score":0.0054466575,"about_ca_system_score_codex":0.0003415268,"about_ca_system_score_gemma":0.00042591584,"threshold_uncertainty_score":0.018220842},"labels":[],"label_agreement":null},{"id":"W4399505299","doi":"10.1158/1538-8514.synthleth24-a010","title":"Abstract A010: Proteasome inhibitors induce a BAX and BAK independent, non-canonical apoptosis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Apoptosome; Cytochrome c; Proteasome; Apoptosis; Programmed cell death; Caspase; Biology; Intrinsic apoptosis; Cell biology; Cancer cell; Molecular biology; Biochemistry; Cancer; Genetics","score_opus":0.014131911110175468,"score_gpt":0.2729970201583335,"score_spread":0.258865109048158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505299","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493727,0.008973944,0.0034437142,0.0011189303,0.0010125249,0.00017058436,0.0025886693,0.0007708167,0.032548115],"genre_scores_gemma":[0.9407836,0.0034091251,0.002017037,0.00026505222,0.00016583207,0.000060821993,0.002310718,0.000051506155,0.05093624],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998958,0.000010500057,0.000011113013,0.000016565386,0.00003847397,0.000027478622],"domain_scores_gemma":[0.99994373,0.000010082682,0.000010974122,0.0000062597633,0.0000124912085,0.000016497346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009192233,0.00023930414,0.00019102634,0.00019863065,0.00013036765,0.00027273153,0.00012627008,0.0001986678,0.013050061],"category_scores_gemma":[0.00009229431,0.000068533096,0.00016292628,0.00011892863,0.00009785135,0.00013565214,0.00013980994,0.0003644271,0.002207728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010523442,0.00020345967,0.00022855219,0.00015518686,0.000014069222,0.00019577668,0.000012572468,0.000039827322,0.9837637,0.00034765067,0.0026364163,0.011350505],"study_design_scores_gemma":[0.0002020191,0.0010588408,0.008005025,0.000018846304,0.000028346802,0.00085788505,0.000028879136,0.00048800473,0.9648108,0.00015041791,0.024346009,0.000005142906],"about_ca_topic_score_codex":0.00034758862,"about_ca_topic_score_gemma":0.0005265107,"teacher_disagreement_score":0.013050061,"about_ca_system_score_codex":0.00024475917,"about_ca_system_score_gemma":0.0003048556,"threshold_uncertainty_score":0.043656766},"labels":[],"label_agreement":null},{"id":"W4399505308","doi":"10.1158/1538-8514.synthleth24-b010","title":"Abstract B010: Drug tolerant persister cancer cells escape therapy-induced senescence","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University","funders":"","keywords":"Autophagy; Medicine; Cancer; Cancer research; Senescence; Breast cancer; Cancer cell; Drug resistance; Chemotherapy; Oncology; Pharmacology; Internal medicine; Biology; Apoptosis","score_opus":0.043022519505777325,"score_gpt":0.3139448282089302,"score_spread":0.27092230870315287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505308","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391195,0.014085764,0.012440693,0.002824347,0.0011789169,0.00024473557,0.008503491,0.0010527618,0.020549808],"genre_scores_gemma":[0.9116709,0.006182973,0.007179766,0.0010851393,0.00013704527,0.00022261961,0.010315363,0.00023288188,0.06297326],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987257,0.000009270914,0.000012148559,0.000034265788,0.00005018457,0.000021558626],"domain_scores_gemma":[0.99987864,0.000015430038,0.000026127504,0.000017084969,0.000026235966,0.000036523234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018117798,0.00029174893,0.0003304421,0.00034124168,0.0004103287,0.0008202013,0.00024299829,0.00050397695,0.00597132],"category_scores_gemma":[0.00015224918,0.00015710395,0.00024546823,0.00028447428,0.00029024328,0.0003560187,0.00033324034,0.0008551283,0.0020591854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022318104,0.000041065854,0.00064856786,0.000090307534,0.0000069907983,0.00015252971,0.000048691672,0.000056551722,0.9882466,0.0005907593,0.0024257037,0.0074691256],"study_design_scores_gemma":[0.00008331588,0.0011362248,0.029204454,0.00005453977,0.000043615008,0.002606558,0.00019491586,0.0014703588,0.8769961,0.0008302158,0.087345384,0.000034398658],"about_ca_topic_score_codex":0.00088957045,"about_ca_topic_score_gemma":0.00092759135,"teacher_disagreement_score":0.00597132,"about_ca_system_score_codex":0.00042987778,"about_ca_system_score_gemma":0.00044161628,"threshold_uncertainty_score":0.01997602},"labels":[],"label_agreement":null},{"id":"W4399505311","doi":"10.1158/1538-8514.synthleth24-ia003","title":"Abstract IA003: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Allosteric regulation; Biology; DNA repair; DNA; Molecular biology; Cell biology; Enzyme; Cancer research; Genetics; Biochemistry; RNA; Gene","score_opus":0.0202534664455088,"score_gpt":0.2925839687847679,"score_spread":0.2723305023392591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505311","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650388,0.006289557,0.014994704,0.0007961007,0.0003010253,0.00038801142,0.0012903764,0.0004915484,0.010409862],"genre_scores_gemma":[0.97478604,0.0033271136,0.0078133065,0.00042742802,0.000050519742,0.00011334446,0.0015588364,0.00003921823,0.01188412],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99994814,0.0000047241106,0.0000030625147,0.000012816677,0.0000176844,0.000013604498],"domain_scores_gemma":[0.99996865,0.0000030898075,0.000008861448,0.0000026447585,0.000007514089,0.00000925142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106152984,0.0003813657,0.00021156359,0.00017880432,0.000091531176,0.00023218596,0.00038205346,0.00037580548,0.0022606687],"category_scores_gemma":[0.00009142405,0.00009033172,0.00018152814,0.00013745435,0.00012423306,0.000108837536,0.0001589751,0.00041158276,0.00046718237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018753762,0.00010024198,0.00019795171,0.00007445005,0.000009011846,0.00009793099,0.000006566551,0.00024440186,0.98969984,0.00027293878,0.0006283797,0.008480642],"study_design_scores_gemma":[0.00011148043,0.0014174357,0.0016685372,0.000008633781,0.00002785156,0.00039905834,0.0000078415815,0.0013514183,0.9869399,0.00006127171,0.00799719,0.000009253186],"about_ca_topic_score_codex":0.00033081215,"about_ca_topic_score_gemma":0.00044557656,"teacher_disagreement_score":0.0022606687,"about_ca_system_score_codex":0.00024522308,"about_ca_system_score_gemma":0.00026957577,"threshold_uncertainty_score":0.0075626373},"labels":[],"label_agreement":null},{"id":"W4399505312","doi":"10.1158/1538-8514.synthleth24-b002","title":"Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Mutant; Cancer research; Poly ADP ribose polymerase; Homologous recombination; PARP1; Mutation; Biology; Polymerase; Genetics; DNA; Gene","score_opus":0.04220035080186927,"score_gpt":0.3308149417042294,"score_spread":0.28861459090236014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505312","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93784404,0.005720631,0.0151144825,0.0018126277,0.0005632596,0.00026743297,0.010476522,0.002055685,0.026145332],"genre_scores_gemma":[0.9388518,0.0028100796,0.007854576,0.00033396864,0.000046336583,0.00022093218,0.008627268,0.0002482875,0.04100682],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999884,0.000012429468,0.000013142065,0.000021188656,0.00004689495,0.000022387898],"domain_scores_gemma":[0.9999174,0.000011551503,0.000024412402,0.000009553417,0.00000768676,0.000029410212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001227036,0.00043049533,0.0002611022,0.00028581618,0.0002581169,0.00028009372,0.0003201276,0.00040879377,0.004888555],"category_scores_gemma":[0.0000801781,0.00022239218,0.00020255813,0.00019333922,0.00017814472,0.00015088417,0.00015719612,0.00092553656,0.0011251715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014840275,0.00004869455,0.00006127466,0.000025386102,0.0000047927615,0.00009790019,0.00000683489,0.00009795717,0.9972978,0.0001884795,0.00063170464,0.0013908645],"study_design_scores_gemma":[0.000056409408,0.0007880028,0.00390197,0.000013886973,0.000015361162,0.00095144054,0.000022237631,0.0008612222,0.98004454,0.0000980753,0.013236152,0.000010636733],"about_ca_topic_score_codex":0.0011526127,"about_ca_topic_score_gemma":0.0012795659,"teacher_disagreement_score":0.004888555,"about_ca_system_score_codex":0.00031799832,"about_ca_system_score_gemma":0.0002610158,"threshold_uncertainty_score":0.016353905},"labels":[],"label_agreement":null},{"id":"W4399505326","doi":"10.1158/1538-8514.synthleth24-a007","title":"Abstract A007: Assessment of metabolic vulnerabilities of breast cancer brain metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cancer; Brain metastasis; Metastasis; Medicine; Oncology; Internal medicine","score_opus":0.023367633508795116,"score_gpt":0.3419840851669647,"score_spread":0.3186164516581696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505326","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94970816,0.0022391777,0.02000254,0.0008063615,0.00016083255,0.000237936,0.00988282,0.001037116,0.015925014],"genre_scores_gemma":[0.95516485,0.0020698812,0.017787995,0.00044366214,0.000017903916,0.00034115944,0.0059239212,0.00023089221,0.018019723],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970645,0.00003213687,0.000016217946,0.00006042478,0.00014369024,0.000040992152],"domain_scores_gemma":[0.9996933,0.00006171095,0.00006850291,0.000020367701,0.00009122766,0.00006483004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002839651,0.00048785805,0.00041263897,0.00088668603,0.0005580968,0.00077108084,0.00031857,0.00072787184,0.006552354],"category_scores_gemma":[0.00036296342,0.00024014206,0.00041892784,0.0006891116,0.00032751999,0.0003087287,0.0005349623,0.0010116758,0.0010241508],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033227832,0.0000855322,0.0041166316,0.00015717218,0.000031846466,0.00015837786,0.000051128485,0.0006141416,0.98453367,0.00052327715,0.0013316171,0.008064374],"study_design_scores_gemma":[0.000033703276,0.0007857451,0.037571236,0.000038061593,0.00008458447,0.00091417896,0.0002812446,0.004917089,0.9422763,0.0008826959,0.012162358,0.000052787982],"about_ca_topic_score_codex":0.0029584274,"about_ca_topic_score_gemma":0.0040262835,"teacher_disagreement_score":0.006552354,"about_ca_system_score_codex":0.00084385683,"about_ca_system_score_gemma":0.0006349416,"threshold_uncertainty_score":0.021919847},"labels":[],"label_agreement":null},{"id":"W4399505334","doi":"10.1158/1538-8514.synthleth24-ia001","title":"Abstract IA001: Exploiting pathway activation as a new form of synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; KRAS; Cancer; Cancer research; Context (archaeology); Biology; Genetic screen; Neuroblastoma RAS viral oncogene homolog; Gene knockout; MAPK/ERK pathway; PTEN; Genetics; DNA repair; Gene; Phenotype; Kinase; PI3K/AKT/mTOR pathway; Signal transduction; Colorectal cancer","score_opus":0.02420162346289654,"score_gpt":0.2950557847781103,"score_spread":0.2708541613152137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75116223,0.0045895595,0.21078761,0.0010523485,0.0004492035,0.0004988664,0.0034120232,0.007269786,0.020778362],"genre_scores_gemma":[0.89394754,0.0026614363,0.081398025,0.00049564923,0.000039390532,0.0003493611,0.0028615743,0.0009647678,0.017282194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995573,0.00004482715,0.000036746835,0.00009163568,0.00019508532,0.00007448593],"domain_scores_gemma":[0.9996197,0.0000982358,0.000103735525,0.000076343225,0.000034822122,0.000067079476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037712758,0.0006513573,0.00038948355,0.0005989399,0.0002332726,0.0008368256,0.0008084021,0.0005349847,0.00385152],"category_scores_gemma":[0.00030809653,0.0003015458,0.00036568395,0.000334032,0.00058258255,0.00037717936,0.00088723795,0.001948701,0.0013729569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071123126,0.000045583223,0.0001132609,0.00005169302,0.0000072480025,0.00007452403,0.000010488432,0.0004617263,0.99219996,0.0011990657,0.0002448595,0.0055206413],"study_design_scores_gemma":[0.000014681443,0.00029073737,0.0004972718,0.000010596573,0.0000147519395,0.00030154936,0.00001056892,0.002652521,0.9859087,0.00035856754,0.009926079,0.000013880783],"about_ca_topic_score_codex":0.00033852668,"about_ca_topic_score_gemma":0.00049677625,"teacher_disagreement_score":0.00385152,"about_ca_system_score_codex":0.00049910264,"about_ca_system_score_gemma":0.00038451306,"threshold_uncertainty_score":0.012884676},"labels":[],"label_agreement":null},{"id":"W4399505344","doi":"10.1158/1538-8514.synthleth24-a001","title":"Abstract A001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Mitosis; Chromosome; Cancer cell lines; Cancer research; Cancer cell; Medicine; Biology; Genetics; Gene","score_opus":0.016284862487596755,"score_gpt":0.2701334875232295,"score_spread":0.25384862503563277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8243245,0.0138544375,0.008902036,0.0043568327,0.0026564486,0.00041982782,0.016659578,0.0025722405,0.12625414],"genre_scores_gemma":[0.8276008,0.0045195846,0.0034392518,0.00064144516,0.00027312813,0.00017527225,0.009869101,0.00023159955,0.15324982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989295,0.0000088322095,0.000007823673,0.000015869347,0.000051442097,0.000022939814],"domain_scores_gemma":[0.99993134,0.000008935914,0.000014710873,0.0000052155196,0.000010085058,0.000029771216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010828732,0.00047435414,0.00025218312,0.00036200724,0.00026962385,0.0004891994,0.00030539464,0.0003007468,0.025513649],"category_scores_gemma":[0.00009775399,0.00012185068,0.00024202737,0.00021336204,0.00017192708,0.00020841935,0.00022097245,0.0007303704,0.0042569935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016116176,0.00025623414,0.0001926124,0.00016151332,0.000020033782,0.00017633554,0.000014709146,0.00023027064,0.95968956,0.0010462516,0.015245369,0.02135556],"study_design_scores_gemma":[0.00024141007,0.0015399737,0.005003192,0.00002025238,0.000025404961,0.00040871138,0.000027996328,0.00082649686,0.94926494,0.00028140622,0.042346727,0.000013450295],"about_ca_topic_score_codex":0.0013583202,"about_ca_topic_score_gemma":0.0015638154,"teacher_disagreement_score":0.025513649,"about_ca_system_score_codex":0.00053013646,"about_ca_system_score_gemma":0.00058589753,"threshold_uncertainty_score":0.085351646},"labels":[],"label_agreement":null},{"id":"W4399505345","doi":"10.1158/1538-8514.synthleth24-a012","title":"Abstract A012: Targeting proteasome vulnerabilities for the treatment of monosomy 7 associated blood disorders","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haploinsufficiency; Biology; Gene dosage; Proteasome inhibitor; Cancer research; Gene expression profiling; Monosomy; Genetics; Proteasome; Gene expression; Gene; Phenotype; Chromosome; Karyotype","score_opus":0.016507640641385664,"score_gpt":0.28274371844658425,"score_spread":0.2662360778051986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97055817,0.017087352,0.0036950961,0.0009036429,0.00025692576,0.00023609909,0.0017483403,0.000583594,0.004930802],"genre_scores_gemma":[0.9839806,0.0046576834,0.0046253284,0.0003029925,0.0000697688,0.000089296605,0.0023494787,0.000032412045,0.0038924452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999213,0.000013058473,0.000008009402,0.000013444217,0.000025869344,0.000018350707],"domain_scores_gemma":[0.9999505,0.0000057680572,0.000011548582,0.0000032505968,0.000008336517,0.00002050236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016270661,0.00037847206,0.00031227982,0.0005002071,0.00015847808,0.00048877945,0.0002811023,0.00030514377,0.0027759573],"category_scores_gemma":[0.0001202371,0.00009754531,0.00028112694,0.00028952857,0.00018994675,0.0001514059,0.00018519962,0.00069652067,0.00065781793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021572215,0.00040816743,0.0016132361,0.00024052341,0.00006566896,0.00026612217,0.000024816209,0.00034126587,0.9475867,0.00035838154,0.0025038938,0.044434045],"study_design_scores_gemma":[0.0014757823,0.01732954,0.029735193,0.00009750703,0.0003836394,0.003680619,0.00012407266,0.0041705566,0.8966226,0.00049204286,0.04584101,0.000047564976],"about_ca_topic_score_codex":0.0004115314,"about_ca_topic_score_gemma":0.0012569609,"teacher_disagreement_score":0.0027759573,"about_ca_system_score_codex":0.00029494756,"about_ca_system_score_gemma":0.0002521562,"threshold_uncertainty_score":0.009286523},"labels":[],"label_agreement":null},{"id":"W4399505349","doi":"10.1158/1538-8514.synthleth24-b008","title":"Abstract B008: Utilizing pathway incompatibility for synthetic lethality: A therapeutic strategy for B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; MAPK/ERK pathway; Cancer research; Lymphoma; Diffuse large B-cell lymphoma; Biology; STAT5; Cancer; Signal transduction; Genetics; Medicine; Immunology; Gene; DNA repair","score_opus":0.04477044937500035,"score_gpt":0.3176650040480756,"score_spread":0.2728945546730753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8392504,0.052068654,0.041841026,0.007195417,0.0015231717,0.000716488,0.002018785,0.0023685035,0.053017505],"genre_scores_gemma":[0.9519684,0.014762199,0.013719459,0.0019000529,0.00016501201,0.0002801429,0.0016695991,0.0001523651,0.0153827695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986887,0.000024863599,0.0000062418294,0.000018386181,0.00004781755,0.000033824876],"domain_scores_gemma":[0.99993944,0.000009941072,0.000011157761,0.0000066049442,0.000009063844,0.000023744635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024499124,0.000375019,0.00033346884,0.00047768152,0.00021919279,0.00061606255,0.00039652872,0.00060254475,0.0058378987],"category_scores_gemma":[0.00017121821,0.00013384587,0.0003802956,0.00020728458,0.00026555746,0.00032815067,0.00045534867,0.0017813025,0.0015337483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014524788,0.00093527435,0.00048587678,0.0005060305,0.000069001886,0.00072941114,0.00008378774,0.00071654946,0.86978036,0.0043454766,0.006816824,0.114079036],"study_design_scores_gemma":[0.0014950462,0.016276257,0.0060577323,0.0003104016,0.0004545679,0.0066869166,0.00021516481,0.0052106054,0.7293925,0.005377859,0.22842172,0.00010123597],"about_ca_topic_score_codex":0.00033206947,"about_ca_topic_score_gemma":0.00050586433,"teacher_disagreement_score":0.0058378987,"about_ca_system_score_codex":0.00034453277,"about_ca_system_score_gemma":0.0002876447,"threshold_uncertainty_score":0.0195297},"labels":[],"label_agreement":null},{"id":"W4399505351","doi":"10.1158/1538-8514.synthleth24-b027","title":"Abstract B027: A pathway-informed framework to infer synthetic lethal relationships in pediatric cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Epistasis; Gene; Indel; Biology; Mutation; Computational biology; Genetics; Cancer; Lethality; Lethal allele; Mutant; Genotype","score_opus":0.025665711285766956,"score_gpt":0.2951549860997575,"score_spread":0.26948927481399054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505351","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09189016,0.001459814,0.876833,0.0009955256,0.00005590977,0.00025117738,0.017166227,0.008186516,0.0031616508],"genre_scores_gemma":[0.54856324,0.0006076098,0.42177096,0.00038706153,0.00007318023,0.0003386444,0.026187705,0.0004152511,0.0016562637],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9994411,0.00020942697,0.0000243126,0.00015452903,0.00012228741,0.00004837601],"domain_scores_gemma":[0.99879956,0.00080015545,0.000099305595,0.00010603123,0.000102677,0.0000922791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013077753,0.0010189775,0.0007489713,0.0028790187,0.0006047586,0.0012689244,0.0014243842,0.0012305932,0.004808607],"category_scores_gemma":[0.0038589286,0.000509703,0.0021185554,0.00151216,0.0005706379,0.0007379259,0.0013471737,0.0011154223,0.00057102717],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032895073,0.00013358617,0.012519173,0.00034828368,0.00033260934,0.0004880872,0.000090234156,0.9265697,0.0032097916,0.013690076,0.004306274,0.03798328],"study_design_scores_gemma":[0.000026448308,0.000024609502,0.00079128286,0.0000184508,0.000033726275,0.000053461812,0.00002094182,0.98241925,0.00044933896,0.014347897,0.0018060149,0.000008548794],"about_ca_topic_score_codex":0.019298404,"about_ca_topic_score_gemma":0.023457017,"teacher_disagreement_score":0.019298404,"about_ca_system_score_codex":0.0011488934,"about_ca_system_score_gemma":0.0019143159,"threshold_uncertainty_score":0.03837216},"labels":[],"label_agreement":null},{"id":"W4399505359","doi":"10.1158/1538-8514.synthleth24-a014","title":"Abstract A014: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Cancer; Phosphorylation; Breast cancer; Triple-negative breast cancer; Cancer research; Citation; Medicine; Library science; Internal medicine; Chemistry; Biochemistry; Computer science","score_opus":0.020628025765530616,"score_gpt":0.3142404357098953,"score_spread":0.29361240994436466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5910016,0.09739256,0.015239549,0.01668051,0.016874354,0.0015212538,0.016131954,0.003086154,0.2420721],"genre_scores_gemma":[0.66734684,0.037225872,0.0076054744,0.0024980912,0.0012879777,0.00034792698,0.010453439,0.00025247902,0.27298188],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988997,0.00001392866,0.0000075876724,0.000014249358,0.000046871217,0.000027367652],"domain_scores_gemma":[0.9999254,0.000009594251,0.0000075782937,0.000005559075,0.000019772546,0.000032083084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025413313,0.00057048013,0.00044672846,0.0005555083,0.0003610434,0.0006394162,0.00035992856,0.00044879128,0.03825347],"category_scores_gemma":[0.00019453173,0.00017310964,0.00043992366,0.0002943422,0.00016869779,0.0002736199,0.00037544055,0.0008646494,0.005636547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003918789,0.0006721959,0.00046653836,0.00088757876,0.00006803794,0.00041719503,0.00003918284,0.00064281427,0.82856953,0.002125624,0.0588029,0.103389524],"study_design_scores_gemma":[0.0012104122,0.0072148065,0.009048536,0.00019246437,0.00016715584,0.0012696194,0.00010034512,0.0016494418,0.71714395,0.0013538158,0.26059523,0.000054272838],"about_ca_topic_score_codex":0.0012544272,"about_ca_topic_score_gemma":0.0022243168,"teacher_disagreement_score":0.03825347,"about_ca_system_score_codex":0.0005859243,"about_ca_system_score_gemma":0.000938138,"threshold_uncertainty_score":0.12797058},"labels":[],"label_agreement":null},{"id":"W4399505367","doi":"10.1158/1538-8514.synthleth24-a023","title":"Abstract A023: Determining genetic interaction from double knockout CRISPR screening","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Computational biology; Genetics; HeLa; Gene; Biology; Genetic analysis; Gene knockout; Cell","score_opus":0.028155571502357132,"score_gpt":0.30483762212633536,"score_spread":0.2766820506239782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55931324,0.0013235981,0.24352789,0.0005237748,0.00017068966,0.000443921,0.16920377,0.018874556,0.0066185845],"genre_scores_gemma":[0.5648114,0.0006265103,0.21041423,0.00078274804,0.00006271562,0.0013440185,0.21551722,0.0030933719,0.0033477594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99664503,0.00057423057,0.00028231362,0.0010975982,0.0012388697,0.00016202555],"domain_scores_gemma":[0.9953986,0.0020630239,0.00078181777,0.0008324693,0.0006794138,0.0002446755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031392674,0.0010305867,0.0011682115,0.0018737654,0.00072138576,0.0014669131,0.00087477977,0.0009768733,0.0032657338],"category_scores_gemma":[0.0062180473,0.00041721892,0.001349663,0.0011965027,0.00045804997,0.0005070797,0.0011455122,0.0011780574,0.002077828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018168712,0.00053810404,0.12060351,0.0022776048,0.0019865932,0.0007047019,0.0002786577,0.03520087,0.6938312,0.0049020285,0.042461734,0.0953982],"study_design_scores_gemma":[0.0003301441,0.001623033,0.32174036,0.00032379958,0.0011360534,0.0023182407,0.00030962334,0.22133926,0.36091247,0.014311757,0.07521385,0.00044145898],"about_ca_topic_score_codex":0.0022886905,"about_ca_topic_score_gemma":0.004764979,"teacher_disagreement_score":0.0032657338,"about_ca_system_score_codex":0.0006780493,"about_ca_system_score_gemma":0.0010745749,"threshold_uncertainty_score":0.016602278},"labels":[],"label_agreement":null},{"id":"W4399505369","doi":"10.1158/1538-8514.synthleth24-b003","title":"Abstract B003: Identification of novel genes that regulate aneuploidy tolerance by attenuating aneuploidy-induced stresses","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aneuploidy; Biology; Genetics; Chromosome instability; Gene; Chromosome","score_opus":0.029410639860997394,"score_gpt":0.29462235743129006,"score_spread":0.26521171757029266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90167063,0.010228809,0.0142182335,0.0010625364,0.00022728038,0.00027957512,0.065797694,0.0023649286,0.004150272],"genre_scores_gemma":[0.7947709,0.007943336,0.028329793,0.0012150301,0.00009825516,0.0003997553,0.1581407,0.00039949198,0.008702729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998921,0.000009493452,0.0000074989316,0.000031606385,0.00003248357,0.000026684094],"domain_scores_gemma":[0.9998375,0.000040457533,0.000035530415,0.0000090164285,0.000027833832,0.00004961638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014107519,0.0008083979,0.00091303815,0.000839924,0.0003893722,0.0005785462,0.000348626,0.0005556523,0.0045324164],"category_scores_gemma":[0.0002591733,0.00016117792,0.000824219,0.0012910947,0.00016709513,0.0002252898,0.00027672746,0.0006288853,0.0017846182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000479838,0.000085279884,0.0033579222,0.00052787794,0.000066120585,0.00027883003,0.000021010002,0.00037845425,0.98520064,0.00010724429,0.0016110819,0.00788572],"study_design_scores_gemma":[0.000341266,0.0017567789,0.301472,0.00026148147,0.00082792505,0.0033580859,0.00036277305,0.013026914,0.62710035,0.0010408491,0.05033129,0.00012027097],"about_ca_topic_score_codex":0.0014539534,"about_ca_topic_score_gemma":0.001815312,"teacher_disagreement_score":0.0045324164,"about_ca_system_score_codex":0.00035674372,"about_ca_system_score_gemma":0.000635036,"threshold_uncertainty_score":0.015162468},"labels":[],"label_agreement":null},{"id":"W4399505374","doi":"10.1158/1538-8514.synthleth24-b005","title":"Abstract B005: Regulation of replication-induced PARP1/PARP2 activation by base excision repair: Implications for PARP and PARG inhibitor resistance","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC1; PARP1; Base excision repair; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; DNA repair; DNA damage; Molecular biology; Polymerase; Biology; Chemistry; DNA; Genetics","score_opus":0.05036201442551773,"score_gpt":0.3601647727333316,"score_spread":0.30980275830781384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96351355,0.013928106,0.0052384464,0.0012120605,0.00019684072,0.0000648433,0.0026087842,0.00037468472,0.0128627205],"genre_scores_gemma":[0.9843575,0.0015502605,0.0016005964,0.00023598578,0.0000437427,0.000030761283,0.001985152,0.00003345595,0.010162621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992096,0.0000087129965,0.000005037879,0.000022440436,0.000019151901,0.000023650973],"domain_scores_gemma":[0.9999155,0.000009564959,0.000027999504,0.0000056651916,0.000009809722,0.000031491556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011051745,0.00024144494,0.00014129018,0.00016087422,0.0001875866,0.00049267546,0.00023540703,0.00037082558,0.010640653],"category_scores_gemma":[0.00010500406,0.00010274037,0.00017204876,0.0001441199,0.0001792425,0.00023114451,0.00015672346,0.00048252792,0.0021079648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046859836,0.000057509194,0.000501462,0.00007177661,0.0000067966544,0.00007883277,0.000008067356,0.00006836391,0.99402064,0.000417692,0.00047674318,0.0038235602],"study_design_scores_gemma":[0.000091788505,0.0006323072,0.04812908,0.000026536149,0.00001946866,0.00061398075,0.000050147235,0.0017649598,0.93682927,0.0004837553,0.011347883,0.000010817129],"about_ca_topic_score_codex":0.00069067907,"about_ca_topic_score_gemma":0.00041709503,"teacher_disagreement_score":0.010640653,"about_ca_system_score_codex":0.00051515864,"about_ca_system_score_gemma":0.00018956787,"threshold_uncertainty_score":0.03559655},"labels":[],"label_agreement":null},{"id":"W4399505390","doi":"10.1158/1538-8514.synthleth24-ia021","title":"Abstract IA021: Environmental challenge rewires functional connections among human genes","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Adaptability; Gene; Epigenetics; Genetic architecture; Context (archaeology); Computational biology; Cancer; Genetics; Ecology; Phenotype","score_opus":0.02020761552575187,"score_gpt":0.25562605260560906,"score_spread":0.23541843707985718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97873265,0.0007802841,0.010179634,0.00042835445,0.00003343838,0.000017838836,0.0027688101,0.0003911112,0.0066677816],"genre_scores_gemma":[0.9948938,0.00021187327,0.002206793,0.00015083485,0.000008152857,0.00001427665,0.001059773,0.000049563525,0.0014048718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997832,0.000026931284,0.0000065219224,0.000094412324,0.000052674914,0.000036186473],"domain_scores_gemma":[0.999642,0.000105187435,0.00009900301,0.00006522236,0.00004583451,0.000042705637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019054118,0.0001918225,0.0002287072,0.0003322946,0.00031356144,0.0005009457,0.00022092253,0.00033168565,0.003139554],"category_scores_gemma":[0.00071196136,0.00014616373,0.00020233306,0.000608051,0.00042975688,0.0002476214,0.0005063233,0.00041340102,0.0004773979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005662556,0.000063114465,0.0990391,0.00031225325,0.00013344879,0.00076381216,0.0003502544,0.018403031,0.7924925,0.008938855,0.0046143266,0.074322976],"study_design_scores_gemma":[0.000036725865,0.0004584208,0.710324,0.000058000875,0.00012753654,0.00161212,0.0007472578,0.03221254,0.20798051,0.011462172,0.034896046,0.00008472512],"about_ca_topic_score_codex":0.004221874,"about_ca_topic_score_gemma":0.008556243,"teacher_disagreement_score":0.004221874,"about_ca_system_score_codex":0.0006506429,"about_ca_system_score_gemma":0.00034700456,"threshold_uncertainty_score":0.010502875},"labels":[],"label_agreement":null},{"id":"W4399505409","doi":"10.1158/1538-8514.synthleth24-pr006","title":"Abstract PR006: DNA repair inhibition via targeting ATR activates cGAS/STING signaling, promotes anti-tumor immunity, and is a synthetic lethal strategy to augment immunotherapy response in preclinical models and clinical samples of small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Blockade; Immunotherapy; Immune checkpoint; Tumor microenvironment; Biology; Immune system; Immunology; Medicine; Receptor","score_opus":0.08230421986962153,"score_gpt":0.4102955688589184,"score_spread":0.3279913489892968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843424,0.0040548802,0.0046123075,0.00052376755,0.00017215089,0.00013728233,0.0014832608,0.000518537,0.004155465],"genre_scores_gemma":[0.98546207,0.001790413,0.0033144038,0.00016664508,0.000050643896,0.00009747057,0.0019623693,0.00003786977,0.007118108],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988425,0.000014349481,0.000008064581,0.000024972273,0.000043509655,0.000024854498],"domain_scores_gemma":[0.9999341,0.0000069870403,0.000019684157,0.000007024629,0.0000059840427,0.00002632364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015086848,0.0005835454,0.00030963274,0.00029277377,0.00014310463,0.00029555388,0.00028418042,0.00033096326,0.00384119],"category_scores_gemma":[0.00007398383,0.00010306211,0.00033215684,0.00019565698,0.00025100843,0.00019646868,0.00015842912,0.0014029332,0.00073075574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047860638,0.00023950158,0.00016872783,0.00007242161,0.000011547279,0.00003780986,0.0000068502914,0.00015244816,0.9931579,0.00008702062,0.0003838937,0.005203035],"study_design_scores_gemma":[0.00012942043,0.0032745884,0.002569003,0.000009157048,0.000028637356,0.00023047034,0.000012732133,0.00086202356,0.989417,0.000045272976,0.003417159,0.000004493289],"about_ca_topic_score_codex":0.00031333673,"about_ca_topic_score_gemma":0.0007229983,"teacher_disagreement_score":0.00384119,"about_ca_system_score_codex":0.00022828477,"about_ca_system_score_gemma":0.0003302204,"threshold_uncertainty_score":0.012850046},"labels":[],"label_agreement":null},{"id":"W4399505421","doi":"10.1158/1538-8514.synthleth24-b004","title":"Abstract B004: An isogenic CRISPR screen identifies novel MYC-driven vulnerabilities","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"CRISPR; Synthetic lethality; Biology; Computational biology; Context (archaeology); Cancer; Gene; Cancer research; Breast cancer; Cancer cell; Drug discovery; Genetics; Bioinformatics; DNA repair","score_opus":0.026187002403998665,"score_gpt":0.33083445030912395,"score_spread":0.30464744790512527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95729625,0.00061690697,0.022369634,0.00036874771,0.00007269103,0.00033614977,0.010340794,0.0019150029,0.0066837845],"genre_scores_gemma":[0.9675955,0.0005101311,0.013811619,0.00025310786,0.00001149227,0.00016466886,0.007384766,0.00035847886,0.00991017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969244,0.000026804673,0.000025415115,0.0000633566,0.00013180757,0.000060243605],"domain_scores_gemma":[0.9997943,0.000055437376,0.00004046774,0.000020260974,0.00002530111,0.00006423003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019967866,0.000752905,0.0005629073,0.0009013428,0.000295734,0.0004277619,0.00043640556,0.00051041454,0.003942657],"category_scores_gemma":[0.00023416306,0.00019941115,0.00041536248,0.0004188354,0.00023006891,0.000111905705,0.00045840882,0.0007484273,0.0010252871],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007887038,0.000044991346,0.00033700993,0.000028505494,0.000009884408,0.00018552251,0.000007303592,0.00017091019,0.99703705,0.000108766304,0.00020261454,0.0017885222],"study_design_scores_gemma":[0.000034247223,0.0005433265,0.009315303,0.000011617591,0.0000532281,0.0011937161,0.00004413126,0.0031987813,0.98068,0.00009519335,0.004805086,0.000025430481],"about_ca_topic_score_codex":0.0014852951,"about_ca_topic_score_gemma":0.0024433949,"teacher_disagreement_score":0.003942657,"about_ca_system_score_codex":0.00042425503,"about_ca_system_score_gemma":0.00030880168,"threshold_uncertainty_score":0.013189554},"labels":[],"label_agreement":null},{"id":"W4399505433","doi":"10.1158/1538-8514.synthleth24-b024","title":"Abstract B024: Leveraging synthetic lethality across EP300-mutant solid cancers through selective CBP degradation","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; CREB-binding protein; Cancer research; Mutant; Genetics; Transcription factor; Gene; CREB","score_opus":0.034946920178070745,"score_gpt":0.347682932035319,"score_spread":0.3127360118572483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95681745,0.0050635114,0.014252418,0.00097172323,0.00024830594,0.0002342503,0.0033574542,0.0014556192,0.017599288],"genre_scores_gemma":[0.9633305,0.002506285,0.008173746,0.00029980892,0.00002908444,0.00013252402,0.0021689027,0.00013597474,0.023223216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989307,0.000011313486,0.0000069288267,0.000020891344,0.000042518674,0.000025211908],"domain_scores_gemma":[0.99992394,0.0000077714885,0.000016994283,0.000009522735,0.000013627634,0.000028078517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014342758,0.0004936064,0.00027881272,0.00032495343,0.00018896855,0.00032842957,0.00041844154,0.00038226857,0.0038277768],"category_scores_gemma":[0.0000951908,0.000150119,0.00027655603,0.00015523394,0.00018238157,0.00021536094,0.00024127374,0.00077171857,0.0012041688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022344905,0.00009890134,0.000077056626,0.00006787705,0.000011498108,0.00013910927,0.000008838828,0.00020349362,0.9916524,0.00025758197,0.001016046,0.0062437593],"study_design_scores_gemma":[0.000057552723,0.000828894,0.0008123897,0.0000057259413,0.000013361929,0.00056612166,0.00000914305,0.00075732946,0.98946035,0.00006039336,0.00742092,0.000007935344],"about_ca_topic_score_codex":0.00079753017,"about_ca_topic_score_gemma":0.0011529905,"teacher_disagreement_score":0.0038277768,"about_ca_system_score_codex":0.0002889564,"about_ca_system_score_gemma":0.0002712777,"threshold_uncertainty_score":0.012805223},"labels":[],"label_agreement":null},{"id":"W4399505443","doi":"10.1158/1538-8514.synthleth24-b029","title":"Abstract B029: Assessing gene expression and methylation of KMT2D and IGF2 genes in patients with non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylation; DNA methylation; Epigenetics; Carcinogenesis; Biology; Gene; CpG site; Bisulfite sequencing; Gene expression; Genomic imprinting; Promoter; Molecular biology; Lung cancer; Cancer; Cancer research; Genetics; Pathology; Medicine","score_opus":0.012648116511731849,"score_gpt":0.27961275147079473,"score_spread":0.26696463495906286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99897313,0.000250451,0.00017261115,0.00002090884,0.000006528942,0.000014178654,0.00028317017,0.0000061260894,0.0002729703],"genre_scores_gemma":[0.9990145,0.00004669986,0.00023309994,0.000016186363,0.000003606293,0.00001927178,0.00027326186,0.000001246065,0.00039220715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985147,0.000038432147,0.000015039842,0.000046726953,0.00003208377,0.000016295153],"domain_scores_gemma":[0.9998702,0.000023811972,0.00002971465,0.0000075114285,0.000028442804,0.00004027227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020794079,0.00017078628,0.00019428243,0.00033245527,0.00020939836,0.00018908139,0.00013078775,0.00024068508,0.0013056421],"category_scores_gemma":[0.00031642843,0.00010740742,0.00013333964,0.00023335335,0.000111351554,0.000108583146,0.00014174236,0.00019221449,0.00021308535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012752418,0.00009712845,0.9608409,0.000058386468,0.00004658612,0.00023860364,0.00007034415,0.00006439285,0.031504028,0.000009111847,0.0001823903,0.005612852],"study_design_scores_gemma":[0.000023940514,0.0005464484,0.9927273,0.0000039778447,0.000029586594,0.0006347739,0.00007445997,0.0002610999,0.005290178,0.000010985348,0.0003941968,0.000003114062],"about_ca_topic_score_codex":0.00100361,"about_ca_topic_score_gemma":0.0016997576,"teacher_disagreement_score":0.0013056421,"about_ca_system_score_codex":0.00020993812,"about_ca_system_score_gemma":0.00013406326,"threshold_uncertainty_score":0.0043678284},"labels":[],"label_agreement":null},{"id":"W4399505656","doi":"10.1158/1538-8514.synthleth24-pr003","title":"Abstract PR003: Mechanisms of therapeutic vulnerability of mismatch repair defective cancers to RNA polymerase I inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; Genetics; Cancer research; DNA repair; Molecular biology; Gene","score_opus":0.023950450692404004,"score_gpt":0.3160822818356816,"score_spread":0.2921318311432776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96981084,0.0090243835,0.010567732,0.0005069585,0.00005762302,0.00018825119,0.0024994994,0.00077744276,0.006567258],"genre_scores_gemma":[0.9932683,0.0015460835,0.0012805003,0.00012787442,0.000013049535,0.00005613951,0.0011242211,0.00004296614,0.0025409374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998267,0.000020429507,0.000014064406,0.000036824524,0.00006929177,0.000032721626],"domain_scores_gemma":[0.999869,0.000030698233,0.000045587727,0.000016910288,0.000017696833,0.000020189094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028533454,0.00037306387,0.00036508238,0.00042742683,0.00010990455,0.00045673497,0.00034022477,0.0003585168,0.0030474176],"category_scores_gemma":[0.00024845576,0.00015544354,0.00029773894,0.00024295565,0.00017697348,0.00029170333,0.00027320022,0.00048411527,0.00061944214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021654028,0.00004593858,0.00073495216,0.000100638186,0.000012728333,0.000118335614,0.000010413042,0.00030739096,0.98862946,0.00045909634,0.00026048676,0.009104077],"study_design_scores_gemma":[0.00003363841,0.0014213487,0.0101689715,0.00001558521,0.000040796876,0.0013479762,0.00003622592,0.0023087594,0.97819144,0.00039665817,0.006030147,0.000008466763],"about_ca_topic_score_codex":0.00026829014,"about_ca_topic_score_gemma":0.00026031025,"teacher_disagreement_score":0.0030474176,"about_ca_system_score_codex":0.000414389,"about_ca_system_score_gemma":0.00015000136,"threshold_uncertainty_score":0.0101946},"labels":[],"label_agreement":null},{"id":"W4399901966","doi":"10.1158/1535-7163.mct-23-0393","title":"Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University","funders":"Institute of Cancer Research","keywords":"Metastasis; Colorectal cancer; Claudin; Cancer; Cancer research; Monoclonal antibody; Antibody; In vivo; Antibody-drug conjugate; Medicine; Liver cancer; Immunology; Biology; Internal medicine; Tight junction","score_opus":0.06740540409596586,"score_gpt":0.41211183557284087,"score_spread":0.344706431476875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399901966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564878,0.024139617,0.0141962655,0.0003924985,0.00009655443,0.0002568614,0.00019776006,0.00017589815,0.004056825],"genre_scores_gemma":[0.9859409,0.005940089,0.005430934,0.00007559858,0.000020674008,0.000063567575,0.00014183634,0.000012035811,0.0023743694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999232,0.000021887605,0.000003817064,0.000012389386,0.000022719347,0.000015890122],"domain_scores_gemma":[0.9999701,0.000005259307,0.000009305977,0.0000023721293,0.0000054718917,0.0000074969566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015705169,0.00028208355,0.0002230337,0.00028822038,0.000107942775,0.00020545482,0.00016307643,0.00023340898,0.0007398845],"category_scores_gemma":[0.00008790302,0.000105526335,0.00012554743,0.0001729379,0.0001137044,0.00016734673,0.00013851456,0.00035307705,0.00015325828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016713717,0.00011515336,0.00020501974,0.00013686348,0.000018398709,0.00012323182,0.000021614609,0.00055501034,0.98092455,0.00042073816,0.00031231888,0.016999958],"study_design_scores_gemma":[0.0001608489,0.0020165672,0.0021829114,0.00001336566,0.000042781372,0.0010672683,0.000012035365,0.0037907618,0.97252524,0.000086791915,0.018088434,0.000012999899],"about_ca_topic_score_codex":0.00046101725,"about_ca_topic_score_gemma":0.00092029606,"teacher_disagreement_score":0.0007398845,"about_ca_system_score_codex":0.0004013431,"about_ca_system_score_gemma":0.00020363112,"threshold_uncertainty_score":0.002911985},"labels":[],"label_agreement":null},{"id":"W4400926625","doi":"10.1158/1535-7163.mct-23-0314","title":"Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Congressionally Directed Medical Research Programs; School of Medicine, Indiana University; York University; National Cancer Institute; School of Medicine, New York University; National Institutes of Health; Ovarian Cancer Alliance of Greater Cincinnati; Van Andel Research Institute; GlaxoSmithKline; Stand Up To Cancer; U.S. Department of Defense","keywords":"HOTAIR; Cancer research; Cancer stem cell; Biology; EZH2; Ovarian cancer; Epigenetics; Long non-coding RNA; Cancer; Genetics; RNA; Gene","score_opus":0.01459618961777851,"score_gpt":0.2807979107888266,"score_spread":0.26620172117104807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400926625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98227274,0.0029886854,0.010432784,0.0002755753,0.00010663119,0.00010349676,0.00046939543,0.00031461872,0.0030360369],"genre_scores_gemma":[0.9934302,0.0009133095,0.0022756099,0.00008428044,0.000013205119,0.00006447164,0.00028046608,0.000017841377,0.002920502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987924,0.000010929591,0.000011620583,0.000030193283,0.00003839815,0.000029655215],"domain_scores_gemma":[0.99995553,0.0000072828157,0.000014417088,0.000005645102,0.000004707591,0.000012463856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012857973,0.00026665351,0.00027240693,0.0001624919,0.00009011594,0.00021159364,0.00020244614,0.00023188112,0.0010252851],"category_scores_gemma":[0.00007657814,0.00013423723,0.00022923398,0.00011058798,0.0002024865,0.00017121888,0.00019131963,0.00050059153,0.00018406658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021938901,0.000058200534,0.00026266545,0.000090092304,0.000020688116,0.000053760465,0.000020676971,0.00024064306,0.9934105,0.00029257603,0.00015158464,0.0051790033],"study_design_scores_gemma":[0.00006769205,0.00053434935,0.0016957029,0.0000045441852,0.000049282302,0.00016615418,0.000022375369,0.0020444389,0.9889893,0.00007498174,0.0063462793,0.000004887302],"about_ca_topic_score_codex":0.00038638242,"about_ca_topic_score_gemma":0.00084265834,"teacher_disagreement_score":0.0010252851,"about_ca_system_score_codex":0.0001722835,"about_ca_system_score_gemma":0.0001847009,"threshold_uncertainty_score":0.0034299493},"labels":[],"label_agreement":null},{"id":"W4403250299","doi":"10.1158/1535-7163.mct-24-0307","title":"Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NAEJA-RGM Pharmaceuticals (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of Alberta","funders":"Leukemia and Lymphoma Society of Canada; Alberta Cancer Foundation; Cancer Research Institute","keywords":"MCL1; Myeloid leukemia; Myristoylation; Cancer research; Leukemia; Biology; Endoplasmic reticulum; Proto-oncogene tyrosine-protein kinase Src; Programmed cell death; Apoptosis; Cell culture; Phosphorylation; Cell biology; Immunology; Downregulation and upregulation; Biochemistry; Genetics","score_opus":0.01172884225734684,"score_gpt":0.2648238642681726,"score_spread":0.2530950220108258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877493,0.003493154,0.00441355,0.00015173106,0.000039166036,0.000102915365,0.00078739,0.00028819428,0.0029745954],"genre_scores_gemma":[0.9899789,0.0028132645,0.0032076903,0.00007444598,0.00001193487,0.00008228788,0.0015325606,0.000030552277,0.0022683684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999083,0.000012827501,0.000010797525,0.000016559085,0.00002666466,0.000024690313],"domain_scores_gemma":[0.9999703,0.000004340111,0.000008912781,0.000004286112,0.0000041730364,0.000007931396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001170589,0.00047268835,0.0003541729,0.00021949247,0.00014015818,0.00017304726,0.00023523155,0.00021297527,0.00076312135],"category_scores_gemma":[0.00007546091,0.00013950512,0.00035702763,0.00021149479,0.00014536204,0.00015945104,0.0001600802,0.0005843546,0.0003121688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002573094,0.0000675618,0.00017496012,0.000047923895,0.000017994405,0.000032910546,0.000008710403,0.00024879276,0.99520206,0.0000824658,0.00013351263,0.0037256791],"study_design_scores_gemma":[0.000074770855,0.00058336154,0.0025311268,0.000004523214,0.000029725432,0.00023299818,0.000009569127,0.0013009775,0.9906448,0.00003372746,0.0045490563,0.000005297163],"about_ca_topic_score_codex":0.0007016677,"about_ca_topic_score_gemma":0.001864414,"teacher_disagreement_score":0.00076312135,"about_ca_system_score_codex":0.0003325209,"about_ca_system_score_gemma":0.00022687219,"threshold_uncertainty_score":0.002552867},"labels":[],"label_agreement":null},{"id":"W4404349036","doi":"10.1158/1538-8514.rnadrivers24-pr002","title":"Abstract PR002: Hypoxia-induced epigenetic changes coordinate transcription start site selection and translational control through remodeling of 5’UTRs","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Alberta; McGill University; Queen's University","funders":"","keywords":"Epigenetics; Transcription (linguistics); Biology; Hypoxia (environmental); Transcription factor; Cell biology; Genetics; Computational biology; Bioinformatics; Chemistry; Gene","score_opus":0.03261615726080063,"score_gpt":0.2898283294451097,"score_spread":0.2572121721843091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8296963,0.018060882,0.062918186,0.008855162,0.0048845937,0.00033183856,0.02377974,0.0038779492,0.047595523],"genre_scores_gemma":[0.8824374,0.006108959,0.0120236,0.0014381796,0.00063558994,0.0001593538,0.013254914,0.0005255916,0.0834164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998235,0.000015372112,0.000010867142,0.000073873525,0.000053609758,0.000022740294],"domain_scores_gemma":[0.9998697,0.000016401626,0.00003856039,0.000018371264,0.000032784097,0.000024071085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020186193,0.00030755124,0.00027889354,0.00023339385,0.0002986552,0.00081093464,0.00031874442,0.00047965988,0.0122528225],"category_scores_gemma":[0.000271332,0.00022131846,0.00023242763,0.00040244433,0.0002991223,0.00044038854,0.00042789668,0.0006731995,0.0035077175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033842388,0.000028422948,0.0011599715,0.000214593,0.000012387155,0.00019872612,0.000048403916,0.00016019403,0.97338086,0.0010044079,0.0061434805,0.017310124],"study_design_scores_gemma":[0.00006558413,0.0005231853,0.054703403,0.00005118015,0.0000547273,0.0012685446,0.00018773055,0.0027921516,0.8540694,0.0015242596,0.08472213,0.000037695572],"about_ca_topic_score_codex":0.0006230839,"about_ca_topic_score_gemma":0.0007570508,"teacher_disagreement_score":0.0122528225,"about_ca_system_score_codex":0.00034172268,"about_ca_system_score_gemma":0.00030237722,"threshold_uncertainty_score":0.040989816},"labels":[],"label_agreement":null},{"id":"W4404349215","doi":"10.1158/1538-8514.rnadrivers24-pr003","title":"Abstract PR003: Preventing and treating HPV-related Cancer with mRNA Therapy Expressing A DC-targeting Antigen","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iProgen Biotech (Canada)","funders":"","keywords":"Medicine; Cancer; Antigen; Cancer research; Immunology; Messenger RNA; Virology; Biology; Internal medicine; Gene; Genetics","score_opus":0.018570002721795736,"score_gpt":0.2936979135475358,"score_spread":0.27512791082574006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349215","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.876149,0.03298888,0.020239582,0.0035083774,0.001424544,0.0008899029,0.0024023473,0.0010650564,0.061332367],"genre_scores_gemma":[0.90321845,0.017866783,0.016241651,0.00073138747,0.0002281135,0.00030716084,0.0022463787,0.00011502252,0.059044957],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999954,0.000007786091,0.0000029568034,0.0000071898,0.000018779887,0.000009226376],"domain_scores_gemma":[0.99997854,0.000003946916,0.000005033357,0.0000022140657,0.0000053998237,0.0000049714345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009354587,0.0002463747,0.00014581486,0.0002263422,0.000090778245,0.00022356148,0.00017257831,0.00031695442,0.0062763914],"category_scores_gemma":[0.00007284669,0.000060479924,0.0001962444,0.00014776038,0.000120101315,0.00013380554,0.000118710974,0.00043748703,0.0012770133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067466486,0.00037685718,0.0005809675,0.00029898842,0.000016452943,0.00019370644,0.000030630166,0.00035283578,0.8967456,0.00066628645,0.0054170615,0.094645925],"study_design_scores_gemma":[0.00026837428,0.0044024237,0.005947448,0.00006403011,0.000067050714,0.00107536,0.00004797976,0.0014713379,0.90954834,0.00021081821,0.07688135,0.000015529906],"about_ca_topic_score_codex":0.00084924605,"about_ca_topic_score_gemma":0.0011090244,"teacher_disagreement_score":0.0062763914,"about_ca_system_score_codex":0.00023417645,"about_ca_system_score_gemma":0.0003472935,"threshold_uncertainty_score":0.02099663},"labels":[],"label_agreement":null},{"id":"W4404349232","doi":"10.1158/1538-8514.rnadrivers24-a008","title":"Abstract A008: Identification of EYA2 as a promising biomarker for DICER1-related tumor predisposition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Identification (biology); Biomarker; Biology; Cancer; Genetic predisposition; Medicine; Computational biology; Cancer research; Genetics; Gene","score_opus":0.026915283655905786,"score_gpt":0.3376645662852509,"score_spread":0.3107492826293451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349232","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97138953,0.010764268,0.010946864,0.000705296,0.0001977462,0.00008509038,0.0027903125,0.00028889716,0.002832007],"genre_scores_gemma":[0.9791044,0.0020847206,0.010630463,0.0004900617,0.0001242017,0.00008021146,0.0036288237,0.000048524536,0.0038086765],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978024,0.000043241558,0.000021364336,0.00006919293,0.00006442279,0.000021525842],"domain_scores_gemma":[0.99953675,0.00012468056,0.00010225111,0.000028118093,0.00012431381,0.00008392863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006385247,0.0005447517,0.00035522116,0.0009130134,0.00020294283,0.00057375664,0.0002098805,0.0006076374,0.0027747762],"category_scores_gemma":[0.0006125636,0.00015649857,0.00030244442,0.0004343159,0.0001986481,0.00026644816,0.00028599362,0.0005865146,0.0009674804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006516532,0.00007449355,0.03169428,0.0002628079,0.00007670483,0.0006641257,0.000033149667,0.00018591243,0.95234853,0.00018290276,0.00080681476,0.013018536],"study_design_scores_gemma":[0.00007887153,0.0015308459,0.23545405,0.000084373445,0.00030325397,0.009695972,0.00014922988,0.0057407827,0.7303412,0.0009869261,0.015585524,0.000048954],"about_ca_topic_score_codex":0.00018069717,"about_ca_topic_score_gemma":0.00014962567,"teacher_disagreement_score":0.0027747762,"about_ca_system_score_codex":0.00021338116,"about_ca_system_score_gemma":0.00017097007,"threshold_uncertainty_score":0.009282529},"labels":[],"label_agreement":null},{"id":"W4405170886","doi":"10.1158/1538-8514.cancerchem24-a003","title":"Abstract A003: In vitro anticancer activities of some organoplatinum (IV) derivatives","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vitro; Chemistry; Pharmacology; Combinatorial chemistry; Stereochemistry; Biology; Biochemistry","score_opus":0.04939737418752027,"score_gpt":0.31224513293350126,"score_spread":0.262847758745981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161166,0.0029448615,0.0017889182,0.000053043026,0.000021913622,0.000032203934,0.00041596152,0.00007528955,0.0030563101],"genre_scores_gemma":[0.9954751,0.00050217257,0.0013282045,0.000015762045,0.0000033533158,0.000014912663,0.0005205016,0.000012019055,0.002128005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993324,0.000014476298,0.000009357517,0.000013481174,0.000016585924,0.0000128509155],"domain_scores_gemma":[0.9999441,0.000014868509,0.000012607542,0.0000056487856,0.000011746332,0.000010900673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089377456,0.00020921657,0.00014558341,0.00014213487,0.00007132434,0.00014970772,0.0001890619,0.00016477311,0.0018105842],"category_scores_gemma":[0.00012497508,0.00006338465,0.000116932715,0.00019960651,0.00006579848,0.00008899687,0.00008357697,0.00024847328,0.00027913693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020724273,0.000031515614,0.00016889077,0.00006256503,0.000008069055,0.000036820158,0.000015810861,0.0002049682,0.9971631,0.00003740242,0.00006256736,0.0020010178],"study_design_scores_gemma":[0.000013431139,0.0005441877,0.0009052732,0.000003899031,0.000009865211,0.00006217234,0.000008680674,0.0003482507,0.9967038,0.000009428175,0.0013890071,0.0000019255544],"about_ca_topic_score_codex":0.00091911096,"about_ca_topic_score_gemma":0.0004457246,"teacher_disagreement_score":0.0018105842,"about_ca_system_score_codex":0.00013718761,"about_ca_system_score_gemma":0.000092664246,"threshold_uncertainty_score":0.006057024},"labels":[],"label_agreement":null},{"id":"W4405170902","doi":"10.1158/1538-8514.cancerchem24-a022","title":"Abstract A022: Discovery of conformationally constrained ALK2 inhibitors for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG)","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Glioma; Medicine; Drug discovery; Chemistry; Cancer research; Biochemistry","score_opus":0.021783403526060348,"score_gpt":0.29722597304466636,"score_spread":0.275442569518606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556851,0.0167213,0.006471895,0.00072655565,0.00023190134,0.00070677133,0.0035680155,0.00038466125,0.015503816],"genre_scores_gemma":[0.97299904,0.007585644,0.0055577047,0.00053721055,0.00005101162,0.00024135983,0.0029976976,0.00004414995,0.009986215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999448,0.000007805074,0.0000032251035,0.000012318398,0.000013408143,0.000018524264],"domain_scores_gemma":[0.99996436,0.0000021878811,0.0000070973256,0.000002224867,0.0000062849203,0.000017791734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014248578,0.0005782995,0.00031996833,0.00026620287,0.00015451993,0.00033390592,0.00044690992,0.00038602477,0.004167182],"category_scores_gemma":[0.00008770591,0.00015071765,0.0003399215,0.00019217546,0.00013887415,0.00025786035,0.00028510884,0.0006765711,0.0011375498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016768066,0.0008667264,0.00066000357,0.00057265756,0.00017079375,0.0006161348,0.00007221738,0.0034779,0.9270139,0.0012792539,0.004530864,0.059062667],"study_design_scores_gemma":[0.0042173527,0.028468216,0.008586022,0.00015870317,0.00042625156,0.003414054,0.00011271118,0.009308279,0.85804164,0.0008994933,0.08623128,0.00013605668],"about_ca_topic_score_codex":0.0008036225,"about_ca_topic_score_gemma":0.0015406918,"teacher_disagreement_score":0.004167182,"about_ca_system_score_codex":0.0002780951,"about_ca_system_score_gemma":0.00033656516,"threshold_uncertainty_score":0.013940573},"labels":[],"label_agreement":null},{"id":"W4405170903","doi":"10.1158/1538-8514.cancerchem24-ia014","title":"Abstract IA014: Mechanistic insights for the advancement of PPARG inverse agonists in muscle invasive urothelial cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peroxisome proliferator-activated receptor gamma; Urothelial cancer; Cancer; Cancer research; Computational biology; Medicine; Pharmacology; Biology; Bioinformatics; Chemistry; Internal medicine; Receptor; Bladder cancer; Peroxisome","score_opus":0.023572853075600766,"score_gpt":0.301992560166491,"score_spread":0.27841970709089026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170903","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30023056,0.32357705,0.07915244,0.040373404,0.005759303,0.0013730621,0.005219318,0.0020198312,0.24229503],"genre_scores_gemma":[0.73353934,0.16425249,0.02189524,0.0052720793,0.0007252463,0.00028050665,0.0020376567,0.00010116694,0.071896225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990475,0.000017127359,0.000005768696,0.000013570762,0.000036840112,0.000022028087],"domain_scores_gemma":[0.99995244,0.000004800338,0.000010347187,0.000004526192,0.000013818007,0.0000139985805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004342404,0.0005690486,0.0003115248,0.00037567705,0.00026583232,0.00076923467,0.00050408556,0.00055809785,0.007640413],"category_scores_gemma":[0.00018322955,0.00018691474,0.00031697468,0.0003373319,0.0004741333,0.0005974097,0.00041980858,0.0012956323,0.0019357759],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011170608,0.0005849015,0.0010857132,0.0023692127,0.00007067465,0.0009929187,0.00026741865,0.004528374,0.6850108,0.079718195,0.033752605,0.19050223],"study_design_scores_gemma":[0.000500738,0.00392923,0.0033215939,0.00040400028,0.0001299454,0.0013633933,0.00022104723,0.005788152,0.4516607,0.014324714,0.5182703,0.00008615307],"about_ca_topic_score_codex":0.0017230215,"about_ca_topic_score_gemma":0.0032088566,"teacher_disagreement_score":0.007640413,"about_ca_system_score_codex":0.0010329802,"about_ca_system_score_gemma":0.0008812139,"threshold_uncertainty_score":0.025559783},"labels":[],"label_agreement":null},{"id":"W4405170909","doi":"10.1158/1538-8514.cancerchem24-ia011","title":"Abstract IA011: Strategies to close the translational gap for nanoscale drug delivery systems","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug delivery; Drug; Medicine; Pharmacology; Nanotechnology; Materials science","score_opus":0.029552377155361534,"score_gpt":0.29235890923163527,"score_spread":0.26280653207627375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170909","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0280509,0.072482236,0.33166027,0.1825856,0.013347069,0.0025227508,0.0004937693,0.004281831,0.36457556],"genre_scores_gemma":[0.3539478,0.09279273,0.36446506,0.04727315,0.003868312,0.0035077545,0.00139172,0.0010445275,0.13170889],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9957183,0.0017445317,0.00025998216,0.00036127423,0.0013690322,0.00054689345],"domain_scores_gemma":[0.99496484,0.0014055084,0.0004888944,0.00060112984,0.0016268861,0.0009128032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012215109,0.001158312,0.00070696895,0.0014391163,0.0021201465,0.0069553494,0.0024332567,0.0042275446,0.027252298],"category_scores_gemma":[0.010272251,0.00058928126,0.0011062588,0.0008632512,0.003053302,0.009459504,0.006980018,0.0061659142,0.010592255],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031297756,0.00058731367,0.0006350523,0.0031157713,0.00004660291,0.00057544524,0.0009525457,0.0021039692,0.04464142,0.48972785,0.089839436,0.36746168],"study_design_scores_gemma":[0.00010703572,0.0009464612,0.00034458,0.0012795439,0.000053578504,0.00050067774,0.0009617106,0.0036651695,0.025747621,0.09078767,0.87553364,0.00007238532],"about_ca_topic_score_codex":0.0009317327,"about_ca_topic_score_gemma":0.0012597266,"teacher_disagreement_score":0.027252298,"about_ca_system_score_codex":0.0034772458,"about_ca_system_score_gemma":0.00851524,"threshold_uncertainty_score":0.09116799},"labels":[],"label_agreement":null},{"id":"W4405181185","doi":"10.1158/1538-8514.cancerchem24-a014","title":"Abstract A014: OICR41103: a chemical probe for investigating DCAF1 function and therapeutic potential","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Structural Genomics Consortium; Ontario Institute for Cancer Research","funders":"","keywords":"Function (biology); Cancer; Chemistry; Computational biology; Biology; Cell biology; Genetics","score_opus":0.019119935887306844,"score_gpt":0.27659563995872405,"score_spread":0.2574757040714172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7547747,0.023707855,0.028662402,0.008135128,0.0021688691,0.0006995835,0.0046246527,0.0016570602,0.17556976],"genre_scores_gemma":[0.88259655,0.007688748,0.018721612,0.0022900375,0.00017388977,0.00023317782,0.0019039045,0.00013364339,0.086258434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990594,0.000010162541,0.0000035721944,0.000020114137,0.000036457583,0.00002369455],"domain_scores_gemma":[0.9999552,0.000007830923,0.00001185468,0.0000034650036,0.000008201167,0.000013488106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013960453,0.00034569684,0.000221879,0.00023456797,0.0003521434,0.00033424576,0.00043978298,0.00075657445,0.013147739],"category_scores_gemma":[0.000089022076,0.0001656553,0.00017195495,0.00023608268,0.0002624409,0.00026878712,0.00021158435,0.00081644166,0.0020223535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029931797,0.00007715735,0.0001337414,0.0001811332,0.000006249152,0.00019550348,0.000020673786,0.00016669517,0.98004866,0.0016033065,0.0045147194,0.012752825],"study_design_scores_gemma":[0.00008471371,0.0006042501,0.0008908959,0.000018411389,0.000014044554,0.0005584013,0.000023347584,0.0005248177,0.9611085,0.00018834177,0.03596667,0.000017594928],"about_ca_topic_score_codex":0.0011489853,"about_ca_topic_score_gemma":0.0012978647,"teacher_disagreement_score":0.013147739,"about_ca_system_score_codex":0.0005264793,"about_ca_system_score_gemma":0.00036714895,"threshold_uncertainty_score":0.04398358},"labels":[],"label_agreement":null},{"id":"W4405181189","doi":"10.1158/1538-8514.cancerchem24-a001","title":"Abstract A001: Navigating the future of therapeutic development: innovations in safety and efficacy through advanced research methodologies and nanotechnology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacogenomics; Risk analysis (engineering); SAFER; Drug delivery; Computer science; Medicine; Nanotechnology; Pharmacology","score_opus":0.10169475308274675,"score_gpt":0.42888031368134283,"score_spread":0.32718556059859605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181189","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020876462,0.12654437,0.15442748,0.2243375,0.033726078,0.0004429144,0.000982128,0.0018220986,0.436841],"genre_scores_gemma":[0.3236901,0.18264894,0.1628567,0.026801,0.017766396,0.0005167123,0.0011805766,0.0010105951,0.28352904],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9986658,0.00040989748,0.000045801582,0.00013142594,0.0006505743,0.000096471806],"domain_scores_gemma":[0.9978666,0.0008303742,0.00017625261,0.000127851,0.0006933859,0.0003055233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027583465,0.0006611169,0.00035915204,0.0008808211,0.0010560286,0.005134009,0.00093580567,0.0033307613,0.029576156],"category_scores_gemma":[0.002506778,0.0002684872,0.00051900477,0.000751894,0.0019364438,0.0038802351,0.0021934635,0.0037109074,0.00772753],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014366076,0.00021059728,0.00066139747,0.0016530278,0.000033130516,0.00034365393,0.00028013936,0.0034450432,0.016467584,0.49771717,0.22605355,0.25299108],"study_design_scores_gemma":[0.000040313887,0.00029672091,0.0007200032,0.0007968938,0.000022603042,0.00042109512,0.00031516948,0.008482401,0.010303892,0.19846404,0.7800852,0.000051653442],"about_ca_topic_score_codex":0.00074397295,"about_ca_topic_score_gemma":0.00067107956,"teacher_disagreement_score":0.029576156,"about_ca_system_score_codex":0.0017342081,"about_ca_system_score_gemma":0.0036517926,"threshold_uncertainty_score":0.0989421},"labels":[],"label_agreement":null},{"id":"W4405181191","doi":"10.1158/1538-8514.cancerchem24-ia013","title":"Abstract IA013: Discovery of the dual A2A/A2B receptor antagonist MK-1088 for the treatment of solid tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Receptor; Adenosine receptor; Antagonist; Adenosine A2A receptor; Pharmacology; Chemistry; Medicine; Internal medicine; Agonist","score_opus":0.021162784562571205,"score_gpt":0.30132039662547233,"score_spread":0.28015761206290113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8508792,0.044870313,0.023378782,0.0040509133,0.0010389031,0.00068836624,0.0023142516,0.0007691565,0.07201012],"genre_scores_gemma":[0.92642796,0.016288942,0.0133334445,0.0008319574,0.00014215898,0.00018767455,0.0011553614,0.000054679935,0.04157777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999685,0.000004698305,0.0000024583985,0.0000061809315,0.000010071899,0.000008063907],"domain_scores_gemma":[0.99997973,0.0000017598002,0.0000031498942,0.0000010479365,0.000004761404,0.00000953428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008445199,0.00023373165,0.00018214798,0.00022488052,0.00011842842,0.00029735852,0.00019447945,0.00025203626,0.003159031],"category_scores_gemma":[0.00008375329,0.00008543705,0.00011323255,0.000110983296,0.000098021694,0.00014923881,0.00017937551,0.00052078377,0.0012091674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047173354,0.0002125047,0.00034658713,0.0002653496,0.000017195825,0.00035937355,0.000066244786,0.00043281107,0.89477015,0.0021456913,0.0071503385,0.09376195],"study_design_scores_gemma":[0.00062668533,0.0066242665,0.005242093,0.00015114312,0.00008418393,0.0024905996,0.00008053881,0.0043039387,0.80980146,0.0006945416,0.16986054,0.00004001435],"about_ca_topic_score_codex":0.000420934,"about_ca_topic_score_gemma":0.00092814426,"teacher_disagreement_score":0.003159031,"about_ca_system_score_codex":0.00026240264,"about_ca_system_score_gemma":0.00022334608,"threshold_uncertainty_score":0.010567963},"labels":[],"label_agreement":null},{"id":"W4405181193","doi":"10.1158/1538-8514.cancerchem24-a018","title":"Abstract A018: Somatic mutations in the <i>PIK3CA</i> gene and its prognostic implications among Ethiopian Breast cancer patients","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Mutation; Medicine; TaqMan; Oncology; Immunohistochemistry; Internal medicine; Cancer; Proportional hazards model; Somatic cell; Cancer research; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.013527528709464463,"score_gpt":0.27751536784514025,"score_spread":0.2639878391356758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992181,0.00015633818,0.00003929485,0.000036452246,0.000005983386,0.0000033690621,0.00020915513,0.0000016698057,0.00032954998],"genre_scores_gemma":[0.99958056,0.000061578074,0.000046046625,0.000019759733,0.000006237019,0.0000023855266,0.00011853002,6.913841e-7,0.00016437333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999069,0.000017673858,0.000011994709,0.000022825281,0.000016751315,0.000023779374],"domain_scores_gemma":[0.9997608,0.00004940544,0.00009428929,0.000007721069,0.000041621886,0.000046176006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019683337,0.00015608293,0.00012871946,0.0005258344,0.00039053592,0.0004487808,0.00013201164,0.00017145429,0.001836192],"category_scores_gemma":[0.0005000922,0.000111669375,0.00016314861,0.0005625096,0.00014306465,0.00016985589,0.00014860662,0.00021905573,0.00025442237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020536406,0.000028289433,0.99590033,0.0000144968335,0.000015481384,0.0005476197,0.00007786517,0.000037295926,0.00089174265,0.000015440246,0.000212588,0.0020534429],"study_design_scores_gemma":[0.000012004299,0.00016804381,0.9925154,0.000021820035,0.00004737941,0.0044621145,0.0007037886,0.00029313425,0.0008464428,0.000061231876,0.00086104823,0.0000076601145],"about_ca_topic_score_codex":0.0023567777,"about_ca_topic_score_gemma":0.0015482287,"teacher_disagreement_score":0.0023567777,"about_ca_system_score_codex":0.00023829144,"about_ca_system_score_gemma":0.00022148754,"threshold_uncertainty_score":0.0061426163},"labels":[],"label_agreement":null},{"id":"W4405181201","doi":"10.1158/1538-8514.cancerchem24-a015","title":"Abstract A015: Design and deciphering of precision peptide inhibitors for cancer stemness using generative deep learning and molecular dynamics simulations","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Machine Learning in Bioinformatics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University","funders":"","keywords":"Computational biology; Peptide; Molecular dynamics; Notch signaling pathway; Molecular mechanics; Amino acid; Biology; Deep learning; Chemistry; Artificial intelligence; Biochemistry; Computer science; Receptor","score_opus":0.020815070898189177,"score_gpt":0.32440934917473274,"score_spread":0.30359427827654356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6838534,0.0015959161,0.2966903,0.0009814554,0.0001271,0.0002340631,0.0003003288,0.00069124164,0.01552619],"genre_scores_gemma":[0.9556227,0.00029062253,0.041724727,0.00014561361,0.000012088456,0.00012306684,0.00011742884,0.00003980103,0.0019239641],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99993837,0.0000113029755,0.0000026055843,0.000011691682,0.000019528226,0.000016433629],"domain_scores_gemma":[0.9998153,0.00007496157,0.000032943684,0.000010450783,0.000032811244,0.00003360171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003430659,0.00043289032,0.0005229217,0.0002496092,0.00017966925,0.00044630386,0.0005110839,0.0007034745,0.0016638547],"category_scores_gemma":[0.0005237288,0.00027343997,0.00043950827,0.00015211712,0.00038071655,0.0003456807,0.00035281968,0.0006138936,0.00022179312],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007129274,0.00007779451,0.00056816766,0.000062784944,0.000022880335,0.00006764882,0.000009661561,0.9797417,0.009434365,0.0022888018,0.00030333397,0.007351703],"study_design_scores_gemma":[0.000010557709,0.000046714747,0.00003329707,0.0000017786526,0.000003942029,0.0000045446614,0.0000022038375,0.9979101,0.0015520043,0.00025880185,0.00017414699,0.0000018618268],"about_ca_topic_score_codex":0.0023774407,"about_ca_topic_score_gemma":0.0021792515,"teacher_disagreement_score":0.0023774407,"about_ca_system_score_codex":0.0006216354,"about_ca_system_score_gemma":0.0009080851,"threshold_uncertainty_score":0.0055661798},"labels":[],"label_agreement":null},{"id":"W4405181202","doi":"10.1158/1538-8514.cancerchem24-a012","title":"Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Hypoxia-inducible factors; Small molecule; Pharmacology; Angiogenesis; Hypoxia (environmental); Pharmacophore; Drug discovery; Biology; Chemistry; Biochemistry; Gene","score_opus":0.027973633052217086,"score_gpt":0.3158958127372145,"score_spread":0.28792217968499745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8846532,0.01699101,0.053768247,0.0019692874,0.00040877043,0.0014556441,0.008166207,0.0007513321,0.031836323],"genre_scores_gemma":[0.95175934,0.004712893,0.020885404,0.00042076324,0.000044778542,0.00023149824,0.0052703135,0.00004547958,0.01662954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999206,0.000008988168,0.000005363273,0.000017454136,0.00003203539,0.000015458965],"domain_scores_gemma":[0.99995804,0.0000027231304,0.000010063662,0.000003372805,0.000011791257,0.000014016438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020422046,0.00047476424,0.0001744164,0.00023332487,0.00013177117,0.0003078866,0.0003434971,0.00034540184,0.0019032311],"category_scores_gemma":[0.00012520551,0.00009617814,0.00018570427,0.00017382982,0.00012091961,0.00019568477,0.00013199629,0.00039716504,0.00083787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038363755,0.00022054353,0.00038564188,0.00024275942,0.000018731382,0.000169438,0.000017966047,0.0014120574,0.96264404,0.0013717399,0.0026134665,0.030520072],"study_design_scores_gemma":[0.00017843978,0.001702984,0.0013777518,0.000027890723,0.00002923486,0.00065049523,0.000013044821,0.004833344,0.9594633,0.00017937135,0.031520702,0.000023402345],"about_ca_topic_score_codex":0.0012528416,"about_ca_topic_score_gemma":0.0016068843,"teacher_disagreement_score":0.0019032311,"about_ca_system_score_codex":0.0004927954,"about_ca_system_score_gemma":0.0005975193,"threshold_uncertainty_score":0.006366968},"labels":[],"label_agreement":null},{"id":"W4405181206","doi":"10.1158/1538-8514.cancerchem24-ia004","title":"Abstract IA004: Overcoming traditional design limitations with AI-based discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Drug discovery; Cancer; Clinical trial; Medicine; Drug; Adverse effect; Cancer therapy; Computational biology; Computer science; Pharmacology; Bioinformatics; Biology; Internal medicine","score_opus":0.11281916508748142,"score_gpt":0.3286391155321317,"score_spread":0.2158199504446503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181206","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007833755,0.003866682,0.93516004,0.014772833,0.00077867176,0.00022563922,0.00040550972,0.0018740336,0.03508282],"genre_scores_gemma":[0.16391794,0.005794887,0.8108398,0.0038508489,0.00038891565,0.00079844263,0.0006812341,0.00066085934,0.013067083],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99397236,0.0035248145,0.00022240882,0.00043402976,0.001717267,0.00012907463],"domain_scores_gemma":[0.98720425,0.008929761,0.00045763448,0.0020360746,0.0011067148,0.0002655196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0115478095,0.0008211851,0.00089306606,0.0009212457,0.00094230176,0.0036103206,0.0020160011,0.0013041873,0.008082189],"category_scores_gemma":[0.02560834,0.00057480234,0.00084070023,0.0011761424,0.0028400994,0.0031194137,0.0022719996,0.0034686085,0.0025270274],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027110867,0.00013516455,0.001670809,0.0011793586,0.00019613434,0.00011722265,0.0002611019,0.0877413,0.0037396217,0.54582846,0.037910365,0.3209493],"study_design_scores_gemma":[0.00014401275,0.00022474393,0.00037214716,0.00033599956,0.000094346484,0.00019216107,0.00009246026,0.31867453,0.004726173,0.528032,0.14704667,0.00006474415],"about_ca_topic_score_codex":0.0012575747,"about_ca_topic_score_gemma":0.0015764844,"teacher_disagreement_score":0.0115478095,"about_ca_system_score_codex":0.0013464226,"about_ca_system_score_gemma":0.0038806277,"threshold_uncertainty_score":0.061071336},"labels":[],"label_agreement":null},{"id":"W4405181241","doi":"10.1158/1538-8514.cancerchem24-a016","title":"Abstract A016: Targeting calpain-1 and calpain-2 for prevention of breast cancer metastasis: In vivo insights and drug discovery approaches","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia; Queen's University","funders":"","keywords":"Calpain; In silico; Proteases; Cancer research; Metastasis; Small molecule; Peptide; Biology; Cancer cell; Cancer; In vivo; Chemistry; Biochemistry; Enzyme; Genetics; Gene","score_opus":0.02110762181405774,"score_gpt":0.2726137891838403,"score_spread":0.2515061673697826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9071125,0.030715495,0.045829616,0.001768897,0.00040749225,0.0007015288,0.0026189706,0.0008439302,0.010001635],"genre_scores_gemma":[0.9373691,0.013298517,0.03631242,0.0006227919,0.000063006795,0.0002358438,0.0025520967,0.00007303697,0.009473277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981385,0.000033107543,0.000013610107,0.000033056935,0.00008170886,0.000024667128],"domain_scores_gemma":[0.99990773,0.000017259123,0.0000250739,0.0000077434415,0.000017506825,0.000024723357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040225795,0.00065946754,0.00049462536,0.00031936917,0.00012858832,0.0005831048,0.00043005662,0.00054471585,0.0021488685],"category_scores_gemma":[0.00018418314,0.00020048927,0.0005622561,0.00021722648,0.0002062944,0.00027493655,0.00025297614,0.00078129204,0.0005853369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016783559,0.00017031464,0.00020037314,0.00016607321,0.000025357538,0.00010238989,0.0000079615065,0.0007098407,0.9917858,0.0003017093,0.000351926,0.006010401],"study_design_scores_gemma":[0.0002100415,0.002335392,0.0013803705,0.0000310947,0.000102602775,0.00060609786,0.000023336721,0.006459167,0.9736859,0.0002485483,0.014899758,0.000017615934],"about_ca_topic_score_codex":0.00050516735,"about_ca_topic_score_gemma":0.0008553214,"teacher_disagreement_score":0.0021488685,"about_ca_system_score_codex":0.00036874902,"about_ca_system_score_gemma":0.00035873184,"threshold_uncertainty_score":0.007188678},"labels":[],"label_agreement":null},{"id":"W4405181306","doi":"10.1158/1538-8514.cancerchem24-a004","title":"Abstract A004: Broad and synergistic anti-tumor effects of small-molecule inhibitors of hypoxia inducible factors when paired with immune checkpoint blockade","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Immune checkpoint; Immune system; Tumor microenvironment; Cancer; Metastasis; Immunotherapy; Angiogenesis; Blockade; Tumor progression; Medicine; Hypoxia (environmental); Tolerability; Cancer cell; Pharmacology; Immunology; Chemistry; Receptor; Internal medicine; Adverse effect","score_opus":0.012570323182186401,"score_gpt":0.23839274607863178,"score_spread":0.22582242289644539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509367,0.013859419,0.00434256,0.0011606474,0.001037843,0.00041693845,0.0023270247,0.000914086,0.025004841],"genre_scores_gemma":[0.96625024,0.0064252703,0.0046986584,0.00046345533,0.00023005223,0.00025879382,0.002011687,0.000068102534,0.019593759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999269,0.000013083328,0.0000058625424,0.000011137252,0.000023342556,0.000019635194],"domain_scores_gemma":[0.99994266,0.000011846733,0.000010051441,0.000004049504,0.000007596985,0.000023798511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013270782,0.00050637714,0.00040343037,0.00064784946,0.00017929242,0.00034798533,0.00033695152,0.0003852678,0.009201568],"category_scores_gemma":[0.00012280777,0.00013122085,0.00042276757,0.0003524393,0.00017241498,0.00022507552,0.00021001282,0.00079603895,0.0010485137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004651232,0.0021926425,0.00048648965,0.00058249873,0.00012356837,0.00031902263,0.000029729468,0.0009276109,0.91163695,0.00058969454,0.0067084334,0.07175218],"study_design_scores_gemma":[0.0016348078,0.02337207,0.0070807035,0.000056645353,0.00027180978,0.0010338222,0.000043202308,0.0023135066,0.9356322,0.0002628483,0.028270738,0.000027674274],"about_ca_topic_score_codex":0.00043501746,"about_ca_topic_score_gemma":0.0009445777,"teacher_disagreement_score":0.009201568,"about_ca_system_score_codex":0.00024758978,"about_ca_system_score_gemma":0.00043442985,"threshold_uncertainty_score":0.030782282},"labels":[],"label_agreement":null},{"id":"W4405181440","doi":"10.1158/1538-8514.cancerchem24-pr003","title":"Abstract PR003: Structure-guided design and optimization of small molecule CD73 inhibitors with excellent drug-like properties: discovery of quemliclustat","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Small molecule; Cancer; Pancreatic cancer; Drug; Medicine; Pharmacology; Drug discovery; Cancer research; Adenosine; Chemistry; Biochemistry; Internal medicine","score_opus":0.020507422312418623,"score_gpt":0.2466415928509153,"score_spread":0.2261341705384967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9015,0.017329054,0.047626812,0.0020340283,0.00033947022,0.0016499433,0.0034622692,0.0008891008,0.025169313],"genre_scores_gemma":[0.9273062,0.01190592,0.04086578,0.0008191087,0.000056903405,0.0004067578,0.002704419,0.00012520952,0.01580971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999105,0.0000118406815,0.0000054143375,0.000017320508,0.000034580105,0.00002038408],"domain_scores_gemma":[0.99993336,0.000006609882,0.000017860066,0.000002579603,0.000021241092,0.000018359855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002130033,0.00047862154,0.00037977012,0.00036931952,0.00016687922,0.0004750922,0.00043425136,0.0003833484,0.0022131137],"category_scores_gemma":[0.000200885,0.00015551604,0.00035429667,0.0002436056,0.00019596616,0.00022377026,0.00020502722,0.00048936054,0.00057595567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011009332,0.0005755464,0.00053147424,0.0002955807,0.000085262436,0.00048511647,0.0000493335,0.014471672,0.9057982,0.00299092,0.0050046374,0.068611264],"study_design_scores_gemma":[0.002228082,0.008172198,0.0024290115,0.00008258765,0.00019286203,0.000835532,0.000051640887,0.033641804,0.89541084,0.00079222274,0.05608824,0.00007500525],"about_ca_topic_score_codex":0.0020635386,"about_ca_topic_score_gemma":0.0050026807,"teacher_disagreement_score":0.0022131137,"about_ca_system_score_codex":0.0008967586,"about_ca_system_score_gemma":0.0007247585,"threshold_uncertainty_score":0.007403612},"labels":[],"label_agreement":null},{"id":"W4405181441","doi":"10.1158/1538-8514.cancerchem24-ia017","title":"Abstract IA017: Transferrin receptor targeting chimeras (TransTACs) for targeted degradation of membrane and extracellular proteins in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transferrin receptor; Epidermal growth factor receptor; Cancer cell; Cancer; Cancer research; Targeted therapy; Extracellular; Receptor; Biology; Chemistry; Medicine; Cell biology; Biochemistry; Internal medicine","score_opus":0.04099871369861158,"score_gpt":0.3359801257257002,"score_spread":0.2949814120270886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8346639,0.037618127,0.06936464,0.0030690269,0.0009648495,0.00048273403,0.0034919619,0.0028411767,0.047503587],"genre_scores_gemma":[0.94690096,0.0079079075,0.017933844,0.0003101501,0.00004622322,0.00011801498,0.0022145545,0.00020374659,0.024364645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998534,0.00002408038,0.000011605575,0.000030173562,0.00005252175,0.00002819395],"domain_scores_gemma":[0.9999349,0.000006887597,0.000014989075,0.000008898808,0.000016012524,0.000018307694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002666502,0.00043115573,0.00031125286,0.00049631356,0.00026300026,0.00045986642,0.00041389195,0.00043637952,0.0037601853],"category_scores_gemma":[0.00013098757,0.0001907184,0.0003145384,0.0003949806,0.00027235397,0.00034877646,0.0003365908,0.00070979894,0.001023566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003685905,0.00005870429,0.0002617889,0.0001361777,0.000023884924,0.0001719339,0.000043913882,0.0004237582,0.97454923,0.0023426367,0.0032985692,0.018320737],"study_design_scores_gemma":[0.00007709318,0.00031235875,0.0011903304,0.000014209259,0.000034780478,0.0017298794,0.00002175266,0.001956599,0.9617902,0.00014978462,0.03270932,0.000013833189],"about_ca_topic_score_codex":0.0021576139,"about_ca_topic_score_gemma":0.0016153705,"teacher_disagreement_score":0.0037601853,"about_ca_system_score_codex":0.00097146514,"about_ca_system_score_gemma":0.0006958191,"threshold_uncertainty_score":0.012579083},"labels":[],"label_agreement":null},{"id":"W4405181476","doi":"10.1158/1538-8514.cancerchem24-ia020","title":"Abstract IA020: Discovery of brain-penetrant inhibitors for the treatment of BRAF mutant tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Penetrant (biochemical); Cancer research; Mutant; Cancer; Kinase; Neuroblastoma RAS viral oncogene homolog; Medicine; Pharmacology; Biology; Gene; Genetics; Internal medicine","score_opus":0.020412385785389217,"score_gpt":0.28341883247375693,"score_spread":0.2630064466883677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6699448,0.09708267,0.04922945,0.008519621,0.003528817,0.0028787334,0.009175372,0.002603116,0.1570373],"genre_scores_gemma":[0.7981963,0.05161496,0.036238972,0.0044393656,0.0008088564,0.00074031425,0.006623308,0.00022297073,0.101114966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992347,0.000014424396,0.000004294196,0.000012310596,0.00002364483,0.000021905778],"domain_scores_gemma":[0.9999255,0.0000050829617,0.000008526089,0.0000028605518,0.00001942274,0.000038537248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028121754,0.00058731815,0.0003573605,0.0005980392,0.00016071185,0.00052369304,0.0004014399,0.00051615835,0.0035257884],"category_scores_gemma":[0.00016033271,0.00019991641,0.0003499565,0.00022360432,0.00016537422,0.00019993205,0.0002754529,0.0009799107,0.0015083561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096289377,0.00085111894,0.0007325149,0.0005327543,0.00008629435,0.0008741837,0.00008504362,0.0022679681,0.744804,0.0053233407,0.033839554,0.20964034],"study_design_scores_gemma":[0.0032442731,0.016961535,0.008140107,0.00023708769,0.00026059544,0.0033222528,0.000062370316,0.009328233,0.5939455,0.002223823,0.3621361,0.0001380851],"about_ca_topic_score_codex":0.0012547199,"about_ca_topic_score_gemma":0.0027289714,"teacher_disagreement_score":0.0035257884,"about_ca_system_score_codex":0.00043146673,"about_ca_system_score_gemma":0.0007608758,"threshold_uncertainty_score":0.011794925},"labels":[],"label_agreement":null},{"id":"W4405181481","doi":"10.1158/1538-8514.cancerchem24-ia010","title":"Abstract IA010: Bioengineering cell-based therapeutics","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Medicine; Immunotherapy; Immune system; Cancer immunotherapy; Clinical trial; Immunology; Cancer research; Internal medicine","score_opus":0.02177684781242973,"score_gpt":0.3098515751553033,"score_spread":0.2880747273428736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181481","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05975919,0.15714452,0.109561816,0.020004869,0.019453099,0.0012759742,0.0070860996,0.0034023353,0.62231207],"genre_scores_gemma":[0.20212643,0.08724306,0.050990127,0.00439191,0.0020209665,0.00076093484,0.006576835,0.00044748804,0.64544225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997527,0.000032628897,0.000014396592,0.000035622703,0.00014021307,0.000024411245],"domain_scores_gemma":[0.999913,0.00001788972,0.000011427886,0.000009739347,0.00003064857,0.000017312892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043547677,0.00072104175,0.00030849242,0.0010114136,0.0003839896,0.0016333044,0.0006250342,0.00083489896,0.030853426],"category_scores_gemma":[0.0002646796,0.00025131518,0.0002821683,0.0005258434,0.0004475368,0.0006383166,0.00059603475,0.0010906309,0.01621942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035342903,0.00027266663,0.00048486065,0.00198821,0.000025068623,0.00032970865,0.00015409014,0.0009989218,0.46024704,0.05659685,0.20270969,0.2758394],"study_design_scores_gemma":[0.00006937374,0.00023294416,0.0009366938,0.00016372859,0.000017618453,0.00060620473,0.000033788496,0.0008683481,0.17534639,0.00406702,0.8176409,0.000017017766],"about_ca_topic_score_codex":0.0011023885,"about_ca_topic_score_gemma":0.0009094012,"teacher_disagreement_score":0.030853426,"about_ca_system_score_codex":0.0013187922,"about_ca_system_score_gemma":0.00091678137,"threshold_uncertainty_score":0.10321498},"labels":[],"label_agreement":null},{"id":"W4405181517","doi":"10.1158/1538-8514.cancerchem24-a002","title":"Abstract A002: Computational identification for missense mutations of bladder cancer candidate genes using TCGA datasets","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Missense mutation; Genetics; Biology; Gene; Bladder cancer; Cancer; Mutation; Genome; Cancer research","score_opus":0.05754441736755274,"score_gpt":0.38405656591091075,"score_spread":0.326512148543358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66227275,0.003950076,0.03005263,0.0032141744,0.00044367893,0.0006733068,0.28120723,0.014028558,0.0041576005],"genre_scores_gemma":[0.5838256,0.0011297953,0.047423404,0.0008316696,0.00015624636,0.0010034563,0.36322293,0.0006816904,0.0017252518],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9995486,0.00016157536,0.000035634697,0.00015207261,0.000059690883,0.000042407417],"domain_scores_gemma":[0.99669135,0.002698146,0.00011765112,0.00017727049,0.0001853733,0.0001302052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012491501,0.0015352439,0.0010835083,0.004252412,0.0008336242,0.0012293174,0.0017332771,0.0013323233,0.0068747504],"category_scores_gemma":[0.006094563,0.00057220476,0.002893916,0.0025128794,0.0003361837,0.0003744249,0.0009050041,0.0010667451,0.0009480647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047586714,0.0014300639,0.22136813,0.0046912394,0.007736383,0.0037441151,0.00040075698,0.38048944,0.007206104,0.0051052608,0.26624432,0.09682549],"study_design_scores_gemma":[0.0017432258,0.0004911014,0.04524494,0.00019507206,0.0014742579,0.000889794,0.0002950361,0.920577,0.0018552968,0.006964991,0.02018036,0.000088873945],"about_ca_topic_score_codex":0.028416155,"about_ca_topic_score_gemma":0.03995469,"teacher_disagreement_score":0.028416155,"about_ca_system_score_codex":0.0009226359,"about_ca_system_score_gemma":0.0017953081,"threshold_uncertainty_score":0.056501508},"labels":[],"label_agreement":null},{"id":"W4405181528","doi":"10.1158/1538-8514.cancerchem24-a020","title":"Abstract A020: Liposomal topotecan with low-intensity focused ultrasound utilization to improve drug penetration with brain parenchyma in pediatric brain tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Topotecan; Liposome; Medicine; Pharmacology; Drug; Blood–brain barrier; Drug delivery; In vivo; Brain tumor; Chemotherapy; Chemistry; Internal medicine; Pathology; Biology; Central nervous system","score_opus":0.01306792124204388,"score_gpt":0.25162254319628446,"score_spread":0.2385546219542406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991533,0.0022194546,0.005153828,0.00007776405,0.000019972851,0.00006334769,0.00011231499,0.00007873002,0.0007415646],"genre_scores_gemma":[0.992716,0.0011378906,0.004732727,0.000050992167,0.000009816486,0.0000482266,0.00014616392,0.000019740186,0.0011384571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999474,0.0000069248563,0.0000038802673,0.000011141177,0.00001780834,0.000012809776],"domain_scores_gemma":[0.9999621,0.000006149618,0.000011270844,0.000001945481,0.000008517771,0.000010010339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010715269,0.00030545433,0.00018938794,0.00020247027,0.00007262051,0.00025182657,0.0002096663,0.00027764554,0.00084916595],"category_scores_gemma":[0.00010249856,0.000075137854,0.00014302183,0.0001464965,0.00014982898,0.00021255937,0.0001472671,0.0002693425,0.00018269154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011135656,0.000035688525,0.00008350463,0.00004811755,0.0000053856957,0.000044281864,0.0000074121926,0.00014876958,0.9969676,0.000039731876,0.00004595811,0.0024621927],"study_design_scores_gemma":[0.000021771566,0.00050220324,0.00090092735,0.0000037008183,0.000019956204,0.0001300643,0.000009927866,0.0011369162,0.9963993,0.000010633701,0.0008606249,0.0000039433835],"about_ca_topic_score_codex":0.0014678976,"about_ca_topic_score_gemma":0.0011826921,"teacher_disagreement_score":0.0014678976,"about_ca_system_score_codex":0.00026898016,"about_ca_system_score_gemma":0.00029294772,"threshold_uncertainty_score":0.0029186606},"labels":[],"label_agreement":null},{"id":"W4405181578","doi":"10.1158/1538-8514.cancerchem24-ia022","title":"Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"GNAQ; Cancer research; Melanoma; Antibody-drug conjugate; Cancer; In vivo; Medicine; Antibody; Biology; Monoclonal antibody; Internal medicine; Immunology; Mutation","score_opus":0.04368181140493892,"score_gpt":0.34694866315720063,"score_spread":0.3032668517522617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830791,0.00352244,0.0059247734,0.00022665683,0.00007891596,0.00037971817,0.00082676637,0.0002635295,0.0056981524],"genre_scores_gemma":[0.9900969,0.0012514563,0.002884183,0.00007657006,0.000020337322,0.000105739564,0.0010463087,0.000026556329,0.004491915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999348,0.000011039134,0.000004181668,0.000013150468,0.000016248125,0.00002065297],"domain_scores_gemma":[0.9999715,0.0000021164406,0.0000084244375,0.0000022315214,0.0000048751513,0.000010733257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012614853,0.00042506206,0.00022731455,0.00024083682,0.00009580777,0.00023183337,0.00027743913,0.00029215252,0.0012268282],"category_scores_gemma":[0.00007354714,0.00011762137,0.00012641345,0.00013643957,0.00011566638,0.00013902453,0.00014830129,0.00044602848,0.0005284006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000868321,0.000347417,0.00047767835,0.0001280876,0.000018402648,0.00018986313,0.000022186974,0.0005449868,0.9750845,0.00021297635,0.00084380433,0.021261813],"study_design_scores_gemma":[0.00060692814,0.0061796065,0.0029204024,0.000011127727,0.00004539495,0.0012630946,0.000010323283,0.0020920946,0.9758649,0.00003228924,0.010965724,0.000008119972],"about_ca_topic_score_codex":0.0005722806,"about_ca_topic_score_gemma":0.0005322136,"teacher_disagreement_score":0.0012268282,"about_ca_system_score_codex":0.0003899158,"about_ca_system_score_gemma":0.00027266366,"threshold_uncertainty_score":0.004104197},"labels":[],"label_agreement":null},{"id":"W4405181590","doi":"10.1158/1538-8514.cancerchem24-a007","title":"Abstract A007: Anti-cancer activity of (Z)-endoxifen-related compounds in ERα+ breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Estrogen receptor; Estrogen; Tamoxifen; Estrogen receptor alpha; Chemistry; Cancer research; Cancer; Breast cancer; Cell culture; Cell growth; Pharmacology; Cancer cell; Internal medicine; Endocrinology; Biology; Medicine; Biochemistry; Genetics","score_opus":0.011732084392369386,"score_gpt":0.28999987400331206,"score_spread":0.2782677896109427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90225565,0.029380905,0.005283597,0.001383151,0.0008529477,0.00043854216,0.008775299,0.00066813536,0.05096186],"genre_scores_gemma":[0.87671226,0.025524614,0.0076479423,0.0008944894,0.00060801115,0.00021976649,0.0104052285,0.00009815386,0.07788949],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992514,0.000010113407,0.0000046690548,0.000008989048,0.00003783264,0.000013304401],"domain_scores_gemma":[0.999918,0.000014953355,0.000015585314,0.0000040264763,0.000028923854,0.0000184786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015182472,0.00034866694,0.00019510405,0.0004448763,0.00017048285,0.00017739653,0.00019307266,0.00026488965,0.018272214],"category_scores_gemma":[0.00009440183,0.00006406165,0.0002410206,0.0003346427,0.00008958951,0.0001268202,0.00014051748,0.00040197102,0.002717596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002009574,0.0004985473,0.001095102,0.001027067,0.00003707582,0.00031701822,0.000025946909,0.00027336602,0.89989895,0.00037605685,0.0053726193,0.08906861],"study_design_scores_gemma":[0.00026297587,0.007819841,0.015807815,0.000097282886,0.0000934805,0.0011983725,0.000057919224,0.00044697584,0.90340835,0.00022567152,0.070564196,0.000017120172],"about_ca_topic_score_codex":0.0004797994,"about_ca_topic_score_gemma":0.00060231995,"teacher_disagreement_score":0.018272214,"about_ca_system_score_codex":0.00015850543,"about_ca_system_score_gemma":0.00031410268,"threshold_uncertainty_score":0.06112665},"labels":[],"label_agreement":null},{"id":"W4405181601","doi":"10.1158/1538-8514.cancerchem24-pr004","title":"Abstract PR004: Brain penetrant allosteric EGFR inhibitors for NSCLC","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; T790M; Osimertinib; Gefitinib; Cancer research; Pharmacology; Epidermal growth factor receptor; EGFR inhibitors; In vivo; Kinome; Mutant; Medicine; Chemistry; Allosteric regulation; Kinase; Cancer; Biology; Internal medicine; Receptor; Biochemistry; Gene; Genetics","score_opus":0.026207182971794737,"score_gpt":0.35854694130504794,"score_spread":0.3323397583332532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181601","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041218955,0.12770082,0.016372638,0.062218823,0.06992328,0.0016729893,0.007923043,0.0076738233,0.6652958],"genre_scores_gemma":[0.06668942,0.048165772,0.0040143486,0.004942459,0.0056968303,0.00017374715,0.0027450945,0.00017462157,0.86739767],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998677,0.000011239127,0.0000071270383,0.00002289253,0.0000688157,0.000022282224],"domain_scores_gemma":[0.9999112,0.000007851224,0.000011701783,0.0000049264395,0.000032461056,0.00003187391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002833561,0.000748668,0.00031353693,0.0007451344,0.0003302818,0.00076273497,0.0012375779,0.0009485462,0.06006686],"category_scores_gemma":[0.00027630854,0.00015140617,0.00029805192,0.00045176558,0.00027596366,0.00063673925,0.00045132873,0.00087837846,0.016187934],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037802625,0.00015313474,0.00022265699,0.0006660528,0.00001539836,0.00068736076,0.000024405032,0.00033694445,0.027466506,0.0056708157,0.66841334,0.29596546],"study_design_scores_gemma":[0.00024616136,0.00065688055,0.0011268519,0.00012488932,0.000028300848,0.001055295,0.000024160987,0.00039417777,0.012026066,0.0010648251,0.983232,0.000020354557],"about_ca_topic_score_codex":0.0013016843,"about_ca_topic_score_gemma":0.0029083136,"teacher_disagreement_score":0.06006686,"about_ca_system_score_codex":0.0007358852,"about_ca_system_score_gemma":0.0006980022,"threshold_uncertainty_score":0.20094365},"labels":[],"label_agreement":null},{"id":"W4405181612","doi":"10.1158/1538-8514.cancerchem24-a013","title":"Abstract A013: Prioritization of Eleven-Nineteen-Leukemia (ENL) inhibitors as orally available drug candidates for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Leukemia; In vivo; Medicine; Cancer; Pharmacology; Drug; Cancer research; Acute leukemia; Potency; Immunology; In vitro; Biology; Internal medicine; Biochemistry","score_opus":0.010768484327422797,"score_gpt":0.2777045741678547,"score_spread":0.26693608984043193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9240882,0.02427798,0.014747934,0.0015686657,0.00043578347,0.0013284913,0.003497292,0.0007724149,0.029283237],"genre_scores_gemma":[0.95172286,0.01181848,0.014611561,0.0006104496,0.00007867509,0.00024220119,0.0030042683,0.00008829286,0.017823342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998821,0.000016283955,0.000010774221,0.000022405393,0.00004237281,0.00002619131],"domain_scores_gemma":[0.9999186,0.000008262223,0.000017955968,0.00000475136,0.000023651999,0.000026807082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023273609,0.00048381585,0.0005049452,0.00043509435,0.00015876513,0.0005863752,0.00028584152,0.00026134052,0.0054905578],"category_scores_gemma":[0.00016106377,0.00013438682,0.0002431916,0.00029297004,0.00013481911,0.0002876853,0.00026243518,0.0006179759,0.0011933998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013547216,0.0004185297,0.0007999973,0.0003820046,0.00003887742,0.00026445722,0.00002576224,0.001116855,0.9331166,0.0011617774,0.0034678476,0.05785246],"study_design_scores_gemma":[0.00081955007,0.006887231,0.0034352606,0.000072985546,0.00015915137,0.00072638725,0.000044363904,0.0034633253,0.9354547,0.00024702653,0.048650846,0.00003925749],"about_ca_topic_score_codex":0.0007259059,"about_ca_topic_score_gemma":0.0016396749,"teacher_disagreement_score":0.0054905578,"about_ca_system_score_codex":0.00038640125,"about_ca_system_score_gemma":0.0005729437,"threshold_uncertainty_score":0.018367767},"labels":[],"label_agreement":null},{"id":"W4405181643","doi":"10.1158/1538-8514.cancerchem24-pr001","title":"Abstract PR001: Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adenosine; Medicine; Adenosine receptor; Pharmacology; Adenosine A2A receptor; Receptor; Immunology; Internal medicine; Agonist","score_opus":0.016733300270360376,"score_gpt":0.29198112175010776,"score_spread":0.2752478214797474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7727448,0.06073539,0.079946905,0.0044084936,0.0014489094,0.002151843,0.0047749076,0.001376979,0.07241185],"genre_scores_gemma":[0.90513927,0.025807073,0.02466608,0.0023859148,0.00021620422,0.00041377556,0.0047100037,0.00008698961,0.036574647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999933,0.0000102545855,0.000003500999,0.00001481514,0.00002091239,0.000017609864],"domain_scores_gemma":[0.9999616,0.0000032620392,0.0000066785087,0.000002038204,0.000008679712,0.000017704042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020552262,0.0005565072,0.00029461086,0.0002977012,0.00012345341,0.0003667706,0.00044619731,0.00047552967,0.0032613191],"category_scores_gemma":[0.00015115949,0.00013267707,0.00031069343,0.0001638628,0.0001612883,0.00028444227,0.00029962804,0.00082801445,0.0013768111],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007941655,0.0010333412,0.0005774063,0.0010889343,0.00012871764,0.0011778043,0.00010112388,0.0031078502,0.8159025,0.0054793027,0.013479296,0.15712965],"study_design_scores_gemma":[0.002247245,0.016916398,0.004261457,0.00032212565,0.0002840898,0.0045997445,0.00008512402,0.014000756,0.7196712,0.0022411935,0.23525597,0.00011487223],"about_ca_topic_score_codex":0.00027024638,"about_ca_topic_score_gemma":0.0004953657,"teacher_disagreement_score":0.0032613191,"about_ca_system_score_codex":0.0002471167,"about_ca_system_score_gemma":0.00034215592,"threshold_uncertainty_score":0.010910213},"labels":[],"label_agreement":null},{"id":"W4405181656","doi":"10.1158/1538-8514.cancerchem24-ia006","title":"Abstract IA006: Progress, pitfalls and promise: the journey to effective and well tolerated DNA damage response inhibitor combinations in the clinic","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Tolerability; Medicine; Cancer; DNA damage; Poly ADP ribose polymerase; Pharmacology; Cancer research; Polymerase; DNA; Adverse effect; Internal medicine; Chemistry; Biochemistry","score_opus":0.032133666429144336,"score_gpt":0.368427072439368,"score_spread":0.33629340601022367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053613004,0.5807955,0.008352268,0.30961716,0.021146372,0.00014871993,0.00078678987,0.001012633,0.07277918],"genre_scores_gemma":[0.045500528,0.7148321,0.022871612,0.07940257,0.021552509,0.00020555173,0.0011859194,0.00045823236,0.113991044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987424,0.00034325972,0.000096494485,0.000094413575,0.0005925608,0.00013095832],"domain_scores_gemma":[0.9988018,0.0002722424,0.00017590472,0.000069661255,0.0003775086,0.0003028531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039440896,0.000804629,0.00084642577,0.00092851045,0.0008306235,0.0047568185,0.0010425121,0.002404566,0.018088106],"category_scores_gemma":[0.0028188226,0.00037564608,0.00043121778,0.0008246263,0.0015775274,0.0055327085,0.0013378877,0.006333761,0.010321229],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005277905,0.00022906775,0.00029282863,0.0009216112,0.000025096248,0.00027122375,0.00015252212,0.00036992374,0.0087578725,0.02483496,0.5153264,0.44829068],"study_design_scores_gemma":[0.00008837171,0.0004933789,0.0004354411,0.00037858228,0.000019932228,0.0006374032,0.00011382159,0.0003229403,0.003015565,0.008110655,0.98635626,0.000027728105],"about_ca_topic_score_codex":0.0010337052,"about_ca_topic_score_gemma":0.0036030775,"teacher_disagreement_score":0.018088106,"about_ca_system_score_codex":0.002246576,"about_ca_system_score_gemma":0.0025943308,"threshold_uncertainty_score":0.060510755},"labels":[],"label_agreement":null},{"id":"W4405181739","doi":"10.1158/1538-8514.cancerchem24-ia007","title":"Abstract IA007: Preclinical Approaches to Discovery and Development of Novel Combination Therapies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Identification (biology); Drug discovery; Computational biology; Combination therapy; Disease; Medicine; Computer science; Bioinformatics; Biology; Pharmacology","score_opus":0.19982647271638201,"score_gpt":0.37102503845031026,"score_spread":0.17119856573392825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181739","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16992553,0.041605886,0.6119596,0.010761215,0.0013866464,0.0033959446,0.004685293,0.0053393263,0.15094054],"genre_scores_gemma":[0.61197156,0.035864104,0.3098909,0.00259146,0.0005687609,0.0029094645,0.004118835,0.0005668097,0.031518098],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983286,0.00070678926,0.000082403305,0.00013932072,0.0006008221,0.00014213756],"domain_scores_gemma":[0.9992092,0.00026146605,0.00012151545,0.00014825305,0.00017025573,0.000089424095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033966512,0.0012747943,0.0011274065,0.0019970834,0.0005750522,0.0027030332,0.001689849,0.0010250049,0.007562765],"category_scores_gemma":[0.002014507,0.0007944499,0.00083149294,0.00091209396,0.0016864536,0.0016981871,0.0013152055,0.0044146837,0.0028019901],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014564894,0.0012024217,0.0017510381,0.001738153,0.00013276134,0.0005243197,0.00024377387,0.01659644,0.65861124,0.096900016,0.013359837,0.20748356],"study_design_scores_gemma":[0.0005621512,0.0099734,0.0032176801,0.00041044282,0.00026779922,0.0018957691,0.00020941989,0.040074136,0.7100104,0.032161426,0.20107828,0.00013905966],"about_ca_topic_score_codex":0.0008755261,"about_ca_topic_score_gemma":0.001299735,"teacher_disagreement_score":0.007562765,"about_ca_system_score_codex":0.0017140759,"about_ca_system_score_gemma":0.0019862754,"threshold_uncertainty_score":0.025299966},"labels":[],"label_agreement":null},{"id":"W4405181913","doi":"10.1158/1538-8514.cancerchem24-ia009","title":"Abstract IA009: An integrative approach to nanomedicine: Leveraging new tools to advance drug delivery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nanomedicine; Drug delivery; Context (archaeology); Medicine; Personalized medicine; Cancer; Nanotechnology; Computer science; Bioinformatics; Biology; Nanoparticle; Internal medicine","score_opus":0.028127996443314887,"score_gpt":0.2954347089554965,"score_spread":0.26730671251218163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181913","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15662733,0.07024597,0.5332876,0.034503028,0.005937267,0.0021762196,0.0032272097,0.0051760925,0.18881932],"genre_scores_gemma":[0.42973164,0.046664942,0.41202205,0.006753049,0.0011237395,0.0008793766,0.0022663584,0.00068651035,0.09987235],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99939954,0.00013031889,0.000033348864,0.00010568775,0.000278461,0.00005268303],"domain_scores_gemma":[0.99964523,0.00007164664,0.00006783917,0.00004689041,0.0001023227,0.000066072935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016175121,0.0006998189,0.00062197377,0.0008728801,0.00051844976,0.0019519839,0.00081378594,0.0006332075,0.005895198],"category_scores_gemma":[0.00073338026,0.0003374239,0.00043997375,0.0005086717,0.0010977366,0.0012216932,0.0017632573,0.0016916454,0.0021279834],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030955274,0.00024819036,0.00049163465,0.0006743705,0.000061251274,0.00023820286,0.00017671323,0.0016485754,0.7226732,0.03964993,0.015926868,0.21790162],"study_design_scores_gemma":[0.000071158014,0.0011327314,0.0017423163,0.000140021,0.00012500465,0.0007878214,0.00012011208,0.0049460274,0.6533946,0.011894603,0.32556194,0.000083681116],"about_ca_topic_score_codex":0.00087150437,"about_ca_topic_score_gemma":0.0021165572,"teacher_disagreement_score":0.005895198,"about_ca_system_score_codex":0.0011825874,"about_ca_system_score_gemma":0.0018580623,"threshold_uncertainty_score":0.019721389},"labels":[],"label_agreement":null},{"id":"W4405181965","doi":"10.1158/1538-8514.cancerchem24-ia003","title":"Abstract IA003: Synthetic lethality: Pathways to therapeutic discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Synthetic lethality; Computational biology; Cancer; Context (archaeology); Drug discovery; Genome; Chromatin; Biology; CRISPR; DNA repair; Bioinformatics; DNA; Genetics; Gene","score_opus":0.02024564830007196,"score_gpt":0.3161788515262899,"score_spread":0.2959332032262179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181965","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053164057,0.10824989,0.18481943,0.18539108,0.014824063,0.0009489884,0.0054047913,0.008044955,0.4391528],"genre_scores_gemma":[0.4362331,0.09951027,0.0595038,0.021588452,0.0044890926,0.0007071445,0.0031251677,0.0008030075,0.37403992],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9995943,0.00010840933,0.000018375014,0.000049389862,0.00017464465,0.00005489089],"domain_scores_gemma":[0.99964356,0.000075955504,0.00007367696,0.00003073847,0.00007742287,0.00009863036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095208065,0.00091024075,0.0004997465,0.00078655814,0.0004152629,0.0027742237,0.00071366003,0.00106502,0.023373554],"category_scores_gemma":[0.0010486811,0.00020817427,0.0003722464,0.00044279467,0.0010939024,0.0012550863,0.0011545258,0.002169284,0.006481698],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012332957,0.00030627364,0.00075671024,0.0010779728,0.00004527312,0.00082647015,0.00016554582,0.0014831133,0.17116372,0.2125011,0.2289935,0.38144708],"study_design_scores_gemma":[0.00019878865,0.00090695603,0.0015467221,0.0002101616,0.000047779075,0.0016520473,0.00013096219,0.002505041,0.09688438,0.065340206,0.8305148,0.00006212027],"about_ca_topic_score_codex":0.00045375066,"about_ca_topic_score_gemma":0.0005985473,"teacher_disagreement_score":0.023373554,"about_ca_system_score_codex":0.0019764155,"about_ca_system_score_gemma":0.0011745649,"threshold_uncertainty_score":0.07819229},"labels":[],"label_agreement":null},{"id":"W4405181970","doi":"10.1158/1538-8514.cancerchem24-ia018","title":"Abstract IA018: Pan-RAF-MEK molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS-MAPK pathway","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"MAPK/ERK pathway; Cancer research; MEK inhibitor; Tolerability; Phosphorylation; Medicine; Kinase; Cancer; Chemistry; Pharmacology; Internal medicine; Biochemistry; Adverse effect","score_opus":0.012600471978043988,"score_gpt":0.2521511944222847,"score_spread":0.2395507224442407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181970","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42790097,0.072914,0.027956123,0.003798275,0.0037762648,0.0017421043,0.012215971,0.0058870874,0.44380918],"genre_scores_gemma":[0.6370134,0.03491423,0.014452103,0.0008897125,0.0004564429,0.00054529804,0.013967813,0.00026607455,0.29749498],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.000008671784,0.0000073415827,0.00001701156,0.000058617752,0.000032645734],"domain_scores_gemma":[0.99993324,0.0000040907184,0.0000071623035,0.000005728106,0.00001647183,0.000033366483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016429633,0.0008559426,0.00034371723,0.0006286076,0.0002989612,0.00044173354,0.0004594916,0.0005886895,0.018796027],"category_scores_gemma":[0.00009958235,0.00026694295,0.0002529952,0.0003819096,0.0001845634,0.0003067284,0.0003395314,0.0009055807,0.0069945026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010918883,0.0003407592,0.00036557775,0.00038523364,0.00002965805,0.00042167946,0.000042568405,0.00043341017,0.8797034,0.0023838733,0.033485886,0.08131607],"study_design_scores_gemma":[0.0006130146,0.0039635403,0.005127777,0.000078675526,0.00007543593,0.00204035,0.00004616361,0.0012030744,0.638427,0.000442089,0.34794623,0.00003662134],"about_ca_topic_score_codex":0.0018903391,"about_ca_topic_score_gemma":0.004130342,"teacher_disagreement_score":0.018796027,"about_ca_system_score_codex":0.00054599904,"about_ca_system_score_gemma":0.00071847986,"threshold_uncertainty_score":0.06287897},"labels":[],"label_agreement":null},{"id":"W4405181977","doi":"10.1158/1538-8514.cancerchem24-ia002","title":"Abstract IA002: Leveraging synthetic lethality for the development of novel cancer therapies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Genetic screen; Cancer; Lethal allele; Biology; RNA interference; Cancer cell; Gene; Population; Mutant; Cancer research; Computational biology; Genetics; Medicine","score_opus":0.04465749761615503,"score_gpt":0.3207776675550195,"score_spread":0.2761201699388645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181977","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055249818,0.20070735,0.18118604,0.07075201,0.07333953,0.0014622104,0.02149011,0.021569103,0.37424383],"genre_scores_gemma":[0.28408486,0.16396306,0.092168175,0.015677018,0.008920415,0.0013949061,0.021676064,0.0021664551,0.409949],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99953496,0.0000771818,0.000034238372,0.0000790192,0.00022015144,0.00005446226],"domain_scores_gemma":[0.9994411,0.00007172908,0.000062834566,0.000075644486,0.00018120713,0.00016755915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011565886,0.00093013083,0.000760054,0.0013968638,0.0005569118,0.0029478131,0.001403,0.0017892383,0.030868292],"category_scores_gemma":[0.0012102074,0.00044431008,0.0006784646,0.00097387214,0.0006820217,0.0018447548,0.0014762185,0.0034160907,0.017186612],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006907001,0.0003356724,0.0004198429,0.0022706636,0.000090608344,0.00065195403,0.00010151717,0.0026598796,0.31376782,0.06715084,0.35771033,0.25415015],"study_design_scores_gemma":[0.00021153776,0.0006134269,0.0007892378,0.00026045582,0.0000686159,0.0006984775,0.000045577453,0.002664919,0.10816088,0.0118494565,0.87455124,0.00008618772],"about_ca_topic_score_codex":0.0004692432,"about_ca_topic_score_gemma":0.0007095443,"teacher_disagreement_score":0.030868292,"about_ca_system_score_codex":0.001113058,"about_ca_system_score_gemma":0.0010198088,"threshold_uncertainty_score":0.10326475},"labels":[],"label_agreement":null},{"id":"W4405182084","doi":"10.1158/1538-8514.cancerchem24-a008","title":"Abstract A008: Evaluation of natural and synthetic compounds on epithelial to mesenchymal transition in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Tannin, Tannase and Anticancer Activities","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epithelial–mesenchymal transition; Vimentin; Triple-negative breast cancer; Cancer research; Mesenchymal stem cell; Cancer; Cancer cell; Metastasis; Chemistry; Breast cancer; Biology; Cell biology; Immunology; Immunohistochemistry","score_opus":0.022583135608798644,"score_gpt":0.3084671364835852,"score_spread":0.28588400087478655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97377056,0.011097393,0.0017271262,0.00045531534,0.0002890871,0.00088142836,0.0023887805,0.00015980093,0.009230475],"genre_scores_gemma":[0.97802645,0.0073712454,0.0034944077,0.00026616183,0.000056352495,0.00029799185,0.001781582,0.00002402883,0.008681761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999064,0.000025300691,0.000010520255,0.000012315177,0.000026966269,0.000018578045],"domain_scores_gemma":[0.99990594,0.000013667057,0.000012983852,0.0000052086766,0.000030144949,0.00003198421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020117404,0.00031482193,0.0003312076,0.00046190777,0.00017638788,0.00021261128,0.00024773122,0.00029200438,0.0048692212],"category_scores_gemma":[0.00013852169,0.00009485057,0.000316978,0.0002552397,0.00012216829,0.00014804836,0.00011493249,0.00039364988,0.00042035917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038800982,0.0024654586,0.00054852356,0.0008209031,0.00006918006,0.00032700962,0.0000648384,0.00082585635,0.95068645,0.00039605694,0.0016722635,0.038243372],"study_design_scores_gemma":[0.00272273,0.0967002,0.009596709,0.00012796649,0.00026302857,0.00086997787,0.000119918084,0.0013213792,0.8667719,0.00014003983,0.021321444,0.000044627457],"about_ca_topic_score_codex":0.0010196879,"about_ca_topic_score_gemma":0.0019021798,"teacher_disagreement_score":0.0048692212,"about_ca_system_score_codex":0.00015897267,"about_ca_system_score_gemma":0.00040316858,"threshold_uncertainty_score":0.016289175},"labels":[],"label_agreement":null},{"id":"W4405182115","doi":"10.1158/1538-8514.cancerchem24-a009","title":"Abstract A009: Genetic disruption of CAPNS1 impedes triple-negative breast cancer metastasis: A case for selective calpain-1/2 inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Calpain; Cancer research; Biology; Metastasis; Cancer; Cell biology; Genetics","score_opus":0.016128409611007265,"score_gpt":0.30366891695897996,"score_spread":0.2875405073479727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9305683,0.010189402,0.0271865,0.00641942,0.0011283378,0.00037409915,0.003165365,0.0020443797,0.0189242],"genre_scores_gemma":[0.97106916,0.0031348718,0.010591389,0.0011984692,0.000079383426,0.00016926619,0.0013625257,0.0001976233,0.012197312],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997986,0.00001867423,0.000020908363,0.0000510262,0.0000773129,0.000033478864],"domain_scores_gemma":[0.9998294,0.00003469655,0.000035233967,0.000021335842,0.000032971275,0.00004622279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027574957,0.00046514036,0.00043435945,0.00028919452,0.00024365669,0.0005546131,0.00044733612,0.0008756233,0.002860232],"category_scores_gemma":[0.00025728985,0.00016516652,0.00041605442,0.00016553863,0.00036530624,0.0004165227,0.00020137345,0.0013656236,0.0007065961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026324095,0.00012406042,0.00022104014,0.00006998239,0.000017274131,0.00039864532,0.000015078306,0.000103291626,0.991336,0.0007116069,0.0008896206,0.0058501004],"study_design_scores_gemma":[0.00010414224,0.0009071146,0.0029800467,0.000031070955,0.00007246625,0.0029501382,0.000050188108,0.0020742973,0.96880555,0.00058426714,0.021423547,0.000017242144],"about_ca_topic_score_codex":0.0006483167,"about_ca_topic_score_gemma":0.0009182404,"teacher_disagreement_score":0.002860232,"about_ca_system_score_codex":0.00036665107,"about_ca_system_score_gemma":0.00025853634,"threshold_uncertainty_score":0.009568393},"labels":[],"label_agreement":null},{"id":"W4405182172","doi":"10.1158/1538-8514.cancerchem24-a011","title":"Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"GAS6; Kinome; MERTK; Cancer research; Receptor tyrosine kinase; Cancer; Cancer cell; AXL receptor tyrosine kinase; Tyrosine kinase; Kinase; Tumor microenvironment; Pharmacology; Tyrosine-kinase inhibitor; Immune checkpoint; Immune system; Biology; Signal transduction; Chemistry; Immunotherapy; Cell biology; Immunology; JAK-STAT signaling pathway","score_opus":0.009851442890421419,"score_gpt":0.2301417661797985,"score_spread":0.2202903232893771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.942161,0.0106083965,0.020537661,0.00073749205,0.00023070123,0.0007061612,0.00334571,0.00043935454,0.0212335],"genre_scores_gemma":[0.9688315,0.0050041336,0.008942029,0.00036848988,0.00006008002,0.00017431381,0.00411726,0.0000594763,0.012442687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999125,0.000011861072,0.0000071310155,0.000015456908,0.000031010954,0.000022012298],"domain_scores_gemma":[0.9999242,0.000006037788,0.000009717708,0.0000043264104,0.000023523684,0.00003218663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018786512,0.00048617867,0.000236728,0.00033478058,0.00015083712,0.00031581064,0.0003271692,0.00030141848,0.0020967976],"category_scores_gemma":[0.0002083528,0.00011637809,0.00020310098,0.00022030389,0.00012993143,0.0002210953,0.00022481901,0.0004681636,0.0013632078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029942227,0.0005277978,0.00043294166,0.00027095655,0.00003119644,0.00026658867,0.00004051961,0.0013424878,0.9710146,0.0006082213,0.001887644,0.023277458],"study_design_scores_gemma":[0.00038021177,0.004295209,0.002077905,0.000043910535,0.00008167214,0.00074544223,0.000027733618,0.0044402047,0.9580468,0.00035879615,0.029471066,0.000031098916],"about_ca_topic_score_codex":0.0006412073,"about_ca_topic_score_gemma":0.0006948168,"teacher_disagreement_score":0.0020967976,"about_ca_system_score_codex":0.0002708482,"about_ca_system_score_gemma":0.00039212644,"threshold_uncertainty_score":0.007014513},"labels":[],"label_agreement":null},{"id":"W4405182221","doi":"10.1158/1538-8514.cancerchem24-pr002","title":"Abstract PR002: EP300 loss of function is a pan-cancer sensitizer to BET inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Google (Canada)","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Biology; Loss function; Regulator; DNA replication; Cancer cell; Gene; Genetics; Phenotype; DNA repair","score_opus":0.017115491448581287,"score_gpt":0.28770267258928095,"score_spread":0.2705871811406997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580561,0.005573747,0.0052625155,0.0010905615,0.0003474728,0.00025537435,0.0038993105,0.0014455973,0.0240693],"genre_scores_gemma":[0.9714533,0.0016473026,0.0017602684,0.00037584474,0.000030425468,0.00009841762,0.0028892967,0.00007748172,0.021667566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991536,0.000008294613,0.000005566993,0.00001639548,0.000032810713,0.000021543701],"domain_scores_gemma":[0.99995446,0.000009240461,0.000007491436,0.0000065348204,0.000005496597,0.000016743088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090779715,0.0003743705,0.00031707744,0.0002768961,0.0001539314,0.00028557456,0.00035408782,0.0004657573,0.008873737],"category_scores_gemma":[0.000098225115,0.00011513301,0.00023205916,0.00018306628,0.0001554434,0.00020838637,0.0001556914,0.0010956263,0.0016121792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005006106,0.0002059369,0.00017557359,0.0000602691,0.000014053368,0.00013853349,0.000008865446,0.0001606606,0.9891522,0.00022674285,0.0015607114,0.0077959513],"study_design_scores_gemma":[0.000116144576,0.0017638392,0.0033217086,0.000009845501,0.000026274158,0.00081341557,0.000021237542,0.0012870466,0.9791462,0.00011393279,0.013370595,0.000009858647],"about_ca_topic_score_codex":0.00054270896,"about_ca_topic_score_gemma":0.00091665564,"teacher_disagreement_score":0.008873737,"about_ca_system_score_codex":0.00030205626,"about_ca_system_score_gemma":0.00016115946,"threshold_uncertainty_score":0.029685616},"labels":[],"label_agreement":null},{"id":"W4405182229","doi":"10.1158/1538-8514.cancerchem24-a017","title":"Abstract A017: The FES tyrosine kinase as an emerging target for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer immunotherapy; Cytotoxic T cell; Innate immune system; Immunotherapy; Immune system; Immunology; Cancer research; Cancer; Biology; Acquired immune system","score_opus":0.024937751555463322,"score_gpt":0.32578274876147373,"score_spread":0.30084499720601043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44532225,0.416297,0.020680634,0.034810428,0.007713741,0.00037705404,0.0022163347,0.0008942572,0.07168834],"genre_scores_gemma":[0.7864962,0.1340027,0.008908031,0.0042549116,0.0018088545,0.00017852448,0.002421524,0.000052737778,0.061876483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995494,0.000007503323,0.0000029876915,0.0000070197593,0.000014957446,0.0000126903215],"domain_scores_gemma":[0.9999484,0.0000050881945,0.000009716239,0.0000020214673,0.000013801819,0.000020888474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020165896,0.00032705165,0.00019463564,0.00023890291,0.00014661795,0.00048058297,0.0002796993,0.0006232422,0.0058523295],"category_scores_gemma":[0.0000908496,0.00006107882,0.00022789616,0.00016210685,0.00022153147,0.00036591096,0.0002439226,0.0008272518,0.0014988863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020243716,0.00052819896,0.0018072735,0.0018206337,0.00008601486,0.00085088075,0.000051819236,0.0011086143,0.6517659,0.016618576,0.039214287,0.2841235],"study_design_scores_gemma":[0.00090524374,0.0048493687,0.011577353,0.000593497,0.00019507705,0.0046666265,0.00020066576,0.005868987,0.32860872,0.012775139,0.62970006,0.000059222177],"about_ca_topic_score_codex":0.0002265296,"about_ca_topic_score_gemma":0.00025048773,"teacher_disagreement_score":0.0058523295,"about_ca_system_score_codex":0.0003989177,"about_ca_system_score_gemma":0.0003140503,"threshold_uncertainty_score":0.01957804},"labels":[],"label_agreement":null},{"id":"W4405182261","doi":"10.1158/1538-8514.cancerchem24-a019","title":"Abstract A019: Discovery of a potent and brain-penetrable tubulin inhibitor SB-216 that shows efficacy in primary tumor growth and brain metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taxane; Medicine; Brain metastasis; Prostate cancer; Cancer; Breast cancer; Cancer research; Metastasis; Ovarian cancer; Pharmacology; Metastatic breast cancer; Internal medicine","score_opus":0.024585093130380844,"score_gpt":0.3082285957801095,"score_spread":0.2836435026497287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95249325,0.018701289,0.0077087367,0.0007843678,0.00038755845,0.00037564727,0.0031360923,0.0007340097,0.015679099],"genre_scores_gemma":[0.9620807,0.011262041,0.008852546,0.00037232475,0.00009431861,0.000140699,0.00464664,0.00008519481,0.012465597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995685,0.0000053274866,0.0000040633568,0.0000077088225,0.000014801568,0.00001126423],"domain_scores_gemma":[0.9999517,0.000003836845,0.0000073364995,0.0000026948296,0.000010843667,0.000023543858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009835689,0.00050837256,0.00032911598,0.00030949345,0.00017268464,0.00036002725,0.0002997209,0.00030785956,0.0020776156],"category_scores_gemma":[0.00008816157,0.00011548024,0.000294136,0.00021162552,0.000116507115,0.00010579233,0.00014192252,0.0005667965,0.0010099881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004982449,0.00032771006,0.0004344153,0.00022361314,0.000036707086,0.0003510867,0.000018026854,0.0004041792,0.9775144,0.00029344883,0.0016668619,0.018231243],"study_design_scores_gemma":[0.00047299074,0.0051995805,0.0031723678,0.00003742134,0.00012379777,0.0014328515,0.000019871291,0.0021582153,0.9651088,0.00012768844,0.02212812,0.000018326014],"about_ca_topic_score_codex":0.0013117522,"about_ca_topic_score_gemma":0.001946392,"teacher_disagreement_score":0.0020776156,"about_ca_system_score_codex":0.00024490882,"about_ca_system_score_gemma":0.000366501,"threshold_uncertainty_score":0.006950319},"labels":[],"label_agreement":null},{"id":"W4405182393","doi":"10.1158/1538-8514.cancerchem24-ia023","title":"Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Tolerability; Drug; Cancer; Pharmacology; Cancer research; Drug resistance; Internal medicine; Antibody; Immunology; Biology; Adverse effect; Monoclonal antibody","score_opus":0.05581262807661499,"score_gpt":0.4060311569159849,"score_spread":0.35021852883936994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6783262,0.047802005,0.16376016,0.0041540978,0.0014361333,0.0014254024,0.005415901,0.0056125,0.092067614],"genre_scores_gemma":[0.9290577,0.006837671,0.037316695,0.00067023496,0.00010745595,0.00031281204,0.0015918253,0.00012213209,0.02398348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990404,0.0000093580475,0.000005949131,0.000020043823,0.000034812198,0.000025764039],"domain_scores_gemma":[0.99995196,0.0000029827117,0.0000100588695,0.0000041803796,0.000016248156,0.000014639981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018342621,0.00040429353,0.0003635296,0.00033302404,0.00018966026,0.0005720153,0.000367455,0.0005509678,0.0046757734],"category_scores_gemma":[0.00012655626,0.00017990221,0.00019686398,0.00024522355,0.00014243294,0.00042024397,0.00038100177,0.0006756773,0.0017292448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030778087,0.00012886194,0.00020887694,0.0002143305,0.00001732208,0.00016992232,0.000028367638,0.0011265503,0.9322333,0.0019577192,0.00714618,0.05646075],"study_design_scores_gemma":[0.00014691973,0.0009169165,0.0010449116,0.000026069976,0.000046373414,0.0006447863,0.000018056457,0.010399363,0.9173247,0.00034726702,0.06905288,0.000031711654],"about_ca_topic_score_codex":0.0009255744,"about_ca_topic_score_gemma":0.0011387961,"teacher_disagreement_score":0.0046757734,"about_ca_system_score_codex":0.0006016748,"about_ca_system_score_gemma":0.00056705024,"threshold_uncertainty_score":0.015642047},"labels":[],"label_agreement":null},{"id":"W4405182420","doi":"10.1158/1538-8514.cancerchem24-ia008","title":"Abstract IA008: Leveraging conformational dynamics for improved selectivity","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mutant; Selectivity; Oncogene; Fibroblast growth factor receptor; Cancer research; Gene; Kinase; Small molecule; Computational biology; Chemistry; Biology; Biochemistry; Receptor; Fibroblast growth factor; Cell cycle","score_opus":0.02282076174909704,"score_gpt":0.31750582159659335,"score_spread":0.2946850598474963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7667603,0.0067992727,0.13451947,0.003030388,0.0009929902,0.00024243529,0.0012499951,0.0058866967,0.080518514],"genre_scores_gemma":[0.96333826,0.0018644216,0.027054736,0.00035654206,0.0000470677,0.00016668055,0.00077589235,0.00038517412,0.006011216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999089,0.000012237656,0.000004505448,0.000020450678,0.000032804397,0.000021106694],"domain_scores_gemma":[0.9998957,0.000028971024,0.000014659414,0.000015188933,0.00001935626,0.000026186744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025249057,0.0003455334,0.00029896008,0.00014929446,0.0002770408,0.00063242106,0.00049556786,0.00041780656,0.006848398],"category_scores_gemma":[0.00043398238,0.00024598013,0.00024269104,0.00015252279,0.0002485844,0.0005855215,0.00054513005,0.0010958293,0.0015156969],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010548071,0.0005126646,0.0016590236,0.0005613475,0.00009052059,0.00035551362,0.00013978702,0.11305597,0.7307653,0.030908318,0.020134103,0.10076267],"study_design_scores_gemma":[0.000475415,0.0014354783,0.0011698125,0.000064943946,0.0000620066,0.00020659268,0.00005466508,0.6409253,0.2750268,0.0071839523,0.0732853,0.00010981183],"about_ca_topic_score_codex":0.0011060981,"about_ca_topic_score_gemma":0.0011715781,"teacher_disagreement_score":0.006848398,"about_ca_system_score_codex":0.0004907086,"about_ca_system_score_gemma":0.0003993851,"threshold_uncertainty_score":0.022910178},"labels":[],"label_agreement":null},{"id":"W4405182464","doi":"10.1158/1538-8514.cancerchem24-pr005","title":"Abstract PR005: Helping academic investigators develop small molecules for the clinic: The NCI Developmental Therapeutics Program and Stepping-Stones","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug development; Drug discovery; Computer science; Medicine; Business; Pharmacology; Bioinformatics; Drug; Biology","score_opus":0.1834990704941047,"score_gpt":0.43125011165171767,"score_spread":0.24775104115761298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182464","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033296514,0.0059662075,0.0061553754,0.8540691,0.014942021,0.00095224817,0.0015834285,0.002176112,0.11082576],"genre_scores_gemma":[0.07313168,0.027758785,0.057119515,0.45470455,0.019848779,0.0026591897,0.009268644,0.002004311,0.35350457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98297507,0.0052808165,0.0007719583,0.0010930347,0.0072535933,0.0026255758],"domain_scores_gemma":[0.92949903,0.0057212496,0.0021450974,0.0029087507,0.017349461,0.042376384],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03090319,0.0010431822,0.0007195056,0.0017224712,0.004157466,0.009778948,0.005399853,0.007009024,0.05933038],"category_scores_gemma":[0.034152843,0.0006383811,0.0010295596,0.0018631463,0.0040789573,0.005509274,0.013488572,0.011584677,0.027643578],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098438446,0.00016762264,0.0006054969,0.00010699046,0.000011880236,0.00008165661,0.000107596316,0.00009215603,0.00032332767,0.005904176,0.9257039,0.06679672],"study_design_scores_gemma":[0.00025862796,0.0004351225,0.0016350196,0.00043800814,0.000025055884,0.0001836215,0.00039369692,0.00041100936,0.0009925945,0.007128339,0.98805237,0.000046473564],"about_ca_topic_score_codex":0.013175707,"about_ca_topic_score_gemma":0.021439567,"teacher_disagreement_score":0.9690968,"about_ca_system_score_codex":0.008313458,"about_ca_system_score_gemma":0.061921474,"threshold_uncertainty_score":0.19847989},"labels":[],"label_agreement":null},{"id":"W4405318800","doi":"10.1158/1535-7163.mct-23-0872","title":"CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute for Health and Care Research; Royal College of Surgeons of England; Wellcome Trust","keywords":"Fibrosis; Cancer research; Biology; Stromal cell; CD8; Immune system; Downregulation and upregulation; Flow cytometry; Pathology; Immunology; Medicine; Gene","score_opus":0.03499067173412827,"score_gpt":0.33885979000763966,"score_spread":0.3038691182735114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405318800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992417,0.002380826,0.003049946,0.0001176744,0.000042452408,0.00006854056,0.00024068616,0.00024790494,0.0014349662],"genre_scores_gemma":[0.9920047,0.0013389648,0.0028144936,0.00007436079,0.000016976537,0.00011271843,0.00039473028,0.00003566237,0.0032073276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987686,0.00001971384,0.000008832927,0.000025801106,0.000029769479,0.00003900825],"domain_scores_gemma":[0.9999312,0.000008957712,0.000024479019,0.000006617942,0.000009347981,0.000019412888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012743285,0.00033191912,0.00037820154,0.0002968351,0.00008466648,0.00022362842,0.00014676915,0.0002514952,0.0015741242],"category_scores_gemma":[0.00008718442,0.00009359575,0.0002036818,0.00013407196,0.00017551064,0.00015432187,0.00011798916,0.00057856605,0.00024605214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003658045,0.00013833508,0.00016925664,0.000085127635,0.000007970015,0.000019581317,0.000015987918,0.00016660303,0.99323773,0.000054939635,0.000100012294,0.0056387256],"study_design_scores_gemma":[0.000090717454,0.003323482,0.0049518812,0.000023518438,0.00006295182,0.00026433755,0.00003937245,0.0017699618,0.98508865,0.00006375075,0.0043143113,0.0000070330666],"about_ca_topic_score_codex":0.0003178171,"about_ca_topic_score_gemma":0.00070883293,"teacher_disagreement_score":0.0015741242,"about_ca_system_score_codex":0.00018541624,"about_ca_system_score_gemma":0.00020290897,"threshold_uncertainty_score":0.0052660108},"labels":[],"label_agreement":null},{"id":"W4408296465","doi":"10.1158/1535-7163.mct-24-0906","title":"Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Guelph; University of Saskatchewan; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Ovarian Cancer Canada","keywords":"Carboplatin; Oncolytic virus; Ovarian cancer; Cancer research; KRAS; PTEN; Tumor microenvironment; Biology; Medicine; Immunotherapy; Cancer; Immunology; Chemotherapy; Immune system; Internal medicine; PI3K/AKT/mTOR pathway; Colorectal cancer; Cisplatin; Apoptosis","score_opus":0.027853922752414526,"score_gpt":0.3608405036014598,"score_spread":0.33298658084904526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408296465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991743,0.00041495977,0.00011156419,0.000012881233,0.000003640345,0.000007841451,0.00004153539,0.0000060489597,0.00022718846],"genre_scores_gemma":[0.9995437,0.000154354,0.000076803015,0.000008320458,0.000001201718,0.0000046699806,0.00005119,0.0000024593962,0.00015732992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998791,0.000028227905,0.000013477899,0.000020324973,0.000024433291,0.00003441676],"domain_scores_gemma":[0.9999212,0.000027053551,0.000021010737,0.000007927633,0.000006107485,0.00001678195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092585644,0.00011549698,0.0001549469,0.00014316742,0.000065192085,0.00022997349,0.000079596684,0.00020239886,0.00060871814],"category_scores_gemma":[0.00019099847,0.00007699941,0.000123312,0.00009819178,0.00013662978,0.00014604071,0.00010610248,0.00030339687,0.000077245044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047435326,0.00014989424,0.0028110333,0.000031667238,0.000010853022,0.000037862857,0.000028652485,0.00040447598,0.9918013,0.000107905485,0.000042375283,0.004099585],"study_design_scores_gemma":[0.00006762713,0.004149625,0.044247724,0.000010522968,0.00007280846,0.0006180194,0.00008904963,0.00344314,0.9445139,0.0001190246,0.0026594615,0.000008987511],"about_ca_topic_score_codex":0.00047804884,"about_ca_topic_score_gemma":0.00041916716,"teacher_disagreement_score":0.00060871814,"about_ca_system_score_codex":0.00021747038,"about_ca_system_score_gemma":0.00012459038,"threshold_uncertainty_score":0.002036333},"labels":[],"label_agreement":null},{"id":"W4408296594","doi":"10.1158/1535-7163.mct-24-0656","title":"5′- <i>S</i> -(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency; Ontario Institute for Cancer Research; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Research Institute; Lotte and John Hecht Memorial Foundation; U.S. Department of Defense","keywords":"Toxicity; Pharmacology; Cytotoxicity; Chemistry; Cancer cell; Cancer research; Cancer; Biochemistry; Medicine; In vitro; Internal medicine","score_opus":0.019357844538171295,"score_gpt":0.3081458575001949,"score_spread":0.2887880129620236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408296594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97740513,0.0076316344,0.010354533,0.00010102148,0.00003118961,0.00009393392,0.00036329892,0.00015237386,0.0038668567],"genre_scores_gemma":[0.9871133,0.002693101,0.008017505,0.0000583979,0.000012543178,0.000048322967,0.00042955836,0.000014414051,0.0016127769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991333,0.00001472522,0.000007102502,0.00002534269,0.00002300353,0.000016429676],"domain_scores_gemma":[0.99995196,0.000008283936,0.000016096825,0.000005120897,0.0000065428976,0.000011975544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001169567,0.0003671434,0.00022956579,0.00019164845,0.00013515442,0.00016609246,0.00019782153,0.00028735967,0.0006606656],"category_scores_gemma":[0.000091619026,0.00014352772,0.00025819664,0.00017407381,0.00011403264,0.00017936509,0.00014377468,0.000335167,0.0002551796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004975881,0.00001877084,0.00011083813,0.000054942164,0.0000037568464,0.000054798573,0.000008486239,0.00014610722,0.9969599,0.00006772569,0.000022711893,0.002502089],"study_design_scores_gemma":[0.000010116431,0.00059385796,0.0011706193,0.0000044349777,0.000015472478,0.0003295532,0.000007791843,0.0005027789,0.99450004,0.000024493032,0.0028358102,0.000004933563],"about_ca_topic_score_codex":0.00033572182,"about_ca_topic_score_gemma":0.0006228805,"teacher_disagreement_score":0.0006606656,"about_ca_system_score_codex":0.00014402084,"about_ca_system_score_gemma":0.00014598934,"threshold_uncertainty_score":0.0022101402},"labels":[],"label_agreement":null},{"id":"W4409890102","doi":"10.1158/1535-7163.mct-24-0998","title":"A Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI–eIF2α–ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Ministry of Science and ICT, South Korea; Korea Drug Development Fund; National Research Foundation","keywords":"Integrated stress response; ATF4; mTORC1; Cancer research; eIF2; Biology; Cell cycle; Cell growth; P70-S6 Kinase 1; Phosphorylation; Signal transduction; Unfolded protein response; Cell biology; Apoptosis; Translation (biology); PI3K/AKT/mTOR pathway; Endoplasmic reticulum; Biochemistry; Gene; Messenger RNA","score_opus":0.015758981806903605,"score_gpt":0.2766060427206724,"score_spread":0.2608470609137688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409890102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97661644,0.0067613376,0.0056335125,0.00031475117,0.00011329498,0.00015175833,0.0009046491,0.00021873257,0.009285608],"genre_scores_gemma":[0.9904156,0.0034946157,0.0022406166,0.00016723377,0.000023217255,0.000045833196,0.0008190155,0.000015097041,0.002778852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999685,0.0000055711816,0.0000024890026,0.000008175459,0.0000053112954,0.000009914907],"domain_scores_gemma":[0.99998116,0.000002186316,0.0000049224445,0.0000014744986,0.0000030479684,0.0000072243965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077465906,0.00032183086,0.00018256878,0.00016573256,0.000085878055,0.00010182452,0.00018667485,0.00016392,0.0020116896],"category_scores_gemma":[0.000053012303,0.000086645196,0.00021374851,0.000104129984,0.0001213338,0.00023327483,0.00012507902,0.0003682832,0.00044783572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035161994,0.00009303619,0.00015983767,0.00023699264,0.000018335573,0.00012727288,0.000017489621,0.00034253602,0.99075645,0.00031731423,0.00024627196,0.007332828],"study_design_scores_gemma":[0.00020633118,0.007116132,0.00279969,0.000021428004,0.000093824696,0.0007657365,0.00003854338,0.0013305903,0.97336346,0.00014149945,0.014098639,0.000024041568],"about_ca_topic_score_codex":0.00032212157,"about_ca_topic_score_gemma":0.0006076495,"teacher_disagreement_score":0.0020116896,"about_ca_system_score_codex":0.0001327139,"about_ca_system_score_gemma":0.00013773603,"threshold_uncertainty_score":0.0067297816},"labels":[],"label_agreement":null},{"id":"W4412110327","doi":"10.1158/1535-7163.mct-24-0995","title":"KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Broad Institute","keywords":"KRAS; MAPK/ERK pathway; PI3K/AKT/mTOR pathway; Colorectal cancer; Cancer research; In vivo; Biology; Signal transduction; Mutation; Cancer; Genetics; Gene","score_opus":0.025798403816910124,"score_gpt":0.30644119302712286,"score_spread":0.28064278921021274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412110327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964893,0.00095957355,0.0005887868,0.00008792166,0.0000355484,0.000029526474,0.00022126554,0.000049438062,0.0015386771],"genre_scores_gemma":[0.99708647,0.0006697741,0.00085511926,0.000054826647,0.000003932661,0.00002269403,0.00031484457,0.000016811042,0.0009755068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998149,0.000032328182,0.00001725456,0.000030741576,0.000056282126,0.000048476875],"domain_scores_gemma":[0.99992526,0.000014685118,0.000018905184,0.00001362756,0.0000076196366,0.000019831254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017474883,0.00033357122,0.00032969227,0.0002856565,0.00011629045,0.0004213698,0.00022462296,0.0003000337,0.0013156233],"category_scores_gemma":[0.00019538515,0.00016786502,0.00033870825,0.00023544449,0.00025906536,0.00023393141,0.0002010055,0.00069677393,0.00033922173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007057371,0.0002785822,0.0014885975,0.00005756813,0.000028078573,0.00008714407,0.000019614758,0.0004793555,0.9892902,0.00018230254,0.0001623408,0.0072205476],"study_design_scores_gemma":[0.00009624099,0.0026875315,0.009233035,0.000010347264,0.00005566528,0.0007199567,0.000065692955,0.0015936671,0.98166335,0.00010091289,0.0037630724,0.000010534354],"about_ca_topic_score_codex":0.0010838484,"about_ca_topic_score_gemma":0.0022437004,"teacher_disagreement_score":0.0013156233,"about_ca_system_score_codex":0.00041227214,"about_ca_system_score_gemma":0.0003376382,"threshold_uncertainty_score":0.004401207},"labels":[],"label_agreement":null},{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","score_opus":0.03920731020912873,"score_gpt":0.42594948924018755,"score_spread":0.38674217903105884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412956201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931861,0.0013667662,0.0025671704,0.00010783903,0.000029240267,0.00019846193,0.000722889,0.000066102744,0.0017555285],"genre_scores_gemma":[0.9937309,0.0010884253,0.0014041287,0.00008622952,0.000021770615,0.00016017418,0.0014018869,0.000027374417,0.0020791763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998652,0.00003049724,0.000009080164,0.00002223269,0.00003944672,0.00003358301],"domain_scores_gemma":[0.9998673,0.000017859737,0.000041553933,0.00001445898,0.000026365724,0.00003245691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030955335,0.0004653202,0.00037755875,0.00023262405,0.00014899795,0.00030762778,0.00024648418,0.00028844937,0.0012683613],"category_scores_gemma":[0.00028779038,0.00019174058,0.00026312415,0.00027556246,0.0002261252,0.00033236717,0.0001363449,0.0008669111,0.000331075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009629121,0.0038530568,0.0028097536,0.00022308121,0.00011093745,0.00026126366,0.00010499242,0.0042262077,0.94238013,0.00030529412,0.001175728,0.034920402],"study_design_scores_gemma":[0.0011995398,0.06580321,0.015400669,0.000022930599,0.0003083799,0.0012362454,0.00008243172,0.011208057,0.88895833,0.00020054389,0.015534275,0.00004543438],"about_ca_topic_score_codex":0.00078931556,"about_ca_topic_score_gemma":0.00075557333,"teacher_disagreement_score":0.0012683613,"about_ca_system_score_codex":0.0004010738,"about_ca_system_score_gemma":0.00047620686,"threshold_uncertainty_score":0.004243076},"labels":[],"label_agreement":null},{"id":"W4413956624","doi":"10.1158/1535-7163.mct-24-0861","title":"CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Terry Fox Research Institute; Canada Foundation for Innovation; Deutsche Forschungsgemeinschaft; Clinical and Translational Science Center, Weill Cornell Medical College; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Radioresistance; Cancer research; Clonogenic assay; DNA repair; Olaparib; HDAC3; Gene knockdown; DNA damage; Radiosensitivity; Synthetic lethality; Biology; Radiosensitizer; Cell; Chemistry; Cell culture; Poly ADP ribose polymerase; Radiation therapy; Medicine; Histone; Genetics; DNA; Histone deacetylase; Internal medicine","score_opus":0.02859787776326449,"score_gpt":0.36494875402170607,"score_spread":0.33635087625844157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413956624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95847666,0.0029624773,0.02434297,0.0003600301,0.00010945999,0.00028657643,0.0058399877,0.0014254799,0.006196338],"genre_scores_gemma":[0.9785992,0.0015103616,0.011551148,0.00018393267,0.000010420783,0.00010500277,0.0036831994,0.00013594536,0.0042208624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982846,0.000017938535,0.0000204903,0.000037383375,0.00006626263,0.000029448853],"domain_scores_gemma":[0.9999274,0.000019280968,0.000017250348,0.00000970111,0.000010382719,0.000015954936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019398904,0.0003900866,0.00058787595,0.00027400575,0.0002133303,0.0003599368,0.00033747102,0.00042507905,0.0015207755],"category_scores_gemma":[0.0001425986,0.00016370273,0.00051363325,0.00023675509,0.00018847533,0.00009296722,0.00022144467,0.00050780864,0.0005967344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075991295,0.000024335692,0.0004344465,0.00006646049,0.000016668748,0.00015738886,0.000010050103,0.0001868768,0.99623555,0.00009231622,0.00017451306,0.0025255105],"study_design_scores_gemma":[0.000042917804,0.00031530723,0.006341132,0.000014610739,0.0001038749,0.0008629767,0.00003263554,0.0030063482,0.98033947,0.000065062355,0.008860345,0.000015332877],"about_ca_topic_score_codex":0.0016512633,"about_ca_topic_score_gemma":0.003609791,"teacher_disagreement_score":0.0016512633,"about_ca_system_score_codex":0.0003822706,"about_ca_system_score_gemma":0.00028154187,"threshold_uncertainty_score":0.0050875545},"labels":[],"label_agreement":null},{"id":"W4414011186","doi":"10.1158/1535-7163.mct-25-0428","title":"Advancing Preclinical Biology for Ewing Sarcoma: An International Effort","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"National Institutes of Health; Alan B. Slifka Foundation; National Cancer Institute; Sarcoma UK","keywords":"Sarcoma; Biology; Preclinical testing; Ewing's sarcoma; Preclinical research; Cancer research; Medicine; Computational biology; Virology; Bioinformatics; Pathology","score_opus":0.022380694008475602,"score_gpt":0.3632700260581574,"score_spread":0.3408893320496818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414011186","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042057015,0.30320805,0.39555344,0.14872463,0.006783882,0.004575794,0.0033489119,0.0037256419,0.092022546],"genre_scores_gemma":[0.091068506,0.39183167,0.45925954,0.020761754,0.0034653072,0.0025616523,0.00629016,0.0020039552,0.022757422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9817535,0.008523376,0.0018148968,0.0014293699,0.005580893,0.00089790503],"domain_scores_gemma":[0.9363906,0.017578358,0.0048650648,0.012196411,0.023494482,0.0054752156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10736564,0.0017247882,0.0019679833,0.00586003,0.0014872093,0.010065189,0.0042511905,0.0032432217,0.0073704286],"category_scores_gemma":[0.03630777,0.000935556,0.001792841,0.004576294,0.0050892276,0.012727033,0.009266578,0.009003475,0.003994738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070139003,0.0021082025,0.0039222715,0.0038463234,0.00017815318,0.0004530748,0.0016401067,0.0032958386,0.09787559,0.11201089,0.052609097,0.72135913],"study_design_scores_gemma":[0.00012719445,0.0028488468,0.002310151,0.0028505358,0.00024038073,0.0012296401,0.0008167039,0.0017816292,0.06905271,0.019034198,0.8996073,0.00010066132],"about_ca_topic_score_codex":0.0016542801,"about_ca_topic_score_gemma":0.0014121291,"teacher_disagreement_score":0.10736564,"about_ca_system_score_codex":0.0040982375,"about_ca_system_score_gemma":0.015809538,"threshold_uncertainty_score":0.56781054},"labels":[],"label_agreement":null},{"id":"W4415444204","doi":"10.1158/1535-7163.targ-25-c122","title":"Abstract C122: Effects of standard-of-care therapies on tumor growth, tumor-induced bone loss and bone pain in preclinical models of breast and prostate cancer bone metastasis and multiple myeloma bone disease","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Prostate cancer; Breast cancer; Multiple myeloma; Bone metastasis; Bone marrow; Bone pain; Bortezomib; Bone disease; Zoledronic acid","score_opus":0.02186134890478176,"score_gpt":0.32442425017968674,"score_spread":0.302562901274905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852813,0.004394372,0.0018899437,0.00042795352,0.000300481,0.00036837513,0.0027558217,0.00024591223,0.004335853],"genre_scores_gemma":[0.978724,0.0025586064,0.003135625,0.00028934013,0.00007240944,0.0006375717,0.003969129,0.0000512695,0.010561979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99947053,0.00007058962,0.000038250542,0.00008035321,0.00020043305,0.00013992334],"domain_scores_gemma":[0.9996606,0.000029076686,0.00007783336,0.000030180812,0.00006698626,0.0001353303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031607147,0.00074639276,0.00080293167,0.0006011829,0.000275804,0.00038795237,0.00050170126,0.0007431967,0.0032637476],"category_scores_gemma":[0.00018732654,0.0002037601,0.0006941913,0.000492351,0.00036709648,0.00021171046,0.00018328932,0.0020028776,0.00061503646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005101456,0.0046340814,0.00036500275,0.00034402523,0.000046148984,0.00016204725,0.000058845202,0.0007922684,0.97842133,0.00026313975,0.0016120771,0.008199505],"study_design_scores_gemma":[0.0007604337,0.042386893,0.0075401384,0.00004677001,0.00010574882,0.00036473796,0.00010188792,0.0027412106,0.93574345,0.000111192436,0.010057579,0.000039891056],"about_ca_topic_score_codex":0.0029028514,"about_ca_topic_score_gemma":0.0050867586,"teacher_disagreement_score":0.0032637476,"about_ca_system_score_codex":0.0005147362,"about_ca_system_score_gemma":0.0007539457,"threshold_uncertainty_score":0.010918319},"labels":[],"label_agreement":null},{"id":"W4415444241","doi":"10.1158/1535-7163.targ-25-c073","title":"Abstract C073: Heritable resistance and phenotypic stochasticity are likely drivers of irreproducibility in experimental determination of <i>in vitro</i> potency of anticancer agents","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Phenotype; Potency; In vitro; Cell; Offspring; Cell culture; Variation (astronomy); Resistance (ecology)","score_opus":0.018460214615827534,"score_gpt":0.29679045021619954,"score_spread":0.278330235600372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8853473,0.000218038,0.10995202,0.0002832403,0.00003606296,0.000081471044,0.0012600984,0.00062979455,0.0021920337],"genre_scores_gemma":[0.98735446,0.000084306106,0.011336463,0.000049553157,0.0000042494726,0.0000781428,0.0006685225,0.000050379513,0.00037396466],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986779,0.00045209963,0.000104870946,0.00030026506,0.00036831756,0.00009650795],"domain_scores_gemma":[0.99219453,0.005241398,0.001112809,0.00070131925,0.00060989696,0.00014013388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021827153,0.00048575623,0.00039233826,0.0003763348,0.00024101186,0.001099829,0.0006827983,0.0007526568,0.0017007807],"category_scores_gemma":[0.007979528,0.00027777554,0.00076732633,0.0004275862,0.00062233343,0.00045803818,0.00045064342,0.00088334543,0.00025492205],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047025882,0.00029352927,0.046493556,0.00034891887,0.00027265944,0.00021912635,0.00012041639,0.7830603,0.14993057,0.0050644353,0.0007879959,0.012938273],"study_design_scores_gemma":[0.000022978036,0.00025882633,0.0131243635,0.000020861075,0.000058812333,0.00012444041,0.000035892128,0.8827162,0.10041074,0.0023257046,0.0008645241,0.00003665911],"about_ca_topic_score_codex":0.0031826,"about_ca_topic_score_gemma":0.0017495188,"teacher_disagreement_score":0.9978173,"about_ca_system_score_codex":0.0014344109,"about_ca_system_score_gemma":0.00091457664,"threshold_uncertainty_score":0.011543453},"labels":[],"label_agreement":null},{"id":"W4415444243","doi":"10.1158/1535-7163.targ-25-c072","title":"Abstract C072: Comparing and combining existing radiological criteria for hyperprogressive disease in patients receiving immune-oncology therapy: Building towards a sensitive and conservative method to assess the presence of hyperprogressive disease","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen's University; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Radiological weapon; Disease; Incidence (geometry); Cancer; Lung cancer; Colorectal cancer","score_opus":0.08760377124632727,"score_gpt":0.41821971517671414,"score_spread":0.33061594393038685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444243","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96616036,0.003170001,0.022537144,0.00020821726,0.000116364135,0.00087125995,0.0027891009,0.00015916076,0.003988426],"genre_scores_gemma":[0.97973204,0.00021028703,0.01690189,0.0000710504,0.00007204296,0.00044095775,0.002193241,0.00003186957,0.00034658817],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9698285,0.017272586,0.0033947693,0.0022739936,0.0065303664,0.0006998724],"domain_scores_gemma":[0.96122414,0.021975009,0.008035932,0.0024040523,0.005175706,0.0011851338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025064923,0.0009201015,0.002103568,0.0059005376,0.00061507575,0.0028337028,0.0015485458,0.0012988583,0.0018427934],"category_scores_gemma":[0.03298346,0.0005134172,0.0023584496,0.004338724,0.0007458292,0.0013538438,0.0024329212,0.0011156491,0.00074015674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024207362,0.000108208405,0.97640765,0.00030844143,0.0011437759,0.0000657988,0.00019945322,0.00095432857,0.0010259675,0.0001718509,0.0006159269,0.016577847],"study_design_scores_gemma":[0.0001498622,0.0020018092,0.9775763,0.00014145162,0.0009649102,0.00085951376,0.00058258284,0.012492996,0.0021772103,0.00041895988,0.0025360796,0.00009825504],"about_ca_topic_score_codex":0.0016967165,"about_ca_topic_score_gemma":0.00244509,"teacher_disagreement_score":0.025064923,"about_ca_system_score_codex":0.00062690803,"about_ca_system_score_gemma":0.0009819743,"threshold_uncertainty_score":0.13255763},"labels":[],"label_agreement":null},{"id":"W4415444339","doi":"10.1158/1535-7163.targ-25-a055","title":"Abstract A055: Treatment and tumor heterogeneity – Effects of competition, variable response to treatment, and finite resources","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Competition (biology); Population; Genotype; Phenotype; Tumor progression; Genetic heterogeneity; Immune system","score_opus":0.015398708554844598,"score_gpt":0.29802094633967297,"score_spread":0.28262223778482837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795284,0.00021901936,0.017792901,0.00035993152,0.00001735833,0.0000614944,0.00033663132,0.000061654,0.0016225451],"genre_scores_gemma":[0.9977671,0.00003431679,0.0014302632,0.000038704173,0.000004230518,0.000025984875,0.00009227994,0.0000076001966,0.0005994931],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993469,0.0002744517,0.000027340948,0.000122014135,0.000108848944,0.00012027861],"domain_scores_gemma":[0.99498135,0.0035447688,0.0006926775,0.00017802227,0.00021561989,0.00038754157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015768582,0.0003788092,0.00075736153,0.00041181396,0.0003720561,0.00081395195,0.00091566617,0.00081259536,0.0039240215],"category_scores_gemma":[0.0050615855,0.00016595775,0.0008797115,0.00036702197,0.0007512359,0.0005020045,0.0004510986,0.0011542279,0.00013445682],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016556429,0.00049938256,0.023136903,0.00020841081,0.00028289587,0.00048571566,0.0001090327,0.91002995,0.03993976,0.011927076,0.00086978497,0.010855492],"study_design_scores_gemma":[0.00010340005,0.0011263102,0.014197401,0.000014922808,0.00014035689,0.00022515723,0.000058509402,0.9708944,0.0061344034,0.006527613,0.0005405855,0.000036955757],"about_ca_topic_score_codex":0.0077601946,"about_ca_topic_score_gemma":0.0038256813,"teacher_disagreement_score":0.0077601946,"about_ca_system_score_codex":0.0023406213,"about_ca_system_score_gemma":0.0012496928,"threshold_uncertainty_score":0.016982436},"labels":[],"label_agreement":null},{"id":"W4415444344","doi":"10.1158/1535-7163.targ-25-a038","title":"Abstract A038: Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Temozolomide; Glioma; Cytotoxic T cell; Drug; Cytotoxicity; Mevalonate pathway; Cancer; Glioblastoma; Prodrug","score_opus":0.0066340411992944544,"score_gpt":0.26711669047576625,"score_spread":0.2604826492764718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921138,0.004118398,0.00065803144,0.00011341601,0.000037929294,0.00009841807,0.0011826727,0.000099637,0.0015776174],"genre_scores_gemma":[0.99007785,0.0032059264,0.001855455,0.0001466839,0.000014904449,0.000062715444,0.0026041898,0.000018301553,0.002013967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993134,0.000008586712,0.0000090253025,0.000012118954,0.000023889948,0.000015092224],"domain_scores_gemma":[0.9999404,0.000011561864,0.000010839761,0.0000043833606,0.000016419814,0.000016331422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001104039,0.00034839546,0.0006206302,0.0005971006,0.0001803541,0.00029797267,0.00019447481,0.00021434894,0.0016423826],"category_scores_gemma":[0.00014371576,0.00010505304,0.0003329304,0.00044761866,0.00010602349,0.00013000629,0.00016256055,0.0003566128,0.00035425698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007000235,0.00038370414,0.0012302238,0.00023876592,0.000049955976,0.00025206973,0.000024047626,0.0004044264,0.98439413,0.00005056952,0.00036940887,0.011902696],"study_design_scores_gemma":[0.00025714852,0.0073916,0.018489815,0.000050166233,0.00025184796,0.00081525085,0.00007770247,0.0024479437,0.9627432,0.000055781074,0.007389179,0.000030282845],"about_ca_topic_score_codex":0.0014786582,"about_ca_topic_score_gemma":0.0031721126,"teacher_disagreement_score":0.0016423826,"about_ca_system_score_codex":0.000249214,"about_ca_system_score_gemma":0.00031701336,"threshold_uncertainty_score":0.0054942966},"labels":[],"label_agreement":null},{"id":"W4415444393","doi":"10.1158/1535-7163.targ-25-b142","title":"Abstract B142: EO3001: A novel agent for ARID1A mutant cancers","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ARID1A; Oxidative stress; Cancer; Cell culture; Ex vivo; Chromatin remodeling; Mitochondrion; In vivo; Cell; Cell growth","score_opus":0.02569021721449196,"score_gpt":0.3146437236870415,"score_spread":0.2889535064725496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83769506,0.06786313,0.03807864,0.0026071807,0.0009171785,0.0009760158,0.0046840725,0.0015464649,0.045632184],"genre_scores_gemma":[0.94791406,0.016432634,0.010364693,0.00081361976,0.000084986976,0.00024633226,0.0024260127,0.000093809256,0.021623831],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999547,0.000007252701,0.0000025198906,0.000010438801,0.000014706462,0.000010423651],"domain_scores_gemma":[0.999966,0.000003813356,0.000005553233,0.0000029143255,0.000007207812,0.000014499086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001350726,0.00034053758,0.00026427413,0.00033808802,0.00013956858,0.00020824374,0.00032645414,0.00041464128,0.0031833504],"category_scores_gemma":[0.00008748966,0.00009636928,0.00024788172,0.00015491617,0.00015383161,0.00020474104,0.00024020046,0.0007628541,0.00085066987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009321649,0.0003395681,0.00018475005,0.00061723636,0.00003374938,0.00037865038,0.000027193026,0.0006951719,0.9321118,0.0013093415,0.0039987005,0.05937172],"study_design_scores_gemma":[0.0005830135,0.0041781566,0.0025600637,0.00011279523,0.00008828812,0.0023349258,0.00003613413,0.002247322,0.889828,0.0007337182,0.09724971,0.000047891313],"about_ca_topic_score_codex":0.00050978706,"about_ca_topic_score_gemma":0.00076363824,"teacher_disagreement_score":0.0031833504,"about_ca_system_score_codex":0.00023224576,"about_ca_system_score_gemma":0.0001932972,"threshold_uncertainty_score":0.010649443},"labels":[],"label_agreement":null},{"id":"W4415444529","doi":"10.1158/1535-7163.targ-25-c108","title":"Abstract C108: The therapeutic candidate antibody PODO447 recognizes a glycopeptide on podocalyxin-expressing tumor cells that have undergone a partial epithelial-mesenchymal transition","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Epitope; Monoclonal antibody; Antibody; Transmembrane protein; Phenotype; Glycopeptide; Cell sorting; MUC1; Cell","score_opus":0.037539001050955666,"score_gpt":0.34695113606352124,"score_spread":0.3094121350125656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479503,0.0013721094,0.0024155322,0.0005895339,0.000116097406,0.0001611945,0.00064455735,0.00013068378,0.009775296],"genre_scores_gemma":[0.9844519,0.0004544836,0.0031611004,0.0002763281,0.000028066022,0.00008093771,0.0011585712,0.000025287296,0.010363436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998666,0.000017624401,0.000006656047,0.00002066884,0.00004249906,0.00004584179],"domain_scores_gemma":[0.9999399,0.000008436778,0.000006936186,0.000004742697,0.000013633545,0.00002641785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111750654,0.00033249773,0.00022521334,0.00023507755,0.00015375008,0.00021194053,0.00026966265,0.00058068306,0.007921744],"category_scores_gemma":[0.00011669123,0.00008975882,0.00019840126,0.000113493275,0.00014111056,0.00015057932,0.00014096062,0.00084407435,0.0013852676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004922912,0.00029259757,0.0009944708,0.000056652832,0.000015353593,0.00017018874,0.000013101249,0.00013143619,0.9884013,0.00019531243,0.0013780629,0.007859282],"study_design_scores_gemma":[0.00018749075,0.0024922392,0.008562646,0.000019280058,0.00005190031,0.0013209984,0.000027739201,0.0025000973,0.9726783,0.000111547444,0.012039539,0.000008249939],"about_ca_topic_score_codex":0.0011608435,"about_ca_topic_score_gemma":0.0009462139,"teacher_disagreement_score":0.007921744,"about_ca_system_score_codex":0.0004246253,"about_ca_system_score_gemma":0.00024694146,"threshold_uncertainty_score":0.02650094},"labels":[],"label_agreement":null},{"id":"W4415444549","doi":"10.1158/1535-7163.targ-25-b102","title":"Abstract B102: Using subclonal dynamics to detect and quantify fitness advantages of resistant subclones in tumors under treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Selection (genetic algorithm); Population; Genetic drift; Dynamics (music); Mutation Accumulation; Evolutionary dynamics; Distribution (mathematics); Cancer","score_opus":0.038737620427158496,"score_gpt":0.36027169737587644,"score_spread":0.32153407694871794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97513276,0.00004776375,0.023881407,0.00004832793,0.0000066549237,0.000024184172,0.00017860228,0.00023014468,0.00045004845],"genre_scores_gemma":[0.9870882,0.000022715043,0.012363602,0.000012930747,0.0000012806862,0.000025133095,0.00021595214,0.00002007379,0.0002501985],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9998634,0.000036933638,0.0000070671895,0.00004085098,0.000037722006,0.000014114935],"domain_scores_gemma":[0.99879104,0.0007114688,0.00016754743,0.000083050836,0.00016898752,0.00007798854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004972476,0.00036592546,0.0003047074,0.00044679662,0.0001854394,0.0004020406,0.00036990124,0.00047393018,0.0008266396],"category_scores_gemma":[0.0022149403,0.00015997996,0.00031719686,0.00022449555,0.00023395818,0.00029094034,0.00024286532,0.00035360156,0.00014035613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005887112,0.00019707548,0.07065485,0.00007928668,0.00011655953,0.00011904223,0.00014072428,0.8223122,0.082725056,0.0010132883,0.0004048243,0.021648314],"study_design_scores_gemma":[0.000011820779,0.000118685675,0.008090689,0.0000032397554,0.000010165494,0.000030423587,0.000009383362,0.9774949,0.013868868,0.00022261204,0.00012911214,0.000010151118],"about_ca_topic_score_codex":0.0059289164,"about_ca_topic_score_gemma":0.002988545,"teacher_disagreement_score":0.0059289164,"about_ca_system_score_codex":0.00066846504,"about_ca_system_score_gemma":0.00041993667,"threshold_uncertainty_score":0.011788785},"labels":[],"label_agreement":null},{"id":"W4415444599","doi":"10.1158/1535-7163.targ-25-b101","title":"Abstract B101: Subclonal drift predicts tumor response to treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Population; Genetic drift; Dominance (genetics); Cancer; Population mean; Fixation (population genetics); Genetic model; Survival analysis","score_opus":0.022892048329930383,"score_gpt":0.3198704918538981,"score_spread":0.29697844352396774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837286,0.000072979856,0.010281518,0.00014684777,0.000009740256,0.00001450815,0.00013416649,0.00007717402,0.0008901736],"genre_scores_gemma":[0.9980355,0.000019975443,0.0014969959,0.000020551846,0.0000017050181,0.0000138345795,0.000105645006,0.00001269162,0.00029312802],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99990714,0.00003742449,0.0000044316957,0.000020159714,0.000018173017,0.00001278807],"domain_scores_gemma":[0.99785656,0.0016607118,0.00016557564,0.0000624664,0.00016192715,0.0000927793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066604314,0.0002864791,0.0002690712,0.00027751984,0.00018403867,0.00043197686,0.00039306807,0.000611992,0.0018075986],"category_scores_gemma":[0.0037978622,0.0001883634,0.00034181797,0.0001650985,0.00022026524,0.00029143173,0.00021691891,0.0005376365,0.00023963592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009668931,0.00006111485,0.017784193,0.000015754034,0.000029377166,0.000029697898,0.000019105551,0.97631764,0.0025290104,0.00040002205,0.00021261418,0.002504788],"study_design_scores_gemma":[0.000009976537,0.00004613412,0.0027862277,0.0000023636317,0.000006288086,0.000011196135,0.0000050086924,0.99565744,0.0010904766,0.00032010174,0.000061312356,0.0000034674683],"about_ca_topic_score_codex":0.0066447947,"about_ca_topic_score_gemma":0.003171116,"teacher_disagreement_score":0.0066447947,"about_ca_system_score_codex":0.001030977,"about_ca_system_score_gemma":0.00050544454,"threshold_uncertainty_score":0.013212204},"labels":[],"label_agreement":null},{"id":"W4415444620","doi":"10.1158/1535-7163.targ-25-c116","title":"Abstract C116: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Drug discovery; Penetrance; Kinase; Cancer; Synthetic biology; DNA damage; Drug; DNA repair","score_opus":0.026453306694786675,"score_gpt":0.29194081987832765,"score_spread":0.26548751318354097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87121403,0.020100055,0.06865339,0.0013621008,0.00038845834,0.0006252022,0.001187641,0.0012601543,0.035209015],"genre_scores_gemma":[0.95524836,0.005943218,0.028228614,0.00035636342,0.00003253082,0.00016633788,0.0010469509,0.00006378806,0.008913867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999281,0.000009521067,0.0000045675392,0.000016658823,0.00002735038,0.000013836092],"domain_scores_gemma":[0.9999502,0.000004599011,0.000014179344,0.000003933581,0.000009585691,0.000017527882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011884609,0.00071129034,0.00047695963,0.00048461827,0.00016122527,0.00057137694,0.00052147696,0.00038349518,0.0013255967],"category_scores_gemma":[0.00016321364,0.00017702309,0.00045386833,0.00035326916,0.00020920619,0.0002728889,0.00040709044,0.001078222,0.0005611575],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080869906,0.0008773717,0.0009053167,0.0007223929,0.0001322992,0.0007125728,0.00005648697,0.06470615,0.75563717,0.006678758,0.003979805,0.16478284],"study_design_scores_gemma":[0.000961655,0.008448351,0.0019369257,0.00010171102,0.00022247278,0.0013237292,0.000028340834,0.21003565,0.7303363,0.0019017304,0.044585075,0.00011800328],"about_ca_topic_score_codex":0.001207214,"about_ca_topic_score_gemma":0.0016713693,"teacher_disagreement_score":0.0013255967,"about_ca_system_score_codex":0.00054637075,"about_ca_system_score_gemma":0.00033389925,"threshold_uncertainty_score":0.0044345856},"labels":[],"label_agreement":null},{"id":"W4415444727","doi":"10.1158/1535-7163.targ-25-a042","title":"Abstract A042: Evolution of resistance in brain tumors: Effects of the blood brain barrier","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Blood–brain barrier; Drug; Pharmacokinetics; Drug resistance; Penetration (warfare); Population; Brain tumor","score_opus":0.008232857330306542,"score_gpt":0.27139404634458325,"score_spread":0.2631611890142767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979844,0.00054285914,0.0160006,0.00027868384,0.000027461023,0.000030346502,0.00034580217,0.00009420765,0.002836082],"genre_scores_gemma":[0.99644023,0.0001596176,0.0016681877,0.000034261513,0.00000462268,0.000024865738,0.00017422563,0.000018940429,0.0014750598],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99987483,0.000033785713,0.0000056298786,0.000026919422,0.000028282484,0.00003057879],"domain_scores_gemma":[0.99951434,0.00022771506,0.00009576138,0.00002565604,0.000092923256,0.00004349555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021254012,0.0003095997,0.0003296052,0.00025100412,0.00017723997,0.00061409955,0.00035389428,0.00066184,0.0024687438],"category_scores_gemma":[0.000962965,0.00013112291,0.0006500844,0.00022547072,0.00027197096,0.00040031786,0.00029666477,0.00054697285,0.00031385722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044078653,0.00026463656,0.0105291065,0.00021528981,0.000111007335,0.00045361213,0.00006705286,0.85382944,0.11908363,0.004745435,0.00136703,0.0088929655],"study_design_scores_gemma":[0.000040159575,0.00058116205,0.0055030845,0.000011943734,0.000042849155,0.00025753764,0.000035776007,0.9624545,0.027778478,0.0018196343,0.0014512598,0.000023612964],"about_ca_topic_score_codex":0.0029438427,"about_ca_topic_score_gemma":0.00088051654,"teacher_disagreement_score":0.0029438427,"about_ca_system_score_codex":0.0006604988,"about_ca_system_score_gemma":0.00043663522,"threshold_uncertainty_score":0.00825876},"labels":[],"label_agreement":null},{"id":"W4415444744","doi":"10.1158/1535-7163.targ-25-a085","title":"Abstract A085: OBP-004, a novel small-molecule dual inhibitor of CDK9/13, reduces bone, brain, lung and lymph node metastases in vivo, with highest potency on bone metastases","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Bioluminescence imaging; Lymph node; Prostate cancer; Bone marrow; Cancer; Breast cancer; Spleen; Metastatic breast cancer; Bone metastasis","score_opus":0.022776783337146733,"score_gpt":0.31268964073595384,"score_spread":0.2899128573988071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885843,0.00300708,0.0019534067,0.00021685692,0.00010382447,0.00018407707,0.0018697417,0.00027637908,0.0038043899],"genre_scores_gemma":[0.9817576,0.0020061245,0.0026096974,0.00011983653,0.000032848766,0.00020955603,0.0029621213,0.00003303412,0.010269213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993014,0.000009603057,0.0000050428616,0.000012163855,0.000017393617,0.000025711595],"domain_scores_gemma":[0.99996054,0.0000047269546,0.000008847974,0.000003092636,0.000004627417,0.000018166502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012657749,0.0005100107,0.00037451473,0.00031618963,0.00009930535,0.0001945961,0.00030879964,0.0002983823,0.003723081],"category_scores_gemma":[0.000064276435,0.00012618005,0.00026297892,0.00019110649,0.00017325049,0.00016411941,0.00010934581,0.0006502771,0.0005632473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025702722,0.0007375437,0.00030434286,0.00019952477,0.000029107598,0.00007513527,0.000010415421,0.00022802684,0.9820024,0.00013486044,0.0009860408,0.012722362],"study_design_scores_gemma":[0.00096510956,0.010348858,0.005278962,0.000011755058,0.00007978085,0.00045183938,0.000014762704,0.0011378003,0.9752759,0.000051118113,0.006374458,0.000009782924],"about_ca_topic_score_codex":0.0011110033,"about_ca_topic_score_gemma":0.0014044631,"teacher_disagreement_score":0.003723081,"about_ca_system_score_codex":0.00029617868,"about_ca_system_score_gemma":0.00044582065,"threshold_uncertainty_score":0.012454987},"labels":[],"label_agreement":null},{"id":"W4415444785","doi":"10.1158/1535-7163.targ-25-c006","title":"Abstract C006: Fitness landscape modeling indicates decreased effectiveness of microtubule assembly targeting drugs in tumors demonstrating chromosomal instability (CIN)","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Aneuploidy; Chromosome instability; Chromosome; Fluorescence in situ hybridization; Chromosome segregation; Karyotype","score_opus":0.008318810987489468,"score_gpt":0.26700331271438726,"score_spread":0.2586845017268978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8114407,0.00031969958,0.17887238,0.00069004815,0.000031096723,0.000056943794,0.00054738065,0.00031942563,0.0077223377],"genre_scores_gemma":[0.98625016,0.00011456236,0.010767395,0.000045988436,0.0000043822524,0.000035754914,0.00020855728,0.000029474788,0.002543737],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99994075,0.000012325105,0.0000032450423,0.000021197538,0.000012046198,0.000010468124],"domain_scores_gemma":[0.9997068,0.00015921697,0.000059943082,0.000015831447,0.00004413022,0.000014073801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027635676,0.00033722565,0.00026618765,0.00044124832,0.00018998714,0.0005597934,0.0003812541,0.00060466497,0.0027036578],"category_scores_gemma":[0.0010642933,0.00014064416,0.00057776703,0.00025986045,0.00029244012,0.00036809046,0.0003238206,0.00035819173,0.00019432134],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049431033,0.000047106736,0.0045222035,0.00006139443,0.000029320092,0.00009486175,0.000038928585,0.9690523,0.016827874,0.003892913,0.0004603502,0.004923288],"study_design_scores_gemma":[0.0000023832233,0.000013366588,0.0006562937,0.0000019774166,0.000003159005,0.00001341903,0.000004308399,0.99781394,0.00096110796,0.00038002664,0.00014726324,0.0000027476603],"about_ca_topic_score_codex":0.010700348,"about_ca_topic_score_gemma":0.004572577,"teacher_disagreement_score":0.010700348,"about_ca_system_score_codex":0.0010561781,"about_ca_system_score_gemma":0.00046167406,"threshold_uncertainty_score":0.021276116},"labels":[],"label_agreement":null},{"id":"W7116690571","doi":"10.1158/1535-7163.mct-25-0298","title":"Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"mTORC2; mTORC1; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Cancer; Carcinogenesis; Cell growth; Targeted therapy","score_opus":0.031107782075481927,"score_gpt":0.303339722933979,"score_spread":0.27223194085849706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116690571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80077595,0.094692156,0.057065684,0.003045838,0.00077873236,0.00093408814,0.0019630238,0.0011526087,0.039591946],"genre_scores_gemma":[0.9315016,0.033490524,0.02202112,0.0007907515,0.00011297749,0.00022677435,0.0014363033,0.000052525134,0.010367492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999335,0.000011284439,0.0000048150105,0.000016432734,0.000020504924,0.000013512649],"domain_scores_gemma":[0.99996567,0.000005513543,0.000011382533,0.000003038509,0.0000057355182,0.000008679473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020660127,0.00043919584,0.00036635742,0.00037375305,0.00017796933,0.0003395825,0.00023050958,0.00025944578,0.0020379266],"category_scores_gemma":[0.00007490085,0.0001752185,0.00035183938,0.00022351736,0.000220509,0.00025054053,0.00021196497,0.00070530205,0.00054719235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048183103,0.00040801626,0.00072426244,0.00059981714,0.000068156645,0.00040762968,0.00004545142,0.0025160897,0.90214926,0.0033058948,0.0018085758,0.08748507],"study_design_scores_gemma":[0.0004784354,0.003298128,0.0033279841,0.000095233976,0.0001718138,0.0019931996,0.000034849112,0.0071802377,0.9052908,0.00095944165,0.077126965,0.000042936823],"about_ca_topic_score_codex":0.00032161432,"about_ca_topic_score_gemma":0.0012892921,"teacher_disagreement_score":0.0020379266,"about_ca_system_score_codex":0.00034576163,"about_ca_system_score_gemma":0.0004156976,"threshold_uncertainty_score":0.0068175197},"labels":[],"label_agreement":null},{"id":"W7116791432","doi":"10.1158/1535-7163.mct-25-0667","title":"Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Fonds de Recherche du Québec - Santé; American Cancer Society; Canadian Institutes of Health Research; Melanoma Research Alliance; National Heart, Lung, and Blood Institute; American Skin Association; Dermatology Foundation","keywords":"Mevalonate pathway; Programmed cell death; Simvastatin; GPX4; Cancer cell; Statin; Cancer; Apoptosis; In vivo","score_opus":0.011335501226152279,"score_gpt":0.2773822437731999,"score_spread":0.26604674254704763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116791432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217844,0.0025098638,0.0034544268,0.00026430245,0.000038211405,0.00008650731,0.0002544255,0.000078792014,0.0011350455],"genre_scores_gemma":[0.9934511,0.0014584737,0.0023303945,0.0000884262,0.000010255922,0.000048692447,0.00028779617,0.0000136198405,0.0023111107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999062,0.000019136081,0.000010015336,0.000013538891,0.000023582832,0.00002755861],"domain_scores_gemma":[0.99995446,0.000007787885,0.000011716337,0.000008651536,0.0000074282475,0.00001000112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013352603,0.00023000134,0.00029862506,0.00015927294,0.00012616032,0.00021926052,0.00013733801,0.00018755585,0.0013507921],"category_scores_gemma":[0.00007538769,0.00009221804,0.00022377945,0.00011649033,0.00015295447,0.00015813648,0.0001762186,0.0004450631,0.0002609852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016513986,0.00004244302,0.00019687654,0.000041749317,0.000009800149,0.000019641848,0.000012975897,0.00009521871,0.99703336,0.000089217036,0.000063678934,0.0022300123],"study_design_scores_gemma":[0.000048250873,0.000836686,0.0019511242,0.0000053298354,0.000019510086,0.00015143456,0.000025054482,0.0006575236,0.9927961,0.000056867957,0.0034490845,0.0000029647354],"about_ca_topic_score_codex":0.00047464564,"about_ca_topic_score_gemma":0.0014374733,"teacher_disagreement_score":0.0013507921,"about_ca_system_score_codex":0.00022842955,"about_ca_system_score_gemma":0.0002118801,"threshold_uncertainty_score":0.0045188665},"labels":[],"label_agreement":null}]}